Term IRI Term label Parent term IRI Parent term label Alternative term Definition http://purl.obolibrary.org/obo/GO_0032640 tumor necrosis factor production http://purl.obolibrary.org/obo/GO_0071706 tumor necrosis factor superfamily cytokine production TNF alpha production The appearance of tumor necrosis factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/TXPO_0000509 bile acid http://purl.obolibrary.org/obo/CHEBI_35341 steroid bile acids Any member of a group of steroid carboxylic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine. http://purl.obolibrary.org/obo/IMR_0000552 proteoglycan http://purl.obolibrary.org/obo/CHEBI_25367 molecule Proteoglycans are a diverse family of molecules characterized by a core protein to which is attached one or more glycosaminoglycan (GAG) side-chains. http://purl.obolibrary.org/obo/IMR_0000249 PKA http://purl.obolibrary.org/obo/CHEBI_25367 molecule PKA is comprised of two types of subunits. Two catalytic (C) subunits bind to a regulatory (R) subunit dimer to form an inactive holoenzyme complex. Binding of cAMP to the regulatory subunit causes the catalytic subunit to be unleashed. http://purl.obolibrary.org/obo/IMR_0000335 Crk http://purl.obolibrary.org/obo/IMR_0000745 Crk family Alternative splicing of the mammal crk gene yields two translation products designated the 28-kDa Crk-I and the 42-kDa Crk-II protein. http://purl.obolibrary.org/obo/IMR_0000414 AP-1 http://purl.obolibrary.org/obo/TXPO_0002107 molecular complex The AP-1 (activator protein 1) transcription factor is a dimeric complex that comprises members of the JUN, FOS, ATF (activating transcription factor) and MAF (musculoaponeurotic fibrosarcoma) protein families. The AP-1 complex can therefore form many different combinations of heterodimers and homodimers, and this combination determines the genes that are regulated by AP-1. http://purl.obolibrary.org/obo/IMR_0000431 RGS http://purl.obolibrary.org/obo/CHEBI_25367 molecule RGS proteins act as negative regulators of G protein dependent signaling, at least in part, because they stimulate hydrolysis of the GTP bound to activated G alpha subunits. http://purl.obolibrary.org/obo/IMR_0010012 nucleoside diphosphate kinase http://purl.obolibrary.org/obo/CHEBI_25367 molecule Nucleoside diphoshate kinases (NDKs), an evolutionarily conserved family of proteins, synthesize nucleoside triphosphates from nucleoside diphosphates and ATP. To date, eight human NDK homologues have been identified. http://purl.obolibrary.org/obo/IMR_0100055 prolactin-releasing hormone http://purl.obolibrary.org/obo/IMR_0100093 pituitary hormone-releasing hormone A polypeptide hormone that originates in the hypothalamus and stimulates the secretion of prolactin in the pituitary gland. http://purl.obolibrary.org/obo/IMR_0000089 PPAR http://purl.obolibrary.org/obo/CHEBI_25367 molecule transcription factors that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes. http://purl.obolibrary.org/obo/IMR_0000188 actin cytoskeleton protein http://purl.obolibrary.org/obo/TXPO_0003689 cytoskeletal protein A role played by the protein contributes to the integrity of the actin cytoskeleton. http://purl.obolibrary.org/obo/IMR_0000909 eIF4F http://purl.obolibrary.org/obo/IMR_0010016 eIF eIF4F is a heterotrimeric complex that binds to the cap structure at the 50 end of the mRNA. It is composed of eIF4G and the cap-binding protein eIF4E and the ATPdependent RNA helicase eIF4A. http://purl.obolibrary.org/obo/IMR_0001689 MAPKAPK2/3 http://purl.obolibrary.org/obo/IMR_0100271 MAPKAPK MAPKAPK2 and MAPKAPK3 can be activated by p38 and activated MAPKAPK2/3 can phosphorylate small heat shock protein 27 (HSP27). http://purl.obolibrary.org/obo/IMR_0000080 FGFR family http://purl.obolibrary.org/obo/CHEBI_25367 molecule The vertebrate Fgfr gene family consists of four highly related genes, Fgfr1-4. http://purl.obolibrary.org/obo/TXPO_0003600 phospholipid metabolite http://purl.obolibrary.org/obo/CHEBI_25212 metabolite Any intermediate or product resulting from phospholipid metabolism. http://purl.obolibrary.org/obo/TXPO_0003601 decreasing ceramide http://purl.obolibrary.org/obo/TXPO_0000644 decreasing lipid Decreasing ceramide is a subtype of decreasing lipid: A process that changes the quantity of the ceramide to be lower. http://purl.obolibrary.org/obo/TXPO_0000262 ATP depletion [toxic course] http://purl.obolibrary.org/obo/TXPO_0000009 toxic course The totality of all processes through which ATP depltion is realized. http://purl.obolibrary.org/obo/TXPO_0000837 liver cancer dependent molecule http://purl.obolibrary.org/obo/TXPO_0000199 liver cancer dependent chemical entity Liver cacer dependent gene is a subtype of toxic course dependent chemical entity. This gene can participate in the course of liver cancer as a gene product. http://purl.obolibrary.org/obo/TXPO_0001278 canalicular cholestasis http://purl.obolibrary.org/obo/TXPO_0002650 intrahepatic cholestasis Impairment of bile flow due to injury to the the canalicular bile ducts. http://purl.obolibrary.org/obo/TXPO_0001279 intrahepatic billiary stasis http://purl.obolibrary.org/obo/TXPO_0002650 intrahepatic cholestasis Impairment of bile flow due to injury to the the intrahepatic bile ducts. http://purl.obolibrary.org/obo/TXPO_0002650 intrahepatic cholestasis http://purl.obolibrary.org/obo/TXPO_0001277 cholestasis [toxic course] Impairment of the bile flow caused by obstruction within the liver. http://purl.obolibrary.org/obo/TXPO_0002651 extrahepatic cholestasis http://purl.obolibrary.org/obo/TXPO_0001277 cholestasis [toxic course] Impairment of the bile flow caused by an obstruction in the portion of the bile duct system located outside of the liver. http://purl.obolibrary.org/obo/TXPO_0003603 mitochondrial damage dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0002012 mitochondrial damage dependent chemical entity Mitochondrial damage dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of Mitochondrial damage as a gene product. Gene profile:Human/in vitro/Hepatocyte/ http://purl.obolibrary.org/obo/TXPO_0004185 liver cancer dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0000837 liver cancer dependent molecule Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of Liver cancer as a gene product. Gene profile:Human/in vitro/Hepatocyte/ http://purl.obolibrary.org/obo/TXPO_0004212 negative regulation of protein-containing complex assembly http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents, or reduces the frequency, rate or extent of protein-containing complex assembly. http://purl.obolibrary.org/obo/TXPO_0004213 negative regulation of mitochondrial respiratory chain complex assembly http://purl.obolibrary.org/obo/TXPO_0004212 negative regulation of protein-containing complex assembly Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex assembly. http://purl.obolibrary.org/obo/TXPO_0004214 negative regulation of mitochondrial respiratory chain complex I assembly http://purl.obolibrary.org/obo/TXPO_0004213 negative regulation of mitochondrial respiratory chain complex assembly Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I assembly. http://purl.obolibrary.org/obo/TXPO_0004215 negative regulation of mitochondrial respiratory chain complex II assembly http://purl.obolibrary.org/obo/TXPO_0004213 negative regulation of mitochondrial respiratory chain complex assembly Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex II assembly. http://purl.obolibrary.org/obo/TXPO_0004216 negative regulation of mitochondrial respiratory chain complex III assembly http://purl.obolibrary.org/obo/TXPO_0004213 negative regulation of mitochondrial respiratory chain complex assembly Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex III assembly. http://purl.obolibrary.org/obo/TXPO_0004217 negative regulation of mitochondrial respiratory chain complex IV assembly http://purl.obolibrary.org/obo/TXPO_0004213 negative regulation of mitochondrial respiratory chain complex assembly Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex IV assembly. http://purl.obolibrary.org/obo/TXPO_0004218 tumorigenesis [Mitochondrial disorder] http://purl.obolibrary.org/obo/NCIT_C18121 tumorigenesis A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004225 Negative regulation of respiratory complex proteins synthesis http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex assembly. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004226 mitochondrial damage dependent molecule (mouse) http://purl.obolibrary.org/obo/TXPO_0002012 mitochondrial damage dependent chemical entity Mitochondrial damage dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of Mitochondrial damage as a gene product. Gene profile:Mouse http://purl.obolibrary.org/obo/TXPO_0004237 cyclin B1-CDK1 complex http://purl.obolibrary.org/obo/TXPO_0002107 molecular complex A protein complex consisting of cyclin B1 and cyclin-dependent kinase 1 (CDK1). Cyclins are characterized by periodicity in protein abundance throughout the cell cycle. Cyclin-dependent kinases represent a family of serine/threonine protein kinases that become active upon binding to a cyclin regulatory partner. http://purl.obolibrary.org/obo/TXPO_0004240 cyclin B1-CDK1 complex inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation cyclin B1-CDK1 complex inactivation is a subtype of molecular inactivation: A process that changes the activity of the cyclin B1-CDK1 complex to be lower. http://purl.obolibrary.org/obo/TXPO_0004241 cyclin B1-CDK1 complex inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process cyclin B1-CDK1 complex inactivation is a subtype of molecular inactivation: A process that changes the activity of the cyclin B1-CDK1 complex to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004242 ACTA2 production [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process ACTA2 production is a subtype of Actin production: A process that makes existent of ACTA2 due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004243 CCL2 production [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004244 binding to DNA by free radicals http://purl.obolibrary.org/obo/TXPO_0003343 binding to DNA by electrophiles Process of binding by which free radicals interact with DNA (deoxyribonucleic acid). http://purl.obolibrary.org/obo/TXPO_0004245 COL1A1 production [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process COL1A1 production is a subtype of collagen production: A process that makes existent of a ollagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004246 negative regulation of cell cycle G2/M phase transition [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Negative regulation of cell cycle G2/M phase transition is a subtype of negative regulation of cell cycle: Any process that stops, prevents or reduces the frequency, rate or extent of cell cycle G2/M phase transition. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004247 GDF15 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process GDF15 inactivation is a subtype of molecular inactivation: A process that changes the activity of the GDF15 (Growth differentiation factor 15) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004248 GDF15 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation GDF15 inactivation is a subtype of molecular inactivation: A process that changes the activity of the GDF15 (Growth differentiation factor 15) to be lower. http://purl.obolibrary.org/obo/TXPO_0004249 JNK signaling (primitive) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ). This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004250 NEAT1 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process NEAT1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NEAT1 (nuclear paraspeckle assembly transcript 1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004251 NfkB signaling (primitive) [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004252 p38 signaling (primitive) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase). This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004253 TLR9 signaling [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process TLR9 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004254 tumor necrosis factor production [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The appearance of tumor necrosis factor due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004255 alcohol intake [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process A moving process of alcohol from the outside to the inside of a body. This entity is a specific course dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004256 interleukin-6 production [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The appearance of interleukin-6 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004257 binding to mtDNA by radicals [mitochondrial disorder]] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Process of binding by which radicals interact with mtDNA (mitochondrial deoxyribonucleic acid). This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004258 increasing free radical [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004259 release of DNA from mitochondria [mitochondria disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The process that results in the movement of mitochondriall DNA from the mitochondria. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004260 decreasing mtDNA level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Decreasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of glycogen level to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004261 mitochondria fission [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004262 mitochondrial DNA catabolic process [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The chemical reactions and pathways resulting in the breakdown of mitochondrial DNA. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004263 release of cytochrome c from mitochondria [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004264 metabolic dysfunction of precursor metabolites and energy generation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Energy metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function. This entity is a specific course-dependent process. This process can constitute the Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004265 Negative regulation of respiratory complex IV proteins synthesis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex IV assembly. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004266 monocyte migration [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The orderly movement of a monocyte from one site to another. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004267 increasing uptake amount of mitochondrial calcium ion [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0002229 increasing uptake amount of mitochondrial calcium ion Increasing uptake amount of mitochondrial calcium ion is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial calcium ion to be higher. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004268 neutrophil migration [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The orderly movement of a neutrophil from one site to another. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004269 cytokine production involved in inflammatory response [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The synthesis or release of a cytokine following a inflammatory stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004270 inflammatory cytokine gene expression [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004271 Inflammatory response [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004272 cellular damage [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004273 Tumor-associated macrophage activation[Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004274 tumor-associated macrophage migration [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The orderly movement of a TAM macrophage from one site to another. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004275 tumor-associated macrophage migration http://purl.obolibrary.org/obo/GO_1905517 macrophage migration The orderly movement of a TAM macrophage from one site to another. http://purl.obolibrary.org/obo/TXPO_0004276 Tumor-associated macrophage activation@hepatocarcinogenesis http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. This entity is a specific course-dependent process. This process can constitute the course of Hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004277 Tumor-associated macrophage activation http://purl.obolibrary.org/obo/GO_0042116 macrophage activation Tumor-associated macrophage (TAM) activation is a subtype of macrophage activation: A change in morphology and behavior of TAMs resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. http://purl.obolibrary.org/obo/TXPO_0004278 lipoperoxidation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0003514 lipoperoxidation Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004279 hepatic fibrosis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004280 hepatocarcinogenesis [toxic course] http://purl.obolibrary.org/obo/TXPO_0000009 toxic course The totality of all processes through which hepatocarcinogenesis is realized. http://purl.obolibrary.org/obo/TXPO_0004281 liver malfunction [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0002074 liver malfunction Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly or not functioning at all. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004282 Scleroprotein production http://purl.obolibrary.org/obo/TXPO_0000382 protein production Scleroprotein production is a subtype of protein production: A process that makes existent of scleroprotein due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0004283 Collagen production http://purl.obolibrary.org/obo/TXPO_0004282 Scleroprotein production Collagen production is a subtype of scleroprotein production: A process that makes existent of collagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0004284 COL1A1 production http://purl.obolibrary.org/obo/TXPO_0004283 Collagen production COL1A1 production is a subtype of collagen production: A process that makes existent of a ollagen due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0004285 cytoskeletal protein production http://purl.obolibrary.org/obo/TXPO_0000382 protein production cytoskeletal protein production is a subtype of protein production: A process that makes existent of cytoskeletal protein due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0004286 actin production http://purl.obolibrary.org/obo/TXPO_0004285 cytoskeletal protein production Actin production is a subtype of cytoskeletal protein production: A process that makes existent of actin due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0004287 ACTA2 production http://purl.obolibrary.org/obo/TXPO_0004286 actin production ACTA2 production is a subtype of Actin production: A process that makes existent of ACTA2 due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0004288 chemokine (C-C motif) ligand 2 production http://purl.obolibrary.org/obo/GO_0032602 chemokine production The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/TXPO_0004289 CCL2 production [Hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The appearance of chemokine (C-C motif) ligand 2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004293 mitochondrial damage dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0002012 mitochondrial damage dependent chemical entity Mitochondrial damage dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of Mitochondrial damage as a gene product. Gene profile:caonical that described in textbooks or articles. http://purl.obolibrary.org/obo/TXPO_0004294 carbon tetrachloride metabolic process http://purl.obolibrary.org/obo/GO_0006805 xenobiotic metabolic process The chemical reactions and pathways involving carbon tetrachloride, a toxic, carcinogenic compound which is used as a general solvent in industrial degreasing operations. It is also used as grain fumigant and a chemical intermediate in the production of refrigerants. http://purl.obolibrary.org/obo/TXPO_0004295 carbon tetrachloride metabolic process [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The chemical reactions and pathways involving carbon tetrachloride, a toxic, carcinogenic compound which is used as a general solvent in industrial degreasing operations. It is also used as grain fumigant and a chemical intermediate in the production of refrigerants. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004296 DNA sensor http://purl.obolibrary.org/obo/TXPO_0000882 sensor A role played by the entity which receives DNA and transmits operand(s). http://purl.obolibrary.org/obo/TXPO_0004297 NEAT1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation NEAT1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NEAT1 (nuclear paraspeckle assembly transcript 1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004298 NfkB signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process NfkB signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transduced with the regulation of transcription of target genes by NF-kappaB. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004299 TLR9 signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process TLR9 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004300 TLR9 signaling (primitive) http://purl.obolibrary.org/obo/TXPO_0004301 TLR signaling (primitive) TLR9 signaling (primitive) is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 9. http://purl.obolibrary.org/obo/TXPO_0004301 TLR signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) TLR signaling (primitive) is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor. http://purl.obolibrary.org/obo/TXPO_0004302 p38 signaling cascade http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway An intracellular protein kinase cascade containing at least a p38 MAPK, a MAPKK and a MAP3K. The cascade can also contain an additional tier: the upstream MAP4K. The kinases in each tier phosphorylate and activate the kinases in the downstream tier to transmit a signal within a cell. (by GO) http://purl.obolibrary.org/obo/TXPO_0004303 p38 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase). http://purl.obolibrary.org/obo/TXPO_0004304 interleukin-6 production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of interleukin-6 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/TXPO_0004305 metabolic dysfunction of precursor metabolites and energy generation http://purl.obolibrary.org/obo/TXPO_0002131 metabolic dysfunction energy metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function. http://purl.obolibrary.org/obo/TXPO_0004306 collagen deposition http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object The aggregation of collagen in a particular location in an organism, tissue or cell, occurring in response to some external stimulus. http://purl.obolibrary.org/obo/TXPO_0004307 collagen deposition [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The aggregation of collagen in a particular location in an organism, tissue or cell, occurring in response to some external stimulus. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004308 binding to mtDNA by radicals http://purl.obolibrary.org/obo/TXPO_0004244 binding to DNA by free radicals Process of binding by which radicals interact with mtDNA (mitochondrial deoxyribonucleic acid). http://purl.obolibrary.org/obo/TXPO_0004309 release of DNA from mitochondria [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The process that results in the movement of mitochondriall DNA from the mitochondria. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004310 decreasing mtDNA level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of mtDNA level to be lower. http://purl.obolibrary.org/obo/TXPO_0004311 mitochondrial fission [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004312 mitochondria disorder dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0002012 mitochondrial damage dependent chemical entity mitochondrial disorder dependent chemical compound is a subtype of toxic course dependent chemical entity. This entity (drug) can participate in the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004313 monocyte migration http://purl.obolibrary.org/obo/GO_0050900 leukocyte migration The orderly movement of a monocyte from one site to another. http://purl.obolibrary.org/obo/TXPO_0004314 respiratory chain inhibitor role http://purl.obolibrary.org/obo/TXPO_0004023 metabolic regulator role A role played by the entity which negative regulates the respiratory chain. http://purl.obolibrary.org/obo/TXPO_0004315 neutrophil migration http://purl.obolibrary.org/obo/GO_0050900 leukocyte migration The orderly movement of a neutrophil from one site to another. http://purl.obolibrary.org/obo/TXPO_0004317 radicals [mitochondrial disorder] http://purl.obolibrary.org/obo/CHEBI_26519 radical A molecular entity possessing an unpaired electron. http://purl.obolibrary.org/obo/TXPO_0004321 drug liver toxicity http://purl.obolibrary.org/obo/TXPO_0004320 drug toxicity An attribute of the finding of liver injury due to the poisonous effects of drugs. http://purl.obolibrary.org/obo/TXPO_0004324 IL6 signaling [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process IL6 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to Interleukin 6. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004325 STAT3 activation[Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004326 STAT3 activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher. http://purl.obolibrary.org/obo/TXPO_0004327 IL-6 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) IL-6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-6. http://purl.obolibrary.org/obo/TXPO_0004340 increasing demand for response to ER stress [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004341 cardiolipin peroxidation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process cardiolipin peroxidation is a subtype of phospholipid oxidation: The degradation of cardiolipin caused by an oxidative attack from free radicals. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004342 necrosis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004343 cellular membrane lipoperoxidation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0003513 cellular membrane lipoperoxidation Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004344 hepatic stellate cell activation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004345 mitochondrial membrane morphology changes [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process mitochondrial membrane morphology changes is a subtype of mitochondria morphology changes: A process that changes the morphology of the mitochondrial membrane. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004346 IL-1beta production [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004347 Insulin resistance (process) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0002189 insulin resistance (process) Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004348 Calcium ion homeostasis imbalance [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004349 Hypofunction of sequestering of calcium ion in ER [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0002192 hypofunction of sequestering of calcium ion Hypofunction of sequestering of calcium ion in ER is a subtype of hypofunctioning: A process that performs a decreased or insufficient sequestering of calcium ion in ER. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder.. http://purl.obolibrary.org/obo/TXPO_0004350 mitochondria morphology change [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process mitochondria morphology changes is a subtype of changing shape: A process that changes the morphology of the mitochondria. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004351 redox changes [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that results in a change in state of redox. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004353 diclofenac [mitochondrial disorder] http://purl.obolibrary.org/obo/CHEBI_47381 diclofenac A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position. http://purl.obolibrary.org/obo/TXPO_0004359 nagative regulation of mitophagy [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that activates or decreases the frequency, rate or extent of mitophagy. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004360 mitochondrial fatty acid beta-oxidation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process A fatty acid oxidation process that results in the complete beta oxidation of a fatty acid in the mitochondria. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004366 hyperfunction of CYP2E1 gene expression [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Hyperfunction of CYP2E1 gene expression is a subtype of hyperfunction of cytochrome 450 gene expression: A process that performs an excesssive gene expression of CYP2E1. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004367 hyperfunction of gluconeogenesis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Hyperfunction of glucose biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive glucose biosynthesis. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004368 Increasing damaged mitochondria [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing damaged mitochondria is a subtype of decreasing quantity: A process that changes the amount of damaged mitochondria to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004369 increasing CPT1 level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing CPT1 level is a subtype of increasing quantity: A process that changes the amount of CPT1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004370 hypofunction of anti-oxidative stress[mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004066 hypofunction of anti-oxidative stress Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004371 gluconeogenesis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The formation of glucose from noncarbohydrate precursors, such as pyruvate, amino acids and glycerol. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004372 lipid biosynthetic process [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004373 increasing demand for response to oxidative stress [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004374 ketone body biosynthetic process [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process ketone body biosynthetic process is a subtype of generating: A process that synthesizes ketone body resulting in having output (s). This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004375 Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I subunit phosphorylation. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004376 cell cycle arrest [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M). This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004377 Increasing HMGB1 level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing HMGB1 level is a subtype of increasing quantity: A process that changes the amount of HMGB1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004378 TLR4 signaling [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process TLR4 signaling is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 4. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004379 Malfunctioning of insulin signaling [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004380 inflammasome activation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004382 HIF1A activation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process HIF1A activation is a subtype of molecular activation: A process that changes the activity of the HIF1A (hypoxia inducible factor 1 subunit alpha) to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004383 inducible nitric oxide synthase production [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process iNOS production is a subtype of protein production: A process that makes existent of iNOS ( inducible nitric oxide synthase) due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004390 Hypofunction of PPARGC1A gene expression [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Hypofunction of PPARGC1A gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient PPARGC1A gene expression. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004391 Increasing IL-6 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing IL-6 level is a subtype of increasing quantity: A process that changes the amount of IL-6 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004392 tumorigenesis [hepatocarcinogenesis] http://purl.obolibrary.org/obo/NCIT_C18121 tumorigenesis A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004393 increasing production amount of reactive aldehyde [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing production amount of reactive aldehyde is a subtype of increasing quantity: A process that changes the production amount of reactive aldehyde to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004394 chemokine (C-X-C motif) ligand 8 production [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The appearance of chemokine (C-X-C motif) ligand 8 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004395 Snail1 signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Snail1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the Snail1 (snail family transcriptional repressor 1) . This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004396 negative regulation of apoptotic process [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004397 Iron accumulation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0003182 iron accumulation Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004398 Increasing ACSL1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing ACSL1 level is a subtype of increasing quantity: A process that changes the amount of ACSL1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004400 Increasing ACSL1 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing ACSL1 level is a subtype of increasing quantity: A process that changes the amount of ACSL1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004402 HNF4A inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process HNF4A inactivation is a subtype of molecular inactivation: A process that changes the activity of the HNF4A (hepatocyte nuclear factor 4 alpha) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004403 positive regulation of cell division [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that activates or increases the frequency, rate or extent of cell division. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004404 tumor cell invasion [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process A moving process of a tumor cell from the outside to the inside of other organ. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004405 Increasing ACSL4 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing ACSL4 level is a subtype of increasing quantity: A process that changes the amount of ACSL4 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004407 Increasing ACSL4 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing ACSL4 level is a subtype of increasing quantity: A process that changes the amount of ACSL4 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004409 Increasing COX-2 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing COX-2 level is a subtype of increasing quantity: A process that changes the amount of COX-2 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004410 positive regulation of arachidonic acid metabolic process [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that activates or increases the frequency, rate or extent of arachidonic acid metabolic process. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004411 Increasing AGGF1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing AGGF1 level is a subtype of increasing quantity: A process that changes the amount of AGGF1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004412 Increasing AGGF1 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing AGGF1 level is a subtype of increasing quantity: A process that changes the amount of AGGF1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004413 Increasing VEGF level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing VEGF level is a subtype of increasing quantity: A process that changes the amount of VEGF level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004414 AGGF1 signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process AGGF1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by AGGF1. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004416 negative regulation of AKT signaling [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004417 AKT signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT). This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004418 GSK3beta signal (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process GSK3beta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by GSK3beta. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004419 TOR signaling (primitive)　[hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004028 TOR signaling (primitive) TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) . This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004420 p38 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process p38 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the p38 (a Mitogen-Activated Protein Kinase). This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004421 Metalloprotease activation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Metalloprotease activation is a subtype of activating: A process that changes the activity of the metalloprotease to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004422 epithelial to mesenchymal transition [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004423 APC signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by APC (Activated protein C). http://purl.obolibrary.org/obo/TXPO_0004424 APC signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) APC signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by APC. http://purl.obolibrary.org/obo/TXPO_0004425 negative regulation of APC signaling http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling Any process that stops, prevents, or reduces the frequency, rate or extent of APC signaling, a series of reactions mediated by APC. http://purl.obolibrary.org/obo/TXPO_0004426 negative regulation of APC signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of APC signaling, a series of reactions mediated by APC. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004427 negative regulation of EPCR signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of EPCR signaling, a series of reactions mediated by EPCR. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004428 ATF4 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation ATF4 inactivation is a subtype of molecular inactivation: A process that changes the activity of the ATF4 (activating transcription factor 4) to be lower. http://purl.obolibrary.org/obo/TXPO_0004429 ATF4 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process ATF4 inactivation is a subtype of molecular inactivation: A process that changes the activity of the ATF4 (activating transcription factor 4) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004431 PMAIP1 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process PMAIP1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the PMAIP1 (phorbol-12-myristate-13-acetate-induced protein 1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004432 ATF6 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004434 Grp78 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Grp78 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Grp78. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004435 Negative regulation of ATP transpot http://purl.obolibrary.org/obo/TXPO_0002682 negative regulation of transport Negative regulation of ATP transport is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of ATP into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/TXPO_0004436 Negative regulation of ATP transport [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Negative regulation of ATP transport is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of ATP into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004437 Increasing BCL-2 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing BCL-2 level is a subtype of increasing quantity: A process that changes the amount of BCL-2 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004438 Increasing BCL-2 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing BCL-2 level is a subtype of increasing quantity: A process that changes the amount of BCL-2 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004439 C9ORF72 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation C9ORF72 inactivation is a subtype of molecular inactivation: A process that changes the activity of the C9ORF72 (C9orf72-SMCR8 complex subunit) to be lower. http://purl.obolibrary.org/obo/TXPO_0004440 C9ORF72 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process C9ORF72 inactivation is a subtype of molecular inactivation: A process that changes the activity of the C9ORF72 (C9orf72-SMCR8 complex subunit) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004442 positive regulation of autophagy [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004443 positive regulation of mitophagy [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that activates or increases the frequency, rate or extent of mitophagy. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004444 Dysregulation of mitochondrion organization http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Dysregulation of mitochondrion organization is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of mitochondrion organization appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004445 Increasing mitochondrial membrane potential [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing mitochondrial membrane potential is a subtype of increasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004446 CAR activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation CAR activation is a subtype of molecular activation: A process that changes the activity of the CAR (constitutive active/androstane receptor) to be higher. http://purl.obolibrary.org/obo/TXPO_0004447 CAR activation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process CAR activation is a subtype of molecular activation: A process that changes the activity of the CAR (constitutive active/androstane receptor) to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004451 CCL2 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) CCL2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CCL2. http://purl.obolibrary.org/obo/TXPO_0004452 CCL2 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process CCL2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CCL2. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004453 hepatic cirrhosis [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Hepatic cirrhosis is a subtype of changing hardness: A process that changes the hardness of the liver to become hard due to the replacement of normal liver tissue to scar tissue. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004455 hepatocarcinogenesis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0000199 liver cancer dependent chemical entity Hepatocarcinogenesis dependent chemical compound is a subtype of toxic course dependent chemical entity. This entity (drug) can participate in the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004456 Increasing CCND1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing CCND1 level is a subtype of increasing quantity: A process that changes the amount of CCND1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004457 Increasing CCND1 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing CCND1 level is a subtype of increasing quantity: A process that changes the amount of CCND1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004459 positive regulation of cell cycle [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that activates or increases the rate or extent of progression through the cell cycle. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004460 CDK1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation CDK1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the CDK1 (cyclin dependent kinase 1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004461 CDK1 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process CDK1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the CDK1 (cyclin dependent kinase 1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004463 Increasing CDK2 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing CDK2 level is a subtype of increasing quantity: A process that changes the amount of CDK2 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004464 Increasing CDK2 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing CDK2 level is a subtype of increasing quantity: A process that changes the amount of CDK2 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004466 CDT1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation CDT1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the CDT1 (chromatin licensing and DNA replication factor 1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004468 CDT1 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process CDT1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the CDT1 (chromatin licensing and DNA replication factor 1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004470 Removing damaged DNA stress [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Removing damaged DNA stress is a subtype of removing damaged object: A process that takes a damaged DNA from an organism or tissue. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004471 Increasing COX-2 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing COX-2 level is a subtype of increasing quantity: A process that changes the amount of COX-2 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004473 increasing CPT1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing CPT1 level is a subtype of increasing quantity: A process that changes the amount of CPT1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004475 Decreasing CXCL8 level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing CXCL8 level is a subtype of decreasing quantity: A process that changes the amount of CXCL8 level to be lower. http://purl.obolibrary.org/obo/TXPO_0004476 Decreasing CXCL8 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Decreasing CXCL8 level is a subtype of decreasing quantity: A process that changes the amount of CXCL8 level to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004477 negative regulation of cellular senescence [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004478 chemokine (C-X-C motif) ligand 8 production http://purl.obolibrary.org/obo/GO_0032602 chemokine production The appearance of chemokine (C-X-C motif) ligand 8 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/TXPO_0004479 metastasis [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor. [def-source: NCI] This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004480 CXCR3 signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process CXCR3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CXCR3. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004481 CXCR3 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) CXCR3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by CXCR3. http://purl.obolibrary.org/obo/TXPO_0004483 endothelial progenitor cell mobilization [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The movement of an endothelial progenitor cell (EPC) within or between different tissues and organs of the body. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004484 CXCR3 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by CXCR3 (CXC chemokine receptor 3). http://purl.obolibrary.org/obo/TXPO_0004485 Increasing CXCR4 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing CXCR4 level is a subtype of increasing quantity: A process that changes the amount of CXCR4 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004487 Increasing CXCR4 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing CXCR4 level is a subtype of increasing quantity: A process that changes the amount of CXCR4 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004489 JNK signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process JNK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JNK (a stress-activated protein kinase (SAPK) ). This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004490 Decreasing CYP1A2 level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing CYP1A2 level is a subtype of decreasing quantity: A process that changes the amount of CYP1A2 level to be lower. http://purl.obolibrary.org/obo/TXPO_0004491 Decreasing CYP1A2 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Decreasing CYP1A2 level is a subtype of decreasing quantity: A process that changes the amount of CYP1A2 level to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004492 Hypofunction of 17β-Estradiol metabolic process [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Hypofunction of 17β-Estradiol metabolic process is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient 17β-Estradiol metabolic process. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004493 Hyperfunction of CYP2E1 gene expression http://purl.obolibrary.org/obo/TXPO_0002051 hyperfunction of Cyp gene expression Hyperfunction of CYP2E1 gene expression is a subtype of hyperfunction of cytochrome 450 gene expression: A process that performs an excesssive gene expression of CYP2E1. http://purl.obolibrary.org/obo/TXPO_0004494 Connexin signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by Cx (Connexin). http://purl.obolibrary.org/obo/TXPO_0004495 connexin signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Connexin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by connexin. http://purl.obolibrary.org/obo/TXPO_0004496 negative regulation of connexin signaling http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling Any process that stops, prevents, or reduces the frequency, rate or extent of connexin signaling, a series of reactions mediated by connexin. http://purl.obolibrary.org/obo/TXPO_0004497 DNA alkylation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The addition of alkyl groups to many positions on all four bases of DNA. Alkylating agents can also modify the bases of incoming nucleotides in the course of DNA synthesis. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004498 chloroethene [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_28509 chloroethene A monohaloethene that is ethene in which one of the hydrogens has been replaced by a chloro group. http://purl.obolibrary.org/obo/TXPO_0004499 Removing damaged DNA stress http://purl.obolibrary.org/obo/TXPO_0000619 removing damaged object Removing damaged DNA stress is a subtype of removing damaged object: A process that takes a damaged DNA from an organism or tissue. http://purl.obolibrary.org/obo/TXPO_0004500 formation of DNA adducts http://purl.obolibrary.org/obo/GO_0005488 binding (with molecule) The process of a structure formation, in n which a chemical is attatched to a segement of DNA. http://purl.obolibrary.org/obo/TXPO_0004501 formation of DNA adducts [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The process of a structure formation, in n which a chemical is attatched to a segement of DNA. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004504 cyproterone acetate [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_50743 cyproterone acetate This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004505 DNA damage [hepatocarcinogenesis] http://purl.obolibrary.org/obo/NCIT_C16507 DNA damage Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004506 proto-oncogene mutation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Proto-oncogene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Proto-oncogene randomly and permanently. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004507 tumor suppressor gene mutation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Tumor suppressor gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004508 negative regulation of DNA repair [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Negative regulation of DNA repair is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of DNA repair. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004512 induction of genomic instability [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that results in induction of genomic instability. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004513 2-acetamidofluorene [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_17356 2-acetamidofluorene The parent of the class of 2-acetamidofluorenes, being an ortho-fused polycyclic arene that consists of 9H-fluorene bearing an acetamido substituent at position 2. It is a carcinogenic and mutagenic derivative of fluorene. http://purl.obolibrary.org/obo/TXPO_0004514 Hyperfunction of DNA biosynthesis [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Hyperfunction of DNA biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive DNA biosynthesis. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004515 Hyperfunction of DNA biosynthesis http://purl.obolibrary.org/obo/TXPO_0002346 hyperfunction of biosynthesis Hyperfunction of DNA biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive DNA biosynthesis. http://purl.obolibrary.org/obo/TXPO_0004516 fumonisin B1 [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_38221 fumonisin B1 A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol. http://purl.obolibrary.org/obo/TXPO_0004517 DNA replication [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004518 Tumor cell proliferation [Hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004520 Increasing DNMT1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing DNMT1 level is a subtype of increasing quantity: A process that changes the amount of DNMT1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004522 Increasing DNMT1 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing DNMT1 level is a subtype of increasing quantity: A process that changes the amount of DNMT1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004524 Increasing DPYD level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing DPYD level is a subtype of increasing quantity: A process that changes the amount of DPYD level to be higher. http://purl.obolibrary.org/obo/TXPO_0004525 Increasing DPYD level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing DPYD level is a subtype of increasing quantity: A process that changes the amount of DPYD level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004526 EGFR signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by EGFR. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004529 sorafenib resistance (process) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process sorafenib resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to sorafenib to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004530 EPCR signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by EPCR (Endothelial protein C receptor). http://purl.obolibrary.org/obo/TXPO_0004531 EPCR signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) EPCR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by EPCR. http://purl.obolibrary.org/obo/TXPO_0004532 negative regulation of EPCR signaling http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling Any process that stops, prevents, or reduces the frequency, rate or extent of EPCR signaling, a series of reactions mediated by EPCR. http://purl.obolibrary.org/obo/TXPO_0004534 ERK signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by ERK (extracellular receptor kinase). http://purl.obolibrary.org/obo/TXPO_0004535 ERK signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) ERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by ERK. http://purl.obolibrary.org/obo/TXPO_0004536 ERK signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process ERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by ERK. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004537 pentadecafluorooctanoic acid http://purl.obolibrary.org/obo/CHEBI_35549 Perfluorooctanoic acid A fluoroalkanoic acid that is perfluorinated octanoic acid. http://purl.obolibrary.org/obo/TXPO_0004538 negative regulation of gap-junctional intercellular communication [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Negative regulation of gap-junctional intercellular communication is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of gap-junctional intercellular communication. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004539 Grp78 signal (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Grp78 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Grp78. http://purl.obolibrary.org/obo/TXPO_0004540 Grp78 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by Grp78 (Glucose-regulated protein 78). http://purl.obolibrary.org/obo/TXPO_0004541 increasing demand for response to ER stress [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004542 inflammatory response [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004543 increasing demand for response to oxidative stress [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004544 FAK signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by FAK (focal adhesion kinase). http://purl.obolibrary.org/obo/TXPO_0004545 FAK signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) FAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAK. http://purl.obolibrary.org/obo/TXPO_0004546 FAK signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process FAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAK. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004548 FAS signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) FAS signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAS. http://purl.obolibrary.org/obo/TXPO_0004549 FAS signaling [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process FAS signaling is a subtype of signaling [biological]: A process that in which a signal is transmitted by FAS. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004550 increasing FGF21 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing FGF21 level is a subtype of increasing quantity: A process that changes the amount of FGF21 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004551 increasing FGF21 level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing FGF21 level is a subtype of increasing quantity: A process that changes the amount of FGF21 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004553 FGF2 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by FGF2. http://purl.obolibrary.org/obo/TXPO_0004554 FGF2 signal (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) FGF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FGF2. http://purl.obolibrary.org/obo/TXPO_0004555 FGF2 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process FGF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by FGF2. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004557 WNT signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process WNT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by WNT. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004558 FOXO1 activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation FOXO1 activation is a subtype of molecular activation: A process that changes the activity of the FOXO1 (forkhead box O1) to be higher. http://purl.obolibrary.org/obo/TXPO_0004559 FOXO1 activation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process FOXO1 activation is a subtype of molecular activation: A process that changes the activity of the FOXO1 (forkhead box O1) to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004561 Hypofunction of heme biosynthesis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Hypofunction of heme biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient heme biosynthesis. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004564 Decreasing GADD45G level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing GADD45G level is a subtype of decreasing quantity: A process that changes the amount of GADD45G level to be lower. http://purl.obolibrary.org/obo/TXPO_0004566 Decreasing GADD45G level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Decreasing GADD45G level is a subtype of decreasing quantity: A process that changes the amount of GADD45G level to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004569 Increasing GDF15 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004570 Increasing GDF15 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004572 negative regulation of gap-junctional intercellular communication http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of gap-junctional intercellular communication is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of gap-junctional intercellular communication. http://purl.obolibrary.org/obo/TXPO_0004573 Decreasing GPHN level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing GPHN level is a subtype of decreasing quantity: A process that changes the amount of GPHN level to be lower. http://purl.obolibrary.org/obo/TXPO_0004574 Decreasing GPHN level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Decreasing GPHN level is a subtype of decreasing quantity: A process that changes the amount of GPHN level to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004575 GSK3beta signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by GSK3beta (glycogen synthase kinase 3 beta). http://purl.obolibrary.org/obo/TXPO_0004576 GSK3beta signal (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) GSK3beta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by GSK3beta. http://purl.obolibrary.org/obo/TXPO_0004577 beta-catenin signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process beta-catenin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by beta-catenin. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004579 cisplatin resistance [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process cisplatin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to cisplatin to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004580 Increasing HBEGF level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing HBEGF level is a subtype of increasing quantity: A process that changes the amount of HBEGF level to be higher. http://purl.obolibrary.org/obo/TXPO_0004582 Increasing HBEGF level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing HBEGF level is a subtype of increasing quantity: A process that changes the amount of HBEGF level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004584 HBV infection http://purl.obolibrary.org/obo/TXPO_0002139 pathogen proliferation HBV infection is a subtype of pathogen colonization: A process that makes HBV present in the liver to increase the number. http://purl.obolibrary.org/obo/TXPO_0004585 HBV infection [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process HBV infection is a subtype of pathogen colonization: A process that makes HBV present in the liver to increase the number. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004586 Notch signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Notch signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Notch. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004587 STAT3 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process STAT3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the STAT3 (signal transducer and activator of transcription 3) . This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004588 TGF beta receptor signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process TGF beta receptor signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the TGF beta receptor (transforming growth factor beta receptor) on the surface of a cell, starting with a ligand binding to a TGFR. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004589 c-Src signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process c-Src signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by c-Src. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004590 telomerase reverse transcriptase gene mutation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Telomerase reverse transcriptase gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Telomerase reverse transcriptase gene randomly and permanently. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004591 necrosis [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004592 dysregulation of immune balance [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Dysregulation of immune balance is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of immune balance appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004593 hepatocyte regeneration [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Hepatocyte regeneration is a subtype of changing material: The regrowth of lost or destroyed hepatocytes. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004594 HCV infection http://purl.obolibrary.org/obo/TXPO_0002139 pathogen proliferation HCV infection is a subtype of pathogen colonization: A process that makes HCV present in the liver to increase the number. http://purl.obolibrary.org/obo/TXPO_0004595 HCV infection [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process HCV infection is a subtype of pathogen colonization: A process that makes HCV present in the liver to increase the number. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004596 Increasing MIR135A level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing MIR135A level is a subtype of increasing quantity: A process that changes the amount of MIR135A level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004597 PPARalpha activation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004598 HGFR signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process HGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by HGFR. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004599 HGFR signal (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) HGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by HGFR. http://purl.obolibrary.org/obo/TXPO_0004600 Increasing HGF level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing HGF level is a subtype of increasing quantity: A process that changes the amount of HGF level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004603 neovascularization [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process neovascularization is a subtype of biological structure formation: A process that constructs an alternate blood vessels. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004605 Increasing HGF level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing HGF level is a subtype of increasing quantity: A process that changes the amount of HGF level to be higher. http://purl.obolibrary.org/obo/TXPO_0004607 HHIP inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation HHIP inactivation is a subtype of molecular inactivation: A process that changes the activity of the HHIP (hedgehog interacting protein) to be lower. http://purl.obolibrary.org/obo/TXPO_0004609 HHIP inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process HHIP inactivation is a subtype of molecular inactivation: A process that changes the activity of the HHIP (hedgehog interacting protein) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004612 HIF1A activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation HIF1A activation is a subtype of molecular activation: A process that changes the activity of the HIF1A (hypoxia inducible factor 1 subunit alpha) to be higher. http://purl.obolibrary.org/obo/TXPO_0004615 Increasing HILPDA level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing HILPDA level is a subtype of increasing quantity: A process that changes the amount of HILPDA level to be higher. http://purl.obolibrary.org/obo/TXPO_0004616 Increasing HILPDA level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing HILPDA level is a subtype of increasing quantity: A process that changes the amount of HILPDA level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004617 Increasing iron uptake level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing iron uptake level is a subtype of increasing quantity: A process that changes the iron uptake level to be larger. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004618 Increasing HMGB1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing HMGB1 level is a subtype of increasing quantity: A process that changes the amount of HMGB1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004620 HNF4A inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation HNF4A inactivation is a subtype of molecular inactivation: A process that changes the activity of the HNF4A (hepatocyte nuclear factor 4 alpha) to be lower. http://purl.obolibrary.org/obo/TXPO_0004624 Increasing HULC level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing HULC level is a subtype of increasing quantity: A process that changes the amount of HULC level to be higher. http://purl.obolibrary.org/obo/TXPO_0004625 Increasing HULC level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing HULC level is a subtype of increasing quantity: A process that changes the amount of HULC level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004627 Increasing PPARA level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing PPARA level is a subtype of increasing quantity: A process that changes the amount of PPARA level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004628 Hedgehog signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by Hedgehog (HH). http://purl.obolibrary.org/obo/TXPO_0004629 Hedgehog signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Hedgehog signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hedgehog. http://purl.obolibrary.org/obo/TXPO_0004630 Hedgehog signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Hedgehog signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hedgehog. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004633 neoplastic cell transformation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process A changing process in which cells become to have neoplastic quality. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004634 glycolytic process [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004635 Hippo signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by Hippo (Mst1 and Mst2 in mammals). http://purl.obolibrary.org/obo/TXPO_0004636 Hippo signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Hippo signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hippo. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004637 Hippo signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Hippo signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Hippo. http://purl.obolibrary.org/obo/TXPO_0004640 YAP signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process YAP signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by YAP. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004641 UHRF1 production http://purl.obolibrary.org/obo/TXPO_0000382 protein production UHRF1 production is a subtype of protein production: A process that makes existent of a UHRF1 protein due to biosynthesis or secretion resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0004642 IFN alpha inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation IFN alpha inactivation is a subtype of molecular inactivation: A process that changes the activity of the IFN alpha (interferon alpha) to be lower. http://purl.obolibrary.org/obo/TXPO_0004643 IFN alpha inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process IFN alpha inactivation is a subtype of molecular inactivation: A process that changes the activity of the IFN alpha (interferon alpha) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004644 IGFBP3 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation IGFBP3 inactivation is a subtype of molecular inactivation: A process that changes the activity of the IGFBP3 (insulin-like growth factor-binding protein 3) to be lower. http://purl.obolibrary.org/obo/TXPO_0004646 IGFBP3 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process IGFBP3 inactivation is a subtype of molecular inactivation: A process that changes the activity of the IGFBP3 (insulin-like growth factor binding protein 3) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004649 IL-6 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation IL-6 inactivation is a subtype of molecular inactivation: A process that changes the activity of the IL-6 (interleukin 6) to be lower. http://purl.obolibrary.org/obo/TXPO_0004650 IL-6 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process IL-6 inactivation is a subtype of molecular inactivation: A process that changes the activity of the IL-6 (interleukin 6) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004652 KIAA0101 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process KIAA0101 inactivation is a subtype of molecular inactivation: A process that changes the activity of the KIAA0101 (PCLAF, PCNA clamp associated factor) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004653 Increasing IL-6 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing IL-6 level is a subtype of increasing quantity: A process that changes the amount of IL-6 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004655 JAK signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process JAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JAK (Janus kinase) . This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004656 IL1 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process IL1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL1. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004657 IL1 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) IL1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL1. http://purl.obolibrary.org/obo/TXPO_0004659 IL-6 signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process IL-6 signaling is a subtype of signaling [biological]: Any series of molecular signals generated as a consequence of binding to Interleukin 6. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004661 Iron accumulation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0003182 iron accumulation Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004662 IP-10 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by IP-10 (Interferon Gamma Induced Protein 10kDa). http://purl.obolibrary.org/obo/TXPO_0004663 IP-10 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) IP-10 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by IP-10. http://purl.obolibrary.org/obo/TXPO_0004664 IP-10 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process IP-10 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by IP-10. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004666 JAK signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by JAK (Janus kinase). http://purl.obolibrary.org/obo/TXPO_0004667 JAK signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) JAK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the JAK (Janus kinase) . http://purl.obolibrary.org/obo/TXPO_0004668 Increasing JUN level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing JUN level is a subtype of increasing quantity: A process that changes the amount of JUN level to be higher. http://purl.obolibrary.org/obo/TXPO_0004669 Increasing JUN level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing JUN level is a subtype of increasing quantity: A process that changes the amount of JUN level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004671 JUN gene promoter demethylation http://purl.obolibrary.org/obo/TXPO_0004672 proto-oncogene promoter demethylation The process of removing one or more methyl groups from JUN gene promoter. http://purl.obolibrary.org/obo/TXPO_0004672 proto-oncogene promoter demethylation http://purl.obolibrary.org/obo/GO_0070988 demethylation The process of removing one or more methyl groups from proto-oncogene promoter. http://purl.obolibrary.org/obo/TXPO_0004673 JUN gene promoter demethylation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The process of removing one or more methyl groups from JUN gene promoter. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004674 dichloroacetic acid [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_36386 dichloroacetic acid An organochlorine compound comprising acetic acid carrying two chloro substituents at the 2-position. It occurs in nature in seaweed, Asparagopsis taxiformis. http://purl.obolibrary.org/obo/TXPO_0004675 trichloroethylene [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_16602 trichloroethylene A member of the class of chloroethenes that is ethene substituted by chloro groups at positions 1, 1 and 2. http://purl.obolibrary.org/obo/TXPO_0004676 trichloroacetic acid [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_30956 trichloroacetic acid A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine. http://purl.obolibrary.org/obo/TXPO_0004677 KIAA0101 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation KIAA0101 inactivation is a subtype of molecular inactivation: A process that changes the activity of the KIAA0101 (PCLAF, PCNA clamp associated factor) to be lower. http://purl.obolibrary.org/obo/TXPO_0004679 negative regulation of autophagy [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004680 Increasing KIAA0101 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing KIAA0101 level is a subtype of increasing quantity: A process that changes the amount of KIAA0101 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004681 Increasing KIAA0101 tv1 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing KIAA0101 tv1 level is a subtype of increasing quantity: A process that changes the amount of KIAA0101 tv1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004683 negative regulation of signal transduction by p53 class mediator [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004684 Decreasing LDLRAD4 level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing LDLRAD4 level is a subtype of decreasing quantity: A process that changes the amount of LDLRAD4 level to be lower. http://purl.obolibrary.org/obo/TXPO_0004686 Decreasing LDLRAD4 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Decreasing LDLRAD4 level is a subtype of decreasing quantity: A process that changes the amount of LDLRAD4 level to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004688 LDLRAD4 gene promoter methylation http://purl.obolibrary.org/obo/GO_0006306 DNA methylation The covalent transfer of a methyl group to LDLRAD4 gene promoter. http://purl.obolibrary.org/obo/TXPO_0004689 LDLRAD4 gene promoter methylation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The covalent transfer of a methyl group to LDLRAD4 gene promoter. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004690 Increasing MIR135A level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing MIR135A level is a subtype of increasing quantity: A process that changes the amount of MIR135A level to be higher. http://purl.obolibrary.org/obo/TXPO_0004693 PTPRD inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process PTPRD inactivation is a subtype of molecular inactivation: A process that changes the activity of the PTPRD (protein tyrosine phosphatase receptor type D) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004694 MMP7 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by MMP7 (matrix metallopeptidase 7). http://purl.obolibrary.org/obo/TXPO_0004695 MMP7 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process MMP7 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by MMP7. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004696 MMP7 signal (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) MMP7 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by MMP7. http://purl.obolibrary.org/obo/TXPO_0004697 Increasing MYC level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing MYC level is a subtype of increasing quantity: A process that changes the amount of MYC level to be higher. http://purl.obolibrary.org/obo/TXPO_0004698 Increasing MYC level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing MYC level is a subtype of increasing quantity: A process that changes the amount of MYC level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004702 MYC gene promoter demethylation http://purl.obolibrary.org/obo/TXPO_0004672 proto-oncogene promoter demethylation The process of removing one or more methyl groups from MYC gene promoter. http://purl.obolibrary.org/obo/TXPO_0004703 MYC gene promoter demethylation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The process of removing one or more methyl groups from MYC gene promoter. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004704 N-nitrosodiethylamine [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_34873 N-nitrosodiethylamine A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom. http://purl.obolibrary.org/obo/TXPO_0004706 NDUFA12 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation NDUFA12 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFA12 (NADH:ubiquinone oxidoreductase subunit A12) to be lower. http://purl.obolibrary.org/obo/TXPO_0004708 NDUFB6 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation NDUFB6 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFB6 (NADH:ubiquinone oxidoreductase subunit B6) to be lower. http://purl.obolibrary.org/obo/TXPO_0004710 NDUFS2 inactivaiton http://purl.obolibrary.org/obo/TXPO_0000021 inactivation NDUFS2 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFS2 (NADH:ubiquinone oxidoreductase core subunit S2) to be lower. http://purl.obolibrary.org/obo/TXPO_0004712 NDUFV1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation NDUFV1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFV1 (NADH:ubiquinone oxidoreductase core subunit V1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004714 NDUFV3 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation NDUFV3 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFV3 (NADH:ubiquinone oxidoreductase core subunit V3) to be lower. http://purl.obolibrary.org/obo/TXPO_0004716 Increasing production quantity of NO http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing production quantity of NO is a subtype of increasing quantity: A process that changes the production amount of nitric oxide (NO) to be higher. http://purl.obolibrary.org/obo/TXPO_0004717 Increasing production quantity of NO [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing production quantity of NO is a subtype of increasing quantity: A process that changes the production amount of nitric oxide (NO) to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004718 increasing production quantity of RNS [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing production quantity of RNS is a subtype of increasing quantity: A process that changes the production amount of reactive nitrogen species (RNS) to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004719 NRF2 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation NRF2 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NRF2 (nuclear factor 2) to be lower. http://purl.obolibrary.org/obo/TXPO_0004720 NRF2 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process NRF2 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NRF2 (nuclear factor 2) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004722 negative regulation of antioxidant enzyme activation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Negative regulation of antioxidant enzyme activation is a subtype of Negative regulation of enzyme activation: A process that stops, prevents, or reduces the frequency, rate or extent of antioxidant enzyme activation. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004723 hypofunction of lipid biosynthesis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0002195 hypofunction of lipid biosynthesis Hypofunction of lipid biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient lipid biosynthesis. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004724 Notch signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Notch signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Notch. http://purl.obolibrary.org/obo/TXPO_0004728 UHRF1 production [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process UHRF1 production is a subtype of protein production: A process that makes existent of a UHRF1 protein due to biosynthesis or secretion resulting in an increase in its levels. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004729 ORC1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation ORC1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the ORC1 (origin recognition complex subunit 1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004731 ORC1 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process ORC1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the ORC1 (origin recognition complex subunit 1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004734 Increasing PANDA level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing PANDA level is a subtype of increasing quantity: A process that changes the amount of PANDA level to be higher. http://purl.obolibrary.org/obo/TXPO_0004735 Increasing PANDA level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing PANDA level is a subtype of increasing quantity: A process that changes the amount of PANDA level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004737 PCK1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation PCK1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004738 PCK1 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process PCK1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004740 PCK1 activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation PCK1 activation is a subtype of molecular activation: A process that changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be higher. http://purl.obolibrary.org/obo/TXPO_0004741 PCK1 activation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process PCK1 activation is a subtype of molecular activation: A process that changes the activity of the PCK1 (phosphoenolpyruvate carboxykinase 1) to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004742 negative regulation of gluconeogenesis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004743 Increasing PCNA level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing PCNA level is a subtype of increasing quantity: A process that changes the amount of PCNA level to be higher. http://purl.obolibrary.org/obo/TXPO_0004745 Increasing PCNA level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing PCNA level is a subtype of increasing quantity: A process that changes the amount of PCNA level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004747 PHB inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation PHB inactivation is a subtype of molecular inactivation: A process that changes the activity of the PHB (prohibitin) to be lower. http://purl.obolibrary.org/obo/TXPO_0004749 PHB inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process PHB inactivation is a subtype of molecular inactivation: A process that changes the activity of the PHB (prohibitin) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004751 PI3K signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase). http://purl.obolibrary.org/obo/TXPO_0004752 PI3K signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) PI3K signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by PI3K. http://purl.obolibrary.org/obo/TXPO_0004753 PI3K signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process PI3K signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by PI3K. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004754 PIM3 activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation PIM3 activation is a subtype of molecular activation: A process that changes the activity of the PIM3 (Pim-3 proto-oncogene, serine/threonine kinase) to be higher. http://purl.obolibrary.org/obo/TXPO_0004755 PIM3 activation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process PIM3 activation is a subtype of molecular activation: A process that changes the activity of the PIM3 (Pim-3 proto-oncogene, serine/threonine kinase) to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004757 changing abnormal cellular structure [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Changing abnormal cellular structure is a subtype of changing structure: A process that changes the structure of the cell abnormally. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004758 liver malfunction [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Liver malfunction is a subtype of organ malfunction: A process that does not perform liver function correctly or not functioning at all. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004759 lipid storage in liver [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004760 PKC activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation PKC activation is a subtype of molecular activation: A process that changes the activity of the PKC ( protein kinase C) to be higher. http://purl.obolibrary.org/obo/TXPO_0004761 PKC activation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process PKC activation is a subtype of molecular activation: A process that changes the activity of the PKC ( protein kinase C) to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004762 PMAIP1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation PMAIP1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the PMAIP1 (phorbol-12-myristate-13-acetate-induced protein 1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004764 negative regulation of caspase-3 activation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Negative regulation of caspase-3 activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of caspase-3 activation. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004765 Increasing PPARA level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing PPARA level is a subtype of increasing quantity: A process that changes the amount of PPARA level to be higher. http://purl.obolibrary.org/obo/TXPO_0004768 Hypofunction of PPARGC1A gene expression http://purl.obolibrary.org/obo/TXPO_0002356 hypofunction of transcription, DNA-templated Hypofunction of PPARGC1A gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient PPARGC1A gene expression. http://purl.obolibrary.org/obo/TXPO_0004771 Decreasing PROC level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing PROC level is a subtype of decreasing quantity: A process that changes the amount of PROC level to be lower. http://purl.obolibrary.org/obo/TXPO_0004773 Decreasing PROC level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Decreasing PROC level is a subtype of decreasing quantity: A process that changes the amount of PROC level to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004775 PROC gene promoter methylation http://purl.obolibrary.org/obo/GO_0006306 DNA methylation The covalent transfer of a methyl group to PROC gene promoter. http://purl.obolibrary.org/obo/TXPO_0004776 PROC gene promoter methylation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The covalent transfer of a methyl group to PROC gene promoter. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004777 Increasing PROM1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing PROM1 level is a subtype of increasing quantity: A process that changes the amount of PROM1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004779 Increasing PROM1 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing PROM1 level is a subtype of increasing quantity: A process that changes the amount of PROM1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004781 Increasing PROX1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing PROX1 level is a subtype of increasing quantity: A process that changes the amount of PROX1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004783 Increasing PROX1 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing PROX1 level is a subtype of increasing quantity: A process that changes the amount of PROX1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004785 PTPRD inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation PTPRD inactivation is a subtype of molecular inactivation: A process that changes the activity of the PTPRD (protein tyrosine phosphatase receptor type D) to be lower. http://purl.obolibrary.org/obo/TXPO_0004787 STAT3 activation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process STAT3 activation is a subtype of molecular activation: A process that changes the activity of the STAT3 to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004788 PTPRD gene promoter methylation http://purl.obolibrary.org/obo/GO_0006306 DNA methylation The covalent transfer of a methyl group to PTPRD gene promoter. http://purl.obolibrary.org/obo/TXPO_0004789 PTPRD gene promoter methylation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The covalent transfer of a methyl group to PTPRD gene promoter. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004790 Increasing PVT1 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing PVT1 level is a subtype of increasing quantity: A process that changes the amount of PVT1 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004791 Increasing PVT1 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing PVT1 level is a subtype of increasing quantity: A process that changes the amount of PVT1 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004793 Decreasing MIR150 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Decreasing MIR150 level is a subtype of decreasing quantity: A process that changes the amount of miR-150 level to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004794 increasing production quantity of ROS [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increaseing production quantity of ROS is a subtype of increasing quantity: A process that changes the production amount of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen, to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004795 hypofunction of S-adenosylmethionine biosynthetic process http://purl.obolibrary.org/obo/TXPO_0001910 hypofunction of biosynthesis hypofunction of S-adenosylmethionine biosynthetic process is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient S-adenosylmethionine biosynthetic process. http://purl.obolibrary.org/obo/TXPO_0004796 hypofunction of S-adenosylmethionine biosynthetic process [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process hypofunction of S-adenosylmethionine biosynthetic process is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient S-adenosylmethionine biosynthetic process. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004797 decreasing glutathione level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Decreasing glutathione level is a subtype of decreasing quantity: A process that changes the amount of glutathione level to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004798 SFRP1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation SFRP1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the SFRP1 (secreted frizzled related protein 1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004800 SFRP1 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process SFRP1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the SFRP1 (secreted frizzled related protein 1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004802 Increasing SPTLC3 level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing SPTLC3 level is a subtype of increasing quantity: A process that changes the amount of SPTLC3 level to be higher. http://purl.obolibrary.org/obo/TXPO_0004803 Increasing SPTLC3 level [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing SPTLC3 level is a subtype of increasing quantity: A process that changes the amount of SPTLC3 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004805 SRC signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by SRC. http://purl.obolibrary.org/obo/TXPO_0004806 STAT3 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by STAT3 (signal transducer and activator of transcription 3). http://purl.obolibrary.org/obo/TXPO_0004807 STAT3 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) STAT3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the STAT3 (signal transducer and activator of transcription 3) . http://purl.obolibrary.org/obo/TXPO_0004809 positive regulation of cancer stem cell division [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that activates or increases the frequency, rate or extent of cancer stem cell division. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004810 Snail1 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Snail1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the Snail1 (snail family transcriptional repressor 1) . http://purl.obolibrary.org/obo/TXPO_0004811 Snail1 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by Snail1 (snail family transcriptional repressor 1). http://purl.obolibrary.org/obo/TXPO_0004813 TAZ signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by TAZ (tafazzin). http://purl.obolibrary.org/obo/TXPO_0004814 TAZ signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) TAZ signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TAZ. http://purl.obolibrary.org/obo/TXPO_0004816 TAZ signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process TAZ signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TAZ. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004818 Hepatic fibrosis [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004820 Hypofunction of TFAM gene expression http://purl.obolibrary.org/obo/TXPO_0002356 hypofunction of transcription, DNA-templated Hypofunction of TFAM gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient TFAM gene expression. http://purl.obolibrary.org/obo/TXPO_0004821 Hypofunction of TFAM gene expression [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Hypofunction of TFAM gene expression is a subtype of hypofunction of transcription, DNA-templated: A process that performs a decreased or insufficient TFAM gene expression. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004823 TGF-alpha signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by TGF-alpha (transforming growth factor alpha). http://purl.obolibrary.org/obo/TXPO_0004824 TGF-alpha signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) TGF-alpha signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TGF-alpha. http://purl.obolibrary.org/obo/TXPO_0004825 TGF-alpha signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process TGF-alpha signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TGF-alpha. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004828 regulatory T cell migration [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The orderly movement of a regulatory T cell from one site to another. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004829 TLR4 signaling (primitive) http://purl.obolibrary.org/obo/TXPO_0004301 TLR signaling (primitive) TLR4 signaling (primitive) is a subtype of TLR signaling [biological]: Any series of molecular signals generated as a consequence of binding to toll-like receptor 4. http://purl.obolibrary.org/obo/TXPO_0004830 cytolysis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The rupture of cell membranes and the loss of cytoplasm. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004832 TNF signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF. http://purl.obolibrary.org/obo/TXPO_0004833 TNF signaling [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004834 TNF signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process TNF signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by TNF. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004837 response to hypoxia [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004838 TSLC signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by TSLC (Tumor suppressor in lung cancer-1) proteins. http://purl.obolibrary.org/obo/TXPO_0004839 TSLC signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) TSLC signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TSLC (Tumor suppressor in lung cancer-1) . http://purl.obolibrary.org/obo/TXPO_0004840 negative regulation of TSLC signaling http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling Any process that stops, prevents, or reduces the frequency, rate or extent of TSLC signaling, a series of reactions mediated by TSLC. http://purl.obolibrary.org/obo/TXPO_0004841 negative regulation of TSLC signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of TSLC signaling, a series of reactions mediated by TSLC. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004844 negative regulation of actin cytoskeleton organization [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Negative regulation of actin cytoskeleton organization is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of actin cytoskeleton organization. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004845 Negative regulation of adherens junction assembly [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0003813 negative regulation of adherens junction assembly Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004846 Twist1 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by twist1. http://purl.obolibrary.org/obo/TXPO_0004847 Twist1 signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Twist1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by Twist1. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004848 Twist1 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Twist1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine Twist1. http://purl.obolibrary.org/obo/TXPO_0004853 UHRF1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation UHRF1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the UHRF1 (ubiquitin like with PHD and ring finger domains 1) to be lower. http://purl.obolibrary.org/obo/TXPO_0004854 UHRF1 inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process UHRF1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the UHRF1 (ubiquitin like with PHD and ring finger domains 1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004856 Increasing VEGF level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing VEGF level is a subtype of increasing quantity: A process that changes the amount of VEGF level to be higher. http://purl.obolibrary.org/obo/TXPO_0004859 WNT signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by WNT (wingless/int-1). http://purl.obolibrary.org/obo/TXPO_0004860 WNT signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) WNT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by WNT. http://purl.obolibrary.org/obo/TXPO_0004867 YAP signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by YAP (Yes associated protein). http://purl.obolibrary.org/obo/TXPO_0004868 YAP signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) YAP signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by YAP. http://purl.obolibrary.org/obo/TXPO_0004870 beta-catenin signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by beta-catenin. http://purl.obolibrary.org/obo/TXPO_0004871 beta-catenin signal (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) beta-catenin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by beta-catenin. http://purl.obolibrary.org/obo/TXPO_0004874 actin cytoskeleton reorganization [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process A process that is carried out at the cellular level which results in dynamic structural changes to the arrangement of constituent parts of cytoskeletal structures comprising actin filaments and their associated proteins. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004875 c-Src signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) c-Src signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by c-Src. http://purl.obolibrary.org/obo/TXPO_0004877 negative regulation of caspase-3 activation http://purl.obolibrary.org/obo/TXPO_0004878 negative regulation of activation Negative regulation of caspase-3 activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of caspase-3 activation. http://purl.obolibrary.org/obo/TXPO_0004878 negative regulation of activation http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of activation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of activation. http://purl.obolibrary.org/obo/TXPO_0004880 cytoplasmic sequestering of cyclin A http://purl.obolibrary.org/obo/TXPO_0000433 keeping position The selective interaction of the cyclin A with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus. http://purl.obolibrary.org/obo/TXPO_0004881 cytoplasmic sequestering of cyclin A [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The selective interaction of the cyclin A with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004882 Malfunctioning of centrosome duplication [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Malfunctioning of centrosome duplication is a subtype of malfunctioning process: A process that cannot perform centrosome duplication appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004883 Malfunctioning of cytokinesis [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Malfunctioning of cytokinesis is a subtype of malfunctioning process: A process that cannot perform cytokinesis appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004884 inducible nitric oxide synthase production http://purl.obolibrary.org/obo/TXPO_0005048 enzyme production iNOS production is a subtype of protein production: A process that makes existent of iNOS ( inducible nitric oxide synthase) due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0004886 Decreasing miR-150 level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing miR-150 level is a subtype of decreasing quantity: A process that changes the amount of miR-150 level to be lower. http://purl.obolibrary.org/obo/TXPO_0004888 mitochondria morphology change http://purl.obolibrary.org/obo/TXPO_0000410 changing shape mitochondria morphology changes is a subtype of changing shape: A process that changes the morphology of the mitochondria. http://purl.obolibrary.org/obo/TXPO_0004890 proto-oncogene mutation http://purl.obolibrary.org/obo/TXPO_0001985 mutation Proto-oncogene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently. http://purl.obolibrary.org/obo/TXPO_0004891 7,12-dimethyltetraphene [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_254496 7,12-dimethyltetraphene A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke. http://purl.obolibrary.org/obo/TXPO_0004897 positive regulation of cancer stem cell division http://purl.obolibrary.org/obo/GO_0051781 positive regulation of cell division Any process that activates or increases the frequency, rate or extent of cancer stem cell division. http://purl.obolibrary.org/obo/TXPO_0004898 cancer stem-like cell proliferation http://purl.obolibrary.org/obo/GO_0008283 cell proliferation Cancer-stem like cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of cancer-stem like cells, resulting in the rapid expansion of a cancer-stem like cell population. http://purl.obolibrary.org/obo/TXPO_0004899 Cancer-stem like cell proliferation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Cancer-stem like cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of cancer-stem like cells, resulting in the rapid expansion of a cancer-stem like cell population. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004900 tumor suppressor inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation Tumor suppressor inactivation is a subtype of molecular inactivation: A process that changes the activity of the tumor suppressor to be lower. http://purl.obolibrary.org/obo/TXPO_0004901 Tumor suppressor inactivation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Tumor suppressor inactivation is a subtype of molecular inactivation: A process that changes the activity of the tumor suppressor to be lower. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004902 Tumor suppressor gene mutation http://purl.obolibrary.org/obo/TXPO_0001985 mutation Tumor suppressor gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Tumor suppressor gene randomly and permanently. http://purl.obolibrary.org/obo/TXPO_0004903 negative regulation of actin cytoskeleton organization http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of actin cytoskeleton organization is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of actin cytoskeleton organization. http://purl.obolibrary.org/obo/TXPO_0004904 acetyl-CoA biosynthetic process http://purl.obolibrary.org/obo/TXPO_0000019 generating substance acetyl-CoA biosynthetic process is a subtype of generating: A process that synthesizes acetyl-CoA resulting in having output (s). http://purl.obolibrary.org/obo/TXPO_0004905 decreasing adiponectin level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing adiponectin level is a subtype of decreasing quantity: A process that changes the amount of adiponectin level to be lower. http://purl.obolibrary.org/obo/TXPO_0004906 decreasing adiponectin level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Decreasing adiponectin level is a subtype of decreasing quantity: A process that changes the amount of adiponectin level to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004907 aflatoxin B1 [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_2504 aflatoxin B1 An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11. http://purl.obolibrary.org/obo/TXPO_0004908 aflatoxin metabolic process [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The chemical reactions and pathways involving aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004919 tumor cell survial [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004920 positive regulation of arachidonic acid metabolic process http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of arachidonic acid metabolic process. http://purl.obolibrary.org/obo/TXPO_0004921 Decreasing arachidonic acid level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing arachidonic acid level is a subtype of decreasing quantity: A process that changes the amount of arachidonic acid level to be lower. http://purl.obolibrary.org/obo/TXPO_0004922 aristolochic acid [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_2825 aristolochic acid A monocarboxylic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic. http://purl.obolibrary.org/obo/TXPO_0004923 alcohol intake [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process A moving process of alcohol from the outside to the inside of a body. This entity is a specific course dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004926 hypofunction of oxysterol biosynthesis http://purl.obolibrary.org/obo/TXPO_0002195 hypofunction of lipid biosynthesis Hypofunction of oxysterol biosynthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient oxysterol biosynthesis. http://purl.obolibrary.org/obo/TXPO_0004927 hypofunction of oxysterol biosynthesis [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Hypofunction of oxysterol biosynthesis is a subtype of hypofunction of lipid biosynthesis: A process that performs a decreased or insufficient oxysterol biosynthesis. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004928 autophagy [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorders. http://purl.obolibrary.org/obo/TXPO_0004929 autophagy [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004931 cardiolipin peroxidation http://purl.obolibrary.org/obo/TXPO_0004932 phospholipid peroxidation cardiolipin peroxidation is a subtype of phospholipid oxidation: The degradation of cardiolipin caused by an oxidative attack from free radicals. http://purl.obolibrary.org/obo/TXPO_0004932 phospholipid peroxidation http://purl.obolibrary.org/obo/TXPO_0003514 lipoperoxidation phospholipid peroxidation is a subtype of lipid oxidation: The degradation of phospholipids caused by an oxidative attack from free radicals. http://purl.obolibrary.org/obo/TXPO_0004933 negative regulation of phospholipid degradation [Phospholipidosis (latent)] http://purl.obolibrary.org/obo/TXPO_0000905 negative regulation of phospholipid degradation [Phospholipidosis] A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent). http://purl.obolibrary.org/obo/TXPO_0004935 Increasing glucagon level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing glucagon level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher. http://purl.obolibrary.org/obo/TXPO_0004936 Increasing glucagon level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing glucagon level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004937 glucose homeostasis imbalance [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Glucose homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a glucose homeostastasis balance. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004938 increasing glucose level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing glucose level is a subtype of increasing quantity: A process that changes the amount of glucose level to be higher. http://purl.obolibrary.org/obo/TXPO_0004939 increasing glucose level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing glucose level is a subtype of increasing quantity: A process that changes the amount of glucose level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004940 decreasing glucose level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing glucose level is a subtype of decreasing quantity: A process that changes the amount of glucose level to be lower. http://purl.obolibrary.org/obo/TXPO_0004941 Decreasing glucose level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Decreasing glucose level is a subtype of decreasing quantity: A process that changes the amount of glucose level to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004942 hyperfunction of gluconeogenesis http://purl.obolibrary.org/obo/TXPO_0002346 hyperfunction of biosynthesis Hyperfunction of gluconeogenesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive gluconeogenesis. http://purl.obolibrary.org/obo/TXPO_0004943 decreasing glutathione level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing glutathione level is a subtype of decreasing quantity: A process that changes the amount of glutathione level to be lower. http://purl.obolibrary.org/obo/TXPO_0004944 Negative regulation of glutathione transport http://purl.obolibrary.org/obo/TXPO_0002682 negative regulation of transport Negative regulation of glutathione transport is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/TXPO_0004945 Increasing ketone body level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing ketone body level is a subtype of increasing quantity: A process that changes the amount of ketone body level to be higher. http://purl.obolibrary.org/obo/TXPO_0004946 Increasing ketone body level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing ketone body level is a subtype of increasing quantity: A process that changes the amount of ketone body level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004947 induction of genomic instability http://purl.obolibrary.org/obo/TXPO_0001984 changing state Any process that results in induction of genomic instability. http://purl.obolibrary.org/obo/TXPO_0004949 Connexin signaling (primitive) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Connexin signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by connexin. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004952 negative regulation of connexin signaling [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of connexin signaling, a series of reactions mediated by connexin. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004954 Increasing cholesterol level http://purl.obolibrary.org/obo/TXPO_0001062 increasing lipid Increasing cholesterol level is a subtype of increasing quantity: A process that changes the amount of cholesterol level to be higher. http://purl.obolibrary.org/obo/TXPO_0004955 Increasing cholesterol level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing cholesterol level is a subtype of increasing quantity: A process that changes the amount of cholesterol level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004956 Increasing triol level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing triol level is a subtype of increasing quantity: A process that changes the amount of triol level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004957 cisplatin resistance http://purl.obolibrary.org/obo/TXPO_0004958 drug resistance cisplatin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to cisplatin to be lower. http://purl.obolibrary.org/obo/TXPO_0004958 drug resistance http://purl.obolibrary.org/obo/TXPO_0000157 decreasing sensitivity drug resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the drug to be lower. http://purl.obolibrary.org/obo/TXPO_0004959 diacylglycerol acumulation http://purl.obolibrary.org/obo/GO_0019915 lipid storage diacylglycerol accumulation is a subtype of accumulation of substances in a biological object: A process that keeps diacylglycerol in an organism, tissue, organelle, or cell. http://purl.obolibrary.org/obo/TXPO_0004960 diacylglycerol accumulation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process diacylglycerol accumulation is a subtype of accumulation of substances in a biological object: A process that keeps diacylglycerol in an organism, tissue, organelle, or cell. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004961 styrene oxide [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_17907 styrene oxide An epoxide that is oxirane in which one of the hydrogens has been replaced by a phenyl group. http://purl.obolibrary.org/obo/TXPO_0004962 Negative regulation of sphingolipid metabolic process http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of sphingolipid metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of sphingolipid metabolic process. http://purl.obolibrary.org/obo/TXPO_0004963 Negative regulation of sphingolipid metabolic process [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Negative regulation of sphingolipid metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of sphingolipid metabolic process. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004964 ceramide accumulation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004143 ceramide acumulation ceramide accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ceramide in an organism, tissue, organelle, or cell. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004965 sorafenib resistance (process) http://purl.obolibrary.org/obo/TXPO_0004958 drug resistance sorafenib resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to sorafenib to be lower. http://purl.obolibrary.org/obo/TXPO_0004966 Telomerase reverse transcriptase gene mutation http://purl.obolibrary.org/obo/TXPO_0001985 mutation Telomerase reverse transcriptase gene mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of Telomerase reverse transcriptase gene randomly and permanently. http://purl.obolibrary.org/obo/TXPO_0004968 Increasing triol level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing triol level is a subtype of increasing quantity: A process that changes the amount of triol level to be higher. http://purl.obolibrary.org/obo/TXPO_0004969 Methapyrilene hydrochloride [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_38213 Methapyrilene hydrochloride A hydrochloride that is the monohydrochloride salt of methapyrilene. http://purl.obolibrary.org/obo/TXPO_0004970 panadiplon http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Panadiplon (U-78875) is an anxiolytic drug with a novel chemical structure that is not closely related to other drugs of this type. (by Wikipedia) http://purl.obolibrary.org/obo/TXPO_0004971 pyrethrins [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_39098 pyrethrins The active insecticidal constituents of Chrysanthemum cinerariifolium flowers. http://purl.obolibrary.org/obo/TXPO_0004972 fialuridine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Fialuridine, or 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU), is a nucleoside analogue that was investigated as a potential therapy for hepatitis B virus infection. (by Wikipedia) http://purl.obolibrary.org/obo/TXPO_0004973 Increasing fructose level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing fructose level is a subtype of increasing quantity: A process that changes the amount of fructose level to be higher. http://purl.obolibrary.org/obo/TXPO_0004974 Increasing fructose level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing fructose level is a subtype of increasing quantity: A process that changes the amount of fructose level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004975 Hypofunction of mitochondrial repair [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Hypofunction of mitochondrial repair is a subtype of hypofunctioning: A process that performs a decreased or insufficient mitochondrial repair. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004976 Increasing uric acid level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing uric acid level is a subtype of increasing quantity: A process that changes the amount of uric acid level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004977 nagative regulation of mitophagy http://purl.obolibrary.org/obo/GO_1901524 regulation of mitophagy Any process that activates or decreases the frequency, rate or extent of mitophagy. http://purl.obolibrary.org/obo/TXPO_0004978 macrophage migration [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The orderly movement of a macrophage from one site to another. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004980 disruption of ER-mitochondria contact sites http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Disruption of ER-mitochondria contact sites is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ER-mitochondria contact site. http://purl.obolibrary.org/obo/TXPO_0004981 Disruption of ER-mitochondria contact sites [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Disruption of ER-mitochondria contact sites is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ER-mitochondria contact site. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004982 increasing mtDNA level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing mtDNA level is a subtype of decreasing quantity: A process that changes the amount of glycogen level to be higher. http://purl.obolibrary.org/obo/TXPO_0004983 glutathione transport from cytoplasm into mitochondria http://purl.obolibrary.org/obo/GO_0034635 glutathione transport glutathione transport from cytoplasm into mitochondria is a subtype of glutathione transport: A process that exports the glutathione from cytoplasm into mitochondria. http://purl.obolibrary.org/obo/TXPO_0004984 Negative regulation of glutathione transport into mitochondria http://purl.obolibrary.org/obo/TXPO_0004944 Negative regulation of glutathione transport Negative regulation of glutathione transport into mitochondria is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into mitochondria by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/TXPO_0004985 Negative regulation of glutathione transport into mitochondria [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Negative regulation of glutathione transport into mitochondria is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of glutathione into mitochondria by means of some agent such as a transporter or pore. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004986 long-chain fatty acid import into mitochondria http://purl.obolibrary.org/obo/GO_0015909 long-chain fatty acid transport The directed movement of long-chain fatty acids into a mitochondria. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22. http://purl.obolibrary.org/obo/TXPO_0004987 long-chain fatty acid import into mitochondria [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process The directed movement of long-chain fatty acids into a mitochondria. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004988 Hypofunction of mitochondrial repair http://purl.obolibrary.org/obo/TXPO_0000436 hypofunctioning Hypofunction of mitochondrial repair is a subtype of hypofunctioning: A process that performs a decreased or insufficient mitochondrial repair. http://purl.obolibrary.org/obo/TXPO_0004989 Increase in mitochondrial calcium level http://purl.obolibrary.org/obo/TXPO_0000353 increasing calcium ion concentration in blood Increase in mitochondrial calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a mitochondria to be higher. http://purl.obolibrary.org/obo/TXPO_0004990 Increase in mitochondrial calcium level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increase in mitochondrial calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a mitochondria to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004991 mitochondrial cholesterol storage http://purl.obolibrary.org/obo/GO_0010878 cholesterol storage Mitochondrial cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the mitochondria. http://purl.obolibrary.org/obo/TXPO_0004992 mitochondrial cholesterol storage [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Mitochondrial cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the mitochondria. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004993 Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation http://purl.obolibrary.org/obo/TXPO_0004994 negative regulation of phosphorylation Negative regulation of mitochondrial respiratory chain complex I subunit phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of mitochondrial respiratory chain complex I subunit phosphorylation. http://purl.obolibrary.org/obo/TXPO_0004994 negative regulation of phosphorylation http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of phosphorylation. http://purl.obolibrary.org/obo/TXPO_0004996 mitochondrial dysfunction [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002361 mitochondrial dysfunction Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function. This entity is a specific course-dependent process. This process can constitute the hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0004997 dysregulation of mitochondrion organization http://purl.obolibrary.org/obo/TXPO_0000532 malfunctioning of controlling Dysregulation of mitochondrion organization is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of mitochondrion organization appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0004998 mitochondrial membrane morphology changes http://purl.obolibrary.org/obo/TXPO_0004888 mitochondria morphology change mitochondrial membrane morphology changes is a subtype of mitochondria morphology changes: A process that changes the morphology of the mitochondrial membrane. http://purl.obolibrary.org/obo/TXPO_0004999 Increasing mitochondrial membrane potential http://purl.obolibrary.org/obo/TXPO_0005000 Increasing membrane potential Increasing mitochondrial membrane potential is a subtype of increasing membrane potential: A process that changes the electrical potential of a mitochondrial membrane to be higher. http://purl.obolibrary.org/obo/TXPO_0005000 Increasing membrane potential http://purl.obolibrary.org/obo/TXPO_0001456 changing membrane potential Increasing membrane potential is a subtype of changing membrane potential: A process that changes the electrical potential across a membrane to be higher. http://purl.obolibrary.org/obo/TXPO_0005001 metalloprotease activation http://purl.obolibrary.org/obo/TXPO_0000401 activating Metalloprotease activation is a subtype of activating: A process that changes the activity of the metalloprotease to be higher. http://purl.obolibrary.org/obo/TXPO_0005004 Negative regulation of methionine metabolic process http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of methionine metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of methionine metabolic process. http://purl.obolibrary.org/obo/TXPO_0005005 Negative regulation of methionine metabolic process [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Negative regulation of methionine metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of methionine metabolic process. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005008 Monuron [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_38214 Monuron A member of the class of phhenylureas that is urea in which one of the nitrogens is substituted by a p-chlorophenyl group while the other is substituted by two methyl groups. http://purl.obolibrary.org/obo/TXPO_0005009 phospholipid peroxidation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process phospholipid peroxidation is a subtype of lipid oxidation: The degradation of phospholipids caused by an oxidative attack from free radicals. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005010 lipoperoxidation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0003514 lipoperoxidation Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005011 redox change http://purl.obolibrary.org/obo/TXPO_0001984 changing state Any process that results in a change in state of redox. http://purl.obolibrary.org/obo/TXPO_0005012 increasing leptin level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing leptin level is a subtype of increasing quantity: A process that changes the amount of leptin level to be higher. http://purl.obolibrary.org/obo/TXPO_0005013 increasing leptin level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing leptin level is a subtype of increasing quantity: A process that changes the amount of glucagon level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005014 tumor malignancy alteration [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Tumor malignancy alteration is a subtype of changing quality of tumor: A process that changes the quality of the tumors to progress, invade surrounding tissues or metastasize. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005015 malfunctioning of centrosome duplication http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process Malfunctioning of centrosome duplication is a subtype of malfunctioning process: A process that cannot perform centrosome duplication appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0005017 hypoxia [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005018 dysregulation of immune balance http://purl.obolibrary.org/obo/TXPO_0000532 malfunctioning of controlling Dysregulation of immune balance is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of immune balance appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0005019 hypofunction of immune response to tumor cell [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Hypofunction of immune response to tumor cell is a subtype of hypofunctioning: A process that performs a decreased or insufficient immune response to tumor cell. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005020 regulatory T cell migration http://purl.obolibrary.org/obo/GO_0050900 leukocyte migration The orderly movement of a regulatory T cell from one site to another. http://purl.obolibrary.org/obo/TXPO_0005021 protooncogene activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation protooncogene activation is a subtype of molecular activation: A process that changes the activity of the protooncogene to be higher. http://purl.obolibrary.org/obo/TXPO_0005022 protooncogene activation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Protooncogene activation is a subtype of molecular activation: A process that changes the activity of the protooncogene to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005023 increasing production amount of reactive aldehyde http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing production amount of reactive aldehyde is a subtype of increasing quantity: A process that changes the production amount of reactive aldehyde to be higher. http://purl.obolibrary.org/obo/TXPO_0005025 4-hydroxynonenal [mitochondrial disorder] http://purl.obolibrary.org/obo/CHEBI_142593 4-hydroxynonenal A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group. http://purl.obolibrary.org/obo/TXPO_0005026 response to endoplasmic reticulum stress [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005027 Increasing uric acid level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing uric acid level is a subtype of increasing quantity: A process that changes the amount of uric acid level to be higher. http://purl.obolibrary.org/obo/TXPO_0005028 hypofunction of immune response to tumor cell http://purl.obolibrary.org/obo/TXPO_0000436 hypofunctioning Hypofunction of immune response to tumor cell is a subtype of hypofunctioning: A process that performs a decreased or insufficient immune response to tumor cell. http://purl.obolibrary.org/obo/TXPO_0005029 negative regulation of antioxidant enzyme activation http://purl.obolibrary.org/obo/TXPO_0001787 negative regulation of enzyme activation Negative regulation of antioxidant enzyme activation is a subtype of Negative regulation of enzyme activation: A process that stops, prevents, or reduces the frequency, rate or extent of antioxidant enzyme activation. http://purl.obolibrary.org/obo/TXPO_0005030 increasing damaged mitochondria http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing damaged mitochondria is a subtype of decreasing quantity: A process that changes the amount of damaged mitochondria to be higher. http://purl.obolibrary.org/obo/TXPO_0005031 release of inflammatory DAMPs [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005139 release of inflammatory DAMPs The process that results in the movement of inflammatory DAMPs from the mitochondria. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005032 negative regulation of ROS formation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ROS. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005033 malfunctioning of cytokinesis http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process Malfunctioning of cytokinesis is a subtype of malfunctioning process: A process that cannot perform cytokinesis appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0005034 increasing blood glucose level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing blood glucose level is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005035 cellular damage [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005036 nodule formation [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process The process in which the anatomical structures of the nodule are generated and organized. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005037 hepatocyte regeneration http://purl.obolibrary.org/obo/GO_0042246 tissue regeneration Hepatocyte regeneration is a subtype of changing material: The regrowth of lost or destroyed hepatocytes. http://purl.obolibrary.org/obo/TXPO_0005038 Increasing lipid [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process Increasing lipid is a subtype of increasing quantity: A process that changes the amount of lipid to be larger. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005039 increasing lipid concentration [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing lipid concentration in blood is a subtype of increasing concentration: A process that changes the lipid concentration in the blood to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005040 tumor malignancy alteration http://purl.obolibrary.org/obo/TXPO_0005141 changing quality of tumor Tumor malignancy alteration is a subtype of changing quality of tumor: A process that changes the quality of the tumors to progress, invade surrounding tissues or metastasize. http://purl.obolibrary.org/obo/TXPO_0005041 increased membrane potential http://purl.obolibrary.org/obo/PATO_0001462 membrane potential A mebrane potential which is relatively high. http://purl.obolibrary.org/obo/TXPO_0005042 Increasing cholesterol concentration in blood http://purl.obolibrary.org/obo/TXPO_0005043 increasing lipid concentration Increasing cholesterol concentration in blood is a subtype of increasing lipid concentration in blood: A process that changes the cholesterol concentration in the blood to be higher. http://purl.obolibrary.org/obo/TXPO_0005043 increasing lipid concentration http://purl.obolibrary.org/obo/TXPO_0000352 increasing concentration Increasing lipid concentration in blood is a subtype of increasing concentration: A process that changes the lipid concentration in the blood to be higher. http://purl.obolibrary.org/obo/TXPO_0005044 Increasing cholesterol concentration in blood [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing cholesterol concentration in blood is a subtype of increasing lipid concentration in blood: A process that changes the cholesterol concentration in the blood to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005045 endothelial progenitor cell mobilization http://purl.obolibrary.org/obo/GO_0016477 cell migration The movement of an endothelial progenitor cell (EPC) within or between different tissues and organs of the body. http://purl.obolibrary.org/obo/TXPO_0005046 neovascularization http://purl.obolibrary.org/obo/TXPO_0000134 biological structure formation neovascularization is a subtype of biological structure formation: A process that constructs an alternate blood vessels. http://purl.obolibrary.org/obo/TXPO_0005048 enzyme production http://purl.obolibrary.org/obo/TXPO_0000382 protein production Enzyme production is a subtype of protein production: A process that makes existent of enzyme due to biosynthesis, secretion, or membrane trafficking, resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0005050 iron metabolic dysfunction http://purl.obolibrary.org/obo/TXPO_0002131 metabolic dysfunction iron metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function. http://purl.obolibrary.org/obo/TXPO_0005051 iron metabolic dysfunction [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0002340 liver carcinogenesis dependent process iron metabolic dysfunction is a subtype of Metabolic dysfunctioning: A process that performs an abnormal and incomplete energy metabolic function. This entity is a specific course-dependent process. This process can constitute the course of hepatocarcinogenesis. http://purl.obolibrary.org/obo/TXPO_0005052 Increasing iron uptake level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing iron uptake level is a subtype of increasing quantity: A process that changes the iron uptake level to be larger. http://purl.obolibrary.org/obo/TXPO_0005053 hypofunction of heme biosynthesis http://purl.obolibrary.org/obo/TXPO_0001910 hypofunction of biosynthesis Hypofunction of heme biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient heme biosynthesis. http://purl.obolibrary.org/obo/TXPO_0005054 Increasing long-chain free fatty acid level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing long-chain free fatty acid level is a subtype of increasing quantity: A process that changes the amount of long-chain free fatty acid level to be higher. http://purl.obolibrary.org/obo/TXPO_0005055 Increasing long-chain free fatty acid level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing long-chain free fatty acid level is a subtype of increasing quantity: A process that changes the amount of long-chain free fatty acid level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005056 increasing saturated fatty acid level http://purl.obolibrary.org/obo/TXPO_0001062 increasing lipid Increasing saturated fatty acid level is a subtype of increasing quantity: A process that changes the amount of saturated fatty acid level to be higher. http://purl.obolibrary.org/obo/TXPO_0005057 Increasing saturated fatty acid level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing saturated fatty acid level is a subtype of increasing quantity: A process that changes the amount of saturated fatty acid level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005059 hypofunction of phospholipid degradation [Phospholipidosis(latent)] http://purl.obolibrary.org/obo/TXPO_0000925 hypofunction of phospholipid degradation [Phospholipidosis] Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent). http://purl.obolibrary.org/obo/TXPO_0005060 1,2-dichloropropane [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_142468 1,2-dichloropropane A chloroalkane that is propane in which a hydrogen from each of two adjacent carbons has been replaced by chlorines. http://purl.obolibrary.org/obo/TXPO_0005061 Hypofunction of 17β-Estradiol metabolic process http://purl.obolibrary.org/obo/TXPO_0001375 hypofunction of hormone metabolic process Hypofunction of 17β-Estradiol metabolic process is a subtype of hypofunction of metabolism: A process that performs a decreased or insufficient 17β-Estradiol metabolic process. http://purl.obolibrary.org/obo/TXPO_0005063 liver cancer dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0000837 liver cancer dependent molecule Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of Liver cancer as a gene product. Gene profile:canonical/in vitro/Hepatocyte/ http://purl.obolibrary.org/obo/TXPO_0005064 AGGF1 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by AGGF1 (angiogenic factor with G-patch and FHA domains 1). http://purl.obolibrary.org/obo/TXPO_0005065 AGGF1 signal (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) AGGF1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by AGGF1. http://purl.obolibrary.org/obo/TXPO_0005070 liver cancer dependent molecule (rat) http://purl.obolibrary.org/obo/TXPO_0000837 liver cancer dependent molecule Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of Liver cancer as a gene product. Gene profile:Mouse http://purl.obolibrary.org/obo/TXPO_0005072 liver cancer dependent molecule (mouse in vitro) http://purl.obolibrary.org/obo/TXPO_0000837 liver cancer dependent molecule Liver cancer dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of Liver cancer as a gene product. Gene profile:Mouse http://purl.obolibrary.org/obo/CHEBI_25512 neurotransmitter http://purl.obolibrary.org/obo/CHEBI_33280 molecular messenger An endogenous compound that is used to transmit information across the synapse between a neuron and another cell. http://purl.obolibrary.org/obo/CHEBI_26347 prostanoid http://purl.obolibrary.org/obo/CHEBI_23899 icosanoid The family of natural prostaglandins and prostaglandin-like compounds. http://purl.obolibrary.org/obo/CHEBI_28494 cardiolipin http://purl.obolibrary.org/obo/CHEBI_37739 glycerophospholipid A phosphatidylglycerol composed of two molecules of phosphatidic acid covalently linked to a molecule of glycerol. http://purl.obolibrary.org/obo/CHEBI_35341 steroid http://purl.obolibrary.org/obo/CHEBI_18059 lipid Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from triterpenoids. http://purl.obolibrary.org/obo/CHEBI_35444 antinematodal drug http://purl.obolibrary.org/obo/CHEBI_35443 anthelminthic drug A substance used in the treatment or control of nematode infestations. http://purl.obolibrary.org/obo/CHEBI_35469 antidepressant http://purl.obolibrary.org/obo/CHEBI_35471 psychotropic drug Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. http://purl.obolibrary.org/obo/CHEBI_49201 anti-ulcer drug http://purl.obolibrary.org/obo/CHEBI_23888 drug One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract. http://purl.obolibrary.org/obo/CHEBI_50902 genotoxin http://purl.obolibrary.org/obo/TXPO_0000038 toxic agent A role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells. http://purl.obolibrary.org/obo/CHEBI_50904 allergen http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy. http://purl.obolibrary.org/obo/CHEBI_55324 gastrointestinal drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion. http://purl.obolibrary.org/obo/CHEBI_64915 antiplasmodial drug http://purl.obolibrary.org/obo/CHEBI_35442 antiparasitic agent An antiparasitic drug which is effective against Apicomplexan parasites in the genus Plasmodium. The genus contains over 200 species and includes those responsible for malaria. http://purl.obolibrary.org/obo/CHEBI_76967 human xenobiotic metabolite http://purl.obolibrary.org/obo/CHEBI_77746 human metabolite Any human metabolite produced by metabolism of a xenobiotic compound in humans. http://purl.obolibrary.org/obo/CHEBI_83056 Daphnia magna metabolite http://purl.obolibrary.org/obo/CHEBI_83057 Daphnia metabolite A Daphnia metabolite produced by the species Daphnia magna. http://purl.obolibrary.org/obo/CHEBI_114785 erlotinib http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions. http://purl.obolibrary.org/obo/CHEBI_116225 nomifensine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively. http://purl.obolibrary.org/obo/CHEBI_17263 estrone http://purl.obolibrary.org/obo/CHEBI_35341 steroid An estrogen that has formula C18H22O2. http://purl.obolibrary.org/obo/CHEBI_17356 2-acetamidofluorene http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity The parent of the class of 2-acetamidofluorenes, being an ortho-fused polycyclic arene that consists of 9H-fluorene bearing an acetamido substituent at position 2. It is a carcinogenic and mutagenic derivative of fluorene. http://purl.obolibrary.org/obo/CHEBI_33231 antitubercular agent http://purl.obolibrary.org/obo/CHEBI_64912 antimycobacterial drug A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis. http://purl.obolibrary.org/obo/CHEBI_3387 carbamazepine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant. http://purl.obolibrary.org/obo/CHEBI_37699 protein kinase inhibitor http://purl.obolibrary.org/obo/CHEBI_76668 EC 2.7.* (P-containing group transferase) inhibitor An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of protein kinases. http://purl.obolibrary.org/obo/CHEBI_39867 valproic acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem. http://purl.obolibrary.org/obo/CHEBI_47868 photosensitizing agent http://purl.obolibrary.org/obo/CHEBI_23888 drug A chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells. http://purl.obolibrary.org/obo/CHEBI_51039 dopamine uptake inhibitor http://purl.obolibrary.org/obo/CHEBI_48560 dopaminergic agent A dopaminergic agent that blocks the transport of dopamine into axon terminals or into storage vesicles within terminals. Most of the adrenergic uptake inhibitors also inhibit dopamine uptake. http://purl.obolibrary.org/obo/CHEBI_68494 apoptosis inhibitor http://purl.obolibrary.org/obo/TXPO_0000327 apoptosis regulator role Any substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms. http://purl.obolibrary.org/obo/CHEBI_6916 mexiletine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol. http://purl.obolibrary.org/obo/CHEBI_132742 lysophosphatidic acid http://purl.obolibrary.org/obo/CHEBI_32957 lysophosphatidic acids A member of the class of lysophosphatidic acids obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid. A 'closed' class. http://purl.obolibrary.org/obo/CHEBI_132933 intermediate-density lipoprotein http://purl.obolibrary.org/obo/CHEBI_6495 lipoprotein A class of lipoproteins with a density between that of low-density and very-low-density lipoproteins. They are formed by the degradatiion of very-low-density lipoproteins. http://purl.obolibrary.org/obo/CHEBI_16337 phosphatidic acid http://purl.obolibrary.org/obo/CHEBI_37739 glycerophospholipid A derivative of glycerol in which one hydroxy group, commonly but not necessarily primary, is esterified with phosphoric acid and the other two are esterified with fatty acids. http://purl.obolibrary.org/obo/CHEBI_16761 AMP http://purl.obolibrary.org/obo/CHEBI_36976 nucleotide A purine ribonucleoside 5'-diphosphate having adenine as the nucleobase. http://purl.obolibrary.org/obo/CHEBI_17347 testosterone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. http://purl.obolibrary.org/obo/CHEBI_17361 CMP http://purl.obolibrary.org/obo/TXPO_0002623 nucleoside phosphate A cytidine 5'-phosphate that has formula C9H14N3O8P. http://purl.obolibrary.org/obo/CHEBI_17517 phosphatidylglycerol http://purl.obolibrary.org/obo/CHEBI_24360 glycerophosphoglycerols A glycerophosphoglycerol that is glycerol in which the hydrogen of one of the primary hydroxy groups has been replaced by a phosphatidyl group. http://purl.obolibrary.org/obo/CHEBI_17855 triglyceride http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Any glyceride resulting from the condensation of all three hydroxy groups of glycerol (propane-1,2,3-triol) with fatty acids. http://purl.obolibrary.org/obo/CHEBI_18059 lipid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity 'Lipids' is a loosely defined term for substances of biological origin that are soluble in nonpolar solvents. They consist of saponifiable lipids, such as glycerides (fats and oils) and phospholipids, as well as nonsaponifiable lipids, principally steroids. http://purl.obolibrary.org/obo/CHEBI_22333 alkylating agent http://purl.obolibrary.org/obo/TXPO_0001316 role related to molecular change Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases. http://purl.obolibrary.org/obo/CHEBI_23357 cofactor http://purl.obolibrary.org/obo/TXPO_0003732 molecular (activity) co-regulator An organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group). http://purl.obolibrary.org/obo/CHEBI_24852 insecticide http://purl.obolibrary.org/obo/CHEBI_25944 pesticide Strictly, a substance intended to kill members of the class Insecta. In common usage, any substance used for preventing, destroying, repelling or controlling insects. http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/CHEBI_23367 molecular entity Any polyatomic entity that is an electrically neutral entity consisting of more than one atom. http://purl.obolibrary.org/obo/CHEBI_25491 nematicide http://purl.obolibrary.org/obo/CHEBI_25944 pesticide A substance used to destroy pests of the phylum Nematoda (roundworms). http://purl.obolibrary.org/obo/CHEBI_26607 saturated fatty acid http://purl.obolibrary.org/obo/CHEBI_18059 lipid Any fatty acid containing no carbon to carbon multiple bonds. Known to produce adverse biological effects when ingested to excess. http://purl.obolibrary.org/obo/CHEBI_27026 toxin http://purl.obolibrary.org/obo/CHEBI_64909 poison Poisonous substance produced by a biological organism such as a microbe, animal or plant. http://purl.obolibrary.org/obo/CHEBI_2825 aristolochic acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic. http://purl.obolibrary.org/obo/CHEBI_32957 lysophosphatidic acids http://purl.obolibrary.org/obo/CHEBI_16961 monoacylglycerol phosphate Any monoacylglycerol phosphate obtained by hydrolytic removal of one of the two acyl groups of any phosphatidic acid or derivatives therein. http://purl.obolibrary.org/obo/CHEBI_33184 long-chain fatty acyl-CoA http://purl.obolibrary.org/obo/CHEBI_37554 fatty acyl-CoA A fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any long-chain (C13 to C22) fatty acid. http://purl.obolibrary.org/obo/CHEBI_35222 inhibitor http://purl.obolibrary.org/obo/TXPO_0003710 regulator role A substance that diminishes the rate of a chemical reaction. http://purl.obolibrary.org/obo/CHEBI_35223 catalyst http://purl.obolibrary.org/obo/CHEBI_51086 chemical role A substance that increases the rate of a reaction without modifying the overall standard Gibbs energy change in the reaction. http://purl.obolibrary.org/obo/CHEBI_35337 central nervous system stimulant http://purl.obolibrary.org/obo/CHEBI_35470 central nervous system drug Any drug that enhances the activity of the central nervous system. http://purl.obolibrary.org/obo/CHEBI_35493 antipyretic http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug that prevents or reduces fever by lowering the body temperature from a raised state. An antipyretic will not affect the normal body temperature if one does not have fever. Antipyretics cause the hypothalamus to override an interleukin-induced increase in temperature. The body will then work to lower the temperature and the result is a reduction in fever. http://purl.obolibrary.org/obo/CHEBI_35497 androgen antagonist http://purl.obolibrary.org/obo/CHEBI_49020 hormone antagonist A compound which inhibits or antagonises the biosynthesis or actions of androgens. http://purl.obolibrary.org/obo/CHEBI_35526 hypoglycemic agent http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug which lowers the blood glucose level. http://purl.obolibrary.org/obo/CHEBI_35530 beta-adrenergic antagonist http://purl.obolibrary.org/obo/CHEBI_48540 beta-adrenergic drug An agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety. http://purl.obolibrary.org/obo/CHEBI_35705 immunosuppressive agent http://purl.obolibrary.org/obo/CHEBI_50846 immunomodulator An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. http://purl.obolibrary.org/obo/CHEBI_35856 lipoxygenase inhibitor http://purl.obolibrary.org/obo/CHEBI_76837 EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitor A compound or agent that combines with lipoxygenase and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of the icosanoid products hydroxyicosatetraenoic acid and various leukotrienes. http://purl.obolibrary.org/obo/CHEBI_36335 trypanocidal drug http://purl.obolibrary.org/obo/CHEBI_35820 antiprotozoal drug A drug used to treat or prevent infections caused by protozoal organisms belonging to the suborder Trypanosomatida. http://purl.obolibrary.org/obo/CHEBI_36976 nucleotide http://purl.obolibrary.org/obo/IMR_0001698 glycoside A nucleotide is a nucleoside phosphate resulting from the condensation of the 3 or 5 hydroxy group of a nucleoside with phosphoric acid. http://purl.obolibrary.org/obo/CHEBI_38161 chelator http://purl.obolibrary.org/obo/CHEBI_52214 ligand A ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate. http://purl.obolibrary.org/obo/CHEBI_38234 DNA polymerase inhibitor http://purl.obolibrary.org/obo/CHEBI_76815 EC 2.7.7.* (nucleotidyltransferase) inhibitor Any inhibitor of a DNA polymerase. http://purl.obolibrary.org/obo/CHEBI_38462 acetylcholinesterase inhibitor role http://purl.obolibrary.org/obo/CHEBI_76759 EC 3.* (hydrolase) inhibitor An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of enzyme acetylcholinesterase (EC 3.1.1.7), which helps breaking down of acetylcholine into choline and acetic acid. http://purl.obolibrary.org/obo/CHEBI_38633 sodium channel blocker http://purl.obolibrary.org/obo/CHEBI_39000 sodium channel modulator An agent that inhibits sodium influx through cell membranes. http://purl.obolibrary.org/obo/CHEBI_48578 radical scavenger http://purl.obolibrary.org/obo/CHEBI_22586 antioxidant A role played by a substance that can react readily with, and thereby eliminate, radicals. http://purl.obolibrary.org/obo/CHEBI_48705 agonist http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role Substance which binds to cell receptors normally responding to naturally occurring substances and which produces a response of its own. http://purl.obolibrary.org/obo/CHEBI_50177 dermatologic drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug used to treat or prevent skin disorders or for the routine care of skin. http://purl.obolibrary.org/obo/CHEBI_50266 prodrug http://purl.obolibrary.org/obo/CHEBI_23888 drug A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. http://purl.obolibrary.org/obo/CHEBI_50427 platelet aggregation inhibitor http://purl.obolibrary.org/obo/CHEBI_50248 hematologic agent A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. http://purl.obolibrary.org/obo/CHEBI_50683 EC 1.5.1.3 (dihydrofolate reductase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76863 EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor An EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of dihydrofolate reductase (EC 1.5.1.3). http://purl.obolibrary.org/obo/CHEBI_50751 anti-estrogen http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug which acts to reduce estrogenic activity in the body, either by reducing the amount of estrogen or by reducing the activity of whatever estrogen is present. http://purl.obolibrary.org/obo/CHEBI_50857 anti-allergic agent http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug used to treat allergic reactions. http://purl.obolibrary.org/obo/CHEBI_51372 neuromuscular agent http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug used for its actions on skeletal muscle. http://purl.obolibrary.org/obo/CHEBI_52206 biochemical role http://purl.obolibrary.org/obo/CHEBI_24432 biological role A biological role played by the molecular entity or part thereof within a biochemical context. http://purl.obolibrary.org/obo/CHEBI_52217 pharmaceutical http://purl.obolibrary.org/obo/BFO_0000023 role Any substance introduced into a living organism with therapeutic or diagnostic purpose. http://purl.obolibrary.org/obo/CHEBI_52290 mitogen http://purl.obolibrary.org/obo/CHEBI_24432 biological role A chemical substance that encourages a cell to commence cell division, triggering mitosis. http://purl.obolibrary.org/obo/CHEBI_52424 EC 3.2.1.* (glycosidase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76761 EC 3.2.* (glycosylase) inhibitor An EC 3.2.* (glycosylase) inhibitor that interferes with the action of any glycosidase (i.e. enzymes hydrolysing O- and S-glycosyl compounds, EC 3.2.1.*). http://purl.obolibrary.org/obo/CHEBI_5855 ibuprofen http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group. http://purl.obolibrary.org/obo/CHEBI_61697 fatty acid derivative http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Any organic molecular entity derived from a fatty acid. http://purl.obolibrary.org/obo/CHEBI_62434 EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor http://purl.obolibrary.org/obo/CHEBI_38637 tyrosine kinase inhibitor An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1). http://purl.obolibrary.org/obo/CHEBI_62872 EC 1.2.3.1 (aldehyde oxidase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76853 EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor An EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor which interferes with the action of aldehyde oxidase (EC 1.2.3.1). http://purl.obolibrary.org/obo/CHEBI_64909 poison http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role Any substance that causes disturbance to organisms by chemical reaction or other activity on the molecular scale, when a sufficient quantity is absorbed by the organism. http://purl.obolibrary.org/obo/CHEBI_64947 anti-HIV-1 agent http://purl.obolibrary.org/obo/CHEBI_64946 anti-HIV agent An anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus. http://purl.obolibrary.org/obo/CHEBI_6495 lipoprotein http://purl.obolibrary.org/obo/CHEBI_33694 biomacromolecule A clathrate complex consisting of a lipid enwrapped in a protein host without covalent binding in such a way that the complex has a hydrophilic outer surface consisting of all the protein and the polar ends of any phospholipids. http://purl.obolibrary.org/obo/CHEBI_65259 GABA antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist A compound that inhibits the action of gamma-aminobutyric acid. http://purl.obolibrary.org/obo/CHEBI_67114 ryanodine receptor agonist http://purl.obolibrary.org/obo/CHEBI_38809 ryanodine receptor modulator A ryanodine receptor modulator which activates the receptor. Ryanodine receptors (RyRs) act as selective ion channels, modulating the release of calcium. Activating the receptors causes the release of calcium, so depleting internal calcium and ultimately preventing further muscle contraction. http://purl.obolibrary.org/obo/CHEBI_67239 EC 3.2.1.20 (alpha-glucosidase) inhibitor http://purl.obolibrary.org/obo/CHEBI_52424 EC 3.2.1.* (glycosidase) inhibitor An EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-glucosidase (EC 3.2.1.20). http://purl.obolibrary.org/obo/CHEBI_70727 topoisomerase inhibitor http://purl.obolibrary.org/obo/CHEBI_76830 EC 5.99.1.* (miscellaneous isomerase) inhibitor An EC 5.99.1.* (miscellaneous isomerase) inhibitor that interferes with the action of any of the topoisomerases (enzymes that regulate the overwinding or underwinding of DNA). http://purl.obolibrary.org/obo/CHEBI_70782 PPARalpha agonist http://purl.obolibrary.org/obo/CHEBI_48705 agonist A PPAR modulator which activates the peroxisome proliferator-activated receptor-alpha. http://purl.obolibrary.org/obo/CHEBI_73216 EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor http://purl.obolibrary.org/obo/CHEBI_76759 EC 3.* (hydrolase) inhibitor Any hydrolase inhibitor that interferes with the action of a hydrolase which acts on acid anhydrides (EC 3.6.*.*). http://purl.obolibrary.org/obo/CHEBI_73240 NF-kappaB inhibitor http://purl.obolibrary.org/obo/TXPO_0003711 molecular inhibitor An inhibitor of NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells), a protein complex involved in the transcription of DNA. http://purl.obolibrary.org/obo/CHEBI_74440 epidermal growth factor receptor antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist An antagonist at the epidermal growth factor receptor. http://purl.obolibrary.org/obo/CHEBI_74518 anti-obesity agent http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role Any substance which is used to reduce or control weight. http://purl.obolibrary.org/obo/CHEBI_75768 mammalian metabolite http://purl.obolibrary.org/obo/CHEBI_75767 animal metabolite Any animal metabolite produced during a metabolic reaction in mammals. http://purl.obolibrary.org/obo/CHEBI_76811 sphingomyelin phosphodiesterase inhibitor role http://purl.obolibrary.org/obo/TXPO_0000559 phospholipase inhibitor role An EC 3.1.4.* (phosphoric diester hydrolase) inhibitor that interferes with the action of sphingomyelin phosphodiesterase (EC 3.1.4.12). http://purl.obolibrary.org/obo/CHEBI_76812 EC 2.7.11.* (protein-serine/threonine kinase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76668 EC 2.7.* (P-containing group transferase) inhibitor An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any protein-serine/threonine kinase (EC 2.7.11.*). http://purl.obolibrary.org/obo/CHEBI_76837 EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitor http://purl.obolibrary.org/obo/CHEBI_76740 EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor An EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor that inhibits the action of any oxidoreductase incorporating 2 atoms of oxygen (EC 1.13.11.*). http://purl.obolibrary.org/obo/CHEBI_76895 EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor http://purl.obolibrary.org/obo/CHEBI_73216 EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor An EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor that interferes with the action of any such enzyme that catalyses transmembrane movement of substances (EC 3.6.3.*). http://purl.obolibrary.org/obo/CHEBI_77748 EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76895 EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of xenobiotic-transporting ATPase (EC 3.6.3.44). http://purl.obolibrary.org/obo/CHEBI_83039 crustacean metabolite http://purl.obolibrary.org/obo/CHEBI_75767 animal metabolite An animal metabolite produced by arthropods such as crabs, lobsters, crayfish, shrimps and krill. http://purl.obolibrary.org/obo/CHEBI_86327 antifungal drug http://purl.obolibrary.org/obo/CHEBI_35718 antifungal agent Any antifungal agent used to prevent or treat fungal infections in humans or animals. http://purl.obolibrary.org/obo/CHEBI_86328 antifungal agrochemical http://purl.obolibrary.org/obo/CHEBI_25944 pesticide Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. http://purl.obolibrary.org/obo/CHEBI_90454 lysophosphatidylglycerol http://purl.obolibrary.org/obo/CHEBI_24360 glycerophosphoglycerols A glycerophosphoglycerol resulting from partial hydrolysis of a phosphatidylglycerol, which removes one of the fatty acid groups. The structure is depicted in the image where R1 = acyl, R2 = H or where R1 = H, R2 = acyl. http://purl.obolibrary.org/obo/CHEBI_20854 ATP synthase inhibitor (mitochondrial respiratory-chain inhibitor) http://purl.obolibrary.org/obo/CHEBI_25355 mitochondrial respiratory-chain inhibitor A mitochondrial respiratory-chain inhibitor that interferes with the action of ATP synthase. http://purl.obolibrary.org/obo/CHEBI_22271 aflatoxin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Any of a group of related and highly toxic secondary metabolites (mycotoxins) whose main structural feature is a fused coumarin-bis(dihydrofuran) ring system and which are produced by strains of the moulds Aspergillus flavus or A. parasiticus, together with further metabolites of these mycotoxins. http://purl.obolibrary.org/obo/CHEBI_22563 anion http://purl.obolibrary.org/obo/CHEBI_24870 ion A monoatomic or polyatomic species having one or more elementary charges of the electron. http://purl.obolibrary.org/obo/CHEBI_23092 chemosterilant http://purl.obolibrary.org/obo/CHEBI_25944 pesticide A substance intended to sterilize any organism. http://purl.obolibrary.org/obo/CHEBI_23367 molecular entity http://purl.obolibrary.org/obo/CHEBI_24431 chemical entity Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity. http://purl.obolibrary.org/obo/CHEBI_2376 acarbose http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A tetrasaccharide derivative consisting of a dideoxy-4-{[4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl C7 cyclitol moiety [called valienol (or valienamine)] linked via nitrogen to isomaltotriose. http://purl.obolibrary.org/obo/CHEBI_23995 N-ethyl-N-nitrosourea http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups. http://purl.obolibrary.org/obo/CHEBI_240107 bromfenac http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure. http://purl.obolibrary.org/obo/CHEBI_24431 chemical entity http://purl.obolibrary.org/obo/BFO_0000030 object A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances. http://purl.obolibrary.org/obo/CHEBI_24432 biological role http://purl.obolibrary.org/obo/BFO_0000023 role A role played by the molecular entity or part thereof within a biological context. http://purl.obolibrary.org/obo/CHEBI_24636 proton http://purl.obolibrary.org/obo/CHEBI_23367 molecular entity Nuclear particle of charge number +1, spin 1/2 and rest mass of 1.007276470(12) u. http://purl.obolibrary.org/obo/CHEBI_24870 ion http://purl.obolibrary.org/obo/CHEBI_23367 molecular entity A molecular entity having a net electric charge. http://purl.obolibrary.org/obo/CHEBI_2504 aflatoxin B1 http://purl.obolibrary.org/obo/CHEBI_22271 aflatoxin An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11. http://purl.obolibrary.org/obo/CHEBI_254496 7,12-dimethyltetraphene http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke. http://purl.obolibrary.org/obo/CHEBI_25710 organophosphorus compound http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An organophosphorus compound is formally a compound containing at least one carbon-phosphorus bond, but the term is often extended to include esters and thioesters. http://purl.obolibrary.org/obo/CHEBI_25944 pesticide http://purl.obolibrary.org/obo/BFO_0000023 role Strictly, a substance intended to kill pests. In common usage, any substance used for controlling, preventing, or destroying animal, microbiological or plant pests. http://purl.obolibrary.org/obo/CHEBI_26519 radical http://purl.obolibrary.org/obo/CHEBI_23367 molecular entity A molecular entity possessing an unpaired electron. http://purl.obolibrary.org/obo/CHEBI_2663 amiodarone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. http://purl.obolibrary.org/obo/CHEBI_2666 amitriptyline http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5. http://purl.obolibrary.org/obo/CHEBI_27385 tetrachloromethane http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups. http://purl.obolibrary.org/obo/CHEBI_27779 griseofulvin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment. http://purl.obolibrary.org/obo/CHEBI_28087 glycogen http://purl.obolibrary.org/obo/CHEBI_18154 polysaccharide A polydisperse, highly branched glucan composed of chains of D-glucopyranose residues in alpha(1->4) glycosidic linkage, joined together by alpha(1->6) glycosidic linkages. A small number of alpha(1->3) glycosidic linkages and some cumulative alpha(1->6) links also may occur. The branches in glycogen typically contain 8 to 12 glucose residues. http://purl.obolibrary.org/obo/CHEBI_28241 papaverine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum. http://purl.obolibrary.org/obo/CHEBI_28680 cytarabine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A pyrimidine nucleoside in which cytosine is attached to D-arabinofuranose via a beta-N(1)-glycosidic bond. Used mainly in the treatment of leukaemia, especially acute non-lymphoblastic leukaemia, cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It also has antiviral and immunosuppressant properties. http://purl.obolibrary.org/obo/CHEBI_28765 phosphatidylinositol phosphate http://purl.obolibrary.org/obo/CHEBI_18179 phosphoinositide Any member of the phosphoinositide family of compounds, of which seven occur naturally. http://purl.obolibrary.org/obo/CHEBI_33250 atom http://purl.obolibrary.org/obo/CHEBI_24431 chemical entity A chemical entity constituting the smallest component of an element having the chemical properties of the element. http://purl.obolibrary.org/obo/CHEBI_35942 neurotransmitter agent http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role A substance used for its pharmacological action on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. http://purl.obolibrary.org/obo/CHEBI_36357 polyatomic entity http://purl.obolibrary.org/obo/CHEBI_23367 molecular entity Any molecular entity consisting of more than one atom. http://purl.obolibrary.org/obo/CHEBI_36386 dichloroacetic acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An organochlorine compound comprising acetic acid carrying two chloro substituents at the 2-position. It occurs in nature in seaweed, Asparagopsis taxiformis. http://purl.obolibrary.org/obo/CHEBI_37550 sphingosine-1-phosphate http://purl.obolibrary.org/obo/CHEBI_35786 phosphosphingolipid A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1 http://purl.obolibrary.org/obo/CHEBI_37554 fatty acyl-CoA http://purl.obolibrary.org/obo/CHEBI_61697 fatty acid derivative An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any fatty acid. http://purl.obolibrary.org/obo/CHEBI_37670 protease inhibitor http://purl.obolibrary.org/obo/CHEBI_60258 EC 3.4.* (hydrolases acting on peptide bond) inhibitor A compound which inhibits or antagonizes the biosynthesis or actions of proteases (endopeptidases). http://purl.obolibrary.org/obo/CHEBI_38496 electron-transport chain inhibitor http://purl.obolibrary.org/obo/CHEBI_76932 pathway inhibitor A role played by the entity that inhibits the electron-transport chain http://purl.obolibrary.org/obo/CHEBI_38497 respiratory-chain inhibitor http://purl.obolibrary.org/obo/CHEBI_38496 electron-transport chain inhibitor A role played by the entity that inhibits the respiratory-chain. http://purl.obolibrary.org/obo/CHEBI_38632 membrane transport modulator http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role Any agent that affects the transport of molecular entities across a biological membrane. http://purl.obolibrary.org/obo/CHEBI_40279 allopurinol http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring. http://purl.obolibrary.org/obo/CHEBI_421707 abacavir http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection. http://purl.obolibrary.org/obo/CHEBI_47381 diclofenac http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position. http://purl.obolibrary.org/obo/CHEBI_4995 felbamate http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy. http://purl.obolibrary.org/obo/CHEBI_50627 EC 3.2.1.1 (alpha-amylase) inhibitor http://purl.obolibrary.org/obo/CHEBI_52424 EC 3.2.1.* (glycosidase) inhibitor An EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-amylase (EC 3.2.1.1). http://purl.obolibrary.org/obo/CHEBI_50949 serotonin uptake inhibitor http://purl.obolibrary.org/obo/CHEBI_48278 serotonergic drug A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. http://purl.obolibrary.org/obo/CHEBI_59739 electrophilic reagent http://purl.obolibrary.org/obo/CHEBI_37527 acid A reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner. http://purl.obolibrary.org/obo/CHEBI_61015 nephrotoxin http://purl.obolibrary.org/obo/CHEBI_64909 poison A poison that interferes with the function of the kidneys. http://purl.obolibrary.org/obo/CHEBI_64482 phosphatidylcholine http://purl.obolibrary.org/obo/CHEBI_137209 glycerophosphonocholine A glycerophosphocholine that is glycero-3-phosphocholine bearing two acyl substituents at positions 1 and 2. http://purl.obolibrary.org/obo/CHEBI_64912 antimycobacterial drug http://purl.obolibrary.org/obo/CHEBI_36047 antibacterial drug A drug used to treat or prevent infections caused by Mycobacteria, a genus of actinobacteria. Aerobic and nonmotile, members of the genus include the pathogens responsible for causing tuberculosis and leprosy. http://purl.obolibrary.org/obo/CHEBI_67105 insect sterilant http://purl.obolibrary.org/obo/CHEBI_23092 chemosterilant A chemosterilant intended to sterilize insects. http://purl.obolibrary.org/obo/CHEBI_76797 EC 2.5.1.18 (glutathione transferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76663 EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of a glutathione transferase (EC 2.5.1.18). http://purl.obolibrary.org/obo/CHEBI_76907 EC 4.2.1.* (hydro-lyases) inhibitor http://purl.obolibrary.org/obo/CHEBI_76712 EC 4.2.* (C-O lyase) inhibitor An EC 4.2.* (C-O lyase) inhibitor that interferes with the action of any hydro-lyase (EC 4.2.1.*). http://purl.obolibrary.org/obo/CHEBI_88230 autophagy inhibitor http://purl.obolibrary.org/obo/TXPO_0002629 autophagy regulator role Any compound that inhibits the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell). http://purl.obolibrary.org/obo/CHEBI_37153 EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76775 EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor Any EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16). http://purl.obolibrary.org/obo/CHEBI_3732 clarithromycin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis. http://purl.obolibrary.org/obo/CHEBI_3750 clofibrate http://purl.obolibrary.org/obo/TXPO_1000442 fibrate The ethyl ester of clofibric acid. http://purl.obolibrary.org/obo/CHEBI_3766 clozapine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia. http://purl.obolibrary.org/obo/CHEBI_37845 growth hormone http://purl.obolibrary.org/obo/CHEBI_24621 hormone A hormone that specifically regulates growth. http://purl.obolibrary.org/obo/CHEBI_38213 Methapyrilene hydrochloride http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A hydrochloride that is the monohydrochloride salt of methapyrilene. http://purl.obolibrary.org/obo/CHEBI_38214 Monuron http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of phhenylureas that is urea in which one of the nitrogens is substituted by a p-chlorophenyl group while the other is substituted by two methyl groups. http://purl.obolibrary.org/obo/CHEBI_38221 fumonisin B1 http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol. http://purl.obolibrary.org/obo/CHEBI_38503 EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor http://purl.obolibrary.org/obo/CHEBI_76866 EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor A respiratory-chain inhibitor that interferes with the action of the the enzyme NADH:ubiquinone reductase (H(+)-translocating), EC 1.6.5.3. http://purl.obolibrary.org/obo/CHEBI_39025 high-density lipoprotein http://purl.obolibrary.org/obo/CHEBI_6495 lipoprotein A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. They are synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). http://purl.obolibrary.org/obo/CHEBI_39027 very-low-density lipoprotein http://purl.obolibrary.org/obo/CHEBI_6495 lipoprotein A class of lipoproteins of large size (30-80 nm), very low density (0.93-1.006 g/ml) particles with a core composed mainly of triglycerides and a surface monolayer of phospholipids and cholesterol into which are imbedded the apolipoproteins B, E, and C. VLDL facilitate the transport of endogenously made triglycerides to extrahepatic tissues. http://purl.obolibrary.org/obo/CHEBI_39124 calcium ion http://purl.obolibrary.org/obo/TXPO_0000052 cation A calcium cation that has formula Ca. http://purl.obolibrary.org/obo/CHEBI_47780 clomipramine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. http://purl.obolibrary.org/obo/CHEBI_49668 gefitinib http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer. http://purl.obolibrary.org/obo/CHEBI_59897 EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor http://purl.obolibrary.org/obo/CHEBI_22587 antiviral agent A DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce. http://purl.obolibrary.org/obo/CHEBI_60258 EC 3.4.* (hydrolases acting on peptide bond) inhibitor http://purl.obolibrary.org/obo/CHEBI_76759 EC 3.* (hydrolase) inhibitor A hydrolase inhibitor that interferes with the action of any hydrolase acting on peptide bonds (peptidase), EC 3.4.*.*). http://purl.obolibrary.org/obo/CHEBI_68563 P2Y12 receptor antagonist http://purl.obolibrary.org/obo/CHEBI_91079 purinergic receptor P2 antagonist An antagonist at the P2Y12 receptor http://purl.obolibrary.org/obo/CHEBI_76668 EC 2.7.* (P-containing group transferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_71300 EC 2.* (transferase) inhibitor A transferase inhibitor that inhibits the action of a phosphorus-containing group transferase (EC 2.7.*.*). http://purl.obolibrary.org/obo/CHEBI_76773 EC 3.1.1.* (carboxylic ester hydrolase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76760 EC 3.1.* (ester hydrolase) inhibitor An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a carboxylic ester hydrolase (EC 3.1.1.*). http://purl.obolibrary.org/obo/CHEBI_76815 EC 2.7.7.* (nucleotidyltransferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76668 EC 2.7.* (P-containing group transferase) inhibitor An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any nucleotidyltransferase (EC 2.7.7.*). http://purl.obolibrary.org/obo/CHEBI_76866 EC 1.6.5.* (oxidoreductase acting on NADH or NADPH with a quinone or similar as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76733 EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor An EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor that interferes with the action of any such enzyme using a quinone or similar as acceptor (EC 1.6.5.*). http://purl.obolibrary.org/obo/CHEBI_76932 pathway inhibitor http://purl.obolibrary.org/obo/TXPO_0003720 pathway regulator An enzyme inhibitor that interferes with one or more steps in a signaling or metabolic pathway. http://purl.obolibrary.org/obo/CHEBI_77402 EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76869 EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitor An EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of trypanothione-disulfide reductase (EC 1.8.1.12). http://purl.obolibrary.org/obo/CHEBI_9588 ticlopidine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group. http://purl.obolibrary.org/obo/CHEBI_4868 estramustine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid. http://purl.obolibrary.org/obo/CHEBI_4885 ethionamide http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide. http://purl.obolibrary.org/obo/CHEBI_49005 deferasirox http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions. http://purl.obolibrary.org/obo/CHEBI_49324 female contraceptive drug http://purl.obolibrary.org/obo/CHEBI_49323 contraceptive drug A chemical substance or agent with contraceptive activity in females. http://purl.obolibrary.org/obo/CHEBI_4953 exemestane http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer. http://purl.obolibrary.org/obo/CHEBI_5001 fenofibrate http://purl.obolibrary.org/obo/TXPO_1000442 fibrate A chlorobenzophenone that is (4-chlorophenyl)(phenyl)methanone substituted by a [2-methyl-1-oxo-1-(propan-2-yloxy)propan-2-yl]oxy group at position 1 on the phenyl ring. http://purl.obolibrary.org/obo/CHEBI_50112 sex hormone http://purl.obolibrary.org/obo/CHEBI_24621 hormone Any hormone that is responsible for controlling sexual characteristics and reproductive function. http://purl.obolibrary.org/obo/CHEBI_50172 acitretin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9. http://purl.obolibrary.org/obo/CHEBI_50689 reproductive control drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A substance used either in the prevention or facilitation of pregnancy. http://purl.obolibrary.org/obo/CHEBI_51061 hormone receptor modulator http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug that modulates the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role http://purl.obolibrary.org/obo/CHEBI_24432 biological role A role played by the molecular entity or part thereof which causes the development of a pathological process. http://purl.obolibrary.org/obo/CHEBI_73913 antifolate http://purl.obolibrary.org/obo/CHEBI_35221 antimetabolite An antimetabolite that impairs the action of folic acids http://purl.obolibrary.org/obo/CHEBI_76760 EC 3.1.* (ester hydrolase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76759 EC 3.* (hydrolase) inhibitor A hydrolase inhibitor that interferes with the action of any ester hydrolase (EC 3.1.*.*). http://purl.obolibrary.org/obo/CHEBI_76838 EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76741 EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any such enzyme incorporating one atom of oxygen and using reduced flavin or flavoprotein as donor (EC 1.14.14.*). http://purl.obolibrary.org/obo/CHEBI_76863 EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76731 EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor An EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.5.1.*). http://purl.obolibrary.org/obo/CHEBI_76898 EC 1.14.14.1 (unspecific monooxygenase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76838 EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor An EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor that interferes with the action of an unspecified monooxygenase (EC 1.14.14.1). http://purl.obolibrary.org/obo/CHEBI_83317 sterol biosynthesis inhibitor http://purl.obolibrary.org/obo/CHEBI_52206 biochemical role Any compound that inhibits the biosynthesis of any sterol. http://purl.obolibrary.org/obo/CHEBI_90710 receptor modulator http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug that acts as an antagonist, agonist, reverse agonist, or in some other fashion when interacting with cellular receptors. http://purl.obolibrary.org/obo/CHEBI_6030 isoniazide http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine. http://purl.obolibrary.org/obo/CHEBI_6067 isotretinoin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases. http://purl.obolibrary.org/obo/CHEBI_6076 itraconazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis. http://purl.obolibrary.org/obo/CHEBI_60798 excitatory amino acid antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist Any substance which inhibits the action of receptors for excitatory amino acids. http://purl.obolibrary.org/obo/CHEBI_60815 lysobisphosphatidic acid http://purl.obolibrary.org/obo/CHEBI_32957 lysophosphatidic acids A lysophosphatidic acid having the unusual property of a phosphodiester moiety linked to positions sn-1 and sn1' of glycerol; and two additional fatty acids esterified to the glycerol head group. http://purl.obolibrary.org/obo/CHEBI_6343 labetalol http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A secondary amino compound formally derived from ammonia by replacing two of the hydrogens by 2-(3-carbamoyl-4-hydroxyphenyl)-2-hydroxyethyl and 4-phenylbutan-2-yl groups. It is an adrenergic antagonist used to treat high blood pressure. http://purl.obolibrary.org/obo/CHEBI_63581 stavudine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase http://purl.obolibrary.org/obo/CHEBI_63589 etravirine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directly to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities http://purl.obolibrary.org/obo/CHEBI_63598 levofloxacin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase http://purl.obolibrary.org/obo/CHEBI_63608 maraviroc http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4,4-difluorocyclohexanecarboxylic acid and the primary amino group of (1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropylamine. An antiretroviral drug, it prevents the interaction of HIV-1 gp120 and chemokine receptor 5 (CCR5) necessary for CCR5-tropic HIV-1 to enter cells. http://purl.obolibrary.org/obo/CHEBI_63613 nevirapine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. http://purl.obolibrary.org/obo/CHEBI_63628 tipranavir http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor. http://purl.obolibrary.org/obo/CHEBI_63629 tizanidine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites. http://purl.obolibrary.org/obo/CHEBI_63630 tolcapone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase. http://purl.obolibrary.org/obo/CHEBI_6367 lamotrigine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of 1,2,4-triazines in which the triazene skeleton is substituted by amino groups at positions 3 and 5, and by a 2,3-dichlorophenyl group at position 6. http://purl.obolibrary.org/obo/CHEBI_63673 chemokine receptor 5 antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist An antogonist that blocks chemokine receptor 5 (CCR5). http://purl.obolibrary.org/obo/CHEBI_63951 estrogen receptor agonist http://purl.obolibrary.org/obo/CHEBI_48705 agonist An agonist at the estrogen receptor. http://purl.obolibrary.org/obo/CHEBI_6402 leflunomide http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide. http://purl.obolibrary.org/obo/CHEBI_64106 protein kinase agonist http://purl.obolibrary.org/obo/CHEBI_48705 agonist An agonist that selectively binds to and activates a protein kinase receptor. http://purl.obolibrary.org/obo/CHEBI_68542 EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor http://purl.obolibrary.org/obo/CHEBI_76858 EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitor An EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitor that interferes with the action of dihydroorotate oxidase (fumarate), EC 1.3.98.1 (formerly EC 1.3.3.1). http://purl.obolibrary.org/obo/CHEBI_68543 pyrimidine synthesis inhibitor http://purl.obolibrary.org/obo/CHEBI_76932 pathway inhibitor A pathway inhibitor that inhibits the synthesis of pyrimidine. http://purl.obolibrary.org/obo/CHEBI_76662 EC 2.4.* (glycosyltransferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_71300 EC 2.* (transferase) inhibitor A transferase inhibitor inhibiting the action of a glycosyltransferase (EC 2.4.*.*). http://purl.obolibrary.org/obo/CHEBI_76790 EC 2.4.2.* (pentosyltransferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76662 EC 2.4.* (glycosyltransferase) inhibitor An EC 2.4.* (glycosyltransferase) inhibitor that interferes with the action of any pentosyltransferase (EC 2.4.2.*). http://purl.obolibrary.org/obo/CHEBI_76817 EC 2.7.10.* (protein-tyrosine kinase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76668 EC 2.7.* (P-containing group transferase) inhibitor An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any protein-tyrosine kinase (EC 2.7.10.*). http://purl.obolibrary.org/obo/CHEBI_76853 EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76727 EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor An EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor that interferes with the action of any such enzyme using oxygen as acceptor (EC 1.2.3.*). http://purl.obolibrary.org/obo/CHEBI_71219 pazopanib http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer. http://purl.obolibrary.org/obo/CHEBI_71300 EC 2.* (transferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_23924 enzyme inhibitor An enzyme inhibitor that inhibits the action of a transferase (EC 2.*) http://purl.obolibrary.org/obo/CHEBI_76830 EC 5.99.1.* (miscellaneous isomerase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76697 EC 5.99.* (other isomerases) inhibitor An EC 5.99.* (other isomerases) inhibitor that interferes with the activity of any enzyme in the EC 5.99.1.* class. http://purl.obolibrary.org/obo/CHEBI_71415 nitrofurantoin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA. http://purl.obolibrary.org/obo/CHEBI_71554 PPARgamma agonist http://purl.obolibrary.org/obo/CHEBI_48705 agonist A PPAR modulator which activates the peroxisome proliferator-activated receptor-gamma. http://purl.obolibrary.org/obo/CHEBI_73044 lumiracoxib http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity. http://purl.obolibrary.org/obo/CHEBI_791 17β-estradiol 17-glucosiduronic acid http://purl.obolibrary.org/obo/CHEBI_35341 steroid A steroid glucosiduronic acid that consists of 17β-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage. http://purl.obolibrary.org/obo/CHEBI_7953 pemoline http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity. http://purl.obolibrary.org/obo/CHEBI_83057 Daphnia metabolite http://purl.obolibrary.org/obo/CHEBI_83039 crustacean metabolite A crustacean metabolite produced by the genus of small planktonic arthropods, Daphnia http://purl.obolibrary.org/obo/MP_0005039 hypoxia http://purl.obolibrary.org/obo/TXPO_0000671 decreasing concentration reduced oxygenation of body tissues resulting in the decreased pressure of this component of body gases; commonly due to hypoxemia http://purl.obolibrary.org/obo/OGMS_0000014 clinical finding http://purl.obolibrary.org/obo/TXPO_0001503 finding A representation that is either the output of a clinical history taking or a physical examination or an image finding, or some combination thereof. http://purl.obolibrary.org/obo/IMR_0100048 cholecystokinin http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety. http://purl.obolibrary.org/obo/IMR_0100195 corticotropin http://purl.obolibrary.org/obo/IMR_0100096 pituitary hormone, anterior An anterior pituitary hormone that stimulates the secretion of CORTICOSTEROIDS and induces growth of the ADRENAL CORTEX. It is a single-chain polypeptide of about 39 amino acids, the first 24 of which are identical in all species. This 24-amino acid segment is said to be responsible for the biological activity of the peptide while the remaining 15-amino acid segment is said to be necessary for any immunological specificity. http://purl.obolibrary.org/obo/IMR_0002688 IGFBP http://purl.obolibrary.org/obo/CHEBI_25367 molecule IGFBPs are a family of secreted proteins that bind IGF with high affinities that are equal to or greater than those of the IGF-IR. Six distinct IGFBPs, designated as IGFBP-1 to -6, have been isolated and characterized from human and a variety of vertebrate species. http://purl.obolibrary.org/obo/IMR_0000542 fibrillar collagen http://purl.obolibrary.org/obo/IMR_0000541 collagen Types I, II and III collagens constitute the classical fibrillar collagens and account for 80-90% of all the collagen in the body. Types V and XI collagens are also classified as fibrillar collagens on the basis of thier homology with types I-III collagens. http://purl.obolibrary.org/obo/IMR_0000544 fibril-associated collagen http://purl.obolibrary.org/obo/IMR_0000541 collagen associate with the surface of fibrils and modify their interactive properties. http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/CHEBI_25367 molecule Translation initiation in eukaryotes is an intricate process requiring at least 11 eukaryotic initiation factors (eIFs). http://purl.obolibrary.org/obo/IMR_0000246 nPKC http://purl.obolibrary.org/obo/IMR_0000245 PKC novel PKC isoforms (delta, epsilon, eta and theta) are regulated by DAG and phospholipids. http://www.ebi.ac.uk/efo/EFO_0008480 mitochondrial DNA http://purl.obolibrary.org/obo/CHEBI_16991 deoxyribonucleic acid Typically small, circular, intronless, and maternally inherited, mitochondrial DNA (mtDNA) is the multicopy deoxyribonucleic acid genome of mitochondria, intracellular organelles responsible for vital respiratory chain and oxidative phosphorylation reactions in higher eukaryotes. Replicated and transcribed by a separate enzymatic machinery from that of nuclear DNA, mtDNA encodes only a subset of mitochondrial functions. (by EFO) http://purl.obolibrary.org/obo/TXPO_0004211 toxicity (attribute) http://purl.obolibrary.org/obo/TXPO_0000305 non-meta generic quality An attribute of the finding of bodily harm due to the poisonous effects of something. http://purl.obolibrary.org/obo/TXPO_0004320 drug toxicity http://purl.obolibrary.org/obo/TXPO_0004211 toxicity (attribute) An attribute of the finding of bodily injury due to the poisonous effects of drugs. http://purl.obolibrary.org/obo/PATO_0000014 color (quality) http://purl.obolibrary.org/obo/BFO_0000019 quality A composite chromatic quality composed of hue, saturation and intensity parts. http://purl.obolibrary.org/obo/PATO_0000016 color brightness quality http://purl.obolibrary.org/obo/BFO_0000019 quality A scalar optical property that is the intensity, value or amount of perceived light. http://purl.obolibrary.org/obo/PATO_0000025 composition http://purl.obolibrary.org/obo/PATO_0000141 structure (quality) A single physical entity inhering in an bearer by virtue of the bearer's quantities or relative ratios of subparts http://purl.obolibrary.org/obo/PATO_0000039 direction http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quality inhering in a bearer by virtue of the bearer's orientation in space. http://purl.obolibrary.org/obo/PATO_0000048 hardness http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quality inhering in a bearer by virtue of the bearer's resistance to pressure, being broken, or pierced http://purl.obolibrary.org/obo/PATO_0000060 spatial pattern http://purl.obolibrary.org/obo/BFO_0000019 quality A spatial quality inhering in a bearer by virtue of the bearer's exhibiting repetition of placement of its parts. http://purl.obolibrary.org/obo/PATO_0000069 normality (quality) http://purl.obolibrary.org/obo/BFO_0000019 quality A quality inhering in a bearer by virtue of the whether the bearer differs from normal or average. http://purl.obolibrary.org/obo/PATO_0000070 quantity (property) http://purl.obolibrary.org/obo/BFO_0000019 quality The number of entities of this type that are part of the whole organism. http://purl.obolibrary.org/obo/PATO_0000078 rhythm quality http://purl.obolibrary.org/obo/PATO_0002323 temporal distribution quality A quality of a single process inhering in a bearer by virtue of the bearer's movement or variation characterized by the regular recurrence or alternation of different quantities or conditions. http://purl.obolibrary.org/obo/PATO_0000082 persistence http://purl.obolibrary.org/obo/PATO_0002323 temporal distribution quality A rhythm quality inhering in a bearer by virtue of the repetitiveness of bearer's rhythm. http://purl.obolibrary.org/obo/PATO_0000083 phase http://purl.obolibrary.org/obo/PATO_0002323 temporal distribution quality A quality that exists by virtue of being a particular point in the time of a cycle. http://purl.obolibrary.org/obo/PATO_0000117 size http://purl.obolibrary.org/obo/BFO_0000019 quality A morphology quality inhering in a bearer by virtue of the bearer's physical magnitude. http://purl.obolibrary.org/obo/PATO_0000119 height http://purl.obolibrary.org/obo/PATO_0000117 size A 1-D extent quality inhering in a bearer by virtue of the bearer's vertical dimension of extension. http://purl.obolibrary.org/obo/PATO_0000128 weight (quality) http://purl.obolibrary.org/obo/PATO_0001035 force (quality) A physical attribute entity inhering in a bearer that has mass near a gravitational body. http://purl.obolibrary.org/obo/PATO_0000141 structure (quality) http://purl.obolibrary.org/obo/BFO_0000019 quality A morphology quality inhering in a bearer by virtue of the bearer's relative position, shape, arrangements and connectivity of an organism's various parts; the pattern underlying its form. http://purl.obolibrary.org/obo/PATO_0000165 time quality http://purl.obolibrary.org/obo/BFO_0000019 quality A quality in which events occur in sequence. http://purl.obolibrary.org/obo/PATO_0000169 viability http://purl.obolibrary.org/obo/BFO_0000019 quality An organismal quality inhering in a bearer or a population by virtue of the bearer's disposition to survive and develop normally or the number of surviving individuals in a given population. http://purl.obolibrary.org/obo/PATO_0000322 red (quality) http://purl.obolibrary.org/obo/PATO_0000014 color (quality) A color hue with high wavelength of the long-wave end of the visible spectrum, evoked in the human observer by radiant energy with wavelengths of approximately 630 to 750 nanometers. http://purl.obolibrary.org/obo/PATO_0000327 color brightness http://purl.obolibrary.org/obo/PATO_0000016 color brightness quality A color brightness which is relatively low. http://purl.obolibrary.org/obo/PATO_0000386 hard http://purl.obolibrary.org/obo/PATO_0000048 hardness A hardness quality of being rigid and resistant to pressure. http://purl.obolibrary.org/obo/PATO_0000387 soft http://purl.obolibrary.org/obo/PATO_0000048 hardness A hardness quality of giving little resistance to pressure. http://purl.obolibrary.org/obo/PATO_0000389 acute http://purl.obolibrary.org/obo/PATO_0001309 duration A quality of a process inhering in a bearer by virtue of the bearer's having a sudden onset, sharp rise, and short course. http://purl.obolibrary.org/obo/PATO_0000427 recurrent http://purl.obolibrary.org/obo/PATO_0001309 duration A quality of a single process inhering in a bearer by virtue of the bearer's occurring or appearing again or repeatedly. http://purl.obolibrary.org/obo/PATO_0000460 abnormal http://purl.obolibrary.org/obo/PATO_0000069 normality (quality) A quality inhering in a bearer by virtue of the bearer's deviation from normal or average. http://purl.obolibrary.org/obo/PATO_0000461 normal http://purl.obolibrary.org/obo/PATO_0000069 normality (quality) A quality inhering in a bearer by virtue of the bearer's exhibiting no deviation from normal or average. http://purl.obolibrary.org/obo/PATO_0000470 increased amount http://purl.obolibrary.org/obo/PATO_0000070 quantity (property) An amount which is relatively high. http://purl.obolibrary.org/obo/PATO_0000498 increased duration http://purl.obolibrary.org/obo/PATO_0001309 duration A duration quality of a process which is relatively high. http://purl.obolibrary.org/obo/PATO_0000499 decreased duration http://purl.obolibrary.org/obo/PATO_0001309 duration A duration quality of a process which is relatively low. http://purl.obolibrary.org/obo/PATO_0000504 arrhythmic http://purl.obolibrary.org/obo/PATO_0000078 rhythm quality A rhythm quality inhering in a bearer by virtue of the bearer's lacking rhythm. http://purl.obolibrary.org/obo/PATO_0000505 rhythmic http://purl.obolibrary.org/obo/PATO_0000078 rhythm quality A rhythm quality inhering in a bearer by virtue of the bearer's having rhythm. http://purl.obolibrary.org/obo/PATO_0000573 increased length http://purl.obolibrary.org/obo/PATO_0000122 length A length quality which is relatively large. http://purl.obolibrary.org/obo/PATO_0000574 decreased length http://purl.obolibrary.org/obo/PATO_0000122 length A length quality which is relatively small. http://purl.obolibrary.org/obo/PATO_0000584 hypertrophic http://purl.obolibrary.org/obo/PATO_0000595 increased volume An increased size quality inhering in a bearer by virtue of the bearer's exhibiting enlargement of a cell or constituent group of cells (for example, organ). http://purl.obolibrary.org/obo/PATO_0000586 increased size http://purl.obolibrary.org/obo/PATO_0000117 size A size quality which is relatively high. http://purl.obolibrary.org/obo/PATO_0000587 decreased size http://purl.obolibrary.org/obo/PATO_0000117 size A size quality which is relatively low. http://purl.obolibrary.org/obo/PATO_0000591 increased thickness http://purl.obolibrary.org/obo/PATO_0000915 thickness A thickness which is relatively high. http://purl.obolibrary.org/obo/PATO_0000592 decreased thickness http://purl.obolibrary.org/obo/PATO_0000915 thickness A thickness which is relatively low. http://purl.obolibrary.org/obo/PATO_0000595 increased volume http://purl.obolibrary.org/obo/PATO_0000918 volume A volume which is relatively high. http://purl.obolibrary.org/obo/PATO_0000596 decreased volume http://purl.obolibrary.org/obo/PATO_0000918 volume A volume which is relatively low. http://purl.obolibrary.org/obo/PATO_0000639 degenerate (quality) http://purl.obolibrary.org/obo/PATO_0002037 degeneration (quality) A structural quality inhering in a bearer whose structure deteriorates or is lost over time due to an active pathological process. http://purl.obolibrary.org/obo/PATO_0000915 thickness http://purl.obolibrary.org/obo/PATO_0000117 size A 1-D extent quality which is equal to the dimension through an object as opposed to its length or width. http://purl.obolibrary.org/obo/PATO_0000970 permeability http://purl.obolibrary.org/obo/BFO_0000019 quality A structural quality inhering in a bearer by virtue of the bearer's disposition to being permeated or pervaded by a gas or liquid (as by osmosis or diffusion). http://purl.obolibrary.org/obo/PATO_0001024 power http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quality inhering in a bearer by virtue of the bearer's rate of doing work. http://purl.obolibrary.org/obo/PATO_0001035 force (quality) http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quaility inhering in a bearer by virtue of the bearer's rate of change of momentum. http://purl.obolibrary.org/obo/PATO_0001159 concentrated http://purl.obolibrary.org/obo/BFO_0000019 quality A concentration quality inhering in a bearer by virtue of the bearer's exhibiting concentration. http://purl.obolibrary.org/obo/PATO_0001162 increased concentration http://purl.obolibrary.org/obo/PATO_0001159 concentrated A concentration which is higher relative to the normal or average. http://purl.obolibrary.org/obo/PATO_0001163 decreased concentration http://purl.obolibrary.org/obo/PATO_0001159 concentrated A concentration which is lower relative to the normal or average. http://purl.obolibrary.org/obo/PATO_0001230 strength quality http://purl.obolibrary.org/obo/BFO_0000019 quality A quality inhering in a bearer by virtue of the bearer's power or force. http://purl.obolibrary.org/obo/PATO_0001236 process quality http://purl.obolibrary.org/obo/BFO_0000019 quality A quality which inheres in an process. http://purl.obolibrary.org/obo/PATO_0001309 duration http://purl.obolibrary.org/obo/BFO_0000019 quality A process quality inhering in a bearer by virtue of the bearer's magnitude of the temporal extent between the starting and ending point. http://purl.obolibrary.org/obo/PATO_0001323 area http://purl.obolibrary.org/obo/PATO_0000117 size A 2-D extent quality inhering in a bearer by virtue of the bearer's two dimensional extent. http://purl.obolibrary.org/obo/PATO_0001416 reguar duration http://purl.obolibrary.org/obo/PATO_0001309 duration A duration which has regular start and/or end times. http://purl.obolibrary.org/obo/PATO_0001417 irregular duration http://purl.obolibrary.org/obo/PATO_0001309 duration A duration quality of a process inhering in a bearer by virtue of the bearer's duration which has irregular start and/or end times. http://purl.obolibrary.org/obo/PATO_0001429 acidic http://purl.obolibrary.org/obo/PATO_0001842 acidity An medium acidity quality inhering in a solution by virtue of the bearer's a high concentration of H+ ions. http://purl.obolibrary.org/obo/PATO_0001430 alkaline http://purl.obolibrary.org/obo/PATO_0001842 acidity An medium acidity quality inhering in a solution by virtue of the bearer's a low concentration of H+ ions. http://purl.obolibrary.org/obo/PATO_0001447 calcified http://purl.obolibrary.org/obo/PATO_0000025 composition A composition quality inhering in an bearer by virtue of the bearer's being encrusted or impregnated with calcium carbonate (CHEBI:3311). http://purl.obolibrary.org/obo/PATO_0001462 membrane potential http://purl.obolibrary.org/obo/PATO_0001464 electric potential A quality inhering in a cell's plasma membrane by virtue of the electrical potential difference across it. http://purl.obolibrary.org/obo/PATO_0001464 electric potential http://purl.obolibrary.org/obo/BFO_0000019 quality A quality that is equal to the potential energy per unit charge associated with a static (time-invariant) electric field, also called the electrostatic potential. http://purl.obolibrary.org/obo/PATO_0001574 flow rate quality http://purl.obolibrary.org/obo/PATO_0001906 movement quality A physical quality inhering in a bearer by virtue of the bearer's motion characteristic. http://purl.obolibrary.org/obo/PATO_0001575 decreased pressure http://purl.obolibrary.org/obo/PATO_0001025 pressure A pressure which is relatively low. http://purl.obolibrary.org/obo/PATO_0001576 increased pressure http://purl.obolibrary.org/obo/PATO_0001025 pressure A pressure which is relatively high. http://purl.obolibrary.org/obo/PATO_0001577 increased permeability http://purl.obolibrary.org/obo/PATO_0000970 permeability A permeability which is relatively high. http://purl.obolibrary.org/obo/PATO_0001578 decreased permeability http://purl.obolibrary.org/obo/PATO_0000970 permeability A permeability which is relatively low. http://purl.obolibrary.org/obo/PATO_0001623 atrophied http://purl.obolibrary.org/obo/PATO_0000587 decreased size A size quality inhering in a bearer by virtue of a part or parts of the bearer's being decreased in size due to reduction in tissue mass through wasting. http://purl.obolibrary.org/obo/PATO_0001629 aggregated http://purl.obolibrary.org/obo/PATO_0000060 spatial pattern A spatial pattern inhering in a bearer by virtue of the bearer's being gathered or tending to gather into a mass or whole. http://purl.obolibrary.org/obo/PATO_0001637 necessity of occurrent http://purl.obolibrary.org/obo/BFO_0000019 quality A quality of single process inhering in a bearer by virtue of whether the bearer is essential or indispensable. http://purl.obolibrary.org/obo/PATO_0001638 necessary (occurrent) http://purl.obolibrary.org/obo/PATO_0001637 necessity of occurrent A necessity quality inhering in a process by virtue of the bearer's being essential or indispensable. http://purl.obolibrary.org/obo/PATO_0001639 unnecessary (occurrent) http://purl.obolibrary.org/obo/PATO_0001637 necessity of occurrent A necessity quality inhering in a process by virtue of the bearer's being non-essential or dispensable. http://purl.obolibrary.org/obo/PATO_0001759 granular http://purl.obolibrary.org/obo/PATO_0000025 composition A composition quality inhering in a bearer by virtue of the bearer's containing granules. http://purl.obolibrary.org/obo/PATO_0001838 decreased fluid flow (quality) http://purl.obolibrary.org/obo/TXPO_0003634 fluid flow rate A flow that is relatively low. http://purl.obolibrary.org/obo/PATO_0001839 increased fluid flow (quality) http://purl.obolibrary.org/obo/TXPO_0003634 fluid flow rate A flow that is relatively high. http://purl.obolibrary.org/obo/PATO_0001842 acidity http://purl.obolibrary.org/obo/BFO_0000019 quality A concentration quality inhering in a bearer by virtue of the bearer's containing acid (hydrogen ions). http://purl.obolibrary.org/obo/PATO_0001843 decreased acidity http://purl.obolibrary.org/obo/PATO_0001842 acidity An acidity which is relatively low. http://purl.obolibrary.org/obo/PATO_0001844 increased acidity http://purl.obolibrary.org/obo/PATO_0001842 acidity An acidity which is relatively high. http://purl.obolibrary.org/obo/PATO_0001850 scarred (quality) http://purl.obolibrary.org/obo/PATO_0000141 structure (quality) A structural quality inhering in a bearer by virtue of the bearer's being fibrous tissue that replaces normal tissue destroyed by injury or disease. http://purl.obolibrary.org/obo/PATO_0001884 hydrophobicity http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quality inhering in a bearer by virtue the bearer's disposition to being water-repellent; tending to repel and not absorb water. http://purl.obolibrary.org/obo/PATO_0001886 hydrophilicity http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quality inhering in a bearer by virtue the bearer's disposition to having an affinity for water; it is readily absorbing or dissolving in water. http://purl.obolibrary.org/obo/PATO_0001906 movement quality http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quality inhering in a bearer by virtue of the bearer's participation in movement. http://purl.obolibrary.org/obo/PATO_0002002 increased number (quality) http://purl.obolibrary.org/obo/TXPO_0003753 counting quality A number quality which is relatively many. http://purl.obolibrary.org/obo/PATO_0002011 neoplastic (quality) http://purl.obolibrary.org/obo/BFO_0000019 quality A structural quality which is held by a bearer when the latter's disposition the presence of abnormally proliferating masses of cells. http://purl.obolibrary.org/obo/PATO_0002037 degeneration (quality) http://purl.obolibrary.org/obo/PATO_0000141 structure (quality) A structural quality inhering in a bearer by virtue of the bearer exhibiting deterioration of its structure. http://purl.obolibrary.org/obo/PATO_0002057 increased area http://purl.obolibrary.org/obo/PATO_0001323 area An area which is relatively high. http://purl.obolibrary.org/obo/PATO_0002058 decreased area http://purl.obolibrary.org/obo/PATO_0001323 area An area which is relatively low. http://purl.obolibrary.org/obo/PATO_0002070 affinity http://purl.obolibrary.org/obo/BFO_0000019 quality A molecular quality that arises from the molecular attraction exerted between two atoms or compounds. http://purl.obolibrary.org/obo/PATO_0002072 decreased affinity http://purl.obolibrary.org/obo/PATO_0002070 affinity An affinity which is relatively low. http://purl.obolibrary.org/obo/PATO_0002091 subacute http://purl.obolibrary.org/obo/PATO_0000389 acute A quality of a single process inhering in a bearer by virtue of the bearer's having an onset and time course between acute and chronic. http://purl.obolibrary.org/obo/PATO_0002094 basophilic http://purl.obolibrary.org/obo/PATO_0002070 affinity An affinity inhering in a tissue constituent by virtue of the bearer exhibiting a molecular interaction for basic dyes under specific ph conditions. http://purl.obolibrary.org/obo/PATO_0002096 neoplastic, non-malignant http://purl.obolibrary.org/obo/PATO_0002011 neoplastic (quality) A disposition inhering in a tumour by virtue of the bearer's disposition not to progress, invade surrounding tissues or metastasize. http://purl.obolibrary.org/obo/PATO_0002097 neoplastic, malignant http://purl.obolibrary.org/obo/PATO_0002011 neoplastic (quality) A disposition inhering in a tumour by virtue of the bearer's disposition to progress, invade surrounding tissues or metastasize. http://purl.obolibrary.org/obo/PATO_0002098 neoplastic, metastatic http://purl.obolibrary.org/obo/PATO_0002011 neoplastic (quality) A disposition inhering in a tumour by virtue of the bearer's disposition to spread and invade distant tissues. http://purl.obolibrary.org/obo/PATO_0002104 inflammatory http://purl.obolibrary.org/obo/PATO_0000025 composition A compositional quality inhering in an bearer by virtue of the bearer's infiltration by leukocytes, local edema and accumulation of plasma proteins. http://purl.obolibrary.org/obo/PATO_0002114 fatty http://purl.obolibrary.org/obo/PATO_0000025 composition A composition quality inhering in a bearer by virtue of the bearer's containing excess lipid. http://purl.obolibrary.org/obo/PATO_0002129 neoplastic, invasive http://purl.obolibrary.org/obo/PATO_0002011 neoplastic (quality) A disposition inhering in a tumour by virtue of the bearer's disposition to invade surrounding tissues. http://purl.obolibrary.org/obo/PATO_0002132 neoplastic, non-invasive http://purl.obolibrary.org/obo/PATO_0002011 neoplastic (quality) A disposition inhering in a tumour by virtue of the bearer's disposition not to invade surrounding tissues. http://purl.obolibrary.org/obo/PATO_0002242 velocity quality http://purl.obolibrary.org/obo/PATO_0001906 movement quality A physical quality inhering in a bearer by virtue of the bearer's rate of change of the position. http://purl.obolibrary.org/obo/PATO_0002269 accumulation (quality) http://purl.obolibrary.org/obo/PATO_0000141 structure (quality) A structural quality of the collection or massing of one physical object within another physical object. http://purl.obolibrary.org/obo/PATO_0002270 increased accumulation (quality) http://purl.obolibrary.org/obo/PATO_0002269 accumulation (quality) An increased number of physical objects that are accumulated within another physical object usually as a result of a failure to break down or remove objects in a timely manner. http://purl.obolibrary.org/obo/PATO_0002271 decreased accumulation (quality) http://purl.obolibrary.org/obo/PATO_0002269 accumulation (quality) An accumulation which is relative low. http://purl.obolibrary.org/obo/PATO_0002323 temporal distribution quality http://purl.obolibrary.org/obo/PATO_0001236 process quality A temporal distribution pattern of process occurrences within a regulation/reference process. http://purl.obolibrary.org/obo/PATO_0002353 activation quality http://purl.obolibrary.org/obo/BFO_0000019 quality A quality that inheres in a bearer in virtue of its realizing one of its functions. http://purl.obolibrary.org/obo/PATO_0002354 active http://purl.obolibrary.org/obo/PATO_0002353 activation quality A quality of an physical object that is currently realizing one of its functions. http://purl.obolibrary.org/obo/PATO_0002355 inactive http://purl.obolibrary.org/obo/PATO_0002353 activation quality A quality of a physical object that is currently realizing none of its functions. http://purl.obolibrary.org/obo/PATO_0002408 watery http://purl.obolibrary.org/obo/PATO_0000025 composition Having the consistency of water. http://purl.obolibrary.org/obo/PATO_0002420 amphiphilic http://purl.obolibrary.org/obo/PATO_0002070 affinity Having both hydrophilic and hydrophobic (or lipophilic) groups. http://purl.obolibrary.org/obo/PATO_0002473 neoplastic, spontaneous http://purl.obolibrary.org/obo/PATO_0002011 neoplastic (quality) A disposition inhering in a tumour by virtue of the bearer's disposition to spontaneously arise. http://purl.obolibrary.org/obo/PATO_0015002 process efficacy http://purl.obolibrary.org/obo/PATO_0001236 process quality The ability of a process to produce its output. http://purl.obolibrary.org/obo/PATO_0015003 decreased efficacy http://purl.obolibrary.org/obo/PATO_0015002 process efficacy A decrease in the ability of a process to produce its output. http://purl.obolibrary.org/obo/PATO_0015004 increased efficacy http://purl.obolibrary.org/obo/PATO_0015002 process efficacy A increase in the ability of a process to produce its output. http://purl.obolibrary.org/obo/IMR_0000372 Co-Smad http://purl.obolibrary.org/obo/IMR_0000370 Smad Co-Smad forms hetero-oligomers with R-Smads, which in turn translocate into the nucleus and regulate transcriptional responses. Only Smad4 has been identified as a common-mediator Smad in vertebrates. A Smad4 homologue has been identified in Drosophila (Medea) and C. elegans (Sma-4). http://purl.obolibrary.org/obo/IMR_0000373 I-Smad http://purl.obolibrary.org/obo/IMR_0000370 Smad Smad6 and Smad7 are inhibitory Smads that serve as decoys interfering with Smad-receptor or Smad-Smad interactions. Inhibitory Smads have also been detected in Drosophila (Dad). http://purl.obolibrary.org/obo/IMR_0100199 gamma-MSH http://purl.obolibrary.org/obo/IMR_0100198 MSH A peptide hormone of about 11 amino acids derived from PRO-OPIOMELANOCORTIN that has natriuretic activity. http://purl.obolibrary.org/obo/IMR_0100212 pancreatic polypeptide http://purl.obolibrary.org/obo/IMR_0100076 pancreatic hormone A 36-amino acid polypeptide secreted by the PANCREAS that has physiological regulatory functions. Plasma pancreatic polypeptide increases after ingestion of food, with age, and in disease states. A lack of pancreatic polypeptide in the ISLETS OF LANGERHANS has been associated with the OBESITY in rats and mice. http://purl.obolibrary.org/obo/IMR_0100019 prostaglandin http://purl.obolibrary.org/obo/CHEBI_26347 prostanoid Naturally occurring compounds derived from the parent C20 acid, prostanoic acid. http://purl.obolibrary.org/obo/IMR_0100486 cPKC http://purl.obolibrary.org/obo/IMR_0000245 PKC classical PKC isoforms (alpha, betaI, betaII and gamma) are regulated by calcium, diacylglycerol (DAG) and phospholipids. http://purl.obolibrary.org/obo/NCIT_C1029 Buthionine sulfoximine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04) http://purl.obolibrary.org/obo/NCIT_C116387 tumor-associated macrophage http://purl.obolibrary.org/obo/CL_0000235 macrophage Non-neoplastic macrophages that are found in close proximity to or within a tumor mass. [ NCI ] http://purl.obolibrary.org/obo/HP_0000118 Phenotypic abnormality http://purl.obolibrary.org/obo/BFO_0000019 quality A phenotypic abnormality. http://purl.obolibrary.org/obo/HP_0003074 Hyperglycemia http://purl.obolibrary.org/obo/PATO_0001162 increased concentration An increased concentration of glucose in the blood. http://purl.obolibrary.org/obo/UBERON_0000004 nose http://purl.obolibrary.org/obo/UBERON_0002268 olfactory organ The olfactory organ of vertebrates, consisting of nares, olfactory epithelia and the structures and skeletal framework of the nasal cavity. http://purl.obolibrary.org/obo/UBERON_0001007 digestive system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that has as its parts the organs devoted to the ingestion, digestion, and assimilation of food and the discharge of residual wastes. http://purl.obolibrary.org/obo/UBERON_0001008 renal system http://purl.obolibrary.org/obo/UBERON_0011216 organ system subdivision The renal system in an anatomical system that maintains fluid balance and contributes to electrolyte balance, acid/base balance, and disposal of nitrogenous waste products.. http://purl.obolibrary.org/obo/UBERON_0001173 biliary tree http://purl.obolibrary.org/obo/UBERON_0011216 organ system subdivision A complex network of conduits that begins with the canals of Hering (intralobar bile duct) and progressively merges into a system of interlobular, septal, and major ducts which then coalesce to form the extrahepatic bile ducts, which finally deliver bile to the intestine, and in some species to the gallbladder. http://purl.obolibrary.org/obo/UBERON_0001264 pancreas http://purl.obolibrary.org/obo/UBERON_0000062 organ An endoderm derived structure that produces precursors of digestive enzymes and blood glucose regulating enzymes[GO]. http://purl.obolibrary.org/obo/UBERON_0001621 coronary artery http://purl.obolibrary.org/obo/UBERON_0003509 arterial blood vessel An artery that supplies the myocardium. http://purl.obolibrary.org/obo/UBERON_0001638 vein http://purl.obolibrary.org/obo/UBERON_0003920 venous blood vessel Any of the tubular branching vessels that carry blood from the capillaries toward the heart. http://purl.obolibrary.org/obo/UBERON_0002371 bone marrow http://purl.obolibrary.org/obo/UBERON_0000479 tissue the soft tissue that fills the cavities of bones http://purl.obolibrary.org/obo/UBERON_0002385 muscle tissue http://purl.obolibrary.org/obo/UBERON_0000479 tissue Muscle tissue is a contractile tissue made up of actin and myosin fibers[GO]. http://purl.obolibrary.org/obo/UBERON_0002390 hematopoietic system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that is involved in the production of hematopoietic cells. http://purl.obolibrary.org/obo/UBERON_0007798 vascular system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that consists of all blood and lymph vessels. http://purl.obolibrary.org/obo/BFO_0000004 independent continuant http://purl.obolibrary.org/obo/BFO_0000002 continuant b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) http://purl.obolibrary.org/obo/BFO_0000015 process http://purl.obolibrary.org/obo/BFO_0000003 occurrent p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) http://purl.obolibrary.org/obo/BFO_0000020 specifically dependent continuant http://purl.obolibrary.org/obo/BFO_0000002 continuant b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) http://purl.obolibrary.org/obo/BFO_0000031 generically dependent continuant http://purl.obolibrary.org/obo/BFO_0000002 continuant b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) http://purl.obolibrary.org/obo/BFO_0000035 process boundary http://purl.obolibrary.org/obo/BFO_0000003 occurrent p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001]) http://purl.obolibrary.org/obo/BFO_0000140 continuant fiat boundary http://purl.obolibrary.org/obo/BFO_0000141 immaterial entity b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001]) http://purl.obolibrary.org/obo/BFO_0000144 process profile http://purl.obolibrary.org/obo/BFO_0000015 process b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002]) http://purl.obolibrary.org/obo/BFO_0000145 relational quality http://purl.obolibrary.org/obo/BFO_0000019 quality b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001]) http://purl.obolibrary.org/obo/CLO_0000001 cell line cell http://purl.obolibrary.org/obo/OBI_0001866 secondary cultured cell A cultured cell that is part of a cell line - a stable and homogeneous population of cells with a common biological origin and propagation history in culture http://purl.obolibrary.org/obo/IAO_0000030 information content entity http://purl.obolibrary.org/obo/BFO_0000031 generically dependent continuant A generically dependent continuant that is about some thing. http://purl.obolibrary.org/obo/IAO_0000109 measurement datum http://purl.obolibrary.org/obo/TXPO_0000614 data item A measurement datum is an information content entity that is a recording of the output of a measurement such as produced by a device. http://purl.obolibrary.org/obo/OBI_0000017 regulatory role http://purl.obolibrary.org/obo/BFO_0000023 role a role which inheres in material entities and is realized in the processes of making, enforcing or being defined by legislation or orders issued by a governmental body. http://purl.obolibrary.org/obo/OBI_0000070 assay http://purl.obolibrary.org/obo/BFO_0000015 process A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies. http://purl.obolibrary.org/obo/OBI_0000093 patient role http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role a role which inheres in a person and is realized by the process of being under the care of a physician or health care provider http://purl.obolibrary.org/obo/OBI_0000185 imaging assay http://purl.obolibrary.org/obo/OBI_0000070 assay An imaging assay is an assay to produce a picture of an entity. http://purl.obolibrary.org/obo/OBI_0000718 pathogen role http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role pathogen role is a role which inheres in an organism and realized in the process of disease course in the organism bearing host role caused by the organism bearing pathogen role http://purl.obolibrary.org/obo/OBI_0001631 electron microscopy imaging assay http://purl.obolibrary.org/obo/TXPO_0001396 microscopy assay An imaging assay in which an electrons are used to probe the density, shape and composition of an input material which are detected in an electron microscope and utilized to produce an image of the material. http://purl.obolibrary.org/obo/OBI_0001866 secondary cultured cell http://purl.obolibrary.org/obo/CL_0000010 cultured cell A cultured cell that has been passaged or derives from a cell that has been passaged in culture. http://purl.obolibrary.org/obo/OBI_0100026 organism http://purl.obolibrary.org/obo/BFO_0000040 material entity An organism is material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. http://purl.obolibrary.org/obo/OBI_0302867 predicted data item http://purl.obolibrary.org/obo/TXPO_0000614 data item A data item that was generated on the basis of a calculation or logical reasoning http://purl.obolibrary.org/obo/OBI_1110008 occurrence of infectious disease http://purl.obolibrary.org/obo/OGMS_0000063 disease course Is an occurrence of a disease caused by an infection http://purl.obolibrary.org/obo/OBI_1110012 occurrence of allergy http://purl.obolibrary.org/obo/OGMS_0000063 disease course The process of an allergic disease occurring in an organism. http://purl.obolibrary.org/obo/OGMS_0000063 disease course http://purl.obolibrary.org/obo/TXPO_0000608 process sequence The totality of all processes through which a given disease instance is realized. http://purl.obolibrary.org/obo/PATO_0000011 age (quality) http://purl.obolibrary.org/obo/PATO_0000165 time quality A time quality inhering in a bearer by virtue of how long the bearer has existed. http://purl.obolibrary.org/obo/PATO_0000122 length http://purl.obolibrary.org/obo/PATO_0000117 size A 1-D extent quality which is equal to the distance between two points. http://purl.obolibrary.org/obo/PATO_0000125 mass (quality) http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quality that inheres in a bearer by virtue of the proportion of the bearer's amount of matter. http://purl.obolibrary.org/obo/PATO_0000146 temperature (quality) http://purl.obolibrary.org/obo/BFO_0000019 quality A physical attribure of the thermal energy of a system. http://purl.obolibrary.org/obo/PATO_0000918 volume http://purl.obolibrary.org/obo/PATO_0000117 size A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies. http://purl.obolibrary.org/obo/PATO_0001025 pressure http://purl.obolibrary.org/obo/BFO_0000019 quality A physical quality that inheres in a bearer by virtue of the bearer's amount of force per unit area it exerts. http://purl.obolibrary.org/obo/PATO_0001422 dead http://purl.obolibrary.org/obo/PATO_0000169 viability A viability quality inhering in a bearer by virtue of the cessation of the bearer's life. http://purl.obolibrary.org/obo/CHEBI_135028 pirprofen http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Pirprofen was a nonsteroidal anti-inflammatory drug (NSAID) that was brought to market by Ciba-Geigy in 1982 as a treatment for arthritis and pain. (by Wikipedia) http://purl.obolibrary.org/obo/OMIT_0003800 neoplastic cell Transformation http://purl.obolibrary.org/obo/GO_0030154 cell differentiation A changing process in which cells become to have neoplastic quality. http://purl.obolibrary.org/obo/IMR_0002954 LRP5/LRP6 http://purl.obolibrary.org/obo/IMR_0002951 Arrow/LRP5/LRP6 Lrp5 and Lrp6 are highly homologous, and are widely co-expressed during embryogenesis and in adult tissues. An orthologue in Drosophila melanogaster is known as arrow, a gene that functions in the canonical Wnt signaling pathway. http://purl.obolibrary.org/obo/IMR_0100087 gonadotropin http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone Hormones that stimulate gonadal functions such as GAMETOGENESIS and sex steroid hormone production in the OVARY and the TESTIS. Major gonadotropins are glycoproteins produced primarily by the adenohypophysis ( GONADOTROPINS, PITUITARY) and the placenta ( CHORIONIC GONADOTROPIN). In some species, pituitary PROLACTIN and PLACENTAL LACTOGEN exert some luteotropic activities. http://purl.obolibrary.org/obo/CHEBI_16914 salicylic acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monohydroxybenzoic acid that is benzoic acid with a hydroxy group at the ortho position. It is obtained from the bark of the white willow and wintergreen leaves. http://purl.obolibrary.org/obo/CHEBI_17984 acyl-CoA http://purl.obolibrary.org/obo/CHEBI_72695 organic molecule A thioester that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any carboxylic acid. http://purl.obolibrary.org/obo/CHEBI_50113 androgen http://purl.obolibrary.org/obo/CHEBI_50112 sex hormone A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors. http://purl.obolibrary.org/obo/CHEBI_50114 estrogen http://purl.obolibrary.org/obo/CHEBI_50112 sex hormone A hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens. http://purl.obolibrary.org/obo/CHEBI_50646 bone density conservation agent http://purl.obolibrary.org/obo/CHEBI_23888 drug An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. http://purl.obolibrary.org/obo/CHEBI_76871 EC 2.1.1.* (methyltransferases) inhibitor http://purl.obolibrary.org/obo/CHEBI_76655 EC 2.1.* (C1-transferase) inhibitor An EC 2.1.* (C1-transferase) inhibitor that interferes with the action of any methyltransferase (EC 2.1.1.*). http://purl.obolibrary.org/obo/CHEBI_72768 aryl hydrocarbon receptor agonist http://purl.obolibrary.org/obo/CHEBI_48705 agonist An agonist that binds to and activates aryl hydrocarbon receptors (AhRs). http://purl.obolibrary.org/obo/CHEBI_76206 xenobiotic metabolite http://purl.obolibrary.org/obo/CHEBI_25212 metabolite Any metabolite produced by metabolism of a xenobiotic compound. http://purl.obolibrary.org/obo/CHEBI_132972 farnesoid X receptor agonist http://purl.obolibrary.org/obo/CHEBI_48705 agonist An agonist that binds to and activates farnesoid X receptors http://purl.obolibrary.org/obo/CHEBI_132992 radiosensitizing agent http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug that makes increases the sensitivity of tumour cells to radiation therapy. http://purl.obolibrary.org/obo/CHEBI_133190 fatty acid oxidation inhibitor http://purl.obolibrary.org/obo/TXPO_0003648 fatty accid metabolic regulator role A role played by the entity which inhibits the oxidation of any fatty acid. http://purl.obolibrary.org/obo/CHEBI_13389 NAD http://purl.obolibrary.org/obo/CHEBI_36976 nucleotide Abbreviation for nicotinamide-adenine dinucleotide when its oxidation state is unknown or unspecified. It is used in metabolic pathways like glycolysis and citric acid cycle. http://purl.obolibrary.org/obo/CHEBI_149836 tigecycline http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Tetracycline in which the hydroxy group at position 5 and the methyl group at position 6 are replaced by hydrogen, and with a dimethylamino substituent and an (N-tert-butylglycyl)amino substituent at positions 7 and 9, respectively. A glycylcycline antibiotic, it has activity against a broad range of Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms. It is used for the intravenous treatment of complicated skin and skin structure infections caused by susceptible organisms. http://purl.obolibrary.org/obo/CHEBI_15343 acetaldehyde http://purl.obolibrary.org/obo/CHEBI_17478 aldehyde The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke. http://purl.obolibrary.org/obo/CHEBI_15846 NAD(+) http://purl.obolibrary.org/obo/CHEBI_13389 NAD The oxidised form of nicotinamide adenine dinucleotide found in all living cells. In metabolism, NAD(+) is involved in redox reactions, carrying electrons from one reaction to another. http://purl.obolibrary.org/obo/CHEBI_15986 polynucleotide http://purl.obolibrary.org/obo/CHEBI_33694 biomacromolecule A nucleobase-containing molecular entity with a polymeric structure comprised of a linear sequence of 13 or more nucleotide residues. http://purl.obolibrary.org/obo/CHEBI_16236 ethanol http://purl.obolibrary.org/obo/CHEBI_30879 alcohol A primary alcohol that is ethane in which one of the hydrogens is substituted by a hydroxy group. http://purl.obolibrary.org/obo/CHEBI_16247 phospholipid http://purl.obolibrary.org/obo/CHEBI_18059 lipid A lipid containing phosphoric acid as a mono- or di-ester. The term encompasses phosphatidic acids and phosphoglycerides. http://purl.obolibrary.org/obo/CHEBI_16335 adenosine http://purl.obolibrary.org/obo/CHEBI_33838 nucleoside A ribonucleoside composed of a molecule of adenine attached to a ribofuranose moiety via a beta-N(9)-glycosidic bond. http://purl.obolibrary.org/obo/CHEBI_16393 sphingosine http://purl.obolibrary.org/obo/CHEBI_26739 sphingolipid A sphing-4-enine in which the double bond is trans. http://purl.obolibrary.org/obo/CHEBI_16474 NADPH http://purl.obolibrary.org/obo/CHEBI_36976 nucleotide NADPH is the reduced form of NADP+; used in anabolic reactions, such as lipid and nucleic acid synthesis, which require NADPH as a reducing agent. http://purl.obolibrary.org/obo/CHEBI_16480 nitric oxide http://purl.obolibrary.org/obo/CHEBI_26519 radical A nitrogen oxide which is a free radical, each molecule of which consists of one nitrogen and one oxygen atom. http://purl.obolibrary.org/obo/CHEBI_16602 trichloroethylene http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of chloroethenes that is ethene substituted by chloro groups at positions 1, 1 and 2. http://purl.obolibrary.org/obo/CHEBI_16646 carbohydrate http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Any member of the class of organooxygen compounds that is a polyhydroxy-aldehyde or -ketone or a lactol resulting from their intramolecular condensation (monosaccharides); substances derived from these by reduction of the carbonyl group (alditols), by oxidation of one or more hydroxy groups to afford the corresponding aldehydes, ketones, or carboxylic acids, or by replacement of one or more hydroxy group(s) by a hydrogen atom; and polymeric products arising by intermolecular acetal formation between two or more such molecules (disaccharides, polysaccharides and oligosaccharides). Carbohydrates contain only carbon, hydrogen and oxygen atoms; prior to any oxidation or reduction, most have the empirical formula Cm(H2O)n. Compounds obtained from carbohydrates by substitution, etc., are known as carbohydrate derivatives and may contain other elements. Cyclitols are generally not regarded as carbohydrates. http://purl.obolibrary.org/obo/CHEBI_16664 albendazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a propylsulfanyl group at position 5. It is commonly used in the treatment of parasitic worm infestations. http://purl.obolibrary.org/obo/CHEBI_16750 guanosine http://purl.obolibrary.org/obo/CHEBI_33838 nucleoside A purine nucleoside in which guanine is attached to ribofuranose via a beta-N(9)-glycosidic bond. http://purl.obolibrary.org/obo/CHEBI_16908 NADH http://purl.obolibrary.org/obo/CHEBI_13389 NAD A coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide. http://purl.obolibrary.org/obo/CHEBI_16961 monoacylglycerol phosphate http://purl.obolibrary.org/obo/CHEBI_37739 glycerophospholipid Derivatives of phosphoglycerols which have only one of the alcohol groups of the glycerol backbone ester-linked with a fatty acid. http://purl.obolibrary.org/obo/CHEBI_16990 bilirubin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of biladienes that is a linear tetrapyrrole with the dipyrrole units being of both exovinyl and endovinyl type. A product of heme degradation, it is produced in the reticuloendothelial system by the reduction of biliverdin and transported to the liver as a complex with serum albumin. http://purl.obolibrary.org/obo/CHEBI_16991 deoxyribonucleic acid http://purl.obolibrary.org/obo/CHEBI_33696 nucleic acid High molecular weight, linear polymers, composed of nucleotides containing deoxyribose and linked by phosphodiester bonds; DNA contain the genetic information of organisms. http://purl.obolibrary.org/obo/CHEBI_17234 glucose http://purl.obolibrary.org/obo/CHEBI_35381 monosaccharide An aldohexose used as a source of energy and metabolic intermediate. http://purl.obolibrary.org/obo/CHEBI_17747 bis(2-ethylhexyl) phthalate http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid. http://purl.obolibrary.org/obo/CHEBI_17833 gentamicin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Gentamicin is a parenterally administered, broad spectrum aminoglycoside antibiotic typically used for moderate to severe gram negative infections. Despite its wide use, gentamicin has not been definitively linked to instances of clinically apparent liver injury. http://purl.obolibrary.org/obo/CHEBI_17907 styrene oxide http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An epoxide that is oxirane in which one of the hydrogens has been replaced by a phenyl group. http://purl.obolibrary.org/obo/CHEBI_18154 polysaccharide http://purl.obolibrary.org/obo/CHEBI_33694 biomacromolecule A biomacromolecule consisting of large numbers of monosaccharide residues linked glycosidically. This term is commonly used only for those containing more than ten monosaccharide residues. http://purl.obolibrary.org/obo/CHEBI_18179 phosphoinositide http://purl.obolibrary.org/obo/CHEBI_28874 phosphatidylinositol Any phosphatidylinositol that is phosphorylated at one or more of the hydroxy groups of inositol. http://purl.obolibrary.org/obo/CHEBI_18248 iron atom http://purl.obolibrary.org/obo/CHEBI_33250 atom An iron group element atom that has atomic number 26. http://purl.obolibrary.org/obo/CHEBI_23888 drug http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role Intended use of the molecular entity or part thereof by humans. http://purl.obolibrary.org/obo/CHEBI_23924 enzyme inhibitor http://purl.obolibrary.org/obo/TXPO_0003711 molecular inhibitor A compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. http://purl.obolibrary.org/obo/CHEBI_24621 hormone http://purl.obolibrary.org/obo/CHEBI_33280 molecular messenger Originally referring to an endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function, the term is now commonly used to include non-endogenous, semi-synthetic and fully synthetic analogues of such compounds. http://purl.obolibrary.org/obo/CHEBI_25442 mycotoxin http://purl.obolibrary.org/obo/CHEBI_27026 toxin Poisonous substance produced by fungi. http://purl.obolibrary.org/obo/CHEBI_27902 tetracycline http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria. http://purl.obolibrary.org/obo/CHEBI_30879 alcohol http://purl.obolibrary.org/obo/CHEBI_72695 organic molecule A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom. http://purl.obolibrary.org/obo/CHEBI_3216 buprenorphine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. http://purl.obolibrary.org/obo/CHEBI_33696 nucleic acid http://purl.obolibrary.org/obo/CHEBI_15986 polynucleotide A macromolecule made up of nucleotide units and hydrolysable into certain pyrimidine or purine bases (usually adenine, cytosine, guanine, thymine, uracil), D-ribose or 2-deoxy-D-ribose and phosphoric acid. http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/CHEBI_72695 organic molecule A carboxylic acid containing one or more amino groups. http://purl.obolibrary.org/obo/CHEBI_33838 nucleoside http://purl.obolibrary.org/obo/IMR_0001698 glycoside An N-glycosyl compound that has both a nucleobase, normally adenine, guanine, xanthine, thymine, cytosine or uracil, and either a ribose or deoxyribose as functional parents. http://purl.obolibrary.org/obo/CHEBI_35443 anthelminthic drug http://purl.obolibrary.org/obo/CHEBI_35442 antiparasitic agent Substance intended to kill parasitic worms (helminths). http://purl.obolibrary.org/obo/CHEBI_35481 non-narcotic analgesic http://purl.obolibrary.org/obo/CHEBI_35480 analgesic A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. http://purl.obolibrary.org/obo/CHEBI_35554 cardiovascular drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. http://purl.obolibrary.org/obo/CHEBI_35820 antiprotozoal drug http://purl.obolibrary.org/obo/CHEBI_36043 antimicrobial drug Any antimicrobial drug which is used to treat or prevent protozoal infections. http://purl.obolibrary.org/obo/CHEBI_36080 protein http://purl.obolibrary.org/obo/CHEBI_33694 biomacromolecule An amino acid chain that is produced de novo by ribosome-mediated translation of a genetically-encoded mRNA. http://purl.obolibrary.org/obo/CHEBI_37527 acid http://purl.obolibrary.org/obo/CHEBI_51086 chemical role An acid is a molecular entity capable of donating a hydron (Bronsted acid) or capable of forming a covalent bond with an electron pair (Lewis acid). http://purl.obolibrary.org/obo/CHEBI_37700 EC 2.7.11.13 (protein kinase C) inhibitor http://purl.obolibrary.org/obo/CHEBI_76812 EC 2.7.11.* (protein-serine/threonine kinase) inhibitor An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13). http://purl.obolibrary.org/obo/CHEBI_38068 antimalarial http://purl.obolibrary.org/obo/CHEBI_64915 antiplasmodial drug A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. http://purl.obolibrary.org/obo/CHEBI_46195 paracetamol http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. http://purl.obolibrary.org/obo/CHEBI_48001 protein synthesis inhibitor http://purl.obolibrary.org/obo/CHEBI_76932 pathway inhibitor A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein. http://purl.obolibrary.org/obo/CHEBI_4877 ethambutol http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone. http://purl.obolibrary.org/obo/CHEBI_48887 bile acid metabolite http://purl.obolibrary.org/obo/CHEBI_25212 metabolite Metabolites of bile acids, four-ringed steroid acids formed along the cholesterol degradation pathway. http://purl.obolibrary.org/obo/CHEBI_50630 cyclooxygenase 1 inhibitor http://purl.obolibrary.org/obo/CHEBI_35544 EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 1. http://purl.obolibrary.org/obo/CHEBI_50905 teratogenic agent http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role A role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect. http://purl.obolibrary.org/obo/CHEBI_50912 cardiotoxic agent http://purl.obolibrary.org/obo/TXPO_0000038 toxic agent A role played by aan entity exihibiting itself through the ability to induce damage to the heart and cardiomyocytes. http://purl.obolibrary.org/obo/CHEBI_50926 angiogenesis modulating agent http://purl.obolibrary.org/obo/CHEBI_23888 drug An agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents. http://purl.obolibrary.org/obo/CHEBI_51086 chemical role http://purl.obolibrary.org/obo/BFO_0000023 role A role played by the molecular entity or part thereof within a chemical context. http://purl.obolibrary.org/obo/CHEBI_51371 muscle relaxant http://purl.obolibrary.org/obo/CHEBI_51372 neuromuscular agent A drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis. http://purl.obolibrary.org/obo/CHEBI_52726 proteasome inhibitor http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug that blocks the action of proteasomes, cellular complexes that break down proteins. http://purl.obolibrary.org/obo/CHEBI_53784 antispasmodic drug http://purl.obolibrary.org/obo/CHEBI_51371 muscle relaxant A drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder. http://purl.obolibrary.org/obo/CHEBI_59740 nucleophilic reagent http://purl.obolibrary.org/obo/CHEBI_22695 base A reagent that forms a bond to its reaction partner (the electrophile) by donating both bonding electrons. http://purl.obolibrary.org/obo/CHEBI_63248 oxidising agent http://purl.obolibrary.org/obo/CHEBI_51086 chemical role A substance that removes electrons from another reactant in a redox reaction. http://purl.obolibrary.org/obo/CHEBI_64911 antimitotic http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role Any compound that inhibits cell division (mitosis). http://purl.obolibrary.org/obo/CHEBI_66993 tocolytic agent http://purl.obolibrary.org/obo/CHEBI_50689 reproductive control drug Any compound used to suppress premature labour and immature birth by suppressing uterine contractions. http://purl.obolibrary.org/obo/CHEBI_67199 AP-1 antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist An antogonist that interferes with the action of activator protein 1 (AP-1). http://purl.obolibrary.org/obo/CHEBI_71476 EC 2.3.1.85 (fatty acid synthase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76878 EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor An EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of fatty acid synthase (EC 2.3.1.85), a multi-enzyme protein involved in fatty acid synthesis. http://purl.obolibrary.org/obo/CHEBI_72695 organic molecule http://purl.obolibrary.org/obo/CHEBI_25367 molecule Any molecule that consists of at least one carbon atom as part of the electrically neutral entity. http://purl.obolibrary.org/obo/CHEBI_73693 ketone body http://purl.obolibrary.org/obo/CHEBI_23899 icosanoid A carbonyl compound produced as a water-soluble byproduct when fatty acids are broken down for energy in the liver. There are three endogenous ketone bodies: acetone, acetoacetic acid, and (R)-3-hydroxybutyric acid; others may be produced as a result of the metabolism of synthetic triglycerides. http://purl.obolibrary.org/obo/CHEBI_76663 EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76834 EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitor A transferase inhibitor that inhibits the transfer of an alkyl (other than methyl) or aryl group (EC 2.5.1.*). http://purl.obolibrary.org/obo/CHEBI_76807 EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76764 EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor An EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor that interferes with the action of any non-peptide linear amide C-N hydrolase (EC 3.5.1.*). http://purl.obolibrary.org/obo/CHEBI_76964 Penicillium metabolite http://purl.obolibrary.org/obo/CHEBI_76946 fungal metabolite Any fungal metabolite produced during a metabolic reaction in Penicillium. http://purl.obolibrary.org/obo/CHEBI_29132 N-acetyl-1,4-benzoquinone imine http://purl.obolibrary.org/obo/CHEBI_24783 imine A ketoimine that has formula C8H7NO2. http://purl.obolibrary.org/obo/CHEBI_2948 azathioprine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS. http://purl.obolibrary.org/obo/CHEBI_29699 tunicamycin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A mixture of antiviral nucleoside antibiotics produced by Streptomyces lysosuperificus. It contains at least 10 homologues comprising uracil, N-acetylglucosamine, an 11-carbon aminodialdose called tunicamine, and a fatty acid linked to the amino group of the tunicamine. The homologues vary in the composition of the fatty acid moiety. http://purl.obolibrary.org/obo/CHEBI_3023 benzbromarone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication. http://purl.obolibrary.org/obo/CHEBI_37886 adrenergic agonist http://purl.obolibrary.org/obo/CHEBI_37962 adrenergic agent An agent that selectively binds to and activates adrenergic receptors. http://purl.obolibrary.org/obo/CHEBI_39548 atorvastatin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases. http://purl.obolibrary.org/obo/CHEBI_49020 hormone antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist A chemical substance which inhibits the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. http://purl.obolibrary.org/obo/CHEBI_50745 progestogen http://purl.obolibrary.org/obo/CHEBI_50112 sex hormone A compound that interacts with progesterone receptors in target tissues to bring about effects similar to those of progesterone. http://purl.obolibrary.org/obo/CHEBI_575568 atovaquone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. http://purl.obolibrary.org/obo/CHEBI_66991 sympatholytic agent http://purl.obolibrary.org/obo/CHEBI_37962 adrenergic agent Any compound which inhibits the postganglionic functioning of the sympathetic nervous system (SNS). http://purl.obolibrary.org/obo/CHEBI_39669 diflunisal http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. http://purl.obolibrary.org/obo/CHEBI_4031 cyclosporin A http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle. http://purl.obolibrary.org/obo/CHEBI_41774 tamoxifen http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Tamoxifen, sold under the brand name Nolvadex among others, is a medication that is used to prevent breast cancer in women and treat breast cancer in women and men. (by Wikipedia) http://purl.obolibrary.org/obo/CHEBI_4305 dacarbazine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. http://purl.obolibrary.org/obo/CHEBI_4317 dantrolene http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. http://purl.obolibrary.org/obo/CHEBI_44423 hydroxyurea http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of ureas that is urea in which one of the hydrogens is replaced by a hydroxy group. An antineoplastic used in the treatment of chronic myeloid leukaemia as well as for sickle-cell disease. http://purl.obolibrary.org/obo/CHEBI_44445 nimesulide http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups. http://purl.obolibrary.org/obo/CHEBI_50673 methimazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen. http://purl.obolibrary.org/obo/CHEBI_50694 minocycline http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5. http://purl.obolibrary.org/obo/CHEBI_51374 GABA agent http://purl.obolibrary.org/obo/CHEBI_35942 neurotransmitter agent A substance, such as agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function, used for its pharmacological actions on GABAergic systems. http://purl.obolibrary.org/obo/CHEBI_52717 bortezomib http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. http://purl.obolibrary.org/obo/CHEBI_566274 malondialdehyde http://purl.obolibrary.org/obo/TXPO_0004328 reactive aldehyde A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form. http://purl.obolibrary.org/obo/CHEBI_63090 EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76790 EC 2.4.2.* (pentosyltransferase) inhibitor An EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of purine nucleoside phosphorylase (EC 2.4.2.1). http://purl.obolibrary.org/obo/CHEBI_64297 reaction intermediate http://purl.obolibrary.org/obo/CHEBI_51086 chemical role Any chemical substance produced during the conversion of a reactant to a product. http://purl.obolibrary.org/obo/CHEBI_64926 serine protease inhibitor http://purl.obolibrary.org/obo/CHEBI_37670 protease inhibitor Any protease inhibitor that restricts the action of a serine protease. http://purl.obolibrary.org/obo/CHEBI_59886 HIV fusion inhibitor http://purl.obolibrary.org/obo/CHEBI_64946 anti-HIV agent A drug which interferes with the binding, fusion and entry of an HIV virion to a human cell. By blocking this step in HIV's replication cycle, such agents slow the progression from HIV infection to AIDS. http://purl.obolibrary.org/obo/CHEBI_76759 EC 3.* (hydrolase) inhibitor http://purl.obolibrary.org/obo/CHEBI_23924 enzyme inhibitor Any enzyme inhibitor that interferes with the action of a hydrolase (EC 3.*.*.*). http://purl.obolibrary.org/obo/CHEBI_76841 EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76741 EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any such enzyme incorporating one atom of oxygen and using NADH or NADPH as one donor (EC 1.14.13.*). http://purl.obolibrary.org/obo/CHEBI_76878 EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor http://purl.obolibrary.org/obo/CHEBI_76661 EC 2.3.* (acyltransferase) inhibitor An EC 2.3.* (acyltransferase) inhibitor that inhibits the action of any acyltransferase transferring groups other than amino-acyl groups (EC 2.3.1.*). http://purl.obolibrary.org/obo/CHEBI_681569 clofarabine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia. http://purl.obolibrary.org/obo/CHEBI_68508 diethyl malate http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A maleate ester resulting from the formal condensation of both carboxy groups of maleic acid with ethanol. A colourless liquid at room temperature (m.p. -10degreeC) with boiling point 220degreeC at 1 atm., it is commonly used as a dienophile for Diels-Alder-type cycloaddition reactions in organic synthesis. http://purl.obolibrary.org/obo/CHEBI_68509 glutathione depleting agent http://purl.obolibrary.org/obo/TXPO_0002037 glutathione conjuation regulating agent role A compound which causes a reduction in the levels of glutathione in cells. http://purl.obolibrary.org/obo/CHEBI_76858 EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitor http://purl.obolibrary.org/obo/CHEBI_76729 EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor An EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor that interferes with the function of any such enzyme in the EC 1.3.98.* (with other, known, acceptors) category. http://purl.obolibrary.org/obo/CHEBI_91079 purinergic receptor P2 antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist An antagonist at purinergic P2 receptors http://purl.obolibrary.org/obo/CHEBI_77102 EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76729 EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor An EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor that interferes with the action of any such enzyme using a quinone or related compound as acceptor (EC 1.3.5.*). http://purl.obolibrary.org/obo/CHEBI_77105 EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76737 EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor An EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor that interferes with the action of any such enzyme using a cytochrome as acceptor (EC 1.10.2.*). http://purl.obolibrary.org/obo/CHEBI_77731 p53 activator http://purl.obolibrary.org/obo/TXPO_0003714 molecular activator A role played by the entity that activates p53. http://purl.obolibrary.org/obo/CHEBI_7864 oxymetholone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects. http://purl.obolibrary.org/obo/CHEBI_9448 terbinafine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A tertiary amine that is N-methyl-1-naphthalenemethylamine in which the amino hydrogen is replaced by a 3-(tertbutylethynyl)allyl group. An antifungal agent administered orally (generally as the hydrochloride salt) for the treatment of skin and nail infections. http://purl.obolibrary.org/obo/CHEBI_9763 trovafloxacin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure. http://purl.obolibrary.org/obo/CHEBI_9907 ursodeoxycholic acid http://purl.obolibrary.org/obo/TXPO_0000509 bile acid A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones. http://purl.obolibrary.org/obo/CHEBI_9753 troglitazone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2. (by Wikipedia) http://purl.obolibrary.org/obo/CL_0000000 cell http://purl.obolibrary.org/obo/GO_0005575 cellular_component A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane. http://purl.obolibrary.org/obo/CL_0000001 primary cultured cell http://purl.obolibrary.org/obo/CL_0000010 cultured cell A cultured cell that is freshly isolated from a organismal source, or derives in culture from such a cell prior to the culture being passaged. http://purl.obolibrary.org/obo/CL_0000010 cultured cell http://purl.obolibrary.org/obo/CL_0000578 experimentally modified cell in vitro A cell in vitro that is or has been maintained or propagated as part of a cell culture. http://purl.obolibrary.org/obo/CL_0000056 myoblast http://purl.obolibrary.org/obo/CL_0000000 cell A cell that is commited to differentiating into a muscle cell. Embryonic myoblasts develop from the mesoderm. They undergo proliferation, migrate to their various sites, and then differentiate into the appropriate form of myocytes. Myoblasts also occur as transient populations of cells in muscles undergoing repair. http://purl.obolibrary.org/obo/CL_0000057 fibroblast http://purl.obolibrary.org/obo/CL_0002320 connective tissue cell A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped. http://purl.obolibrary.org/obo/CL_0000066 epithelial cell http://purl.obolibrary.org/obo/CL_0000000 cell A cell that is usually found in a two-dimensional sheet with a free surface. The cell has a cytoskeleton that allows for tight cell to cell contact and for cell polarity where apical part is directed towards the lumen and the basal part to the basal lamina. http://purl.obolibrary.org/obo/CL_0000084 T cell http://purl.obolibrary.org/obo/CL_0000542 lymphocyte A type of lymphocyte whose defining characteristic is the expression of a T cell receptor complex. http://purl.obolibrary.org/obo/CL_0000091 Kupffer cell http://purl.obolibrary.org/obo/CL_0000864 tissue-resident macrophage A tissue-resident macrophage of the reticuloendothelial system found on the luminal surface of the hepatic sinusoids involved in erythrocyte clearance. Markers include F4/80+, CD11b-low, CD68-positive, sialoadhesin-positive, CD163/SRCR-positive. Irregular, with long processes including lamellipodia extending into the sinusoid lumen, have flattened nucleus with cytoplasm containing characteristic invaginations of the plasma membrane (vermiform bodies); lie within the sinusoid lumen attached to the endothelial surface; derived from the bone marrow, form a major part of the body's mononuclear phagocyte system. Markers: Mouse: F4/80+, CD11b-low, CD68+, sialoadhesin+, CD163/SRCR+; role or process: immune, antigen-presentation, clearance of senescent erythrocytes, iron metabolism. Kupffer cells are also reportedly C3aR-positive, CD14-low, CD54-positive, CD88-positive, and CD284-positive. They are also capable of producing IL-1, IL-6, TNF-alpha, nitric oxide, PGD2, PGE2, PGF2alpha, and TXA2. http://purl.obolibrary.org/obo/CL_0000094 granulocyte http://purl.obolibrary.org/obo/CL_0000988 hematopoietic cell A leukocyte with abundant granules in the cytoplasm. http://purl.obolibrary.org/obo/CL_0000097 mast cell http://purl.obolibrary.org/obo/CL_0000738 leukocyte A cell that is found in almost all tissues containing numerous basophilic granules and capable of releasing large amounts of histamine and heparin upon activation. Progenitors leave bone marrow and mature in connective and mucosal tissue. Mature mast cells are found in all tissues, except the bloodstream. Their phenotype is CD117-high, CD123-negative, CD193-positive, CD200R3-positive, and FceRI-high. Stem-cell factor (KIT-ligand; SCF) is the main controlling signal of their survival and development. http://purl.obolibrary.org/obo/CL_0000136 fat cell http://purl.obolibrary.org/obo/CL_0002320 connective tissue cell A fat-storing cell found mostly in the abdominal cavity and subcutaneous tissue of mammals. Fat is usually stored in the form of triglycerides. http://purl.obolibrary.org/obo/CL_0000151 secretory cell http://purl.obolibrary.org/obo/CL_0000000 cell A cell that specializes in controlled release of one or more substances. http://purl.obolibrary.org/obo/CL_0000168 insulin secreting cell http://purl.obolibrary.org/obo/CL_0000151 secretory cell insulin secreting cell is a secretory cell and is capable of some insulin secretion http://purl.obolibrary.org/obo/CL_0000169 type B pancreatic cell http://purl.obolibrary.org/obo/CL_0000168 insulin secreting cell Pancreatic beta cells are also reportedly CD284-positive. Upon activation, they upregulate their CD14 expression. A cell that secretes insulin and is located towards the center of the islets of Langerhans. http://purl.obolibrary.org/obo/CL_0000182 hepatocyte http://purl.obolibrary.org/obo/CL_0000066 epithelial cell The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. Majority of cell population of liver, polygonal in shape, arranged in plates or trabeculae between sinusoids; may have single nucleus or binucleated. http://purl.obolibrary.org/obo/CL_0000232 erythrocyte http://purl.obolibrary.org/obo/CL_0000988 hematopoietic cell A red blood cell. In mammals, mature erythrocytes are biconcave disks containing hemoglobin whose function is to transport oxygen. http://purl.obolibrary.org/obo/CL_0000233 platelet http://purl.obolibrary.org/obo/CL_0000151 secretory cell A non-nucleated disk-shaped cell formed by extrusion from megakaryocytes, found in the blood of all mammals, and mainly involved in blood coagulation. http://purl.obolibrary.org/obo/CL_0000234 phagocyte http://purl.obolibrary.org/obo/CL_0000000 cell Any cell capable of ingesting particulate matter via phagocytosis. http://purl.obolibrary.org/obo/CL_0000235 macrophage http://purl.obolibrary.org/obo/CL_0000234 phagocyte A mononuclear phagocyte present in variety of tissues, typically differentiated from monocytes, capable of phagocytosing a variety of extracellular particulate material, including immune complexes, microorganisms, and dead cells. http://purl.obolibrary.org/obo/CL_0000236 B cell http://purl.obolibrary.org/obo/CL_0000542 lymphocyte A lymphocyte of B lineage with the phenotype CD19-positive, CD20-positive, and capable of B cell mediated immunity. http://purl.obolibrary.org/obo/CL_0000448 white fat cell http://purl.obolibrary.org/obo/CL_0000136 fat cell Fat cells with light coloration and few mitochondria. They contain a scant ring of cytoplasm surrounding a single large lipid droplet or vacuole. http://purl.obolibrary.org/obo/CL_0000449 brown fat cell http://purl.obolibrary.org/obo/CL_0000136 fat cell A cell from the thermogenic form of adipose tissue found in many species, particularly in newborns and hibernating mammals, but also in lesser amounts in adults of other mammals including humans. Brown fat is capable of rapid liberation of energy and seems to be important in the maintenance of body temperature immediately after birth and upon waking from hibernation. http://purl.obolibrary.org/obo/CL_0000451 dendritic cell http://purl.obolibrary.org/obo/CL_0000738 leukocyte A cell of hematopoietic origin, typically resident in particular tissues, specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation. These cells are lineage negative (CD3-negative, CD19-negative, CD34-negative, and CD56-negative). http://purl.obolibrary.org/obo/CL_0000542 lymphocyte http://purl.obolibrary.org/obo/CL_0000842 mononuclear cell A lymphocyte is a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin. http://purl.obolibrary.org/obo/CL_0000576 monocyte http://purl.obolibrary.org/obo/CL_0000842 mononuclear cell Myeloid mononuclear recirculating leukocyte that can act as a precursor of tissue macrophages, osteoclasts and some populations of tissue dendritic cells. http://purl.obolibrary.org/obo/CL_0000578 experimentally modified cell in vitro http://purl.obolibrary.org/obo/CL_0000000 cell A cell in vitro that has undergone physical changes as a consequence of a deliberate and specific experimental procedure. http://purl.obolibrary.org/obo/CL_0000632 hepatic stellate cell http://purl.obolibrary.org/obo/CL_0000057 fibroblast A cell that is found in the perisinusoidal space of the liver that is capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components that can contribute to liver fibrosis. This activated state has a myofibroblast-like phenotype, though it's not clear in the literature if this is terminally differentiated. This cell type comprises approximately 8-15% of total cells in the liver. http://purl.obolibrary.org/obo/CL_0000738 leukocyte http://purl.obolibrary.org/obo/CL_0000988 hematopoietic cell An achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue. http://purl.obolibrary.org/obo/CL_0000767 basophil http://purl.obolibrary.org/obo/CL_0000094 granulocyte Any of the immature or mature forms of a granular leukocyte that in its mature form has an irregularly shaped, pale-staining nucleus that is partially constricted into two lobes, and with cytoplasm that contains coarse, bluish-black granules of variable size. Basophils contain vasoactive amines such as histamine and serotonin, which are released on appropriate stimulation. A basophil is CD123-positive, CD193-positive, CD203c-positive, and FceRIa-positive. http://purl.obolibrary.org/obo/CL_0000771 eosinophil http://purl.obolibrary.org/obo/CL_0000094 granulocyte Any of the immature or mature forms of a granular leukocyte with a nucleus that usually has two lobes connected by one or more slender threads of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and which can be stained by the dye eosin. Eosinophils are CD9-positive, CD191-positive, and CD193-positive. http://purl.obolibrary.org/obo/CL_0000775 neutrophil http://purl.obolibrary.org/obo/CL_0000094 granulocyte Any of the immature or mature forms of a granular leukocyte that in its mature form has a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. http://purl.obolibrary.org/obo/CL_0000786 plasma cell http://purl.obolibrary.org/obo/CL_0000236 B cell A terminally differentiated, post-mitotic, antibody secreting cell of the B cell lineage with the phenotype CD138-positive, surface immunonoglobulin-negative, and MHC Class II-negative. Plasma cells are oval or round with extensive rough endoplasmic reticulum, a well-developed Golgi apparatus, and a round nucleus having a characteristic cartwheel heterochromatin pattern and are devoted to producing large amounts of immunoglobulin. http://purl.obolibrary.org/obo/CL_0000789 alpha-beta T cell http://purl.obolibrary.org/obo/CL_0000084 T cell A T cell that expresses an alpha-beta T cell receptor complex. http://purl.obolibrary.org/obo/CL_0000842 mononuclear cell http://purl.obolibrary.org/obo/CL_0000738 leukocyte A leukocyte with a single non-segmented nucleus in the mature form. http://purl.obolibrary.org/obo/CL_0000863 inflammatory macrophage http://purl.obolibrary.org/obo/CL_0000235 macrophage An elicited macrophage that is recruited into the tissues in response to injury and infection as part of an inflammatory response, expresses high levels of pro-inflammatory cytokines, ROS and NO, and shows potent microbicidal activity. http://purl.obolibrary.org/obo/CL_0000864 tissue-resident macrophage http://purl.obolibrary.org/obo/CL_0000235 macrophage A macrophage constitutively resident in a particular tissue under non-inflammatory conditions, and capable of phagocytosing a variety of extracellular particulate material, including immune complexes, microorganisms, and dead cells. http://purl.obolibrary.org/obo/CL_0000891 foam cell http://purl.obolibrary.org/obo/CL_0000000 cell A type of cell containing lipids in small vacuoles and typically seen in atherolosclerotic lesions, as well as other conditions. http://purl.obolibrary.org/obo/CL_0000988 hematopoietic cell http://purl.obolibrary.org/obo/CL_0000000 cell A cell of a hematopoietic lineage. http://purl.obolibrary.org/obo/CL_0002320 connective tissue cell http://purl.obolibrary.org/obo/CL_0000000 cell A cell of the supporting or framework tissue of the body, arising chiefly from the embryonic mesoderm and including adipose tissue, cartilage, and bone. http://purl.obolibrary.org/obo/DOID_14504 Niemann-Pick disease http://purl.obolibrary.org/obo/DOID_4 disease A sphingoliidosis characterized by the accumulation of the lipid sphingomyelin in lysosomes in cells. http://purl.obolibrary.org/obo/DOID_4 disease http://purl.obolibrary.org/obo/BFO_0000016 disposition A disease is a disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism. http://purl.obolibrary.org/obo/DOID_9351 diabetes mellitus http://purl.obolibrary.org/obo/DOID_4 disease A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. http://purl.obolibrary.org/obo/DOID_9352 type 2 diabetes mellitus http://purl.obolibrary.org/obo/DOID_9351 diabetes mellitus A diabetes mellitus that involves high blood glucose resulting from cells fail to use insulin properly. http://purl.obolibrary.org/obo/DOID_9744 type 1 diabetes mellitus http://purl.obolibrary.org/obo/DOID_9351 diabetes mellitus A diabetes mellitus that results from the body's failure to produce insulin and has_material_basis_in autoimmune destruction of insulin-producing beta cells of the pancreas. http://purl.obolibrary.org/obo/HP_0000969 edema http://purl.obolibrary.org/obo/HP_0000118 Phenotypic abnormality An abnormal accumulation of fluid beneath the skin, or in one or more cavities of the body. http://purl.obolibrary.org/obo/UBERON_0000020 sense organ http://purl.obolibrary.org/obo/UBERON_0000062 organ An organ that is capable of transducing sensory stimulus to the nervous system. http://purl.obolibrary.org/obo/UBERON_0000056 ureter http://purl.obolibrary.org/obo/UBERON_0000025 tube (anatomical) Muscular duct that propels urine from the kidneys to the urinary bladder, or related organs. http://purl.obolibrary.org/obo/UBERON_0000059 large intestine http://purl.obolibrary.org/obo/UBERON_0000160 intestine A subdivision of the digestive tract that connects the small intestine to the cloaca or anus. Lacks or has few villi[Kardong]. http://purl.obolibrary.org/obo/UBERON_0000160 intestine http://purl.obolibrary.org/obo/UBERON_0013765 digestive system element Segment of the alimentary canal extending from the stomach to the anus and, in humans and other mammals, consists of two segments, the small intestine and the large intestine http://purl.obolibrary.org/obo/UBERON_0000178 blood http://purl.obolibrary.org/obo/UBERON_0000179 haemolymphatic fluid A fluid that is composed of blood plasma and erythrocytes. http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system http://purl.obolibrary.org/obo/UBERON_0000061 anatomical structure Multicellular, connected anatomical structure that has multiple organs as parts and whose parts work together to achieve some shared function. http://purl.obolibrary.org/obo/UBERON_0000945 stomach http://purl.obolibrary.org/obo/UBERON_0013765 digestive system element An expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ. A stomach is lined, in whole or in part by a glandular epithelium. http://purl.obolibrary.org/obo/UBERON_0000948 heart http://purl.obolibrary.org/obo/UBERON_0000062 organ A myogenic muscular circulatory organ found in the vertebrate cardiovascular system composed of chambers of cardiac muscle. It is the primary circulatory organ. [database_cross_reference: http://orcid.org/0000-0002-6601-2165][database_cross_reference: http://en.wikipedia.org/wiki/Heart] http://purl.obolibrary.org/obo/UBERON_0000949 endocrine system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that consists of the glands and parts of glands that produce endocrine secretions and help to integrate and control bodily metabolic activity. http://purl.obolibrary.org/obo/UBERON_0000955 brain http://purl.obolibrary.org/obo/UBERON_0000062 organ The brain is the center of the nervous system in all vertebrate, and most invertebrate, animals. Some primitive animals such as jellyfish and starfish have a decentralized nervous system without a brain, while sponges lack any nervous system at all. In vertebrates, the brain is located in the head, protected by the skull and close to the primary sensory apparatus of vision, hearing, balance, taste, and smell[WP]. http://purl.obolibrary.org/obo/UBERON_0000966 retina http://purl.obolibrary.org/obo/UBERON_0000064 organ part The retina is the innermost layer or coating at the back of the eyeball, which is sensitive to light and in which the optic nerve terminates. http://purl.obolibrary.org/obo/UBERON_0000970 eye http://purl.obolibrary.org/obo/UBERON_0000020 sense organ An organ that detects light. http://purl.obolibrary.org/obo/UBERON_0000990 reproductive system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that has as its parts the organs concerned with reproduction. http://purl.obolibrary.org/obo/UBERON_0001004 respiratory system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Functional system which consists of structures involved in respiration. http://purl.obolibrary.org/obo/UBERON_0001016 nervous system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system The nervous system is an organ system containing predominantly neuron and glial cells. In bilaterally symmetrical organism, it is arranged in a network of tree-like structures connected to a central body. The main functions of the nervous system are to regulate and control body functions, and to receive sensory input, process this information, and generate behavior [CUMBO]. http://purl.obolibrary.org/obo/UBERON_0001017 central nervous system http://purl.obolibrary.org/obo/UBERON_0011216 organ system subdivision The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the neural tube derivatives: the brain and spinal cord. In invertebrates it includes central ganglia plus nerve cord. http://purl.obolibrary.org/obo/UBERON_0001032 sensory system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that overlaps the nervous system and is responsible for receiving and processing sensory information. http://purl.obolibrary.org/obo/UBERON_0001043 esophagus http://purl.obolibrary.org/obo/UBERON_0013765 digestive system element Tube that connects the pharynx to the stomach. In mammals, the oesophagus connects the buccal cavity with the stomach. The stratified squamous non-keratinised epithelium lining the buccal cavity is continued through the pharynx down into the oesophagus. The lowest part of the oesophagus (ca. 2 cm) is lined with gastric mucosa and covered by peritoneum. The main body of the oesophagus is lined with small, simple mucous glands. Each gland opens into the lumen by a long duct which pierces the muscularis mucosae (Wilson and Washington, 1989). A sphincter is situated at the point where the oesophagus enters the stomach to prevent gastro-oesophageal reflux, i.e. to prevent acidic gastric contents from reaching stratified epithelia of the oesophagus, where they can cause inflammation and irritation (Wilson and Washington, 1989; Brown et al., 1993). http://purl.obolibrary.org/obo/UBERON_0001052 rectum http://purl.obolibrary.org/obo/UBERON_0000160 intestine the terminal portion of the intestinal tube, terminating with the anus http://purl.obolibrary.org/obo/UBERON_0001134 skeletal muscle tissue http://purl.obolibrary.org/obo/UBERON_0000479 tissue Muscle tissue that consists primarily of skeletal muscle fibers. http://purl.obolibrary.org/obo/UBERON_0001155 colon http://purl.obolibrary.org/obo/UBERON_0000160 intestine Last portion of the large intestine before it becomes the rectum. http://purl.obolibrary.org/obo/UBERON_0001637 artery http://purl.obolibrary.org/obo/UBERON_0003509 arterial blood vessel An epithelial tube or tree of tibes that transports blood away from the heart[modified from AEO definition]. http://purl.obolibrary.org/obo/UBERON_0001723 tongue http://purl.obolibrary.org/obo/UBERON_0000020 sense organ A muscular organ in the floor of the mouth. http://purl.obolibrary.org/obo/UBERON_0002048 lung http://purl.obolibrary.org/obo/UBERON_0000171 respiration organ Respiration organ that develops as an oupocketing of the esophagus. http://purl.obolibrary.org/obo/UBERON_0002106 spleen http://purl.obolibrary.org/obo/UBERON_0000062 organ the organ that functions to filter blood and to store red corpuscles and platelets http://purl.obolibrary.org/obo/UBERON_0002107 liver http://purl.obolibrary.org/obo/UBERON_0013765 digestive system element An exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes. http://purl.obolibrary.org/obo/UBERON_0002108 small intestine http://purl.obolibrary.org/obo/UBERON_0000160 intestine Subdivision of digestive tract that connects the stomach to the large intestine and is where much of the digestion and absorption of food takes place (with the exception of ruminants). The mammalian small intestine is long and coiled and can be differentiated histologically into: duodenum, jejunem, ileum[WP,cjm,Kardong]. http://purl.obolibrary.org/obo/UBERON_0002110 gall bladder http://purl.obolibrary.org/obo/UBERON_0013765 digestive system element An organ that aids digestion and stores bile produced by the liver[WP]. http://purl.obolibrary.org/obo/UBERON_0002113 kidney http://purl.obolibrary.org/obo/UBERON_0000062 organ A paired organ of the urinary tract which has the production of urine as its primary function. http://purl.obolibrary.org/obo/UBERON_0002204 musculoskeletal system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that consists of the muscular and skeletal systems. http://purl.obolibrary.org/obo/UBERON_0002240 spinal cord http://purl.obolibrary.org/obo/UBERON_0000062 organ Part of the central nervous system located in the vertebral canal continuous with and caudal to the brain; demarcated from brain by plane of foramen magnum. It is composed of an inner core of gray matter in which nerve cells predominate, and an outer layer of white matter in which myelinated nerve fibers predominate, and surrounds the central canal. (CUMBO) http://purl.obolibrary.org/obo/UBERON_0002330 exocrine system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that consists of the glands and parts of glands that produce exocrine secretions and help to integrate and control bodily metabolic activity. Exocrine glands are glands that secrete their products (hormones) into ducts (duct glands). They are the counterparts to endocrine glands, which secrete their products (hormones) directly into the bloodstream (ductless glands) or release hormones (paracrines) that affect only target cells nearby the release site. [Wikipedia]. http://purl.obolibrary.org/obo/UBERON_0002368 endocrine gland http://purl.obolibrary.org/obo/UBERON_0002530 gland Endocrine glands are glands of the endocrine system that secrete their products directly into the circulatory system rather than through a duct. http://purl.obolibrary.org/obo/UBERON_0002384 connective tissue http://purl.obolibrary.org/obo/UBERON_0000479 tissue Tissue with cells that deposit non-polarized extracellular matrix including connective tissue fibers and ground substance. http://purl.obolibrary.org/obo/UBERON_0002394 bile duct http://purl.obolibrary.org/obo/UBERON_0000025 tube (anatomical) Any of the ducts that form the biliary tree, carrying bile from the liver to the small intestine. http://purl.obolibrary.org/obo/UBERON_0002405 immune system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that protects the body from foreign substances, cells, and tissues by producing the immune response and that includes especially the thymus, spleen, lymphoid tissue, lymphocytes including the B cells and T cells, and antibodies. http://purl.obolibrary.org/obo/UBERON_0002416 integumental system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Connected anatomical system that forms a barrier between an animal and its environment. In vertebrates, the integumental system consists of the epidermis, dermis plus associated glands and adnexa such as hair and scales. In invertebrates, the integumental system may include cuticle. http://purl.obolibrary.org/obo/UBERON_0003133 reproductive organ http://purl.obolibrary.org/obo/UBERON_0000062 organ An organ involved in reproduction http://purl.obolibrary.org/obo/UBERON_0003134 female reproductive organ http://purl.obolibrary.org/obo/UBERON_0003133 reproductive organ A female organ involved in reproduction http://purl.obolibrary.org/obo/UBERON_0004535 cardiovascular system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that has as its parts the heart and blood vessels. http://purl.obolibrary.org/obo/OGG_0000000002 gene http://purl.obolibrary.org/obo/BFO_0000040 material entity A gene is a material entity that represents the entire DNA sequence required for synthesis of a functional protein or RNA molecule. http://purl.obolibrary.org/obo/OGG_2000002759 gene of Eukaryota http://purl.obolibrary.org/obo/OGG_0000000002 gene A gene of an organism of Eukaryota http://purl.obolibrary.org/obo/OGG_2000009606 gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_2000002759 gene of Eukaryota A gene of an organism of Homo sapiens http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_2000009606 gene of Homo sapiens A gene of Homo sapiens that has a protein-coding gene disposition http://purl.obolibrary.org/obo/OGG_2070009606 pseudo gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_2000009606 gene of Homo sapiens A gene of Homo sapiens that has a pseudo gene disposition http://purl.obolibrary.org/obo/OGG_2100009606 ncRNA gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_2110009606 RNA gene of Homo sapiens A gene of Homo sapiens that has a ncRNA gene disposition http://purl.obolibrary.org/obo/OGG_2110009606 RNA gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_2000009606 gene of Homo sapiens A gene of Homo sapiens that has a RNA gene disposition http://purl.obolibrary.org/obo/OGG_3000001649 DDIT3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens Other designations: C/EBP zeta|CCAAT/enhancer-binding protein homologous protein|DDIT-3|DNA damage-inducible transcript 3 protein|c/EBP-homologous protein 10|growth arrest and DNA damage-inducible protein GADD153 http://purl.obolibrary.org/obo/IMR_0001409 Gab http://purl.obolibrary.org/obo/CHEBI_25367 molecule Gab proteins contain a pleckstrin homology (PH) domain and binding sites for SH2 and SH3 domains. Gab family include mammalian Gab1, Gab2, Gab3, Drosophila Dos, and C. elegans Soc1. http://purl.obolibrary.org/obo/IMR_0000247 aPKC http://purl.obolibrary.org/obo/IMR_0000245 PKC atypical PKC isoforms (zeta and lambda/iota; PKC-lambda is the mouse ortholog of human PKC-iota) are insensitive to both calcium and DAG. http://purl.obolibrary.org/obo/IMR_0000262 MKK4/7(JNKK1/2) http://purl.obolibrary.org/obo/IMR_0000259 MAPKK MKK4 and MKK7 phosphorylate and activate JNK MAP kinases. http://purl.obolibrary.org/obo/IMR_0000263 MKK3/6 http://purl.obolibrary.org/obo/IMR_0000259 MAPKK MKK3 and MKK6 phosphorylate and activate p38 MAP kinases. http://purl.obolibrary.org/obo/IMR_0000370 Smad http://purl.obolibrary.org/obo/CHEBI_25367 molecule Smads is a conserved family of signal transducers. Functionally, Smads fall into three subfamilies:R-Smads; Co-Smads; I-Smads. Eight Smad proteins are encoded in vertebrate, four in Drosophila, and three in C. elegans. http://purl.obolibrary.org/obo/IMR_0002515 nonclassical MHC class I molecule http://purl.obolibrary.org/obo/IMR_0000142 MHC family The MHC class Ib family members include HLA-E, HLA-F, HLA-G and HFE (HLA-H) in humans and gene products from the H2-M, H2-Q and H2-T regions in mice. http://purl.obolibrary.org/obo/IMR_0000559 GADD45 http://purl.obolibrary.org/obo/CHEBI_25367 molecule The MyD118/CR6/Gadd45 gene family (also termed Gadd45b, Gadd45g, Gadd45a) encodes for small (18 kd), evolutionary conserved proteins that are highly homologous to each other (55 57% overall identity at the amino acid level), are highly acidic (pI=4.0 4.2), and are primarily localized within the cell nucleus. MyD118/CR6/GADD45 serve similar, but not identical, functions along different apoptotic and growth inhibitory pathways. They interact with cell cycle proteins. http://purl.obolibrary.org/obo/GOCHE_52214 substance with ligand role http://purl.obolibrary.org/obo/GOCHE_50906 substance with role Substance with ligand role is a subtype of substance with role. This entity is participating in signaling and playing a ligand role. http://purl.obolibrary.org/obo/CHEBI_10023 voriconazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4. http://purl.obolibrary.org/obo/CHEBI_100241 ciprofloxacin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively. http://purl.obolibrary.org/obo/CHEBI_10110 zidovudine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase. http://purl.obolibrary.org/obo/CHEBI_10112 zileuton http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogen at position 2 is replaced by a 1-[carbamoyl(hydroxy)amino]ethyl group. A selective 5-lipoxygenase inhibitor, it inhibits the formation of leukotrienes LTB4, LTC4, LDT4, and LTE4. It is used for the management of chronic asthma. http://purl.obolibrary.org/obo/CHEBI_101278 diltiazem http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension. http://purl.obolibrary.org/obo/CHEBI_16359 cholic acid http://purl.obolibrary.org/obo/TXPO_0000509 bile acid A bile acid that is 5β-cholan-24-oic acid bearing threeα-hydroxy substituents at position 3, 7 and 12. http://purl.obolibrary.org/obo/CHEBI_16670 peptide http://purl.obolibrary.org/obo/CHEBI_23367 molecular entity Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. http://purl.obolibrary.org/obo/CHEBI_22586 antioxidant http://purl.obolibrary.org/obo/CHEBI_51086 chemical role A role that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides. http://purl.obolibrary.org/obo/CHEBI_22587 antiviral agent http://purl.obolibrary.org/obo/CHEBI_33281 antimicrobial agent A substance that destroys or inhibits replication of viruses. http://purl.obolibrary.org/obo/CHEBI_22693 barbiturates http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Members of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure. http://purl.obolibrary.org/obo/CHEBI_23018 EC 4.2.1.1 (carbonic anhydrase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76907 EC 4.2.1.* (hydro-lyases) inhibitor An EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule. http://purl.obolibrary.org/obo/CHEBI_25212 metabolite http://purl.obolibrary.org/obo/CHEBI_52206 biochemical role Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. http://purl.obolibrary.org/obo/CHEBI_28794 coumarin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A chromenone having the keto group located at the 2-position. http://purl.obolibrary.org/obo/CHEBI_33281 antimicrobial agent http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. http://purl.obolibrary.org/obo/CHEBI_33282 antibacterial agent http://purl.obolibrary.org/obo/CHEBI_33281 antimicrobial agent A substance (or active part thereof) that kills or slows the growth of bacteria. http://purl.obolibrary.org/obo/CHEBI_33853 phenols http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. http://purl.obolibrary.org/obo/CHEBI_35221 antimetabolite http://purl.obolibrary.org/obo/CHEBI_52206 biochemical role A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization. http://purl.obolibrary.org/obo/CHEBI_35441 antiinfective agent http://purl.obolibrary.org/obo/CHEBI_23888 drug A substance used in the prophylaxis or therapy of infectious diseases. http://purl.obolibrary.org/obo/CHEBI_35470 central nervous system drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A class of drugs producing both physiological and psychological effects through a variety of mechanisms involving the central nervous system. http://purl.obolibrary.org/obo/CHEBI_35471 psychotropic drug http://purl.obolibrary.org/obo/CHEBI_35470 central nervous system drug A loosely defined grouping of drugs that have effects on psychological function. http://purl.obolibrary.org/obo/CHEBI_35472 anti-inflammatory drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A substance that reduces or suppresses inflammation. http://purl.obolibrary.org/obo/CHEBI_35474 anxiolytic drug http://purl.obolibrary.org/obo/CHEBI_35473 tranquilizing drug Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. http://purl.obolibrary.org/obo/CHEBI_35475 non-steroidal anti-inflammatory drug http://purl.obolibrary.org/obo/CHEBI_35842 antirheumatic drug An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. http://purl.obolibrary.org/obo/CHEBI_35476 antipsychotic agent http://purl.obolibrary.org/obo/CHEBI_35473 tranquilizing drug Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. http://purl.obolibrary.org/obo/CHEBI_35480 analgesic http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. http://purl.obolibrary.org/obo/CHEBI_35488 central nervous system depressant http://purl.obolibrary.org/obo/CHEBI_35470 central nervous system drug A loosely defined group of drugs that tend to reduce the activity of the central nervous system. http://purl.obolibrary.org/obo/CHEBI_35498 diuretic http://purl.obolibrary.org/obo/CHEBI_23888 drug An agent that promotes the excretion of urine through its effects on kidney function. http://purl.obolibrary.org/obo/CHEBI_35610 antineoplastic agent http://purl.obolibrary.org/obo/CHEBI_23888 drug A substance that inhibits or prevents the proliferation of neoplasms. http://purl.obolibrary.org/obo/CHEBI_35620 vasodilator agent http://purl.obolibrary.org/obo/CHEBI_35554 cardiovascular drug A drug used to cause dilation of the blood vessels. http://purl.obolibrary.org/obo/CHEBI_35623 anticonvulsant http://purl.obolibrary.org/obo/CHEBI_35488 central nervous system depressant A drug used to prevent seizures or reduce their severity. http://purl.obolibrary.org/obo/CHEBI_35674 antihypertensive agent http://purl.obolibrary.org/obo/CHEBI_35554 cardiovascular drug Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. http://purl.obolibrary.org/obo/CHEBI_35703 xenobiotic http://purl.obolibrary.org/obo/CHEBI_24432 biological role A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. http://purl.obolibrary.org/obo/CHEBI_35717 sedative http://purl.obolibrary.org/obo/CHEBI_35488 central nervous system depressant A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. http://purl.obolibrary.org/obo/CHEBI_35718 antifungal agent http://purl.obolibrary.org/obo/CHEBI_33281 antimicrobial agent An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce. http://purl.obolibrary.org/obo/CHEBI_36044 antiviral drug http://purl.obolibrary.org/obo/CHEBI_36043 antimicrobial drug A substance used in the prophylaxis or therapy of virus diseases. http://purl.obolibrary.org/obo/CHEBI_36047 antibacterial drug http://purl.obolibrary.org/obo/CHEBI_36043 antimicrobial drug A drug used to treat or prevent bacterial infections. http://purl.obolibrary.org/obo/CHEBI_37890 alpha-adrenergic antagonist http://purl.obolibrary.org/obo/CHEBI_48539 alpha-adrenergic drug An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. http://purl.obolibrary.org/obo/CHEBI_37956 histamine antagonist http://purl.obolibrary.org/obo/CHEBI_37957 histaminergic drug Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. http://purl.obolibrary.org/obo/CHEBI_38215 calcium channel blocker http://purl.obolibrary.org/obo/CHEBI_38808 calcium channel modulator One of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools. http://purl.obolibrary.org/obo/CHEBI_48279 serotonergic antagonist http://purl.obolibrary.org/obo/CHEBI_48278 serotonergic drug Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. http://purl.obolibrary.org/obo/CHEBI_48422 angiogenesis inhibitor http://purl.obolibrary.org/obo/CHEBI_23888 drug An agent and endogenous substances that antagonize or inhibit the development of new blood vessels. http://purl.obolibrary.org/obo/CHEBI_48550 EC 1.1.1.21 (aldehyde reductase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76835 EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor An EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of aldehyde reductase (EC 1.1.1.21). http://purl.obolibrary.org/obo/CHEBI_48561 dopaminergic antagonist http://purl.obolibrary.org/obo/CHEBI_48560 dopaminergic agent A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. http://purl.obolibrary.org/obo/CHEBI_48876 muscarinic antagonist http://purl.obolibrary.org/obo/CHEBI_48873 cholinergic antagonist A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists. http://purl.obolibrary.org/obo/CHEBI_49103 drug metabolite http://purl.obolibrary.org/obo/CHEBI_76967 human xenobiotic metabolite Any human metabolite produced by metabolism of drugs in humans. http://purl.obolibrary.org/obo/CHEBI_49159 leukotriene antagonist http://purl.obolibrary.org/obo/CHEBI_49020 hormone antagonist A drug designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. http://purl.obolibrary.org/obo/CHEBI_49167 anti-asthmatic drug http://purl.obolibrary.org/obo/CHEBI_65023 anti-asthmatic agent A drug used to treat asthma. http://purl.obolibrary.org/obo/CHEBI_50176 keratolytic drug http://purl.obolibrary.org/obo/CHEBI_50177 dermatologic drug A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. http://purl.obolibrary.org/obo/CHEBI_50183 P450 inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances. http://purl.obolibrary.org/obo/CHEBI_50249 anticoagulant http://purl.obolibrary.org/obo/CHEBI_50248 hematologic agent An agent that prevents blood clotting. http://purl.obolibrary.org/obo/CHEBI_50267 protective agent http://purl.obolibrary.org/obo/CHEBI_23888 drug Synthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. http://purl.obolibrary.org/obo/CHEBI_50502 EC 2.5.1.15 (dihydropteroate synthase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76663 EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate. http://purl.obolibrary.org/obo/CHEBI_50514 vasoconstrictor agent http://purl.obolibrary.org/obo/CHEBI_35554 cardiovascular drug Drug used to cause constriction of the blood vessels. http://purl.obolibrary.org/obo/CHEBI_50629 cyclooxygenase 2 inhibitor http://purl.obolibrary.org/obo/CHEBI_35544 EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor A cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2. http://purl.obolibrary.org/obo/CHEBI_50750 EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor http://purl.obolibrary.org/obo/CHEBI_70727 topoisomerase inhibitor A topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity http://purl.obolibrary.org/obo/CHEBI_24431 chemical entity Any molecular entity that contains carbon. http://purl.obolibrary.org/obo/CHEBI_50903 carcinogenic agent http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities. http://purl.obolibrary.org/obo/CHEBI_50925 EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor http://purl.obolibrary.org/obo/CHEBI_23924 enzyme inhibitor An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine. http://purl.obolibrary.org/obo/CHEBI_52214 ligand http://purl.obolibrary.org/obo/CHEBI_51086 chemical role Any molecule or ion capable of binding to a central metal atom to form coordination complexes. http://purl.obolibrary.org/obo/CHEBI_53559 topoisomerase IV inhibitor http://purl.obolibrary.org/obo/CHEBI_70727 topoisomerase inhibitor A topoisomerase inhibitor that inhibits DNA topoisomerase IV, which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. http://purl.obolibrary.org/obo/CHEBI_53756 HIV-1 reverse transcriptase inhibitor http://purl.obolibrary.org/obo/CHEBI_52629 EC 3.1.26.13 (retroviral ribonuclease H) inhibitor An entity which inhibits the activity of HIV-1 reverse transcriptase. http://purl.obolibrary.org/obo/CHEBI_59517 DNA synthesis inhibitor http://purl.obolibrary.org/obo/CHEBI_76932 pathway inhibitor Any substance that inhibits the synthesis of DNA. http://purl.obolibrary.org/obo/CHEBI_63726 neuroprotective agent http://purl.obolibrary.org/obo/CHEBI_50267 protective agent Any compound that can be used for the treatment of neurodegenerative disorders. http://purl.obolibrary.org/obo/CHEBI_64964 EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76837 EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitor A lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34). http://purl.obolibrary.org/obo/CHEBI_65023 anti-asthmatic agent http://purl.obolibrary.org/obo/CHEBI_23888 drug Any compound that has anti-asthmatic effects. http://purl.obolibrary.org/obo/CHEBI_68495 apoptosis inducer http://purl.obolibrary.org/obo/TXPO_0000327 apoptosis regulator role Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. http://purl.obolibrary.org/obo/CHEBI_75767 animal metabolite http://purl.obolibrary.org/obo/CHEBI_75763 eukaryotic metabolite Any eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals. http://purl.obolibrary.org/obo/CHEBI_75771 mouse metabolite http://purl.obolibrary.org/obo/CHEBI_75768 mammalian metabolite Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). http://purl.obolibrary.org/obo/CHEBI_76946 fungal metabolite http://purl.obolibrary.org/obo/CHEBI_75763 eukaryotic metabolite Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds. http://purl.obolibrary.org/obo/CHEBI_76971 Escherichia coli metabolite http://purl.obolibrary.org/obo/CHEBI_76969 bacterial metabolite Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. http://purl.obolibrary.org/obo/CHEBI_78298 environmental contaminant http://purl.obolibrary.org/obo/CHEBI_51086 chemical role Any minor or unwanted substance introduced into the environment that can have undesired effects. http://purl.obolibrary.org/obo/CHEBI_8069 phenobarbital http://purl.obolibrary.org/obo/CHEBI_22693 barbiturates A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups. http://purl.obolibrary.org/obo/CHEBI_8107 phenytoin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5. http://purl.obolibrary.org/obo/CHEBI_88188 drug allergen http://purl.obolibrary.org/obo/CHEBI_23888 drug Any drug which causes the onset of an allergic reaction. http://purl.obolibrary.org/obo/CHEBI_9334 sulfasalazine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. http://purl.obolibrary.org/obo/CHEBI_16749 1-phosphatidyl-1D-myo-inositol http://purl.obolibrary.org/obo/CHEBI_28874 phosphatidylinositol A phosphatidylinositol in which the inositol moiety is the 1D-myo isomer and the phosphatidyl group is located at its position 1. http://purl.obolibrary.org/obo/CHEBI_18320 1,4-dithiothreitol http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol. http://purl.obolibrary.org/obo/CHEBI_23354 coenzyme http://purl.obolibrary.org/obo/CHEBI_23357 cofactor A low-molecular-weight, non-protein organic compound participating in enzymatic reactions as dissociable acceptor or donor of chemical groups or electrons. http://purl.obolibrary.org/obo/CHEBI_27136 triol http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A chemical compound containing three hydroxy groups. http://purl.obolibrary.org/obo/CHEBI_28077 rifampicin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of rifamycins that is a a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (previously known as Amycolatopsis mediterranei and Streptomyces mediterranei) http://purl.obolibrary.org/obo/CHEBI_42355 erythromycin A http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. http://purl.obolibrary.org/obo/CHEBI_50185 fatty acid synthesis inhibitor http://purl.obolibrary.org/obo/TXPO_0003648 fatty accid metabolic regulator role Any pathway inhibitor that inhibits the synthesis of fatty acids. http://purl.obolibrary.org/obo/CHEBI_63247 reducing agent http://purl.obolibrary.org/obo/CHEBI_51086 chemical role The element or compound in a reduction-oxidation (redox) reaction that donates an electron to another species. http://purl.obolibrary.org/obo/CHEBI_65001 EC 3.1.1.3 (triacylglycerol lipase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76773 EC 3.1.1.* (carboxylic ester hydrolase) inhibitor Any EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of triacylglycerol lipase (EC 3.1.1.3). http://purl.obolibrary.org/obo/CHEBI_75763 eukaryotic metabolite http://purl.obolibrary.org/obo/CHEBI_25212 metabolite Any metabolite produced during a metabolic reaction in eukaryotes, the taxon that include members of the fungi, plantae and animalia kingdoms. http://purl.obolibrary.org/obo/CHEBI_76969 bacterial metabolite http://purl.obolibrary.org/obo/CHEBI_75787 prokaryotic metabolite Any prokaryotic metabolite produced during a metabolic reaction in bacteria. http://purl.obolibrary.org/obo/CHEBI_16412 liposaccharide http://purl.obolibrary.org/obo/CHEBI_18154 polysaccharide Liposaccharide natural compounds consisting of a trisaccharide repeating unit (two heptose units and octulosonic acid) with oligosaccharide side chains and 3-hydroxytetradecanoic acid units (they are a major constituent of the cell walls of Gram-negative bacteria). http://purl.obolibrary.org/obo/CHEBI_16856 L-gamma-glutamyl-L-cysteinylglycine http://purl.obolibrary.org/obo/CHEBI_16670 peptide A tripeptide compound consisting of glutamic acid attached via its side chain to the N-terminus of cysteinylglycine. http://purl.obolibrary.org/obo/CHEBI_17761 ceramide http://purl.obolibrary.org/obo/CHEBI_26739 sphingolipid Ceramides (N-acyl-sphingoid bases) are a major subclass of sphingoid base derivatives with an amide-linked fatty acid. The fatty acids are typically saturated or monounsaturated with chain lengths from 14 to 26 carbon atoms; the presence of a hydroxyl group on carbon 2 is fairly common. Ceramides are generally precursors of more complex sphingolipids. In the illustrated generalised structure, R(1) = OH, OX (where X = acyl, glycosyl, phosphate, phosphonate, etc.), or H. http://purl.obolibrary.org/obo/CHEBI_25435 mutagen http://purl.obolibrary.org/obo/CHEBI_50902 genotoxin An agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution. http://purl.obolibrary.org/obo/CHEBI_35442 antiparasitic agent http://purl.obolibrary.org/obo/CHEBI_35441 antiinfective agent A substance used to treat or prevent parasitic infections. http://purl.obolibrary.org/obo/CHEBI_50790 EC 1.14.14.14 (aromatase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76838 EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor An EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor which interferes with the action of aromatase (EC 1.14.14.14) and so reduces production of estrogenic steroid hormones. http://purl.obolibrary.org/obo/CHEBI_127342 atomoxetine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents. http://purl.obolibrary.org/obo/CHEBI_16038 phosphatidylethanolamine http://purl.obolibrary.org/obo/CHEBI_36314 glycerophosphoethanolamine A class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxy group of ethanolamine. http://purl.obolibrary.org/obo/CHEBI_35381 monosaccharide http://purl.obolibrary.org/obo/CHEBI_16646 carbohydrate Parent monosaccharides are polyhydroxy aldehydes H[CH(OH)]nC(=O)H or polyhydroxy ketones H-[CHOH]n-C(=O)[CHOH]m-H with three or more carbon atoms. The generic term 'monosaccharide' (as opposed to oligosaccharide or polysaccharide) denotes a single unit, without glycosidic connection to other such units. It includes aldoses, dialdoses, aldoketoses, ketoses and diketoses, as well as deoxy sugars, provided that the parent compound has a (potential) carbonyl group. http://purl.obolibrary.org/obo/CHEBI_35640 adrenergic uptake inhibitor http://purl.obolibrary.org/obo/CHEBI_37962 adrenergic agent Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. http://purl.obolibrary.org/obo/CHEBI_38070 anti-arrhythmia drug http://purl.obolibrary.org/obo/CHEBI_35554 cardiovascular drug A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. http://purl.obolibrary.org/obo/CHEBI_4909 etodolac http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active. http://purl.obolibrary.org/obo/CHEBI_61115 EC 3.5.1.98 (histone deacetylase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76807 EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98). http://purl.obolibrary.org/obo/CHEBI_16325 lithocholic acid http://purl.obolibrary.org/obo/TXPO_0000509 bile acid A monohydroxy-5β-cholanic acid with aα-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action. http://purl.obolibrary.org/obo/CHEBI_16755 chenodeoxycholic acid http://purl.obolibrary.org/obo/TXPO_0000509 bile acid A dihydroxy-5β-cholanic acid that is (5β)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively. http://purl.obolibrary.org/obo/CHEBI_23965 estradiol http://purl.obolibrary.org/obo/CHEBI_35341 steroid A 3-hydroxy steroid that is estra-1,3,5(10)-triene substituted by hydroxy groups at positions 3 and 17. http://purl.obolibrary.org/obo/CHEBI_25355 mitochondrial respiratory-chain inhibitor http://purl.obolibrary.org/obo/CHEBI_38497 respiratory-chain inhibitor A role played by the entity that inhibits the mitochondrial respiratory-chain. http://purl.obolibrary.org/obo/CHEBI_26523 reactive oxygen species http://purl.obolibrary.org/obo/CHEBI_25806 oxygen molecular entity Molecules or ions formed by the incomplete one-electron reduction of oxygen. They contribute to the microbicidal activity of phagocytes, regulation of signal transduction and gene expression, and the oxidative damage to biopolymers. http://purl.obolibrary.org/obo/CHEBI_28757 fructose http://purl.obolibrary.org/obo/CHEBI_35381 monosaccharide A ketohexose that is an isomer of glucose. http://purl.obolibrary.org/obo/CHEBI_28834 deoxycholic acid http://purl.obolibrary.org/obo/TXPO_0000509 bile acid A bile acid that is 5β-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively. http://purl.obolibrary.org/obo/CHEBI_28874 phosphatidylinositol http://purl.obolibrary.org/obo/CHEBI_36315 glycerophosphoinositol Any glycerophosphoinositol having one phosphatidyl group esterified to one of the hydroxy groups of inositol. http://purl.obolibrary.org/obo/CHEBI_35487 EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor http://purl.obolibrary.org/obo/CHEBI_76852 EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor An EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of aldehyde dehydrogenase (NAD(+)), EC 1.2.1.3. http://purl.obolibrary.org/obo/CHEBI_35679 antilipemic drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A substance used to treat hyperlipidemia (an excess of lipids in the blood). http://purl.obolibrary.org/obo/CHEBI_35821 anticholesteremic drug http://purl.obolibrary.org/obo/CHEBI_35679 antilipemic drug A substance used to lower plasma cholesterol levels. http://purl.obolibrary.org/obo/CHEBI_36043 antimicrobial drug http://purl.obolibrary.org/obo/CHEBI_35441 antiinfective agent A drug used to treat or prevent microbial infections. http://purl.obolibrary.org/obo/CHEBI_36315 glycerophosphoinositol http://purl.obolibrary.org/obo/CHEBI_37739 glycerophospholipid Any glycerophospholipid having the polar alcohol inositol esterified to the phosphate group at the sn-3 position of the glycerol backbone. http://purl.obolibrary.org/obo/CHEBI_37733 EC 3.1.1.8 (cholinesterase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76773 EC 3.1.1.* (carboxylic ester hydrolase) inhibitor An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8). http://purl.obolibrary.org/obo/CHEBI_37739 glycerophospholipid http://purl.obolibrary.org/obo/CHEBI_35741 glycerolipid Any glycerolipid having a phosphate group ester-linked to a terminal carbon of the glycerol backbone. http://purl.obolibrary.org/obo/CHEBI_37962 adrenergic agent http://purl.obolibrary.org/obo/CHEBI_35942 neurotransmitter agent Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter. http://purl.obolibrary.org/obo/CHEBI_46787 solvent http://purl.obolibrary.org/obo/CHEBI_51086 chemical role A liquid that can dissolve other substances (solutes) without any change in their chemical composition. http://purl.obolibrary.org/obo/CHEBI_48407 antiparkinson drug http://purl.obolibrary.org/obo/CHEBI_66956 antidyskinesia agent A drug used in the treatment of Parkinson's disease. http://purl.obolibrary.org/obo/CHEBI_48560 dopaminergic agent http://purl.obolibrary.org/obo/CHEBI_35942 neurotransmitter agent A drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. http://purl.obolibrary.org/obo/CHEBI_490877 didanosine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS. http://purl.obolibrary.org/obo/CHEBI_49323 contraceptive drug http://purl.obolibrary.org/obo/CHEBI_50689 reproductive control drug A chemical substance that prevents or reduces the probability of conception. http://purl.obolibrary.org/obo/CHEBI_50248 hematologic agent http://purl.obolibrary.org/obo/CHEBI_23888 drug Drug that acts on blood and blood-forming organs and those that affect the hemostatic system. http://purl.obolibrary.org/obo/CHEBI_50276 EC 5.99.1.2 (DNA topoisomerase) inhibitor http://purl.obolibrary.org/obo/CHEBI_70727 topoisomerase inhibitor A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA. http://purl.obolibrary.org/obo/CHEBI_50469 phospholipase A2 inhibitor http://purl.obolibrary.org/obo/CHEBI_76759 EC 3.* (hydrolase) inhibitor An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of phospholipase A2 (EC 3.1.1.4). http://purl.obolibrary.org/obo/CHEBI_59826 progestin http://purl.obolibrary.org/obo/CHEBI_50745 progestogen A synthetic progestogen. http://purl.obolibrary.org/obo/CHEBI_60169 phosphatidylinositol trisphosphate http://purl.obolibrary.org/obo/CHEBI_28765 phosphatidylinositol phosphate A derivative of phosphatidylinositol in which the inositol ring is phosphorylated at three unspecified positions. http://purl.obolibrary.org/obo/CHEBI_60832 tubulin modulator http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role Any substance that interacts with tubulin to inhibit or promote polymerisation of microtubules. http://purl.obolibrary.org/obo/CHEBI_61951 microtubule-destabilising agent http://purl.obolibrary.org/obo/CHEBI_60832 tubulin modulator Any substance that interacts with tubulin to inhibit polymerisation of microtubules. http://purl.obolibrary.org/obo/CHEBI_64018 protein kinase C agonist http://purl.obolibrary.org/obo/CHEBI_64106 protein kinase agonist An agonist that selectively binds to and activates a protein kinase C receptor http://purl.obolibrary.org/obo/CHEBI_65207 vascular endothelial growth factor receptor antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist An antagonist at the vascular endothelial growth factor receptor. http://purl.obolibrary.org/obo/CHEBI_65232 EC 3.4.21.5 (thrombin) inhibitor http://purl.obolibrary.org/obo/CHEBI_5924 EC 3.4.21.* (serine endopeptidase) inhibitor An EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of thrombin (EC 3.4.21.5). http://purl.obolibrary.org/obo/CHEBI_66956 antidyskinesia agent http://purl.obolibrary.org/obo/CHEBI_23888 drug Any compound which can be used to treat or alleviate the symptoms of dyskinesia. http://purl.obolibrary.org/obo/CHEBI_76779 EC 3.4.21.26 (prolyl oligopeptidase) inhibitor http://purl.obolibrary.org/obo/CHEBI_5924 EC 3.4.21.* (serine endopeptidase) inhibitor Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26). http://purl.obolibrary.org/obo/CHEBI_77113 IkappaB kinase inhibitor http://purl.obolibrary.org/obo/CHEBI_23924 enzyme inhibitor An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of IkappaB kinase (EC 2.7.11.10). http://purl.obolibrary.org/obo/CHEBI_78444 EC 3.1.1.1 (carboxylesterase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76773 EC 3.1.1.* (carboxylic ester hydrolase) inhibitor Any EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of carboxylesterase (EC 3.1.1.1 ). http://purl.obolibrary.org/obo/CHEBI_175901 gemcitabine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. http://purl.obolibrary.org/obo/CHEBI_26739 sphingolipid http://purl.obolibrary.org/obo/CHEBI_18059 lipid Sphingolipids are a complex family of compounds that share a common structural feature, a sphingoid base backbone. http://purl.obolibrary.org/obo/CHEBI_27226 uric acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An oxopurine that is the final oxidation product of purine metabolism. http://purl.obolibrary.org/obo/CHEBI_28901 busulfan http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A methanesulfonate ester that is butane-1,4-diol in which the hydrogens of the hydroxy groups are replaced by methanesulfonyl groups. An alkylating antineoplastic agent, it is used for the treatment of chronic myeloid leukemia (although it has been largely replaced by newer drugs). It is also used as an insect sterilant. http://purl.obolibrary.org/obo/CHEBI_3179 bromobenzene http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity The simplest member of the class of bromobenzenes, that is benzene in which a single hydrogen has been substituted by a bromine. A liquid at room temperature (m.p. -30degreeC; b.p.760 156degreeC), it is used as a solvent, particularly for large-scale crystallisations, and for the introduction of phenyl groups in organic synthesis. http://purl.obolibrary.org/obo/CHEBI_33694 biomacromolecule http://purl.obolibrary.org/obo/CHEBI_36357 polyatomic entity A macromolecule formed by a living organism. http://purl.obolibrary.org/obo/CHEBI_33697 ribonucleic acid http://purl.obolibrary.org/obo/CHEBI_33696 nucleic acid High molecular weight, linear polymers, composed of nucleotides containing ribose and linked by phosphodiester bonds; RNA is central to the synthesis of proteins. http://purl.obolibrary.org/obo/CHEBI_35544 EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76840 EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor A compound or agent that combines with cyclooxygenases (EC 1.14.99.1) and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of icosanoids, prostaglandins, and thromboxanes. http://purl.obolibrary.org/obo/CHEBI_35569 alpha-adrenergic agonist http://purl.obolibrary.org/obo/CHEBI_48539 alpha-adrenergic drug An agent that selectively binds to and activates alpha-adrenergic receptors. http://purl.obolibrary.org/obo/CHEBI_35741 glycerolipid http://purl.obolibrary.org/obo/CHEBI_18059 lipid Any member of the group of lipids containing a common glycerol backbone to which at least one fatty acid-derived group is attached. http://purl.obolibrary.org/obo/CHEBI_36413 anabolic agent http://purl.obolibrary.org/obo/CHEBI_24621 hormone A compound which stimulates anabolism and inhibits catabolism. Anabolic agents stimulate the development of muscle mass, strength, and power. http://purl.obolibrary.org/obo/CHEBI_38147 cardiotonic drug http://purl.obolibrary.org/obo/CHEBI_35554 cardiovascular drug A drug that has a strengthening effect on the heart or that can increase cardiac output. http://purl.obolibrary.org/obo/CHEBI_38637 tyrosine kinase inhibitor http://purl.obolibrary.org/obo/CHEBI_37699 protein kinase inhibitor Any protein kinase inhibitor that interferes with the action of tyrosine kinase. http://purl.obolibrary.org/obo/CHEBI_38807 calcium channel agonist http://purl.obolibrary.org/obo/CHEBI_38808 calcium channel modulator Agents that increase calcium influx into calcium channels of excitable tissues. http://purl.obolibrary.org/obo/CHEBI_38808 calcium channel modulator http://purl.obolibrary.org/obo/CHEBI_38632 membrane transport modulator A membrane transport modulator that is able to regulate intracellular calcium levels. http://purl.obolibrary.org/obo/CHEBI_4439 dermatan http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A mucopolysaccharide consisting of repeating beta-(1->4)-linked L-iduronyl-(beta1->3)-N-acetyl-D-galactosamine units. http://purl.obolibrary.org/obo/CHEBI_48873 cholinergic antagonist http://purl.obolibrary.org/obo/CHEBI_38323 cholinergic drug Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. http://purl.obolibrary.org/obo/CHEBI_50671 antithyroid drug http://purl.obolibrary.org/obo/CHEBI_49020 hormone antagonist A drug used to treat hyperthyroidism by reducing the excessive production of thyroid hormones. http://purl.obolibrary.org/obo/CHEBI_50748 antipsoriatic http://purl.obolibrary.org/obo/CHEBI_50177 dermatologic drug A drug used to treat psoriasis. http://purl.obolibrary.org/obo/CHEBI_50846 immunomodulator http://purl.obolibrary.org/obo/CHEBI_23888 drug Biologically active substance whose activity affects or plays a role in the functioning of the immune system. http://purl.obolibrary.org/obo/CHEBI_50908 hepatotoxic agent http://purl.obolibrary.org/obo/TXPO_0000038 toxic agent A role played by an entity exihibiting itself through the ability to induce damage to the liver in animals. http://purl.obolibrary.org/obo/CHEBI_74213 EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76848 EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitor An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that inhibits the action of ribonucleoside-diphosphate reductase (EC 1.17.4.1). http://purl.obolibrary.org/obo/CHEBI_77326 androstane receptor agonist http://purl.obolibrary.org/obo/CHEBI_48705 agonist An agonist that selectively binds to and activates androstane receptors. http://purl.obolibrary.org/obo/CHEBI_3090 bicalutamide http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism. http://purl.obolibrary.org/obo/CHEBI_31183 alclofenac http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash. http://purl.obolibrary.org/obo/CHEBI_31257 bendazac http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts. http://purl.obolibrary.org/obo/CHEBI_31596 febuxostat http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout. http://purl.obolibrary.org/obo/CHEBI_31653 glafenine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market. http://purl.obolibrary.org/obo/CHEBI_31781 lopinavir http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A dicarboxylic acid amide in which a parent structure of amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir. http://purl.obolibrary.org/obo/CHEBI_31941 oxaliplatin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A platinum coordination entity that is a commonly used chemothrepeutic drug for treatment of colorectal cancer. http://purl.obolibrary.org/obo/CHEBI_35660 HIV protease inhibitor http://purl.obolibrary.org/obo/CHEBI_64946 anti-HIV agent An inhibitor of HIV protease, an enzyme required for production of proteins needed for viral assembly. http://purl.obolibrary.org/obo/CHEBI_37887 adrenergic antagonist http://purl.obolibrary.org/obo/CHEBI_37962 adrenergic agent An agent that binds to but does not activate adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. http://purl.obolibrary.org/obo/CHEBI_37924 atazanavir http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV). http://purl.obolibrary.org/obo/CHEBI_45783 imatinib http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. http://purl.obolibrary.org/obo/CHEBI_46081 fluconazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis. http://purl.obolibrary.org/obo/CHEBI_48539 alpha-adrenergic drug http://purl.obolibrary.org/obo/CHEBI_37962 adrenergic agent Any drug that acts on an alpha-adrenergic receptor. http://purl.obolibrary.org/obo/CHEBI_48676 fibrin modulating drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug that affects the function of fibrin in blood coagulation. http://purl.obolibrary.org/obo/CHEBI_50691 abortifacient http://purl.obolibrary.org/obo/CHEBI_50689 reproductive control drug A chemical substance that interrupts pregnancy after implantation. http://purl.obolibrary.org/obo/CHEBI_50739 estrogen receptor modulator http://purl.obolibrary.org/obo/CHEBI_23888 drug A substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure. http://purl.obolibrary.org/obo/CHEBI_50792 estrogen receptor antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist An antagonist at the estrogen receptor. http://purl.obolibrary.org/obo/CHEBI_50837 estrogen antagonist http://purl.obolibrary.org/obo/CHEBI_49020 hormone antagonist A compound which inhibits or antagonises the biosynthesis or actions of estrogens. http://purl.obolibrary.org/obo/CHEBI_50864 insulin-sensitizing drug http://purl.obolibrary.org/obo/CHEBI_48705 agonist An agent which overcomes insulin resistance by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma). http://purl.obolibrary.org/obo/CHEBI_59285 EC 1.14.13.132 (squalene monooxygenase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76841 EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor An EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of squalene monooxygenase (EC 1.14.13.132). http://purl.obolibrary.org/obo/CHEBI_65191 second generation antipsychotic http://purl.obolibrary.org/obo/TXPO_0003658 antipsychotic agent Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements. http://purl.obolibrary.org/obo/CHEBI_32499 amineptine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne. http://purl.obolibrary.org/obo/CHEBI_33290 food role http://purl.obolibrary.org/obo/CHEBI_24432 biological role Any material that can be ingested by an organism. http://purl.obolibrary.org/obo/CHEBI_35477 antimanic drug http://purl.obolibrary.org/obo/CHEBI_35473 tranquilizing drug Antimanic drugs are agents used to treat bipolar disorders or mania associated with other affective disorders. http://purl.obolibrary.org/obo/CHEBI_64370 glutamate transporter activator http://purl.obolibrary.org/obo/CHEBI_64371 neurotransmitter transporter modulator A neurotransmitter transporter modulator that activates glutamate transporters. http://purl.obolibrary.org/obo/CHEBI_45409 ritonavir http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An L-valine derivative that is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. http://purl.obolibrary.org/obo/CHEBI_45979 thiabendazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of benzimidazoles carrying a 1,3-thiazol-4-yl substituent at position 2. A mainly post-harvest fungicide used to control a wide range of diseases including Aspergillus, Botrytis, Cladosporium and Fusarium. http://purl.obolibrary.org/obo/CHEBI_45980 tacrine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease. http://purl.obolibrary.org/obo/CHEBI_4659 disulfiram http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid. A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties. http://purl.obolibrary.org/obo/CHEBI_474180 caspofungin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A semisynthetic cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. http://purl.obolibrary.org/obo/CHEBI_47499 imipramine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Imipramine is a tricyclic antidepressant that continues to be widely used in the therapy of depression. Imipramine can cause mild and transient serum enzyme elevations and is rare cause of clinically apparent acute cholestatic liver injury. http://purl.obolibrary.org/obo/CHEBI_47519 ketoconazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-ketoconazole. http://purl.obolibrary.org/obo/CHEBI_48406 EC 2.1.1.6 (catechol O-methyltransferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76871 EC 2.1.1.* (methyltransferases) inhibitor An EC 2.1.1.* (methyltransferase) inhibitor that interferes with the action of catechol O-methyltransferase (EC 2.1.1.6). http://purl.obolibrary.org/obo/CHEBI_50924 sorafenib http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 4-chloro-3-trifluorophenyl group while the other is substituted by a phenyl group which, in turn, is substituted at the para position by a [2-(methylcarbamoyl)pyridin-4-yl]oxy group. http://purl.obolibrary.org/obo/CHEBI_5924 EC 3.4.21.* (serine endopeptidase) inhibitor http://purl.obolibrary.org/obo/CHEBI_60258 EC 3.4.* (hydrolases acting on peptide bond) inhibitor Any EC 3.4.* (hydrolases acting on peptide bond) inhibitor that inhibits the activity of a serine endopeptidase (EC 3.4.21.*). http://purl.obolibrary.org/obo/CHEBI_600520 micafungin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy. http://purl.obolibrary.org/obo/CHEBI_51451 endothelin receptor antagonist http://purl.obolibrary.org/obo/CHEBI_49020 hormone antagonist A hormone antagonist that blocks endothelin receptors. http://purl.obolibrary.org/obo/CHEBI_52629 EC 3.1.26.13 (retroviral ribonuclease H) inhibitor http://purl.obolibrary.org/obo/CHEBI_76785 EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitor An inhibitor of ribonuclease H (EC 3.1.26.13), an enzyme required for specific hydrolysis of the RNA strand of an RNA/DNA hybrid. http://purl.obolibrary.org/obo/CHEBI_61910 very long-chain fatty acyl-CoA http://purl.obolibrary.org/obo/CHEBI_37554 fatty acyl-CoA A fatty acyl-CoA in which the fatty acyl group has a chain length greater than C22. http://purl.obolibrary.org/obo/CHEBI_76761 EC 3.2.* (glycosylase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76759 EC 3.* (hydrolase) inhibitor A hydrolase inhibitor that interferes with the action of any glycosylase (EC 3.2.*.*). http://purl.obolibrary.org/obo/CHEBI_76785 EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitor http://purl.obolibrary.org/obo/CHEBI_76760 EC 3.1.* (ester hydrolase) inhibitor An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of any endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*). http://purl.obolibrary.org/obo/CHEBI_6717 mefenamic acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. http://purl.obolibrary.org/obo/CHEBI_6741 meloxicam http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis. http://purl.obolibrary.org/obo/CHEBI_7466 nandrolone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17. http://purl.obolibrary.org/obo/CHEBI_7496 nelfinavir http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. http://purl.obolibrary.org/obo/CHEBI_75142 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. http://purl.obolibrary.org/obo/CHEBI_76848 EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76744 EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that interferes with the activity of any such enzyme that uses a disulfide as acceptor (EC 1.17.4.*). http://purl.obolibrary.org/obo/CHEBI_9337 sulfathiazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position. http://purl.obolibrary.org/obo/GO_0005504 fatty acid binding http://purl.obolibrary.org/obo/GO_0008289 lipid binding Interacting selectively and non-covalently with fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis. http://purl.obolibrary.org/obo/GO_0005575 cellular_component http://purl.obolibrary.org/obo/UBERON_0001062 anatomical entity The part of a cell or its extracellular environment in which a gene product is located. A gene product may be located in one or more parts of a cell and its location may be as specific as a particular macromolecular complex, that is, a stable, persistent association of macromolecules that function together. http://purl.obolibrary.org/obo/GO_0005576 extracellular region http://purl.obolibrary.org/obo/GO_0044464 cell part The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. http://purl.obolibrary.org/obo/GO_0005615 extracellular space http://purl.obolibrary.org/obo/GO_0044464 cell part That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. http://purl.obolibrary.org/obo/GO_0005743 mitochondrial inner membrane http://purl.obolibrary.org/obo/GO_0031966 mitochondrial membrane The inner, i.e. lumen-facing, lipid bilayer of the mitochondrial envelope. It is highly folded to form cristae. http://purl.obolibrary.org/obo/GO_0005747 mitochondrial respiratory chain complex I http://purl.obolibrary.org/obo/GO_0098800 inner mitochondrial membrane protein complex A protein complex located in the mitochondrial inner membrane that forms part of the mitochondrial respiratory chain. It contains about 25 different polypeptide subunits, including NADH dehydrogenase (ubiquinone), flavin mononucleotide and several different iron-sulfur clusters containing non-heme iron. The iron undergoes oxidation-reduction between Fe(II) and Fe(III), and catalyzes proton translocation linked to the oxidation of NADH by ubiquinone. http://purl.obolibrary.org/obo/GO_0005751 mitochondrial respiratory chain complex IV http://purl.obolibrary.org/obo/GO_0098800 inner mitochondrial membrane protein complex A protein complex located in the mitochondrial inner membrane that forms part of the mitochondrial respiratory chain. Contains the 13 polypeptide subunits of cytochrome c oxidase, including cytochrome a and cytochrome a3. Catalyzes the oxidation of reduced cytochrome c by dioxygen (O2). http://purl.obolibrary.org/obo/GO_0005765 lysosomal membrane http://purl.obolibrary.org/obo/GO_0031090 organelle membrane The lipid bilayer surrounding the lysosome and separating its contents from the cell cytoplasm. http://purl.obolibrary.org/obo/GO_0005769 early endosome http://purl.obolibrary.org/obo/GO_0005768 endosome A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways. http://purl.obolibrary.org/obo/GO_0005770 late endosome http://purl.obolibrary.org/obo/GO_0005768 endosome A prelysosomal endocytic organelle differentiated from early endosomes by lower lumenal pH and different protein composition. Late endosomes are more spherical than early endosomes and are mostly juxtanuclear, being concentrated near the microtubule organizing center. http://purl.obolibrary.org/obo/GO_0005777 peroxisome http://purl.obolibrary.org/obo/GO_0042579 microbody A small organelle enclosed by a single membrane, and found in most eukaryotic cells. Contains peroxidases and other enzymes involved in a variety of metabolic processes including free radical detoxification, lipid catabolism and biosynthesis, and hydrogen peroxide metabolism. http://purl.obolibrary.org/obo/GO_0005788 endoplasmic reticulum lumen http://purl.obolibrary.org/obo/GO_0043233 organelle lumen The volume enclosed by the membranes of the endoplasmic reticulum. http://purl.obolibrary.org/obo/GO_0005790 smooth endoplasmic reticulum http://purl.obolibrary.org/obo/GO_0005783 endoplasmic reticulum The smooth endoplasmic reticulum (smooth ER or SER) has no ribosomes attached to it. The smooth ER is the recipient of the proteins synthesized in the rough ER. Those proteins to be exported are passed to the Golgi complex, the resident proteins are returned to the rough ER and the lysosomal proteins after phosphorylation of their mannose residues are passed to the lysosomes. Glycosylation of the glycoproteins also continues. The smooth ER is the site of synthesis of lipids, including the phospholipids. The membranes of the smooth ER also contain enzymes that catalyze a series of reactions to detoxify both lipid-soluble drugs and harmful products of metabolism. Large quantities of certain compounds such as phenobarbital cause an increase in the amount of the smooth ER. http://purl.obolibrary.org/obo/GO_0005791 rough endoplasmic reticulum http://purl.obolibrary.org/obo/GO_0005783 endoplasmic reticulum The rough (or granular) endoplasmic reticulum (ER) has ribosomes adhering to the outer surface; the ribosomes are the site of translation of the mRNA for those proteins which are either to be retained within the cisternae (ER-resident proteins), the proteins of the lysosomes, or the proteins destined for export from the cell. Glycoproteins undergo their initial glycosylation within the cisternae. http://purl.obolibrary.org/obo/GO_0005794 golgi apparatus http://purl.obolibrary.org/obo/GO_0043227 membrane-bounded organelle A compound membranous cytoplasmic organelle of eukaryotic cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack. The Golgi apparatus differs from the endoplasmic reticulum in often having slightly thicker membranes, appearing in sections as a characteristic shallow semicircle so that the convex side (cis or entry face) abuts the endoplasmic reticulum, secretory vesicles emerging from the concave side (trans or exit face). In vertebrate cells there is usually one such organelle, while in invertebrates and plants, where they are known usually as dictyosomes, there may be several scattered in the cytoplasm. The Golgi apparatus processes proteins produced on the ribosomes of the rough endoplasmic reticulum; such processing includes modification of the core oligosaccharides of glycoproteins, and the sorting and packaging of proteins for transport to a variety of cellular locations. Three different regions of the Golgi are now recognized both in terms of structure and function: cis, in the vicinity of the cis face, trans, in the vicinity of the trans face, and medial, lying between the cis and trans regions. http://purl.obolibrary.org/obo/GO_0005796 Golgi lumen http://purl.obolibrary.org/obo/GO_0043233 organelle lumen The volume enclosed by the membranes of any cisterna or subcompartment of the Golgi apparatus, including the cis- and trans-Golgi networks. http://purl.obolibrary.org/obo/GO_0005856 cytoskeleton http://purl.obolibrary.org/obo/GO_0043226 organelle Any of the various filamentous elements that form the internal framework of cells, and typically remain after treatment of the cells with mild detergent to remove membrane constituents and soluble components of the cytoplasm. The term embraces intermediate filaments, microfilaments, microtubules, the microtrabecular lattice, and other structures characterized by a polymeric filamentous nature and long-range order within the cell. The various elements of the cytoskeleton not only serve in the maintenance of cellular shape but also have roles in other cellular functions, including cellular movement, cell division, endocytosis, and movement of organelles. http://purl.obolibrary.org/obo/GO_0005975 carbohydrate metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. Includes the formation of carbohydrate derivatives by the addition of a carbohydrate residue to another molecule. http://purl.obolibrary.org/obo/GO_0005978 glycogen biosynthetic process http://purl.obolibrary.org/obo/GO_0016051 carbohydrate biosynthetic process The chemical reactions and pathways resulting in the formation of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues. http://purl.obolibrary.org/obo/GO_0005980 glycogen catabolic process http://purl.obolibrary.org/obo/GO_0016052 carbohydrate catabolic process The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues. http://purl.obolibrary.org/obo/GO_0006066 alcohol metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving alcohols, any of a class of compounds containing one or more hydroxyl groups attached to a saturated carbon atom. http://purl.obolibrary.org/obo/GO_0006091 generation of precursor metabolites and energy http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and any process involved in the liberation of energy from these substances. http://purl.obolibrary.org/obo/GO_0006094 gluconeogenesis http://purl.obolibrary.org/obo/GO_0016051 carbohydrate biosynthetic process The formation of glucose from noncarbohydrate precursors, such as pyruvate, amino acids and glycerol. http://purl.obolibrary.org/obo/GO_0006096 glycolytic process http://purl.obolibrary.org/obo/GO_0016052 carbohydrate catabolic process The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules. http://purl.obolibrary.org/obo/GO_0006099 tricarboxylic acid cycle http://purl.obolibrary.org/obo/GO_0008152 metabolic process A nearly universal metabolic pathway in which the acetyl group of acetyl coenzyme A is effectively oxidized to two CO2 and four pairs of electrons are transferred to coenzymes. The acetyl group combines with oxaloacetate to form citrate, which undergoes successive transformations to isocitrate, 2-oxoglutarate, succinyl-CoA, succinate, fumarate, malate, and oxaloacetate again, thus completing the cycle. In eukaryotes the tricarboxylic acid is confined to the mitochondria. http://purl.obolibrary.org/obo/GO_0006109 regulation of carbohydrate metabolic process http://purl.obolibrary.org/obo/GO_0019222 regulation of metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving carbohydrates. http://purl.obolibrary.org/obo/GO_0006120 mitochondrial electron transport, NADH to ubiquinone http://purl.obolibrary.org/obo/GO_0022904 respiratory electron transport chain The transfer of electrons from NADH to ubiquinone that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex I. http://purl.obolibrary.org/obo/GO_0006121 mitochondrial electron transport, succinate to ubiquinone http://purl.obolibrary.org/obo/GO_0022904 respiratory electron transport chain The transfer of electrons from succinate to ubiquinone that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex II. http://purl.obolibrary.org/obo/GO_0006122 mitochondrial electron transport, ubiquinol to cytochrome c http://purl.obolibrary.org/obo/GO_0022904 respiratory electron transport chain The transfer of electrons from ubiquinol to cytochrome c that occurs during oxidative phosphorylation, mediated by the multisubunit enzyme known as complex III. http://purl.obolibrary.org/obo/GO_0006305 DNA alkylation http://purl.obolibrary.org/obo/GO_0008152 metabolic process The addition of alkyl groups to many positions on all four bases of DNA. Alkylating agents can also modify the bases of incoming nucleotides in the course of DNA synthesis. http://purl.obolibrary.org/obo/GO_0006306 DNA methylation http://purl.obolibrary.org/obo/GO_0032259 methylation The covalent transfer of a methyl group to either N-6 of adenine or C-5 or N-4 of cytosine. http://purl.obolibrary.org/obo/GO_0006309 apoptotic DNA fragmentation http://purl.obolibrary.org/obo/GO_0006308 DNA catabolic process The cleavage of DNA during apoptosis, which usually occurs in two stages: cleavage into fragments of about 50 kbp followed by cleavage between nucleosomes to yield 200 bp fragments. http://purl.obolibrary.org/obo/GO_0006338 chromatin remodeling http://purl.obolibrary.org/obo/TXPO_0002566 changing structure Dynamic structural changes to eukaryotic chromatin occurring throughout the cell division cycle. These changes range from the local changes necessary for transcriptional regulation to global changes necessary for chromosome segregation. http://purl.obolibrary.org/obo/GO_0006379 mRNA cleavage http://purl.obolibrary.org/obo/TXPO_0000333 separating Any process in which a pre-mRNA or mRNA molecule is cleaved at specific sites or in a regulated manner. http://purl.obolibrary.org/obo/GO_0006417 regulation of translation http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA. http://purl.obolibrary.org/obo/GO_0006457 protein folding http://purl.obolibrary.org/obo/TXPO_0002565 changing protein fold The process of assisting in the covalent and noncovalent assembly of single chain polypeptides or multisubunit complexes into the correct tertiary structure. http://purl.obolibrary.org/obo/GO_0006461 protein complex assembly http://purl.obolibrary.org/obo/GO_0065003 protein-containing complex assembly The aggregation, arrangement and bonding together of a set of components to form a protein complex. http://purl.obolibrary.org/obo/GO_0006473 protein acetylation http://purl.obolibrary.org/obo/GO_0043543 protein acylation The addition of an acetyl group to a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid. http://purl.obolibrary.org/obo/GO_0006476 protein deacetylation http://purl.obolibrary.org/obo/GO_0035601 protein deacylation The removal of an acetyl group from a protein amino acid. An acetyl group is CH3CO-, derived from acetic [ethanoic] acid. http://purl.obolibrary.org/obo/GO_0006486 protein glycosylation http://purl.obolibrary.org/obo/GO_0070085 glycosylation A protein modification process that results in the addition of a carbohydrate or carbohydrate derivative unit to a protein amino acid, e.g. the addition of glycan chains to proteins. http://purl.obolibrary.org/obo/GO_0006497 protein lipidation http://purl.obolibrary.org/obo/GO_0036211 protein modification process The covalent attachment of lipid groups to an amino acid in a protein. http://purl.obolibrary.org/obo/GO_0006517 protein deglycosylation http://purl.obolibrary.org/obo/GO_0036211 protein modification process The removal of sugar residues from a glycosylated protein. http://purl.obolibrary.org/obo/GO_0006555 methionine metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving methionine (2-amino-4-(methylthio)butanoic acid), a sulfur-containing, essential amino acid found in peptide linkage in proteins. http://purl.obolibrary.org/obo/GO_0006556 S-adenosylmethionine biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions and pathways resulting in the formation of S-adenosylmethionine, S-(5'-adenosyl)-L-methionine, an important intermediate in one-carbon metabolism. http://purl.obolibrary.org/obo/GO_0006629 lipid metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. Includes fatty acids; neutral fats, other fatty-acid esters, and soaps; long-chain (fatty) alcohols and waxes; sphingoids and other long-chain bases; glycolipids, phospholipids and sphingolipids; and carotenes, polyprenols, sterols, terpenes and other isoprenoids. http://purl.obolibrary.org/obo/GO_0006635 fatty acid beta-oxidation http://purl.obolibrary.org/obo/GO_0019395 fatty acid oxidation A fatty acid oxidation process that results in the complete oxidation of a long-chain fatty acid. Fatty acid beta-oxidation begins with the addition of coenzyme A to a fatty acid, and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A; the cycle continues until only two or three carbons remain (as acetyl-CoA or propionyl-CoA respectively). http://purl.obolibrary.org/obo/GO_0006644 phospholipid metabolic process http://purl.obolibrary.org/obo/GO_0006629 lipid metabolic process The chemical reactions and pathways involving phospholipids, any lipid containing phosphoric acid as a mono- or diester. http://purl.obolibrary.org/obo/GO_0006646 phosphatidylethanolamine biosynthetic process http://purl.obolibrary.org/obo/GO_0046474 glycerophospholipid biosynthetic process The chemical reactions and pathways resulting in the formation of phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine. http://purl.obolibrary.org/obo/GO_0006649 phospholipid transfer to membrane http://purl.obolibrary.org/obo/GO_0015914 phospholipid transport The transfer of a phospholipid from its site of synthesis to the plasma membrane. http://purl.obolibrary.org/obo/GO_0006650 glycerophospholipid metabolic process http://purl.obolibrary.org/obo/GO_0006644 phospholipid metabolic process The chemical reactions and pathways involving glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue. http://purl.obolibrary.org/obo/GO_0006654 phosphatidic acid biosynthetic process http://purl.obolibrary.org/obo/GO_0046474 glycerophospholipid biosynthetic process The chemical reactions and pathways resulting in the formation of phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids. http://purl.obolibrary.org/obo/GO_0006655 phosphatidylglycerol biosynthetic process http://purl.obolibrary.org/obo/GO_0046474 glycerophospholipid biosynthetic process The chemical reactions and pathways resulting in the formation of phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol. http://purl.obolibrary.org/obo/GO_0006656 phosphatidylcholine biosynthetic process http://purl.obolibrary.org/obo/GO_0046474 glycerophospholipid biosynthetic process The chemical reactions and pathways resulting in the formation of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. http://purl.obolibrary.org/obo/GO_0006658 phosphatidylserine metabolic process http://purl.obolibrary.org/obo/GO_0006650 glycerophospholipid metabolic process The chemical reactions and pathways involving phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine. They are important constituents of cell membranes. http://purl.obolibrary.org/obo/GO_0006659 phosphatidylserine biosynthetic process http://purl.obolibrary.org/obo/GO_0046474 glycerophospholipid biosynthetic process The chemical reactions and pathways resulting in the formation of phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine. http://purl.obolibrary.org/obo/GO_0006660 phosphatidylserine catabolic process http://purl.obolibrary.org/obo/GO_0046475 glycerophospholipid catabolic process The chemical reactions and pathways resulting in the breakdown of phosphatidylserines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of L-serine. http://purl.obolibrary.org/obo/GO_0006661 phosphatidylinositol biosynthetic process http://purl.obolibrary.org/obo/GO_0046488 phosphatidylinositol metabolic process The chemical reactions and pathways resulting in the formation of phosphatidylinositol, any glycophospholipid in which the sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol. http://purl.obolibrary.org/obo/GO_0006665 sphingolipid metabolic process http://purl.obolibrary.org/obo/GO_0006629 lipid metabolic process The chemical reactions and pathways involving sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). http://purl.obolibrary.org/obo/GO_0006684 sphingomyelin metabolic process http://purl.obolibrary.org/obo/GO_0006644 phospholipid metabolic process The chemical reactions and pathways involving sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine, any of a class of phospholipids in which the amino group of sphingosine is in amide linkage with one of several fatty acids, while the terminal hydroxyl group of sphingosine is esterified to phosphorylcholine. http://purl.obolibrary.org/obo/GO_0006685 sphingomyelin catabolic process http://purl.obolibrary.org/obo/TXPO_0001465 sphingophospholipid catabolic process The chemical reactions and pathways resulting in the breakdown of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine. http://purl.obolibrary.org/obo/GO_0006686 sphingomyelin biosynthetic process http://purl.obolibrary.org/obo/TXPO_0001291 phosphosphingolipid biosynthesis The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine. http://purl.obolibrary.org/obo/GO_0006695 cholesterol biosynthetic process http://purl.obolibrary.org/obo/GO_0008610 lipid biosynthetic process The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. http://purl.obolibrary.org/obo/GO_0006699 bile acid biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile. http://purl.obolibrary.org/obo/GO_0006711 estrogen catabolic process http://purl.obolibrary.org/obo/GO_0009056 catabolic process The chemical reactions and pathways resulting in the breakdown of estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants http://purl.obolibrary.org/obo/GO_0006735 NADH regeneration http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process A metabolic process that generates a pool of NADH by the reduction of NAD+. http://purl.obolibrary.org/obo/GO_0006740 NADPH regeneration http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process A metabolic process that generates a pool of NADPH by the reduction of NADP+. http://purl.obolibrary.org/obo/GO_0006749 glutathione metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins; it has a specific role in the reduction of hydrogen peroxide (H2O2) and oxidized ascorbate, and it participates in the gamma-glutamyl cycle http://purl.obolibrary.org/obo/GO_0006754 ATP biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reaction resulting in the formation of ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. http://purl.obolibrary.org/obo/GO_0006783 heme biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions and pathways resulting in the formation of heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring, from less complex precursors. http://purl.obolibrary.org/obo/GO_0006793 phosphorus metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving the nonmetallic element phosphorus or compounds that contain phosphorus, usually in the form of a phosphate group (PO4). http://purl.obolibrary.org/obo/GO_0006805 xenobiotic metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and physical changes involving a xenobiotic compound, a compound foreign to living organisms. Used of chemical compounds, e. g. a xenobiotic chemical, such as a pesticide. (Gene Ontology) http://purl.obolibrary.org/obo/GO_0006810 transport http://purl.obolibrary.org/obo/TXPO_0000442 transmitting The directed movement of substances (such as macromolecules, small molecules, ions) or cellular components (such as complexes and organelles) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter, pore or motor protein. http://purl.obolibrary.org/obo/GO_0006811 ion transport http://purl.obolibrary.org/obo/TXPO_0000111 molecule transport The directed movement of charged atoms or small charged molecules into, out of, within or between cells. http://purl.obolibrary.org/obo/GO_0006813 potassium ion transport http://purl.obolibrary.org/obo/GO_0006811 ion transport The directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0006897 endocytosis http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle. http://purl.obolibrary.org/obo/GO_0006910 phagocytosis, recognition http://purl.obolibrary.org/obo/TXPO_0000379 receiving The initial step in phagocytosis involving adhesion to bacteria, immune complexes and other particulate matter, or an apoptotic cell and based on recognition of factors such as bacterial cell wall components, opsonins like complement and antibody or protein receptors and lipids like phosphatidyl serine, and leading to intracellular signaling in the phagocytosing cell. http://purl.obolibrary.org/obo/GO_0006928 cell motility http://purl.obolibrary.org/obo/GO_0040011 locomotion Any process involved in the controlled self-propelled movement of a cell that results in translocation of the cell from one place to another. http://purl.obolibrary.org/obo/GO_0006996 organelle organization http://purl.obolibrary.org/obo/GO_0071840 cellular component organization or biogenesis A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of an organelle within a cell. An organelle is an organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton. http://purl.obolibrary.org/obo/GO_0007015 actin filament organization http://purl.obolibrary.org/obo/GO_0030036 actin cytoskeleton organization and biogenesis A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments. Includes processes that control the spatial distribution of actin filaments, such as organizing filaments into meshworks, bundles, or other structures, as by cross-linking. http://purl.obolibrary.org/obo/GO_0007028 cytoplasm organization http://purl.obolibrary.org/obo/GO_0071840 cellular component organization or biogenesis A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of the cytoplasm. The cytoplasm is all of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. http://purl.obolibrary.org/obo/GO_0007041 lysosomal transport http://purl.obolibrary.org/obo/GO_0006810 transport The directed movement of substances into, out of or within a lysosome. http://purl.obolibrary.org/obo/GO_0007050 cell cycle arrest http://purl.obolibrary.org/obo/TXPO_0003798 maintaining cyclicity A regulatory process that halts progression through the cell cycle during one of the normal phases (G1, S, G2, M). http://purl.obolibrary.org/obo/GO_0007173 epidermal growth factor receptor signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor EGFR (ERBB1) on the surface of a cell. The pathway ends with regulation of a downstream cellular process, e.g. transcription. http://purl.obolibrary.org/obo/GO_0007249 I-kappaB kinase/NF-kappaB signaling http://purl.obolibrary.org/obo/TXPO_0000027 integrated signaling pathway The process in which a signal is passed on to downstream components within the cell through the I-kappaB-kinase (IKK)-dependent activation of NF-kappaB. The cascade begins with activation of a trimeric IKK complex (consisting of catalytic kinase subunits IKKalpha and/or IKKbeta, and the regulatory scaffold protein NEMO) and ends with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. PMID:12773372 http://purl.obolibrary.org/obo/GO_0007253 cytoplasmic sequestering of NF-kappaB http://purl.obolibrary.org/obo/TXPO_0000433 keeping position The selective interaction of the transcription factor NF-kappaB with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus. http://purl.obolibrary.org/obo/GO_0008152 metabolic process http://purl.obolibrary.org/obo/TXPO_0000261 changing relationship between operands The chemical reactions and pathways, including anabolism and catabolism, by which living organisms transform chemical substances. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. http://purl.obolibrary.org/obo/GO_0008210 estrogen metabolic process http://purl.obolibrary.org/obo/GO_0042445 hormone metabolic process The chemical reactions and pathways involving estrogens, C18 steroid hormones that can stimulate the development of female sexual characteristics. Also found in plants. http://purl.obolibrary.org/obo/GO_0008286 insulin receptor signaling pathway http://purl.obolibrary.org/obo/TXPO_0000027 integrated signaling pathway The series of molecular signals generated as a consequence of the insulin receptor binding to insulin. http://purl.obolibrary.org/obo/GO_0008610 lipid biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. http://purl.obolibrary.org/obo/GO_0008643 carbohydrate transport http://purl.obolibrary.org/obo/TXPO_0000111 molecule transport The directed movement of carbohydrate into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Carbohydrates are any of a group of organic compounds based of the general formula Cx(H2O)y. http://purl.obolibrary.org/obo/GO_0008654 phospholipid biosynthetic process http://purl.obolibrary.org/obo/GO_0008610 lipid biosynthetic process The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester. http://purl.obolibrary.org/obo/GO_0009247 glycolipid biosynthetic process http://purl.obolibrary.org/obo/GO_0008610 lipid biosynthetic process The chemical reactions and pathways resulting in the formation of glycolipid, a class of 1,2-di-O-acylglycerols joined at oxygen 3 by a glycosidic linkage to a carbohydrate part (usually a mono-, di- or tri-saccharide). http://purl.obolibrary.org/obo/GO_0009395 phospholipid catabolic process http://purl.obolibrary.org/obo/GO_0016042 lipid catabolic process The chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester. http://purl.obolibrary.org/obo/GO_0010324 membrane invagination http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B The infolding of a membrane. http://purl.obolibrary.org/obo/GO_0010629 negative regulation of gene expression http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form. http://purl.obolibrary.org/obo/GO_0015893 drug transport http://purl.obolibrary.org/obo/GO_0006810 transport The directed movement of a drug, a substance used in the diagnosis, treatment or prevention of a disease, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0015909 long-chain fatty acid transport http://purl.obolibrary.org/obo/GO_0015908 fatty acid transport The directed movement of long-chain fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22. http://purl.obolibrary.org/obo/GO_0015910 long-chain fatty acid import into peroxisome http://purl.obolibrary.org/obo/GO_0015909 long-chain fatty acid transport The directed movement of long-chain fatty acids into a peroxisome. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22. http://purl.obolibrary.org/obo/GO_0016042 lipid catabolic process http://purl.obolibrary.org/obo/GO_0009056 catabolic process The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. http://purl.obolibrary.org/obo/GO_0016192 vesicle-mediated transport http://purl.obolibrary.org/obo/GO_0006810 transport A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. The process begins with a step that directs a substance to the forming vesicle, and includes vesicle budding and coating. Vesicles are then targeted to, and fuse with, an acceptor membrane. http://purl.obolibrary.org/obo/GO_0016197 endosomal transport http://purl.obolibrary.org/obo/GO_0016192 vesicle-mediated transport The directed movement of substances mediated by an endosome, a membrane-bounded organelle that carries materials enclosed in the lumen or located in the endosomal membrane. http://purl.obolibrary.org/obo/GO_0016310 phosphorylation http://purl.obolibrary.org/obo/GO_0006793 phosphorus metabolic process The process of introducing a phosphate group into a molecule, usually with the formation of a phosphoric ester, a phosphoric anhydride or a phosphoric amide. http://purl.obolibrary.org/obo/GO_0016311 dephosphorylation http://purl.obolibrary.org/obo/GO_0006793 phosphorus metabolic process The process of removing one or more phosphoric (ester or anhydride) residues from a molecule. http://purl.obolibrary.org/obo/GO_0016579 protein deubiquitination http://purl.obolibrary.org/obo/GO_0070646 protein modification by small protein removal The removal of one or more ubiquitin groups from a protein. http://purl.obolibrary.org/obo/GO_0016925 protein sumoylation http://purl.obolibrary.org/obo/TXPO_0004107 protein modification by small protein conjugation The process in which a SUMO protein (small ubiquitin-related modifier) is conjugated to a target protein via an isopeptide bond between the carboxyl terminus of SUMO with an epsilon-amino group of a lysine residue of the target protein. http://purl.obolibrary.org/obo/GO_0018377 protein myristoylation http://purl.obolibrary.org/obo/GO_0006497 protein lipidation The covalent attachment of a myristoyl group to a protein. http://purl.obolibrary.org/obo/GO_0019538 protein metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving a protein. Includes protein modification. http://purl.obolibrary.org/obo/GO_0019585 glucuronate metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving glucuronate, any salt or ester of glucuronic acid, the uronic acid formally derived from glucose by oxidation of the hydroxymethylene group at C-6 to a carboxyl group. http://purl.obolibrary.org/obo/GO_0022411 extracellular matrix disassembly http://purl.obolibrary.org/obo/TXPO_0000343 decomposing A process that results in the breakdown of the extracellular matrix. http://purl.obolibrary.org/obo/GO_0022904 respiratory electron transport chain http://purl.obolibrary.org/obo/GO_0022900 electron transport chain A process in which a series of electron carriers operate together to transfer electrons from donors such as NADH and FADH2 to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient. http://purl.obolibrary.org/obo/GO_0030036 actin cytoskeleton organization and biogenesis http://purl.obolibrary.org/obo/GO_0007010 cytoskeleton organization A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures comprising actin filaments and their associated proteins. http://purl.obolibrary.org/obo/GO_0030163 protein catabolic process http://purl.obolibrary.org/obo/GO_0009056 catabolic process The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds. http://purl.obolibrary.org/obo/GO_0030968 endoplasmic reticulum unfolded protein response http://purl.obolibrary.org/obo/GO_0034976 response to endoplasmic reticulum stress The series of molecular signals generated as a consequence of the presence of unfolded proteins in the endoplasmic reticulum (ER) or other ER-related stress; results in changes in the regulation of transcription and translation. http://purl.obolibrary.org/obo/GO_0031012 extracellular matrix http://purl.obolibrary.org/obo/TXPO_0000065 cellular tissue A structure lying external to one or more cells, which provides structural support for cells or tissues. http://purl.obolibrary.org/obo/GO_0031532 actin cytoskeleton reorganization http://purl.obolibrary.org/obo/GO_0030036 actin cytoskeleton organization and biogenesis A process that is carried out at the cellular level which results in dynamic structural changes to the arrangement of constituent parts of cytoskeletal structures comprising actin filaments and their associated proteins. http://purl.obolibrary.org/obo/GO_0031965 nuclear membrane http://purl.obolibrary.org/obo/GO_0031090 organelle membrane Either of the lipid bilayers that surround the nucleus and form the nuclear envelope; excludes the intermembrane space. http://purl.obolibrary.org/obo/GO_0031966 mitochondrial membrane http://purl.obolibrary.org/obo/GO_0031090 organelle membrane Either of the lipid bilayers that surround the mitochondrion and form the mitochondrial envelope. http://purl.obolibrary.org/obo/GO_0032259 methylation http://purl.obolibrary.org/obo/GO_0008152 metabolic process The process in which a methyl group is covalently attached to a molecule. http://purl.obolibrary.org/obo/GO_0033209 tumor necrosis factor-mediated signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals initiated by the binding of a tumor necrosis factor to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. http://purl.obolibrary.org/obo/GO_0034329 cell junction assembly http://purl.obolibrary.org/obo/TXPO_0000468 assembling A cellular process that results in the aggregation, arrangement and bonding together of a set of components to form a cell junction. http://purl.obolibrary.org/obo/GO_0034333 adherens junction assembly http://purl.obolibrary.org/obo/GO_0022607 cellular component assembly The aggregation, arrangement and bonding together of a set of components to form an adherens junction. An adherens junction is a cell junction at which the cytoplasmic face of the plasma membrane is attached to actin filaments. http://purl.obolibrary.org/obo/GO_0034976 response to endoplasmic reticulum stress http://purl.obolibrary.org/obo/GO_0006950 response to stress Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen. http://purl.obolibrary.org/obo/GO_0036211 protein modification process http://purl.obolibrary.org/obo/GO_0019538 protein metabolic process The covalent alteration of one or more amino acids occurring in proteins, peptides and nascent polypeptides (co-translational, post-translational modifications). Includes the modification of charged tRNAs that are destined to occur in a protein (pre-translation modification). http://purl.obolibrary.org/obo/GO_0038110 interleukin-2-mediated signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals initiated by the binding of interleukin-2 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. http://purl.obolibrary.org/obo/GO_0040029 regulation of gene expression, epigenetic http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression Any process that modulates the frequency, rate or extent of gene expression; the process is mitotically or meiotically heritable, or is stably self-propagated in the cytoplasm of a resting cell, and does not entail a change in DNA sequence. http://purl.obolibrary.org/obo/GO_0042059 negative regulation of epidermal growth factor receptor signaling pathway http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling Any process that stops, prevents, or reduces the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity. http://purl.obolibrary.org/obo/GO_0042158 lipoprotein biosynthetic process http://purl.obolibrary.org/obo/TXPO_0000306 protein biosynthesis The chemical reaction resulting in the formation of any conjugated, water-soluble protein in which the covalently attached nonprotein group consists of a lipid or lipids. http://purl.obolibrary.org/obo/GO_0042579 microbody http://purl.obolibrary.org/obo/GO_0043227 membrane-bounded organelle Cytoplasmic organelles, spherical or oval in shape, that are bounded by a single membrane and contain oxidative enzymes, especially those utilizing hydrogen peroxide (H2O2). http://purl.obolibrary.org/obo/GO_0042775 mitochondrial ATP synthesis coupled electron transport http://purl.obolibrary.org/obo/GO_0042773 ATP synthesis coupled electron transport The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP, as it occurs in the mitochondrial inner membrane or chloroplast thylakoid membrane. http://purl.obolibrary.org/obo/GO_0043066 negative regulation of apoptotic process http://purl.obolibrary.org/obo/GO_0042981 regulation of apoptotic process Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. http://purl.obolibrary.org/obo/GO_0043543 protein acylation http://purl.obolibrary.org/obo/GO_0036211 protein modification process The addition of an acyl group, any group or radical of the form RCO- where R is an organic group, to a protein amino acid. http://purl.obolibrary.org/obo/GO_0044281 small molecule metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process Small molecules in GO include monosaccharides but exclude disaccharides and polysaccharides. http://purl.obolibrary.org/obo/GO_0044464 cell part http://purl.obolibrary.org/obo/GO_0005575 cellular_component Any constituent part of a cell, the basic structural and functional unit of all organisms. http://purl.obolibrary.org/obo/GO_0046034 ATP metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving ATP, adenosine triphosphate, a universally important coenzyme and enzyme regulator. http://purl.obolibrary.org/obo/GO_0046470 phosphatidylcholine metabolic process http://purl.obolibrary.org/obo/GO_0006650 glycerophospholipid metabolic process The chemical reactions and pathways involving phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. They are important constituents of cell membranes. http://purl.obolibrary.org/obo/GO_0046471 phosphatidylglycerol metabolic process http://purl.obolibrary.org/obo/GO_0006650 glycerophospholipid metabolic process The chemical reactions and pathways involving phosphatidylglycerols, any of a class of phospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol. They are important constituents of cell membranes. http://purl.obolibrary.org/obo/GO_0046473 phosphatidic acid metabolic process http://purl.obolibrary.org/obo/GO_0006650 glycerophospholipid metabolic process The chemical reactions and pathways involving phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids. http://purl.obolibrary.org/obo/GO_0046474 glycerophospholipid biosynthetic process http://purl.obolibrary.org/obo/GO_0008654 phospholipid biosynthetic process The chemical reactions and pathways resulting in the formation of glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue. http://purl.obolibrary.org/obo/GO_0046475 glycerophospholipid catabolic process http://purl.obolibrary.org/obo/GO_0009395 phospholipid catabolic process The chemical reactions and pathways resulting in the breakdown of glycerophospholipids, any derivative of glycerophosphate that contains at least one O-acyl, O-alkyl, or O-alkenyl group attached to the glycerol residue. http://purl.obolibrary.org/obo/GO_0046488 phosphatidylinositol metabolic process http://purl.obolibrary.org/obo/GO_0006650 glycerophospholipid metabolic process The chemical reactions and pathways involving phosphatidylinositol, any glycophospholipid in which a sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol. http://purl.obolibrary.org/obo/GO_0046514 ceramide catabolic process http://purl.obolibrary.org/obo/TXPO_0000071 sphingolipid catabolic process The chemical reactions and pathways resulting in the breakdown of ceramides, any N-acetylated sphingoid. http://purl.obolibrary.org/obo/GO_0048012 HGFR signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway The series of molecular signals generated as a consequence of the hepatocyte growth factor receptor binding to one of its physiological ligands. http://purl.obolibrary.org/obo/GO_0048193 Golgi vesicle transport http://purl.obolibrary.org/obo/GO_0006810 transport The directed movement of substances into, out of or within the Golgi apparatus, mediated by vesicles. http://purl.obolibrary.org/obo/GO_0050896 response to stimulus http://purl.obolibrary.org/obo/TXPO_0001984 changing state Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism. http://purl.obolibrary.org/obo/GO_0051168 nuclear export http://purl.obolibrary.org/obo/GO_0051169 nuclear transport The directed movement of substances out of the nucleus. http://purl.obolibrary.org/obo/GO_0051169 nuclear transport http://purl.obolibrary.org/obo/GO_0006810 transport The directed movement of substances into, out of, or within the nucleus. http://purl.obolibrary.org/obo/GO_0051170 import into nucleus http://purl.obolibrary.org/obo/GO_0051169 nuclear transport The directed movement of substances into the nucleus. http://purl.obolibrary.org/obo/GO_0055085 transmembrane transport http://purl.obolibrary.org/obo/GO_0006810 transport The process in which a solute is transported across a lipid bilayer, from one side of a membrane to the other. http://purl.obolibrary.org/obo/GO_0055114 oxidation-reduction process http://purl.obolibrary.org/obo/GO_0008152 metabolic process A metabolic process that results in the removal or addition of one or more electrons to or from a substance, with or without the concomitant removal or addition of a proton or protons. http://purl.obolibrary.org/obo/GO_0061024 membrane organization http://purl.obolibrary.org/obo/GO_0071840 cellular component organization or biogenesis A process which results in the assembly, arrangement of constituent parts, or disassembly of a membrane. A membrane is a double layer of lipid molecules that encloses all cells, and, in eukaryotes, many organelles; may be a single or double lipid bilayer; also includes associated proteins. http://purl.obolibrary.org/obo/GO_0065003 protein-containing complex assembly http://purl.obolibrary.org/obo/TXPO_0003815 molecular assembly The aggregation, arrangement and bonding together of a set of macromolecules to form a complex. http://purl.obolibrary.org/obo/GO_0070102 interleukin-6-mediated signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals initiated by the binding of interleukin-6 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. http://purl.obolibrary.org/obo/GO_0070498 IL-1 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals initiated by the binding of interleukin-1 to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. http://purl.obolibrary.org/obo/GO_0070988 demethylation http://purl.obolibrary.org/obo/GO_0008152 metabolic process The process of removing one or more methyl groups from a molecule. http://purl.obolibrary.org/obo/GO_0099024 plasma membrane invagination http://purl.obolibrary.org/obo/GO_0010324 membrane invagination An infolding of the plasma membrane. http://purl.obolibrary.org/obo/GO_0045806 negative regulation of endocytosis http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents, or reduces the frequency, rate or extent of endocytosis. http://purl.obolibrary.org/obo/GO_0045820 negative regulation of glycolytic process http://purl.obolibrary.org/obo/TXPO_0000115 negative regulation of decomposing Any process that stops, prevents, or reduces the frequency, rate or extent of glycolysis. http://purl.obolibrary.org/obo/GO_0046338 phosphatidylethanolamine catabolic process http://purl.obolibrary.org/obo/GO_0046475 glycerophospholipid catabolic process The chemical reactions and pathways resulting in the breakdown of phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine. http://purl.obolibrary.org/obo/GO_0046676 negative regulation of insulin secretion http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents, or reduces the frequency, rate or extent of the release of insulin. http://purl.obolibrary.org/obo/GO_0051208 sequestering of calcium ion http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object The process of binding or confining calcium ions such that they are separated from other components of a biological system. http://purl.obolibrary.org/obo/GO_0051898 negative regulation of protein kinase B signaling http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling Any process that stops, prevents, or reduces the frequency, rate or extent of protein kinase B signaling, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B. http://purl.obolibrary.org/obo/GO_1901567 fatty acid derivative binding http://purl.obolibrary.org/obo/GO_0005488 binding (with molecule) Interacting selectively and non-covalently with fatty acid derivative. http://purl.obolibrary.org/obo/GO_1901889 negative regulation of cell junction assembly http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of cell junction assembly is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of cell junction assembly. http://purl.obolibrary.org/obo/GO_1905517 macrophage migration http://purl.obolibrary.org/obo/GO_0050900 leukocyte migration The orderly movement of a macrophage from one site to another. http://purl.obolibrary.org/obo/GO_1903788 positive regulation of glutathione biosynthetic process http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of glutathione biosynthetic process. http://purl.obolibrary.org/obo/GO_1904592 positive regulation of protein refolding http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of protein refolding. http://purl.obolibrary.org/obo/GO_1990922 hepatic stellate cell proliferation http://purl.obolibrary.org/obo/GO_0008283 cell proliferation The multiplication or reproduction of hepatic stellate cells, resulting in the expansion of a hepatic stellate cell population. Hepatic stellate cells are found in the perisinusoidal space of the liver, and are capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components. This cell type comprises approximately 8-15% of total cells in the liver. http://purl.obolibrary.org/obo/UBERON_0000025 tube (anatomical) http://purl.obolibrary.org/obo/UBERON_0004111 anatomical conduit Any hollow cylindrical anatomical structure containing a lumen through which substances are transported. http://purl.obolibrary.org/obo/UBERON_0000058 duct http://purl.obolibrary.org/obo/UBERON_0000025 tube (anatomical) A tubular structure that transports secreted or excreted substances. http://purl.obolibrary.org/obo/UBERON_0000061 anatomical structure http://purl.obolibrary.org/obo/UBERON_0001062 anatomical entity Material anatomical entity that is a single connected structure with inherent 3D shape generated by coordinated expression of the organism's own genome. http://purl.obolibrary.org/obo/UBERON_0000062 organ http://purl.obolibrary.org/obo/UBERON_0000061 anatomical structure Anatomical structure that performs a specific function or group of functions [WP]. http://purl.obolibrary.org/obo/UBERON_0000064 organ part http://purl.obolibrary.org/obo/UBERON_0000061 anatomical structure A multicellular structure that is a part of an organ. http://purl.obolibrary.org/obo/UBERON_0000170 pair of lungs http://purl.obolibrary.org/obo/UBERON_0034925 anatomical collection The pair of anatomical structures comprised of a left lung and right lung. http://purl.obolibrary.org/obo/UBERON_0000171 respiration organ http://purl.obolibrary.org/obo/UBERON_0000062 organ Organ that functions in gaseous exchange between an organism and its environment. In plants, microorganisms, and many small animals, air or water makes direct contact with the organism's cells or tissue fluids, and the processes of diffusion supply the organism with dioxygen (O2) and remove carbon dioxide (CO2). In larger animals the efficiency of gaseous exchange is improved by specialized respiratory organs, such as lungs and gills, which are ventilated by breathing mechanisms. http://purl.obolibrary.org/obo/UBERON_0000179 haemolymphatic fluid http://purl.obolibrary.org/obo/UBERON_0006314 bodily fluid Circulating fluid that is part of the hemolymphoid system. Blood, lymph, interstitial fluid or its analogs. http://purl.obolibrary.org/obo/UBERON_0000463 organism substance http://purl.obolibrary.org/obo/BFO_0000027 object aggregate Material anatomical entity in a gaseous, liquid, semisolid or solid state; produced by anatomical structures or derived from inhaled and ingested substances that have been modified by anatomical structures as they pass through the body. http://purl.obolibrary.org/obo/UBERON_0000464 anatomical space http://purl.obolibrary.org/obo/UBERON_0001062 anatomical entity Non-material anatomical entity of three dimensions, that is generated by morphogenetic or other physiologic processes; is surrounded by one or more anatomical structures; contains one or more organism substances or anatomical structures. http://purl.obolibrary.org/obo/UBERON_0000479 tissue http://purl.obolibrary.org/obo/TXPO_0000065 cellular tissue Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation. http://purl.obolibrary.org/obo/UBERON_0000483 epithelium http://purl.obolibrary.org/obo/UBERON_0000479 tissue Portion of tissue, that consists of one or more layers of epithelial cells connected to each other by cell junctions and which is underlain by a basal lamina. Examples: simple squamous epithelium, glandular cuboidal epithelium, transitional epithelium, myoepithelium[CARO]. http://purl.obolibrary.org/obo/UBERON_0001009 circulatory system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system organ system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells, etc. to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis[WP]. http://purl.obolibrary.org/obo/UBERON_0001013 adipose tissue http://purl.obolibrary.org/obo/UBERON_0000479 tissue Portion of connective tissue composed of adipocytes enmeshed in areolar tissue http://purl.obolibrary.org/obo/UBERON_0001062 anatomical entity http://purl.obolibrary.org/obo/BFO_0000030 object Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species. http://purl.obolibrary.org/obo/UBERON_0001088 urine http://purl.obolibrary.org/obo/UBERON_0000463 organism substance Excretion that is the output of a kidney http://purl.obolibrary.org/obo/UBERON_0001113 lobe of liver http://purl.obolibrary.org/obo/BFO_0000024 fiat object part Traditional gross anatomy divided the liver into four lobes based on surface features. The falciform ligament is visible on the front (anterior side) of the liver. This divides the liver into a left anatomical lobe, and a right anatomical lobe. http://purl.obolibrary.org/obo/UBERON_0001115 left lobe of liver http://purl.obolibrary.org/obo/UBERON_0001113 lobe of liver The left lobe is smaller and more flattened than the right. It is situated in the epigastric and left hypochondriac regions. Its upper surface is slightly convex and is moulded on to the diaphragm; its under surface presents the gastric impression and omental tuberosity. http://purl.obolibrary.org/obo/UBERON_0001143 hepatic vein http://purl.obolibrary.org/obo/UBERON_0015796 liver blood vessel Vein that carries blood away from the liver. http://purl.obolibrary.org/obo/UBERON_0001193 hepatic artery http://purl.obolibrary.org/obo/UBERON_0015796 liver blood vessel An artery that supplies the liver. http://purl.obolibrary.org/obo/UBERON_0001281 hepatic sinusoid http://purl.obolibrary.org/obo/UBERON_0015796 liver blood vessel Wide thin-walled blood vessels in the liver. In mammals they have neither veinous or arterial markers. http://purl.obolibrary.org/obo/UBERON_0001283 bile canaliculus http://purl.obolibrary.org/obo/UBERON_0000464 anatomical space An intercellular channel that takes up bile from hepatocytes, transporting it to the bile ducts. http://purl.obolibrary.org/obo/UBERON_0001434 skeletal system http://purl.obolibrary.org/obo/UBERON_0011216 organ system subdivision Anatomical system that is a multi-element, multi-tissue anatomical cluster that consists of the skeleton and the articular system. http://purl.obolibrary.org/obo/UBERON_0001630 muscle organ http://purl.obolibrary.org/obo/UBERON_0000062 organ Organ consisting of a tissue made up of various elongated cells that are specialized to contract and thus to produce movement and mechanical work[GO]. http://purl.obolibrary.org/obo/UBERON_0001690 ear http://purl.obolibrary.org/obo/UBERON_0000020 sense organ Sense organ in vertebrates that is specialized for the detection of sound, and the maintenance of balance. Includes the outer ear and middle ear, which collect and transmit sound waves; and the inner ear, which contains the organs of balance and (except in fish) hearing. Also includes the pinna, the visible part of the outer ear, present in some mammals. http://purl.obolibrary.org/obo/UBERON_0001969 blood plasma http://purl.obolibrary.org/obo/UBERON_0000179 haemolymphatic fluid The liquid component of blood, in which erythrocytes are suspended. http://purl.obolibrary.org/obo/UBERON_0001970 bile http://purl.obolibrary.org/obo/UBERON_0006314 bodily fluid vital aqueous secretion of the liver that is formed by hepatocytes and modified down stream by absorptive and secretory properties of the bile duct epithelium. http://purl.obolibrary.org/obo/UBERON_0001981 blood vessel http://purl.obolibrary.org/obo/UBERON_0000025 tube (anatomical) A vessel through which blood circulates in the body. http://purl.obolibrary.org/obo/UBERON_0002097 skin of body http://purl.obolibrary.org/obo/UBERON_0000062 organ The organ covering the body that consists of the dermis and epidermis. http://purl.obolibrary.org/obo/UBERON_0002167 right lung http://purl.obolibrary.org/obo/UBERON_0002048 lung Lung which consists of the right upper lobe, middle lobe and right lower lobe.[FMA] http://purl.obolibrary.org/obo/UBERON_0002168 left lung http://purl.obolibrary.org/obo/UBERON_0002048 lung Lung which consists of the left upper lobe and left lower lobe.[FMA] http://purl.obolibrary.org/obo/UBERON_0002193 hemolymphoid system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical cluster consisting of the hematopoietic system and the lymphoid system, or its analogs. http://purl.obolibrary.org/obo/UBERON_0002268 olfactory organ http://purl.obolibrary.org/obo/UBERON_0000020 sense organ An organ that houses olfactory neurons and is responsible for the sense of smell. Examples include the vertebrate nose and the Drosophila dorsal organ. http://purl.obolibrary.org/obo/UBERON_0002294 biliary system http://purl.obolibrary.org/obo/UBERON_0011216 organ system subdivision Organ system subdivision that consists of the organs and ducts that are involved in the production and transportation of bile. In most species this is the gallbladder and the bile ducts (biliary tree). http://purl.obolibrary.org/obo/UBERON_0002365 exocrine gland http://purl.obolibrary.org/obo/UBERON_0002530 gland A gland that secretes products (excluding hormones and other chemical messengers) into ducts (duct glands) which lead directly into the external environment. Typical exocrine glands include sweat glands, salivary glands, mammary glands, stomach, liver, pancreas http://purl.obolibrary.org/obo/UBERON_0002423 hepatobiliary system http://purl.obolibrary.org/obo/UBERON_0011216 organ system subdivision The part of the digestive system that contains the liver and the biliary system http://purl.obolibrary.org/obo/UBERON_0002481 bone tissue http://purl.obolibrary.org/obo/UBERON_0004755 skeletal tissue Skeletal tissue with a collagen-rich extracellular matrix vascularized, mineralized with hydroxyapatite and typically including osteocytes located in lacunae that communicate with one another by cell processes (in canaliculi). Bone is deposited by osteoblasts. http://purl.obolibrary.org/obo/UBERON_0002530 gland http://purl.obolibrary.org/obo/UBERON_0000062 organ An organ that functions as a secretory or excretory organ http://purl.obolibrary.org/obo/UBERON_0003501 retina blood vessel http://purl.obolibrary.org/obo/UBERON_0001981 blood vessel A blood vessel that is part of a retina. http://purl.obolibrary.org/obo/UBERON_0003509 arterial blood vessel http://purl.obolibrary.org/obo/UBERON_0001981 blood vessel A blood vessel that is part of the arterial system. Includes artery, arteriole and aorta. http://purl.obolibrary.org/obo/UBERON_0003909 sinusoid http://purl.obolibrary.org/obo/UBERON_0001981 blood vessel small blood vessel similar to a capillary but with a fenestrated endothelium. Sinusoids are found in the liver, lymphoid tissue, endocrine organs, and hematopoietic organs such as the bone marrow and the spleen. Sinusoids found within terminal villi of the placenta are not comparable to these; they possess a continuous endothelium and complete basal lamina[WP]. http://purl.obolibrary.org/obo/UBERON_0003920 venous blood vessel http://purl.obolibrary.org/obo/UBERON_0001981 blood vessel A blood vessel that carries blood from the capillaries toward the heart http://purl.obolibrary.org/obo/UBERON_0003928 digestive system duct http://purl.obolibrary.org/obo/UBERON_0000058 duct A duct that is part of a digestive system [Automatically generated definition]. http://purl.obolibrary.org/obo/UBERON_0004111 anatomical conduit http://purl.obolibrary.org/obo/UBERON_0000061 anatomical structure Any tube, opening or passage that connects two distinct anatomical spaces. http://purl.obolibrary.org/obo/UBERON_0004122 genitourinary system http://purl.obolibrary.org/obo/UBERON_0000467 anatomical system Anatomical system that has as its parts the organs concerned with the production and excretion of urine and those concerned with reproduction. http://purl.obolibrary.org/obo/UBERON_0004288 skeleton http://purl.obolibrary.org/obo/UBERON_0034925 anatomical collection Anatomical cluster that consists of all the skeletal elements (eg., bone, cartilage, and teeth) of the body. http://purl.obolibrary.org/obo/UBERON_0004571 systemic arterial system http://purl.obolibrary.org/obo/UBERON_0007798 vascular system The part of the arterial system which carries oxygenated blood away from the heart to the body, and returns deoxygenated blood back to the heart. http://purl.obolibrary.org/obo/UBERON_0004572 arterial system http://purl.obolibrary.org/obo/UBERON_0007798 vascular system The part of the cardiovascular system consisting of all arteries. http://purl.obolibrary.org/obo/UBERON_0004582 venous system http://purl.obolibrary.org/obo/UBERON_0007798 vascular system The part of the cardiovascular system consisting of all venous vessels. In vertebrates with a double circulation, this can be divided into systemic and pulmonary portions. http://purl.obolibrary.org/obo/UBERON_0004755 skeletal tissue http://purl.obolibrary.org/obo/UBERON_0002384 connective tissue A specialized form of connective tissue in which the extracellular matrix is firm, providing the tissue with resilience, and/or mineralized and that functions in mechanical and structural support.[VSAO] http://purl.obolibrary.org/obo/UBERON_0004770 articular system http://purl.obolibrary.org/obo/UBERON_0034925 anatomical collection Anatomical system that consists of all the joints of the body. http://purl.obolibrary.org/obo/UBERON_0006314 bodily fluid http://purl.obolibrary.org/obo/UBERON_0000463 organism substance Liquid components of living organisms. includes fluids that are excreted or secreted from the body as well as body water that normally is not. http://purl.obolibrary.org/obo/UBERON_0006841 central vein of liver http://purl.obolibrary.org/obo/UBERON_0001143 hepatic vein Vein that is central to a lobule in the liver. http://purl.obolibrary.org/obo/UBERON_0010000 multicellular anatomical structure http://purl.obolibrary.org/obo/UBERON_0000061 anatomical structure An anatomical structure that has more than one cell as a part. http://purl.obolibrary.org/obo/UBERON_0011216 organ system subdivision http://purl.obolibrary.org/obo/UBERON_0000061 anatomical structure A subdivision of an anatomical system. http://purl.obolibrary.org/obo/UBERON_0013686 anatomical conduit space http://purl.obolibrary.org/obo/UBERON_0000464 anatomical space An anatomical space which is the lumen of some anatomical conduit and connects two or more spaces together [FMA,modified]. http://purl.obolibrary.org/obo/UBERON_0013756 venous blood http://purl.obolibrary.org/obo/UBERON_0000178 blood A blood that is part of a vein. http://purl.obolibrary.org/obo/UBERON_0013765 digestive system element http://purl.obolibrary.org/obo/UBERON_0000062 organ Any of the organs or elements that are part of the digestive system. Examples: tongue, esophagus, spleen, crop, lunge feeding organ, tooth elements. http://purl.obolibrary.org/obo/UBERON_0014892 skeletal muscle organ http://purl.obolibrary.org/obo/UBERON_0001630 muscle organ A muscle organ that consists of skeletal muscle tissue ensheathed in epimysium, that develops from myotome and that is innervated by some somatic motor neuron. Skeletal muscles are typically attached (via a tendon) to a bone but there are exceptions (e.g. intrinsic tongue muscles). http://purl.obolibrary.org/obo/UBERON_0015480 hepatic artery proper http://purl.obolibrary.org/obo/UBERON_0001193 hepatic artery The hepatic artery proper (also proper hepatic artery), arises from the common hepatic artery and runs alongside the portal vein and the common bile duct to form the portal triad. The hepatic artery proper gives off a small supraduodenal artery to the duodenal bulb. Then the right gastric artery comes off and runs to the left along the lesser curvature of the stomach to meet the left gastric artery, which is a branch of the celiac trunk. It subsequently gives off the cystic artery, which feeds the gallbladder, before bifurcating into the right and left hepatic arteries. Of note, the right and left hepatic arteries may demonstrate variant anatomy. A replaced right hepatic artery may arise from the superior mesenteric artery (SMA) and a replaced left hepatic artery may arise from the left gastric artery. http://purl.obolibrary.org/obo/UBERON_0015481 left hepatic artery http://purl.obolibrary.org/obo/UBERON_0001193 hepatic artery A hepatic artery that is part of a left lobe of liver. http://purl.obolibrary.org/obo/UBERON_0015482 right hepatic artery http://purl.obolibrary.org/obo/UBERON_0001193 hepatic artery A hepatic artery that is part of a right lobe of liver. http://purl.obolibrary.org/obo/UBERON_0034925 anatomical collection http://purl.obolibrary.org/obo/UBERON_0001062 anatomical entity A collection of anatomical structures that are alike in terms of their morphology or developmental origin. http://purl.obolibrary.org/obo/OGG_3000008431 NR0B2 (mol) http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens The protein encoded by this gene is an unusual orphan receptor that contains a putative ligand-binding domain but lacks a conventional DNA-binding domain. The gene product is a member of the nuclear hormone receptor family, a group of transcription factors regulated by small hydrophobic hormones, a subset of which do not have known ligands and are referred to as orphan nuclear receptors. The protein has been shown to interact with retinoid and thyroid hormone receptors, inhibiting their ligand-dependent transcriptional activation. In addition, interaction with estrogen receptors has been demonstrated, leading to inhibition of function. Studies suggest that the protein represses nuclear hormone receptor-mediated transactivation via two separate steps: competition with coactivators and the direct effects of its transcriptional repressor function. [provided by RefSeq, Jul 2008] http://purl.obolibrary.org/obo/IMR_0000910 eIF4G http://purl.obolibrary.org/obo/IMR_0000912 eIF4F subunit Mammalian cells contain two isoforms of eIF4G (I&II). eIF4G is a subunit of the heterotrimeric eIF4F complex that binds to the cap structure at the 50 end of the mRNA. http://purl.obolibrary.org/obo/NCIT_C16702 hydrolysis http://purl.obolibrary.org/obo/TXPO_0000185 biochemical degradation A chemical reaction that uses water to break down a compound. http://purl.obolibrary.org/obo/NCIT_C19151 metastasis http://purl.obolibrary.org/obo/GO_0016477 cell migration The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor. http://purl.obolibrary.org/obo/NCIT_C21204 Organic Cation Transporter http://purl.obolibrary.org/obo/CHEBI_25367 molecule Organic Cation Transporter proteins carry positively charged chemical substances containing covalently bound carbon atoms through solubility barriers, such as lipid membranes or across epithelial layers. After binding substrate, transmembrane transporters often undergo an energy-dependent conformational change that moves the substrate across the membrane with (symport) or against (antiport) concentration gradients. http://purl.obolibrary.org/obo/CHEBI_142593 4-hydroxynonenal http://purl.obolibrary.org/obo/TXPO_0004328 reactive aldehyde A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group. http://purl.obolibrary.org/obo/CHEBI_15422 ATP http://purl.obolibrary.org/obo/CHEBI_36976 nucleotide An adenosine 5'-phosphate in which the 5'-phosphate is a triphosphate group. It is involved in the transportation of chemical energy during metabolic pathways. http://purl.obolibrary.org/obo/CHEBI_17268 myo-inositol http://purl.obolibrary.org/obo/CHEBI_24848 inositol An inositol having myo- configuration. http://purl.obolibrary.org/obo/CHEBI_17478 aldehyde http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A compound RC(2O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group. http://purl.obolibrary.org/obo/CHEBI_24127 fungicide http://purl.obolibrary.org/obo/CHEBI_35718 antifungal agent A substance used to destroy fungal pests. http://purl.obolibrary.org/obo/CHEBI_24783 imine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Compounds having the structure RN=CR2 (R = H, hydrocarbyl). Thus analogues of aldehydes or ketones, having NR doubly bonded to carbon; aldimines have the structure RCH=NR, ketimines have the structure R'2C=NR (where R' is not H). Imines include azomethines and Schiff bases. Imine is used as a suffix in systematic nomenclature to denote the C=NH group excluding the carbon atom. http://purl.obolibrary.org/obo/CHEBI_51006 unsaturated fatty acyl-CoA http://purl.obolibrary.org/obo/CHEBI_37554 fatty acyl-CoA A fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any unsaturated fatty acid. http://purl.obolibrary.org/obo/CHEBI_77746 human metabolite http://purl.obolibrary.org/obo/CHEBI_75768 mammalian metabolite Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). http://purl.obolibrary.org/obo/CHEBI_119486 efavirenz http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection. http://purl.obolibrary.org/obo/CHEBI_16469 17β-Estradiol http://purl.obolibrary.org/obo/CHEBI_23965 estradiol The 17beta-isomer of estradiol. http://purl.obolibrary.org/obo/CHEBI_18303 phosphatidyl-L-serine http://purl.obolibrary.org/obo/CHEBI_35766 glycerophosphoserine A class of aminophospholipids in which a phosphatidyl group is esterified to the hydroxy group of serine. http://purl.obolibrary.org/obo/CHEBI_27881 resveratrol http://purl.obolibrary.org/obo/TXPO_0000591 polyphenol A stilbenol that is stilbene in which the phenyl groups are substituted at positions 3, 5, and 4' by hydroxy groups. http://purl.obolibrary.org/obo/CHEBI_64583 sphingomyelin http://purl.obolibrary.org/obo/CHEBI_35786 phosphosphingolipid Any of a class of phospholipids in which the amino group of a sphingoid base is in amide linkage with one of several fatty acids, while the terminal hydroxy group of the sphingoid base is esterified to phosphorylcholine. http://purl.obolibrary.org/obo/CHEBI_16113 cholesterol http://purl.obolibrary.org/obo/CHEBI_35341 steroid A cholestanoid consisting of cholestane having a double bond at the 5,6-position as well as a 3β-hydroxy group. http://purl.obolibrary.org/obo/CHEBI_23899 icosanoid http://purl.obolibrary.org/obo/CHEBI_61697 fatty acid derivative Any member of the group of signalling molecules arising from oxidation of the three C20 essential fatty acids (EFAs) icosapentaenoic acid (EPA), arachidonic acid (AA) and dihomo-gamma-linolenic acid (DGLA). http://purl.obolibrary.org/obo/CHEBI_48706 antagonist http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role Substance that attaches to and blocks cell receptors that normally bind naturally occurring substances. http://purl.obolibrary.org/obo/CHEBI_26995 thromboxane http://purl.obolibrary.org/obo/CHEBI_26347 prostanoid A class of oxygenated oxane derivatives, originally derived from prostaglandin precursors in platelets, that stimulate aggregation of platelets and constriction of blood vessels. http://purl.obolibrary.org/obo/CHEBI_28509 chloroethene http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monohaloethene that is ethene in which one of the hydrogens has been replaced by a chloro group. http://purl.obolibrary.org/obo/CHEBI_30956 trichloroacetic acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine. http://purl.obolibrary.org/obo/CHEBI_35634 EC 1.17.3.2 (xanthine oxidase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76850 EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor An EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor that interferes with the action of xanthine oxidase (EC 1.17.3.2). http://purl.obolibrary.org/obo/CHEBI_35816 leprostatic drug http://purl.obolibrary.org/obo/CHEBI_64912 antimycobacterial drug A substance that suppresses Mycobacterium leprae, ameliorates the clinical manifestations of leprosy, and/or reduces the incidence and severity of leprous reactions. http://purl.obolibrary.org/obo/CHEBI_35842 antirheumatic drug http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug used to treat rheumatoid arthritis. http://purl.obolibrary.org/obo/CHEBI_38323 cholinergic drug http://purl.obolibrary.org/obo/CHEBI_35942 neurotransmitter agent Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. http://purl.obolibrary.org/obo/CHEBI_39098 pyrethrins http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity The active insecticidal constituents of Chrysanthemum cinerariifolium flowers. http://purl.obolibrary.org/obo/CHEBI_48923 erythromycin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus). http://purl.obolibrary.org/obo/CHEBI_64946 anti-HIV agent http://purl.obolibrary.org/obo/CHEBI_22587 antiviral agent An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. http://purl.obolibrary.org/obo/CHEBI_34873 N-nitrosodiethylamine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom. http://purl.obolibrary.org/obo/CHEBI_35473 tranquilizing drug http://purl.obolibrary.org/obo/CHEBI_35488 central nervous system depressant A traditional grouping of drugs said to have a soothing or calming effect on mood, thought or behaviour. http://purl.obolibrary.org/obo/CHEBI_35549 Perfluorooctanoic acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A fluoroalkanoic acid that is perfluorinated octanoic acid. http://purl.obolibrary.org/obo/CHEBI_35553 perhexiline http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Perhexiline (Pexsig) is a prophylactic antianginal agent used primarily in Australia and New Zealand. Perhexiline is thought to act by inhibiting mitochondrial carnitine palmitoyltransferase-1. (by Wikipedia) http://purl.obolibrary.org/obo/CHEBI_35841 uricosuric drug http://purl.obolibrary.org/obo/CHEBI_35846 renal agent A gout suppressant that acts directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma. http://purl.obolibrary.org/obo/CHEBI_35845 gout suppressant http://purl.obolibrary.org/obo/CHEBI_35842 antirheumatic drug A drug that increases uric acid excretion by the kidney (uricosuric drug), decreases uric acid production (antihyperuricemic), or alleviates the pain and inflammation of acute attacks of gout. http://purl.obolibrary.org/obo/CHEBI_35846 renal agent http://purl.obolibrary.org/obo/CHEBI_23888 drug A drug used for its effect on the kidneys' regulation of body fluid composition and volume. http://purl.obolibrary.org/obo/CHEBI_3619 chlormezanone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions. http://purl.obolibrary.org/obo/CHEBI_3647 chlorpromazine http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety. http://purl.obolibrary.org/obo/CHEBI_3655 chlorzoxazone http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm. http://purl.obolibrary.org/obo/CHEBI_367163 darunavir http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors. http://purl.obolibrary.org/obo/CHEBI_37957 histaminergic drug http://purl.obolibrary.org/obo/CHEBI_35942 neurotransmitter agent Drugs used for their actions on histaminergic systems. http://purl.obolibrary.org/obo/CHEBI_48540 beta-adrenergic drug http://purl.obolibrary.org/obo/CHEBI_37962 adrenergic agent Any of the drugs that act on beta-adrenergic receptors. http://purl.obolibrary.org/obo/CHEBI_5004 fenoprofen http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. http://purl.obolibrary.org/obo/CHEBI_52210 pharmacological role http://purl.obolibrary.org/obo/BFO_0000023 role A biological role which describes how a drug interacts within a biological system and how the interactions affect its medicinal properties. http://purl.obolibrary.org/obo/CHEBI_76775 EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76760 EC 3.1.* (ester hydrolase) inhibitor An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of any phosphoric monoester hydrolase (EC 3.1.3.*). http://purl.obolibrary.org/obo/CHEBI_76835 EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76726 EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor An EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor that uses NAD(+) or NADP(+) as acceptor (EC 1.1.1.*). http://purl.obolibrary.org/obo/CHEBI_76840 EC 1.14.99.* (miscellaneous oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor http://purl.obolibrary.org/obo/CHEBI_76741 EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any enzyme in the EC 1.14.99.* (miscellaneous) category. http://purl.obolibrary.org/obo/CHEBI_76850 EC 1.17.3.* (oxidoreductase acting on CH or CH2 with oxygen as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76744 EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that interferes with the function of any such enzyme that uses oxygen as acceptor (EC 1.17.3.*). http://purl.obolibrary.org/obo/CHEBI_76852 EC 1.2.1.* (oxidoreductase acting on donor aldehyde/oxo group with NAD(+) or NADP(+) as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76727 EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor An EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.2.1.*). http://purl.obolibrary.org/obo/CHEBI_9516 thapsigargin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations. http://purl.obolibrary.org/obo/CHEBI_55346 anidulafungin http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis. http://purl.obolibrary.org/obo/CHEBI_77103 EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor http://purl.obolibrary.org/obo/CHEBI_77102 EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor An EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor that interferes with the action of dihydroorotate dehydrogenase (quinone), EC 1.3.5.2. http://purl.obolibrary.org/obo/CHEBI_77106 EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor http://purl.obolibrary.org/obo/CHEBI_77105 EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor An EC 1.10.2.* (oxidoreductase acting on diphenols and related substances as donors with a cytochrome as acceptor) inhibitor that interferes with the action of quinol--cytochrome-c reductase (EC 1.10.2.2). http://purl.obolibrary.org/obo/CHEBI_64355 posaconazole http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An N-arylpiperazine that consists of piperazine carrying two 4-substituted phenyl groups at positions 1 and 4. A triazole antifungal drug. http://purl.obolibrary.org/obo/CHEBI_64371 neurotransmitter transporter modulator http://purl.obolibrary.org/obo/CHEBI_38632 membrane transport modulator A membrane transport modulator that affects the transport of neurotransmitters. http://purl.obolibrary.org/obo/CHEBI_65172 ximelagatran http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage. http://purl.obolibrary.org/obo/CHEBI_76733 EC 1.6.* (oxidoreductase acting on NADH or NADPH) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on NADH or NADPH (EC 1.6.*.*). http://purl.obolibrary.org/obo/CHEBI_76869 EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitor http://purl.obolibrary.org/obo/CHEBI_76735 EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor An EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.8.1.*). http://purl.obolibrary.org/obo/CHEBI_9352 sulindac http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions. http://purl.obolibrary.org/obo/CHEBI_75596 EC 5.* (isomerase) inhibitor http://purl.obolibrary.org/obo/CHEBI_23924 enzyme inhibitor An enzyme inhibitor that inhibits the action of an isomerase (EC 5.*.*.*). http://purl.obolibrary.org/obo/CHEBI_7573 nilutamide http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer. (by Wikipedia) http://purl.obolibrary.org/obo/CHEBI_75787 prokaryotic metabolite http://purl.obolibrary.org/obo/CHEBI_25212 metabolite Any metabolite produced during a metabolic reaction in prokaryotes, the taxon that include members of domains such as the bacteria and archaea. http://purl.obolibrary.org/obo/CHEBI_76114 benoxaprofen http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals. http://purl.obolibrary.org/obo/CHEBI_76133 droxicam http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. http://purl.obolibrary.org/obo/CHEBI_76158 ibufenac http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects. http://purl.obolibrary.org/obo/CHEBI_7640 nortriptyline http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline. http://purl.obolibrary.org/obo/CHEBI_76603 Chlorendic Acid http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A bridged organochlorine compound resulting from the Diels-Alder reaction of hexachlorocyclopentadiene with maleic anhydride followed by hydrolysis of the resulting anhydride. A chemical intermediate used in the preparation of fire-retardant polyester resins and plasticisers. http://purl.obolibrary.org/obo/CHEBI_76655 EC 2.1.* (C1-transferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_71300 EC 2.* (transferase) inhibitor A transferase inhibitor inhibiting the action of transferase of a one-carbon-containing group (EC 2.1.*.*). http://purl.obolibrary.org/obo/CHEBI_76661 EC 2.3.* (acyltransferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_71300 EC 2.* (transferase) inhibitor A transferase inhibitor that interferes with the action of an acyltransferase (EC 2.3.*.*). http://purl.obolibrary.org/obo/CHEBI_76697 EC 5.99.* (other isomerases) inhibitor http://purl.obolibrary.org/obo/CHEBI_75596 EC 5.* (isomerase) inhibitor An isomerase inhibitor that interferes with the action of any member of the group of 'other isomerases' (EC 5.99.*.*). http://purl.obolibrary.org/obo/CHEBI_76710 EC 4.* (lyase) inhibitor http://purl.obolibrary.org/obo/CHEBI_23924 enzyme inhibitor An enzyme inhibitor which interferes with the action of a lyase (EC 4.*.*.*). Lyases are enzymes cleaving C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation. http://purl.obolibrary.org/obo/CHEBI_76712 EC 4.2.* (C-O lyase) inhibitor http://purl.obolibrary.org/obo/CHEBI_76710 EC 4.* (lyase) inhibitor A lyase inhibitor which inhibits the action of a C-O lyase (EC 4.2.*.*). http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor http://purl.obolibrary.org/obo/CHEBI_23924 enzyme inhibitor An enzyme inhibitor which interferes with the action of an oxidoreductase (EC 1.*.*.*). http://purl.obolibrary.org/obo/CHEBI_76726 EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-OH group of donors (EC 1.1.*.*). http://purl.obolibrary.org/obo/CHEBI_76727 EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the aldehyde or oxo group of donors (EC 1.2.*.*). http://purl.obolibrary.org/obo/CHEBI_76729 EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-CH group of donors (EC 1.3.*.*). http://purl.obolibrary.org/obo/CHEBI_76731 EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-NH group of donors (EC 1.5.*.*). http://purl.obolibrary.org/obo/CHEBI_76735 EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase of class EC 1.8.*.* (acting on a sulfur group of donors). http://purl.obolibrary.org/obo/CHEBI_76737 EC 1.10.* (oxidoreductase acting on diphenols and related substances as donors) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on diphenols and related substances as donors (EC 1.10.*.*). http://purl.obolibrary.org/obo/CHEBI_76740 EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases), EC 1.13.*.*. http://purl.obolibrary.org/obo/CHEBI_76741 EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on hydrogen as donors (EC 1.14.*.*). http://purl.obolibrary.org/obo/CHEBI_76744 EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor http://purl.obolibrary.org/obo/CHEBI_76725 EC 1.* (oxidoreductase) inhibitor An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on CH or CH2 (EC 1.17.*.*). http://purl.obolibrary.org/obo/CHEBI_76764 EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor http://purl.obolibrary.org/obo/CHEBI_76759 EC 3.* (hydrolase) inhibitor Any hydrolase inhibitor that interferes with the action of a hydrolase acting on C-N bonds, other than peptide bonds (EC 3.5.*.*). http://purl.obolibrary.org/obo/CHEBI_76834 EC 2.5.* (non-methyl-alkyl or aryl transferase) inhibitor http://purl.obolibrary.org/obo/CHEBI_71300 EC 2.* (transferase) inhibitor An EC 2.5.* (transferase) inhibitor that inhibits the action of any transferase that transfers an alkyl (other than methyl) or aryl group (EC 2.5.*). http://purl.obolibrary.org/obo/CHEBI_76998 aryl hydrocarbon receptor antagonist http://purl.obolibrary.org/obo/CHEBI_48706 antagonist An antagonist that binds to and inactivates aryl hydrocarbon receptors (AhRs). http://purl.obolibrary.org/obo/CHEBI_83612 hepatic steatosis inducing agent http://purl.obolibrary.org/obo/CHEBI_50908 hepatotoxic agent Any hepatotoxic agent capable of inducing liver steatosis or fatty liver disease. http://purl.obolibrary.org/obo/CHEBI_85010 eltrombopag http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A hydrazine in which each nitrogen atom is substituted, one by a 3'-carboxy-2-hydroxy[1,1'-biphenyl]-3-yl group and the other by a 1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene group. A small molecule agonist of the c-mpl (TpoR) receptor (the physiological target of the hormone thrombopoietin), it has been developed as a medication for conditions that lead to thrombocytopenia (abnormally low platelet counts). http://purl.obolibrary.org/obo/CHEBI_85012 thrombopoietin receptor agonist http://purl.obolibrary.org/obo/CHEBI_48705 agonist An agonist that selectively binds to and activates the thrombopoietin receptor [myeloproliferative leukemia protein or CD110 (Cluster of Differentiation 110)]. http://purl.obolibrary.org/obo/CHEBI_94686 orlistat http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug. http://purl.obolibrary.org/obo/IMR_0000320 G-alpha-o http://purl.obolibrary.org/obo/IMR_0000318 G-alpha-i class Galphao, the most abundant G protein in mammalian brain, occurs at least in two subforms, i.e., Galphao1 and Galphao2, derived by alternative splicing of the mRNA. http://purl.obolibrary.org/obo/IMR_0100216 ERK5 http://purl.obolibrary.org/obo/IMR_0000224 MAPK ERK5, also known as big MAP kinase 1 (BMK1), is twice the size of other MAPKs. The amino-terminal half contains the kinase domain, which is similar to that of ERK1/2 and has the TEY activation motif, whereas the carboxy-terminal half is unique. MEK5 phosphorylates and activates ERK5, and then the activated ERK5 phosphorylates substrates including myocyte enhancer factor 2 (MEF2). http://purl.obolibrary.org/obo/IMR_0000435 Sos http://purl.obolibrary.org/obo/IMR_0100440 RasGEF Drosophila Son of Sevenless (SOS) is homologous to the yeast exchange factor for Ras, CDC25. Mammalian cells contain two closely related homologs of Drosophila SOS: SOS1 and SOS2. Biochemical studies have established that SOS indeed functions as a guanine nucleotide exchange factor for Ras. http://purl.obolibrary.org/obo/IMR_0000339 Grb2 family http://purl.obolibrary.org/obo/CHEBI_25367 molecule The best characterised member of the SH2/SH3 adaptor protein family is Grb2, the human homologue of the nematode Caenorhabditis elegans protein Sem-5. The structure of Grb2 consists of one SH2 domain flanked by two SH3 domains. Recently, further members of the Grb2 family have been isolated, Grap protein and Gads. http://purl.obolibrary.org/obo/IMR_0000224 MAPK http://purl.obolibrary.org/obo/CHEBI_25367 molecule Mammals express at least four distinctly regulated groups of MAPKs, ERK-1/2, JNK/SAPK, p38 and ERK5. MAPKs are activated by dual phosphorylation on both tyrosine and threonine residues of a conserved TXY motif. http://purl.obolibrary.org/obo/IMR_0100271 MAPKAPK http://purl.obolibrary.org/obo/CHEBI_25367 molecule Four groups of kinases have been shown to be activated by MAP kinases, ribosomal S6 kinase (RSK also known as MAPKAPK1), MAP kinase-activated protein kinase 2/3 (MAPKAPK2/3), MAP kinase-interacting kinase or MAP kinase signal-integrating kinase (MNK) and MAPKAPK5 (PRAK). http://purl.obolibrary.org/obo/GO_0005776 autophagosome http://purl.obolibrary.org/obo/GO_0005773 vacuole A double-membrane-bounded compartment that engulfs endogenous cellular material as well as invading microorganisms to target them to the vacuole/lysosome for degradation as part of macroautophagy. http://purl.obolibrary.org/obo/IMR_0100051 motilin http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones A peptide of about 22-amino acids isolated from the DUODENUM. At low pH it inhibits gastric motor activity, whereas at high pH it has a stimulating effect. http://purl.obolibrary.org/obo/IMR_0100075 secretin http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones A peptide hormone of about 27 amino acids from the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level. http://purl.obolibrary.org/obo/IMR_0100106 chorionic gonadotropin http://purl.obolibrary.org/obo/IMR_0100086 placental hormone, peptide A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. http://purl.obolibrary.org/obo/IMR_0000741 Gads http://purl.obolibrary.org/obo/IMR_0000339 Grb2 family Gads is a member of the family of SH2 and SH3 domain containing adaptor proteins that is expressed specifically in hematopoietic cells and functions in the coordination of tyrosine kinase mediated signal transduction. Gads is a unique member of the Grb2 adaptor family. http://purl.obolibrary.org/obo/IMR_0000745 Crk family http://purl.obolibrary.org/obo/CHEBI_25367 molecule Alternative splicing of the mammal crk gene yields two translation products designated the 28-kDa Crk-I and the 42-kDa Crk-II protein. The Crk-II protein contains an amino-terminal SH2 domain followed by two SH3 domains. The Crk-I protein does not contain the second SH3 domain. The 36-kDa Crk-L protein is similar to CrkII, but is encoded by a separate gene. http://purl.obolibrary.org/obo/IMR_0000227 ERK1/2 http://purl.obolibrary.org/obo/IMR_0000224 MAPK ERK1 and ERK2 are isoforms of the 'classical' MAPK. Both ERK1 and ERK2 (referred to as ERK1/2) are activated by MAP/ERK kinase 1 (MEK1) and MEK2 (referred to as MEK1/2). MEK1/2 phosphorylates threonine and tyrosine residues in the Thr-Glu-Tyr (TEY) sequence of ERK1/2. Activated ERK1/2 phosphorylates many substrates including transcription factors, such as Elk1 and c-Myc, and protein kinases, such as ribosomal S6 kinase (RSK). http://purl.obolibrary.org/obo/IMR_0000248 RSK http://purl.obolibrary.org/obo/IMR_0001844 S6K A family of 90 kDa ribosomal S6 kinases (RSK; also known as p90rsk or MAPK-activated protein kinase-1, MAPKAP-K1). The RSK family of kinases includes three isoforms: RSK1, RSK2 and RSK3 that are encoded by distinct genes and show 75-80% amino acid identity. RSK proteins is regulated by the ERK kinase pathway. http://purl.obolibrary.org/obo/IMR_0002576 inositol 1,4,5-trisphosphate 3-kinase http://purl.obolibrary.org/obo/CHEBI_25367 molecule Ins(1,4,5)P3 3-kinases (IP3-3K) are the enzymes responsible for the ATP-dependent conversion of Ins(1,4,5)P3 to Ins(1,3,4,5)P4. Three mammalian isoforms of this enzyme have so far been isolated and designated the A, B and C isoforms. http://purl.obolibrary.org/obo/IMR_0001699 peptidoglycan http://purl.obolibrary.org/obo/CHEBI_18154 polysaccharide Peptidoglycan (PGN) is a unique and essential component of the cell wall of virtually all bacteria, is not present in eukaryotes, and is an excellent target for the innate immune system. http://purl.obolibrary.org/obo/IMR_0002516 nonclassical MHC class II molecule http://purl.obolibrary.org/obo/IMR_0000142 MHC family MHC class II-like proteins are produced from the class II region of the MHC, HLA-DM (DM) and HLA-DO (DO) (called H2-M, or H2-DM and H2-O in the mouse). http://purl.obolibrary.org/obo/IMR_0100021 leukotriene http://purl.obolibrary.org/obo/CHEBI_23899 icosanoid Any icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated. http://purl.obolibrary.org/obo/IMR_0100070 gastrin-releasing peptide http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS. http://purl.obolibrary.org/obo/IMR_0001693 amine http://purl.obolibrary.org/obo/CHEBI_72695 organic molecule A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed) http://purl.obolibrary.org/obo/IMR_0000417 BCL-6 http://purl.obolibrary.org/obo/CHEBI_25367 molecule BCL-6 belongs to a subset of transcription factors which all have a similar structure composed of an amino-terminal 'POZ' domain and several zinc finger modules at the carboxy-terminus. BCL-6 is highly conserved among vertebrate species. BCL-6 homologues have been identified from human, mouse, frog, and chicken species. http://purl.obolibrary.org/obo/IMR_0100093 pituitary hormone-releasing hormone http://purl.obolibrary.org/obo/IMR_0100082 hypothalamic hormone Hormones released by one structure (e.g., the hypothalamus or the thyroid gland) that effect the secretion of hormones from the pituitary gland. http://purl.obolibrary.org/obo/IMR_0000310 26S proteasome http://purl.obolibrary.org/obo/CHEBI_25367 molecule The 26S proteasome is a 2.5-MDa molecular machine built from ~31 different subunits, which catalyzes protein degradation. It contains a barrel-shaped proteolytic core complex (the 20S proteasome), capped at one or both ends by 19S regulatory complexes, which recognize ubiquitinated proteins. http://purl.obolibrary.org/obo/IMR_0000456 14-3-3 http://purl.obolibrary.org/obo/CHEBI_25367 molecule The term 14-3-3 denotes a large family of ~30 kDa acidic proteins that exist primarily as homo- and heterodimers within all eukaryotic cells. Their unusual name refers to their elution position on DEAE-cellulose chromatography and gel electrophoresis during a systematic attempt at classifying bovine brain proteins. In humans, there are seven distinct 14-3-3 genes denoted beta, gamma, epsilon, eta, sigma, tau (theta) and zeta (as well as a number of potential pseudogenes), while yeast and plants contain between 2 and 15 genes. http://purl.obolibrary.org/obo/IMR_0000371 R-Smad http://purl.obolibrary.org/obo/IMR_0000370 Smad There are five vertebrate R-Smads, Smad1, Smad2, Smad3, Smad5 and Smad8 and they are phosphorylated in response to different types of TGF-beta ligands. Phosphorylated R-Smads can form complexes with Smad4 and positively or negatively regulate transcription. The Mad protein in Drosophila is the ortholog of Smad1/5, whereas dSmad2 is the ortholog of Smad2/3. In C. elegans, sma-2 and sma-3 proved to be homologous to Mad of Drosophila. http://purl.obolibrary.org/obo/IMR_0000144 MHC class II molecule http://purl.obolibrary.org/obo/IMR_0000142 MHC family MHC class II molecules are composed of membrane-spanning alpha and beta chains. http://purl.obolibrary.org/obo/IMR_0000811 CD80 http://purl.obolibrary.org/obo/IMR_0002950 CD80/CD86 B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively. http://purl.obolibrary.org/obo/IMR_0100076 pancreatic hormone http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone Peptide hormones secreted into the blood by cells in the ISLETS OF LANGERHANS of the pancreas. The alpha cells secrete glucagon; the beta cells secrete insulin; the delta cells secrete somatostatin; and the PP cells secrete pancreatic polypeptide. http://purl.obolibrary.org/obo/IMR_0100084 pituitary hormone http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone Hormones secreted by the PITUITARY GLAND including those from the anterior lobe (adenohypophysis), the posterior lobe (neurohypophysis), and the ill-defined intermediate lobe. http://purl.obolibrary.org/obo/IMR_0100086 placental hormone, peptide http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone Hormones produced by the placenta include CHORIONIC GONADOTROPIN, and PLACENTAL LACTOGEN. Not include steroid hormones ( ESTROGENS; PROGESTERONE). http://purl.obolibrary.org/obo/IMR_0100098 gonadotropin, pituitary http://purl.obolibrary.org/obo/IMR_0100096 pituitary hormone, anterior Hormones secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR) that stimulate gonadal functions in both males and females. They include FOLLICLE STIMULATING HORMONE that stimulates germ cell maturation ( OOGENESIS; SPERMATOGENESIS), and LUTEINIZING HORMONE that stimulates the production of sex steroids ( ESTROGENS; PROGESTERONE; ANDROGENS). http://purl.obolibrary.org/obo/IMR_0000904 eIF3 http://purl.obolibrary.org/obo/IMR_0010016 eIF consists of a core of five non-identical subunits (eIF3a, eIF3b, eIF3c, eIF3i and eIF3g in yeast) and up to six additional subunits in mammals (eIF3d, eIF3e, eIF3f, eIF3h, eIFj and eIF3k). binding to and stabilization of ternary complex, binding to the 40S ribosome, facilitating the binding of mRNA to the 40S ribosome, and promoting dissociation of 40S and 60S ribosomal subunits http://purl.obolibrary.org/obo/DOID_0070111 Niemann-Pick disease type A http://purl.obolibrary.org/obo/DOID_14504 Niemann-Pick disease A Niemann-Pick disease characterized by onset in infancy and involvement of neurological tissues that has_material_basis_in an autosomal recessive mutation of SMPD1 on chromosome 11p15.4. http://purl.obolibrary.org/obo/DOID_0070112 Niemann-Pick disease type B http://purl.obolibrary.org/obo/DOID_14504 Niemann-Pick disease A Niemann-Pick disease characterized by visceral involvement only and survival into adulthood that has_material_basis_in an autosomal recessive mutation of SMPD1 on chromosome 11p15.4. http://purl.obolibrary.org/obo/DOID_0070113 Niemann-Pick disease type C1 http://purl.obolibrary.org/obo/DOID_14504 Niemann-Pick disease A Niemann-Pick disease that has_material_basis_in an autosomal recessive mutation of NPC1 on chromosome 18q11.2. http://purl.obolibrary.org/obo/DOID_0070114 Niemann-Pick disease type C2 http://purl.obolibrary.org/obo/DOID_14504 Niemann-Pick disease A Niemann-Pick disease that has_material_basis_in an autosomal recessive mutation of NPC2 on chromosome 14q24.3. http://purl.obolibrary.org/obo/GO_0000062 fatty-acyl-CoA binding http://purl.obolibrary.org/obo/GO_1901567 fatty acid derivative binding Interacting selectively and non-covalently with acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thiolester linkage with a fatty acyl group. http://purl.obolibrary.org/obo/GO_0000229 cytoplasmic chromosome http://purl.obolibrary.org/obo/GO_0005694 chromosome A chromosome found in the cytoplasm. http://purl.obolibrary.org/obo/GO_0000266 mitochondrial fission http://purl.obolibrary.org/obo/TXPO_0002576 splitting The division of a mitochondrion within a cell to form two or more separate mitochondrial compartments. http://purl.obolibrary.org/obo/GO_0000279 M phase http://purl.obolibrary.org/obo/GO_0022403 cell cycle phase A cell cycle phase during which nuclear division occurs, and which is comprises the phases: prophase, metaphase, anaphase and telophase. http://purl.obolibrary.org/obo/GO_0000422 autophagy of mitochondrion http://purl.obolibrary.org/obo/GO_0006914 autophagy The autophagic process in which mitochondria are delivered to the vacuole and degraded in response to changing cellular conditions. http://purl.obolibrary.org/obo/GO_0000423 mitohagy http://purl.obolibrary.org/obo/GO_0000422 autophagy of mitochondrion Degradation of a mitochondrion by macroautophagy. http://purl.obolibrary.org/obo/GO_0000425 pexophagy http://purl.obolibrary.org/obo/GO_0030242 autophagy of peroxisome The selective autophagy process in which a peroxisome is degraded by macroautophagy. http://purl.obolibrary.org/obo/GO_0001666 response to hypoxia http://purl.obolibrary.org/obo/GO_0006950 response to stress Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. http://purl.obolibrary.org/obo/GO_0001676 long-chain fatty acid metabolic process http://purl.obolibrary.org/obo/GO_0006631 fatty acid metabolic process The chemical reactions and pathways involving long-chain fatty acids, A long-chain fatty acid is a fatty acid with a chain length between C13 and C22. http://purl.obolibrary.org/obo/GO_0001732 formation of cytoplasmic translation initiation complex http://purl.obolibrary.org/obo/GO_0006461 protein complex assembly Joining of the large subunit, with release of IF2/eIF2 and IF3/eIF3. This leaves the functional ribosome at the AUG, with the methionyl/formyl-methionyl-tRNA positioned at the P site. http://purl.obolibrary.org/obo/GO_0001775 cell activation http://purl.obolibrary.org/obo/TXPO_0000401 activating A change in the morphology or behavior of a cell resulting from exposure to an activating factor such as a cellular or soluble ligand. http://purl.obolibrary.org/obo/GO_0001787 natural killer cell proliferation http://purl.obolibrary.org/obo/GO_0046651 lymphocyte proliferation The expansion of a natural killer cell population by cell division. http://purl.obolibrary.org/obo/GO_0001816 cytokine production http://purl.obolibrary.org/obo/TXPO_0000382 protein production The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0001836 release of cytochrome c from mitochondria http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation. http://purl.obolibrary.org/obo/GO_0001837 epithelial to mesenchymal transition http://purl.obolibrary.org/obo/GO_0030154 cell differentiation A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. http://purl.obolibrary.org/obo/GO_0001845 phagolysosome assembly http://purl.obolibrary.org/obo/GO_0071840 cellular component organization or biogenesis The process that results in the fusion of a phagosome, a vesicle formed by phagocytosis, with a lysosome. http://purl.obolibrary.org/obo/GO_0001865 NK T cell differentiation http://purl.obolibrary.org/obo/GO_0030217 T cell differentiation The process in which a precursor cell type acquires the specialized features of a NK T cell. http://purl.obolibrary.org/obo/GO_0002224 TLR signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway Any series of molecular signals generated as a consequence of binding to a toll-like receptor. Toll-like receptors directly bind pattern motifs from a variety of microbial sources to initiate innate immune response. http://purl.obolibrary.org/obo/GO_0002228 natural killer cell mediated immunity http://purl.obolibrary.org/obo/GO_0045087 innate immune response The promotion of an immune response by natural killer cells through direct recognition of target cells or through the release of cytokines. http://purl.obolibrary.org/obo/GO_0002250 adaptive immune response http://purl.obolibrary.org/obo/GO_0006955 immune response An immune response based on directed amplification of specific receptors for antigen produced through a somatic diversification process, and allowing for enhanced response to subsequent exposures to the same antigen (immunological memory). http://purl.obolibrary.org/obo/GO_0002367 cytokine production involved in immune response http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of a cytokine due to biosynthesis or secretion following a cellular stimulus contributing to an immune response, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0002384 hepatic immune response http://purl.obolibrary.org/obo/GO_0006955 immune response An immune response taking place in the liver. http://purl.obolibrary.org/obo/GO_0002418 immune response to tumor cell http://purl.obolibrary.org/obo/GO_0006955 immune response An immune system process that functions in the response of an organism to a tumor cell. http://purl.obolibrary.org/obo/GO_0002521 leukocyte differentiation http://purl.obolibrary.org/obo/GO_0030154 cell differentiation The process in which a relatively unspecialized hemopoietic precursor cell acquires the specialized features of a leukocyte. A leukocyte is an achromatic cell of the myeloid or lymphoid lineages capable of ameboid movement, found in blood or other tissue. http://purl.obolibrary.org/obo/GO_0002534 cytokine production involved in inflammatory response http://purl.obolibrary.org/obo/GO_0001816 cytokine production The synthesis or release of a cytokine following a inflammatory stimulus as part of an inflammatory response, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0003677 DNA binding http://purl.obolibrary.org/obo/GO_0005488 binding (with molecule) Process of any molecular function by which a gene product interacts selectively and non-covalently with DNA (deoxyribonucleic acid). http://purl.obolibrary.org/obo/GO_0005488 binding (with molecule) http://purl.obolibrary.org/obo/TXPO_0000469 joining The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more specific sites on another molecule. http://purl.obolibrary.org/obo/GO_0005515 protein binding http://purl.obolibrary.org/obo/GO_0005488 binding (with molecule) Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules). http://purl.obolibrary.org/obo/GO_0005543 phospholipid binding http://purl.obolibrary.org/obo/GO_0008289 lipid binding Interacting selectively and non-covalently with phospholipids, a class of lipids containing phosphoric acid as a mono- or diester. http://purl.obolibrary.org/obo/GO_0005622 intracellular http://purl.obolibrary.org/obo/GO_0044464 cell part The living contents of a cell; the matter contained within (but not including) the plasma membrane, usually taken to exclude large vacuoles and masses of secretory or ingested material. In eukaryotes it includes the nucleus and cytoplasm. http://purl.obolibrary.org/obo/GO_0005634 nucleus http://purl.obolibrary.org/obo/GO_0043227 membrane-bounded organelle A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. http://purl.obolibrary.org/obo/GO_0005694 chromosome http://purl.obolibrary.org/obo/GO_0043226 organelle A structure composed of a very long molecule of DNA and associated proteins (e.g. histones) that carries hereditary information. http://purl.obolibrary.org/obo/GO_0005737 cytoplasm http://purl.obolibrary.org/obo/TXPO_0000065 cellular tissue All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. http://purl.obolibrary.org/obo/GO_0005739 mitochondrion http://purl.obolibrary.org/obo/GO_0043227 membrane-bounded organelle A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration. http://purl.obolibrary.org/obo/GO_0005741 mitochondrial outer membrane http://purl.obolibrary.org/obo/GO_0031966 mitochondrial membrane The outer, i.e. cytoplasm-facing, lipid bilayer of the mitochondrial envelope. http://purl.obolibrary.org/obo/GO_0005764 lysosome http://purl.obolibrary.org/obo/GO_0005773 vacuole A small lytic vacuole that has cell cycle-independent morphology and is found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions. http://purl.obolibrary.org/obo/GO_0005768 endosome http://purl.obolibrary.org/obo/GO_0031982 vesicle A vacuole to which materials ingested by endocytosis are delivered. http://purl.obolibrary.org/obo/GO_0005773 vacuole http://purl.obolibrary.org/obo/GO_0043227 membrane-bounded organelle A closed structure, found only in eukaryotic cells, that is completely surrounded by unit membrane and contains liquid material. Cells contain one or several vacuoles, that may have different functions from each other. Vacuoles have a diverse array of functions. They can act as a storage organelle for nutrients or waste products, as a degradative compartment, as a cost-effective way of increasing cell size, and as a homeostatic regulator controlling both turgor pressure and pH of the cytosol. http://purl.obolibrary.org/obo/GO_0005783 endoplasmic reticulum http://purl.obolibrary.org/obo/GO_0043227 membrane-bounded organelle The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached). http://purl.obolibrary.org/obo/GO_0005789 endoplasmic reticulum membrane http://purl.obolibrary.org/obo/GO_0031090 organelle membrane The lipid bilayer surrounding the endoplasmic reticulum. http://purl.obolibrary.org/obo/GO_0005815 microtubule organizing center http://purl.obolibrary.org/obo/GO_0044464 cell part An intracellular structure that can catalyze gamma-tubulin-dependent microtubule nucleation and that can anchor microtubules by interacting with their minus ends, plus ends or sides. http://purl.obolibrary.org/obo/GO_0005829 cytosol http://purl.obolibrary.org/obo/TXPO_0000065 cellular tissue The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. http://purl.obolibrary.org/obo/GO_0005840 ribosome http://purl.obolibrary.org/obo/GO_0043226 organelle An intracellular organelle, about 200 A in diameter, consisting of RNA and protein. It is the site of protein biosynthesis resulting from translation of messenger RNA (mRNA). It consists of two subunits, one large and one small, each containing only protein and RNA. Both the ribosome and its subunits are characterized by their sedimentation coefficients, expressed in Svedberg units (symbol: S). Hence, the prokaryotic ribosome (70S) comprises a large (50S) subunit and a small (30S) subunit, while the eukaryotic ribosome (80S) comprises a large (60S) subunit and a small (40S) subunit. Two sites on the ribosomal large subunit are involved in translation, namely the aminoacyl site (A site) and peptidyl site (P site). Ribosomes from prokaryotes, eukaryotes, mitochondria, and chloroplasts have characteristically distinct ribosomal proteins. http://purl.obolibrary.org/obo/GO_0005886 plasma membrane http://purl.obolibrary.org/obo/TXPO_0000895 biological membrane The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins http://purl.obolibrary.org/obo/GO_0005977 glycogen metabolic process http://purl.obolibrary.org/obo/GO_0005975 carbohydrate metabolic process The chemical reactions and pathways involving glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues in alpha-(1->4) glycosidic linkage, joined together by alpha-(1->6) glycosidic linkages. http://purl.obolibrary.org/obo/GO_0006119 oxidative phosphorylation http://purl.obolibrary.org/obo/GO_0016310 phosphorylation The phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis. http://purl.obolibrary.org/obo/GO_0006260 DNA replication http://purl.obolibrary.org/obo/TXPO_0000093 increasing number of objects The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA. http://purl.obolibrary.org/obo/GO_0006281 DNA repair http://purl.obolibrary.org/obo/TXPO_0000535 repairing The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway. http://purl.obolibrary.org/obo/GO_0006308 DNA catabolic process http://purl.obolibrary.org/obo/GO_0009056 catabolic process The cellular DNA metabolic process resulting in the breakdown of DNA, deoxyribonucleic acid, one of the two main types of nucleic acid, consisting of a long unbranched macromolecule formed from one or two strands of linked deoxyribonucleotides, the 3'-phosphate group of each constituent deoxyribonucleotide being joined in 3',5'-phosphodiester linkage to the 5'-hydroxyl group of the deoxyribose moiety of the next one. http://purl.obolibrary.org/obo/GO_0006351 transcription, DNA-templated http://purl.obolibrary.org/obo/GO_0010467 gene expression The cellular synthesis of RNA on a template of DNA. http://purl.obolibrary.org/obo/GO_0006355 regulation of transcription, DNA-templated http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription. http://purl.obolibrary.org/obo/GO_0006402 mRNA catabolic process http://purl.obolibrary.org/obo/GO_0009056 catabolic process The chemical reactions and pathways resulting in the breakdown of mRNA, messenger RNA, which is responsible for carrying the coded genetic 'message', transcribed from DNA, to sites of protein assembly at the ribosomes. http://purl.obolibrary.org/obo/GO_0006412 translation http://purl.obolibrary.org/obo/GO_0010467 gene expression The cellular metabolic process in which a protein is formed, using the sequence of a mature mRNA or circRNA molecule to specify the sequence of amino acids in a polypeptide chain. Translation is mediated by the ribosome, and begins with the formation of a ternary complex between aminoacylated initiator methionine tRNA, GTP, and initiation factor 2, which subsequently associates with the small subunit of the ribosome and an mRNA or circRNA. Translation ends with the release of a polypeptide chain from the ribosome. http://purl.obolibrary.org/obo/GO_0006508 proteolysis http://purl.obolibrary.org/obo/TXPO_0000333 separating The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds. http://purl.obolibrary.org/obo/GO_0006520 cellular amino acid metabolic process http://purl.obolibrary.org/obo/GO_0044281 small molecule metabolic process The chemical reactions and pathways involving amino acids, carboxylic acids containing one or more amino groups, as carried out by individual cells. http://purl.obolibrary.org/obo/GO_0006631 fatty acid metabolic process http://purl.obolibrary.org/obo/GO_0006629 lipid metabolic process The chemical reactions and pathways involving fatty acids, aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis. http://purl.obolibrary.org/obo/GO_0006633 fatty acid biosynthetic process http://purl.obolibrary.org/obo/GO_0008610 lipid biosynthetic process The chemical reactions and pathways resulting in the formation of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes. http://purl.obolibrary.org/obo/GO_0006750 glutathione biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions and pathways resulting in the formation of glutathione, the tripeptide glutamylcysteinylglycine, which acts as a coenzyme for some enzymes and as an antioxidant in the protection of sulfhydryl groups in enzymes and other proteins. http://purl.obolibrary.org/obo/GO_0006836 neurotransmitter transport http://purl.obolibrary.org/obo/GO_0006810 transport The directed movement of a neurotransmitter into, out of, within or between cells. Neurotransmitters are any chemical substance that is capable of transmitting (or inhibiting the transmission of) a nerve impulse from a neuron to another cell. http://purl.obolibrary.org/obo/GO_0006869 lipid transport http://purl.obolibrary.org/obo/TXPO_0000111 molecule transport The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. http://purl.obolibrary.org/obo/GO_0006909 phagocytosis http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B A vesicle-mediated transport process that results in the engulfment of external particulate material by phagocytes and their delivery to the lysosome. The particles are initially contained within phagocytic vacuoles (phagosomes), which then fuse with primary lysosomes to effect digestion of the particles. http://purl.obolibrary.org/obo/GO_0006913 nucleocytoplasmic transport http://purl.obolibrary.org/obo/GO_0051169 nuclear transport The directed movement of molecules between the nucleus and the cytoplasm. http://purl.obolibrary.org/obo/GO_0006914 autophagy http://purl.obolibrary.org/obo/GO_0009056 catabolic process The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation http://purl.obolibrary.org/obo/GO_0006915 apoptotic process http://purl.obolibrary.org/obo/GO_0008219 cell death A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. http://purl.obolibrary.org/obo/GO_0006950 response to stress http://purl.obolibrary.org/obo/GO_0050896 response to stimulus Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a disturbance in organismal or cellular homeostasis, usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation). http://purl.obolibrary.org/obo/GO_0006955 immune response http://purl.obolibrary.org/obo/GO_0050896 response to stimulus Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. http://purl.obolibrary.org/obo/GO_0006974 cellular response to DNA damage stimulus http://purl.obolibrary.org/obo/GO_0050896 response to stimulus Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism. http://purl.obolibrary.org/obo/GO_0006979 response to oxidative stress http://purl.obolibrary.org/obo/GO_0006950 response to stress Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals. http://purl.obolibrary.org/obo/GO_0007005 mitochondrion organization http://purl.obolibrary.org/obo/TXPO_0000468 assembling A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a mitochondrion; includes mitochondrial morphogenesis and distribution, and replication of the mitochondrial genome as well as synthesis of new mitochondrial components. http://purl.obolibrary.org/obo/GO_0007010 cytoskeleton organization http://purl.obolibrary.org/obo/GO_0006996 organelle organization A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of cytoskeletal structures. http://purl.obolibrary.org/obo/GO_0007033 vacuole organization http://purl.obolibrary.org/obo/GO_0071840 cellular component organization or biogenesis A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a vacuole. http://purl.obolibrary.org/obo/GO_0007049 cell cycle http://purl.obolibrary.org/obo/TXPO_0000425 changing phase The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division. http://purl.obolibrary.org/obo/GO_0007155 cell adhesion http://purl.obolibrary.org/obo/TXPO_0002581 making contact between A and B The attachment of a cell, either to another cell or to the extracellular matrix, via cell adhesion molecules. http://purl.obolibrary.org/obo/GO_0007179 transforming growth factor beta receptor signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals initiated by the binding of an extracellular ligand to a transforming growth factor beta receptor on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription. http://purl.obolibrary.org/obo/GO_0007219 Notch signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals initiated by the binding of an extracellular ligand to the receptor Notch on the surface of a target cell, and ending with regulation of a downstream cellular process, e.g. transcription. http://purl.obolibrary.org/obo/GO_0007631 feeding behavior http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B Behavior associated with the intake of food. http://purl.obolibrary.org/obo/GO_0008283 cell proliferation http://purl.obolibrary.org/obo/TXPO_0000093 increasing number of objects The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population. http://purl.obolibrary.org/obo/GO_0008289 lipid binding http://purl.obolibrary.org/obo/GO_0005488 binding (with molecule) Interacting selectively and non-covalently with a lipid. http://purl.obolibrary.org/obo/GO_0008380 RNA splicing http://purl.obolibrary.org/obo/TXPO_0000333 separating The process of removing sections of the primary RNA transcript to remove sequences not present in the mature form of the RNA and joining the remaining sections to form the mature form of the RNA. http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process http://purl.obolibrary.org/obo/TXPO_0000019 generating substance The chemical reactions and pathways resulting in the formation of substances; typically the energy-requiring part of metabolism in which simpler substances are transformed into more complex ones. http://purl.obolibrary.org/obo/GO_0009062 fatty acid catabolic process http://purl.obolibrary.org/obo/GO_0016042 lipid catabolic process The chemical reactions and pathways resulting in the breakdown of a fatty acid, any of the aliphatic monocarboxylic acids that can be liberated by hydrolysis from naturally occurring fats and oils. Fatty acids are predominantly straight-chain acids of 4 to 24 carbon atoms, which may be saturated or unsaturated; branched fatty acids and hydroxy fatty acids also occur, and very long chain acids of over 30 carbons are found in waxes. http://purl.obolibrary.org/obo/GO_0009605 response to external stimulus http://purl.obolibrary.org/obo/GO_0050896 response to stimulus Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an external stimulus. http://purl.obolibrary.org/obo/GO_0010467 gene expression http://purl.obolibrary.org/obo/TXPO_0002282 converting type The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form. http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form. http://purl.obolibrary.org/obo/GO_0015908 fatty acid transport http://purl.obolibrary.org/obo/GO_0006869 lipid transport The directed movement of fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fatty acids are aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis http://purl.obolibrary.org/obo/GO_0015914 phospholipid transport http://purl.obolibrary.org/obo/GO_0006869 lipid transport The directed movement of phospholipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Phospholipids are any lipids containing phosphoric acid as a mono- or diester. http://purl.obolibrary.org/obo/GO_0016049 cell growth http://purl.obolibrary.org/obo/GO_0040007 growth The process in which a cell irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present. http://purl.obolibrary.org/obo/GO_0016051 carbohydrate biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions and pathways resulting in the formation of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. http://purl.obolibrary.org/obo/GO_0016052 carbohydrate catabolic process http://purl.obolibrary.org/obo/GO_0009056 catabolic process The chemical reactions and pathways resulting in the breakdown of carbohydrates, any of a group of organic compounds based of the general formula Cx(H2O)y. http://purl.obolibrary.org/obo/GO_0016477 cell migration http://purl.obolibrary.org/obo/TXPO_0000003 moving solid The controlled self-propelled movement of a cell from one site to a destination guided by molecular cues. Cell migration is a central process in the development and maintenance of multicellular organisms. http://purl.obolibrary.org/obo/GO_0016485 protein processing http://purl.obolibrary.org/obo/GO_0006508 proteolysis Any protein maturation process achieved by the cleavage of a peptide bond or bonds within a protein. Protein maturation is the process leading to the attainment of the full functional capacity of a protein. http://purl.obolibrary.org/obo/GO_0019395 fatty acid oxidation http://purl.obolibrary.org/obo/GO_0034440 lipid oxidation The removal of one or more electrons from a fatty acid, with or without the concomitant removal of a proton or protons, by reaction with an electron-accepting substance, by addition of oxygen or by removal of hydrogen. http://purl.obolibrary.org/obo/GO_0022403 cell cycle phase http://purl.obolibrary.org/obo/PATO_0000083 phase One of the distinct periods or stages into which the cell cycle is divided. Each phase is characterized by the occurrence of specific biochemical and morphological events. http://purl.obolibrary.org/obo/GO_0022607 cellular component assembly http://purl.obolibrary.org/obo/TXPO_0000468 assembling The aggregation, arrangement and bonding together of a cellular component. http://purl.obolibrary.org/obo/GO_0023051 regulation of signaling http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of a signaling process. http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents, or reduces the frequency, rate or extent of a signaling process. http://purl.obolibrary.org/obo/GO_0030032 lamellipodium biogenesis http://purl.obolibrary.org/obo/GO_0071840 cellular component organization or biogenesis Formation of a lamellipodium, a thin sheetlike extension of the surface of a migrating cell. http://purl.obolibrary.org/obo/GO_0030098 lymphocyte differentiation http://purl.obolibrary.org/obo/GO_0002521 leukocyte differentiation The process in which a relatively unspecialized precursor cell acquires specialized features of a lymphocyte. A lymphocyte is a leukocyte commonly found in the blood and lymph that has the characteristics of a large nucleus, a neutral staining cytoplasm, and prominent heterochromatin. http://purl.obolibrary.org/obo/GO_0030101 natural killer cell activation http://purl.obolibrary.org/obo/GO_0046649 lymphocyte activation The change in morphology and behavior of a natural killer cell in response to a cytokine, chemokine, cellular ligand, or soluble factor. http://purl.obolibrary.org/obo/GO_0030154 cell differentiation http://purl.obolibrary.org/obo/TXPO_0002282 converting type The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state. http://purl.obolibrary.org/obo/GO_0030217 T cell differentiation http://purl.obolibrary.org/obo/GO_0030098 lymphocyte differentiation The process in which a precursor cell type acquires characteristics of a more mature T-cell. A T cell is a type of lymphocyte whose definin characteristic is the expression of a T cell receptor complex. http://purl.obolibrary.org/obo/GO_0030242 autophagy of peroxisome http://purl.obolibrary.org/obo/GO_0006914 autophagy The process in which peroxisomes are delivered to the vacuole and degraded in response to changing nutrient conditions. http://purl.obolibrary.org/obo/GO_0030595 leukocyte chemotaxis http://purl.obolibrary.org/obo/GO_0050900 leukocyte migration The movement of a leukocyte in response to an external stimulus. http://purl.obolibrary.org/obo/GO_0030855 epithelial cell differentiation http://purl.obolibrary.org/obo/GO_0030154 cell differentiation The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell, any of the cells making up an epithelium. http://purl.obolibrary.org/obo/GO_0031333 negative regulation of protein complex assembly http://purl.obolibrary.org/obo/TXPO_0004212 negative regulation of protein-containing complex assembly Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex assembly. http://purl.obolibrary.org/obo/GO_0031649 heat generation http://purl.obolibrary.org/obo/TXPO_0000381 generating Any homeostatic process in which an organism produces heat, thereby raising its internal temperature. http://purl.obolibrary.org/obo/GO_0035601 protein deacylation http://purl.obolibrary.org/obo/GO_0036211 protein modification process The removal of an acyl group, any group or radical of the form RCO- where R is an organic group, from a protein amino acid. http://purl.obolibrary.org/obo/GO_0040007 growth http://purl.obolibrary.org/obo/TXPO_0000138 increasing size The increase in size or mass of an entire organism, a part of an organism or a cell. http://purl.obolibrary.org/obo/GO_0042089 cytokine biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions and pathways resulting in the formation of cytokines, any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity. http://purl.obolibrary.org/obo/GO_0042098 T cell proliferation http://purl.obolibrary.org/obo/GO_0046651 lymphocyte proliferation The expansion of a T cell population by cell division. Follows T cell activation. http://purl.obolibrary.org/obo/GO_0042100 B cell proliferation http://purl.obolibrary.org/obo/GO_0046651 lymphocyte proliferation The expansion of a B cell population by cell division. Follows B cell activation. http://purl.obolibrary.org/obo/GO_0042110 T cell activation http://purl.obolibrary.org/obo/GO_0046649 lymphocyte activation The change in morphology and behavior of a mature or immature T cell resulting from exposure to a mitogen, cytokine, chemokine, cellular ligand, or an antigen for which it is specific. http://purl.obolibrary.org/obo/GO_0042116 macrophage activation http://purl.obolibrary.org/obo/GO_0045321 leukocyte activation A change in morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. http://purl.obolibrary.org/obo/GO_0042592 homeostatic process http://purl.obolibrary.org/obo/TXPO_0000682 maintaining balance Any biological process involved in the maintenance of an internal steady state. http://purl.obolibrary.org/obo/GO_0042981 regulation of apoptotic process http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the occurrence or rate of cell death by apoptotic process. http://purl.obolibrary.org/obo/GO_0043226 organelle http://purl.obolibrary.org/obo/GO_0005575 cellular_component Organized structure of distinctive morphology and function. Includes the nucleus, mitochondria, plastids, vacuoles, vesicles, ribosomes and the cytoskeleton, and prokaryotic structures such as anammoxosomes and pirellulosomes. Excludes the plasma membrane. http://purl.obolibrary.org/obo/GO_0043467 regulation of generation of precursor metabolites and energy http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances. http://purl.obolibrary.org/obo/GO_0044839 cell cycle G2/M phase transition http://purl.obolibrary.org/obo/GO_0044770 cell cycle phase transition The cell cycle process by which a cell in G2 phase commits to M phase. http://purl.obolibrary.org/obo/GO_0044843 cell cycle G1/S phase transition http://purl.obolibrary.org/obo/GO_0044770 cell cycle phase transition The cell cycle process by which a cell in G1 phase commits to S phase. http://purl.obolibrary.org/obo/GO_0045087 innate immune response http://purl.obolibrary.org/obo/GO_0006955 immune response Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens. http://purl.obolibrary.org/obo/GO_0045088 regulation of innate immune response http://purl.obolibrary.org/obo/GO_0050776 regulation of immune response Any process that modulates the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection. http://purl.obolibrary.org/obo/GO_0045321 leukocyte activation http://purl.obolibrary.org/obo/GO_0001775 cell activation A change in morphology and behavior of a leukocyte resulting from exposure to a specific antigen, mitogen, cytokine, cellular ligand, or soluble factor. http://purl.obolibrary.org/obo/GO_0045446 endothelial cell differentiation http://purl.obolibrary.org/obo/GO_0030855 epithelial cell differentiation The process in which a mesodermal, bone marrow or neural crest cell acquires specialized features of an endothelial cell, a thin flattened cell. A layer of such cells lines the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium. http://purl.obolibrary.org/obo/GO_0045892 negative regulation of transcription, DNA-templated http://purl.obolibrary.org/obo/GO_0006355 regulation of transcription, DNA-templated Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription. http://purl.obolibrary.org/obo/GO_0046513 ceramide biosynthetic process http://purl.obolibrary.org/obo/GO_0008610 lipid biosynthetic process The chemical reactions and pathways resulting in the formation of ceramides, any N-acylated sphingoid. http://purl.obolibrary.org/obo/GO_0046649 lymphocyte activation http://purl.obolibrary.org/obo/GO_0045321 leukocyte activation A change in morphology and behavior of a lymphocyte resulting from exposure to a specific antigen, mitogen, cytokine, chemokine, cellular ligand, or soluble factor. http://purl.obolibrary.org/obo/GO_0046651 lymphocyte proliferation http://purl.obolibrary.org/obo/GO_0008283 cell proliferation The expansion of a lymphocyte population by cell division. http://purl.obolibrary.org/obo/GO_0050663 cytokine secretion http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The regulated release of cytokines from a cell. Cytokines are any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity. http://purl.obolibrary.org/obo/GO_0050776 regulation of immune response http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus. http://purl.obolibrary.org/obo/GO_0050900 leukocyte migration http://purl.obolibrary.org/obo/GO_0016477 cell migration The movement of a leukocyte within or between different tissues and organs of the body. http://purl.obolibrary.org/obo/GO_0051258 protein polymerization http://purl.obolibrary.org/obo/GO_0006461 protein complex assembly The process of creating protein polymers, compounds composed of a large number of component monomers; polymeric proteins may be made up of different or identical monomers. Polymerization occurs by the addition of extra monomers to an existing poly- or oligomeric protein. http://purl.obolibrary.org/obo/GO_0051276 chromosome organization http://purl.obolibrary.org/obo/TXPO_0002566 changing structure A process that is carried out at the cellular level that results in the assembly, arrangement of constituent parts, or disassembly of chromosomes, structures composed of a very long molecule of DNA and associated proteins that carries hereditary information. This term covers covalent modifications at the molecular level as well as spatial relationships among the major components of a chromosome. http://purl.obolibrary.org/obo/GO_0051301 cell division http://purl.obolibrary.org/obo/TXPO_0002576 splitting The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells. http://purl.obolibrary.org/obo/GO_0051318 G1 phase http://purl.obolibrary.org/obo/GO_0022403 cell cycle phase The cell cycle 'gap' phase which is the interval between the completion of DNA segregation (usually by mitosis or meiosis) and the beginning of DNA synthesis. http://purl.obolibrary.org/obo/GO_0051319 G2 phase http://purl.obolibrary.org/obo/GO_0022403 cell cycle phase The cell cycle 'gap' phase which is the interval between the completion of DNA synthesis and the beginning of DNA segregation (usually by mitosis or meiosis). http://purl.obolibrary.org/obo/GO_0051320 S phase http://purl.obolibrary.org/obo/GO_0022403 cell cycle phase The cell cycle phase, following G1, during which DNA synthesis takes place. http://purl.obolibrary.org/obo/GO_0051726 regulation of cell cycle http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the rate or extent of progression through the cell cycle. http://purl.obolibrary.org/obo/GO_0065005 protein-lipid complex assembly http://purl.obolibrary.org/obo/GO_0065003 protein-containing complex assembly The aggregation, arrangement and bonding together of proteins and lipids to form a protein-lipid complex. http://purl.obolibrary.org/obo/GO_0070646 protein modification by small protein removal http://purl.obolibrary.org/obo/GO_0070647 protein modification by small protein conjugation or removal A protein modification process in which one or more covalently attached groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are removed from a target protein. http://purl.obolibrary.org/obo/GO_0071897 DNA biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The cellular DNA metabolic process resulting in the formation of DNA, deoxyribonucleic acid, one of the two main types of nucleic acid, consisting of a long unbranched macromolecule formed from one or two strands of linked deoxyribonucleotides, the 3'-phosphate group of each constituent deoxyribonucleotide being joined in 3',5'-phosphodiester linkage to the 5'-hydroxyl group of the deoxyribose moiety of the next one. http://purl.obolibrary.org/obo/GO_0098800 inner mitochondrial membrane protein complex http://purl.obolibrary.org/obo/TXPO_0002107 molecular complex Any protein complex that is part of the inner mitochondrial membrane. http://purl.obolibrary.org/obo/GO_1903409 reactive oxygen species biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen. http://purl.obolibrary.org/obo/GO_0019216 regulation of lipid metabolic process http://purl.obolibrary.org/obo/GO_0019222 regulation of metabolic process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids. http://purl.obolibrary.org/obo/GO_0019835 cytolysis http://purl.obolibrary.org/obo/TXPO_0000437 arresting function The rupture of cell membranes and the loss of cytoplasm. http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) http://purl.obolibrary.org/obo/TXPO_0000471 signaling The entirety of a process in which information is transmitted within a biological system. This process begins with an active signal and ends when a cellular response has been triggered. http://purl.obolibrary.org/obo/GO_0030073 insulin secretion http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The regulated release of proinsulin from secretory granules accompanied by cleavage of proinsulin to form mature insulin. In vertebrates, insulin is secreted from B granules in the B cells of the vertebrate pancreas and from insulin-producing cells in insects. http://purl.obolibrary.org/obo/GO_0030512 negative regulation of transforming growth factor beta receptor signaling pathway http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling Any process that stops, prevents, or reduces the frequency, rate or extent of any TGF-beta receptor signaling pathway. http://purl.obolibrary.org/obo/GO_0030970 retrograde protein transport, ER to cytosol http://purl.obolibrary.org/obo/TXPO_0000111 molecule transport The directed movement of unfolded or misfolded proteins from the endoplasmic reticulum to the cytosol through the translocon. http://purl.obolibrary.org/obo/GO_0031098 stress-activated protein kinase signaling cascade http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals in which a stress-activated protein kinase (SAPK) cascade relays one or more of the signals. http://purl.obolibrary.org/obo/GO_0031161 phosphatidylinositol catabolic process http://purl.obolibrary.org/obo/GO_0046488 phosphatidylinositol metabolic process The chemical reactions and pathways resulting in the breakdown of phosphatidylinositol, any glycophospholipid with its sn-glycerol 3-phosphate residue is esterified to the 1-hydroxyl group of 1D-myo-inositol. http://purl.obolibrary.org/obo/GO_0031210 phosphatidylcholine binding http://purl.obolibrary.org/obo/GO_0005543 phospholipid binding Interacting selectively and non-covalently with phosphatidylcholine, a class of glycophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of choline. http://purl.obolibrary.org/obo/GO_0031929 TOR signaling http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by TOR (Target of rapamycin) proteins, members of the phosphoinositide (PI) 3-kinase related kinase (PIKK) family that act as serine/threonine kinases in response to nutrient availability or growth factors. http://purl.obolibrary.org/obo/GO_0032043 mitochondrial DNA catabolic process http://purl.obolibrary.org/obo/GO_0006308 DNA catabolic process The chemical reactions and pathways resulting in the breakdown of mitochondrial DNA. http://purl.obolibrary.org/obo/GO_0032049 cardiolipin biosynthetic process http://purl.obolibrary.org/obo/GO_0006655 phosphatidylglycerol biosynthetic process The chemical reactions and pathways resulting in the formation of cardiolipin, 1,3-bis(3-phosphatidyl)glycerol. http://purl.obolibrary.org/obo/GO_0032060 bleb assembly http://purl.obolibrary.org/obo/GO_0071840 cellular component organization or biogenesis The assembly of a bleb, a cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion. Plasma membrane blebbing occurs during apoptosis and other cellular processes, including cell locomotion, cell division, and as a result of physical or chemical stresses. http://purl.obolibrary.org/obo/GO_0032456 endocytic recycling http://purl.obolibrary.org/obo/GO_0016197 endosomal transport The directed movement of membrane-bounded vesicles from recycling endosomes back to the plasma membrane where they are recycled for further rounds of transport. http://purl.obolibrary.org/obo/GO_0032602 chemokine production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of a chemokine due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0032606 type I interferon production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of type I interferon due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families. http://purl.obolibrary.org/obo/GO_0032609 interferon-gamma production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of interferon-gamma due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Interferon-gamma is also known as type II interferon. http://purl.obolibrary.org/obo/GO_0032611 IL-1 beta production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of interleukin-1 beta due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0032612 interleukin-1 production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of interleukin-1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0032623 interleukin-2 production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of interleukin-2 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0032905 transforming growth factor beta1 production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of transforming growth factor-beta1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0032981 mitochondrial respiratory chain complex I assembly http://purl.obolibrary.org/obo/GO_0033108 mitochondrial respiratory chain complex assembly The aggregation, arrangement and bonding together of a set of components to form mitochondrial respiratory chain complex I. http://purl.obolibrary.org/obo/GO_0033108 mitochondrial respiratory chain complex assembly http://purl.obolibrary.org/obo/GO_0065003 protein-containing complex assembly The aggregation, arrangement and bonding together of a set of components to form a mitochondrial respiratory chain complex. http://purl.obolibrary.org/obo/GO_0033617 mitochondrial respiratory chain complex IV assembly http://purl.obolibrary.org/obo/GO_0033108 mitochondrial respiratory chain complex assembly The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex IV (also known as cytochrome c oxidase) in the mitochondrial inner membrane. http://purl.obolibrary.org/obo/GO_0033700 phospholipid efflux http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The directed movement of a phospholipid out of a cell or organelle. http://purl.obolibrary.org/obo/GO_0034142 TLR4 signaling pathway http://purl.obolibrary.org/obo/GO_0002224 TLR signaling pathway Any series of molecular signals generated as a consequence of binding to toll-like receptor 4. http://purl.obolibrary.org/obo/GO_0034162 TLR9 signaling pathway http://purl.obolibrary.org/obo/GO_0002224 TLR signaling pathway Any series of molecular signals generated as a consequence of binding to toll-like receptor 9. http://purl.obolibrary.org/obo/GO_0034197 triglyceride transport http://purl.obolibrary.org/obo/GO_0006869 lipid transport The directed movement of triglyceride into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Triglycerides are important components of plant oils, animal fats and animal plasma lipoproteins. http://purl.obolibrary.org/obo/GO_0034440 lipid oxidation http://purl.obolibrary.org/obo/GO_0055114 oxidation-reduction process The removal of one or more electrons from a lipid, with or without the concomitant removal of a proton or protons, by reaction with an electron-accepting substance, by addition of oxygen or by removal of hydrogen. http://purl.obolibrary.org/obo/GO_0036498 IRE1-mediated unfolded protein response http://purl.obolibrary.org/obo/TXPO_0002155 IRE1 signal transduction pathway A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). Begins with activation of IRE1 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. One target of activated IRE1 is the transcription factor HAC1 in yeast, or XBP1 in mammals; IRE1 cleaves an intron of a mRNA coding for HAC1/XBP1 to generate an activated HAC1/XBP1 transcription factor, which controls the up regulation of UPR-related genes. At least in mammals, IRE1 can also signal through additional intracellular pathways including JNK and NF-kappaB. http://purl.obolibrary.org/obo/GO_0036503 ERAD pathway http://purl.obolibrary.org/obo/GO_0010498 proteasomal protein catabolic process The protein catabolic pathway which targets endoplasmic reticulum (ER)-resident proteins for degradation by the cytoplasmic proteasome. It begins with recognition of the ER-resident protein, includes retrotranslocation (dislocation) of the protein from the ER to the cytosol, protein modifications necessary for correct substrate transfer (e.g. ubiquitination), transport of the protein to the proteasome, and ends with degradation of the protein by the cytoplasmic proteasome. http://purl.obolibrary.org/obo/GO_0040011 locomotion http://purl.obolibrary.org/obo/TXPO_0000765 generating motion Self-propelled movement of a cell or organism from one location to another. http://purl.obolibrary.org/obo/GO_0042246 tissue regeneration http://purl.obolibrary.org/obo/TXPO_0002590 changing material Tissue regeneration is a subtype of changing material: The regrowth of lost or destroyed tissues. http://purl.obolibrary.org/obo/GO_0043161 proteasome-mediated ubiquitin-dependent protein catabolic process http://purl.obolibrary.org/obo/GO_0010498 proteasomal protein catabolic process The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome. http://purl.obolibrary.org/obo/GO_0043227 membrane-bounded organelle http://purl.obolibrary.org/obo/GO_0043226 organelle Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. http://purl.obolibrary.org/obo/GO_0043233 organelle lumen http://purl.obolibrary.org/obo/UBERON_0000464 anatomical space The internal volume enclosed by the membranes of a particular organelle; includes the volume enclosed by a single organelle membrane, e.g. endoplasmic reticulum lumen, or the volume enclosed by the innermost of the two lipid bilayers of an organelle envelope, e.g. nuclear lumen. http://purl.obolibrary.org/obo/GO_0043473 accumulation of pigments http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object The aggregation of coloring matter in a particular location in an organism, tissue or cell, occurring in response to some external stimulus. http://purl.obolibrary.org/obo/GO_0045234 protein palmitoleylation http://purl.obolibrary.org/obo/GO_0006497 protein lipidation The covalent attachment of a palmitoleyl group to a protein. http://purl.obolibrary.org/obo/GO_0045738 negative regulation of DNA repair http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of DNA repair is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of DNA repair. http://purl.obolibrary.org/obo/GO_0046777 protein autophosphorylation http://purl.obolibrary.org/obo/GO_0016310 phosphorylation The phosphorylation by a protein of one or more of its own amino acid residues (cis-autophosphorylation), or residues on an identical protein (trans-autophosphorylation). http://purl.obolibrary.org/obo/GO_0051781 positive regulation of cell division http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of cell division. http://purl.obolibrary.org/obo/GO_0070085 glycosylation http://purl.obolibrary.org/obo/GO_0008152 metabolic process The covalent attachment and further modification of carbohydrate residues to a substrate molecule. http://purl.obolibrary.org/obo/GO_0070647 protein modification by small protein conjugation or removal http://purl.obolibrary.org/obo/GO_0036211 protein modification process A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to or removed from a target protein. http://purl.obolibrary.org/obo/GO_0071604 transforming growth factor beta production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of any member of the transforming growth factor-beta family of cytokines due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. Transforming growth factor-beta family members include TGF-B1, TGF-B2, and TGF-B3. http://purl.obolibrary.org/obo/GO_0071706 tumor necrosis factor superfamily cytokine production http://purl.obolibrary.org/obo/GO_0001816 cytokine production The appearance of any member of the TNF superfamily due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0072331 signal transduction by p53 class mediator http://purl.obolibrary.org/obo/TXPO_0001902 gene regulation pathway A series of molecular signals transduced with the regulation of transcription of target genes by p53. http://purl.obolibrary.org/obo/GO_1901799 negative regulation of proteasomal protein catabolic process http://purl.obolibrary.org/obo/GO_0042177 negative regulation of protein catabolic process Any process that stops, prevents or reduces the frequency, rate or extent of proteasomal protein catabolic process. http://purl.obolibrary.org/obo/GO_1902576 negative regulation of nuclear cell cycle DNA replication http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents or reduces the frequency, rate or extent of nuclear cell cycle DNA replication. http://purl.obolibrary.org/obo/GO_0034379 very-low-density lipoprotein particle assembly http://purl.obolibrary.org/obo/GO_0065005 protein-lipid complex assembly The non-covalent aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle. http://purl.obolibrary.org/obo/GO_0034389 lipid droplet organization http://purl.obolibrary.org/obo/TXPO_0000468 assembling A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of a lipid particle. http://purl.obolibrary.org/obo/GO_0034478 phosphatidylglycerol catabolic process http://purl.obolibrary.org/obo/GO_0046475 glycerophospholipid catabolic process The chemical reactions and pathways resulting in the breakdown of phosphatidylglycerols, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of glycerol. http://purl.obolibrary.org/obo/GO_0034551 mitochondrial respiratory chain complex III assembly http://purl.obolibrary.org/obo/GO_0033108 mitochondrial respiratory chain complex assembly The aggregation, arrangement and bonding together of a set of components to form the cytochrome bc(1) complex (also known as ubiquinol-cytochrome c reductase), in the mitochondrial inner membrane. http://purl.obolibrary.org/obo/GO_0034553 mitochondrial respiratory chain complex II assembly http://purl.obolibrary.org/obo/GO_0033108 mitochondrial respiratory chain complex assembly The aggregation, arrangement and bonding together of a set of components to form respiratory chain complex II, in the mitochondrial inner membrane. http://purl.obolibrary.org/obo/GO_0034635 glutathione transport http://purl.obolibrary.org/obo/GO_0006810 transport The directed movement of glutathione, the tripeptide glutamylcysteinylglycine, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0035195 gene silencing by miRNA http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression Downregulation of gene expression through the action of microRNAs (miRNAs), endogenous 21-24 nucleotide small RNAs processed from stem-loop RNA precursors (pre-miRNAs). Once incorporated into a RNA-induced silencing complex (RISC), miRNAs can downregulate gene expression by either of two posttranscriptional mechanisms: endolytic cleavage of mRNA cleavage or translational repression, usually accompanied by poly-A tail shortening and subsequent degradation of the mRNA. http://purl.obolibrary.org/obo/GO_0035397 helper T cell enhancement of adaptive immune response http://purl.obolibrary.org/obo/GO_0002250 adaptive immune response Positive regulation of an adaptive immune response mediated via cytokine production by helper T cell. http://purl.obolibrary.org/obo/GO_0035733 hepatic stellate cell activation http://purl.obolibrary.org/obo/GO_0001775 cell activation A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor. http://purl.obolibrary.org/obo/GO_0035794 positive regulation of mitochondrial membrane permeability http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane. http://purl.obolibrary.org/obo/GO_0036041 long-chain fatty acid binding http://purl.obolibrary.org/obo/GO_0005504 fatty acid binding Interacting selectively and non-covalently with a long-chain fatty acid. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22. http://purl.obolibrary.org/obo/GO_0036042 long-chain fatty acyl-CoA binding http://purl.obolibrary.org/obo/GO_0000062 fatty-acyl-CoA binding Interacting selectively and non-covalently with a long-chain fatty acyl-CoA. A long-chain fatty acyl-CoA is any derivative of coenzyme A in which the sulfhydryl group is in a thioester linkage with a long-chain fatty-acyl group. Long-chain fatty-acyl-CoAs have chain lengths of C13 or more. http://purl.obolibrary.org/obo/GO_0036337 Fas signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals initiated by the binding of a ligand to the receptor Fas on the surface of the cell, and ending with regulation of a downstream cellular process, e.g. transcription. Fas is a death domain-containing member of the tumor necrosis factor receptor (TNFR) superfamily. http://purl.obolibrary.org/obo/GO_0036499 PERK-mediated unfolded protein response http://purl.obolibrary.org/obo/TXPO_0000285 PERK signal transduction pathway A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor PERK (PKR-like ER kinase). Begins with activation of PERK in response to endoplasmic reticulum (ER) stress and ends with regulation of a downstream cellular process, e.g. transcription. The main substrate of PERK is the translation initiation factor eIF2alpha. Serine-phosphorylation of eIF2alpha by PERK inactivates eIF2alpha and inhibits general protein translation. In addition, eIF2alpha phosphorylation preferentially increases the translation of selective mRNAs such as ATF4 (activating transcription factor 4), which up regulates a subset of UPR genes required to restore folding capacity. http://purl.obolibrary.org/obo/GO_0036500 ATF6-mediated unfolded protein response http://purl.obolibrary.org/obo/TXPO_0002126 ATF6 signal transduction pathway A series of molecular signals mediated by the endoplasmic reticulum membrane stress sensor ATF6 (activating transcription factor 6). Begins with activation of ATF6 in response to endoplasmic reticulum (ER) stress, and ends with regulation of a downstream cellular process, e.g. transcription. Under conditions of endoplasmic reticulum stress, ATF6 translocates to the Golgi where it is processed by proteases to release a cytoplasmic domain (ATF6f), which operates as a transcriptional activator of many genes required to restore folding capacity. http://purl.obolibrary.org/obo/GO_0038151 CCL2 signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by CCL2 (C-C chemokine CCL2). A series of molecular signals initiated by the binding of the C-C chemokine CCL2 to a C-C chemokine type 2 receptor (CCR2) on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. http://purl.obolibrary.org/obo/GO_0042026 protein refolding http://purl.obolibrary.org/obo/GO_0006457 protein folding The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones. http://purl.obolibrary.org/obo/GO_0042177 negative regulation of protein catabolic process http://purl.obolibrary.org/obo/TXPO_0000115 negative regulation of decomposing Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with or without the hydrolysis of peptide bonds. http://purl.obolibrary.org/obo/GO_0042245 RNA repair http://purl.obolibrary.org/obo/TXPO_0000535 repairing Any process that results in the repair of damaged RNA. http://purl.obolibrary.org/obo/GO_0042773 ATP synthesis coupled electron transport http://purl.obolibrary.org/obo/GO_0022904 respiratory electron transport chain The transfer of electrons through a series of electron donors and acceptors, generating energy that is ultimately used for synthesis of ATP. http://purl.obolibrary.org/obo/GO_0043266 regulation of potassium ion transport http://purl.obolibrary.org/obo/GO_0051049 regulation of transport (biology) Any process that modulates the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0043267 negative regulation of potassium ion transport http://purl.obolibrary.org/obo/GO_0043266 regulation of potassium ion transport Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0043268 positive regulation of potassium ion transport http://purl.obolibrary.org/obo/GO_0043266 regulation of potassium ion transport Any process that activates or increases the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0043276 anoikis http://purl.obolibrary.org/obo/GO_0006915 apoptotic process Apoptosis triggered by inadequate or inappropriate adherence to substrate e.g. after disruption of the interactions between normal epithelial cells and the extracellular matrix. http://purl.obolibrary.org/obo/GO_0043277 apoptotic cell clearance http://purl.obolibrary.org/obo/TXPO_0000458 removing (from A) The recognition and removal of an apoptotic cell by a neighboring cell or by a phagocyte. http://purl.obolibrary.org/obo/GO_0043335 protein unfolding http://purl.obolibrary.org/obo/TXPO_0002565 changing protein fold The process of assisting in the disassembly of non-covalent linkages in a protein or protein aggregate, often where the proteins are in a non-functional or denatured state. http://purl.obolibrary.org/obo/GO_0043491 protein kinase B signaling http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of reactions, mediated by the intracellular serine/threonine kinase protein kinase B (also called AKT), which occurs as a result of a single trigger reaction or compound. PMID:20517722 http://purl.obolibrary.org/obo/GO_0044565 dendritic cell proliferation http://purl.obolibrary.org/obo/GO_0046651 lymphocyte proliferation The expansion of a dendritic cell population by cell division. A dendritic cell is a cell of hematopoietic origin, typically resident in particular tissues, specialized in the uptake, processing, and transport of antigens to lymph nodes for the purpose of stimulating an immune response via T cell activation. http://purl.obolibrary.org/obo/GO_0044770 cell cycle phase transition http://purl.obolibrary.org/obo/TXPO_0000425 changing phase The cell cycle process by which a cell commits to entering the next cell cycle phase. http://purl.obolibrary.org/obo/GO_0044838 cell quiescence http://purl.obolibrary.org/obo/GO_0022403 cell cycle phase A specialized resting state that cells enter in response to cues from the cell's environment. Quiescence is characterized by the absence of cell growth and division, by a reprogramming of global gene expression, and by changes characteristic of the organism and specific cell type. Depending on external conditions, quiescence may persist until cell death or cells may resume cell growth and division. In some cell types or under certain conditions, cellular metabolism may proceed. http://purl.obolibrary.org/obo/GO_0045444 Adipocyte differentiation http://purl.obolibrary.org/obo/GO_0030154 cell differentiation The process whereby a relatively unspecialized cell acquires specialized features of an adipocyte, an animal connective tissue cell specialized for the synthesis and storage of fat. http://purl.obolibrary.org/obo/GO_0045721 negative regulation of gluconeogenesis http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis. http://purl.obolibrary.org/obo/GO_0045787 positive regulation of cell cycle http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the rate or extent of progression through the cell cycle. http://purl.obolibrary.org/obo/GO_0046222 aflatoxin metabolic process http://purl.obolibrary.org/obo/GO_0009404 toxin metabolic process The chemical reactions and pathways involving aflatoxin, a fungal metabolite found as a contaminant in moldy grains that induces liver cancer. Aflatoxin induces a G to T transversion at codon 249 of p53, leading to its inactivation. Aflatoxin is converted to a chemical carcinogen by P450. http://purl.obolibrary.org/obo/GO_0046951 ketone body biosynthetic process http://purl.obolibrary.org/obo/TXPO_0000019 generating substance ketone body biosynthetic process is a subtype of generating: A process that synthesizes ketone body resulting in having output (s). http://purl.obolibrary.org/obo/GO_0048770 pigment granule http://purl.obolibrary.org/obo/GO_0031982 vesicle A small, subcellular membrane-bounded vesicle containing pigment and/or pigment precursor molecules. Pigment granule biogenesis is poorly understood, as pigment granules are derived from multiple sources including the endoplasmic reticulum, coated vesicles, lysosomes, and endosomes. http://purl.obolibrary.org/obo/GO_0055037 recycling endosome http://purl.obolibrary.org/obo/GO_0005768 endosome An organelle consisting of a network of tubules that functions in targeting molecules, such as receptors transporters and lipids, to the plasma membrane. http://purl.obolibrary.org/obo/GO_1901797 negative regulation of p53 signaling http://purl.obolibrary.org/obo/GO_0023057 negative regulation of signaling Any process that stops, prevents or reduces the frequency, rate or extent of signal transduction by p53 class mediator. http://purl.obolibrary.org/obo/GO_0090117 endosome to lysosome transport of low-density lipoprotein particle http://purl.obolibrary.org/obo/GO_0030301 cholesterol transport The directed movement of low-density lipoprotein particle from endosomes to lysosomes. http://purl.obolibrary.org/obo/GO_0090158 endoplasmic reticulum membrane organization http://purl.obolibrary.org/obo/GO_0061024 membrane organization A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of an endoplasmic reticulum membrane. http://purl.obolibrary.org/obo/GO_0090398 cellular senescence http://purl.obolibrary.org/obo/TXPO_0000392 changing an operand A cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest. http://purl.obolibrary.org/obo/GO_0097314 apoptosome assembly http://purl.obolibrary.org/obo/GO_0006461 protein complex assembly The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process. http://purl.obolibrary.org/obo/GO_0097390 chemokine (C-X-C motif) ligand 12 production http://purl.obolibrary.org/obo/GO_0032602 chemokine production The appearance of chemokine (C-X-C motif) ligand 12 (CXCL12) due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0097707 feroptosis http://purl.obolibrary.org/obo/GO_0008219 cell death A programmed cell death characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter are involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism. Glutathione peroxidase 4 (GPX4), heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes. http://purl.obolibrary.org/obo/GO_1900409 positive regulation of cellular response to oxidative stress http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of cellular response to oxidative stress. http://purl.obolibrary.org/obo/GO_1901526 positive regulation of mitophagy http://purl.obolibrary.org/obo/GO_1901524 regulation of mitophagy Any process that activates or increases the frequency, rate or extent of mitophagy. http://purl.obolibrary.org/obo/GO_1901524 regulation of mitophagy http://purl.obolibrary.org/obo/GO_0010506 regulation of autophagy Any process that modulates the frequency, rate or extent of macromitophagy. http://purl.obolibrary.org/obo/GO_1901611 phosphatidylglycerol binding http://purl.obolibrary.org/obo/GO_0005543 phospholipid binding Interacting selectively and non-covalently with phosphatidylglycerol. http://purl.obolibrary.org/obo/GO_1902292 cell cycle DNA replication initiation http://purl.obolibrary.org/obo/TXPO_0001984 changing state Any DNA replication initiation that is involved in cell cycle DNA replication. http://purl.obolibrary.org/obo/GO_1902957 negative regulation of mitochondrial electron transport, NADH to ubiquinone http://purl.obolibrary.org/obo/TXPO_0002342 negative regulation of respiratory electron transport chain Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone. http://purl.obolibrary.org/obo/GO_1903597 negative regulation of gap junction assembly http://purl.obolibrary.org/obo/GO_1901889 negative regulation of cell junction assembly Any process that stops, prevents or reduces the frequency, rate or extent of gap junction assembly. http://purl.obolibrary.org/obo/GO_1904294 positive regulation of ERAD http://purl.obolibrary.org/obo/GO_0045862 positive regulation of proteolysis Any process that activates or increases the frequency, rate or extent of ERAD pathway. http://purl.obolibrary.org/obo/GO_2000773 negative regulation of cellular senescence http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents or reduces the frequency, rate or extent of cellular senescence. http://purl.obolibrary.org/obo/IMR_0000213 JAK http://purl.obolibrary.org/obo/CHEBI_25367 molecule Janus kinases (Jaks) are non-receptor tyrosine kinases. In mammals, the family has four members, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2). In Drosophila there is only one Jak kinase, Hopscotch (Hop). http://purl.obolibrary.org/obo/IMR_0000261 MEK1/2(MKK1/2) http://purl.obolibrary.org/obo/IMR_0000259 MAPKK MEK1 and MEK2 phosphorylate and activate ERK1 and ERK2 MAP kinases. http://purl.obolibrary.org/obo/IMR_0100504 Smad2/3 http://purl.obolibrary.org/obo/IMR_0000371 R-Smad Smads 2 and 3 serve principally as substrates for the TGFbeta, activin, and Nodal receptors. http://purl.obolibrary.org/obo/IMR_0100104 oxytocin http://purl.obolibrary.org/obo/IMR_0100103 pituitary hormone, posterior A nonapeptide posterior pituitary hormone that causes UTERINE CONTRACTIONS and stimulates MILK EJECTION. http://purl.obolibrary.org/obo/IMR_0001698 glycoside http://purl.obolibrary.org/obo/CHEBI_16646 carbohydrate Any compound that contains a constituent sugar, in which the hydroxyl group attached to the first carbon is substituted by an alcoholic, phenolic, or other group. They are named specifically for the sugar contained, such as glucoside (glucose), pentoside (pentose), fructoside (fructose), etc. Upon hydrolysis, a sugar and nonsugar component (aglycone) are formed. (From Dorland, 28th ed; From Miall's Dictionary of Chemistry, 5th ed) http://purl.obolibrary.org/obo/IMR_0100077 glucagon http://purl.obolibrary.org/obo/IMR_0100076 pancreatic hormone A pancreatic peptide hormone of about 29 amino acids secreted by PANCREATIC ALPHA CELLS. It has an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. http://purl.obolibrary.org/obo/IMR_0100095 gonadotropin-releasing hormone http://purl.obolibrary.org/obo/IMR_0100093 pituitary hormone-releasing hormone A decapeptide hormone released by the hypothalamus. It stimulates the synthesis and secretion of both FOLLICLE STIMULATING HORMONE and luteinizing hormone (LH) from the pituitary gland. http://purl.obolibrary.org/obo/GO_0008219 cell death http://purl.obolibrary.org/obo/TXPO_0000437 arresting function Any biological process that results in permanent cessation of all vital functions of a cell. A cell should be considered dead when any one of the following molecular or morphological criteria is met: (1) the cell has lost the integrity of its plasma membrane; (2) the cell, including its nucleus, has undergone complete fragmentation into discrete bodies (frequently referred to as apoptotic bodies). The cell corpse (or its fragments) may be engulfed by an adjacent cell in vivo, but engulfment of whole cells should not be considered a strict criteria to define cell death as, under some circumstances, live engulfed cells can be released from phagosomes (see PMID:18045538). http://purl.obolibrary.org/obo/GO_0008429 phosphatidylethanolamine binding http://purl.obolibrary.org/obo/GO_0005543 phospholipid binding Interacting selectively and non-covalently with phosphatidylethanolamine, any of a class of glycerophospholipids in which a phosphatidyl group is esterified to the hydroxyl group of ethanolamine. http://purl.obolibrary.org/obo/GO_0008625 extrinsic apoptotic signaling pathway via death domain receptors http://purl.obolibrary.org/obo/TXPO_0000611 death domain signanaling pathway A series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with a ligand binding to a death domain receptor on the cell surface, and ends when the execution phase of apoptosis is triggered. http://purl.obolibrary.org/obo/GO_0009056 catabolic process http://purl.obolibrary.org/obo/TXPO_0000185 biochemical degradation The chemical reactions and pathways resulting in the breakdown of substances, including the breakdown of carbon compounds with the liberation of energy for use by the cell or organism. http://purl.obolibrary.org/obo/GO_0009236 cobalamin biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions and pathways resulting in the formation of cobalamin (vitamin B12), a water-soluble vitamin characterized by possession of a corrin nucleus containing a cobalt atom. http://purl.obolibrary.org/obo/GO_0009386 attenuation of translation http://purl.obolibrary.org/obo/GO_0006417 regulation of translation Translational attenuation is a regulatory mechanism analogous to ribosome-mediated transcriptional attenuation. the system requires the presence of a short orf, called a leader peptide, encoded in the mrna upstream of the ribosome-binding site and start codon of the gene whose translation is to be regulated. certain conditions, such as presence of the antibiotic tetracycline in bacteria or amino acid starvation, may cause slowing or stalling of the ribosome translating the leader peptide. the stalled ribosome masks a region of the mrna and affects which of two alternative mrna folded structures will form, therefore controlling whether or not a ribosome will bind and initiate translation of the downstream gene. translational attenuation is analogous to ribosome-mediated transcriptional attenuation, in which mrna remodeling caused by ribosome stalling regulates transcriptional termination rather than translational initiation. http://purl.obolibrary.org/obo/GO_0009404 toxin metabolic process http://purl.obolibrary.org/obo/GO_0008152 metabolic process The chemical reactions and pathways involving a toxin, a poisonous compound (typically a protein) that is produced by cells or organisms and that can cause disease when introduced into the body or tissues of an organism. http://purl.obolibrary.org/obo/GO_0009719 response to endogenous stimulus http://purl.obolibrary.org/obo/GO_0050896 response to stimulus Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus arising within the organism. http://purl.obolibrary.org/obo/GO_0010498 proteasomal protein catabolic process http://purl.obolibrary.org/obo/GO_0030163 protein catabolic process The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds that is mediated by the proteasome. http://purl.obolibrary.org/obo/GO_0010506 regulation of autophagy http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. http://purl.obolibrary.org/obo/GO_0010507 negative regulation of autophagy http://purl.obolibrary.org/obo/GO_0010506 regulation of autophagy Any process that stops, prevents, or reduces the frequency, rate or extent of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. http://purl.obolibrary.org/obo/GO_0010508 positive regulation of autophagy http://purl.obolibrary.org/obo/GO_0010506 regulation of autophagy Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. http://purl.obolibrary.org/obo/GO_0010628 positive regulation of gene expression http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that increases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form. http://purl.obolibrary.org/obo/GO_0010716 negative regulation of extracellular matrix disassembly http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that decreases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix. http://purl.obolibrary.org/obo/GO_0010742 macrophage derived foam cell differentiation http://purl.obolibrary.org/obo/GO_0090077 foam cell differentiation The process in which a monocyte acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. http://purl.obolibrary.org/obo/GO_0010743 regulation of macrophage derived foam cell differentiation http://purl.obolibrary.org/obo/GO_0045595 regulation of cell differentiation Any process that modulates the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. http://purl.obolibrary.org/obo/GO_0010744 positive regulation of macrophage derived foam cell differentiation http://purl.obolibrary.org/obo/GO_0010743 regulation of macrophage derived foam cell differentiation Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. http://purl.obolibrary.org/obo/GO_0010745 negative regulation of macrophage derived foam cell differentiation http://purl.obolibrary.org/obo/GO_0010743 regulation of macrophage derived foam cell differentiation Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. http://purl.obolibrary.org/obo/GO_0010878 cholesterol storage http://purl.obolibrary.org/obo/GO_0019915 lipid storage The accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. http://purl.obolibrary.org/obo/GO_0010888 negative regulation of lipid storage http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development. http://purl.obolibrary.org/obo/GO_0010900 negative regulation of phosphatidylcholine catabolic process http://purl.obolibrary.org/obo/TXPO_0001304 negative regulation of glycerophospholipid degradation Any process that decreases the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. http://purl.obolibrary.org/obo/GO_0010941 regulation of cell death http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death. [ http://purl.obolibrary.org/obo/GO_0015721 bile acid and bile salt transport http://purl.obolibrary.org/obo/GO_0006810 transport The directed movement of bile acid and bile salts into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0015722 canalicular bile acid transport http://purl.obolibrary.org/obo/GO_0015721 bile acid and bile salt transport Enables the transfer of bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus. Bile canaliculi are the thin tubes formed by hepatocyte membranes. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine. http://purl.obolibrary.org/obo/GO_0015871 choline transport http://purl.obolibrary.org/obo/TXPO_0000111 molecule transport The directed movement of choline into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Choline (2-hydroxyethyltrimethylammonium) is an amino alcohol that occurs widely in living organisms as a constituent of certain types of phospholipids and in the neurotransmitter acetylcholine. http://purl.obolibrary.org/obo/GO_0015990 electron transport coupled proton transport http://purl.obolibrary.org/obo/GO_1902600 proton transmembrane transport The transport of protons against an electrochemical gradient, using energy from electron transport. http://purl.obolibrary.org/obo/GO_0016264 gap junction assembly http://purl.obolibrary.org/obo/GO_0034329 cell junction assembly Assembly of gap junctions, which are found in most animal tissues, and serve as direct connections between the cytoplasms of adjacent cells. They provide open channels through the plasma membrane, allowing ions and small molecules (less than approximately a thousand daltons) to diffuse freely between neighboring cells, but preventing the passage of proteins and nucleic acids. http://purl.obolibrary.org/obo/GO_0017129 triglyceride binding http://purl.obolibrary.org/obo/GO_0008289 lipid binding Interacting selectively and non-covalently with any triester of glycerol. http://purl.obolibrary.org/obo/GO_0017144 drug metabolic process http://purl.obolibrary.org/obo/GO_0006805 xenobiotic metabolic process The chemical reactions and pathways involving a drug, a substance used in the diagnosis, treatment or prevention of a disease; as used here antibiotic substances (see antibiotic metabolism) are considered to be drugs, even if not used in medical or veterinary practice. http://purl.obolibrary.org/obo/GO_0018411 protein glucuronidation http://purl.obolibrary.org/obo/GO_0036211 protein modification process The modification of a protein by amino acid glucuronidation. http://purl.obolibrary.org/obo/GO_0019222 regulation of metabolic process http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. http://purl.obolibrary.org/obo/GO_0019915 lipid storage http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object The accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development. http://purl.obolibrary.org/obo/GO_0022900 electron transport chain http://purl.obolibrary.org/obo/GO_0055114 oxidation-reduction process A process in which a series of electron carriers operate together to transfer electrons from donors to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient. http://purl.obolibrary.org/obo/GO_0030091 protein repair http://purl.obolibrary.org/obo/TXPO_0000535 repairing The process of restoring a protein to its original state after damage by such things as oxidation or spontaneous decomposition of residues. http://purl.obolibrary.org/obo/GO_0030198 extracellular matrix organization http://purl.obolibrary.org/obo/TXPO_0000468 assembling A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures in the space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane, and also covers the host cell environment outside an intracellular parasite. http://purl.obolibrary.org/obo/GO_0030225 macrophage differentiation http://purl.obolibrary.org/obo/GO_0002521 leukocyte differentiation The process in which a relatively unspecialized monocyte acquires the specialized features of a macrophage. http://purl.obolibrary.org/obo/GO_0030301 cholesterol transport http://purl.obolibrary.org/obo/GO_0006869 lipid transport The directed movement of cholesterol, cholest-5-en-3-beta-ol, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0030730 sequestering of triglyceride http://purl.obolibrary.org/obo/GO_0019915 lipid storage The process of binding or confining any triester of glycerol such that it is separated from other components of a biological system. http://purl.obolibrary.org/obo/GO_0030908 protein splicing http://purl.obolibrary.org/obo/GO_0016485 protein processing The post-translational removal of peptide sequences from within a protein sequence. http://purl.obolibrary.org/obo/GO_0031090 organelle membrane http://purl.obolibrary.org/obo/TXPO_0000895 biological membrane A membrane that is one of the two lipid bilayers of an organelle envelope or the outermost membrane of single membrane bound organelle. http://purl.obolibrary.org/obo/GO_0031982 vesicle http://purl.obolibrary.org/obo/GO_0043227 membrane-bounded organelle Any small, fluid-filled, spherical organelle enclosed by membrane. http://purl.obolibrary.org/obo/GO_0032782 bile acid secretion http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The regulated release of bile acid, composed of any of a group of steroid carboxylic acids occurring in bile, by a cell or a tissue. http://purl.obolibrary.org/obo/GO_0033344 cholesterol efflux http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle. http://purl.obolibrary.org/obo/GO_0034638 phosphatidylcholine catabolic process http://purl.obolibrary.org/obo/GO_0046475 glycerophospholipid catabolic process The chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline. http://purl.obolibrary.org/obo/GO_0043065 positive regulation of apoptotic process http://purl.obolibrary.org/obo/GO_0042981 regulation of apoptotic process Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. http://purl.obolibrary.org/obo/GO_0045445 myoblast differentiation http://purl.obolibrary.org/obo/TXPO_0002703 converting cell type The process in which a relatively unspecialized cell acquires specialized features of a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into striated muscle fibers. http://purl.obolibrary.org/obo/GO_0045595 regulation of cell differentiation http://purl.obolibrary.org/obo/TXPO_0000113 controlling Any process that modulates the frequency, rate or extent of cell differentiation, the process in which relatively unspecialized cells acquire specialized structural and functional features. http://purl.obolibrary.org/obo/GO_0045862 positive regulation of proteolysis http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein. http://purl.obolibrary.org/obo/GO_0046618 drug export http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The directed movement of a drug, a substance used in the diagnosis, treatment or prevention of a disease, out of a cell or organelle. http://purl.obolibrary.org/obo/GO_0046889 positive regulation of lipid biosynthetic process http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. http://purl.obolibrary.org/obo/GO_0048878 chemical homeostasis http://purl.obolibrary.org/obo/GO_0042592 homeostatic process Any biological process involved in the maintenance of an internal steady state of a chemical. http://purl.obolibrary.org/obo/GO_0050996 positive regulation of lipid catabolic process http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the breakdown of lipids. http://purl.obolibrary.org/obo/GO_0051049 regulation of transport (biology) http://purl.obolibrary.org/obo/TXPO_0003636 regulation of transmitting Any process that modulates the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/GO_0051055 negative regulation of lipid biosynthetic process http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. http://purl.obolibrary.org/obo/GO_0070265 necrosis http://purl.obolibrary.org/obo/GO_0008219 cell death A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues. http://purl.obolibrary.org/obo/GO_0071073 positive regulation of phospholipid biosynthetic process http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. http://purl.obolibrary.org/obo/GO_0071840 cellular component organization or biogenesis http://purl.obolibrary.org/obo/TXPO_0000134 biological structure formation A process that results in the biosynthesis of constituent macromolecules, assembly, arrangement of constituent parts, or disassembly of a cellular component. http://purl.obolibrary.org/obo/GO_0090077 foam cell differentiation http://purl.obolibrary.org/obo/GO_0030154 cell differentiation The process in which a relatively unspecialized cell acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. http://purl.obolibrary.org/obo/GO_0097193 intrinsic apoptotic signaling pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.), and ends when the execution phase of apoptosis is triggered. The intrinsic apoptotic signaling pathway is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP). http://purl.obolibrary.org/obo/GO_0098754 detoxification http://purl.obolibrary.org/obo/TXPO_0000458 removing (from A) Any process that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance. http://purl.obolibrary.org/obo/GO_0098869 cellular oxidant detoxification http://purl.obolibrary.org/obo/GO_1990748 cellular detoxification Any process carried out at the cellular level that reduces or removes the toxicity superoxide radicals or hydrogen peroxide. http://purl.obolibrary.org/obo/GO_1902600 proton transmembrane transport http://purl.obolibrary.org/obo/GO_0006811 ion transport The directed movement of a proton across a membrane. http://purl.obolibrary.org/obo/GO_1903427 negative regulation of ROS formation http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of ROS. http://purl.obolibrary.org/obo/GO_0052697 xenobiotic glucuronidation http://purl.obolibrary.org/obo/GO_0019585 glucuronate metabolic process The modification of a xenobiotic substance by the conjugation of glucuronic acid. The resultant glucuronosides are often much more water-soluble than the xenobiotic precursor, enabling efficient excretion. http://purl.obolibrary.org/obo/GO_0055091 maintaining phospholipid homeostasis http://purl.obolibrary.org/obo/GO_0042592 homeostatic process Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell. http://purl.obolibrary.org/obo/GO_0060290 Transdifferentiation http://purl.obolibrary.org/obo/GO_0030154 cell differentiation The conversion of a differentiated cell of one fate into a differentiated cell of another fate without first undergoing cell division or reversion to a more primitive or stem cell-like fate. http://purl.obolibrary.org/obo/GO_0060697 positive regulation of phospholipid catabolic process http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that increases the rate, frequency, or extent of phospholipid catabolism, the chemical reactions and pathways resulting in the breakdown of phospholipids, any lipid containing phosphoric acid as a mono- or diester. http://purl.obolibrary.org/obo/GO_0061702 inflammasome complex http://purl.obolibrary.org/obo/TXPO_0002107 molecular complex A cytosolic protein complex that is capable of activating caspase-1. http://purl.obolibrary.org/obo/GO_0061736 engulfment of target by autophagosome http://purl.obolibrary.org/obo/GO_0010324 membrane invagination The membrane invagination process by which an autophagosomal membrane surrounds an object that will be degraded by macroautophagy. http://purl.obolibrary.org/obo/GO_0070269 pyroptosis http://purl.obolibrary.org/obo/GO_0008219 cell death A caspase-1-dependent cell death subroutine that is associated with the generation of pyrogenic mediators such as IL-1beta and IL-18. http://purl.obolibrary.org/obo/GO_0070300 phosphatidic acid binding http://purl.obolibrary.org/obo/GO_0005543 phospholipid binding Interacting selectively and non-covalently with phosphatidic acid, any of a class of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids. http://purl.obolibrary.org/obo/GO_0071606 chemokine (C-C motif) ligand 4 production http://purl.obolibrary.org/obo/GO_0032602 chemokine production The appearance of chemokine (C-C motif) ligand 4 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0071610 chemokine (C-C motif) ligand 1 production http://purl.obolibrary.org/obo/GO_0032602 chemokine production The appearance of chemokine (C-C motif) ligand 1 due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. http://purl.obolibrary.org/obo/GO_0071712 endoplasmic reticulum-associated degradation http://purl.obolibrary.org/obo/GO_0036503 ERAD pathway The chemical reactions and pathways resulting in the breakdown of misfolded proteins transported from the endoplasmic reticulum and targeted to cytoplasmic proteasomes for degradation. http://purl.obolibrary.org/obo/GO_0072574 hepatocyte proliferation http://purl.obolibrary.org/obo/GO_0008283 cell proliferation The multiplication or reproduction of hepatocytes, resulting in the expansion of a cell population. Hepatocytes form the main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. http://purl.obolibrary.org/obo/GO_1990748 cellular detoxification http://purl.obolibrary.org/obo/GO_0098754 detoxification Any process carried out at the cellular level that reduces or removes the toxicity of a toxic substance. These may include transport of the toxic substance away from sensitive areas and to compartments or complexes whose purpose is sequestration of the toxic substance. http://purl.obolibrary.org/obo/PR_000009897 lipoprotein lipase http://purl.obolibrary.org/obo/TXPO_0002283 lipase A protein that is a translation product of the human LPL gene or a 1:1 ortholog thereof. Category=gene. http://purl.obolibrary.org/obo/IMR_0000902 eIF2 http://purl.obolibrary.org/obo/IMR_0010016 eIF heterotrimer of alpha, beta, gamma subunits. binds the initiator Met-tRNA to the 40S ribosomal subunit. GTP binding to eIF2 is necessary for formation of a stable eIF2:GTP:Met-tRNA ternary complex (TC). Following TC binding to the ribosome triggers GTP hydrolysis by eIF2. http://purl.obolibrary.org/obo/IMR_0100105 placental lactogen http://purl.obolibrary.org/obo/IMR_0100086 placental hormone, peptide A polypeptide hormone of approximately 25 kDa that is produced by the SYNCYTIOTROPHOBLASTS of the PLACENTA, also known as chorionic somatomammotropin. It has both GROWTH HORMONE and PROLACTIN activities on growth, lactation, and luteal steroid production. http://purl.obolibrary.org/obo/IMR_0001789 beta-1,3-glucan http://purl.obolibrary.org/obo/CHEBI_18154 polysaccharide component of fungal cell walls. http://purl.obolibrary.org/obo/IMR_0100064 beta-MSH http://purl.obolibrary.org/obo/IMR_0100198 MSH A peptide hormone of about 22 amino acids. It is derived from PRO-OPIOMELANOCORTIN and has natriuretic activity. http://purl.obolibrary.org/obo/IMR_0000409 NF1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule The NFI family is composed of four members in vertebrates (NFI-A, NFI-B, NFI-C and NFI-X). http://purl.obolibrary.org/obo/IMR_0000327 ubiquitin activating enzyme http://purl.obolibrary.org/obo/TXPO_0003660 enzyme Catalysis role of the reaction: E1 + ubiquitin + ATP--> E1-ubiquitin + AMP + PPi, where the E1-ubiquitin linkage is a thioester bond between the C-terminal glycine of Ub and a sulfhydryl side group of an E1 cysteine residue. This is the first step in a cascade of reactions in which ubiquitin is ultimately added to a protein substrate. http://purl.obolibrary.org/obo/GO_00042181 ketone biosynthetic process http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process The chemical reactions and pathways resulting in the formation of ketones, a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups. http://purl.obolibrary.org/obo/HINO_0016364 amino acid conjugation http://purl.obolibrary.org/obo/GO_0006520 cellular amino acid metabolic process Xenobiotics that contain either a carboxylic group or an aromatic hydroxylamine group are possible substrates for amino acid conjugation. Xenobiotics with a carboxylic group conjugate with an amino group of amino acids such as glycine, taurine and glutamine. The hydroxylamine group conjugates with the carboxylic group of amino acids such as proline and serine. http://purl.obolibrary.org/obo/HINO_0016374 Glutathione synthesis and recycling http://purl.obolibrary.org/obo/TXPO_0000610 metabolic pathway The combination of glutamate, cysteine and ATP is required to form glutathione. The steps involved in the synthesis and recycling of glutathione are outlined (Meister, 1988). http://purl.obolibrary.org/obo/HINO_0017769 Translocation of NF-kappaB from the cytosol to the nucleus http://purl.obolibrary.org/obo/TXPO_0002494 NF-kappaB transport into nucleus Transport of NF-kappaB, a transcription factor for eukaryotic RNA polymerase II promoters, from the cytoplasm into the nucleus, across the nuclear membrane. http://purl.obolibrary.org/obo/IMR_0000342 Nck family http://purl.obolibrary.org/obo/CHEBI_25367 molecule The widely expressed Nck is a 47-kDa cytosolic protein exclusively composed of one SH2 and three SH3 domains. Recently, a second member of the Nck family has been isolated (Nck beta/Grb4) which shows 68% amino acid identity to Nck (Nck alpha). http://purl.obolibrary.org/obo/IMR_0000382 NF-kappaB http://purl.obolibrary.org/obo/CHEBI_25367 molecule Members of this family include p50, p52, p65, c-Rel, v-Rrel, RelB, and the Drosophila proteins, Dorsal, Dif and Relish. Most of these transcription factors bind as homo- and heterodimers to the consensus a DNA sequence motif termed kappa-B. http://purl.obolibrary.org/obo/IMR_0001423 GAF http://purl.obolibrary.org/obo/CHEBI_25367 molecule STAT1 dimers form the IFNgamma-activated factor (GAF). http://purl.obolibrary.org/obo/IMR_0001711 vinculin http://purl.obolibrary.org/obo/CHEBI_25367 molecule Involved in cell adhesion. May be involved in the attachment of the actin-based microfilaments to the plasma membrane. http://purl.obolibrary.org/obo/IMR_0001967 Epac http://purl.obolibrary.org/obo/IMR_0001976 RapGEF Epac1 (cAMP-GEFI) and Epac2 (cAMP-GEFII) are closely related guanine nucleotide exchange factors (GEFs) for the small GTPase Rap1 and Rap2, which are directly regulated by cAMP. http://purl.obolibrary.org/obo/IMR_0100272 MAPKAPK5 http://purl.obolibrary.org/obo/IMR_0100271 MAPKAPK MAPKAPK5 (PRAK) activity is regulated by p38 and activated MAPKAPK5 in turn phosphorylates small heat shock protein 27 (HSP27). http://purl.obolibrary.org/obo/TXPO_0000000 MDM2 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002045 glutathione depletion dependent molecule (canonical) This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013] http://purl.obolibrary.org/obo/TXPO_0000001 p53 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor role. http://purl.obolibrary.org/obo/TXPO_0000002 phospholipase transport to lysosome http://purl.obolibrary.org/obo/TXPO_0000111 molecule transport Phospholipase transport to lysosome is a subtype of molecule transport: A process of the directed movement of phospholipase to the lysosome. http://purl.obolibrary.org/obo/TXPO_0000003 moving solid http://purl.obolibrary.org/obo/TXPO_0000429 moving Moving solid is a subtype of moving. A process that change the location of the solid. . http://purl.obolibrary.org/obo/TXPO_0000007 generating periodic motion http://purl.obolibrary.org/obo/TXPO_0000765 generating motion Generating periodic motion is a subtype of generating motion: A process that generates the directed movement in which the object decreases in volume. http://purl.obolibrary.org/obo/TXPO_0000008 cell ceath [cell death (toxic course)] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Any biological process that results in permanent cessation of all vital functions of a cell. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000009 toxic course http://purl.obolibrary.org/obo/TXPO_0000608 process sequence Toxic course is a subtype of process sequence: A series of process in an organism from latent to the manifestation of toxicity, which is not part of the life of the organism. http://purl.obolibrary.org/obo/TXPO_0000010 changing membrane fluidity [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0000011 generating signal http://purl.obolibrary.org/obo/TXPO_0000381 generating Generating signal is a subtype of generating: A process that produces a signal as an output. http://purl.obolibrary.org/obo/TXPO_0000013 PPARalpha activation http://purl.obolibrary.org/obo/TXPO_0000158 nuclear receptor activation PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher. http://purl.obolibrary.org/obo/TXPO_0000015 changing sensitivity http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing sensitivity is a subtype of changing quality: A process that changes the sensitivity of the object. http://purl.obolibrary.org/obo/TXPO_0000016 hypofunction of detoxification [hepatic encephalopathy] http://purl.obolibrary.org/obo/TXPO_0001354 hypofunction of detoxification Hypofunction of detoxification is a subtype of hypofunctioning: A process that performs a decreased or insufficient detoxification. This entity is a specific course-dependent process. This process can constitute the course of Hepatic encephalopathy. http://purl.obolibrary.org/obo/TXPO_0000017 increasing ammonia concentration in blood [Hepatic encephalopathy] http://purl.obolibrary.org/obo/TXPO_0001355 increasing ammonia concentration in blood Increasing ammonia concentration in blood is a subtype of increasing concentration: A process that changes the ammonia concentration in the blood to be higher. This entity is a specific course-dependent process. This process can constitute the course of Hepatic encephalopathy. http://purl.obolibrary.org/obo/TXPO_0000018 ubiquitin-conjugating enzyme http://purl.obolibrary.org/obo/TXPO_0003660 enzyme Arole played by the entity that isoenergetic transfer of ubiquitin from one protein to another via the reaction X-ubiquitin + Y -> Y-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue. http://purl.obolibrary.org/obo/TXPO_0000019 generating substance http://purl.obolibrary.org/obo/TXPO_0000381 generating Generating substance is a subtype of generating: A process that produces a substance as an output. http://purl.obolibrary.org/obo/TXPO_0000020 changing activity http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing activity is a subtype of changing quality: A process that changes the activity of the object. http://purl.obolibrary.org/obo/TXPO_0000021 inactivation http://purl.obolibrary.org/obo/TXPO_0000020 changing activity Inactivation is a subtype of changing activity: A process that changes the activity of the object to be lower. http://purl.obolibrary.org/obo/TXPO_0000022 changing direction http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing direction is a subtype of changing quality: A process that changes the direction of the object. http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation http://purl.obolibrary.org/obo/TXPO_0000401 activating Molecular activation is a subtype of activating: A process that changes the activity of the moleule to be higher. http://purl.obolibrary.org/obo/TXPO_0000024 changing bond http://purl.obolibrary.org/obo/TXPO_0000261 changing relationship between operands Changing bond is a subtype of changing between operands: A process that changes a bond between objects. http://purl.obolibrary.org/obo/TXPO_0000025 changing disulfide bond http://purl.obolibrary.org/obo/TXPO_0000024 changing bond Changing disulfide bond is a subtype of changing bond: A process that changes a disulfide bond which is a covalent bond mediated by 2 sulfur atoms. http://purl.obolibrary.org/obo/TXPO_0000027 integrated signaling pathway http://purl.obolibrary.org/obo/NCIT_C54214 pathway Integrated signaling pathway is a subtype of pathway: Sequence of linked reactions, which has signaling pathway and gene regulated pathway. http://purl.obolibrary.org/obo/TXPO_0000028 eosinophilic granular degeneration [toxic course] http://purl.obolibrary.org/obo/TXPO_0000009 toxic course The totality of all processes through which eosinogranular degeneration is realized. http://purl.obolibrary.org/obo/TXPO_0000029 hepatic fibrosis dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0003749 hepatic fibrosis dependent chemical entity Hepatic fibrosis dependent gene is a subtype of toxic course dependent chemical entity. This gene can participate in the course of hepatic fibrosis as a gene product. Gene profile:Human/in vitro/Hepatocyte/ http://purl.obolibrary.org/obo/TXPO_0000030 dysfunction of calcium transport [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Dysfunction of calcium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete calcium transport. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000031 CREB3L3 activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation CREBPH activation is a subtype of molecular activation: A process that changes the activity of the CRBPH to be higher. http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Cholestasis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of cholestasis. http://purl.obolibrary.org/obo/TXPO_0000035 hypofunction of extracellular matrix disassembly http://purl.obolibrary.org/obo/TXPO_0000940 hypofunction of decomposing Hypofunction of extracellular matrix disassembly is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient extracellular matrix disassembly. http://purl.obolibrary.org/obo/TXPO_0000036 tranport regulator role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which regulates tranport process. http://purl.obolibrary.org/obo/TXPO_0000037 changing disulfide bond [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Changing disulfide bond is a subtype of changing bond: A process that changes a disulfide bond which is a covalent bond mediated by 2 sulfur atoms. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000038 toxic agent http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role A role played by the entity that has a toxic effect. http://purl.obolibrary.org/obo/TXPO_0000040 increasing weight http://purl.obolibrary.org/obo/TXPO_0000589 changing weight Increasing weight is a subtype of changing weight: A process that changes the weight of the object to be higher. http://purl.obolibrary.org/obo/TXPO_0000041 inreasing blood ALP concentration [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001346 inreasing blood ALP concentration Inreasing blood ALP concentration is a subtype of increasing concentration: A process that changes the bilirubin concentration in the blood to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000042 mitochondrial dysfunction [Oxidative stress] http://purl.obolibrary.org/obo/TXPO_0002361 mitochondrial dysfunction Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function. This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress. http://purl.obolibrary.org/obo/TXPO_0000045 hypofunction of bile acid and bile salt transport http://purl.obolibrary.org/obo/TXPO_0001911 hypofunction of transport Hypofunction of bile acid and bile salt transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient bile acid and bile salt transport. http://purl.obolibrary.org/obo/TXPO_0000046 cleavage of ATF6-alpha by S2P http://purl.obolibrary.org/obo/TXPO_0000333 separating Cleavage of ATF6-alpha by S2P is a subtype of proteolysis: A process n which ATF6-alpha is cleaved by endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage. http://purl.obolibrary.org/obo/TXPO_0000048 cleavage of ATF6-alpha by S1P http://purl.obolibrary.org/obo/TXPO_0000333 separating Cleavage of ATF6-alpha by S1P is a subtype of proteolysis: A process in which ATF6-alpha is cleaved by endopeptidase S1P( MBTPS1). http://purl.obolibrary.org/obo/TXPO_0000049 cleavage of ATF6-alpha by S1P [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Cleavage of ATF6-alpha by S1P is a subtype of proteolysis: A process in which ATF6-alpha is cleaved by endopeptidase S1P( MBTPS1). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000050 inflammatory cytokine gene expression [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0000051 ChREBP activation http://purl.obolibrary.org/obo/TXPO_0000124 transcription factor activation ChREBP activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating ChREBP to be higher. http://purl.obolibrary.org/obo/TXPO_0000052 cation http://purl.obolibrary.org/obo/CHEBI_24870 ion A monoatomic or polyatomic species having one or more elementary charges of the proton. http://purl.obolibrary.org/obo/TXPO_0000053 Translocation of ATF6 from the cytosol to the nucleus http://purl.obolibrary.org/obo/GO_0051169 nuclear transport Translocation of ATF6 from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of ATF6 from the cytoplasm to the nucleus. http://purl.obolibrary.org/obo/TXPO_0000054 increasing liver weight http://purl.obolibrary.org/obo/TXPO_0000040 increasing weight Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher. http://purl.obolibrary.org/obo/TXPO_0000055 Translocation of ATF6 from the cytosol to the nucleus [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Translocation of ATF6 from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of ATF6 from the cytoplasm to the nucleus. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000056 bile acid transport regulator role http://purl.obolibrary.org/obo/TXPO_0000036 tranport regulator role A role played by the entity which regulatess bile acid transport process. http://purl.obolibrary.org/obo/TXPO_0000057 transmembrane signaling receptor role http://purl.obolibrary.org/obo/TXPO_0002463 signaling receptor Combining role with an extracellular or intracellular signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity or state as part of signal transduction. http://purl.obolibrary.org/obo/TXPO_0000058 death receptor role http://purl.obolibrary.org/obo/TXPO_0000057 transmembrane signaling receptor role Combining role with an extracellular messenger (called a death ligand), and transmitting the signal from one side of the plasma membrane to the other to initiate apoptotic or necrotic cell death. http://purl.obolibrary.org/obo/TXPO_0000059 lysosome damage http://purl.obolibrary.org/obo/TXPO_0000070 organelle damage lysosome damage is a subtype of organelle damage. http://purl.obolibrary.org/obo/TXPO_0000060 ground glass appearance [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0000662 cytoplasmic alternation [Liver Pathological Findings] Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes. http://purl.obolibrary.org/obo/TXPO_0000061 PERK signaling to eIF2a [ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0002449 PERK signaling to eIF2a [ER stress] A process in which a signal to eIF2a is transduced by PERK. This process is dependent on the translation attenuation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000062 PERK signaling to eIF2a [PERK - eIF2A pathway] http://purl.obolibrary.org/obo/TXPO_0000454 PERK signaling (primitive) [PERK pathway] A process in which a signal to eIF2a is transduced by PERK. This entity is a specific course-dependent process. This process can constitute the course of PERK - eIF2A pathway. http://purl.obolibrary.org/obo/TXPO_0000063 PERK dimerization [ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0000713 PERK dimerization [ER stress] PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This entity is a specific course-dependent process. This process can constitute the course of ER stress and involves inflammation. http://purl.obolibrary.org/obo/TXPO_0000064 unfolded protein role http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role A role played by the protein that has a structure of misfolding http://purl.obolibrary.org/obo/TXPO_0000065 cellular tissue http://purl.obolibrary.org/obo/BFO_0000027 object aggregate Cellular tissue is a subtype of object aggregate that consists of cells or tissues. http://purl.obolibrary.org/obo/TXPO_0000066 changing cytoskeleton [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000238 changing cytoskeleton Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000067 PERK signaling (integrated pathway) http://purl.obolibrary.org/obo/TXPO_0000027 integrated signaling pathway PERK signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway. http://purl.obolibrary.org/obo/TXPO_0000068 negative regulation of formation of cytoplasmic translation initiation complex http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of formation of cytoplasmic translation initiation complex is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex. http://purl.obolibrary.org/obo/TXPO_0000070 organelle damage http://purl.obolibrary.org/obo/TXPO_0000222 damaging organelle damage is a subtype of damaging. http://purl.obolibrary.org/obo/TXPO_0000071 sphingolipid catabolic process http://purl.obolibrary.org/obo/GO_0016042 lipid catabolic process The chemical reactions and pathways resulting in the breakdown of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). http://purl.obolibrary.org/obo/TXPO_0000072 insulin deficiency http://purl.obolibrary.org/obo/TXPO_0000482 insufficient functioning Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required. http://purl.obolibrary.org/obo/TXPO_0000073 natural killer cell activation [Phospholipidosis (excessive defense)] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process natural killer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a natural killer (NK) cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense). http://purl.obolibrary.org/obo/TXPO_0000074 insulin deficiency [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000075 increasing GDF15 level [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing GDF15 level is a subtype of increasing quantity: A process that changes the amount of GDF15 level to be higher. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0000080 tumor progression marker role http://purl.obolibrary.org/obo/TXPO_0001225 toxicity prediction related role A role played by the entity that shows an expression change according to the degree of tumor progression. http://purl.obolibrary.org/obo/TXPO_0000082 bile acid transport inhibitor role http://purl.obolibrary.org/obo/TXPO_0000056 bile acid transport regulator role A role played by the entity which inhibits bile acid transport process. http://purl.obolibrary.org/obo/TXPO_0000083 bile pigment deposition http://purl.obolibrary.org/obo/GO_0043473 accumulation of pigments Bile pigment deposition is a subtype of accumulation of pigments: The aggregation of bile pigmentin a particular location in an organism, tissue or cell. http://purl.obolibrary.org/obo/TXPO_0000084 changing membrane fluidity [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000412 changing membrane fluidity Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000085 hypofunction of transmembrane transport http://purl.obolibrary.org/obo/TXPO_0001911 hypofunction of transport Hypofunction of transmembrane transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient transmembrane transport. http://purl.obolibrary.org/obo/TXPO_0000086 hypofunction of transmembrane transport [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000085 hypofunction of transmembrane transport Hypofunction of transmembrane transport is a subtype of hypofunction of transport: A process that performs a decreased or insufficient transmembrane transport. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000088 increasing acetyl CoA http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger. http://purl.obolibrary.org/obo/TXPO_0000089 apoptotic process [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000091 endoplasmic reticulum proliferation in hepatocyte http://purl.obolibrary.org/obo/TXPO_0003303 hepatocyte organelle proliferation Endoplasmic reticulum proliferation in hepatocyte is a subtype of increasing number of hepatocyte organelle: A process that becomes larger in the number of endoplasmic reticulum in hepatocyte(s). http://purl.obolibrary.org/obo/TXPO_0000092 increasing number of hepatocellular endoplasmic reticulum This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Endoplasmic reticulum proliferation in hepatocyte is a subtype of increasing number of hepatocyte organelle: A process that becomes larger in the number of endoplasmic reticulum in hepatocyte(s). This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0000093 increasing number of objects http://purl.obolibrary.org/obo/TXPO_0000387 changing Increasing number of objects is a subtype of changing: A process that becomes larger in the number of physical objects. http://purl.obolibrary.org/obo/TXPO_0000094 maintaining permeability http://purl.obolibrary.org/obo/TXPO_0002704 changing permeability Maintaining permeability is a subtype of changing permeability: A process that changes the permeability of the membrane to be lower. http://purl.obolibrary.org/obo/TXPO_0000095 hyperfunction of fatty acid beta-oxidation http://purl.obolibrary.org/obo/TXPO_0000099 hyperfunction of fatty acid oxidation Hyperfunction of fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid oxidation: A process that performs an excessive fatty acid beta-oxidation. http://purl.obolibrary.org/obo/TXPO_0000096 increasing liver weight [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000097 fatty acid omega-oxidation http://purl.obolibrary.org/obo/GO_0019395 fatty acid oxidation A fatty acid oxidation process in which the methyl group at the end of the fatty acid molecule (the omega carbon) is first oxidized to a hydroxyl group, then to an oxo group, and finally to a carboxyl group. The long chain dicarboxylates derived from omega-oxidation then enter the beta-oxidation pathway for further degradation. http://purl.obolibrary.org/obo/TXPO_0000098 hyperfunction of lipid oxidation http://purl.obolibrary.org/obo/TXPO_0000435 hyperfunctioning Hyperfunction of lipid oxidation is a subtype of hyperfunction of lipid catabolic process: A process that performs an excessive lipid degradation. http://purl.obolibrary.org/obo/TXPO_0000099 hyperfunction of fatty acid oxidation http://purl.obolibrary.org/obo/TXPO_0000098 hyperfunction of lipid oxidation Hyperfunction of fatty acid oxidation is a subtype of hyperfunction of lipid oxidation: A process that performs an excessive lipid oxidation. http://purl.obolibrary.org/obo/TXPO_0000100 hyperfunction of lipid degradation http://purl.obolibrary.org/obo/TXPO_0002349 hyperfunction of decompoing Hyperfunction of lipid degradation is a subtype of hyperfunction of decompoing: A process that performs an excessive lipid degradation. http://purl.obolibrary.org/obo/TXPO_0000101 hyperfunction of cerramide phagocytosis by Kupffer cells or macrophges [Phospholipidosis-sphingomyelin disorder] http://purl.obolibrary.org/obo/TXPO_0004151 hyperfunction of ceramide phagocytosis by Kupffer cell or macrophage Removing ceramide by Kupffer cell or macrophage is a subtype of removing: A process that takes a ceramide from a cell by Kupffer cells or macrophages . This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder). http://purl.obolibrary.org/obo/TXPO_0000102 increasing demand for response to oxidative stress http://purl.obolibrary.org/obo/TXPO_0000361 increasing demand for response to stress Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher. http://purl.obolibrary.org/obo/TXPO_0000103 increasing demand for response to oxidative stress [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000104 peroxisomal proliferation in hepatocyte http://purl.obolibrary.org/obo/TXPO_0003303 hepatocyte organelle proliferation Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). http://purl.obolibrary.org/obo/TXPO_0000105 peroxisomal proliferation in hepatocyte [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000106 hyperfunction of phenobarbital metabolism [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process hyperfunction of phenobarbital metabolism is a subtype of hyperfunctioning of drug metabolism: A process that performs an excessive phenobarbital metabolism. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0000107 peroxisomal Acox biosynthetic process http://purl.obolibrary.org/obo/TXPO_0000382 protein production Peroxisomal Acox biosynthetic process is a subtype of protein production: A process that makes existent of a Peroxisomal acyl -coenzyme A oxidase (ACOX) due to biosynthesis or secretion resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0000108 organelle proliferation http://purl.obolibrary.org/obo/TXPO_0000093 increasing number of objects Organelle proliferation is a subtype of increasing number of objects: A process that becomes larger in the number of organelles. http://purl.obolibrary.org/obo/TXPO_0000109 long-chain fatty acid import into peroxisome [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process The directed movement of long-chain fatty acids into a peroxisome. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000110 peroxisomal Acox biosynthetic process [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Peroxisomal Acox biosynthetic process is a subtype of protein production: A process that makes existent of a Peroxisomal acyl -coenzyme A oxidase (ACOX) due to biosynthesis or secretion resulting in an increase in its levels. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000111 molecule transport http://purl.obolibrary.org/obo/GO_0006810 transport Molecule transport is a subtype of transport: A process of the directed movement of molecules into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore.. http://purl.obolibrary.org/obo/TXPO_0000112 fatty acid alpha-oxidation http://purl.obolibrary.org/obo/GO_0019395 fatty acid oxidation A metabolic process by which 3-methyl branched fatty acids are degraded. These compounds are not degraded by the normal peroxisomal beta-oxidation pathway, because the 3-methyl blocks the dehydrogenation of the hydroxyl group by hydroxyacyl-CoA dehydrogenase. The 3-methyl branched fatty acid is converted in several steps to pristenic acid, which can then feed into the beta-oxidative pathway. http://purl.obolibrary.org/obo/TXPO_0000113 controlling http://purl.obolibrary.org/obo/TXPO_0002541 optional contribution process Controlling is a subtype of meta-function of "ToControl". When a function fa regularizes the behavior of ft, its meta-function is said to be 'to control ft'. http://purl.obolibrary.org/obo/TXPO_0000114 phosphoethanolamine catabolic process http://purl.obolibrary.org/obo/GO_0009056 catabolic process Phosphoethanolamine catabolic process is a subtype of catabolic process: A process of the chemical reactions resulting in the breakdown of phosphoethanolamine. http://purl.obolibrary.org/obo/TXPO_0000115 negative regulation of decomposing http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of decomposing is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of decomposing. http://purl.obolibrary.org/obo/TXPO_0000116 regulation of lipid metabolic process [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000117 drug metabolism phase I by Cytochrome P450 [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001559 drug metabolism phase I by Cytochrome P450 Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily . This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0000118 regulation of beta oxidation related gene expression [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Regulation of beta oxidation related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of fatty acid beta oxidation related gene expression. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000119 regulation of beta oxidation related gene expression http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression Regulation of beta oxidation related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of fatty acid beta oxidation related gene expression. http://purl.obolibrary.org/obo/TXPO_0000120 PLA1 (mol) http://purl.obolibrary.org/obo/TXPO_0000635 Phospholipase family phosphatidylcholine + H2O = 2-acylglycerophosphocholine + a carboxylate. http://purl.obolibrary.org/obo/TXPO_0000122 WY14643 [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0002383 eosinogranular degeneration dependent chemical compound Pirinixic Acid is a synthetic thiacetic acid derivative used in biomedical research, carcinogenic Pirinixic acid is a peroxisome proliferator that activates specific peroxisome proliferator-activated receptors (PPAR). PPARs play an important role in diverse cellular functions, including lipid metabolism, cell proliferation, differentiation, adipogenesis, and inflammatory signaling. (NCI04). Pirinixic Acid was discovered as WY-14,643 in 1974. http://purl.obolibrary.org/obo/TXPO_0000123 receiving abnormal protein signal by PERK [ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0002741 receiving abnormal protein signal by PERK [ER stress] Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK. This process is dependent on the translation attenuation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000124 transcription factor activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation Transcription factor activation is a subtype of molecular activation: A process that changes the activity of the molecule with a transcription factor role to be higher. http://purl.obolibrary.org/obo/TXPO_0000125 PPARalpha activation (severe) [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001005 PPARalpha activation [Eosinophilic granular degeneration] PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be higher. The degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000126 negative regulation of mRNA catabolic process http://purl.obolibrary.org/obo/TXPO_0000115 negative regulation of decomposing Negative regulation of mRNA catabolic process is a subtype of negative regulation of decomposing: Any process that stops, prevents or reduces the frequency, rate or extent of mRNA catabolic process. http://purl.obolibrary.org/obo/TXPO_0000127 autophagy [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000128 regulation of mitochondrial beta oxidation related gene [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Regulation of mitochondrial beta oxidation related gene is a subtype of regulation of beta oxidation related gene expression: A process that modulates the frequency, rate or extent of mitochondrial fatty acid beta oxidation related gene expression. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000129 regulation of mitochondrial beta oxidation related gene http://purl.obolibrary.org/obo/TXPO_0000119 regulation of beta oxidation related gene expression Regulation of mitochondrial beta oxidation related gene is a subtype of regulation of beta oxidation related gene expression: A process that modulates the frequency, rate or extent of mitochondrial fatty acid beta oxidation related gene expression. http://purl.obolibrary.org/obo/TXPO_0000130 negative regulation of lipid storage [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Any process that decreases the rate, frequency or extent of lipid storage. Lipid storage is the accumulation and maintenance in cells or tissues of lipids, compounds soluble in organic solvents but insoluble or sparingly soluble in aqueous solvents. Lipid reserves can be accumulated during early developmental stages for mobilization and utilization at later stages of development. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000131 lipid transport to mitochondria http://purl.obolibrary.org/obo/GO_0006869 lipid transport Lipid transport to mitochondria is a subtype of lipid transport: A process that of the directed movement of lipids into a mitochondrion. http://purl.obolibrary.org/obo/TXPO_0000132 unfolded protein [ER stress] http://purl.obolibrary.org/obo/TXPO_0002106 unfolded protein Unfolded protein is a subtype of substance with role. This entity can participate in a unfolded protein response in the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000133 maintaining membrane permeability http://purl.obolibrary.org/obo/TXPO_0000094 maintaining permeability Maintaining membrane permeability is a subtype of maintaining permeability: A process that keeps the permeability of the membrane. http://purl.obolibrary.org/obo/TXPO_0000134 biological structure formation http://purl.obolibrary.org/obo/TXPO_0000168 having extra parts Biological structure formation is a subtype of having extra parts: A process that changes to form a structure component. http://purl.obolibrary.org/obo/TXPO_0000136 tumorigenesis [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/NCIT_C18121 tumorigenesis A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000138 increasing size http://purl.obolibrary.org/obo/TXPO_0002705 changing size Increasing size is a subtype of changing size: A process that changes the size of the object to be larger. http://purl.obolibrary.org/obo/TXPO_0000139 increasing volume http://purl.obolibrary.org/obo/TXPO_0000417 changing volume Increasing volume is a subtype of increasing size: A process that changes the volume of the object to be higher. http://purl.obolibrary.org/obo/TXPO_0000140 increasing area http://purl.obolibrary.org/obo/TXPO_0000544 changing area Increasing area is a subtype of changing area: A process that changes the area of the object to be larger. http://purl.obolibrary.org/obo/TXPO_0000141 increasing length http://purl.obolibrary.org/obo/TXPO_0000552 changing length Increasing length is a subtype of changing length: A process that changes the length of the object to be higher. http://purl.obolibrary.org/obo/TXPO_0000142 increasing cell volume http://purl.obolibrary.org/obo/TXPO_0000139 increasing volume Increasing cell volume is a changing process to change the volume of the cell to increase. http://purl.obolibrary.org/obo/TXPO_0000143 increasing volume of mitochondria http://purl.obolibrary.org/obo/TXPO_0003741 increasing organelle volume Increasing volume of mitochondria is a changing process to change the volume of the mitochondria to increase. http://purl.obolibrary.org/obo/TXPO_0000144 increasing energy http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger. http://purl.obolibrary.org/obo/TXPO_0000145 function-related process http://purl.obolibrary.org/obo/TXPO_0000271 primitive process Function-related process is a process that related to the execution of a function, a metafunction, and the malfunction. http://purl.obolibrary.org/obo/TXPO_0000146 hyperfunction of mitochondrial fatty acid beta-oxidation [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0002344 hyperfunction of mitochondrial fatty acid beta-oxidation Hyperfunction of mitochondrial fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive mitochondrial fatty acid beta-oxidation. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000147 refolding-unfolding imbalance [ER stress] http://purl.obolibrary.org/obo/TXPO_0002459 refolding-unfolding imbalance Refolding-unfolding imbalance is a subtype of imbalance: A process that lacks a balance between protein refolding and unfolding. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000148 massive hepatic necrosis http://purl.obolibrary.org/obo/TXPO_0000520 classification of cell death by distribution Massive hepatic necrosis is a subtype of classification of cell death by distribution: A hepatocyte necrosis localized around multiple lobules. http://purl.obolibrary.org/obo/TXPO_0000149 regulation of carbohydrate metabolic process [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving carbohydrates. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000151 increasing energy [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000152 TIMP1 production http://purl.obolibrary.org/obo/TXPO_0000382 protein production TIMP1 production is a subtype of protein production: A process that makes existent of a TIMP1 protein due to biosynthesis or secretion resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0000153 glycolytic process [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process The chemical reactions and pathways resulting in the breakdown of a carbohydrate into pyruvate, with the concomitant production of a small amount of ATP and the reduction of NAD(P) to NAD(P)H. Glycolysis begins with the metabolism of a carbohydrate to generate products that can enter the pathway and ends with the production of pyruvate. Pyruvate may be converted to acetyl-coenzyme A, ethanol, lactate, or other small molecules. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000154 electron transfer moecule http://purl.obolibrary.org/obo/TXPO_0003638 transporter A role played by the entity that serves as an electron acceptor and electron donor in an electron transport chain. An electron transport chain is a process in which a series of electron carriers operate together to transfer electrons from donors to any of several different terminal electron acceptors to generate a transmembrane electrochemical gradient. http://purl.obolibrary.org/obo/TXPO_0000155 hematopoietic factor http://purl.obolibrary.org/obo/TXPO_0000622 cytokine A role played by the entity that causes blood cells to grow and mature (Haematopoiesis). http://purl.obolibrary.org/obo/TXPO_0000156 inflammatory cell infiltration [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0000157 decreasing sensitivity http://purl.obolibrary.org/obo/TXPO_0000015 changing sensitivity Decreasing sensitivity is a subtype of changing sensitivity: A process that changes the sensitivity to be lower. http://purl.obolibrary.org/obo/TXPO_0000158 nuclear receptor activation http://purl.obolibrary.org/obo/TXPO_0000124 transcription factor activation Nuclear receptor activation is a subtype of activation of transcription factor: A process that changes the activity of the molecule with a nuclear receptor role to be higher. http://purl.obolibrary.org/obo/TXPO_0000163 release of phospholipid from lysosome http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B Release of phospholipid from lysosome is a subtype of moving A to the outside of B: A process that that moves phospholipids to the outside of the lysosome. http://purl.obolibrary.org/obo/TXPO_0000164 increasing hepatocellular volume http://purl.obolibrary.org/obo/TXPO_0000142 increasing cell volume Increasing hepatocellular volume is a subtype of increasing cell volume to change the volume of the hepatocyte to increase. http://purl.obolibrary.org/obo/TXPO_0000165 increasing hepatocellular volume [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000166 addition of foreign substance http://purl.obolibrary.org/obo/TXPO_0000468 assembling Addition of foreign substance is a subtype of assembling: A process that foreign substance to make an addition. http://purl.obolibrary.org/obo/TXPO_0000167 dysfunction of calcium transport http://purl.obolibrary.org/obo/TXPO_0000438 dysfunctioning Dysfunction of calcium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete calcium transport. http://purl.obolibrary.org/obo/TXPO_0000168 having extra parts http://purl.obolibrary.org/obo/TXPO_0002566 changing structure Having extra parts is a subtype of changing structure: A process that changes to have additional parts of the structure. http://purl.obolibrary.org/obo/TXPO_0000169 accumulation of xenobiotics http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object Accumulation of xenobiotics is a subtype of accumulation of substances in a biological object: A process that keeps xenobiotics in an organism, tissue, organelle, or cell. http://purl.obolibrary.org/obo/TXPO_0000170 accumulation of compound in ER [ER stress] http://purl.obolibrary.org/obo/TXPO_0002212 accumulation of compound in ER Accumulation of compound in ER is a subtype of accumulation of xenobiotics: A process that keeps compound in the ER (endoplasmic reticulum). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000171 ligase http://purl.obolibrary.org/obo/TXPO_0003660 enzyme A role played by the role which catalyse the joining of two molecules with concomitant hydrolysis of the diphosphate bond in ATP or a similar triphosphate. http://purl.obolibrary.org/obo/TXPO_0000172 ultimate toxicant http://purl.obolibrary.org/obo/CHEBI_64909 poison A role played by a chemical substance that reacts with the endogenous target molecule or critically alters the biological environment, initiating structural/functional alternations that result in toxicity. http://purl.obolibrary.org/obo/TXPO_0000173 drug metabolism phase I http://purl.obolibrary.org/obo/GO_0017144 drug metabolic process Drug metabolism phase I is a subtype of drug metabolic process: A process that of biotransformation reactions involving hydrolysis, reduction, and oxidation or introduces a functional group (such as -OH, -NH2, -SH or -COOH) to increase in the water solubility of a xenobiotic. http://purl.obolibrary.org/obo/TXPO_0000174 peroxisome fatty acid beta oxidation gene expression [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) . This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000175 peroxisome fatty acid beta oxidation gene expression http://purl.obolibrary.org/obo/GO_0010467 gene expression Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) . http://purl.obolibrary.org/obo/TXPO_0000176 hyperfunction of peroxisomal fatty acid beta-oxidation [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000177 hyperfunction of peroxisomal fatty acid beta-oxidation http://purl.obolibrary.org/obo/TXPO_0000095 hyperfunction of fatty acid beta-oxidation Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation. http://purl.obolibrary.org/obo/TXPO_0000179 increasing demand for peroxisomal fatty acid beta oxidation [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Increasing demand for peroxisomal fatty acid beta oxidation is a subtype of increasing functional demand: A process that changes the functional demand for peroxisomal fatty acid beta oxidation to be higher. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000180 increasing demand for peroxisomal fatty acid beta oxidation http://purl.obolibrary.org/obo/TXPO_0000633 increasing functional demand Increasing demand for peroxisomal fatty acid beta oxidation is a subtype of increasing functional demand: A process that changes the functional demand for peroxisomal fatty acid beta oxidation to be higher. http://purl.obolibrary.org/obo/TXPO_0000181 accumulation of drug in hepatocyte [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002325 accumulation of drug in hepatocyte Accumulation of drug in hepatocyte is a subtype of accumulation of xenobiotics: A process that keeps compound in the hepatocyte. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0000182 negative regulation of lipid biosynthetic process [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000183 regulation of cell cycle related gene expression http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression. http://purl.obolibrary.org/obo/TXPO_0000184 regulation of cell cycle related gene expression [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000185 biochemical degradation http://purl.obolibrary.org/obo/TXPO_0000343 decomposing Biochemical degradation is a subtype of decompoing: A process that biochemically decomposes a single chemical entity into multiple element http://purl.obolibrary.org/obo/TXPO_0000186 microtubule cytoskeletal protein http://purl.obolibrary.org/obo/TXPO_0003689 cytoskeletal protein A role played by the protein related to the microtubules of the cytoskeleton. http://purl.obolibrary.org/obo/TXPO_0000187 lipid catabolic process [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process The chemical reactions and pathways resulting in the breakdown of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000189 inhibitor of obesity http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity that ihibits the obesity. http://purl.obolibrary.org/obo/TXPO_0000190 negative regulation of cytokine gene expression [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0003218 negative regulation of cytokine gene expression Negative regulation of cytokine gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory cytokine gene expression. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000191 inflammatory cytokine gene expression [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000192 inflammatory response http://purl.obolibrary.org/obo/TXPO_0002590 changing material Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. http://purl.obolibrary.org/obo/TXPO_0000194 accumulation of abnormal proteins in ER [ER stress] http://purl.obolibrary.org/obo/TXPO_0002187 accumulation of abnormal proteins in ER Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000195 regulation of gene expression by miRNA http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression Any process that modulates the frequency, rate or extent of gene expression by miRNA. http://purl.obolibrary.org/obo/TXPO_0000196 regulation of gene expression by miRNA [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Any process that modulates the frequency, rate or extent of gene expression by miRNA. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000197 oncogene mRNA stabilization http://purl.obolibrary.org/obo/TXPO_0003733 keeping structure Oncogene mRNA stabilization is a subtype of keeping structure: A process that maintaing the mRNA structure of ongogenes. http://purl.obolibrary.org/obo/TXPO_0000198 oncogene mRNA stabilization [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Oncogene mRNA stabilization is a subtype of keeping structure: A process that maintaing the mRNA structure of ongogenes. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000199 liver cancer dependent chemical entity http://purl.obolibrary.org/obo/TXPO_0001731 toxic course dependent chemical entity Liver cacer dependent chemical entity is a subtype of toxic course dependent chemical entity. This entity can participate in the course of liver cancer. http://purl.obolibrary.org/obo/TXPO_0000200 phospholipid transport from lysosome into cytosol [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003388 phospholipid transport from lysosome Phospholipid transport from lysosome is a subtype of phospholipid transfer : A process of the transfer of a phospholipid from the lysosome. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0000201 oxygen radical http://purl.obolibrary.org/obo/CHEBI_26519 radical An inorganic radical in which a free electron resides on one or more oxygen atoms of an oxygen species. http://purl.obolibrary.org/obo/TXPO_0000203 liver dysfunction http://purl.obolibrary.org/obo/TXPO_0000438 dysfunctioning Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function. http://purl.obolibrary.org/obo/TXPO_0000204 autophagy [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000205 redox-active reactant formation http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process Redox-active reactant formation is a subtype of biosynthetic process: A process that that generates a redox-active reactant. http://purl.obolibrary.org/obo/TXPO_0000206 liver dysfunction [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000207 dysfunction of sodium transport http://purl.obolibrary.org/obo/TXPO_0000438 dysfunctioning Dysfunction of sodium transport is a subtype of dysfunctioning: A process that performs an abnormal and incomplete sodium transport http://purl.obolibrary.org/obo/TXPO_0000208 dysfunction of generating protein http://purl.obolibrary.org/obo/TXPO_0000438 dysfunctioning Dysfunction of generating protein is a subtype of dysfunctioning: A process that performs an abnormal and incomplete generating protein. http://purl.obolibrary.org/obo/TXPO_0000209 free radicals formation http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process Free radicals formation is a subtype of biosynthetic process: A process that that generates a free radical, a highly reactive molecule with an unsatisfied electron valence pair. http://purl.obolibrary.org/obo/TXPO_0000210 nucleophiles formation http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process Nucleophiles formation is a subtype of biosynthetic process: The chemical reaction resulting in the formation of nucleophiles by donating electrons. http://purl.obolibrary.org/obo/TXPO_0000211 IL-2 gene expression http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression IL-2 gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature IL-2 gene product or products (proteins or RNA). http://purl.obolibrary.org/obo/TXPO_0000212 electrophiles formation http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process Electrophiles formation is a subtype of biosynthetic process: A process that that generates electrophiles. Electrophile is a reagent that forms a bond to its reaction partner (the nucleophile) by accepting both bonding electrons from that reaction partner.. http://purl.obolibrary.org/obo/TXPO_0000213 protein quality control for unfolded proteins http://purl.obolibrary.org/obo/TXPO_0000474 keeping quality Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains the protein quality. http://purl.obolibrary.org/obo/TXPO_0000214 protein quality control for unfolded via gene expression regulation [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Protein quality control for misfolded or incompletely synthesized proteins is a subtype of keeping quality: A process that maintains the protein quality mediated by the gene expression regulation. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000215 dysfunction of protein quality control http://purl.obolibrary.org/obo/TXPO_0000438 dysfunctioning Dysfunction of protein quality control is a subtype of dysfunctioning: A process that performs an abnormal and incomplete protein quality control function. http://purl.obolibrary.org/obo/TXPO_0000216 increasing number of stress responses http://purl.obolibrary.org/obo/TXPO_0000344 increasing number of action Increasing number of stress responses is a subtype of increasing number of actions: A process that becomes larger in the number of stress responses. http://purl.obolibrary.org/obo/TXPO_0000217 hepatocyte proliferation [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process A process that results in an increase in hepatic cell number by cell division, often leading to an increase in the size of an liver. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0000218 icreasing volume of endoplasmic reticulum http://purl.obolibrary.org/obo/TXPO_0003741 increasing organelle volume Icreasing volume of endoplasmic reticulum is a subtype of increasing organelle volume: A process that changes the volume of the endoplasmic reticulum to be higher. http://purl.obolibrary.org/obo/TXPO_0000219 fibrosis http://purl.obolibrary.org/obo/TXPO_0002590 changing material Fibrosis is a subtype of changing material: A process that replaces tissues to fibrous connective tissues/ http://purl.obolibrary.org/obo/TXPO_0000220 deacreasing size http://purl.obolibrary.org/obo/TXPO_0002705 changing size Deacreasing size is a subtype of changing size: A process that changes the size of the object to be smaller. http://purl.obolibrary.org/obo/TXPO_0000221 hepatocellular atrophy http://purl.obolibrary.org/obo/TXPO_0000243 decreasing volume Hepatocellular atrophy is a subtype of decreasing volume: A process that changes the volume of the hepatocyte to be relatively low. http://purl.obolibrary.org/obo/TXPO_0000222 damaging http://purl.obolibrary.org/obo/TXPO_0002566 changing structure Damaging is a subtype of changing structure: A process that injuries the structure as the direct or indirect result of an external force. http://purl.obolibrary.org/obo/TXPO_0000223 DNA damage [Cell death] http://purl.obolibrary.org/obo/NCIT_C16507 DNA damage Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000224 TIMP1 production [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process TIMP1 production is a subtype of protein production: A process that makes existent of a TIMP1 protein due to biosynthesis or secretion resulting in an increase in its levels. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0000225 cellular damage http://purl.obolibrary.org/obo/TXPO_0000222 damaging Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force. http://purl.obolibrary.org/obo/TXPO_0000226 cellular damage [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Cellular damage is a subtype of damaging: A process that injuries the structure of the cell as the direct or indirect result of an external force. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000227 cytoskeleton damage http://purl.obolibrary.org/obo/TXPO_0000225 cellular damage Cytoskeleton damage is a subtype of cellular damage: A process that injuries the structure of the cytoskeleton as the direct or indirect result of an external force. http://purl.obolibrary.org/obo/TXPO_0000230 gene expression by AP-1 http://purl.obolibrary.org/obo/TXPO_0000375 Gene expression by transcriptional regulator Gene expression by AP-1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by AP-1. http://purl.obolibrary.org/obo/TXPO_0000231 membrane blebbing [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process The assembly of a bleb, a cell extension caused by localized decoupling of the cytoskeleton from the plasma membrane and characterized by rapid formation, rounded shape, and scarcity of organelles within the protrusion. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000232 increasing membrane permeabilization http://purl.obolibrary.org/obo/TXPO_0002704 changing permeability Increasing membrane permeabilization is a subtype of changing permeability: A process that changes the permeability of the membrane to be higher. http://purl.obolibrary.org/obo/TXPO_0000233 positive regulation of mitochondrial membrane permeability [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0000234 positive regulation of mitochondrial membrane permeability [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Any process that increases the frequency, rate or extent of the passage or uptake of molecules by the mitochondrial membrane. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000235 dysregulation of apoptosis http://purl.obolibrary.org/obo/TXPO_0000532 malfunctioning of controlling Dysregulation of apoptosis is a subtype of malfunctioning of controlling: A process that cannot perform a regulation of apoptotic process appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0000236 tumorigenesis [Cell death] http://purl.obolibrary.org/obo/NCIT_C18121 tumorigenesis A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000237 gene expression by p53 http://purl.obolibrary.org/obo/TXPO_0000375 Gene expression by transcriptional regulator Gene expression by p53 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1. http://purl.obolibrary.org/obo/TXPO_0000238 changing cytoskeleton http://purl.obolibrary.org/obo/TXPO_0002566 changing structure Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton. http://purl.obolibrary.org/obo/TXPO_0000239 changing cytoskeleton [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Changing cytoskeleton is a subtype of changing structure: A process that changes the structure of cytoskeleton. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000240 hypofunction of keeping structure http://purl.obolibrary.org/obo/TXPO_0000436 hypofunctioning Hypofunction of keeping structure is a subtype of hypofunctioning: A process that performs a decreased or insufficient keeping structure. http://purl.obolibrary.org/obo/TXPO_0000241 hypofunction of keeping structure [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Hypofunction of keeping structure is a subtype of hypofunctioning: A process that performs a decreased or insufficient keeping structure. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000242 decreasing area http://purl.obolibrary.org/obo/TXPO_0000544 changing area Decreasing area is a subtype of changing area: A process that changes the area of the object to be smaller. http://purl.obolibrary.org/obo/TXPO_0000243 decreasing volume http://purl.obolibrary.org/obo/TXPO_0000417 changing volume Decreasing volume is a subtype of changing volume: A process that changes the volume of the object to be relatively low http://purl.obolibrary.org/obo/TXPO_0000244 decreasing length http://purl.obolibrary.org/obo/TXPO_0000552 changing length Decreasing length is a subtype of changing length: A process that changes the length of the object to be lower. http://purl.obolibrary.org/obo/TXPO_0000245 decreasing contact area with ECM http://purl.obolibrary.org/obo/TXPO_0000242 decreasing area Decreasing contact area with ECM is a subtype of decreasing area: A process that changes the contact area with extracellular matrix (ECM) to be smaller. http://purl.obolibrary.org/obo/TXPO_0000246 decreasing contact area with ECM [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Decreasing contact area with ECM is a subtype of decreasing area: A process that changes the contact area with extracellular matrix (ECM) to be smaller. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object http://purl.obolibrary.org/obo/TXPO_0000601 storing Accumulation of substances in a biological object is a subtype of storing: A process that keeps substances in an organism, tissue, organelle, or cell. http://purl.obolibrary.org/obo/TXPO_0000248 protein accumulation http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object Protein accumulation is a subtype of accumulation of substances in a biological object: A process that keeps protein(s) in a biological object. http://purl.obolibrary.org/obo/TXPO_0000249 increasing sensitivity http://purl.obolibrary.org/obo/TXPO_0000015 changing sensitivity Increasing sensitivity is a subtype of changing sensitivity: A process that changes the sensitivity to be lhigher. http://purl.obolibrary.org/obo/TXPO_0000250 accumulation of abnormal proteins in ER [ER stress (severe) ] http://purl.obolibrary.org/obo/TXPO_0003528 severe accumulation of abnormal proteins in ER Accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum). And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of ER stress (severe) . http://purl.obolibrary.org/obo/TXPO_0000251 accumulation of abnormal proteins http://purl.obolibrary.org/obo/TXPO_0000248 protein accumulation Accumulation of abnormal proteins is a subtype of protein accumulation: A process that keeps abnormal protein(s) in a biological object. http://purl.obolibrary.org/obo/TXPO_0000252 mitochondrial dysfunction [Cell death] http://purl.obolibrary.org/obo/TXPO_0002361 mitochondrial dysfunction Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function. This entity is a specific course-dependent process. This process can constitute the course of cell death. http://purl.obolibrary.org/obo/TXPO_0000253 increasing size of liver http://purl.obolibrary.org/obo/TXPO_0000138 increasing size Increasing size of liver is a subtype of increasing size: A process that changes the size of the liver to be larger. http://purl.obolibrary.org/obo/TXPO_0000254 vitamine accumulation http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object Vitamine accumulation is a subtype of accumulation of substances in a biological object: A process that keeps vitamin in a biological object. http://purl.obolibrary.org/obo/TXPO_0000255 accumulation of protein aggregates http://purl.obolibrary.org/obo/TXPO_0000248 protein accumulation Accumulation of protein aggregates is a subtype of protein accumulation: A process that keeps protein aggregates in a biological object. http://purl.obolibrary.org/obo/TXPO_0000256 fatty acid strorage http://purl.obolibrary.org/obo/GO_0019915 lipid storage Fatty acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps fatty acid in a biological object. http://purl.obolibrary.org/obo/TXPO_0000257 substance with stress sensor role http://purl.obolibrary.org/obo/GOCHE_50906 substance with role Substance with stress sensor role is a subtype of substance with role. This entity is participating in a stress response and playing a stress sensor role. http://purl.obolibrary.org/obo/TXPO_0000258 melanin deposition http://purl.obolibrary.org/obo/GO_0043473 accumulation of pigments Melanin deposition is a subtype of accumulation of pigments: The aggregation of melanin in a particular location in an organism, tissue or cell. http://purl.obolibrary.org/obo/TXPO_0000259 lipofuscin deposition http://purl.obolibrary.org/obo/GO_0043473 accumulation of pigments Lipofuscin deposition is a subtype of accumulation of pigments: The aggregation of lipofuscin in a particular location in an organism, tissue or cell. http://purl.obolibrary.org/obo/TXPO_0000260 substance with apoptosis inducer role http://purl.obolibrary.org/obo/GOCHE_50906 substance with role Substance with apoptosis inducer role is a subtype of substance with role. This entity is participating in a positive regulation of apoptosis process and playing an apoptosis inducer role. http://purl.obolibrary.org/obo/TXPO_0000261 changing relationship between operands http://purl.obolibrary.org/obo/TXPO_0000387 changing Changing relationship between operands is a subtype of changing: A process that changing the relationship between multiple objects. http://purl.obolibrary.org/obo/TXPO_0000263 bile acid accumulation in hepatocyte http://purl.obolibrary.org/obo/TXPO_0003130 bile accumulation Bile acid strorage is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the liver (intrahepatic), or outside the liver (extrahepatic) in the bile duct system. http://purl.obolibrary.org/obo/TXPO_0000264 bile acid accumulation in hepatocyte [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000263 bile acid accumulation in hepatocyte Bile acid accumulation in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the hepatocute in the liver (intrahepatic). This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000265 increasing hepatocellular volume [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000164 increasing hepatocellular volume Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000266 ubiquitin ligase http://purl.obolibrary.org/obo/TXPO_0000171 ligase A role played by the entity that catalyses the transfer of ubiquitin to a substrate protein via the reaction X-ubiquitin + S -> X + S-ubiquitin, where X is either an E2 or E3 enzyme, the X-ubiquitin linkage is a thioester bond, and the S-ubiquitin linkage is an amide bond: an isopeptide bond between the C-terminal glycine of ubiquitin and the epsilon-amino group of lysine residues in the substrate or, in the linear extension of ubiquitin chains, a peptide bond the between the C-terminal glycine and N-terminal methionine of ubiquitin residues. http://purl.obolibrary.org/obo/TXPO_0000267 increasing amount of carbohydrate http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing amount of carbohydrate is a subtype of increasing quantity: A process that changes the amount of carbohydrates to be higher. http://purl.obolibrary.org/obo/TXPO_0000268 bile acid biosynthetic process [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process Bile acid biosynthetic process is a subtype of biosynthetic process: The chemical reactions resulting in the formation of bile acids, any of a group of steroid carboxylic acids occurring in bile. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000269 bile acid transport to hepatocyte http://purl.obolibrary.org/obo/GO_0015721 bile acid and bile salt transport Bile acid transport to hepatocyte is a subtype of bile acid and bile salt transport: A process that transports bile acid within a hepatocyte by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/TXPO_0000271 primitive process http://purl.obolibrary.org/obo/BFO_0000015 process Primitive process is a unit of process. Process series at a certain granular level can appear as one primitive process at the higher level. http://purl.obolibrary.org/obo/TXPO_0000273 cholestasis dependent chemical entity http://purl.obolibrary.org/obo/TXPO_0001731 toxic course dependent chemical entity Cholestasis dependent chemical entity is a subtype of toxic course dependent chemical entity. This entity can participate in the course of cholestasis. http://purl.obolibrary.org/obo/TXPO_0000274 PERK signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) PERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor role. http://purl.obolibrary.org/obo/TXPO_0000275 quality value http://purl.obolibrary.org/obo/BFO_0000031 generically dependent continuant Value of quality. Although this is essentially a role played by quantity, YAMATO doesn't deal with it so for simplicity. http://purl.obolibrary.org/obo/TXPO_0000276 cholestasis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0000273 cholestasis dependent chemical entity Cholestasis dependent gene is a subtype of toxic course dependent chemical entity. This gene can participate in the course of cholestasis as a gene product. Gene profile:caonical that described in textbooks or articles. http://purl.obolibrary.org/obo/TXPO_0000277 categorical http://purl.obolibrary.org/obo/TXPO_0000275 quality value This is essentially a value and non-quantitative, therefore, there is no ordering among values, unlike non-categorial values. Categorical quality has typicality which no quantity has. It is generically dependent on entity because it is always referred to with something as a species. http://purl.obolibrary.org/obo/TXPO_0000278 quantity http://purl.obolibrary.org/obo/TXPO_0000275 quality value It is just a quantity independent of what quantity it is of. That is, 10cm and 11cm exist just as it is in the quantity space and are just different. On the other hand, when a thing's length is 10cm long at time t1 and 11cm long at t2, we say the length of the thing CHANGED. The 10cm long of a thing has its identity which persists having possibly different values. Note that quantity is not specifically dependent on anything, but generically dependent on physical entity. http://purl.obolibrary.org/obo/TXPO_0000279 dysfunction of fatty acid degradation [Alcoholic fatty liver] http://purl.obolibrary.org/obo/TXPO_0003361 dysfunction of fatty acid degradation [Lipidosis] Dysfunction of fatty acid degradation is a subtype of hypofunctioning: A process that performs a decreased or insufficient lipid degradation. This entity is a specific course-dependent process. This process can constitute the course of Alcoholic fatty liver. http://purl.obolibrary.org/obo/TXPO_0000280 tumor cell survial http://purl.obolibrary.org/obo/NCIT_C16407 cell survival Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell. http://purl.obolibrary.org/obo/TXPO_0000281 phospholipid accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0001244 phospholipid accumulation Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome. http://purl.obolibrary.org/obo/TXPO_0000283 converting to acetyl CoA http://purl.obolibrary.org/obo/GO_0008152 metabolic process Converting to acetyl CoA is a subtype of metabolic process that transforms into acetyl CoA. http://purl.obolibrary.org/obo/TXPO_0000284 Increaseing fatty acid synthesis substrate http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing fatty acid synthesis substrate is a subtype of increasing quantity: A process that changes the production amount of the substrate of the fatty acid synthesis. http://purl.obolibrary.org/obo/TXPO_0000285 PERK signal transduction pathway http://purl.obolibrary.org/obo/TXPO_0000609 signaling pathway A series of molecular signals mediated by PERK (PKR-like ER kinase). http://purl.obolibrary.org/obo/TXPO_0000286 large (value) http://purl.obolibrary.org/obo/TXPO_0000288 qualitative quantity A value which is greater than the normal or average. http://purl.obolibrary.org/obo/TXPO_0000287 small (value) http://purl.obolibrary.org/obo/TXPO_0000288 qualitative quantity A qualitative value which is lower than the threshold, normal or average. http://purl.obolibrary.org/obo/TXPO_0000288 qualitative quantity http://purl.obolibrary.org/obo/TXPO_0000278 quantity Although these are qualitative values, they are essentially quantitative because they are derived from the quantitative values by introducing threshold value, and hence the values are ordinal. http://purl.obolibrary.org/obo/TXPO_0000293 times quality value http://purl.obolibrary.org/obo/TXPO_0000289 meta attribute value Times quality value is a subtype of meta attribute value. http://purl.obolibrary.org/obo/TXPO_0000296 acute phase proteins coding gene expression via cytokine http://purl.obolibrary.org/obo/GO_0010467 gene expression Acute phase proteins coding gene expression via cytokine is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature acute phase proteins coding gene product or products (proteins or RNA) by cytokine. Casarett & Doull's Toxicology: The Basic Science of Poisons, Eighth Edition http://purl.obolibrary.org/obo/TXPO_0000297 oxidative dependent chemical entity http://purl.obolibrary.org/obo/TXPO_0001731 toxic course dependent chemical entity Oxidative stress dependent chemical entity is a subtype of toxic course dependent chemical entity. This entity can participate in the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000300 attribute http://purl.obolibrary.org/obo/BFO_0000020 specifically dependent continuant This is an abstraction of the kinds at the class level. In the use case, it is sometimes referred to with # operator as a class constraint like "#generic quality". In a common term, it would be called "attribute". Its instance is not equal to its value. The value itself belongs to "quality value". Its instance is still an attribute which refers to a specific quantity. Its instnace plays a quality role like length plays one's height as a quality role. Quality such as one's height, one's weight, etc. are roles, and hence must be defined in the context of respective contexts(entities). Therefore, they are not defined as basic type like length, weight, etc. See "physical" in which a most generic quality is defined. Quality in DOLCE corresponds to quality role type in YAMATO. This is why "quality" is invisible in YAMATO in spite of it knows "quality". http://purl.obolibrary.org/obo/TXPO_0000302 counting generic quality http://purl.obolibrary.org/obo/TXPO_0000309 meta generic quality An attribute that counting numbers of objects and how many times an event happens are essential not to individuals in them but to collectives of objects or events. http://purl.obolibrary.org/obo/TXPO_0000304 number of objects http://purl.obolibrary.org/obo/TXPO_0000302 counting generic quality not numerals but "number" of somethings(=how many things) http://purl.obolibrary.org/obo/TXPO_0000306 protein biosynthesis http://purl.obolibrary.org/obo/GO_0009058 biosynthetic process Protein biosynthesis is a subtype of biosynthetic process:The chemical reactions resulting in the formation of proteins. http://purl.obolibrary.org/obo/TXPO_0000307 weight attribute http://purl.obolibrary.org/obo/TXPO_0002419 force attribute A physical attribute entity inhering in a bearer that has mass near a gravitational body. http://purl.obolibrary.org/obo/TXPO_0000308 lyase http://purl.obolibrary.org/obo/TXPO_0003660 enzyme A role played by the entity which catalyses the cleavage of C-C, C-O, C-N and other bonds by other means than by hydrolysis or oxidation, or conversely adding a group to a double bond. They differ from other enzymes in that two substrates are involved in one reaction direction, but only one in the other direction. When acting on the single substrate, a molecule is eliminated and this generates either a new double bond or a new ring. http://purl.obolibrary.org/obo/TXPO_0000310 area (attribute) http://purl.obolibrary.org/obo/TXPO_0000305 non-meta generic quality A 2-D extent attribute inhering in a bearer by virtue of the bearer's two dimensional extent. http://purl.obolibrary.org/obo/TXPO_0000311 color (attribute) http://purl.obolibrary.org/obo/TXPO_0000305 non-meta generic quality Color as a kind is a generic quality. Red is a subclass of color and/or a value of color as discussed below, and being red is a property of things. The differentiation between red as a value of color and being red as a property is critical. In summary, there are three kinds of red. It is unary rather than binary just like ordinary classes such as animal, car, etc http://purl.obolibrary.org/obo/TXPO_0000312 moving drug to the inside of liver http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into a liver. http://purl.obolibrary.org/obo/TXPO_0000314 apoptosis [liver tumor via ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001026 apoptotic process [Ground glass appearance] A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. This entity is a specific course-dependent process. This process can constitute the course of liver tumor via ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0000315 colorness (quality) http://purl.obolibrary.org/obo/PATO_0000068 qualitative property A composite chromatic quality composed of hue, saturation and intensity parts. http://purl.obolibrary.org/obo/TXPO_0000316 high brightness http://purl.obolibrary.org/obo/PATO_0000016 color brightness quality A color brightness which is relatively high. http://purl.obolibrary.org/obo/TXPO_0000320 acute phase response role http://purl.obolibrary.org/obo/TXPO_0003728 role related to receiving A role played by the entity which receives acute phase response signal and transmits operand(s). http://purl.obolibrary.org/obo/TXPO_0000322 myelin figureformation in lysosome http://purl.obolibrary.org/obo/TXPO_0000134 biological structure formation Lamellar body formation in lysosome is a subtype of biological structure formation: A process that costructs lamellar body in lysosome. http://purl.obolibrary.org/obo/TXPO_0000323 cell death (toxic course) http://purl.obolibrary.org/obo/TXPO_0000009 toxic course The totality of all processes through which cell death is realized. http://purl.obolibrary.org/obo/TXPO_0000324 apoptosis (course) http://purl.obolibrary.org/obo/TXPO_0000323 cell death (toxic course) Apoptosis (course) is a subtype of cell death (course). The totality of all processes through which apoptosis is realized. http://purl.obolibrary.org/obo/TXPO_0000325 increasing drug metabolite [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002364 increasing drug metabolite Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0000326 pyroptosis (course) http://purl.obolibrary.org/obo/TXPO_0000323 cell death (toxic course) Pyroptosis (course) is a subtype of cell death (course). The totality of all processes through which pyroptosis is realized. http://purl.obolibrary.org/obo/TXPO_0000327 apoptosis regulator role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role Apoptosis modulator is a role played by any substance that regulates the process of apoptosis (programmed cell death) in multi-celled organisms. http://purl.obolibrary.org/obo/TXPO_0000328 ion channel http://purl.obolibrary.org/obo/TXPO_0003639 channel A role played by the entity which enables the facilitated diffusion of an ion (by an energy-independent process) by passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. May be either selective (it enables passage of a specific ion only) or non-selective (it enables passage of two or more ions of same charge but different size). http://purl.obolibrary.org/obo/TXPO_0000329 inhibitor of tumor cell activity role http://purl.obolibrary.org/obo/TXPO_0003725 regulator of tumor cell activity role A role played by the entity that ihibits the activity of tumor cells. http://purl.obolibrary.org/obo/TXPO_0000330 transcription regulator http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role that controls the rate, timing and/or magnitude of transcription of genetic information. The function of transcriptional regulators is to modulate gene expression at the transcription step so that they are expressed in the right cell at the right time and in the right amount throughout the life of the cell and the organism. http://purl.obolibrary.org/obo/TXPO_0000331 drug transmembrane transporter http://purl.obolibrary.org/obo/TXPO_0003698 transmembrane transporter A role played by the entity which enables the transfer of a drug from one side of a membrane to the other. A drug is any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease. http://purl.obolibrary.org/obo/TXPO_0000332 genome http://purl.obolibrary.org/obo/GO_0005575 cellular_component The totality of genetic information belonging to a cell or an organism; in particular, the DNA that carries this information. http://purl.obolibrary.org/obo/TXPO_0000333 separating http://purl.obolibrary.org/obo/TXPO_0000261 changing relationship between operands Separating is a subtype of changing between operands: A process that divides the whole object into multiple components. http://purl.obolibrary.org/obo/TXPO_0000334 hyperfunction of Kupffer cell differentiation [Phospholipidosis (excessive defense)] http://purl.obolibrary.org/obo/TXPO_0000636 hyperfunction of Kupffer cell differentiation [Phospholipidosis] Hyperfunction of Kupffer cell differentiation is a subtype of hyperfunction of cell differentiation: A process that performs an excesssive kupffer cell differentiation. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense). http://purl.obolibrary.org/obo/TXPO_0000335 ATF6 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role. http://purl.obolibrary.org/obo/TXPO_0000336 amino acid conjugatied bile acid transport into bile canaliculus http://purl.obolibrary.org/obo/GO_0015722 canalicular bile acid transport Amino acid conjugatied bile acid transport into bile canaliculus is a subtype of canalicular bile acid transport: A process that enables the transfer of amino acid conjugated bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus. http://purl.obolibrary.org/obo/TXPO_0000337 changing fluidity http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing fluidity is a subtype of changing quality: A process that changes the fluidity of the object. http://purl.obolibrary.org/obo/TXPO_0000338 cell proliferation [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000339 tumor cell proliferation http://purl.obolibrary.org/obo/GO_0008283 cell proliferation Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population. http://purl.obolibrary.org/obo/TXPO_0000340 tumor cell proliferation [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000341 increasing number of dead cells in liver http://purl.obolibrary.org/obo/TXPO_0000093 increasing number of objects Increasing number of dead cells in liver is a subtype of increasing number of objects: A process that becomes larger in the number of dead cells in the liver. http://purl.obolibrary.org/obo/TXPO_0000342 increasing number of dead cells in liver [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000343 decomposing http://purl.obolibrary.org/obo/TXPO_0000333 separating Decomposing is a subtype of separating: A process that divides a whole object into constituents. http://purl.obolibrary.org/obo/TXPO_0000344 increasing number of action http://purl.obolibrary.org/obo/TXPO_0000387 changing Increasing number of action is a subtype of changing: A process that becomes larger in the number of actions or activities. http://purl.obolibrary.org/obo/TXPO_0000345 increasing autodigestion of abnormal lysosome http://purl.obolibrary.org/obo/TXPO_0000484 increasing autophagy Increasing autodigestion of abnormal lysosome is a subtype of increasing autophagy: A process that becomes larger in the number of autodigestion of abnormal lysosome. http://purl.obolibrary.org/obo/TXPO_0000346 hypofunction of ATP biosynthesis [cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000347 increasing number of bile duct in liver http://purl.obolibrary.org/obo/TXPO_0000093 increasing number of objects Increasing number of bile duct in liver is a subtype of increasing number of objects: A process that becomes larger in the number of bile duct in the liver. http://purl.obolibrary.org/obo/TXPO_0000348 decreasing number of objects http://purl.obolibrary.org/obo/TXPO_0000387 changing Decreasing number of objects is a subtype of changing: A process that becomes smaller in number of physical objects. http://purl.obolibrary.org/obo/TXPO_0000349 cleavage of ATF6-alpha by S2P [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Cleavage of ATF6-alpha by S2P is a subtype of proteolysis: A process n which ATF6-alpha is cleaved by endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000350 cholestasis process [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001345 cholestasis (primitive process) Cholestasis (primitive process) is a subtype of stagnating: A process that changes the bile flow to be slower due to obstruction. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000351 decreasing number of cells http://purl.obolibrary.org/obo/TXPO_0000348 decreasing number of objects Decreasing number of cells is a subtype of decreasing number of objects: A process that becomes smaller in number of cells. http://purl.obolibrary.org/obo/TXPO_0000352 increasing concentration http://purl.obolibrary.org/obo/TXPO_0002438 changing concentration Increasing concentration is a subtype of changing concentration: A process that changes the concentration of the object to be higher. http://purl.obolibrary.org/obo/TXPO_0000353 increasing calcium ion concentration in blood http://purl.obolibrary.org/obo/TXPO_0000352 increasing concentration Increasing calcium ion concentration in blood is a subtype of increasing concentration: A process that changes the calcium ion concentration in the blood to be higher. http://purl.obolibrary.org/obo/TXPO_0000354 increase in intracellular calcium level http://purl.obolibrary.org/obo/TXPO_0000353 increasing calcium ion concentration in blood Increase in intracellular calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a cell to be higher. http://purl.obolibrary.org/obo/TXPO_0000355 increase in intracellular calcium level [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Increase in intracellular calcium level is a subtype of increase in calcium level: A process that changes the calcium ion concentration within a cell to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000356 amino acid conjugatied bile acid transport into bile canaliculus [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000336 amino acid conjugatied bile acid transport into bile canaliculus Amino acid conjugatied bile acid transport into bile canaliculus is a subtype of canalicular bile acid transport: A process that enables the transfer of amino acid conjugated bile acid from one side of a hepatocyte plasma membrane into a bile canaliculus. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0000357 PERK activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher. http://purl.obolibrary.org/obo/TXPO_0000358 AMPK activation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000359 decreasing blood flow http://purl.obolibrary.org/obo/TXPO_0002672 decreasing flow Decreasing blood flow is a subtype of decreasing flow: A process that changes the blood flow to be smaller. http://purl.obolibrary.org/obo/TXPO_0000360 Oxidative dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0000297 oxidative dependent chemical entity Oxidative stress dependent chemical compound is a subtype of toxic course dependent chemical entity. This entity (drug) can participate in the course of Oxidative stress. http://purl.obolibrary.org/obo/TXPO_0000361 increasing demand for response to stress http://purl.obolibrary.org/obo/TXPO_0000633 increasing functional demand Increasing demand for response to stress is a subtype of increasing functional demand: A process that changes the functional demand for the response to the stress to be higher. http://purl.obolibrary.org/obo/TXPO_0000362 increasing demand for response to ER stress http://purl.obolibrary.org/obo/TXPO_0000361 increasing demand for response to stress Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the endoplasmic reticulum (ER) stress to be higher. http://purl.obolibrary.org/obo/TXPO_0000363 increasing demand for response to ER stress [ER stress (severe) ] http://purl.obolibrary.org/obo/TXPO_0000734 increasing demand for response to ER stress [ER stress] Increasing demand for response to ER stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the edoplasmic reticulum (ER) stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress (severe) . http://purl.obolibrary.org/obo/TXPO_0000364 increasing production quantity of ROS http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increaseing production quantity of ROS is a subtype of increasing quantity: A process that changes the production amount of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen, to be higher. http://purl.obolibrary.org/obo/TXPO_0000365 increasing production quantity of RNS http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing production quantity of RNS is a subtype of increasing quantity: A process that changes the production amount of reactive nitrogen species (RNS) to be higher http://purl.obolibrary.org/obo/TXPO_0000366 increasing calcium ion inflow into cell http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing calcium ion is a subtype of increasing quantity: A process that changes the calcium ion becomes larger. http://purl.obolibrary.org/obo/TXPO_0000367 increasing sodium ion inflow into cell http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing sodium ion inflow into cell is a subtype of increasing quantity: A process that changes the sodium ion inflow into the cell to be larger. http://purl.obolibrary.org/obo/TXPO_0000368 increasing extracellular potassium outflow http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity increasing extracellular potassium outflow is a subtype of increasing quantity: A process that changes the phospholipid inflow into the hepatocyte to be larger. http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process http://purl.obolibrary.org/obo/TXPO_0000113 controlling Negative regulation process is a subtype of controlling: A process that that stops, prevents, or reduces the frequency, rate or extent of function. http://purl.obolibrary.org/obo/TXPO_0000370 negative regulation of cell cycle G2/M phase transition http://purl.obolibrary.org/obo/TXPO_0000548 negative regulation of cell cycle Negative regulation of cell cycle G2/M phase transition is a subtype of negative regulation of cell cycle: Any process that stops, prevents or reduces the frequency, rate or extent of cell cycle G2/M phase transition. http://purl.obolibrary.org/obo/TXPO_0000371 negative regulation of apoptotic process [ER stress (mild)] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. This entity is a specific course-dependent process. This process can constitute the course of ER stress (mild). http://purl.obolibrary.org/obo/TXPO_0000373 drug metabolism phase I by Cytochrome P450 [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily . This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0000374 regulation of cell cycle [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Any process that modulates the rate or extent of progression through the cell cycle. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000375 Gene expression by transcriptional regulator http://purl.obolibrary.org/obo/GO_0010467 gene expression The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA) by transcription factor http://purl.obolibrary.org/obo/TXPO_0000376 cell survival [ER stress] http://purl.obolibrary.org/obo/NCIT_C16407 cell survival Cell survial is a subtype of keeong quantity: A process that keeps the viability of a cell. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000377 normal cell survival [Cell death] http://purl.obolibrary.org/obo/NCIT_C16407 cell survival Cell survial is a subtype of keeong quantity: A process that keeps the viability of a cell. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000378 functioning process http://purl.obolibrary.org/obo/TXPO_0000145 function-related process Functioning process is a subtype of function-related process: A process that executes and manifests function. http://purl.obolibrary.org/obo/TXPO_0000379 receiving http://purl.obolibrary.org/obo/TXPO_0000378 functioning process Receiving is a subtype of functioning process: A process that that gets an object as input. http://purl.obolibrary.org/obo/TXPO_0000380 making existence http://purl.obolibrary.org/obo/TXPO_0000378 functioning process Making existence is a subtype of functioning process: A process that makes a target object to be present in another object. http://purl.obolibrary.org/obo/TXPO_0000381 generating http://purl.obolibrary.org/obo/TXPO_0000378 functioning process Generating is a subtype of funcioning: A process that produces output from nothing. http://purl.obolibrary.org/obo/TXPO_0000382 protein production http://purl.obolibrary.org/obo/TXPO_0000019 generating substance Protein production is a subtype of generating: A process that synthesizes protein (s) resulting in having output (s). http://purl.obolibrary.org/obo/TXPO_0000383 abnormal protein-degrading enzyme production [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Abnormal protein-degrading enzyme production is a subtype of protein production: A process that makes existent of an abnormal protein-degrading enzyme protein due to biosynthesis or secretion resulting in an increase in its levels. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000384 chaperon production http://purl.obolibrary.org/obo/TXPO_0000382 protein production Chaperon production is a subtype of protein production: A process that makes existent of a protein with a chaperon role due to biosynthesis or secretion resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0000385 abnormal protein-degrading enzyme production http://purl.obolibrary.org/obo/TXPO_0000382 protein production Abnormal protein-degrading enzyme production is a subtype of protein production: A process that makes existent of an abnormal protein-degrading enzyme protein due to biosynthesis or secretion resulting in an increase in its levels. http://purl.obolibrary.org/obo/TXPO_0000386 positive regulation of ERAD [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Any process that activates or increases the frequency, rate or extent of ERAD pathway. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000387 changing http://purl.obolibrary.org/obo/TXPO_0000380 making existence Changing is a subtype of making existence: A process that makes a target object different. http://purl.obolibrary.org/obo/TXPO_0000388 PERK autophosphorylation [ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0000674 PERK autophosphorylation [ER stress] PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation). This process is dependent on the translation attenuation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000389 converting signal to information http://purl.obolibrary.org/obo/TXPO_0002567 converting to information Converting signal to information is a subtype of converting to information: A process that changes a signal to information. http://purl.obolibrary.org/obo/TXPO_0000390 converting signal to information [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Converting signal to information is a subtype of converting to information: A process that changes a signal to information. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000391 converting signal to information [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Converting signal to information is a subtype of converting to information: A process that changes a signal to information. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000392 changing an operand http://purl.obolibrary.org/obo/TXPO_0000387 changing Changing an operand is a subtype of changing: A process that makes one object different. http://purl.obolibrary.org/obo/TXPO_0000393 membrane phospholipid catabolic process http://purl.obolibrary.org/obo/GO_0009395 phospholipid catabolic process Membrane phospholipid catabolic process is a subtype of lipid catabolic process: The chemical reactions resulting in the breakdown of membrane phopholipids http://purl.obolibrary.org/obo/TXPO_0000394 changing quantity http://purl.obolibrary.org/obo/TXPO_0000392 changing an operand Changing quantity is a subtype of changing attribute: A process that changes the amount of the object as an output. http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity http://purl.obolibrary.org/obo/TXPO_0000394 changing quantity Increasing quantity is a subtype of changing quantity: A process that changes the magnitude of the object to be larger. http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity http://purl.obolibrary.org/obo/TXPO_0000394 changing quantity Decreasing quantity is a subtype of changing quantity: A process that changes the magnitude of the object to be smaller. http://purl.obolibrary.org/obo/TXPO_0000397 decreasing production quantity of protein [ER stress] http://purl.obolibrary.org/obo/TXPO_0001830 decreasing production quantity of protein Decreasing production quantity of protein is a subtype of decreasing quantity: A process that changes the production quantity of the protein to be lower. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000398 hyperfunction of hypoxia resonsive gene expression http://purl.obolibrary.org/obo/TXPO_0002345 hyperfunction of gene expression Hyperfunction of hypoxia resonsive gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive hypoxia resonsive gene expression. http://purl.obolibrary.org/obo/TXPO_0000399 gene expression [Cell death] http://purl.obolibrary.org/obo/GO_0010467 gene expression The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA or circRNA (for protein-coding genes) and the translation of that mRNA or circRNA into protein. Protein maturation is included when required to form an active form of a product from an inactive precursor form. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000400 uncoupling dependent chemical entity http://purl.obolibrary.org/obo/TXPO_0002012 mitochondrial damage dependent chemical entity Uncoupling dependent chemical entity is a subtype of toxic course dependent chemical entity. This entity can participate in the course of uncoupling of mitochondrial damage. http://purl.obolibrary.org/obo/TXPO_0000401 activating http://purl.obolibrary.org/obo/TXPO_0000020 changing activity Activating is a subtype of changing activity: A process that changes the activity of the object to be higher. http://purl.obolibrary.org/obo/TXPO_0000402 PERK activation [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000403 NRF2 activation by PERK [ER stress (mild)] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process NRF2 activation by PERK is a subtype of NRF2 activation: A process that changes the activity of NRF2 (Nuclear Factor, Erythroid 2 Like 2) to be higher by PERK. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000405 AMPK activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher. http://purl.obolibrary.org/obo/TXPO_0000406 positive regulation of autophagy by AMPK http://purl.obolibrary.org/obo/GO_0010508 positive regulation of autophagy Positive regulation of autophagy by AMPK is a subtype of positive regulation of autophagy: A process that that activates or increases the frequency, rate or extent of autophagy by AMPK. http://purl.obolibrary.org/obo/TXPO_0000407 GRP78 activation by MLX http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation GRP78 activation by MLX is a subtype of molecular activation: A process that changes the activity of the GRP78/ HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) to be higher by MLX. http://purl.obolibrary.org/obo/TXPO_0000408 PLA2 activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation PLA2 activation is a subtype of molecular activation: A process that changes the activity of the member of the phospholipase A2 family (PLA2) to be higher. http://purl.obolibrary.org/obo/TXPO_0000409 protease activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation Protease activation is a subtype of molecular activation: A process that changes the activity of the molecule with a protease role to be higher. http://purl.obolibrary.org/obo/TXPO_0000410 changing shape http://purl.obolibrary.org/obo/TXPO_0002566 changing structure Changing shape is a subtype of changing structure: A process that changes the form of the operand. http://purl.obolibrary.org/obo/TXPO_0000411 liver X receptor activation http://purl.obolibrary.org/obo/TXPO_0000158 nuclear receptor activation Liver X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating LXR ( liver X receptor) with a nuclear receptor role to be higher. http://purl.obolibrary.org/obo/TXPO_0000412 changing membrane fluidity http://purl.obolibrary.org/obo/TXPO_0000337 changing fluidity Changing membrane fluidity is a subtype of changing fluidity: A process that changes the fluidity of the membrane. http://purl.obolibrary.org/obo/TXPO_0000413 positive regulation of protein refolding [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Any process that activates or increases the frequency, rate or extent of protein refolding. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000414 keeping quantity http://purl.obolibrary.org/obo/TXPO_0000394 changing quantity Keeping quantity is a subtype of changing amount: A process that maintains the magnitude of the object at a constant level . http://purl.obolibrary.org/obo/TXPO_0000415 changing quality http://purl.obolibrary.org/obo/TXPO_0000392 changing an operand Changing quality is a subtype of changing an operand: A process that changes the quality of the object. http://purl.obolibrary.org/obo/TXPO_0000416 negative regulation of formation of cytoplasmic translation initiation complex by eIF2a [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Negative regulation of formation of cytoplasmic translation initiation complex by eIF2a is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex by eIF2a. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000417 changing volume http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing volume is a subtype of changing quality: A process that changes the volume of the object. http://purl.obolibrary.org/obo/TXPO_0000418 homeostatic imbalance of number of smooth endoplasmic reticulum http://purl.obolibrary.org/obo/TXPO_0000567 imbalance Homeostatic imbalance of number of smooth endoplasmic reticulum is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the proliferation and elimination of smooth endoplasmic reticulum. http://purl.obolibrary.org/obo/TXPO_0000421 keeps volume http://purl.obolibrary.org/obo/TXPO_0000417 changing volume Keeps volume is a subtype of changing volume: A process that keeps the volume of the object. http://purl.obolibrary.org/obo/TXPO_0000422 changing density http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing density is a subtype of changing quality: A process that changes the density of the object. http://purl.obolibrary.org/obo/TXPO_0000424 changing hardness http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing hardness is a subtype of changing quality: A process that changes the hardness of the object. http://purl.obolibrary.org/obo/TXPO_0000425 changing phase http://purl.obolibrary.org/obo/TXPO_0000392 changing an operand Changing phase is a subtype of changing an operand: A process that changes the phase of the operand. http://purl.obolibrary.org/obo/TXPO_0000426 solidifying http://purl.obolibrary.org/obo/TXPO_0000425 changing phase Solidifying is a subtype of changing phase: A process that changes the phase of the operand to a solid phase. http://purl.obolibrary.org/obo/TXPO_0000427 vaporizing http://purl.obolibrary.org/obo/TXPO_0000425 changing phase Vaporizing is a subtype of changing phase: A process that changes the phase of the operand to a vapor phase. http://purl.obolibrary.org/obo/TXPO_0000428 liquefying http://purl.obolibrary.org/obo/TXPO_0000425 changing phase Liquefying is a subtype of changing phase: A process that changes the phase of the operand to a liquid phase. http://purl.obolibrary.org/obo/TXPO_0000429 moving http://purl.obolibrary.org/obo/TXPO_0000392 changing an operand Moving is a subtype of changing an operand: A process that change the location of the operand. http://purl.obolibrary.org/obo/TXPO_0000430 elevating http://purl.obolibrary.org/obo/TXPO_0000429 moving Elevating is a subtype of moving: A process that changes the location of the operand from a lower to a higher place or position. http://purl.obolibrary.org/obo/TXPO_0000431 lowering http://purl.obolibrary.org/obo/TXPO_0000429 moving Lowering is a subtype of moving: A process that changes the location of the operand from a higher to a lower place or position. http://purl.obolibrary.org/obo/TXPO_0000432 moving fluid http://purl.obolibrary.org/obo/TXPO_0000429 moving Moving fluid is a subtype of moving: A process that changes the location of the liquid. http://purl.obolibrary.org/obo/TXPO_0000433 keeping position http://purl.obolibrary.org/obo/TXPO_0000429 moving Keeping position is a subtype of moving: A process that maintains in the fixed position. http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process http://purl.obolibrary.org/obo/TXPO_0000145 function-related process Malfunctioning process is a subtype of function-related process: A process that cannot perform a function appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0000435 hyperfunctioning http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process Hyperfunctioning is a subtype of malfunctioning process: A process that performs an excessive function. http://purl.obolibrary.org/obo/TXPO_0000436 hypofunctioning http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process Hypofunctioning is a subtype of malfunctioning process: A process that performs a decreased or insufficient functioning. http://purl.obolibrary.org/obo/TXPO_0000437 arresting function http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process Arresting function is a subtype of malfunctioning process: A process that arrests the progress of function execution. http://purl.obolibrary.org/obo/TXPO_0000438 dysfunctioning http://purl.obolibrary.org/obo/TXPO_0000436 hypofunctioning Dysfunctioning is a subtype of malfunctioning process: A process that performs an abnormal and incomplete functioning. http://purl.obolibrary.org/obo/TXPO_0000439 loss of function (process) http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process Loss of function (process) is a subtype of malfunctioning process: A process that results in no longer having a function or the process that gradually loses it. http://purl.obolibrary.org/obo/TXPO_0000440 negative regulation of phospholipase C mediated phosphatidylinositol degradation http://purl.obolibrary.org/obo/TXPO_0001659 negative regulation of phosphatidylinositol degradation Negative regulation of phospholipase C mediated phosphatidylinositol is a subtype of negative regulation of phospholipase C mediated phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase C mediated phosphatidylinositol degradation. http://purl.obolibrary.org/obo/TXPO_0000441 sifting http://purl.obolibrary.org/obo/TXPO_0000261 changing relationship between operands Sifting is a subtype of changing between operands: A process to move an operand from one medium to another medium. http://purl.obolibrary.org/obo/TXPO_0000442 transmitting http://purl.obolibrary.org/obo/TXPO_0000441 sifting Transmitting is a subtype of sifting: A process to send out an operand from a medium A to a medium B. http://purl.obolibrary.org/obo/TXPO_0000443 hyperfunction of drug metabolism [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002347 hyperfunction of drug metabolism Hyperfunction of drug metabolism is a subtype of hyperfunctioning of metabolism: A process that performs an excessive drug metabolism. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0000444 caspase signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase. http://purl.obolibrary.org/obo/TXPO_0000445 caspase signaling (primitive) [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000446 caspase signaling (primitive) [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Caspase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000447 extrinsic (Death Domain) signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Death Domain sgnaling (primitive) is a subtype of signaling [biological]: A process in which a signal is transmitted from the cell membrane receptor starting with a ligand. The death domain at the cytoplsmic tail of the receptor binds the other death domain of the docking protein to form a death-inducing signaling complex (DISC). http://purl.obolibrary.org/obo/TXPO_0000448 extrinsic (Death domain) signaling (primitive) [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Death Domain signaling (primitive) is a subtype of signaling [biological]: A process in which a signal is transmitted from the cell membrane receptor starting with a ligand. The death domain at the cytoplsmic tail of the receptor binds the other death domain of the docking protein to form a death-inducing signaling complex (DISC). This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000449 NRF2 signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) NRF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the NRF2. http://purl.obolibrary.org/obo/TXPO_0000450 NRF2 signaling (primitive) [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process NRF2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the NRF2. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000452 p53 signaling (primitive) [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process P53 signaling (primitive) isis a subtype of signaling [biological]: A process that in which a signal is transmitted by the p53. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000453 p53 signaling (primitive) [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by p53. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000454 PERK signaling (primitive) [PERK pathway] http://purl.obolibrary.org/obo/TXPO_0000274 PERK signaling (primitive) PERK signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the PERK. PERK generally plays a endoplasmic reticulum membrane stress sensor role. This entity is a specific course-dependent process. This process can constitute the course of PERK pathway. http://purl.obolibrary.org/obo/TXPO_0000455 increasing demand for response to oxidative stress [Oxidative stress] http://purl.obolibrary.org/obo/TXPO_0001730 oxidative stress dependent process Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to oxidative stress: A process that changes the functional demand for the response to the oxidative stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress. http://purl.obolibrary.org/obo/TXPO_0000456 retrograde protein transport from ER to cytosol [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process The directed movement of unfolded or misfolded proteins from the endoplasmic reticulum to the cytosol through the translocon. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000457 release of arachidonic acid from cell membrane http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The process that results in the movement of arachidonic acid from the cell membrane. http://purl.obolibrary.org/obo/TXPO_0000458 removing (from A) http://purl.obolibrary.org/obo/TXPO_0002577 taking Removing (from A) is a subtype of taking: A process that takes an unnecessary operand from a medium. http://purl.obolibrary.org/obo/TXPO_0000459 giving http://purl.obolibrary.org/obo/TXPO_0000441 sifting Giving is a subtype of sifting: A process that provides an object to a medium. http://purl.obolibrary.org/obo/TXPO_0000460 ER to Golgi transport http://purl.obolibrary.org/obo/GO_0006810 transport ER to Golgi transport is a subtype of transport: A process of the directed movement of substances from the endoplasmic reticulum (ER) to the Golgi. http://purl.obolibrary.org/obo/TXPO_0000461 oxidation-antioxidtion inbalance [Oxidative stress] http://purl.obolibrary.org/obo/TXPO_0002748 oxidation-antioxidtion inbalance Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation. This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress. http://purl.obolibrary.org/obo/TXPO_0000462 detaching http://purl.obolibrary.org/obo/TXPO_0000333 separating Detaching is a subtype of separating: A process that disaggregates the whole object into constituent components. http://purl.obolibrary.org/obo/TXPO_0000463 Dissociation of PERK:BIP Heterodimer [ER stress translation attenuation] http://purl.obolibrary.org/obo/TXPO_0002213 Dissociation of PERK:BIP Heterodimer [ER stress] Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK. This process is dependent on the translation attenuation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0000464 changing position http://purl.obolibrary.org/obo/TXPO_0000261 changing relationship between operands Changing position is a subtype of changing between operands: A process that that changes the relative position between objects. http://purl.obolibrary.org/obo/TXPO_0000465 changing distance http://purl.obolibrary.org/obo/TXPO_0000464 changing position Changing distance is a subtype of changing position: A process that changes the relative position between objects. http://purl.obolibrary.org/obo/TXPO_0000466 increasing distance http://purl.obolibrary.org/obo/TXPO_0000465 changing distance Increasing distance is a subtype of changing distance: A process that keeps object A away from object B. http://purl.obolibrary.org/obo/TXPO_0000467 increasing free radical [Oxidative stress] http://purl.obolibrary.org/obo/TXPO_0001790 increasing free radical Increasing free radical is a subtype of increasing quantity: A process that changes the amount of free radicals to be larger. This entity is a specific course-dependent process. This process can constitute the course of Oxidative stress. http://purl.obolibrary.org/obo/TXPO_0000468 assembling http://purl.obolibrary.org/obo/TXPO_0002568 changing composition Assembling is a subtype of changing composition: A process that combines multiple components as one configuration. http://purl.obolibrary.org/obo/TXPO_0000469 joining http://purl.obolibrary.org/obo/TXPO_0002569 combining Joining is a subtype of combining: A process that makes bonds between the components. http://purl.obolibrary.org/obo/TXPO_0000470 lysosome homeostasis http://purl.obolibrary.org/obo/GO_0042592 homeostatic process Lysosome homeostasis is a subtype of homeostatic process: A process that that preserves a lysosome in a stable functional or structural state. http://purl.obolibrary.org/obo/TXPO_0000471 signaling http://purl.obolibrary.org/obo/TXPO_0000442 transmitting Signaling is a subtype of transmitting: A process that transmits signals from medium A to medium B. http://purl.obolibrary.org/obo/TXPO_0000472 ground glass appearance dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0000984 ground glass appearance dependent chemical entity Ground glass appearance dependent molecule is a subtype of toxic course dependent chemical entity. This molecule can participate in the course of ground glass appearance as a gene product. Gene profile:caonical that described in textbooks or articles. http://purl.obolibrary.org/obo/TXPO_0000473 hyperfunction of increasing number http://purl.obolibrary.org/obo/TXPO_0001724 hyperfunction of increasing Hyperfunction of increasing number is a subtype of hyperfunction of increasing: A process that performs an excessive nu,ber of the object. http://purl.obolibrary.org/obo/TXPO_0000474 keeping quality http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Keeping quality is a subtype of changing quality: A process that keeps the quality of the object constant. http://purl.obolibrary.org/obo/TXPO_0000475 changing pressure http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing pressure is a subtype of changing quality: A process that changes the pressure of the object . http://purl.obolibrary.org/obo/TXPO_0000476 changing temperature http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing temperature is a subtype of changing quality: A process that changes the temperature of the object. http://purl.obolibrary.org/obo/TXPO_0000477 insulin signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Insulin signaling (primitive) is a subtype of signaing (primitive), in which a signal mediated by insulin. http://purl.obolibrary.org/obo/TXPO_0000478 hyperfunction of long-chain fatty acid import into peroxisome http://purl.obolibrary.org/obo/TXPO_0002351 hyperfunction of transport Hyperfunction of lipid transport to peroxisome is a subtype of hyperfunction of transport: A process that performs an excesssive lipid transport to peroxisome. http://purl.obolibrary.org/obo/TXPO_0000479 hyperfunction of long-chain fatty acid import into peroxisome [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Hyperfunction of long-chain fatty acid import into peroxisome is a subtype of hyperfunction of transport: A process that performs an excesssive long-chain fatty acid import into peroxisome. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0000480 hyperfunction of lipid transport to mitochondria http://purl.obolibrary.org/obo/TXPO_0002351 hyperfunction of transport Hyperfunction of lipid transport to mitochondria is a subtype of hyperfunction of transport: A process that performs an excesssive lipid transport to mitochondria. http://purl.obolibrary.org/obo/TXPO_0000481 decreased membrane potential http://purl.obolibrary.org/obo/PATO_0001462 membrane potential A mebrane potential which is relatively low. http://purl.obolibrary.org/obo/TXPO_0000482 insufficient functioning http://purl.obolibrary.org/obo/TXPO_0000436 hypofunctioning Insufficient functioning is a subtype of malfunctioning process: A process that lacks performing the function required. http://purl.obolibrary.org/obo/TXPO_0000483 glutathione depletion http://purl.obolibrary.org/obo/TXPO_0000602 depleting Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione. http://purl.obolibrary.org/obo/TXPO_0000484 increasing autophagy http://purl.obolibrary.org/obo/TXPO_0000344 increasing number of action Increasing autophagy is a subtype of increasing number of actions: A process that becomes larger in the number of autophagy. http://purl.obolibrary.org/obo/TXPO_0000485 ATP depletion http://purl.obolibrary.org/obo/TXPO_0000602 depleting ATP depletion is a subtype of depleting: A process that lessens markedly in the amount of adenosine triphosphate (ATP) . http://purl.obolibrary.org/obo/TXPO_0000486 ATP depletion [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process ATP depletion is a subtype of depleting: A process that lessens markedly in the amount of adenosine triphosphate (ATP) . This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0000487 autophagy inducer http://purl.obolibrary.org/obo/TXPO_0002629 autophagy regulator role Autophagy inducer is a role played by any compound that promotes the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell). http://purl.obolibrary.org/obo/TXPO_0000488 accumulation of fluids http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object Accumulation of fluids is a subtype of accumulation of substances in a biological object: A process that keeps fluid in an organism, tissue, organelle, or cell. http://purl.obolibrary.org/obo/TXPO_0000489 in vivo assay http://purl.obolibrary.org/obo/OBI_0000070 assay A laboratory test or analysis of the biological properties or activities of a substance performed by testing its effect on an organism. http://purl.obolibrary.org/obo/TXPO_0000490 ligand molecule [signal transduction system] http://purl.obolibrary.org/obo/TXPO_0001821 signal transduction system dependent molecule Ligand molecule is a subtype of signaling dependent molecule. This entity is dependent on a signal transduction system and can participate in signaling process. http://purl.obolibrary.org/obo/TXPO_0000491 excretory tube http://purl.obolibrary.org/obo/UBERON_0000025 tube (anatomical) A tube that is part of a excretory system. http://purl.obolibrary.org/obo/TXPO_0000492 glycogen accumulation http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object Glycogen accumulation is a subtype of accumulation of substances in a biological object: A process that keeps glycogen in a biological object. http://purl.obolibrary.org/obo/TXPO_0000493 toxicological imbalance L arachidonate + ethanolaminium(1+) http://purl.obolibrary.org/obo/TXPO_0001545 hypofunction of phosphoethanolamine degradation http://purl.obolibrary.org/obo/TXPO_0001418 hypofunction of glycerophospholipid degradation Hypofunction of phosphoethanolamine degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phosphoethanolamine degradation. http://purl.obolibrary.org/obo/TXPO_0001546 regulation of hepatocyte cell cycle [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0001580 regulation of hepatocyte cell cycle [hypertrophy] Regulation of hepatocyte cell cycle is a subtype of regulation of cell cycle: A process that modulates the frequency, rate or extent of hepatocyte cell cycle. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0001547 p53 signaling (primitive) [Phospholipidosis (excessive defense) ] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process P53 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by p53. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0001548 hydroxylysine kinase http://purl.obolibrary.org/obo/TXPO_0001515 kinase Catalysis role of the reaction: erythro-5-hydroxy-L-lysine + GTP = 5-phosphonooxy-L-lysine + GDP + 2 H(+) http://purl.obolibrary.org/obo/TXPO_0001550 hypofunction of drug metabolism phase I http://purl.obolibrary.org/obo/TXPO_0002190 hypofunction of drug metabolism Hypofunction of drug metabolism phase I is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient drug metabolism phase I. http://purl.obolibrary.org/obo/TXPO_0001551 hyperfunction of drug metabolism phase I [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002049 hyperfunction of drug metabolism phase I Hyperfunction of drug metabolism phase I is a subtype of hyperfunction of drug metabolism: A process that performs an excesssive drug metabolism phase I. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001552 Cyp1 http://purl.obolibrary.org/obo/TXPO_0001558 Cytochrome P450 Cyp1 is a subtype of cytochrome P450. http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_0001558 Cytochrome P450 Cyp2 is a subtype of cytochrome P450. http://purl.obolibrary.org/obo/TXPO_0001554 Cyp3 http://purl.obolibrary.org/obo/TXPO_0001558 Cytochrome P450 Cyp3 is a subtype of cytochrome P450. http://purl.obolibrary.org/obo/TXPO_0001555 Cyp4 http://purl.obolibrary.org/obo/TXPO_0001558 Cytochrome P450 Cyp4 is a subtype of cytochrome P450. http://purl.obolibrary.org/obo/TXPO_0001556 hypofunction of cholesterol transport in lysosome [Niemann-Pick type C] . http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Hypofunction of cholesterol transport from lysosome is a subtype of hypofunction of transport: A process that performs a decreased or insufficient cholestsrol transport from lysosomes. This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick type C. http://purl.obolibrary.org/obo/TXPO_0001557 cholesterol transport gene mutation [Niemann Pick Type C] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Cholesteroltransport gene mutation is a subtype of gene mutation: A process thatchanges the sequence of a cholesterol transport gene. This process is dependent on the genetic and can constitute the course of Niemann Pick Type C. http://purl.obolibrary.org/obo/TXPO_0001559 drug metabolism phase I by Cytochrome P450 http://purl.obolibrary.org/obo/TXPO_0000173 drug metabolism phase I Drug metabolism phase I by Cytochrome P450 is a subtype of drug metabolism phase I: A process that is biotransformed by cytochrome P450 (CYP) superfamily . http://purl.obolibrary.org/obo/TXPO_0001561 DNA repair agent role http://purl.obolibrary.org/obo/TXPO_0003712 changer role A role played by the entity to repair the damaged DNA. http://purl.obolibrary.org/obo/TXPO_0001564 amitriptyline metabolism [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Amitriptyline metabolism is a subtype of drug metabolism phase I by Cytochrome P450: A process that that is biotransformed of amitriptyline by cytochrome P450 (CYP) superfamily (CYP2D6, CYP1A2, and CYP2C9. ) This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001565 amitriptyline metabolism phase I http://purl.obolibrary.org/obo/TXPO_0001559 drug metabolism phase I by Cytochrome P450 Amitriptyline metabolism is a subtype of drug metabolism phase I by Cytochrome P450: A process that that is biotransformed of amitriptyline by cytochrome P450 (CYP) superfamily (CYP2D6, CYP1A2, and CYP2C9. ) http://purl.obolibrary.org/obo/TXPO_0001567 long (value) http://purl.obolibrary.org/obo/TXPO_0000286 large (value) A length quality value which is greater than the normal or average. http://purl.obolibrary.org/obo/TXPO_0001569 decreasing ceramide [sphingomyelin disorder ] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Decreasing ceramide is a subtype of decreasing lipid: A process that changes the quantity of the ceramide to be lower. This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder. http://purl.obolibrary.org/obo/TXPO_0001570 hepatocyte cell division http://purl.obolibrary.org/obo/GO_0051301 cell division Hepatocyte cell division is a subtype of cell division: The process resulting in division and partitioning of components of a heoatocyte cell to form more cells. http://purl.obolibrary.org/obo/TXPO_0001571 PPARalpha inactivation http://purl.obolibrary.org/obo/TXPO_0001589 nuclear receptor inactivation PPARalpha inactivation is a subtype of inactivating: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be lower. http://purl.obolibrary.org/obo/TXPO_0001574 short (value) http://purl.obolibrary.org/obo/TXPO_0000287 small (value) A length quality value which is small. http://purl.obolibrary.org/obo/TXPO_0001575 PERK-eIF2a-ATF4-CHOP signal integration system http://purl.obolibrary.org/obo/TXPO_0001533 PERK-eIF2a-ATF4 signal integration system PERK-eIF2a-ATF4 signal integration system signal integration system is a subtype of PERK pathway system. This entity has sub-parts and has a goal of transmitting signals and a gene regulation via PERK, eIF2a, ATF4, and CHOP as a systemic context. http://purl.obolibrary.org/obo/TXPO_0001576 glycerophospholipid metabolism balance http://purl.obolibrary.org/obo/TXPO_0001434 phospholipid metabolism balance Glycerophospholipid metabolism balance is a subtype of phospholipid metabolism balance: A process that keeps a balance of glycerophospholipid metabolism. http://purl.obolibrary.org/obo/TXPO_0001577 glycerophospholipid metabolism balance [phospholipidosis - glycerophospholipid disorder] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Glycerophospholipid metabolism balance is a subtype of phospholipid metabolism balance: A process that keeps a balance of glycerophospholipid metabolism. This process is dependent on the glycerophospholipid disorder and can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001578 heoatocyte growth http://purl.obolibrary.org/obo/GO_0016049 cell growth Heoatocyte growth is a subtype of cell growth: A process that The process in which a hepatocyte, the main structural component of the liver, increases in size. http://purl.obolibrary.org/obo/TXPO_0001579 phosphatidylcholine metabolism balance http://purl.obolibrary.org/obo/TXPO_0001576 glycerophospholipid metabolism balance Phosphatidylcholine metabolism balance is a subtype of glycerophospholipid metabolism balance: A process that keeps a balance of phosphatidylcholine metabolism. http://purl.obolibrary.org/obo/TXPO_0001580 regulation of hepatocyte cell cycle [hypertrophy] http://purl.obolibrary.org/obo/GO_0051726 regulation of cell cycle Regulation of hepatocyte cell cycle [hypertrophy] is a subtype of regulation of cell cycle: A process that modulates the frequency, rate or extent of hepatocyte cell cycle. http://purl.obolibrary.org/obo/TXPO_0001581 stagnating http://purl.obolibrary.org/obo/TXPO_0000711 Deacreasing velocity Stagnating is a subtype of decreasing velocity: A process that changes the flow velocity to be slower or stops it in progress. http://purl.obolibrary.org/obo/TXPO_0001582 increasing distance between hepatocytes [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Increasing distance between hepatocytes is a subtype of increasing distance between cells: A process that places a distance between hepatocytes. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001583 increasing phosphatidylcholine material http://purl.obolibrary.org/obo/TXPO_0001317 increasing glycerophospholipid material Increasing phosphatidylcholine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylcholine material to be larger. http://purl.obolibrary.org/obo/TXPO_0001584 drug metabolic process [Ground glass appearance] http://purl.obolibrary.org/obo/GO_0017144 drug metabolic process The chemical reactions and pathways involving a drug, a substance used in the diagnosis, treatment or prevention of a disease; as used here antibiotic substances (see antibiotic metabolism) are considered to be drugs, even if not used in medical or veterinary practice. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001585 phosphatidylcholine metabolism imbalance http://purl.obolibrary.org/obo/TXPO_0001295 glycerophospholipid metabolism imbalance Phosphatidylcholine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylcholine metabolism. http://purl.obolibrary.org/obo/TXPO_0001587 hyperfunction of Phosphatidylcholine synthesis gene expression http://purl.obolibrary.org/obo/TXPO_0001264 hyperfunction of glycerophospholipid synthesis gene expression Hyperfunction of Phosphatidylcholine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylcholine ssynthetic gene expression. http://purl.obolibrary.org/obo/TXPO_0001588 ground glass appearance with Cytochrome P450 activation by phenobarbital http://purl.obolibrary.org/obo/TXPO_0003857 ground glass appearance with Cytochrome P450 activation [toxic course] The totality of all processes through which ground glass appearance is realized. This toxic course has a process of Cytochrome P450 (CYP) activation by phenobarbital. http://purl.obolibrary.org/obo/TXPO_0001589 nuclear receptor inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation Nuclear receptor inactivation is a subtype of inactivation : A process that changes the activity of the molecule with a nuclear receptor role to be lower. http://purl.obolibrary.org/obo/TXPO_0001590 increasing distance between hepatocytes http://purl.obolibrary.org/obo/TXPO_0001617 increasing distance between cells Increasing distance between hepatocytes is a subtype of increasing distance between cells: A process that places a distance between hepatocytes. http://purl.obolibrary.org/obo/TXPO_0001591 drug metabolism phase II http://purl.obolibrary.org/obo/GO_0017144 drug metabolic process Drug metabolism phase II is a subtype of drug metabolic process: A process that of biotransformation reactions involving conjugate enabling efficient excretion. http://purl.obolibrary.org/obo/TXPO_0001592 increasing phosphatidylethanolamine material http://purl.obolibrary.org/obo/TXPO_0001317 increasing glycerophospholipid material Increasing phosphatidylethanolamine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylethanolamine material to be larger. http://purl.obolibrary.org/obo/TXPO_0001593 drug metabolism phase II [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Drug metabolism phase II is a subtype of drug metabolic process: A process that of biotransformation reactions involving conjugate enabling efficient excretion. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001594 phosphatidylethanolamine metabolism imbalance http://purl.obolibrary.org/obo/TXPO_0001295 glycerophospholipid metabolism imbalance Phosphatidylethanolamine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylethanolamine metabolism. http://purl.obolibrary.org/obo/TXPO_0001595 negative regulation of apoptotic process [Phospholipidosis-sphingomyelin disorder] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder) . http://purl.obolibrary.org/obo/TXPO_0001596 hyperfunctioning of phosphatidylethanolamine synthesis gene expression http://purl.obolibrary.org/obo/TXPO_0001264 hyperfunction of glycerophospholipid synthesis gene expression Hyperfunctioning of phosphatidylethanolamine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylethanolamine synthetic gene expression. http://purl.obolibrary.org/obo/TXPO_0001597 drug metabolism phase I [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Drug metabolism phase I is a subtype of drug metabolic process: A process that of biotransformation reactions involving hydrolysis, reduction, and oxidation or introduces a functional group (such as -OH, -NH2, -SH or -COOH) to increase in the water solubility of a xenobiotic. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001598 negative regulation of phosphatidylethanolamine degradation http://purl.obolibrary.org/obo/TXPO_0001304 negative regulation of glycerophospholipid degradation Negative regulation of phosphatidylethanolamine degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylethanolamine degradation. http://purl.obolibrary.org/obo/TXPO_0001599 xenobiotic glucuronidation [Ground glass appearance] http://purl.obolibrary.org/obo/GO_0052697 xenobiotic glucuronidation The modification of a xenobiotic substance by the conjugation of glucuronic acid. The resultant glucuronosides are often much more water-soluble than the xenobiotic precursor, enabling efficient excretion. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001600 hyperfunction of phosphatidylinositol biosynthesis http://purl.obolibrary.org/obo/TXPO_0001411 hyperfunction of glycerophospholipid biosynthesis Hyperfunction of phosphatidylinositol biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylinositol biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001601 hyperfunction of phosphatidylethanolamine biosynthesis http://purl.obolibrary.org/obo/TXPO_0001411 hyperfunction of glycerophospholipid biosynthesis Hyperfunction of phosphatidylethanolamine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylethanolamine biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001602 hyperfunction of phosphatidylglycerol biosynthesis http://purl.obolibrary.org/obo/TXPO_0001411 hyperfunction of glycerophospholipid biosynthesis Hyperfunction of phosphatidylglycerol biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylglycerol biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001603 hyperfunction of phosphatidylcholine biosynthesis http://purl.obolibrary.org/obo/TXPO_0001411 hyperfunction of glycerophospholipid biosynthesis Hyperfunction of phosphatidylcholine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidylcholine biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001604 hyperfunction of phosphatidyl-L-serine biosynthesis http://purl.obolibrary.org/obo/TXPO_0001411 hyperfunction of glycerophospholipid biosynthesis Hyperfunction of phosphatidyl-L-serine biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidyl-L-serine biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001605 glutathione conjugation [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003991 glutathione conjugation Glutathione conjugation is a subtype of drug metabolism phase II: Glutathione conjugation is a detoxication reaction. Four types of activation reaction have been recognized: direct-acting compounds, conjugates that are activated through cysteine conjugate beta-lyase, conjugates that are activated through redox cycling and lastly conjugates that release the original reactive parent compound. The glutathione S-transferases have three connections with the formation of biactivated conjugatesto make them more soluble for excretion. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001606 increasing phosphatidylglycerol material http://purl.obolibrary.org/obo/TXPO_0001317 increasing glycerophospholipid material Increasing phosphatidylglycerol material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylglycerol material to be larger. http://purl.obolibrary.org/obo/TXPO_0001607 gene expression of cytochrome p450 [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Gene expression of cytochrome p450 is a subtype of gene expression: The process in which a gene sequence is converted into a mature cytochrome p450 gene product or products (proteins or RNA) . This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001608 phosphatidylglycerol metabolism imbalance http://purl.obolibrary.org/obo/TXPO_0001295 glycerophospholipid metabolism imbalance Phosphatidylglycerol metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylglycerol metabolism. http://purl.obolibrary.org/obo/TXPO_0001610 hypofunction of phosphatidylglycerol degradation http://purl.obolibrary.org/obo/TXPO_0001418 hypofunction of glycerophospholipid degradation Hypofunction of phosphatidylglycerol degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylglycerol degradation. http://purl.obolibrary.org/obo/TXPO_0001611 gene expression of cytochrome p450 http://purl.obolibrary.org/obo/GO_0010467 gene expression Gene expression of cytochrome p450 is a subtype of gene expression: The process in which a gene sequence is converted into a mature cytochrome p450 gene product or products (proteins or RNA) . http://purl.obolibrary.org/obo/TXPO_0001612 hyperfunction of phosphatidylglycerol synthesis gene expression http://purl.obolibrary.org/obo/TXPO_0001264 hyperfunction of glycerophospholipid synthesis gene expression Hyperfunction of phosphatidylglycerol synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylglycerol synthetic gene expression. http://purl.obolibrary.org/obo/TXPO_0001613 smooth endoplasmic reticulum membrane organization [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001614 negative regulation of phosphatidylglycerol degradation http://purl.obolibrary.org/obo/TXPO_0001304 negative regulation of glycerophospholipid degradation Negative regulation of phosphatidylglycerol degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylglycerol degradation. http://purl.obolibrary.org/obo/TXPO_0001615 smooth endoplasmic reticulum membrane organization http://purl.obolibrary.org/obo/GO_0090158 endoplasmic reticulum membrane organization Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane. http://purl.obolibrary.org/obo/TXPO_0001616 changing color http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing color is a subtype of changing quality: A process that chnges the color of the object. http://purl.obolibrary.org/obo/TXPO_0001617 increasing distance between cells http://purl.obolibrary.org/obo/TXPO_0000466 increasing distance Increasing distance between cells is a subtype of increasing distance: A process that places a distance between cells. http://purl.obolibrary.org/obo/TXPO_0001618 PPAR alpha inactivation [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process PPARalpha inactivation is a subtype of inactivation: A process that changes the activity of the activating PPAR alpha (Peroxisome Proliferator Activated Receptor Alpha) with a nuclear receptor role to be lower. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0001619 regulation of generation of precursor metabolites and energy [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001620 phosphatidic acid degradation http://purl.obolibrary.org/obo/GO_0046475 glycerophospholipid catabolic process Phosphatidic acid degradation is a subtype of glycerophospholipid catabolic process: A process of the chemical reactions resulting in the breakdown of phosphatidic acid. http://purl.obolibrary.org/obo/TXPO_0001621 hyperfunction of drug metabolism phase I by Cytochrome P450 [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000938 hyperfunction of drug metabolism phase I [Ground glass appearance] Hyperfunction of drug metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001622 hyperfunction of phosphatidic acid biosynthesis http://purl.obolibrary.org/obo/TXPO_0001411 hyperfunction of glycerophospholipid biosynthesis Hyperfunction of phosphatidic acid biosynthesis is a subtype of hyperfunction of glycerophospholipid biosynthesis: A process that performs an excessive phosphatidic acid biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001623 hyperfunction of drug metabolism phase I by Cytochrome P450 http://purl.obolibrary.org/obo/TXPO_0002049 hyperfunction of drug metabolism phase I Hyperfunction of drug metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450. http://purl.obolibrary.org/obo/TXPO_0001624 hyperfunction of phosphosphingolipid biosynthesis http://purl.obolibrary.org/obo/TXPO_0001410 hyperfunction of phospholipid biosynthesis Hyperfunction of phosphosphingolipid biosynthesis is a subtype of hyperfunction of phospholipid biosynthesis: A process that performs an excessive phosphosphingolipid biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001625 hyperfunction of sphingomyelin biosynthesis http://purl.obolibrary.org/obo/TXPO_0001624 hyperfunction of phosphosphingolipid biosynthesis Hyperfunction of sphingomyelin biosynthesis is a subtype of hyperfunction of phosphosphingolipid biosynthesis: A process that performs an excessive sphingomyelin biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001626 ER stress response gene expression via PERK http://purl.obolibrary.org/obo/GO_0010467 gene expression ER stress response gene expression via PERK is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER stress response gene product or products (proteins or RNA) by PERK. http://purl.obolibrary.org/obo/TXPO_0001627 hyperfunction of cytochrome p450 gene expression by phenobarbital (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003858 hyperfunction of cytochrome p450 gene expression by phenobarbital [Ground glass appearance] Hyperfunction of cytochrome p450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0001628 increasing phosphatidic acid material http://purl.obolibrary.org/obo/TXPO_0001317 increasing glycerophospholipid material Increasing phosphatidic acid material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidic acid material to be larger. http://purl.obolibrary.org/obo/TXPO_0001629 hyperfunction of drug metabolism phase I by Cytochrome P450 (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003846 hyperfunction of drug metabolism phase I (sustained) [Ground glass appearance] Hyperfunction of drug metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive drug metabolism phase I by Cytochrome P450. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0001630 increasing phosphatidylserine material http://purl.obolibrary.org/obo/TXPO_0001317 increasing glycerophospholipid material Increasing phosphatidylserine material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylserine material to be larger. http://purl.obolibrary.org/obo/TXPO_0001631 increasing amount of foreign substance http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing amount of foreign substance is a subtype of increasing quantity: A process that changes the amount of foreign substance to be higher. http://purl.obolibrary.org/obo/TXPO_0001633 increasing amount of xenobiotics http://purl.obolibrary.org/obo/TXPO_0001631 increasing amount of foreign substance Increasing amount of xenobiotics is a subtype of increasing amount of foreign substance: A process that changes the amount of xenobiotics to be higher. http://purl.obolibrary.org/obo/TXPO_0001635 increasing amount of drug http://purl.obolibrary.org/obo/TXPO_0001633 increasing amount of xenobiotics Increasing amount of drug is a subtype of increasing amount of xenobiotics: A process that changes the amount of drug to be higher. http://purl.obolibrary.org/obo/TXPO_0001636 AMPK inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation AMPK inactivation is a subtype of molecular inactivation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be lower. http://purl.obolibrary.org/obo/TXPO_0001637 increasing amount of drug [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Increasing amount of drug is a subtype of increasing amount of xenobiotics: A process that changes the amount of drug to be higher. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001638 AMPK inactivation [lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process AMPK inactivation is a subtype of molecular inactivation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be lower. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0001639 decreasing amount of drug http://purl.obolibrary.org/obo/TXPO_0000822 decreasing amount of xenobiotics Decreasing amount of drug is a subtype of decreasing amount of xenobiotics: A process that changes the quantity of the drug to be lower. http://purl.obolibrary.org/obo/TXPO_0001640 phosphatidylserine metabolism imbalance http://purl.obolibrary.org/obo/TXPO_0001295 glycerophospholipid metabolism imbalance Phosphatidylserine metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylserine metabolism. http://purl.obolibrary.org/obo/TXPO_0001641 removing myelin figure by Kupffer cell or macrophage http://purl.obolibrary.org/obo/TXPO_0000458 removing (from A) Removing myelin figure by Kupffer cell or macrophage is a subtype of removing: A process that takes myelin figure from a cell by Kupffer cells or macrophages. http://purl.obolibrary.org/obo/TXPO_0001642 phosphatidic acid metabolism imbalance http://purl.obolibrary.org/obo/TXPO_0001295 glycerophospholipid metabolism imbalance Phosphatidic acid metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidic acid metabolism. http://purl.obolibrary.org/obo/TXPO_0001643 removing myelin figure by Kupffer cell or macrophage [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Removing myelin figure by Kupffer cell or macrophage is a subtype of removing: A process that takes myelin figure from a cell by Kupffer cells or macrophages. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001644 phosphatidylinositol metabolism imbalance http://purl.obolibrary.org/obo/TXPO_0001295 glycerophospholipid metabolism imbalance Phosphatidylinositol metabolism imbalance is a subtype of glycerophospholipid metabolism imbalance : A process that becomes lacking a homeostastasis balance of phosphatidylinositol metabolism. http://purl.obolibrary.org/obo/TXPO_0001645 lipid accumulation in hepatocyte [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003623 lipid accumulation in hepatocyte Lipid accumulation in hepatocyte is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes mildly. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001646 hyperfunction of Phosphatidylserine synthesis gene expression http://purl.obolibrary.org/obo/TXPO_0001264 hyperfunction of glycerophospholipid synthesis gene expression Hyperfunction of Phosphatidylserine synthesis gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylserine synthetic gene expression. http://purl.obolibrary.org/obo/TXPO_0001647 decreasing amount of drug [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Decreasing amount of drug is a subtype of decreasing amount of xenobiotics: A process that changes the quantity of the drug to be lower. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001648 hypofunction of phosphatidylserine degradation http://purl.obolibrary.org/obo/TXPO_0001418 hypofunction of glycerophospholipid degradation Hypofunction of phosphatidylserine degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylcholine degradation. http://purl.obolibrary.org/obo/TXPO_0001649 keeping amount of drug http://purl.obolibrary.org/obo/TXPO_0000414 keeping quantity Keeping amount of drug is a subtype of keeping amount: A process that maintains the amount of the drug at a constant level . http://purl.obolibrary.org/obo/TXPO_0001650 negative regulation of phosphatidylserine degradation http://purl.obolibrary.org/obo/TXPO_0001304 negative regulation of glycerophospholipid degradation Negative regulation of phosphatidylserine degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylserine degradation. http://purl.obolibrary.org/obo/TXPO_0001651 cell rupture http://purl.obolibrary.org/obo/TXPO_0000462 detaching Cell rupture is the tearing apart of a cell. http://purl.obolibrary.org/obo/TXPO_0001653 increasing phosphatidylinositol material http://purl.obolibrary.org/obo/TXPO_0001317 increasing glycerophospholipid material Increasing phosphatidylinositol material is a subtype of increasing glycerophospholipid material: A process that changes the amount of phosphatidylinositol material to be larger. http://purl.obolibrary.org/obo/TXPO_0001654 hyperfunction of decreasing the amount of phenobarbital [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003861 hyperfunction of decreasing the amount of drugs by Cytochrome P450 [Ground glass appearance] Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001655 hyperfunction of phosphatidylinositol synthetic gene expression http://purl.obolibrary.org/obo/TXPO_0001264 hyperfunction of glycerophospholipid synthesis gene expression Hyperfunction of phosphatidylinositol synthetic gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidylinositol synthetic gene expression. http://purl.obolibrary.org/obo/TXPO_0001656 chemical homeostasis imbalance http://purl.obolibrary.org/obo/TXPO_0000568 homeostasis imbalance Chemical homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a chemical homeostastasis balance. http://purl.obolibrary.org/obo/TXPO_0001657 hypofunction of phosphatidylinositol degradation http://purl.obolibrary.org/obo/TXPO_0001418 hypofunction of glycerophospholipid degradation Hypofunction of phosphatidylinositol degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidylinositol degradation. http://purl.obolibrary.org/obo/TXPO_0001658 changing balance of drug metabolism http://purl.obolibrary.org/obo/TXPO_0001847 changing balance Changing balance of drug metabolism is a subtype of changing balance: A process that that changes the balance between break down and the continued presence of the drug. http://purl.obolibrary.org/obo/TXPO_0001659 negative regulation of phosphatidylinositol degradation http://purl.obolibrary.org/obo/TXPO_0001304 negative regulation of glycerophospholipid degradation Negative regulation of phosphatidylinositol degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidylinositol degradation. http://purl.obolibrary.org/obo/TXPO_0001660 changing balance of drug metabolism [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001658 changing balance of drug metabolism Changing balance of drug metabolism is a subtype of changing balance: A process that that changes the balance between break down and the continued presence of the drug. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001661 drug metabolism imbalance http://purl.obolibrary.org/obo/TXPO_0000567 imbalance Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism. http://purl.obolibrary.org/obo/TXPO_0001662 hyperfunction of hosphatidic acid gene expression http://purl.obolibrary.org/obo/TXPO_0001264 hyperfunction of glycerophospholipid synthesis gene expression Hyperfunction of hosphatidic acid gene expression is a subtype of hyperfunction of glycerophospholipid synthesis gene expression: A process that performs an excesssive phosphatidic acid synthetic gene expression. http://purl.obolibrary.org/obo/TXPO_0001663 hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003902 hyperfunction of drug metabolism phase II [Ground glass appearance - Cyp] Hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite is a subtype of hyperfunction of glucuronic acid conjugation: A process that performs an excessive glucuronic acid conjugation. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001664 hypofunction of phosphatidic acid degradation http://purl.obolibrary.org/obo/TXPO_0001418 hypofunction of glycerophospholipid degradation Hypofunction of phosphatidic acid degradation is a subtype of hypofunction of glycerophospholipid degradation: A process that performs a decreased or insufficient phosphatidic acid degradation. http://purl.obolibrary.org/obo/TXPO_0001665 drug metabolism imbalance [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001666 negative regulation of phosphatidic acid degradation http://purl.obolibrary.org/obo/TXPO_0001304 negative regulation of glycerophospholipid degradation Negative regulation of phosphatidic acid degradation is a subtype of Negative regulation of glycerophospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phosphatidic acid degradation. http://purl.obolibrary.org/obo/TXPO_0001667 drug metabolism imbalance [Ground glass appearance (severe) - tumorigenesis] http://purl.obolibrary.org/obo/TXPO_0001665 drug metabolism imbalance [Ground glass appearance] Drug metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of drug metabolism. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of liver tumor via ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001668 chemcal compound accumulation in liver [Ground glass appearance (severe)] http://purl.obolibrary.org/obo/TXPO_0002068 chemical compound accumulation in liver [Ground glass appearance] Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (severe). http://purl.obolibrary.org/obo/TXPO_0001669 increasing sphingophopholipid material http://purl.obolibrary.org/obo/TXPO_0001314 increasing phospholipid material Increasing sphingophopholipid material is a subtype of increasing materials for lipid formation: A process that changes the amount of sphingophopholipid material to be larger. http://purl.obolibrary.org/obo/TXPO_0001670 increasing sphingomyelin material http://purl.obolibrary.org/obo/TXPO_0001669 increasing sphingophopholipid material Increasing sphingomyelin material is a subtype of increasing sphingophopholipid material: A process that changes the amount of sphingomyelin material to be larger. http://purl.obolibrary.org/obo/TXPO_0001671 increasing sphingomyelin material [Phospholipidosis - genetic- sphingomyelin disorder ] http://purl.obolibrary.org/obo/TXPO_0001794 increasing glycerophospholipid material [Phospholipidosis - sphingophospholipid disorder] Increasing sphingomyelin material is a subtype of increasing sphingophopholipid material: A process that changes the amount of sphingomyelin material to be larger. This process is dependent on the genetic and can constitute the course of Phospholipidosis (genetic). http://purl.obolibrary.org/obo/TXPO_0001672 sphingomyelin metabolism imbalance http://purl.obolibrary.org/obo/TXPO_0001293 sphingophopholipid metabolism imbalance Sphingomyelin metabolism imbalance is a subtype of sphingophopholipid metabolism imbalance: A process that becomes lacking a homeostastasis balance of sphingomyelin metabolism. http://purl.obolibrary.org/obo/TXPO_0001673 increase in fatty acid inflow into hepatocyte [Phpspholipidosis] http://purl.obolibrary.org/obo/TXPO_0003492 increaing in fatty acid inflow into hepatocyte Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001674 hyperfunction of sphingomyelin synthetic gene expression http://purl.obolibrary.org/obo/TXPO_0001290 hyperfunction of sphingophospholipid synthesis gene expression Hyperfunction of sphingomyelin synthetic gene expression is a subtype of hyperfunction of sphingophospholipid synthesis gene expression: A process that performs an excesssive sphingomyelin synthetic gene expression. http://purl.obolibrary.org/obo/TXPO_0001675 phenobarbital accumulation in liver [Ground glass appearance (severe)] http://purl.obolibrary.org/obo/TXPO_0000934 phenobarbital accumulation in liver [Ground glass appearance] Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (severe). http://purl.obolibrary.org/obo/TXPO_0001676 hypofunction of sphingomyelin degradation http://purl.obolibrary.org/obo/TXPO_0001287 hypofunction of phosphosphingolipid degradation Hypofunction of sphingomyelin degradation is a subtype of hypofunction of phosphosphingolipid degradation: A process that performs a decreased or insufficient sphingomyelin degradation. http://purl.obolibrary.org/obo/TXPO_0001677 smooth endoplasmic reticulum proliferation in hepatocyte (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003903 smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance - Cyp - PB] Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s). This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0001678 negative regulation of sphingophopholipid degradation http://purl.obolibrary.org/obo/TXPO_0001256 negative regulation of phospholipid degradation Negative regulation of sphingophopholipid degradation is a subtype of negative regulation of phospholipid degradation: Any process that stops, prevents, or reduces the frequency, rate or extent of the sphingophospholipid catabolic process. http://purl.obolibrary.org/obo/TXPO_0001679 ground glass appearance with hypertrophy http://purl.obolibrary.org/obo/TXPO_0001432 ground glass apperance [toxic corse] The totality of all processes through which ground glass appearance accompanied with hypertrophy is realized. http://purl.obolibrary.org/obo/TXPO_0001680 negative regulation of sphingomyelin catabolic process http://purl.obolibrary.org/obo/TXPO_0001678 negative regulation of sphingophopholipid degradation Negative regulation of sphingomyelin catabolic process is a subtype of negative regulation of sphingophopholipid degradation: Any process that stops, prevents, or reduces the frequency, rate or extent of the sphingomyelin catabolic process. http://purl.obolibrary.org/obo/TXPO_0001681 hyperfunction of moving A to the inside of B http://purl.obolibrary.org/obo/TXPO_0000435 hyperfunctioning Hyperfunction of moving A to the inside of B is a subtype of hyperfunctioning: A process that performs an excesssive moving A to the inside of B. http://purl.obolibrary.org/obo/TXPO_0001682 energy sensor http://purl.obolibrary.org/obo/TXPO_0000882 sensor A role played by the entity which receives energy and transmits operand(s). http://purl.obolibrary.org/obo/TXPO_0001683 maintaining phospholipid homeostasis [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0000951 changing phospholipid homeostasis [Phospholipidosis] Any process involved in the maintenance of an internal steady state of phospholipid within an organism or cell. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001684 moving drug to inside of hepatocyte http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into hepatocytes. http://purl.obolibrary.org/obo/TXPO_0001685 sphingomyelin disorder (genetic) http://purl.obolibrary.org/obo/TXPO_0004157 sphingomyelin disorder (phospholipidosis)　 The totality of all processes through which the sphingomyelin disorder is realized. This causal process is heredity. http://purl.obolibrary.org/obo/TXPO_0001686 dysfunction of sphingomyelin degradation http://purl.obolibrary.org/obo/TXPO_0001474 dysfunction of phosphosphingolipid degradation Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation. http://purl.obolibrary.org/obo/TXPO_0001687 dysfunction of sphingomyelin degradation [Phospholipidosis - genetic- sphingomyelin disorder] http://purl.obolibrary.org/obo/TXPO_0004156 dysfunction of sphingomyelin degradation [Phospholipidosis-sphingomyelin disorder] Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation. This process is dependent on the sphingomyelin disorder and can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001688 sphingomyelinase gene mutation [Phospholipidosis - genetic- sphingomyelin disorder ] http://purl.obolibrary.org/obo/TXPO_0001463 phopholipase gene mutation [Phospholipidosis - genetic] Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene. This process is dependent on the genetic and can constitute the course of Phospholipidosis (genetic). http://purl.obolibrary.org/obo/TXPO_0001689 increasing pressure http://purl.obolibrary.org/obo/TXPO_0000475 changing pressure Increasing pressure is a subtype of changing pressure: A process that changes the pressure of the object to be higher. http://purl.obolibrary.org/obo/TXPO_0001690 sphingomyelin accumulation in lysosome [Phospholipidosis - genetic- sphingomyelin disorder] http://purl.obolibrary.org/obo/TXPO_0003381 sphingomyelin accumulation in lysosome [Phospholipidosis - sphingomyelin disorder ] Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome. This process is dependent on the sphingomyelin disorder and can constitute the course of Phospholipidosis (genetic). http://purl.obolibrary.org/obo/TXPO_0001691 sphingomyelin accumulation in lysosome of nervous system http://purl.obolibrary.org/obo/TXPO_0001764 sphingomyelin accumulation in lysosome Sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome: A process that keeps sphingomyelin in the lysosome of nervous system. http://purl.obolibrary.org/obo/TXPO_0001692 sphingomyelin accumulation in lysosome of nervous system [Niemann Pick Disease Type A (severe) ] http://purl.obolibrary.org/obo/TXPO_0003615 severe sphingomyelin accumulation in lysosome of nervous system Severe sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome of nervous system: A process that keeps sphingomyelin in the lysosome of nervous system severely. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A (severe). http://purl.obolibrary.org/obo/TXPO_0001693 protein binding by NAPQI http://purl.obolibrary.org/obo/GO_0005515 protein binding Protein binding by NAPQI is a subtype of protein binding: Interacting between a protein and NAPQI. http://purl.obolibrary.org/obo/TXPO_0001694 chemical compound accumulation in liver http://purl.obolibrary.org/obo/TXPO_0000169 accumulation of xenobiotics Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver. http://purl.obolibrary.org/obo/TXPO_0001695 chemical compound accumulation in lysosome [Phospholipidosis (severe)] http://purl.obolibrary.org/obo/TXPO_0000930 compound accumulation in lysosome [Phospholipidosis] Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0001696 PERK signal transduction system http://purl.obolibrary.org/obo/TXPO_0000634 signal transduction system PERK signal transduction system is a subtype of pathway system. This entity has sub-parts and has a goal of transmitting signals via PERK as a systemic context. http://purl.obolibrary.org/obo/TXPO_0001697 glycerophospholipid accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0000281 phospholipid accumulation in lysosome Glycerophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps glycerophospholipid in the lysosome. http://purl.obolibrary.org/obo/TXPO_0001698 increaing in fatty acid inflow into hepatocyte [Phpspholipidosis (severe)] http://purl.obolibrary.org/obo/TXPO_0001673 increase in fatty acid inflow into hepatocyte [Phpspholipidosis] Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. The degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001699 leaking http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B Leaking is a subtype of moving A to the outside of B: A process that lets gas or liquid flow through. http://purl.obolibrary.org/obo/TXPO_0001700 increase in fatty acid inflow into hepatocyte [Phpspholipidosis(moderate)] http://purl.obolibrary.org/obo/TXPO_0001673 increase in fatty acid inflow into hepatocyte [Phpspholipidosis] Increase in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. The digree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001701 phosphatidic acid accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0001697 glycerophospholipid accumulation in lysosome Phosphatidic acid accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidic acid in the lysosome. http://purl.obolibrary.org/obo/TXPO_0001702 increasing phospholipid material[Phospholipidosis (moderate )] http://purl.obolibrary.org/obo/TXPO_0001762 increasing phospholipid material[Phospholipidosis ] Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0001703 phosphatidylserine accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0001697 glycerophospholipid accumulation in lysosome Phosphatidylserine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylserine in the lysosome. http://purl.obolibrary.org/obo/TXPO_0001704 hyperfunction of phospholipid biosynthesis [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0000908 hyperfunction of phospholipid biosynthesis [Phospholipidosis] Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0001705 phosphatidylcholine accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0001697 glycerophospholipid accumulation in lysosome Phosphatidylcholine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylcholine in the lysosome. http://purl.obolibrary.org/obo/TXPO_0001706 S1P inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation S1P inactivation is a subtype of molecular inactivation: A process that changes the activity of the S1P (Sphingosine-1-phosphate) to be lower. http://purl.obolibrary.org/obo/TXPO_0001707 phosphatidylglycerol accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0001697 glycerophospholipid accumulation in lysosome Phosphatidylglycerol accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylglycerol in the lysosome. http://purl.obolibrary.org/obo/TXPO_0001708 hyperfunction of phospholipid biosynthesis [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0000908 hyperfunction of phospholipid biosynthesis [Phospholipidosis] Hyperfunction of phospholipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive phospholipid biosynthesis. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0001709 phosphatidylethanolamine accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0001697 glycerophospholipid accumulation in lysosome Phosphatidylethanolamine accumulation in lysosome is a subtype of glycerophospholipid accumulation in lysosome: A process that keeps phosphatidylethanolamine in the lysosome. http://purl.obolibrary.org/obo/TXPO_0001710 positive regulation of phospholipid biosynthetic process [Phospholipidosis] http://purl.obolibrary.org/obo/GO_0071073 positive regulation of phospholipid biosynthetic process Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001712 PERK-eIF2a signal transduction system http://purl.obolibrary.org/obo/TXPO_0001696 PERK signal transduction system PERK-eIF2a signal transduction system is a subtype of pathway system. This entity has sub-parts and has a goal of transmitting signals via PERK and eIF2a as a systemic context. http://purl.obolibrary.org/obo/TXPO_0001713 PERK signal transduction system [ER stress] http://purl.obolibrary.org/obo/TXPO_0001696 PERK signal transduction system PERK signal transduction system is a subtype of pathway system. This entity has sub-parts and has a goal of transmitting signals via PERK as a systemic context. This entity is dependent on ER stress. http://purl.obolibrary.org/obo/TXPO_0001714 moving drug to the inside of liver [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Moving drug to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of drug into a liver. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process http://purl.obolibrary.org/obo/TXPO_0000271 primitive process Toxic course dependent process is a subtype of primitive process: A process that can constitute the toxic course. http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Phospholipidosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of phospholipidosis . http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process ER stress dependent process is a subtype of toxic course dependent process: A process that can constitute the course of endoplasmic reticulum stress. http://purl.obolibrary.org/obo/TXPO_0001718 malfunctioning of hepatic blood circulation http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process Malfunctioning of hepatic blood circulation is a subtype of malfunctioning process: A process that cannot perform hepatic blood circulation function appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0001719 moving phenobarbital to the inside of liver [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Moving phenobarbital to the inside of liver is a subtype of moving A to the inside of B: A process that of the movement of phenobarbital into a liver. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Hepatic steatosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic steatosis (fatty degeneration). http://purl.obolibrary.org/obo/TXPO_0001721 MMP inactivation by TIMP1 [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process MMP inactivation by TIMP1 is a subtype of inactivating: A process that changes the activity of the MMP to be lower by TIMP1. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0001722 hypofunction of ATP biosynthesis http://purl.obolibrary.org/obo/TXPO_0001910 hypofunction of biosynthesis Hypofunction of ATP biosynthesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient ATP biosynthesis. http://purl.obolibrary.org/obo/TXPO_0001723 hypofunction of phospholipid deradation by phospholipase http://purl.obolibrary.org/obo/TXPO_0001253 hypofunction of phospholipid degradation Hypofunction of phospholipid deradation by phospholipase is a subtype of hypofunction of phospholipid degradation: A process that performs a decreased or insufficient phospholipid deradation by phospholipase. http://purl.obolibrary.org/obo/TXPO_0001724 hyperfunction of increasing http://purl.obolibrary.org/obo/TXPO_0000435 hyperfunctioning Hyperfunction of increasing is a subtype of hyperfunctioning: A process that performs an excessive function of increasing. http://purl.obolibrary.org/obo/TXPO_0001725 PERK-eIF2a signal transduction system http://purl.obolibrary.org/obo/TXPO_0001712 PERK-eIF2a signal transduction system PERK-eIF2a signal transduction system is a subtype of pathway system. This entity has sub-parts and has a goal of transmitting signals via PERK and eIF2a as a systemic context. This entity is dependent on the translation attenuation of ER stress. http://purl.obolibrary.org/obo/TXPO_0001726 hyperfunction of phospholipid synthesis gene expression http://purl.obolibrary.org/obo/TXPO_0002345 hyperfunction of gene expression Hyperfunction of phospholipid synthesis gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipid synthetic gene expression. http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Cell death dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatocyte cell death. http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Ground glass degeneration is a subtype of toxic course dependent process: A process that can constitute the course of ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Eosinophlic granular degeneration dependent process is a subtype of toxic course dependent process: A process that can constitute the course of eosinophilicgranular degeneration. http://purl.obolibrary.org/obo/TXPO_0001730 oxidative stress dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Oxidative stress dependent process is a subtype of toxic course dependent process: A process that can constitute the course of oxidative stress. http://purl.obolibrary.org/obo/TXPO_0001731 toxic course dependent chemical entity http://purl.obolibrary.org/obo/CHEBI_24431 chemical entity Toxic course dependent chemical entity is a subtype of chemical entity. This entity can participate in a specific toxic course. http://purl.obolibrary.org/obo/TXPO_0001732 ATF6 signal transduction system http://purl.obolibrary.org/obo/TXPO_0000634 signal transduction system ATF6 signal transduction system is a subtype of pathway system. This entity has sub-parts and has a goal of transmitting signals via ATF6 as a systemic context. http://purl.obolibrary.org/obo/TXPO_0001734 balance state http://purl.obolibrary.org/obo/TXPO_0000270 state In the imbalance model, the basic units are as follows: 1) a functioning process (supply) for biological defense and maintaining homeostasis; 2) a functional demand process (demand) as toxic activity; 3) balance/imbalance between toxic activity and defense processes; and 4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations. This entity is step 3: a state of balance between toxic activity and defense processes. http://purl.obolibrary.org/obo/TXPO_0001735 imbalance state http://purl.obolibrary.org/obo/TXPO_0000270 state In the imbalance model, the basic units are as follows: 1) a functioning process (supply) for biological defense and maintaining homeostasis; 2) a functional demand process (demand) as toxic activity; 3) balance/imbalance between toxic activity and defense processes; and 4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations. This entity indicates step 3: a state of imbalance between toxic activity and defense processes. http://purl.obolibrary.org/obo/TXPO_0001736 state of functional supply http://purl.obolibrary.org/obo/TXPO_0000270 state In the imbalance model, the basic units are as follows: 1) a functioning process (supply) for biological defense and maintaining homeostasis; 2) a functional demand process (demand) as toxic activity; 3) balance/imbalance between toxic activity and defense processes; and 4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations. This entity indicates step 1: a state of functioning (supply) for biological defense and maintaining homeostasis. http://purl.obolibrary.org/obo/TXPO_0001737 cell part damage http://purl.obolibrary.org/obo/TXPO_0000222 damaging Cell part damage is a subtype of damaging: A process that injuries the structure of the cellular part as the direct or indirect result of an external force. http://purl.obolibrary.org/obo/TXPO_0001738 membrane damage http://purl.obolibrary.org/obo/TXPO_0001737 cell part damage Membrane damage is a subtype of damaging: A process that injuries the structure of the membrane as the direct or indirect result of an external force. http://purl.obolibrary.org/obo/TXPO_0001739 dysfunction of mitochondrial fatty acid degradation [Alchoric fatty liver] http://purl.obolibrary.org/obo/TXPO_0003652 dysfunction of fatty acid degradation Dysfunction of mitochondrial fatty acid beta-oxidation (severe) is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid beta-oxidation severely. This entity is a specific course-dependent process. This process can constitute the course of Alcholic fatty liver. http://purl.obolibrary.org/obo/TXPO_0001740 very high level http://purl.obolibrary.org/obo/TXPO_0004208 degree level The level of degree is very high in comparison to the medium. http://purl.obolibrary.org/obo/TXPO_0001741 dysfunction of lipid degradation http://purl.obolibrary.org/obo/TXPO_0000438 dysfunctioning Dysfunction of lipid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete lipid degradation. http://purl.obolibrary.org/obo/TXPO_0001742 medium level http://purl.obolibrary.org/obo/TXPO_0004208 degree level The level of degree is middle. http://purl.obolibrary.org/obo/TXPO_0001743 low level http://purl.obolibrary.org/obo/TXPO_0004208 degree level The level of degree is lower than medium. http://purl.obolibrary.org/obo/TXPO_0001744 inflammasome activation [lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0001745 oxidative phosphorylation [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process The phosphorylation of ADP to ATP that accompanies the oxidation of a metabolite through the operation of the respiratory chain. Oxidation of compounds establishes a proton gradient across the membrane, providing the energy for ATP synthesis. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0001746 functional demand state http://purl.obolibrary.org/obo/TXPO_0000270 state In the imbalance model, the basic units are as follows: 1) a functioning process (supply) for biological defense and maintaining homeostasis; 2) a functional demand process (demand) as toxic activity; 3) balance/imbalance between toxic activity and defense processes; and 4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations. This entity indicates step 2: a state of functional demand as toxic activity. http://purl.obolibrary.org/obo/TXPO_0001747 malfunctioning of mitochondrial ATP synthesis coupled electron transfer [lipidosis] http://purl.obolibrary.org/obo/TXPO_0001846 malfunctioning of mitochondrial ATP synthesis coupled electron transpor Malfunctioning of mitochondrial ATP synthesis coupled electron transfer is a subtype of malfunctioning process: A process that cannot perform a respiratory electron transport chain appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0001748 negative regulation of respiratory electron transport chain [lipidosis] http://purl.obolibrary.org/obo/TXPO_0002342 negative regulation of respiratory electron transport chain Negative regulation of respiratory electron transport chain is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of mrespiratory electron transport chain. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0001749 negative regulation of oxidative phosphorylation [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001771 negative regulation of oxidative phosphorylation Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of the oxidative phosphorylation. This entity is a specific course-dependent process. This process can constitute the course of lipidosis. http://purl.obolibrary.org/obo/TXPO_0001750 ATF6 signal integration system http://purl.obolibrary.org/obo/TXPO_0001513 signal integration system ATF6 signal integration system is a subtype of pathway system. This entity has sub-parts and has a goal of transmitting signals and a gene regulation via ATF6 as a systemic context. http://purl.obolibrary.org/obo/TXPO_0001751 NAPQI accumulation http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object NAPQI accumulation is a subtype of accumulation of substances in a biological object: A process that keeps NAPQI (N-acetyl-p-benzoquinone imine) within a biological object(s). NAPQI is an intermediate metabolite of the paracetamol and plays a role as a toxic substance in the body. http://purl.obolibrary.org/obo/TXPO_0001752 hypofunction of maintaining lysosome homeostasis [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Hypofunction of maintaining lysosome homeostasis is a subtype of hypofunctioning: A process that performs a decreased or insufficient maintaining lysosome homeostasis. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0001753 preventing http://purl.obolibrary.org/obo/TXPO_0000600 meta-functioning process Preventing is a type of functioning process of meta-function of "ToPrevent". Two meta-functions "ToAllow" and "Toprevent" are concerned with the undesirable side effects of functions. A function fa having positive effects on the side effect of a function ft1 is said to have a meta-function “to allow the side-effects of ft1”. The “undesirable side effect” is defined in a relation with another function ft2 or the whole system. The “positive effect” means such a causal relation that increase of the focused attribute of fa causes decrease of the side effect. If a serious trouble (e.g., faults) will be caused in a function ft2 when a function fa is not achieved, function fa is said to have a meta-function “to prevent malfunction of ft2”. For example, the “to super-heat” function of the boiler prevents malfunction of the turbine, because the steam of low temperature would damage the turbine blade by water particles. For almost all fa performing a ToAllow meta-function for ft1, in general, there exists a ToPrevent meta-function for another function ft2. http://purl.obolibrary.org/obo/TXPO_0001754 providing http://purl.obolibrary.org/obo/TXPO_0000600 meta-functioning process Providing is a subtype of metafunctioning process. When a function fa generates (or transfers) the materials which another function ft intentionally processes, the function fa is said to perform a meta-function “to provide material” for the function ft. The material of ft can be basically defined as input objects (entity or energy) which will be a part of the output objects on which the function ft focuses. http://purl.obolibrary.org/obo/TXPO_0001755 abnormality of membrane http://purl.obolibrary.org/obo/TXPO_0001770 changing abnormal cellular structure Abnormality of membrane is a subtype of changing abnormal cellular structure: A process that changes the membrane stucture abnormally. http://purl.obolibrary.org/obo/TXPO_0001756 driving http://purl.obolibrary.org/obo/TXPO_0000600 meta-functioning process Driving is a type of functioning process of meta-function. The function which generates or transfers a driving energy is said to have meta-function “driving”. For example, the “to heat water” function of the boiler has a ToDrive meta-function for the “to generate torque” function of the turbine , because the amount of the heat energy transferred by the heating has a proportional causal relation to the torque and is consumed by the rotation. http://purl.obolibrary.org/obo/TXPO_0001757 enabling http://purl.obolibrary.org/obo/TXPO_0000600 meta-functioning process Enabling is a subtype of meta-functioning process. To enable is a meta-function that sets conditions for other functions to work correctly. http://purl.obolibrary.org/obo/TXPO_0001758 cytochrome P450 activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation Cytochrome P450 activation is a subtype of molecular activation: A process that changes the activity of the cytochrome P450 to be higher. http://purl.obolibrary.org/obo/TXPO_0001759 importing substances into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003124 import substances into hepatocyte vascular side (sinusoidal side) membrane Importing substances into hepatocyte vascular side (sinusoidal side) membrane is a subtype of transport: A process of the directed movement of substances into hepatocyte vascular side (sinusoidal side) membrane. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0001760 ATF6-CHOP signal integration system http://purl.obolibrary.org/obo/TXPO_0001750 ATF6 signal integration system ATF6-CHOP signal integration system is a subtype of ATF6 pathway system. This entity has sub-parts and has a goal of transmitting signals and a gene regulation via ATF6 and CHOP as a systemic context. http://purl.obolibrary.org/obo/TXPO_0001761 positive regulation of phospholipid biosynthetic process [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0001710 positive regulation of phospholipid biosynthetic process [Phospholipidosis] Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0001762 increasing phospholipid material[Phospholipidosis ] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0001763 sphingophospholipid accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0000281 phospholipid accumulation in lysosome Sphingophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps sphingophospholipid in the lysosome. http://purl.obolibrary.org/obo/TXPO_0001764 sphingomyelin accumulation in lysosome http://purl.obolibrary.org/obo/TXPO_0001763 sphingophospholipid accumulation in lysosome Sphingomyelin accumulation in lysosome is a subtype of sphingophospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome. http://purl.obolibrary.org/obo/TXPO_0001765 calcium ion homeostasis imbalance http://purl.obolibrary.org/obo/TXPO_0001656 chemical homeostasis imbalance Calcium ion homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a calcium ion homeostastasis balance. http://purl.obolibrary.org/obo/TXPO_0001766 hypofunction of xenobiotic glucuronidation http://purl.obolibrary.org/obo/TXPO_0002190 hypofunction of drug metabolism Hypofunction of xenobiotic glucuronidation is a subtype of decreasing function of: A process that performs a decreased or insufficient xenobiotic glucuronidation. http://purl.obolibrary.org/obo/TXPO_0001768 sphingomyelin metabolism imbalance [Phospholipidosis - genetic- sphingomyelin disorder ] http://purl.obolibrary.org/obo/TXPO_0001823 sphingomyelin metabolism imbalance [Phospholipidosis - sphingomyelin disorder] A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism. This process is dependent on the genetic and can constitute the course of Phospholipidosis (genetic). http://purl.obolibrary.org/obo/TXPO_0001769 hypofunction of phospholipase transport to lysosome http://purl.obolibrary.org/obo/TXPO_0001911 hypofunction of transport Hypofunction of phospholipase transport to lysosome is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipase transport to lysosome . http://purl.obolibrary.org/obo/TXPO_0001770 changing abnormal cellular structure http://purl.obolibrary.org/obo/TXPO_0002566 changing structure Changing abnormal cellular structure is a subtype of changing structure: A process that changes the structure of the cell abnormally. http://purl.obolibrary.org/obo/TXPO_0001771 negative regulation of oxidative phosphorylation http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of oxodative phosphorylation. http://purl.obolibrary.org/obo/TXPO_0001772 keeping amount of phospholipid in lysosome (normal condition) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003358 keeping amount of phospholipid in lysosome [Phospholipidosis] Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal). http://purl.obolibrary.org/obo/TXPO_0001773 glutathione deficiency http://purl.obolibrary.org/obo/TXPO_0000482 insufficient functioning Glutathione deficiency is a subtype of malfunctioning process: A process that lacks performing the glutathione function required. http://purl.obolibrary.org/obo/TXPO_0001775 hypofunction of glutathione conjugation http://purl.obolibrary.org/obo/TXPO_0002190 hypofunction of drug metabolism Hypofunction of glutathione conjugation is a subtype of hypofunction of drug metabolism: A process that performs a decreased or insufficient glutathione conjugation. http://purl.obolibrary.org/obo/TXPO_0001776 phospholipid metabolism imbalance [Phospholipidosis - genetic] http://purl.obolibrary.org/obo/TXPO_0002324 phospholipid metabolism imbalance [Phospholipidosis] Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism. This process is dependent on the genetic and can constitute the course of Phospholipidosis (genetic). http://purl.obolibrary.org/obo/TXPO_0001777 phospholipid metabolism imbalance [Phospholipidosis (mild)] http://purl.obolibrary.org/obo/TXPO_0002324 phospholipid metabolism imbalance [Phospholipidosis] Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild). http://purl.obolibrary.org/obo/TXPO_0001778 phospholipid metabolism imbalance [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0002324 phospholipid metabolism imbalance [Phospholipidosis] Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0001779 toxicological imbalance VH (toxic action) http://purl.obolibrary.org/obo/TXPO_0003992 toxicological imbalance In the imbalance model, the basic units are as follows: 1) a functioning process (supply) for biological defense and maintaining homeostasis; 2) a functional demand process (demand) as toxic activity; 3) balance/imbalance between toxic activity and defense processes; and 4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations. This entity is a compound state that includes step 1 to 4, and the toxic activity level is higher (Very High, VH) than usual to imbalance and toxicity manifestations. http://purl.obolibrary.org/obo/TXPO_0001780 toxicological balance H=H (maintining homeostasis at higher level) http://purl.obolibrary.org/obo/TXPO_0003992 toxicological imbalance In the imbalance model, the basic units are as follows: 1) a functioning process (supply) for biological defense and maintaining homeostasis; 2) a functional demand process (demand) as toxic activity; 3) balance/imbalance between toxic activity and defense processes; and 4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations. This entity is a compound state that inculdes step 1 to 4. The defense performance level and the functional demand level are high, as a result, keeping the balance. This state reflects the adaptation in the body. http://purl.obolibrary.org/obo/TXPO_0001781 toxicological imbalance H0) http://purl.obolibrary.org/obo/TXPO_0002583 keeping distance Keeping distance (d>0) is a subtype of keeping distance: A process that maintains the relative positional relationship between objects with a certain distance (>0) . http://purl.obolibrary.org/obo/TXPO_0002586 changing the relationship between inside and outside http://purl.obolibrary.org/obo/TXPO_0000464 changing position Changing the relationship between inside and outside is a subtype of changing position: A process that that changes the relative position between an inside object and an outside object. http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B http://purl.obolibrary.org/obo/TXPO_0002586 changing the relationship between inside and outside Moving A to the inside of B is a subtype of changing the relationship between inside and outside: A process that that places an object from the outside to the inside of the boundary. http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B http://purl.obolibrary.org/obo/TXPO_0002586 changing the relationship between inside and outside Moving A to the outside of B is a subtype of changing the relationship between inside and outside: A process that that places an object from the inside to the outside of the boundary. http://purl.obolibrary.org/obo/TXPO_0002589 discharging unnecessary object http://purl.obolibrary.org/obo/TXPO_0000459 giving Discharging unnecessary object is a subtype of giving: A process that sends out an unnecessary object to an other medium. http://purl.obolibrary.org/obo/TXPO_0002590 changing material http://purl.obolibrary.org/obo/TXPO_0000261 changing relationship between operands Changing material is a subtype of changing relationship between operands: A process that replaces the old material into new material. http://purl.obolibrary.org/obo/TXPO_0002591 IRE1 activation [IRE1 pathway] http://purl.obolibrary.org/obo/TXPO_0000729 IRE1 activation IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher. This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway. http://purl.obolibrary.org/obo/TXPO_0002592 XBP1 activation by IRE1 [IRE1 pathway] http://purl.obolibrary.org/obo/TXPO_0000723 XBP1 activation XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1. This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway. http://purl.obolibrary.org/obo/TXPO_0002593 IRE1 signaling (primitive) [IRE1 pathway] http://purl.obolibrary.org/obo/TXPO_0000720 IRE1 signaling (primitive) IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role. This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway. http://purl.obolibrary.org/obo/TXPO_0002594 IRE1 signaling to TRAF2 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002571 IRE1 signaling (primitive) [ER stress] A process in which a signal to TRAF2 is transduced by the IRE1. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002595 IRE1 dimerization http://purl.obolibrary.org/obo/TXPO_0003641 protein dimerization IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. http://purl.obolibrary.org/obo/TXPO_0002596 IRE1 dimerization [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002597 IRE1 autophosphorylation http://purl.obolibrary.org/obo/GO_0046777 protein autophosphorylation IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation). http://purl.obolibrary.org/obo/TXPO_0002598 IRE1 autophosphorylation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002599 IRE1-Traf2-ASK-JNK-AP1 pathway [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002563 IRE1 signaling (integrated pathway) IRE1-Traf2-ASK-JNK-AP1 pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-Traf2-ASK-JNK signaling and gene regulation by AP1. This pathway is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002600 hyperfunction of moving drug to the inside of liver [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002359 hyperfunction of moving drug to the inside of liver Hyperfunction of moving drug to the inside of liver is a subtype of hyperfunction of moving A to the inside of B: A process that performs an excesssive moving drug to the inside of liver. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0002604 receiving signal in IRE1 signal transduction pathway [ILE1 pathway] http://purl.obolibrary.org/obo/TXPO_0002174 receiving signal Receiving signal in IRE1 signal transduction pathway is a subtype of receiving signal: A process that recognizes another object and changes into a signal in a IRE1 signal transduction pathway. This entity is a specific course-dependent process. This process can constitute the course of IRE1 pathway. http://purl.obolibrary.org/obo/TXPO_0002606 gene expression by XBP1 http://purl.obolibrary.org/obo/TXPO_0000375 Gene expression by transcriptional regulator Gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1. http://purl.obolibrary.org/obo/TXPO_0002607 gene expression by XBP1 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002606 gene expression by XBP1 Gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002608 ERAD gene expression by XBP1 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002607 gene expression by XBP1 [ER stress] ERAD gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA)related to the ER associated degradation (ERAD) by XBP1. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002609 IRE1-XBP1 mediated pathway [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002563 IRE1 signaling (integrated pathway) IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1. This process is dependent on refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002610 IRE1-XBP1 mediated pathway [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0002563 IRE1 signaling (integrated pathway) IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1. This process is dependent on ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002611 Hyou gene expression by XBP1 [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002919 refolding gene expression by XBP1 [ER stress - refolding] Hyou gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a Hyou gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002612 DNAJB9 gene expression by XBP1 [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002919 refolding gene expression by XBP1 [ER stress - refolding] DNAJB9 gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a DNAJB9 gene sequence is converted into a mature gene product or products (proteins or RNA) by XBP1. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002613 hyperfunction of glutathione conjugates excretion from hepatocyte [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002701 hyperfunctioning of glutathione conjugates excretion from hepatocyte Hyperfunctio of glutathione conjugates excretion from hepatocyte is a subtype of compound excretion: A process that excretes the glutathione conjugates from the hepatocyte. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0002614 cholesterol efflux (from heptocyte menbrane to canaliculus) [cholestasis] http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process A release process of the cholesterol from one side of a membrane of hepatocyte to the other side of canaliculus. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002617 enabling translation http://purl.obolibrary.org/obo/TXPO_0001757 enabling Enabling translation is a subtype of enabling: A process that sets conditions for translation to work correctly. http://purl.obolibrary.org/obo/TXPO_0002618 antioxidant gene expression [ER stress] http://purl.obolibrary.org/obo/TXPO_0002061 antioxidant gene expression Antioxidant gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature antioxidant gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002620 negative regulator role of stress sensor http://purl.obolibrary.org/obo/TXPO_0003711 molecular inhibitor A role played by the entity that inhibits or desensitizes the stress sensor. By dissociating this inhibitor from the sensor, it can be received the stress and converted into a molecular signal. http://purl.obolibrary.org/obo/TXPO_0002624 PERK-eIF2a-ATF4 pathway [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002513 PERK-eIF2a-ATF4 mediated pathway PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation by ATF4. This pathway is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002626 phosphatidylcholine efflux (from heptocyte menbrane to canaliculus) [cholestasis] http://purl.obolibrary.org/obo/TXPO_0003539 phosphatidylcholine efflux A release process of the phosphatidylcholine from one side of a membrane of hepatocyte to the other side of canaliculus. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002627 phospholipid efflux (from heptocyte menbrane to canaliculus) [cholestasis] http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process A release process of the phospholipids from one side of a membrane of hepatocyte to the other side of canaliculus. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002628 intracellular ligand-gated ion channel http://purl.obolibrary.org/obo/TXPO_0003680 ligand-gated ion channel A role played by the entity which enables the transmembrane transfer of an ion by a channel that opens when a specific intracellular ligand has been bound by the channel complex or one of its constituent parts. http://purl.obolibrary.org/obo/TXPO_0002629 autophagy regulator role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role Autophagy regulator is a role played by any compound that regulates the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell). http://purl.obolibrary.org/obo/TXPO_0002630 bile secretion (from heptocyte menbrane to canaliculus) [cholestasis] http://purl.obolibrary.org/obo/TXPO_0002692 bile secretion to bile canaliculus A release process of the bile from one side of a membrane of hepatocyte to the other side of canaliculus druing the cholestasis. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002632 oranic anion export (from heptocyte menbrane to canaliculus) [cholestasis] http://purl.obolibrary.org/obo/TXPO_0003609 oranic anion export A release process of organic anions from one side of a membrane of hepatocyte to the other side of canaliculus. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002633 Translocation of NF-kappaB [ER stress] http://purl.obolibrary.org/obo/TXPO_0002779 Translocation of NF-kappaB [NfKB pathway] NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002637 drug export from the hepatocyte to to bile tube [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003153 drug export from the hepatocyte to to bile tube Drug export from the hepatocyte to to bile tube is a subtype of compound excretion: A process that excretes the drug from the hepatocyte to the bile tube. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002638 expcretion of drug metabolite from hepatocyte to bile tube [cholestasis] http://purl.obolibrary.org/obo/TXPO_0003152 excretion of drug metabolite from hepatocyte to bile tube Expcretion of drug metabolite from hepatocyte to bile tube is a subtype of excretion of compound: A process that excretes the drug metabolite from the hepatocyte to to the bile tube. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002639 importing substance into hepatocyte vascular side (sinusoidal side) membrane [cholestasis] [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001759 importing substances into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis] The directed movement of drugs into hepatocyte vascular side (sinusoidal side) membrane. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002641 bile tube occlusion [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002713 bile tube occlusion Bile tube occlusion is a subtype of occlusion: Obstruction or a closure of bile tube. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002644 farnesoid X receptor activation [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003143 farnesoid X receptor activation Farnesoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002645 positive regulation of bile export [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002732 positive regulation of bile export Positive regulation of bile export is a subtype of positive regulation process: A process that that activates or increases the frequency, rate or extent of bile acid secretion. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002646 negative regularuion of bile acid and bile salt transport [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003126 negative regularuion of bile acid and bile salt transport Negative regularuion of bile acid and bile salt transport is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of a bile acid and bile salts transport . This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002648 decreasing cross-sectional area http://purl.obolibrary.org/obo/TXPO_0000242 decreasing area Decreasing cross-sectional area is a subtype of decreasing area: A process that changes the cross-sectional area of the object to be smaller. http://purl.obolibrary.org/obo/TXPO_0002649 bile acid secretion [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process The regulated release of bile acid, composed of any of a group of steroid carboxylic acids occurring in bile, by a cell or a tissue. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002652 binding to bile canaliculus membrane transporter by drug [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003117 binding to bile canaliculus membrane transporter by drug Binding to bile canaliculus membrane transporter by drug is a subtype of protein binding: Interacting process with the membrane transporter of bile canaliculus by the drug. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002653 bile transport (import-export) imbalance http://purl.obolibrary.org/obo/TXPO_0000567 imbalance Bile transport (import-export) imbalance is a subtype of imbalance: A process that lacks a balance between bile import and export. http://purl.obolibrary.org/obo/TXPO_0002654 bile transport (import-export) imbalance [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002653 bile transport (import-export) imbalance Bile transport (import-export) imbalance is a subtype of imbalance: A process that lacks a balance between bile import and export. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002655 biliary tract stenosis http://purl.obolibrary.org/obo/TXPO_0002648 decreasing cross-sectional area Biliary tract stenosis is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the biliary tract to be smaller. http://purl.obolibrary.org/obo/TXPO_0002656 changing topology http://purl.obolibrary.org/obo/TXPO_0002566 changing structure Changing topology is a subtype of changing structure: A process that changes the setting of the subsets of a topological space. http://purl.obolibrary.org/obo/TXPO_0002657 decreasing bile flow in bile canaliculus [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002348 decreasing bile flow in bile canaliculus Decreasing bile flow in bile canaliculus is a subtype of decreasing bile flow: A process that changes the amount of bile flow in bile canaliculus to be lower. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002658 decreasing bile acid production level [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003140 decreasing bile acid production level Decreasing bile acid production level is a subtype of decreasing quantity: A process that changes the production amount of bile acid to be lower. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002659 regulation of bile acid and bile salt transport [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003637 regulation of bile acid and bile salt transport Regulation of bile acid and bile salt transport is a subtype of regulation of transport (biology): Any process that modulates the frequency, rate or extent of the directed movement of bile acid and bile salts . This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002660 bile thrombus formation in bile canaliculus [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003142 bile thrombus formation in bile canaliculus Bile thrombus formation in bile canaliculus is a subtype of bile thrombus formation: A process that constructs bile thrombus in bile canaliculus. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002661 protein aggregation http://purl.obolibrary.org/obo/TXPO_0003815 molecular assembly Protein aggregation is a subtype of molecular assembly: The aggregation, arrangement and bonding together of molecules. http://purl.obolibrary.org/obo/TXPO_0002662 increasing vomume of bile canaliculus [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002717 increasing vomume of bile canaliculus Increasing vomume of bile canaliculus is a subtype of increasing volume: A process that changes the volume of the bile canaliculus to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002663 increasing canalicular membrane permeability [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002706 increasing canalicular membrane permeability Increasing canalicular membrane permeability is a subtype of increasing membrane permeabilization: A process that changes the permeability of the canalicular membrane to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002664 bile reflux [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000590 bile reflux Bile reflux is a subtype of back-flow: A process that changes the bile flow to the opposite direction. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002665 regulation of cell survival http://purl.obolibrary.org/obo/TXPO_0000113 controlling Regulation of cell survival is a subtype of controlling: A process that modulates the frequency, rate or extent of cell survival. http://purl.obolibrary.org/obo/TXPO_0002666 contraction of bile canaliculus [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002695 contraction of bile canaliculus Contraction of bile canaliculus is a subtype of contraction: A process that generates the directed movement in which the bile canaliculus decreases in volume. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002667 negative regulation of contractile movement of bile canaliculus [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003155 negative regulation of contractile movement of bile canaliculus Negative regulation of contractile movement of bile canaliculus is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of contractile movement of bile canaliculus. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002669 necrosis [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002670 inflammatory response [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000192 inflammatory response Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002671 type I diabetes course http://purl.obolibrary.org/obo/TXPO_0002033 diabetes course The totality of all processes through which a given type I diabetes instance is realized. http://purl.obolibrary.org/obo/TXPO_0002672 decreasing flow http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing flow is a subtype of decreasing quantity: A process that changes the amount of flow to be lower. http://purl.obolibrary.org/obo/TXPO_0002673 decreasing bile flow http://purl.obolibrary.org/obo/TXPO_0002672 decreasing flow Decreasing bile flow is a subtype of decreasing flow: A process that changes the amount of bile flow to be lower. http://purl.obolibrary.org/obo/TXPO_0002674 decreasing bile flow [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002673 decreasing bile flow Decreasing bile flow is a subtype of decreasing flow: A process that changes the amount of bile flow to be lower. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002675 enterohepatic circulation [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001979 enterohepatic circulation Enterohepatic circulation is a subtype of changing between operands: Bile salts secreted by the liver pass into the intestine, are absorbed in large part by the ileum, and return to the liver by way of the portal vein. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002676 increasing bile concentration in blood [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002715 increasing bile concentration in blood Increasing bile concentration in blood is a subtype of increasing concentration: A process that changes the concentration of the bile in the blood to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002678 acumulation of bile pigment in bile canaliculus [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001906 acumulation of bile pigment in bile canaliculus Acumulation of bile pigment in bile canaliculus is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a bile canaliculus. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002679 acumulation of bile pigment in hepatocyte [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003150 acumulation of bile pigment in hepatocyte Acumulation of bile pigment in hepatocyte is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a hepatocyte. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002680 XBP1 activation by IRE1 [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0002690 XBP1 activation by IRE1 [ER stress] XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1. This entity is a specific course-dependent process. This process is dependent on the ERAD process and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002681 negative regulation of bile acid and bile salts export from the hepatocyte to bile tube [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001892 negative regulation of bile acid and bile salts export from the hepatocyte Negative regulation of bile acid and bile salts export from the hepatocyte to bile tube is a subtype of negative regulation of transport: A process that stops, prevents, or reduces the frequency, rate or extent of bile acid and bile salts export from the hepatocyte to the bile tube. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002682 negative regulation of transport http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of transport is a subtype of negative regulation process: Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/TXPO_0002683 bile secretion http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B Bile secretion is a subtype of moving A to the outside of B: A process of the release of the bile to the outside of the liver. http://purl.obolibrary.org/obo/TXPO_0002684 IRE1 signaling (primitive) [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role. This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002685 IRE1 activation [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0000730 IRE1 activation [ER stress] IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher. This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002686 IRE1 activation [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0000730 IRE1 activation [ER stress] IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002687 IRE1 activation [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0000730 IRE1 activation [ER stress] IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002688 IRE1 activation [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000730 IRE1 activation [ER stress] IRE1 activation is a subtype of molecular activation: A process that changes the activity of the IRE1 to be higher. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002689 XBP1 activation by IRE1 [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002690 XBP1 activation by IRE1 [ER stress] XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002690 XBP1 activation by IRE1 [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002691 ATF6 signaling (primitive) [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0000719 ATF6 signaling (primitive) [ER stress] ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role. This process is dependent on ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002692 bile secretion to bile canaliculus http://purl.obolibrary.org/obo/TXPO_0002683 bile secretion Bile secretion to bile canaliculus is a subtype of bile secretion: A process that of the release from one side of a hepatocyte plasma membrane to a bile canaliculus. Bile canaliculi are the thin tubes formed by hepatocyte membranes. http://purl.obolibrary.org/obo/TXPO_0002693 bile acid and bile salt transport to hepatocyte http://purl.obolibrary.org/obo/GO_0015721 bile acid and bile salt transport Bile acid and bile salt transport to hepatocyte is a subtype of bile acid and bile salt transport: A process that transports bile acid and bile salts within a hepatocyte by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/TXPO_0002694 ABC transporter http://purl.obolibrary.org/obo/CHEBI_25367 molecule A family of transmembrane proteins that usually function as dimers to hydrolyze ATP, which permits them to transport a wide variety of substrates across cellular membranes. These proteins consist of two distinct domains, a transmembrane domain and a nucleotide-binding domain. ATP binding is required for both dimerization and transporter activity. http://purl.obolibrary.org/obo/TXPO_0002695 contraction of bile canaliculus http://purl.obolibrary.org/obo/TXPO_0003129 contraction Contraction of bile canaliculus is a subtype of contraction: A process that generates the directed movement in which the bile canaliculus decreases in volume. http://purl.obolibrary.org/obo/TXPO_0002696 ERAD related gene expression byXBP1s [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process ERAD related gene expression by XBP1s is a subtype of gene expression: The process in which a gene sequence is converted into a mature ER-associated degradation (ERAD) gene product or products (proteins or RNA) by XBP1s. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002698 importing substance into hepatocyte vascular side (sinusoidal side) membrane by OATP [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001759 importing substances into hepatocyte vascular side (sinusoidal side) membrane [Cholestasis] The directed movement of drugs into hepatocyte vascular side (sinusoidal side) membrane by OATP. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0002699 EDEM (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000871 ER stress dependent molecule (canonical) Extracts misfolded glycoproteins, but not glycoproteins undergoing productive folding, from the calnexin cycle. It is directly involved in endoplasmic reticulum-associated degradation (ERAD) and targets misfolded glycoproteins for degradation in an N-glycan-independent manner, probably by forming a complex with SEL1L. It has low mannosidase activity, catalyzing mannose trimming from Man8GlcNAc2 to Man7GlcNAc2. http://purl.obolibrary.org/obo/TXPO_0002701 hyperfunctioning of glutathione conjugates excretion from hepatocyte http://purl.obolibrary.org/obo/TXPO_0002279 hyperfunction of removing Hyperfunctioning of glutathione conjugates excretion from hepatocyte is a subtype of hyperfunctioning: A process that performs an excessive excretion of the glutathione conjugates from the hepatocyte. http://purl.obolibrary.org/obo/TXPO_0002703 converting cell type http://purl.obolibrary.org/obo/TXPO_0002282 converting type Converting cell type is a subtype of converting type: A process that changes the type of the cell. http://purl.obolibrary.org/obo/TXPO_0002704 changing permeability http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing permeability is a subtype of changing quality: A process that changes the temperature of the object. http://purl.obolibrary.org/obo/TXPO_0002705 changing size http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing size is a subtype of changing quality: A process that changes the size of the object. http://purl.obolibrary.org/obo/TXPO_0002706 increasing canalicular membrane permeability http://purl.obolibrary.org/obo/TXPO_0000232 increasing membrane permeabilization Increasing canalicular membrane permeability is a subtype of increasing membrane permeabilization: A process that changes the permeability of the canalicular membrane to be higher. http://purl.obolibrary.org/obo/TXPO_0002707 estrone [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound An estrogen that has formula C18H22O2. This compound might be participated in the process involved in the course of cholestasis. http://purl.obolibrary.org/obo/TXPO_0002708 hyperfunction of glutathione export from hepatocyte http://purl.obolibrary.org/obo/TXPO_0002351 hyperfunction of transport Hyperfunction of glutathione export from hepatocyte is a subtype of hyperfunction of transport: A process that performs an excesssive export of the glutathione from the hepatocyte. http://purl.obolibrary.org/obo/TXPO_0002709 IRE1 signaling to XBP1 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002571 IRE1 signaling (primitive) [ER stress] A process in which a signal to XBP1 is transduced by the IRE1. This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002710 receiving abnormal protein signal by IRE1 [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1. This process is dependent on the ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002711 hyperfunction of glutathione export from hepatocyte [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002708 hyperfunction of glutathione export from hepatocyte Hyperfunction of glutathione export from hepatocyte is a subtype of hyperfunction of transport: A process that performs an excesssive export of the glutathione from the hepatocyte. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0002712 regulator of OATP bile acid transport http://purl.obolibrary.org/obo/TXPO_0000056 bile acid transport regulator role A role played by the entity which regulatess OATP bile acid transport process. http://purl.obolibrary.org/obo/TXPO_0002713 bile tube occlusion http://purl.obolibrary.org/obo/NCIT_C50678 occlusion Bile tube occlusion is a subtype of occlusion: Obstruction or a closure of bile tube. http://purl.obolibrary.org/obo/TXPO_0002714 increasing bile level http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing bile level is a subtype of increasing quantity: A process that changes the amount of bile to be higher. http://purl.obolibrary.org/obo/TXPO_0002715 increasing bile concentration in blood http://purl.obolibrary.org/obo/TXPO_0000352 increasing concentration Increasing bile concentration in blood is a subtype of increasing concentration: A process that changes the concentration of the bile in the blood to be higher. http://purl.obolibrary.org/obo/TXPO_0002716 refolding promoting gene expression [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Refolding promoting gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) . This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002717 increasing vomume of bile canaliculus http://purl.obolibrary.org/obo/TXPO_0000139 increasing volume Increasing vomume of bile canaliculus is a subtype of increasing volume: A process that changes the volume of the bile canaliculus to be higher. http://purl.obolibrary.org/obo/TXPO_0002718 hyperfunction of protein unfolding http://purl.obolibrary.org/obo/TXPO_0000435 hyperfunctioning Hyperfunction of protein unfolding is a subtype of hyperfunctioning: A process that performs an excesssive protein unfolding. http://purl.obolibrary.org/obo/TXPO_0002719 hyperfunction of moving phenobarbital to the inside of liver [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002600 hyperfunction of moving drug to the inside of liver [Ground glass appearance] A process that performs an excesssive moving phenobarbital to the inside of liver. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0002721 ATF4 gene expression by eIF2a [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0000707 ATF4 gene expression by eIF2a [ER stress] ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002722 Chop expression by ATF4 [ER stress] [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0000698 gene expression by ATF4 [ER stress] Chop expession by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a sequence of the Chop is converted into a mature gene product or products (proteins or RNA) by ATF4. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002723 SHP1 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_1000358 PTPN6 (mol) Nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. SHP-1 represses expression of CYP7A1 by inhibiting the activity of liver receptor homolog 1 (LRH-1), an orphan nuclear receptor known to regulate CYP7A1 expression. http://purl.obolibrary.org/obo/TXPO_0002727 ubiquitination of IkB http://purl.obolibrary.org/obo/TXPO_0004096 protein ubiquitination Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB. http://purl.obolibrary.org/obo/TXPO_0002731 receiving abnormal protein signal by PERK [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002741 receiving abnormal protein signal by PERK [ER stress] Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK. This process is dependent on the apoptosis and can constitute the course of ER stress via apoptosis. http://purl.obolibrary.org/obo/TXPO_0002732 positive regulation of bile export http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Positive regulation of bile export is a subtype of positive regulation process: A process that that activates or increases the frequency, rate or extent of bile acid secretion. http://purl.obolibrary.org/obo/TXPO_0002733 negative regulation of bile acid and bile salts export from the hepatocyte to bile tube [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001892 negative regulation of bile acid and bile salts export from the hepatocyte Negative regulation of bile acid and bile salts export from the hepatocyte to bile tube is a subtype of negative regulation of transport: A process that stops, prevents, or reduces the frequency, rate or extent of bile acid and bile salts export from the hepatocyte to the bile tube. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0002734 cholestasis [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001345 cholestasis (primitive process) Cholestasis is a subtype of stagnating: A process that changes the bile flow to be slower due to obstruction. This entity is a specific course-dependent process. This process can constitute the course of glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0002735 PERK-Nrf2 mediated pathway (integrated pathway) http://purl.obolibrary.org/obo/TXPO_0000067 PERK signaling (integrated pathway) PERK-Nrf2 mediated pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK signaling and gene regulation pathway. http://purl.obolibrary.org/obo/TXPO_0002736 NRF2 activation by PERK [PERK - NRF2 pathway] http://purl.obolibrary.org/obo/TXPO_0001861 changing activity of target molecule by PERK [PERK pathway] A process that changes the activity of the NRF2 to be higher by PERK. This entity is a specific course-dependent process. This process can constitute the course of PERK - NRF2 pathway. http://purl.obolibrary.org/obo/TXPO_0002737 dissociation of Nrf2-Keap1 complex http://purl.obolibrary.org/obo/TXPO_0000462 detaching Dissociation of Nrf2-Keap1 complex is a subtype of detaching: A process that disaggregates a Nrf2-Keap1 complexe into Nrf2 and Keap1. http://purl.obolibrary.org/obo/TXPO_0002738 dissociation of Nrf2-Keap1 complex by PERK [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Dissociation of Nrf2-Keap1 complex by Perk is a subtype of detaching: A process that disaggregates a Nrf2-Keap1 complex into Nrf2 and Keap1 by Perk. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002739 NRF2 activation by PERK [ER stress] http://purl.obolibrary.org/obo/TXPO_0002736 NRF2 activation by PERK [PERK - NRF2 pathway] A process that changes the activity of the NRF2 to be higher by PERK. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002740 PERK-Nrf2 mediated pathway http://purl.obolibrary.org/obo/TXPO_0002735 PERK-Nrf2 mediated pathway (integrated pathway) PERK-NRF2 mediated pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-NRF2 signaling and gene regulation pathway. This pathway is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002741 receiving abnormal protein signal by PERK [ER stress] http://purl.obolibrary.org/obo/TXPO_0001837 receiving signal in PERK signal transduction pathway [PERK pathway] Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002742 PERK signaling to Nrf2 [PERK - eIF2A pathway] http://purl.obolibrary.org/obo/TXPO_0000454 PERK signaling (primitive) [PERK pathway] A process in which a signal to NRF2 is transduced PERK. This entity is a specific course-dependent process. This process can constitute the course of PERK - eIF2A pathway. http://purl.obolibrary.org/obo/TXPO_0002743 PERK signaling to Nrf2 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002742 PERK signaling to Nrf2 [PERK - eIF2A pathway] A process in which a signal to NRF2 is transduced PERK . This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002744 antioxidant gene expression by NRF2 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002618 antioxidant gene expression [ER stress] Antioxidant gene expression by NRF2 is a subtype of gene expression: The process in which an antioxidant gene sequence is converted into a mature antioxidant gene product or products (proteins or RNA) by NRF2. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002746 positive regulation of cellular response to oxidative stress [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Any process that activates or increases the frequency, rate or extent of cellular response to oxidative stress. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002747 oxidation-antioxidtion inbalance [ER stress] http://purl.obolibrary.org/obo/TXPO_0002748 oxidation-antioxidtion inbalance Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002748 oxidation-antioxidtion inbalance http://purl.obolibrary.org/obo/TXPO_0000567 imbalance Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation. http://purl.obolibrary.org/obo/TXPO_0002749 receiving oxidative signal by PERK [ER stress] http://purl.obolibrary.org/obo/TXPO_0001837 receiving signal in PERK signal transduction pathway [PERK pathway] Receiving oxidative signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into a oxidative signal by PERK. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002750 PERK activation [ER stress - antioxidation] http://purl.obolibrary.org/obo/TXPO_0000402 PERK activation [ER stress] PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher. This process is dependent on the antioxidation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002751 enabling translation [ER stress] http://purl.obolibrary.org/obo/TXPO_0002617 enabling translation Enabling translation is a subtype of enabling: A process that sets conditions for translation to work correctly. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002752 dephosphorylation of eIF2a [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) The process of removing one or more phosphoric (ester or anhydride) residues from the eIF2a. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002753 gene expression patheway dependent molecule http://purl.obolibrary.org/obo/TXPO_0001820 system dependent functional molecule Gene expression patheway dependent molecule is a subtype of system dependeny functional molecule. This entity is dependent on a gene expresion system for functioning. http://purl.obolibrary.org/obo/TXPO_0002754 eIF2a gene regulation pathway http://purl.obolibrary.org/obo/TXPO_0001902 gene regulation pathway eIF2a gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate translation of genes by eIF2a. http://purl.obolibrary.org/obo/TXPO_0002755 regulation of translation by eIF2a [ER stress] http://purl.obolibrary.org/obo/TXPO_0002874 regulation of translation by eIF2a Regulation of translation by eIF2a is a subtype of regulation of translation: A process that modulates the frequency, rate or extent of eIF2 alpha mediated translation. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002756 positive regulation of uORF dependent gene expression http://purl.obolibrary.org/obo/GO_0010628 positive regulation of gene expression Positive regulation of uORF dependent gene expression is a subtype of positive regulation of gene expression: A process that modulates the frequency, rate or extent of uORF dependent gene expression. http://purl.obolibrary.org/obo/TXPO_0002757 positive regulation of uORF dependent gene expression [eIF2a [translation regulation] http://purl.obolibrary.org/obo/TXPO_0002756 positive regulation of uORF dependent gene expression Positive regulation of uORF dependent gene expression is a subtype of positive regulation of gene expression: A process that modulates the frequency, rate or extent of uORF dependent gene expression. This entity is a specific eIF2a translational system depedent. http://purl.obolibrary.org/obo/TXPO_0002758 degradation of I-kappaB http://purl.obolibrary.org/obo/GO_0030163 protein catabolic process Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein http://purl.obolibrary.org/obo/TXPO_0002759 Bile acid accumulation in hepatocyte [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process Bile acid accumulation in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps bile acid within the hepatocute in the liver (intrahepatic). This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0002760 refolding promoting gene expression by XBP1s [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Refolding promoting gene expression by XBP1s is a subtype of gene expression: The process in which a gene sequence is converted into a mature refolding inducing gene product or products (proteins or RNA) by XbP1s . This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002761 IRE1 signaling to XBP1 [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002571 IRE1 signaling (primitive) [ER stress] A process in which a signal to XBP1 is transduced by the IRE1. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002762 regulation of translation by eIF2a [ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of proteins by the translation of mRNA or circRNA by eIF2A in the course of ER stress. This process is dependent on the translation attenuation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002763 gene expression by NRF2 http://purl.obolibrary.org/obo/TXPO_0000375 Gene expression by transcriptional regulator Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2. http://purl.obolibrary.org/obo/TXPO_0002764 gene expression by NRF2 [PERK - NRF2 pathway] http://purl.obolibrary.org/obo/TXPO_0002763 gene expression by NRF2 Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2. This entity is a specific course-dependent process. This process can constitute the course of PERK - NRF2 pathway. http://purl.obolibrary.org/obo/TXPO_0002765 gene expression by NRF2 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002764 gene expression by NRF2 [PERK - NRF2 pathway] Gene expression by NRF2 is a subtype of Gene expression by transcriptional regulator: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NRF2. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002766 inflammatory cytokine gene expression [ER stress] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002767 gene expression by CHOP (DDIT3, GADD153) [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0001874 gene expression by CHOP (DDIT3, GADD153) Gene expression by CHOP (DDIT3, GADD153) is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by CHOP (DDIT3, GADD153). This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002770 gene expression bu NF-kappaB http://purl.obolibrary.org/obo/TXPO_0000375 Gene expression by transcriptional regulator Gene expression bu NF-kappaB is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by NF-kappaB. http://purl.obolibrary.org/obo/TXPO_0002772 I-kappaB phosphorylation [NfKB pathway] http://purl.obolibrary.org/obo/TXPO_0002495 I-kappaB phosphorylation I-kappaB phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002773 XBP1 splicing [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000726 XBP1 splicing [ER stress] XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002774 NfkB gene regulation pathway http://purl.obolibrary.org/obo/TXPO_0001902 gene regulation pathway A series of molecular signals transduced with the regulation of transcription of target genes by NF-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. http://purl.obolibrary.org/obo/TXPO_0002775 inflammatory gene expression by NF-kappa B [ER stress - inflammation - IRE1-TRAF-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002770 gene expression bu NF-kappaB Inflammatory gene expression by NF-kappa B is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B. This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002777 ubiquitination of IkB [NfKB pathway] http://purl.obolibrary.org/obo/TXPO_0002727 ubiquitination of IkB Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002778 degradation of IKB [NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002758 degradation of I-kappaB Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002779 Translocation of NF-kappaB [NfKB pathway] http://purl.obolibrary.org/obo/HINO_0017769 Translocation of NF-kappaB from the cytosol to the nucleus NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002780 IKK activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation IKK activation is a subtype of molecular activation: A process that changes the activity of the IKK (kappaB Kinase) to be higher. http://purl.obolibrary.org/obo/TXPO_0002781 IKK activation [NfKB pathway] http://purl.obolibrary.org/obo/TXPO_0002780 IKK activation IKK activation is a subtype of molecular activation: A process that changes the activity of the IIKK (kappaB Kinase) to be higher. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002782 NF-kappaB activation http://purl.obolibrary.org/obo/TXPO_0000124 transcription factor activation NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher. http://purl.obolibrary.org/obo/TXPO_0002783 NF-kappaB activation [NfKB pathway] http://purl.obolibrary.org/obo/TXPO_0002782 NF-kappaB activation NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002784 regulation of gene expression by NfKB http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB. http://purl.obolibrary.org/obo/TXPO_0002785 regulation of gene expression by NfKB [NfKB pathway] http://purl.obolibrary.org/obo/TXPO_0002784 regulation of gene expression by NfKB Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002786 Binding of NF-kappaB and I-kappaB in cytosol http://purl.obolibrary.org/obo/GO_0005515 protein binding Binding of NF-kappaB and I-kappaB in cytosol is a subtype of binding: The selective interaction of a inhibitory-kappaB (I-kappaB/IKB) protein with NF-kappaB. In the resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. http://purl.obolibrary.org/obo/TXPO_0002788 forming disulfide bond 2 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002118 forming disulfide bond Forming disulfide bond 2 is a subtype of binding: The interaction between molecules with interchain disulfide bonds. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002789 cytoplasmic sequestering of NF-kappaB [NfKB pathway] http://purl.obolibrary.org/obo/GO_0007253 cytoplasmic sequestering of NF-kappaB The selective interaction of the transcription factor NF-kappaB with specific molecules in the cytoplasm, thereby inhibiting its translocation into the nucleus. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002790 Binding of NF-kappaB and I-kappaB in cytosol [NfKB pathway] http://purl.obolibrary.org/obo/TXPO_0002786 Binding of NF-kappaB and I-kappaB in cytosol The selective interaction of a inhibitory-kappaB (I-kappaB/IKB) protein with NF-kappaB. In the resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002791 dissociation of NF-kappaB - IkappaB [NfKB pathway] http://purl.obolibrary.org/obo/TXPO_0002492 dissociation of NF-kappaB-I-kappaB Dissociation of NF-kappaB -I-kappaB is a subtype of detaching: A process that disaggregates a NF-kappaB-I-kappaB to NF-kappaB dimers and I-kappaB. In a resting state, NF-kappaB dimers are bound to I-kappaB proteins, sequestering NF-kappaB in the cytoplasm. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing the NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. This entity is a specific course-dependent process. This process can constitute the course of NfKB pathway. http://purl.obolibrary.org/obo/TXPO_0002793 PERK-NFkB pathway [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000067 PERK signaling (integrated pathway) PERK-NFkB pathway is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK signaling and gene regulation pathway. This pathway is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002794 PERK-eIF2a-NFkB pathway [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000701 PERK-eIF2a signaling (integrated pathway) PERK-eIF2a-NFkB pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation by NF-kappa B. This pathway is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002795 IRE1-TRAF2-NFkB signal transduction pathway [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002563 IRE1 signaling (integrated pathway) IRE1-TRAF2-NFkB signal transduction pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-TRAF2 signaling and gene regulation by NF-kappaB. This pathway is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002796 ATF6-NFkB signal transduction pathway [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002548 ATF6 signaling (integrated pathway) ATF6-NFkB signal transduction pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation by NF-kappaB. This process is dependent on positive inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002797 PERK-eIF2a signaling [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000701 PERK-eIF2a signaling (integrated pathway) PERK-eIF2a signaling is a subtype of PERK signaling (integrated pathway): Sequence of linked reactions, which has PERK-eIF2a signaling and gene regulation pathway. This pathway is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002798 NF-kappaB activation [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002799 decreasing I-kappaB production http://purl.obolibrary.org/obo/TXPO_0001830 decreasing production quantity of protein Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower. http://purl.obolibrary.org/obo/TXPO_0002800 decreasing I-kappaB production [ER stress - inflammation -Perk-eIF2a-NfkB] http://purl.obolibrary.org/obo/TXPO_0002799 decreasing I-kappaB production Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower. This process is dependent on the Perk-eIF2a-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002803 cation channel http://purl.obolibrary.org/obo/TXPO_0000328 ion channel A role played by the entity which enables the energy-independent passage of cations across a lipid bilayer down a concentration gradient. http://purl.obolibrary.org/obo/TXPO_0002804 Translocation of NF-kappaB [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002633 Translocation of NF-kappaB [ER stress] NF-kappaB transport into nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002805 inflammatory cytokine gene expression by NF-kappa B via PERK [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory gene expression by NF-kappa B via PERK is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B via PERK. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002806 inflammatory cytokine gene expression via JNK [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory cytokine gene expression via JNK is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) via JNK pathway. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002807 NF-kappaB activation [ER stress - inflammation - IRE1-TRAF2-IkB-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher. This process is dependent on the IRE1-TRAF2-IkB-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002808 I-kappaB phosphorylation [ER stress - inflammation - IRE1-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002495 I-kappaB phosphorylation I-kappaB phosphorylation is a subtype of phosphorylation: The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002809 ubiquitination of IkB [ER stress - inflammation - IRE1-NfKB pathway] http://purl.obolibrary.org/obo/TXPO_0002727 ubiquitination of IkB Ubiquitination of IkB is a subtype of protein ubiquitination: The process in which one or more ubiquitin groups are added to IkB. This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002810 degradation of I-kappaB [ER stress] http://purl.obolibrary.org/obo/TXPO_0002758 degradation of I-kappaB Degradation of I-kappaB is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of inhibitor of kappa B (I-kappaB) protein. This process is dependent on the IRE1-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002811 inflammatory cytokine gene expression by NF-kappa B via IRE1 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory gene expression by NF-kappa B via IRE1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by NF-kappa B via IRE1. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002812 regulation of gene expression by NfKB [ER stress - inflammation - PERK-eIF2a-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002784 regulation of gene expression by NfKB Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB. This process is dependent on the PERK-eIF2a-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002813 regulation of gene expression by NfKB [ER stress - inflammation - IRE1-Traf2-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002784 regulation of gene expression by NfKB Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB. This process is dependent on the IRE1-TARF2-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002814 Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - Perk-eIF2a-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002633 Translocation of NF-kappaB [ER stress] Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus. This process is dependent on the Perk-eIF2a-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002815 Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - IRE1-TRAF2-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002633 Translocation of NF-kappaB [ER stress] Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus. This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002816 TRAF2 activation by IRE1 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002820 TRAF2 activation by IRE1 [ER stress] TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1. This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002817 IKK activation [ER stress - inflammation - IRE1-TRAF2-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002781 IKK activation [NfKB pathway] IKK activation is a subtype of molecular activation: A process that changes the activity of the IIKK (kappaB Kinase) to be higher. This process is dependent on the IRE1-TRAF2-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002820 TRAF2 activation by IRE1 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002872 TRAF2 activation by IRE1 TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002821 TRAF2 activation by IRE1 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway] http://purl.obolibrary.org/obo/TXPO_0002820 TRAF2 activation by IRE1 [ER stress] TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1. This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002823 ASK activation [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002824 ASK activation [IRE-TRAF2-ASK-JNK pathway] ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002824 ASK activation [IRE-TRAF2-ASK-JNK pathway] http://purl.obolibrary.org/obo/TXPO_0002825 ASK activation ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher. This entity is a specific course-dependent process. This process can constitute the course of IRE-TRAF2-ASK-JNK pathway. http://purl.obolibrary.org/obo/TXPO_0002825 ASK activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK （apoptosis signal-regulating kinase) family to be higher. http://purl.obolibrary.org/obo/TXPO_0002826 JNK activation [JNK pathway] http://purl.obolibrary.org/obo/TXPO_0002828 JNK activation JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher. This entity is a specific course-dependent process. This process can constitute the course of JNK pathway. http://purl.obolibrary.org/obo/TXPO_0002827 JNK activation [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher. This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002828 JNK activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher. http://purl.obolibrary.org/obo/TXPO_0002829 AP-1 activation by JNK [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway] http://purl.obolibrary.org/obo/TXPO_0001321 AP-1 activation by JNK AP-1 activation is a subtype of AP-1 activation: A process that changes the activity of the AP-1 to be higher by JNK. This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002830 inflammatory cytokine gene expression by XBP1s [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory gene expression by XBP1s is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by XBP1s. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002831 IRE1 signaling to XBP1 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002571 IRE1 signaling (primitive) [ER stress] A process in which a signal to XBP1 is transduced by the IRE1. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002832 XBP1 activation by IRE1 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002690 XBP1 activation by IRE1 [ER stress] XBP1 activation by IRE1 is a subtype of activation of transcription factor: A process that changes the activity of XBP1 (X-Box Binding Protein 1) to be higher by IRE1. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002833 inflammatory cytokine gene expression by AP-1 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Inflammatory gene expression by AP-1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by AP-1. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002834 IRE1 signaling to TRAF2 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002594 IRE1 signaling to TRAF2 [ER stress - inflammation] A process in which a signal to TRAF2 is transduced by the IRE1. This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002835 IRE1 signaling to TRAF2 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway] http://purl.obolibrary.org/obo/TXPO_0002594 IRE1 signaling to TRAF2 [ER stress - inflammation] A process in which a signal to TRAF2 is transduced by the IRE1. This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002836 IRE1-XBP1 mediated pathway [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002563 IRE1 signaling (integrated pathway) IRE1-XBP1 mediated pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1 signaling and gene regulation by XBP1. This process is dependent on inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002837 Translocation of NF-kappaB from the Cytosol to the Nucleus [ER stress - inflammation - ATF6-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002633 Translocation of NF-kappaB [ER stress] Translocation of NF-kappaB from the Cytosol to the Nucleus is a subtype of nuclear transport: A process that of the directed movement of NF-kappaB from the cytoplasm to the nucleus. This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002838 ATF6 signaling (primitive) [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000719 ATF6 signaling (primitive) [ER stress] ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002840 regulation of gene expression by NfKB [ER stress - inflammation - ATF6-NfkB Pathway] http://purl.obolibrary.org/obo/TXPO_0002784 regulation of gene expression by NfKB Regulation of gene expression by NfKB is a subtype of regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gene expression by NfkB. This process is dependent on the ATF6-NfkB Pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002841 NF-kappaB activation [ER stress - inflammation - ATF6-NfkB] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) NF-kappaB activation is a subtype of transcription factor activation: A process that changes the activity of the NF-kappaB to be higher. This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002842 decreasing I-kappaB production [ER stress -inflmmation- ATF6-NfkB] http://purl.obolibrary.org/obo/TXPO_0002799 decreasing I-kappaB production Decreasing I-kappaB production is a subtype of decreasing production quantity of protein: A process that changes the quantity of the Iinhibitor of kappa B (I-kappaB) to be lower. This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002843 inflammatory cytokine gene expression by NF-kappa B via ATF6 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory cytokine gene expression by NF-kappaB via ATF6 is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) by NF-kappaB via ATF6 signaling. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002844 ATF6 signaling (primitive) [ER stress - inflammation - ATF6-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002838 ATF6 signaling (primitive) [ER stress - inflammation] ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role. This process is dependent on the ATF6-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002847 receiving abnormal protein signal by PERK [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002741 receiving abnormal protein signal by PERK [ER stress] Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK. This process is dependent on the inflammation and can constitute the course of ER stress via inflammation. http://purl.obolibrary.org/obo/TXPO_0002849 PERK signaling to eIF2a [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002449 PERK signaling to eIF2a [ER stress] A process in which a signal to eIF2a is transduced by PERK. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002851 XBP1 splicing [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0000726 XBP1 splicing [ER stress] XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences. This process is dependent on the refolding process and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002852 changing activity of eIF2a by PERK [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002378 changing activity of eIF2a by PERK [ER stress PERK - eIF2A pathway] A process that changes the activity of the eIF2a by PERK. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002853 attenuation of I-kappaB translation by eIF2a [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000722 attenuation of translation [ER stress] Any process that stops, prevents, or reduces the frequency, rate or extent of I-Kappa B translation by eIF2a. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002854 PERK activation [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000402 PERK activation [ER stress] PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002855 PERK dimerization [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000713 PERK dimerization [ER stress] PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002865 Dissociation of PERK:BIP Heterodimer [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002213 Dissociation of PERK:BIP Heterodimer [ER stress] Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002866 PERK dimerization [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0000713 PERK dimerization [ER stress] PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002867 PERK dimerization [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0000713 PERK dimerization [ER stress] PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002868 PERK autophosphorylation [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000674 PERK autophosphorylation [ER stress] PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation). This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002869 PERK autophosphorylation [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0000674 PERK autophosphorylation [ER stress] PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation). This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002870 PERK autophosphorylation [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0000674 PERK autophosphorylation [ER stress] PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation). This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002871 XBP1 splicing [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0000726 XBP1 splicing [ER stress] XBP1 splicing is a subtype of removing: The process of removing sections of the XBP1 RNA transcript to remove sequences. This entity is a specific course-dependent process. This process is dependent on the ERAD process and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002872 TRAF2 activation by IRE1 http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1. http://purl.obolibrary.org/obo/TXPO_0002873 chronic http://purl.obolibrary.org/obo/PATO_0001309 duration A duration quality of a process inhering in a bearer by virtue of the bearer's having slow progressive course of indefinite duration. http://purl.obolibrary.org/obo/TXPO_0002874 regulation of translation by eIF2a http://purl.obolibrary.org/obo/GO_0006417 regulation of translation Regulation of translation by eIF2a is a subtype of regulation of translation: A process that modulates the frequency, rate or extent of eIF2 alpha mediated translation. http://purl.obolibrary.org/obo/TXPO_0002875 IRE1 pathway [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002487 IRE1-mediated unfolded protein response [ER stress] A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). This process is dependent on the apoptosis that can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002876 IRE1 pathway [ER stress - inflammation - IRE1-XBP1 pathway] http://purl.obolibrary.org/obo/TXPO_0002487 IRE1-mediated unfolded protein response [ER stress] A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). This process is dependent on the inflammation via IRE1-XBP1 pathway that can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002877 IRE1 pathway [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0002487 IRE1-mediated unfolded protein response [ER stress] A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). This process is dependent on the inflammation that can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002878 IRE1 pathway [ER stress - inflammation - IRE1-JNK pathway] http://purl.obolibrary.org/obo/TXPO_0002487 IRE1-mediated unfolded protein response [ER stress] A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). This process is dependent on the inflammation via IRE1-JNK pathway that can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002879 IRE1 pathway [ER stress - inflammation - IRE1-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002487 IRE1-mediated unfolded protein response [ER stress] A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). This process is dependent on the inflammation via IRE1-NfkB pathway that can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002885 Dissociation of IRE1:BIP Heterodimer [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002176 Dissociation of IRE1:BIP Heterodimer [ER stress] Dissociation of IRE1:BIP heterodimer is a subtype of detaching: A process that disaggregates IRE-1-BIP heterodimers into BIP and IRE1. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002887 receiving abnormal protein signal by IRE1 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002888 receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-TRAF2-ASK-JNK pathway] http://purl.obolibrary.org/obo/TXPO_0002887 receiving abnormal protein signal by IRE1 [ER stress - inflammation] Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1. This process is dependent on the IRE1-TRAF2-ASK-JNK pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002889 receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-TRAF2-IKK-NfkB pathway] http://purl.obolibrary.org/obo/TXPO_0002887 receiving abnormal protein signal by IRE1 [ER stress - inflammation] Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1. This process is dependent on the IRE1-TRAF2-IKK-NfkB pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002895 receiving abnormal protein signal by IRE1 [ER stress - inflammation - IRE1-XBP1 pathway] http://purl.obolibrary.org/obo/TXPO_0002887 receiving abnormal protein signal by IRE1 [ER stress - inflammation] Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1. This process is dependent on the IRE1-XBP1 pathway mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002903 Dissociation of ATF6-alpha:BIP Complex [ER stress] http://purl.obolibrary.org/obo/TXPO_0000505 dissociation of BIP complex [ER stress] Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002904 Dissociation of ATF6-alpha:BIP Complex [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002903 Dissociation of ATF6-alpha:BIP Complex [ER stress] Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002905 Bip-unfolded protein complex 1 [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0003157 Bip-unfolded protein complex [ER stress] Bip-unfolded protein is a subtype of a molecular complex. This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein. This entity can participate in the infmallation of ER stress via PERK pathway. http://purl.obolibrary.org/obo/TXPO_0002906 Bip-Unfolded Protein complex 2 [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0003157 Bip-unfolded protein complex [ER stress] Bip-unfolded protein is a subtype of a molecular complex. This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein. This entity can participate in the protein refolding of ER stress. http://purl.obolibrary.org/obo/TXPO_0002907 Bip-unfolded protein complex 3 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003157 Bip-unfolded protein complex [ER stress] Bip-unfolded protein is a subtype of a molecular complex. This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein. This entity can participate in the inflammation of ER stress via IRE1 pathway. http://purl.obolibrary.org/obo/TXPO_0002908 ATF6 mediated proapoptic gene production pathway [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002548 ATF6 signaling (integrated pathway) ATF6 mediated proapoptic gene production pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway. This process is dependent on positive regulation of apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002909 ATF6 signaling (primitive) [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0000719 ATF6 signaling (primitive) [ER stress] ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002911 ATF6 activation [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002912 apoptotic gene expression by ATF6 [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002521 The process in which a gene's sequence is converted into a mature gene product or products (proteins or RNA) by ATF6. Refolding gene expression by ATF6 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the apoptosis by ATF6. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002916 apoptosis promoting gene expression [ER stress] http://purl.obolibrary.org/obo/TXPO_0002917 apoptosis promoting gene expression Apoptosis inducing gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature apoptosis inducing gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002917 apoptosis promoting gene expression http://purl.obolibrary.org/obo/GO_0010467 gene expression Apoptosis inducing gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature apoptosis inducing gene product or products (proteins or RNA). http://purl.obolibrary.org/obo/TXPO_0002918 ATF6 activation [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher. This process is dependent on ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002919 refolding gene expression by XBP1 [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002607 gene expression by XBP1 [ER stress] Refolding gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the protein refolding function by XBP1. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002922 co-chaperone http://purl.obolibrary.org/obo/TXPO_0003732 molecular (activity) co-regulator A role played by the entity that assists chaperon and ensures correct protein folding. http://purl.obolibrary.org/obo/TXPO_0002924 ATF6 activation [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002925 positive regulation of gene expression via JNK signaling [ER stress] http://purl.obolibrary.org/obo/TXPO_0003116 positive regulation of gene expression via JNK signaling Positive regulation of gene expression via JNK signaling is a subtype of positive regulation of gene expression: A process that that activates or increases the frequency, rate or extent of gene expression via JNK signaling. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002926 receiving abnormal protein signal by IRE1 [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002933 positive regulator role of translational initiation http://purl.obolibrary.org/obo/TXPO_0002557 translation regulator role A role played by the entity that activates, or increases the frequency, rate or extent of translation initiation http://purl.obolibrary.org/obo/TXPO_0002936 IRE1-Traf2-ASK-JNK-Bcl2 pathway [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002563 IRE1 signaling (integrated pathway) IRE1-Traf2-ASK-JNK-Bcl2 pathway is a subtype of IRE1 signaling (integrated pathway): Sequence of linked reactions, which has IRE1-Traf2-ASK-JNK-BCL2 pathway and gene regulation. This pathway is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002937 TRAF2 activation by IRE1 [ER stress - apoptosis - IRE1−TRAF2-ASK-JNK-Bcl2 pathway] http://purl.obolibrary.org/obo/TXPO_0002820 TRAF2 activation by IRE1 [ER stress] TRAF2 activation by IRE1 is a subtype of molecular activation: A process that changes the activity of the TARF2 to be higher by IRE1. This process is dependent on the IRE1−TRAF2-ASK-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002939 ASK activation [ER stress - apoptosis - IRE1-TRAF2-ASK-JNK-Bcl2 pathway] http://purl.obolibrary.org/obo/TXPO_0002824 ASK activation [IRE-TRAF2-ASK-JNK pathway] ASK activation is a subtype of molecular activation: A process that changes the activity of one of the ASK (apoptosis signal-regulating kinase) family to be higher. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002940 JNK activation [ER stress - apoptosis - IRE1−TRAF2-ASK-JNK-Bcl2 pathway] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) JNK activation is a subtype of molecular activation: A process that changes the activity of the JNK to be higher. This process is dependent on the IRE1−TRAF2-ASK-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002946 Bcl2 inactivation by JNK [ER stress - apoptosis - IRE1-TRAF2-JNK pathway] http://purl.obolibrary.org/obo/TXPO_0002947 Bcl2 inactivation by JNK A process that changes the activity of the Bcl2 to be lower by JNK. This process is dependent on the IRE1-TRAF2-JNK pathway mediated apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002947 Bcl2 inactivation by JNK http://purl.obolibrary.org/obo/TXPO_0000021 inactivation Bcl2 inactivation by JNK is a subtype of inactivating: A process that changes the activity of the Bcl2 to be lower by JNK. http://purl.obolibrary.org/obo/TXPO_0002948 BIM activation [ER stress - apoptosis - IRE1−TRAF2-JNK-Bcl2 pathway] http://purl.obolibrary.org/obo/TXPO_0002949 BIM activation BIM activation is a subtype of molecular activation: A process that changes the activity of the BIM (BCL2L11), BH3-only BCL-2 family, to be higher. This process is dependent on the IRE1−TRAF2-JNK-Bcl2 pathway mediated apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002949 BIM activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation BIM activation is a subtype of molecular activation: A process that changes the activity of the BIM (BCL2L11), BH3-only BCL-2 family, to be higher. http://purl.obolibrary.org/obo/TXPO_0002950 Bcl2 phosphorylation by JNK [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002951 Bcl2 phosphorylation by JNK [ER stress] Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002951 Bcl2 phosphorylation by JNK [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002952 Bcl2 phosphorylation by JNK http://purl.obolibrary.org/obo/TXPO_0001392 Bcl2 phosphorylation Bcl2 phosphorylation by JNK is a subtype of Bcl2 phosphorylation: A process that The process of introducing a phosphate group into Bcl2 by JNK. http://purl.obolibrary.org/obo/TXPO_0002953 IRE1 signaling (primitive) [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) IRE1 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the IRE1 (Inositol-requiring transmembrane kinase/endonuclease). IRE1 generally plays a endoplasmic reticulum membrane stress sensor role. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002956 IRE1 pathway [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002487 IRE1-mediated unfolded protein response [ER stress] A series of molecular signals mediated by the endoplasmic reticulum stress sensor IRE1 (Inositol-requiring transmembrane kinase/endonuclease). This process is dependent on the protein refolding that can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002957 receiving abnormal protein signal by IRE1 [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Receiving abnormal protein signal by IRE1 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by IRE1. This entity is a specific course-dependent process. This process can constitute the course of ER stress via protein refolding. http://purl.obolibrary.org/obo/TXPO_0002959 XBP1s gene regulation pathway [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002486 XBP1s gene regulation pathway XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression. This process is dependent on the protein refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002960 XBP1s gene regulation pathway [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0002486 XBP1s gene regulation pathway XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression. This process is dependent on the inflammation that can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002961 CHOP gene regulation pathway [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002485 CHOP gene regulation pathway CHOP gene regulation pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by CHOP. This pathway is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002962 NRF2 gene regulation pathway [ER stress] http://purl.obolibrary.org/obo/TXPO_0002490 NRF2 signaling pathway NRF2 signaling (integrated pathway) is a subtype of integrated signaling pathway: Sequence of linked reactions, which has NRF2 signaling and gene regulation pathway. This pathway is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002963 Refolding gene regulation pathway by ATF4 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002483 ATF4 gene regulation pathway Refolding gene regulation pathway by ATF4 is a subtype of ATF4 gene regulation pathway: Sequence of reactions to regulate refolding genes by ATF4. This pathway can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002964 refolding gene expression by ATF4 [ER stress] http://purl.obolibrary.org/obo/TXPO_0000698 gene expression by ATF4 [ER stress] Refolding gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the refolding by ATF4. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002966 apoptotic gene expression by ATF4 [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0000698 gene expression by ATF4 [ER stress] Inflammatiory gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to apoptosis by ATF4. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002967 carbohydrate metabolism gene expression by ATF4 [ER stress] http://purl.obolibrary.org/obo/TXPO_0000698 gene expression by ATF4 [ER stress] Carbohydrate metabolism related gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related carbohydrate metabolism by ATF4. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002968 lipid metabolism gene expression by ATF4 [ER stress] http://purl.obolibrary.org/obo/TXPO_0000698 gene expression by ATF4 [ER stress] Lipid metabolism gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the lipid metabolism by ATF4. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002971 IRE1 dimerization [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002596 IRE1 dimerization [ER stress] IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002975 IRE1 dimerization [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0002596 IRE1 dimerization [ER stress] IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This entity is a specific course-dependent process. This process is dependent on ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002976 IRE1 autophosphorylation [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation). This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002977 IRE1 autophosphorylation [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation). This process is dependent on the ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002980 Translocation of XBP1s from the cytosol to the nucleus http://purl.obolibrary.org/obo/GO_0051169 nuclear transport Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus. http://purl.obolibrary.org/obo/TXPO_0002981 Translocation of XBP1s from the cytosol to the nucleus [ER stress] http://purl.obolibrary.org/obo/TXPO_0002980 Translocation of XBP1s from the cytosol to the nucleus Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002982 Translocation of XBP1s from the cytosol to the nucleus [ER stress - refolding] http://purl.obolibrary.org/obo/TXPO_0002981 Translocation of XBP1s from the cytosol to the nucleus [ER stress] Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus. This process is dependent on the refolding and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002983 Translocation of XBP1s from the cytosol to the nucleus [ER stress - ERAD] http://purl.obolibrary.org/obo/TXPO_0002981 Translocation of XBP1s from the cytosol to the nucleus [ER stress] Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus. This entity is a specific course-dependent process. This process is dependent on the ERAD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002984 XBP1s gene regulation pathway[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002486 XBP1s gene regulation pathway XBP1s gene regulation pathway is a subtype of gene regulation pathway: A series of process in which XBP1s regulates the gene expression. This pathway is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002985 Translocation of XBP1s from the cytosol to the nucleus [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002981 Translocation of XBP1s from the cytosol to the nucleus [ER stress] Translocation of XBP1s from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of XBP1s from the cytoplasm to the nucleus. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002986 PERK-eIF2a-CyclinD1 pathway [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0000701 PERK-eIF2a signaling (integrated pathway) PERK-eIF2a-CyclinD1 pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and CyclinD1 gene regulation. This pathway is dependent on the cell cycle arrest and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002987 regulation of cell cycle related gene expression [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Regulation of cell cycle related gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of cel cycle related gene expression. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002988 negative regulation of formation of cytoplasmic translation initiation complex by eIF2a [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Negative regulation of formation of cytoplasmic translation initiation complex is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of formation of cytoplasmic translation initiation complex. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002989 attenuation of Cyclin D1 translation by eIF2a [ER stress] http://purl.obolibrary.org/obo/TXPO_0000722 attenuation of translation [ER stress] Any process that stops, prevents, or reduces the frequency, rate or extent of Cyclin D1 translation by eIF2a. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002990 negative regulation of cell cycle regulator gene expression [ER stress] http://purl.obolibrary.org/obo/TXPO_0003455 negative regulation of cell cycle gene expression Negative regulation of cell cycle regulator gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell cycle regulator gene expression. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002991 PERK signaling to eIF2a [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0002449 PERK signaling to eIF2a [ER stress] A process in which a signal to eIF2a is transduced by PERK. This process is dependent on the cell cycle arrest and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002992 receiving abnormal protein signal by PERK [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0002741 receiving abnormal protein signal by PERK [ER stress] Receiving abnormal protein signal by PERK is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by PERK. This entity is a specific course-dependent process. This process can constitute the course of ER stress via cell cycle arrest. http://purl.obolibrary.org/obo/TXPO_0002995 Dissociation of PERK:BIP Heterodimer [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0002213 Dissociation of PERK:BIP Heterodimer [ER stress] Dissociation of PERK:BIP heterodimer is a subtype of detaching: A process that disaggregates PERK-BIP heterodimers into BIP and PERK. This process is dependent on the cell cycle arrest and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0002997 PERK autophosphorylation [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0000674 PERK autophosphorylation [ER stress] PERK autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by PERK of one or more of its own amino acid residues (cis-autophosphorylation), or residues on PERK (trans-autophosphorylation). This process is dependent on the cell cycle arrest and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003000 Phosphorylation of eIF2-alpha by PERK [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0000700 Phosphorylation of eIF2-alpha by PERK [ER stress] Phosphorylation of eIF2-alpha by PERK is a subtype of eIF2a phosphorylation: A process that The process of introducing a phosphate group into eIF2a by PERK. This process is dependent on the cell cycle arrest and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003001 changing activity of eIF2a by PERK [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0002378 changing activity of eIF2a by PERK [ER stress PERK - eIF2A pathway] A process that changes the activity of the eIF2a by PERK. This process is dependent on the cell cycle arrest and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003002 PERK activation [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0000402 PERK activation [ER stress] PERK activation is a subtype of Molecular activation: A process that changes the activity of PERK to be higher. This process is dependent on the cell cycle arrest and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003004 PERK dimerization [ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0000713 PERK dimerization [ER stress] PERK dimerization is a subtype of protein dimerization: The formation of a PERK dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This entity is a specific course-dependent process. This process is dependent on the process of cell cycle arrest and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003007 changing calcium ion concentration http://purl.obolibrary.org/obo/TXPO_0002438 changing concentration Changing calcium ion concentration is a subtype of changing concentration: A process that changes the calcium ion concentration in the blood. http://purl.obolibrary.org/obo/TXPO_0003008 changing calcium ion concentration in ER [ER stress] http://purl.obolibrary.org/obo/TXPO_0003009 changing calcium ion concentration in ER Changing calcium ion concentration in ER is a subtype of changing calcium ion concentration: A process that changes the calcium ion concentration in the endoplasmic reticulum (ER). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003009 changing calcium ion concentration in ER http://purl.obolibrary.org/obo/TXPO_0003007 changing calcium ion concentration Changing calcium ion concentration in ER is a subtype of changing calcium ion concentration: A process that changes the calcium ion concentration in the endoplasmic reticulum (ER). http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0000794 ER stress dependent chemical entity ER stress dependent chemical compound is a subtype of toxic course dependent chemical entity. This entity (drug) can participate in the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003013 negative regulation of SERCA gene expression http://purl.obolibrary.org/obo/GO_0010629 negative regulation of gene expression Negative regulation of SERCA gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of SERCA gene expression. http://purl.obolibrary.org/obo/TXPO_0003014 negative regulation of SERCA gene expression [ER stress] http://purl.obolibrary.org/obo/TXPO_0003013 negative regulation of SERCA gene expression Negative regulation of SERCA gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of SERCA gene expression. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003016 negative regulation of endoplasmic reticulum-associated degradation [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Negative regulation of endoplasmic reticulum-associated degradation is a subtype of negative regulation of protein catabolic process: A process that stops, prevents, or reduces the frequency, rate or extent of endoplasmic reticulum-associated degradation. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003017 negative regulation of proteasomal protein catabolic process [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Any process that stops, prevents or reduces the frequency, rate or extent of proteasomal protein catabolic process. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003026 intrinsic apotosis signaling (primitive) http://purl.obolibrary.org/obo/TXPO_0003237 intrinsic apoptosis signaling (primitive) Intrinsic apoptosis signaling (primitive) is a subtype of signaling [biological]: A process in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The process starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.). This process is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP). This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003030 receiving abnormal protein signal by ATF6 [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Receiving abnormal protein signal by ATF6 is a subtype of receiving signal: A process that recognizes another object and changes into an abnormal protein (e.g., misfolded protein, etc.) signal by ATF6. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003031 Dissociation of ATF6-alpha:BIP Complex [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002903 Dissociation of ATF6-alpha:BIP Complex [ER stress] Dissociation of ATF6:BIP heterodimer is a subtype of detaching: A process that disaggregates ATF6-BIP heterodimers into BIP and ATF6. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003033 proapoptic gene regulation pathway by ATF6 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002520 ATF6 gene regulation pathway Proapoptic gene regulation pathway by ATF6 is a subtype of ATF6 gene regulation pathway: Sequence of reactions to regulate genes which have a proapoptosis inducer role by ATF6. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003035 ATF4 gene expression by eIF2a [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000707 ATF4 gene expression by eIF2a [ER stress] ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003036 inflammatory gene expression by ATF4 [ER stress] http://purl.obolibrary.org/obo/TXPO_0000698 gene expression by ATF4 [ER stress] Inflammatiory gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the induction of inflammation by ATF4. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003041 inflammatory substance role http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role A role played by the entity that has inflammatory effects. http://purl.obolibrary.org/obo/TXPO_0003042 type II diabetes course http://purl.obolibrary.org/obo/TXPO_0002033 diabetes course The totality of all processes through which a typeII instance is realized. http://purl.obolibrary.org/obo/TXPO_0003043 inflammatory cytokine gene expression via ATF4 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Inflammatory cytokine gene expression via ATF4 is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA) via ATF4. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003044 ATF6-CREBPH-APR pathway [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002548 ATF6 signaling (integrated pathway) ATF6-CREBPH-APR pathway is a subtype of ATF6 signaling (integrated pathway): Sequence of linked reactions, which has ATF6 signaling and gene regulation pathway. This process is dependent on positive inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003045 APR gene expression by ATF6 [ER stress - inflammation - ATF6-ARP] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) APR gene expression by ATF6. is a subtype of Gene expression by transcriptional regulator: The process in which the sequence of APR is converted into a mature gene product or products (proteins or RNA) by ATF6. This process is dependent on the ATF6-ARP mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003051 refolding promoting factor role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role Refolding promotor is a role played by any substance that promotes the process of refolding. http://purl.obolibrary.org/obo/TXPO_0003054 ATF4 gene expression by eIF2a [ER stress - translation] http://purl.obolibrary.org/obo/TXPO_0000707 ATF4 gene expression by eIF2a [ER stress] ATF4 gene expression by eIF2a is a subtype of gene expression: The process in which a gene sequence is converted into a mature ATF4 gene product or products (proteins or RNA) by eIF2a. This process is dependent on the retranslation process and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003056 tranlation promotion gene expression by ATF4 [ER stress] http://purl.obolibrary.org/obo/TXPO_0000698 gene expression by ATF4 [ER stress] Tranlation promotion gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the translation promotion by ATF4. This process is dependent on the retranslation process and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003057 GADD34 gene expression by ATF4 [ER stress] http://purl.obolibrary.org/obo/TXPO_0003056 tranlation promotion gene expression by ATF4 [ER stress] GADD34 gene expression by ATF4 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence of GADD34 is converted into a mature gene product or products (proteins or RNA) by ATF4. This process is dependent on the retranslation process and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003058 PERK-ATF4-GADD34 signaling [ER stress - retranslation] http://purl.obolibrary.org/obo/TXPO_0002513 PERK-eIF2a-ATF4 mediated pathway PERK-eIF2a-ATF4 mediated pathway is a subtype of PERK-eIF2a signaling: Sequence of linked reactions, which has PERK-eIF2a signaling and GADD34 gene regulation by ATF4. This pathway is dependent on the retranslation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003059 PERK signaling to eIF2a [ER stress - translation] http://purl.obolibrary.org/obo/TXPO_0002449 PERK signaling to eIF2a [ER stress] A process in which a signal to eIF2a is transduced by PERK. This process is dependent on the translation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003060 peroxisome fatty acid beta oxidation gene expression(sustained) [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0000175 peroxisome fatty acid beta oxidation gene expression Peroxisome fatty acid beta oxidation gene expression is a subtype of gene expression: A process that The process in which a gene sequence is converted into a mature peroxisome fatty acid beta oxidation gene product or products (proteins or RNA) persistently. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0003061 extrinsic apoptotic signaling pathway via death domain receptors [cell death] http://purl.obolibrary.org/obo/GO_0008625 extrinsic apoptotic signaling pathway via death domain receptors A series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with a ligand binding to a death domain receptor on the cell surface, and ends when the execution phase of apoptosis is triggered. This pathway is a specific course-dependent and can constitute the course of cell death. http://purl.obolibrary.org/obo/TXPO_0003063 ATF6 processing http://purl.obolibrary.org/obo/GO_0016485 protein processing ATF6 processing is a subtype of protein processing: A process that ATF6 maturation process achieved by the cleavage of a peptide bond or bonds within ATF6 protein. http://purl.obolibrary.org/obo/TXPO_0003064 IRE1 autophosphorylation [ER stress - RIDD] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) IRE1 autophosphorylation is a subtype of protein autophosphorylation: The phosphorylation by IRE1 of one or more of its own amino acid residues (cis-autophosphorylation), or residues on IRE1 (trans-autophosphorylation). This entity is a specific course-dependent process. This process is dependent on RODD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003065 inflammatory gene expression by XBP1 [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002607 gene expression by XBP1 [ER stress] Inflammatory gene expression by XBP1 is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) related to the inflammation by XBP1. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003068 ARP related gene expression via ATF6 [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) ARP related gene expression via ATF6 is a subtype of gene expression: The process in which a gene sequence is converted into a mature ARP gene product or products (proteins or RNA) ia ATF6. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003071 ARP related gene expression http://purl.obolibrary.org/obo/GO_0010467 gene expression ARP related gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature ARP gene product or products (proteins or RNA) by PERK. http://purl.obolibrary.org/obo/TXPO_0003072 ATF6 signaling (primitive) [ER stress - inflammation - ATF6-ARP] http://purl.obolibrary.org/obo/TXPO_0002838 ATF6 signaling (primitive) [ER stress - inflammation] ATF6 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the ATF6 (activating transcription factor 6). ATF6 generally plays a endoplasmic reticulum membrane stress sensor role. This process is dependent on the ATF6-ARP mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003073 ATF6 activation [ER stress - inflammation - ARP] http://purl.obolibrary.org/obo/TXPO_0002924 ATF6 activation [ER stress - inflammation] ATF6 activation is a subtype of molecular activation: A process that changes the activity of the ATF6 (Activating Transcription Factor 6) to be higher. This process is dependent on the ARP mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003074 ATF6 processing [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) ATF6 processing is a subtype of protein processing: A process that ATF6 maturation process achieved by the cleavage of a peptide bond or bonds within ATF6 protein. This process is dependent on the inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003075 cleavage of CREB by S1P [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Cleavage of CREB by S1P is a subtype of proteolysis: A process in which CREB is cleaved by endopeptidase S1P( MBTPS1). This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003076 cleavage of CREB by S1P http://purl.obolibrary.org/obo/TXPO_0000333 separating Cleavage of CREB by S1P is a subtype of proteolysis: A process in which CREB is cleaved by endopeptidase S1P( MBTPS1). http://purl.obolibrary.org/obo/TXPO_0003077 cleavage of CREB by S2P http://purl.obolibrary.org/obo/TXPO_0000333 separating Cleavage of CREB by S2P is a subtype of proteolysis: A process in which CREB is cleaved by endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage http://purl.obolibrary.org/obo/TXPO_0003078 cleavage of CREB by S2P [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Cleavage of CREB by S2P is a subtype of proteolysis: A process in which CREB is cleaved by endopeptidase S2P( MBTPS2). Site-2 cleavage comes after site-1 cleavage This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003079 CERB processing [ER stress - inflammation -ARP] http://purl.obolibrary.org/obo/TXPO_0003766 CERB processing CERB processing is a subtype of protein processing: CREB maturation process achieved by the cleavage of a peptide bond or bonds within CREB protein. This process is dependent on the ARP mediated inflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003080 CREB3L3 activation [ER stress - inflammation - ARP] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) CREB3L3 activation is a subtype of molecular activation: A process that changes the activity of the CREBL3 to be higher. This process is dependent on the rinflammation and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003081 CREB3L3 signaling [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) CREB3L3 signaling is a subtype of signaling [biological]: A process that in which a signal transmitted by CREB3L3. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003084 ARP gene regulation pathway by ATF6 [ER stress] http://purl.obolibrary.org/obo/TXPO_0002520 ATF6 gene regulation pathway ARP gene regulation pathway by ATF6 is a subtype of ATF6 gene regulation pathway: Sequence of reactions to regulate acute response protein (ARP) genes by ATF6. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003089 IRE1 dimerization [ER stress - RIDD] http://purl.obolibrary.org/obo/TXPO_0002596 IRE1 dimerization [ER stress] IRE1 dimerization is a subtype of protein dimerization: The formation of a IRE1 dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. This entity is a specific course-dependent process. This process is dependent on RIDD and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003091 caspase 12 signaling (primitive) [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase 12 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 12. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003092 caspase 4 signaling (primitive) [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase 4 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 4. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003093 caspase-12 activation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase-12 activation is a subtype of caspase activation: A process that changes the activity of the caspase-12, intracellular cysteine endopeptidase family members, to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003094 caspase-4 activation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase-4 activation is a subtype of caspase activation: A process that changes the activity of the caspase-4, intracellular cysteine endopeptidase family members, to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003095 caspase activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation Caspase activation is a subtype of molecular activation: A process that changes the activity of the caspase, intracellular cysteine endopeptidase family members, to be higher. http://purl.obolibrary.org/obo/TXPO_0003096 caspase-9 activation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase-9 activation is a subtype of caspase activation: A process that changes the activity of the caspase-9, intracellular cysteine endopeptidase family members, to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003097 caspase-3 activation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase-3 activation is a subtype of caspase activation: A process that changes the activity of the caspase-3, intracellular cysteine endopeptidase family members, to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003098 caspase-3 activation http://purl.obolibrary.org/obo/TXPO_0003095 caspase activation Caspase-3 activation is a subtype of caspase activation: A process that changes the activity of the caspase-3, intracellular cysteine endopeptidase family members, to be higher. http://purl.obolibrary.org/obo/TXPO_0003099 caspase-9 activation http://purl.obolibrary.org/obo/TXPO_0003095 caspase activation Caspase-9 activation is a subtype of caspase activation: A process that changes the activity of the caspase-9, intracellular cysteine endopeptidase family members, to be higher. http://purl.obolibrary.org/obo/TXPO_0003100 caspase-12 activation http://purl.obolibrary.org/obo/TXPO_0003095 caspase activation Caspase-12 activation is a subtype of caspase activation: A process that changes the activity of the caspase-12, intracellular cysteine endopeptidase family members, to be higher. http://purl.obolibrary.org/obo/TXPO_0003101 caspase-4 activation http://purl.obolibrary.org/obo/TXPO_0003095 caspase activation Caspase-4 activation is a subtype of caspase activation: A process that changes the activity of the caspase-4, intracellular cysteine endopeptidase family members, to be higher. http://purl.obolibrary.org/obo/TXPO_0003102 caspase pathway [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0002482 caspase pathway A series of molecular signals mediated by Caspase family. This pathway is a specific course-dependent and can constitute the course of ER stress. This pathway is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003103 caspase 9 signaling (primitive) [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase 9 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 9. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003104 caspase 3 signaling (primitive) [ER stress - apoptosis] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Caspase 3 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the caspase 3. This process is dependent on the apoptosis and can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003105 release of cytochrome c from mitochondria [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003106 BAK activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family, to be higher. http://purl.obolibrary.org/obo/TXPO_0003107 BAK activation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family, to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003108 BAX activation http://purl.obolibrary.org/obo/TXPO_0000023 molecular activation BAX activation is a subtype of molecular activation: A process that changes the activity of the BAX (BCL2 Associated X, Apoptosis Regulator), BCL-2 family, to be higher. http://purl.obolibrary.org/obo/TXPO_0003109 BAX activation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) BAX activation is a subtype of molecular activation: A process that changes the activity of the BAX (BCL2 Associated X, Apoptosis Regulator), BCL-2 family, to be higher. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003110 apoptosome assembly [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003111 intrinsic apoptotic signaling pathway [cell death] http://purl.obolibrary.org/obo/GO_0097193 intrinsic apoptotic signaling pathway A series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.), and ends when the execution phase of apoptosis is triggered. The intrinsic apoptotic signaling pathway is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP). This pathway is a specific course-dependent and can constitute the course of cell death. http://purl.obolibrary.org/obo/TXPO_0003112 allowing http://purl.obolibrary.org/obo/TXPO_0000600 meta-functioning process Preventing is a type of functioning process of meta-function of "ToPrevent". Two meta-functions "ToAllow" and "ToPrevent" are concerned with the undesirable side effects of functions. A function fa having positive effects on the side effect of a function ft1 is said to have a meta-function “to allow the side-effects of ft1”. The “undesirable side effect” is defined in a relation with another function ft2 or the whole system. The “positive effect” means such a causal relation that increase of the focused attribute of fa causes decrease of the side effect. If a serious trouble (e.g., faults) will be caused in a function ft2 when a function fa is not achieved, function fa is said to have a meta-function “to prevent malfunction of ft2”. For example, the “to super-heat” function of the boiler prevents malfunction of the turbine, because the steam of low temperature would damage the turbine blade by water particles. For almost all fa performing a ToAllow meta-function for ft1, in general, there exists a ToPrevent meta-function for another function ft2. http://purl.obolibrary.org/obo/TXPO_0003113 Bax/Bak complex formation [ER stress] http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) Bax/Bak complex formation is a subtype of protein complex assembly: A process that forms a complex consisting of BAX/BAK, a member of the Bcl-2 family. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003114 Bax-Bak complex formation http://purl.obolibrary.org/obo/GO_0006461 protein complex assembly Bax-Bak complex formation is a subtype of protein complex assembly: A process that forms a complex consisting of BAX/BAK, a member of the Bcl-2 family. http://purl.obolibrary.org/obo/TXPO_0003116 positive regulation of gene expression via JNK signaling http://purl.obolibrary.org/obo/GO_0010628 positive regulation of gene expression Positive regulation of gene expression via JNK signaling is a subtype of positive regulation of gene expression: A process that that activates or increases the frequency, rate or extent of gene expression via JNK signaling. http://purl.obolibrary.org/obo/TXPO_0003117 binding to bile canaliculus membrane transporter by drug http://purl.obolibrary.org/obo/GO_0005515 protein binding Binding to bile canaliculus membrane transporter by drug is a subtype of protein binding: Interacting process with the membrane transporter of bile canaliculus by the drug. http://purl.obolibrary.org/obo/TXPO_0003122 back-flow http://purl.obolibrary.org/obo/TXPO_0000022 changing direction Back-flow is a subtype of changing direction: A process that changes the flow to the opposite direction. http://purl.obolibrary.org/obo/TXPO_0003123 BAK activation [Cell death] http://purl.obolibrary.org/obo/TXPO_0003106 BAK activation BAK activation is a subtype of molecular activation: A process that changes the activity of the BAK1 (BCL2 Antagonist/Killer 1), BCL-2 family, to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003124 import substances into hepatocyte vascular side (sinusoidal side) membrane http://purl.obolibrary.org/obo/GO_0006810 transport Import substances into hepatocyte vascular side (sinusoidal side) membrane is a subtype of transport: A process of the directed movement of substances into hepatocyte vascular side (sinusoidal side) membrane. http://purl.obolibrary.org/obo/TXPO_0003126 negative regularuion of bile acid and bile salt transport http://purl.obolibrary.org/obo/TXPO_0002682 negative regulation of transport Negative regularuion of bile acid and bile salt transport is a subtype of negative regulation of transport: Any process that stops, prevents, or reduces the frequency, rate or extent of a bile acid and bile salts transport . http://purl.obolibrary.org/obo/TXPO_0003129 contraction http://purl.obolibrary.org/obo/TXPO_0000765 generating motion Contraction is a subtype of generating motion: A process that generates the directed movement in which the object decreases in volume. http://purl.obolibrary.org/obo/TXPO_0003130 bile accumulation http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object Bile accumulation is a subtype of accumulation of substances in a biological object: A process that keeps bile within the liver (intrahepatic), or outside the liver (extrahepatic) in the bile duct system. http://purl.obolibrary.org/obo/TXPO_0003133 vesicle-mediated transport [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process A cellular transport process in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003134 increasing glutathione [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003151 increasing glutathione Increasing glutathione is a subtype of increasing quantity: A process that changes the amount of glutathione to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003135 cholesterol biosynthetic process [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000034 cholestasis dependent process Cholesterol biosynthetic process is a subtype of lipid biosynthetic process: The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003136 increasing bile level [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002714 increasing bile level Increasing bile level is a subtype of increasing quantity: A process that changes the amount of bile to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003137 increasing materials for bile formation [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003144 increasing materials for bile formation Increasing materials for bile formation is a subtype of increasing quantity: A process that changes the amount of bile formation material to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003138 regulation of transporter gene expression by cytokine http://purl.obolibrary.org/obo/TXPO_0003139 regulation of transporter gene expression Regulation of transporter gene expression by cytokine is a subtype of regulation of transporter gene expression: A process that changes the the gene expression level of the transporter by cytokines. http://purl.obolibrary.org/obo/TXPO_0003139 regulation of transporter gene expression http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression Regulation of transporter gene expression is a subtype of regulation of gene expression: A process that changes the the gene expression level of the transporter. http://purl.obolibrary.org/obo/TXPO_0003140 decreasing bile acid production level http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing bile acid production level is a subtype of decreasing quantity: A process that changes the production amount of bile acid to be lower. http://purl.obolibrary.org/obo/TXPO_0003141 bile thrombus formation http://purl.obolibrary.org/obo/TXPO_0000134 biological structure formation Bile thrombus formation is a subtype of biological structure formation: A process that construcyss bile thrombus. http://purl.obolibrary.org/obo/TXPO_0003142 bile thrombus formation in bile canaliculus http://purl.obolibrary.org/obo/TXPO_0003141 bile thrombus formation Bile thrombus formation in bile canaliculus is a subtype of bile thrombus formation: A process that constructs bile thrombus in bile canaliculus. http://purl.obolibrary.org/obo/TXPO_0003143 farnesoid X receptor activation http://purl.obolibrary.org/obo/TXPO_0000158 nuclear receptor activation Farnesoid X receptor activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be higher. http://purl.obolibrary.org/obo/TXPO_0003144 increasing materials for bile formation http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing materials for bile formation is a subtype of increasing quantity: A process that changes the amount of bile formation material to be higher. http://purl.obolibrary.org/obo/TXPO_0003145 Farnesoid X Receptor Pathway http://purl.obolibrary.org/obo/TXPO_0001902 gene regulation pathway Farnesoid X Receptor Pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by nuclear receptor Farnesoid X Receptor. http://purl.obolibrary.org/obo/TXPO_0003146 gene expression by farnesoid X receptor http://purl.obolibrary.org/obo/TXPO_0000375 Gene expression by transcriptional regulator Gene expression by farnesoid X receptor is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by Farnesoid X receptor (FXR). http://purl.obolibrary.org/obo/TXPO_0003147 gene expression by farnesoid X receptor [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003146 gene expression by farnesoid X receptor Gene expression by farnesoid X receptor is a subtype of gene expression by transcriptional factor: The process in which a gene sequence is converted into a mature gene product or products (proteins or RNA) by Farnesoid X receptor (FXR). This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003149 Farnesoid X Receptor Pathway [cholestasis] http://purl.obolibrary.org/obo/TXPO_0003145 Farnesoid X Receptor Pathway Farnesoid X Receptor Pathway is a subtype of gene regulation pathway: Sequence of reactions to regulate genes by nuclear receptor Farnesoid X Receptor. This entity is a specific course-dependent process. This process can constitute the course of cholestasis. http://purl.obolibrary.org/obo/TXPO_0003150 acumulation of bile pigment in hepatocyte http://purl.obolibrary.org/obo/TXPO_0000083 bile pigment deposition Acumulation of bile pigment in hepatocyte is a subtype of bile pigment deposition: The aggregation of bile pigmentin a particular location in a hepatocyte. http://purl.obolibrary.org/obo/TXPO_0003151 increasing glutathione http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing glutathione is a subtype of increasing quantity: A process that changes the amount of glutathione to be higher. http://purl.obolibrary.org/obo/TXPO_0003152 excretion of drug metabolite from hepatocyte to bile tube http://purl.obolibrary.org/obo/TXPO_0002077 chemical compound excretion Excretion of drug metabolite from hepatocyte to bile tube is a subtype of compound excretion: A process that excretes the drug metabolite from the hepatocyte to to the bile tube. http://purl.obolibrary.org/obo/TXPO_0003153 drug export from the hepatocyte to to bile tube http://purl.obolibrary.org/obo/TXPO_0002077 chemical compound excretion Drug export from the hepatocyte to to bile tube is a subtype of compound excretion: A process that excretes the drug from the hepatocyte to the bile tube. http://purl.obolibrary.org/obo/TXPO_0003154 regulation of transporter gene expression by cytokine [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003138 regulation of transporter gene expression by cytokine Regulation of transporter gene expression by cytokine is a subtype of regulation of transporter gene expression: A process that changes the the gene expression level of the transporter by cytokines. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003155 negative regulation of contractile movement of bile canaliculus http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of contractile movement of bile canaliculus is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of contractile movement of bile canaliculus. http://purl.obolibrary.org/obo/TXPO_0003156 constituent of toxic course http://purl.obolibrary.org/obo/TXPO_0002178 toxicological role A role played by a process that consitutes the toxic course. http://purl.obolibrary.org/obo/TXPO_0003157 Bip-unfolded protein complex [ER stress] http://purl.obolibrary.org/obo/TXPO_0002115 Bip-unfolded protein complex Bip-unfolded protein is a subtype of a molecular complex. This entity has sub-parts of molecules: BIP/GRP78, and an unfolded protein. This entity is dependent on ER stress. http://purl.obolibrary.org/obo/TXPO_0003159 regulator of cell proliferation http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which regulates the process of cell proliferation. http://purl.obolibrary.org/obo/TXPO_0003160 hypofunction of glycogen degradation http://purl.obolibrary.org/obo/TXPO_0000940 hypofunction of decomposing Hypofunction of glycogen degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient glycogen degradation. http://purl.obolibrary.org/obo/TXPO_0003161 calcium channel http://purl.obolibrary.org/obo/TXPO_0002803 cation channel A role played by the entity which enables the facilitated diffusion of a calcium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. http://purl.obolibrary.org/obo/TXPO_0003163 Activation and oligomerization of BAK protein [cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Activation and oligomerization of BAK protein is a subtype of molecular subpathway. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003164 GLUTATHIONE (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002045 glutathione depletion dependent molecule (canonical) A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. http://purl.obolibrary.org/obo/TXPO_0003168 inflammatory response [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003169 hepatic fibrosis [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003173 reactive oxygen species biosynthetic process [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003174 increasing demand for response to oxidative stress [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process Increasing demand for response to oxidative stress is a subtype of increasing the demand for response to stress: A process that changes the functional demand for the response to the oxidative stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003175 increasing anti-oxidation demand [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003176 increasing anti-oxidation demand Increasing anti-oxidation demand is a subtype of increasing functional demand: A process changes the functional demand of oxidation to be higher. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003176 increasing anti-oxidation demand http://purl.obolibrary.org/obo/TXPO_0000633 increasing functional demand Increasing anti-oxidation demand is a subtype of increasing functional demand: A process changes the functional demand of oxidation to be higher. http://purl.obolibrary.org/obo/TXPO_0003177 oxidation-antioxidtion inbalance [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002748 oxidation-antioxidtion inbalance Oxidation-antioxidtion inbalance is a subtype of imbalance: A process that lacks a balance between oxidation and anti-oxidation that inhibits oxidation. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003178 ROS accumulation [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003179 ROS accumulation ROS accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ROS (Reactive Oxygen Species) in a biological object. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003179 ROS accumulation http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object ROS accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ROS (Reactive Oxygen Species) in a biological object. http://purl.obolibrary.org/obo/TXPO_0003180 hyperfunction of peroxisomal fatty acid beta-oxidation [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process Hyperfunction of peroxisomal fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive peroxisomal fatty acid beta-oxidation. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003181 ATP biosynthetic process [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process The chemical reaction resulting in the formation of ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003182 iron accumulation http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell. http://purl.obolibrary.org/obo/TXPO_0003183 iron accumulation [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003182 iron accumulation Iron accumulation is a subtype of accumulation of substances in a biological object: A process that keeps iron in an organism, tissue, organelle, or cell. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003184 kupffer cell activation http://purl.obolibrary.org/obo/GO_0042116 macrophage activation Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. http://purl.obolibrary.org/obo/TXPO_0003185 kupffer cell activation [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003184 kupffer cell activation Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003186 accumulation of ethanol in intestine [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003187 accumulation of ethanol in intestine Accumulation of ethanol in intestine is a subtype of accumulation of xenobiotics: A process that keeps ethanol in the intestine. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003187 accumulation of ethanol in intestine http://purl.obolibrary.org/obo/TXPO_0000169 accumulation of xenobiotics Accumulation of ethanol in intestine is a subtype of accumulation of xenobiotics: A process that keeps ethanol in the intestine. http://purl.obolibrary.org/obo/TXPO_0003188 LPS translocation from gut to liver http://purl.obolibrary.org/obo/GO_0006810 transport LPS translocation from gut to liver is a subtype of transmitting: A process that of the directed movement of LPS from the gut to the liver. http://purl.obolibrary.org/obo/TXPO_0003189 LPS translocation from gut to liver [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003188 LPS translocation from gut to liver LPS translocation from gut to liver is a subtype of transmitting: A process that of the directed movement of LPS from the gut to the liver. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0000838 cell death dependent chemical entity Cell death dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of cell death as a gene product. Gene profile:caonical that described in textbooks or articles. http://purl.obolibrary.org/obo/TXPO_0003207 negative regulation of inflammatory response [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0002243 negative regulation of inflammatory response Negative regulation of inflammatory response is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory response. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0003208 inflammatory cytokine gene expression [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003209 tumorigenesis [Glutathione depletion] http://purl.obolibrary.org/obo/NCIT_C18121 tumorigenesis A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003210 lipid storage in liver [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Lipid storage in liver is a subtype of lipid storage: The accumulation and maintenance in cells or tissues of lipids in the liver. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003211 hepatic fibrosis [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000816 hepatic fibrosis Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003212 liver dysfunction [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000203 liver dysfunction Liver dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete liver function. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001133 phospholipidosis dependent chemical entity Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of phospholipidosis as a gene product. Gene profile:caonical that described in textbooks or articles. http://purl.obolibrary.org/obo/TXPO_0003218 negative regulation of cytokine gene expression http://purl.obolibrary.org/obo/GO_0010629 negative regulation of gene expression Negative regulation of cytokine gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of inflammatory cytokine gene expression. http://purl.obolibrary.org/obo/TXPO_0003219 pexophagy [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process The selective autophagy process in which a peroxisome is degraded by macroautophagy. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0003221 AMPK (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule AMPK is a highly evolutionarily conserved serine/threonine kinase, and orthologs of the AMPK subunits are found in all eukaryotic species. At the molecular level, AMPK is a heterotrimer complex comprising a catalytic alpha subunit, with a conventional serine/threonine protein kinase domain, and two regulatory subunits, beta and gamma. In mammals, each subunit is encoded by multiple genes (alpha1, alpha2, beta1, beta2, gamma1, gamma2, gamma3), which results in 12 possible combinations of AMPK complex. http://purl.obolibrary.org/obo/TXPO_0003222 molecular subpathway http://purl.obolibrary.org/obo/NCIT_C54214 pathway A set or series of molecular interactions. http://purl.obolibrary.org/obo/TXPO_0003224 nuclear receptor http://purl.obolibrary.org/obo/TXPO_0002463 signaling receptor A combining role with a signal and transmitting the signal to the transcriptional machinery by interacting selectively and non-covalently with a specific DNA sequence in order to modulate transcription by RNA polymerase II. http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role http://purl.obolibrary.org/obo/TXPO_0003710 regulator role A role played by the entity which involves in regulating a process. http://purl.obolibrary.org/obo/TXPO_0003231 regulation of cell cycle [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Any process that modulates the rate or extent of progression through the cell cycle. This entity is a specific course-dependent process. This process can constitute the course of eosinogranular dgeneration. http://purl.obolibrary.org/obo/TXPO_0003232 tumor cell proliferation [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001729 eosinophlic granular degeneration dependent process Tumor cell proliferation is a subtype of cell proliferation: A process of the multiplication or reproduction of tumor cells, resulting in the rapid expansion of a tumor cell population. This entity is a specific course-dependent process. This process can constitute the course of Eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0003233 increasing liver weight [toxic course] http://purl.obolibrary.org/obo/TXPO_0000009 toxic course The totality of all processes through which increasing liver weight is realized. http://purl.obolibrary.org/obo/TXPO_0003234 tumorigenesis via eosinophilic granular degeneration [toxic course] http://purl.obolibrary.org/obo/TXPO_0000028 eosinophilic granular degeneration [toxic course] The totality of all processes through which eosinogranular degeneration and is realized and finally, tumorigenesis can be occured. http://purl.obolibrary.org/obo/TXPO_0003235 Activation, translocation and oligomerization of BAX [cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process The activation, translocation and oligomerization of BAX involved in the apoptosis. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003237 intrinsic apoptosis signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) Intrinsic apoptosis signaling (primitive) is a subtype of signaling [biological]: A processin which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The process starts with reception of an intracellular signal (e.g. DNA damage, endoplasmic reticulum stress, oxidative stress etc.). This process is crucially regulated by permeabilization of the mitochondrial outer membrane (MOMP). http://purl.obolibrary.org/obo/TXPO_0003251 drug transporter http://purl.obolibrary.org/obo/TXPO_0003638 transporter A role played by the entity which enables the transfer of drugs. http://purl.obolibrary.org/obo/TXPO_0003256 farnesoid X receptor inactivation http://purl.obolibrary.org/obo/TXPO_0001589 nuclear receptor inactivation Farnesoid X receptor inactivation is a subtype of inactivating nuclear receptor: A process that changes the activity of the inactivating FxR (farnesoid X receptor) with a nuclear receptor role to be lower. http://purl.obolibrary.org/obo/TXPO_0003257 hyperfunction of drug transporter gene expression http://purl.obolibrary.org/obo/TXPO_0002345 hyperfunction of gene expression Hyperfunction of drug transporter gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug transporter gene expression. http://purl.obolibrary.org/obo/TXPO_0003258 hyperfunction of drug transporter gene expression [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003257 hyperfunction of drug transporter gene expression Hyperfunction of drug transporter gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive drug transporter gene expression. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003259 hyperfunction of bile acid transport http://purl.obolibrary.org/obo/TXPO_0002351 hyperfunction of transport Hyperfunction of bile acid transport is a subtype of hyperfunction of transport: A process that performs an excesssive bile acid transport. http://purl.obolibrary.org/obo/TXPO_0003260 hyperfunction of bile acid transport [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003259 hyperfunction of bile acid transport Hyperfunction of bile acid transport is a subtype of hyperfunction of transport: A process that performs an excesssive bile acid transport. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003264 Farnesoid X Receptor inactivation [lipidosis] http://purl.obolibrary.org/obo/TXPO_0003256 farnesoid X receptor inactivation Farnesoid X receptor inactivation is a subtype of inactivating nuclear receptor: A process that changes the activity of the activating FxR (farnesoid X receptor) with a nuclear receptor role to be lower. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003267 malfunction of biosynthesis http://purl.obolibrary.org/obo/TXPO_0000434 malfunctioning process Malfunction of biosynthesis is a subtype of malfunctioning: A process that cannot perform the biosynthesis function appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0003268 malfunction of lipid biosynthesis http://purl.obolibrary.org/obo/TXPO_0003267 malfunction of biosynthesis Malfunction of lipid biosynthesis is a subtype of malfunctioning: A process that cannot perform the lipid biosynthesis function appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0003269 hypofunction of phospholipid transport from ER to mitochondrial membrane http://purl.obolibrary.org/obo/TXPO_0001911 hypofunction of transport Hypofunction of phospholipid transport from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipid transport from ER to mitochondrial membrane. http://purl.obolibrary.org/obo/TXPO_0003270 hypofunction of phospholipid transport from ER to mitochondrial membrane [ER stress] http://purl.obolibrary.org/obo/TXPO_0003269 hypofunction of phospholipid transport from ER to mitochondrial membrane Hypofunction of phospholipid transport from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient phospholipid transport from ER to mitochondrial membrane. This entity is a specific course-dependent process. This process can constitute the course of ER stress http://purl.obolibrary.org/obo/TXPO_0003271 increasing liver weight [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process Increasing liver weight is a subtype of increasing weight: A process that changes the weight of the liver to be higher. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003275 malfunction of phospholipid biosynthesis http://purl.obolibrary.org/obo/TXPO_0003267 malfunction of biosynthesis Malfunction of phospholipid biosynthesis is a subtype of malfunctioning: A process that cannot perform the phospholipid biosynthesis function appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0003276 malfunction of phospholipid biosynthesis [ER stress] http://purl.obolibrary.org/obo/TXPO_0003275 malfunction of phospholipid biosynthesis Malfunction of phospholipid biosynthesis is a subtype of malfunctioning: A process that cannot perform the phospholipid biosynthesis function appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003278 phospholipidosis dependent molecule (mouse) http://purl.obolibrary.org/obo/TXPO_0001133 phospholipidosis dependent chemical entity Phospholipidosis dependent molecule is a subtype of toxic course dependent chemical entity. This gene can participate in the course of phospholipidosis as a gene product. Gene profile:Mouse/Liver/ http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Increasing liver weight dependent process is a subtype of toxic course dependent process: A process that can constitute the course of liver hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003282 hypofunction of phospholipid degradation [Phospholipidosis (moderate)] http://purl.obolibrary.org/obo/TXPO_0000925 hypofunction of phospholipid degradation [Phospholipidosis] Hypofunction of phospholipid degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient phospholipid degradation. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003286 cell proliferation [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process The multiplication or reproduction of cells, resulting in the rapid expansion of a cell population. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003288 hypofunction of glutathione conjugation [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001775 hypofunction of glutathione conjugation Hypofunction of alcohol metabolism is a subtype of hyperfunctioning: A process that performs a decreased or insufficient glutathione conjugation. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003289 insulin deficiency [diabetes course] http://purl.obolibrary.org/obo/TXPO_0003342 Diabetes dependent process [diabetes course] Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required. This entity is a specific course-dependent process. This process can constitute the course of diabetes. http://purl.obolibrary.org/obo/TXPO_0003290 increasing blood glucose level [diabetes coruse] http://purl.obolibrary.org/obo/TXPO_0003342 Diabetes dependent process [diabetes course] Increasing blood glucose level is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher. This entity is a specific course-dependent process. This process can constitute the course of diabetes. http://purl.obolibrary.org/obo/TXPO_0003291 diabetic retinopathy course http://purl.obolibrary.org/obo/TXPO_0002033 diabetes course The totality of all processes through which a given diabetic retinopathy instance is realized. http://purl.obolibrary.org/obo/TXPO_0003292 microvascular dysfunction http://purl.obolibrary.org/obo/TXPO_0002073 organ malfunction Mcrovascular dysfunction is a subtype of organ malfunction: A process that does not perform microvascular function correctly or not functioning at all. http://purl.obolibrary.org/obo/TXPO_0003293 narrowing of the retinal artery http://purl.obolibrary.org/obo/TXPO_0002648 decreasing cross-sectional area Narrowing of the retinal artery is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the retinal arteries to be smaller. http://purl.obolibrary.org/obo/TXPO_0003294 narrowing of the retinal artery [Diabetic retinopathy] http://purl.obolibrary.org/obo/TXPO_0003342 Diabetes dependent process [diabetes course] Narrowing of the retinal artery is a subtype of decreasing cross-sectional area: A process that changes the cross-sectional area of the retinal arteries to be smaller. This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy. http://purl.obolibrary.org/obo/TXPO_0003295 retinal degeneration [Diabetic retinopathy] http://purl.obolibrary.org/obo/TXPO_0003342 Diabetes dependent process [diabetes course] Retinal degeneration is a subtype of changing material: A process that degenerates retinal photoreceptors and pigmented epithelial cells. This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy. http://purl.obolibrary.org/obo/TXPO_0003296 regulation of cell cycle [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process Any process that modulates the rate or extent of progression through the cell cycle. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003297 increasing hepatocellular volume [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003298 cell division [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process The process resulting in division and partitioning of components of a cell to form more cells. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003299 water accumulation [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process A process of liquid water accumulation in a particular location in an organism, tissue or cell. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003300 peroxisomal proliferation in hepatocyte [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process Peroxisomal proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of peroxisome in hepatocyte(s). This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003301 mitochondria proliferation in hepatocyte http://purl.obolibrary.org/obo/TXPO_0003303 hepatocyte organelle proliferation Mitochondria proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of mitochondria in hepatocyte(s). http://purl.obolibrary.org/obo/TXPO_0003302 mitochondria proliferation in hepatocyte [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003301 mitochondria proliferation in hepatocyte Mitochondria proliferation in hepatocyte is a subtype of hepatocyte organelle proliferation: A process that becomes larger in the number of mitochondria in hepatocyte(s). This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003303 hepatocyte organelle proliferation http://purl.obolibrary.org/obo/TXPO_0000108 organelle proliferation Hepatocyte organelle proliferation is a subtype of increasing number of organelle: A process that becomes larger in the number of organelles in hepatocyte(s). http://purl.obolibrary.org/obo/TXPO_0003304 hepatocyte organelle proliferation [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003303 hepatocyte organelle proliferation Hepatocyte organelle proliferation is a subtype of increasing number of organelle: A process that becomes larger in the number of organelles in hepatocyte(s). This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003305 smooth endoplasmic reticulum proliferation in hepatocyte [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s). This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003306 increasing osmotic pressure. http://purl.obolibrary.org/obo/TXPO_0001689 increasing pressure Increasing osmotic pressure. is a subtype of increasing pressure: A process that changes the osmotic pressure of the object to be higher. http://purl.obolibrary.org/obo/TXPO_0003307 decreasing osmotic pressure. http://purl.obolibrary.org/obo/TXPO_0001913 decresing pressure Decreasing osmotic pressure. is a subtype of decresing pressure: A process that changes the osmotic pressure to be lower. http://purl.obolibrary.org/obo/TXPO_0003308 increasing osmotic pressure in cell http://purl.obolibrary.org/obo/TXPO_0003306 increasing osmotic pressure. Increasing osmotic pressure in cell is a subtype of increasing osmotic pressure.: A process that changes the osmotic pressure of the cell to be higher. http://purl.obolibrary.org/obo/TXPO_0003309 increasing osmotic pressure in cell [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003308 increasing osmotic pressure in cell A process that changes the osmotic pressure of the cell to be higher. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003310 lipid strorage in hepatocyte [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003623 lipid accumulation in hepatocyte Lipid strorage in hepatocyte is a subtype of lipid storage: A process that keeps lipids in hepatocytes. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003311 improving http://purl.obolibrary.org/obo/TXPO_0002541 optional contribution process Improving is a type of functioning process of meta-function. Both enhancing and improveing represents optional contribution to other function. The “optional” means that the effect of fa is not mandatory to ft, that is, the target function can be performed without improving or enhancing. The discrimination between improving and enhancing is made by whether augmentation of the output can be made without increase of the amount of the input energy or not. For example, the “to make low pressure” of the condenser contributes to the efficiency of the “to generate torque” function without increment of input energy, so its functioning is “Improving”. On the other hand, the “to super-heat” function of the boiler optionally increases the amount of the input energy to make a contribution. Its meta-function is “Enhancing” . http://purl.obolibrary.org/obo/TXPO_0003312 increasing number of dead cells in liver [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000341 increasing number of dead cells in liver Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003313 accumulation of substance in hepatocyte http://purl.obolibrary.org/obo/TXPO_0000247 accumulation of substances in a biological object Accumulation of substance in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps substances in the hepatocyte. http://purl.obolibrary.org/obo/TXPO_0003314 accumulation of substance in hepatocyte [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003313 accumulation of substance in hepatocyte Accumulation of substance in hepatocyte is a subtype of accumulation of substances in a biological object: A process that keeps substances in the hepatocyte. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003315 decreasing retinal blood flow http://purl.obolibrary.org/obo/TXPO_0000359 decreasing blood flow Decreasing retinal blood flow is a subtype of decreasing flow: A process that changes the amount of retinal flow to be lower. http://purl.obolibrary.org/obo/TXPO_0003316 moving water to the inside of cell [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003318 moving water to the inside of cell Moving water to the inside of cell is a subtype of moving A to the inside of B: A process of the movement of water into a cell. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003317 decreasing retinal blood flow [Diabetic retinopathy] http://purl.obolibrary.org/obo/TXPO_0003342 Diabetes dependent process [diabetes course] Decreasing retinal blood flow is a subtype of decreasing flow: A process that changes the amount of retinal flow to be lower. This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy. http://purl.obolibrary.org/obo/TXPO_0003318 moving water to the inside of cell http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B Moving water to the inside of cell is a subtype of moving A to the inside of B: A process of the movement of water into a cell. http://purl.obolibrary.org/obo/TXPO_0003319 cell growth [Hypertrophy] http://purl.obolibrary.org/obo/TXPO_0003279 increasing liver weight dependent process The process in which a cell irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present. This entity is a specific course-dependent process. This process can constitute the course of Hypertrophy. http://purl.obolibrary.org/obo/TXPO_0003321 ceramidase http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase Catalysis role of the reaction: N-acylsphingosine + H2O = a fatty acid + sphingosine. http://purl.obolibrary.org/obo/TXPO_0003324 AP1S1 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000004 AP1S1 (mol) The protein encoded by this gene is part of the clathrin coat assembly complex which links clathrin to receptors in coated vesicles. These vesicles are involved in endocytosis and Golgi processing. This protein, as well as beta-prime-adaptin, gamma-adaptin, and the medium (mu) chain AP47, form the AP-1 assembly protein complex located at the Golgi vesicle. [provided by RefSeq, Jul 2008] http://purl.obolibrary.org/obo/TXPO_0003326 fatty acid elongase http://purl.obolibrary.org/obo/IMR_0010252 fatty acid synthase Catalysis of the reaction: fatty acid (C-16 or longer) + 2-C = fatty acid (C-16 or longer + 2-C). http://purl.obolibrary.org/obo/TXPO_0003328 acyl-coA desaturase http://purl.obolibrary.org/obo/TXPO_0000519 oxidoreductase Catalysis role of the reaction: acyl-CoA + reduced acceptor + O2 = desaturated-acyl-CoA + acceptor + 2 H2O http://purl.obolibrary.org/obo/TXPO_0003329 stearoyl-CoA 9-desaturase http://purl.obolibrary.org/obo/TXPO_0003328 acyl-coA desaturase Catalysis role of the reaction: stearoyl-CoA + 2 ferrocytochrome b5 + O2 + 2 H+ = oleoyl-CoA + 2 ferricytochrome b5 + H2O. http://purl.obolibrary.org/obo/TXPO_0003331 cytokine receptor http://purl.obolibrary.org/obo/TXPO_0000057 transmembrane signaling receptor role Combining role with a cytokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. http://purl.obolibrary.org/obo/TXPO_0003332 cholesterol biosynthetic process [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Cholesterol biosynthetic process is a subtype of lipid biosynthetic process: The chemical reaction resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003336 glucose transmembrane transporter http://purl.obolibrary.org/obo/TXPO_0003701 sugar transmembrane transporter A role played by the entity which enables the transfer of the hexose monosaccharide glucose from one side of a membrane to the other. http://purl.obolibrary.org/obo/TXPO_0003337 FABP1 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000137 FABP1 (mol) This gene encodes the fatty acid binding protein found in liver. Fatty acid binding proteins are a family of small, highly conserved, cytoplasmic proteins that bind long-chain fatty acids and other hydrophobic ligands. This protein and FABP6 (the ileal fatty acid binding protein) are also able to bind bile acids. It is thought that FABPs roles include fatty acid uptake, transport, and metabolism. [provided by RefSeq, Mar 2011] http://purl.obolibrary.org/obo/TXPO_0003338 long-chain fatty acid transporter http://purl.obolibrary.org/obo/TXPO_0003699 lipid transportor A role played by the entity which transfers long-chain fatty acids from one side of a membrane to the other. A long-chain fatty acid is a fatty acid with a chain length between C13 and C22 http://purl.obolibrary.org/obo/TXPO_0003339 SERPINA3 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000336 SERPINA3 (mol) The protein encoded by this gene is a plasma protease inhibitor and member of the serine protease inhibitor class. Polymorphisms in this protein appear to be tissue specific and influence protease targeting. Variations in this protein's sequence have been implicated in Alzheimer's disease, and deficiency of this protein has been associated with liver disease. Mutations have been identified in patients with Parkinson disease and chronic obstructive pulmonary disease. [provided by RefSeq, Jul 2008] http://purl.obolibrary.org/obo/TXPO_0003340 increasing blood glucose level [Diabetic retinopathy] http://purl.obolibrary.org/obo/TXPO_0003290 increasing blood glucose level [diabetes coruse] Increasing blood glucose lebvel is a subtype of increasing concentration: A process that changes the blood glucose concentration in the blood to be higher. This entity is a specific course-dependent process. This process can constitute the course of Diabetic retinopathy. http://purl.obolibrary.org/obo/TXPO_0003342 Diabetes dependent process [diabetes course] http://purl.obolibrary.org/obo/TXPO_0000808 disease course dependent process Diabetes dependent process is a subtype of disease course dependent process: A process that can constitute the course of diabetes. http://purl.obolibrary.org/obo/TXPO_0003343 binding to DNA by electrophiles http://purl.obolibrary.org/obo/GO_0005488 binding (with molecule) Process of binding by which electrophiles interact with DNA (deoxyribonucleic acid). http://purl.obolibrary.org/obo/TXPO_0003344 binding to DNA by electrophiles [cell death] http://purl.obolibrary.org/obo/TXPO_0003343 binding to DNA by electrophiles Process of binding by which electrophiles interact with DNA (deoxyribonucleic acid). This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003345 CAD [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003353 substance with cationic amphiphilic drug role Substance with substance with cationic amphiphilic drug role is a subtype of substance with role. This entity is participating in a phospholipidosis and playing a cationic amphiphilic drug role. http://purl.obolibrary.org/obo/TXPO_0003348 linoleoyl-CoA desaturase role http://purl.obolibrary.org/obo/TXPO_0003328 acyl-coA desaturase Catalysis role of the reaction: linoleoyl-CoA + reduced acceptor + O2 = gamma-linolenoyl-CoA + acceptor + 2 H2O. http://purl.obolibrary.org/obo/TXPO_0003350 ASAH1 (human)[Phospholipidosis - insulin resistance inhibition] http://purl.obolibrary.org/obo/TXPO_0000529 ASAH1 (human)[Phospholipidosis] This gene encodes a member of the acid ceramidase family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. Processing of this preproprotein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme, which catalyzes the degradation of ceramide into sphingosine and free fatty acid. This enzyme is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene are associated with the lysosomal storage disorder, Farber lipogranulomatosis, and a neuromuscular disorder, spinal muscular atrophy with progressive myoclonic epilepsy. [provided by RefSeq, Oct 2015] http://purl.obolibrary.org/obo/TXPO_0003351 inhibitor of insulin resistance http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity that ihibits the insulin resistance. http://purl.obolibrary.org/obo/TXPO_0003352 negative regulation of increasing insulin resistance [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002537 negative regulation of increasing insulin resistance Negative regulation of increasing insulin resistance is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of insulin resistance. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003353 substance with cationic amphiphilic drug role http://purl.obolibrary.org/obo/GOCHE_50906 substance with role Substance with substance with cationic amphiphilic drug role is a subtype of substance with role. This entity is participating in a biological process and playing a cationic amphiphilic drug role. http://purl.obolibrary.org/obo/TXPO_0003354 lysosomal enzyme transport (to lysosome) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003355 transportng lysosomal enzyme from ribosome to lysosome lysosomal enzyme transport to lysosome is a subtype of transport: A process that of the transfer of a lysosomal enzyme (from the ribosome to the lysosome). This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003355 transportng lysosomal enzyme from ribosome to lysosome http://purl.obolibrary.org/obo/GO_0006810 transport lysosomal enzyme transport (from ribosome to lysosome) is a subtype of transport: A process that of the transfer of a lysosomal enzyme (from the ribosome to the lysosome). http://purl.obolibrary.org/obo/TXPO_0003356 phospholipidosis (normal course) http://purl.obolibrary.org/obo/TXPO_0003382 phospholipidosis (course) Phospholipidosis (normal course) is a subtype of process sequences: The courses of processes through which phospholipid homeostasis balance is keeping. http://purl.obolibrary.org/obo/TXPO_0003357 keeping amount of phospholipid in lysosome http://purl.obolibrary.org/obo/TXPO_0000414 keeping quantity Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid. http://purl.obolibrary.org/obo/TXPO_0003358 keeping amount of phospholipid in lysosome [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003357 keeping amount of phospholipid in lysosome Keeping amount of phospholipid in lysosome is a subtype of keeping amount: A process that maintaining the amount of lysosomal phospholipid. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003359 phospholipidosis (mild) http://purl.obolibrary.org/obo/TXPO_0002215 phospholipidosis (toxic course) The totality of all processes through which the phospholipidosis is realized. The severity is mild. http://purl.obolibrary.org/obo/TXPO_0003361 dysfunction of fatty acid degradation [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Dysfunction of fatty acid degradation is a subtype of hypofunctioning: A process that performs a decreased or insufficient lipid degradation. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003362 CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (mild)] http://purl.obolibrary.org/obo/TXPO_0001399 CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis] CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild). http://purl.obolibrary.org/obo/TXPO_0003363 forming a complex of CAD and phospholipid [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003364 forming a complex of CAD and phospholipid Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003364 forming a complex of CAD and phospholipid http://purl.obolibrary.org/obo/TXPO_0001254 forming a complex of drugs and biological substance Forming a complex of CAD (Cationic Amphiphilic Drugs) and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD in the lysosomal membrane, which causes structural change of the membrane. http://purl.obolibrary.org/obo/TXPO_0003365 forming a complex of CAD and phospholipid [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0003567 forming a complex of CAD and phospholipid (severe) Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosomal membrane, which causes structural change of the membrane. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003366 hypofunction of phospholipid export from lysosome [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Hypofunction of phospholipid export from lysosome is a subtype of hypofunction of export: A process that performs a decreased or insufficient phospholipid export from lysosome. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003367 CAD accumulation in lysosome [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drug) in the lysosome. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003368 CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0001399 CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis] CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003369 phospholipidosis (moderate) http://purl.obolibrary.org/obo/TXPO_0002215 phospholipidosis (toxic course) The totality of all processes through which the phospholipidosis is realized. The severity is moderate. http://purl.obolibrary.org/obo/TXPO_0003370 phospholipid homeostasis imbalance [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0000907 phospholipid homeostasis imbalance [Phospholipidosis] Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003371 phospholipid accumulation in lysosome [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0000910 phospholipid accumulation in lysosome [Phospholipidosis] Phospholipid accumulation in lysosome is a subtype of phospholipid accumulation: A process that keeps phospholipid in the lysosome. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003372 phospholipid metabolism imbalance [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0002324 phospholipid metabolism imbalance [Phospholipidosis] Phospholipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of phospholipid metabolism. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003373 glycerophospholipid accumulation in lysosome [Phospholipidosis - glycerophospholipid disorder ] http://purl.obolibrary.org/obo/TXPO_0001697 glycerophospholipid accumulation in lysosome Glycerophospholipid accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps glycerophospholipid in the lysosome. And the degree is moderate. This process is dependent on the glycerophospholipid disorder (moderate) and can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003374 phosphatidylinositol accumulation in lysosome [Phospholipidosis - phosphatidylinositol disorder] http://purl.obolibrary.org/obo/TXPO_0001831 phosphatidylinositol accumulation in lysosome A process that keeps phosphatidylinositol in the lysosome. This process can constitute the course of Phospholipidosis (phosphatidylinositol disorder ). http://purl.obolibrary.org/obo/TXPO_0003375 phosphatidylethanolamine accumulation in lysosome [Phospholipidosis - phosphatidylethanolamine disorder] http://purl.obolibrary.org/obo/TXPO_0001709 phosphatidylethanolamine accumulation in lysosome A process that keeps phosphatidylethanolamine in the lysosome. This process can constitute the course of Phospholipidosis (phosphatidylethanolamine disorder). http://purl.obolibrary.org/obo/TXPO_0003376 phosphatidylglycerol accumulation in lysosome [Phospholipidosis - phosphatidylglycerol disorder] http://purl.obolibrary.org/obo/TXPO_0001707 phosphatidylglycerol accumulation in lysosome A process that keeps phosphatidylglycerol in the lysosome. This process can constitute the course of Phospholipidosis (phosphatidylglycerol disorder ). http://purl.obolibrary.org/obo/TXPO_0003377 phosphatidylcholine accumulation in lysosome [Phospholipidosis - phosphatidylcholine disorder] http://purl.obolibrary.org/obo/TXPO_0001705 phosphatidylcholine accumulation in lysosome A process that keeps phosphatidylcholine in the lysosome. This process can constitute the course of Phospholipidosis (phosphatidylethanolamine disorder). http://purl.obolibrary.org/obo/TXPO_0003378 phosphatidylserine accumulation in lysosome [Phospholipidosis - phosphatidylserine disorder ] http://purl.obolibrary.org/obo/TXPO_0001703 phosphatidylserine accumulation in lysosome A process that keeps phosphatidylserine in the lysosome. This process can constitute the course of Phospholipidosis (phosphatidylserine disorder). http://purl.obolibrary.org/obo/TXPO_0003379 phosphatidic acid accumulation in lysosome [Phospholipidosis - phosphatidic acid disorder] http://purl.obolibrary.org/obo/TXPO_0001701 phosphatidic acid accumulation in lysosome A process that keeps phosphatidic acid in the lysosome. This process can constitute the course of Phospholipidosis　phosphatidic acid disorder). http://purl.obolibrary.org/obo/TXPO_0003381 sphingomyelin accumulation in lysosome [Phospholipidosis - sphingomyelin disorder ] http://purl.obolibrary.org/obo/TXPO_0001764 sphingomyelin accumulation in lysosome Sphingomyelin accumulation in lysosome is a subtype of phospholipid accumulation in lysosome: A process that keeps sphingomyelin in the lysosome. This process can constitute the course of sphingomyelin disorder. http://purl.obolibrary.org/obo/TXPO_0003382 phospholipidosis (course) http://purl.obolibrary.org/obo/TXPO_0000009 toxic course Phosphoipidosis is a subtype of process sequences: The courses of processes through which phospholipidosis is realized. http://purl.obolibrary.org/obo/TXPO_0003383 phosholipase gene expression http://purl.obolibrary.org/obo/GO_0010467 gene expression Phosholipase gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipase gene product or products (proteins or RNA). http://purl.obolibrary.org/obo/TXPO_0003384 phosholipase gene expression [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003383 phosholipase gene expression Phosholipase gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipase gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003385 hyperfunction of phospholipid synthesis gene expression [Phospholipidosis - normal] http://purl.obolibrary.org/obo/TXPO_0001726 hyperfunction of phospholipid synthesis gene expression Hyperfunction of phospholipid synthesis gene expression is a subtype of hyperfunction of gene expression: A process that performs an excesssive phospholipid synthetic gene expression. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition). http://purl.obolibrary.org/obo/TXPO_0003386 increasing phospholipid [Phospholipidosis (normal condition)] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Increasing phospholipid is a subtype of increasing quantity: A process that changes the amount of phospholipid to be larger. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition). http://purl.obolibrary.org/obo/TXPO_0003387 phospholipid biosynthetic process [Phospholipidosis(normal)] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003388 phospholipid transport from lysosome http://purl.obolibrary.org/obo/GO_0015914 phospholipid transport Phospholipid transport from lysosome into cytosol is a subtype of phospholipid transfer to membrane: A process of the transfer of a phospholipid from the lysosome to the plasma membrane. http://purl.obolibrary.org/obo/TXPO_0003390 decreasing number of cells [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Decreasing number of cells is a subtype of decreasing number of objects: A process that becomes smaller in number of cells. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003391 apoptotic process [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003392 hyperfunctioning of apoptotic process http://purl.obolibrary.org/obo/TXPO_0000435 hyperfunctioning Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive apoptosis. http://purl.obolibrary.org/obo/TXPO_0003393 decreasing number of lysosomes http://purl.obolibrary.org/obo/TXPO_0000348 decreasing number of objects Decreasing number of lysosomes is a subtype of decreasing number of objects: A process that becomes smaller in number of lysosomes. http://purl.obolibrary.org/obo/TXPO_0003394 decreasing number of lysosomes [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003393 decreasing number of lysosomes Decreasing number of lysosomes is a subtype of decreasing number of objects: A process that becomes smaller in number of lysosomes. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003395 removing phospholipid by Kupffer cell or macrophage [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003396 removing phospholipid by Kupffer cell or macrophage Removing phospholipid by Kupffer cell or macrophage is a subtype of removing: A process that takes a phospholipid from a cell by Kupffer cells or macrophages . This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition). http://purl.obolibrary.org/obo/TXPO_0003396 removing phospholipid by Kupffer cell or macrophage http://purl.obolibrary.org/obo/TXPO_0000458 removing (from A) Removing phospholipid by Kupffer cell or macrophage is a subtype of removing: A process that takes a phospholipid from a cell by Kupffer cells or macrophages . http://purl.obolibrary.org/obo/TXPO_0003397 phospholipid synthesis gene expression [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003398 phospholipid synthesis gene expression Phospholipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipid synthesis gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003398 phospholipid synthesis gene expression http://purl.obolibrary.org/obo/GO_0010467 gene expression Phospholipid synthesis gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature phospholipid synthesis gene product or products (proteins or RNA). http://purl.obolibrary.org/obo/TXPO_0003400 positive regulation of phospholipid biosynthetic process [Phospholipidosis (normal)] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of phospholipids. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(normal condition). http://purl.obolibrary.org/obo/TXPO_0003401 moving phopholipid to lysosome [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003402 moving phopholipid to lysosome Moving phopholipid to lysosome is a subtype of moving A to the inside of B: A process that of the movement of phospholipids into lysosomes. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003402 moving phopholipid to lysosome http://purl.obolibrary.org/obo/TXPO_0002587 moving A to the inside of B Moving phopholipid to lysosome is a subtype of moving A to the inside of B: A process that of the movement of phospholipids into lysosomes. http://purl.obolibrary.org/obo/TXPO_0003403 increasing phospholipid material (normal condition) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Increasing phospholipid material is a subtype of increasing quantity: A process that changes the amount of phospholipid material to be larger. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosisb(normal condition). http://purl.obolibrary.org/obo/TXPO_0003404 phosphholipid binding by phospholipase [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003640 phosphholipid binding by phospholipase Phosphholipid binding by phospholipase is a subtype of phospholipid binding: Interacting selectively and non-covalently with phospholipids byphospholipases. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(normal condition). http://purl.obolibrary.org/obo/TXPO_0003405 IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - inflammation ] http://purl.obolibrary.org/obo/TXPO_0000833 IL-2 signaling (primitive) [Phospholipidosis (excessive defense) ] IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2. This process is dependent on the inflammation and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003406 IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - apoptosis inhibition ] http://purl.obolibrary.org/obo/TXPO_0000833 IL-2 signaling (primitive) [Phospholipidosis (excessive defense) ] IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2. This process is dependent on the apoptosis inhibition and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003407 IL-2 signaling (primitive) [Phospholipidosis (excessive defense) - cell cycle arrest ] http://purl.obolibrary.org/obo/TXPO_0000833 IL-2 signaling (primitive) [Phospholipidosis (excessive defense) ] IL-2 signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine IL-2. This process is dependent on the cell cycle arrest and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003410 phospholipid hydrolysis [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003411 phospholipid hydrolysis Phospholipid hydrolysis is a subtype of hydrolysis: A chemical reaction that uses water to break down a phospholipid. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003411 phospholipid hydrolysis http://purl.obolibrary.org/obo/NCIT_C16702 hydrolysis Phospholipid hydrolysis is a subtype of hydrolysis: A chemical reaction that uses water to break down a phospholipid. http://purl.obolibrary.org/obo/TXPO_0003412 negative regulation of phospholipid hydrolysis [Phospholipidosis (mild)] http://purl.obolibrary.org/obo/TXPO_0003448 negative regulation of phospholipid hydrolysis [Phospholipidosis] A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis mildly. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild). http://purl.obolibrary.org/obo/TXPO_0003413 negative regulation of phospholipid hydrolysis http://purl.obolibrary.org/obo/TXPO_0001256 negative regulation of phospholipid degradation Negative regulation of phospholipid degradation is a subtype of negative regulation of phospholipid hydrolysis: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis. http://purl.obolibrary.org/obo/TXPO_0003414 negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003446 negative regulation of phospholipase-mediated phospholipid degradation by CAD Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003415 AKT signaling (primitive) [phospholipidosis (excessive defense) - cell proliferation ] http://purl.obolibrary.org/obo/TXPO_0001796 AKT signaling (primitive) [Phospholipidosis (excessive defense) ] AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT). This process is dependent on the cell proliferation and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003416 AKT signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ] http://purl.obolibrary.org/obo/TXPO_0001796 AKT signaling (primitive) [Phospholipidosis (excessive defense) ] AKT signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the intracellular serine/threonine kinase protein kinase B (also called AKT). This process is dependent on the tumor cell proliferation and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003418 phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) - cell proliferation ] http://purl.obolibrary.org/obo/TXPO_0001495 phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) ] Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K). This process is dependent on the cell proliferation and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003421 phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ] http://purl.obolibrary.org/obo/TXPO_0001495 phosphatidylinositol 3-kinase signaling (primitive) [Phospholipidosis (excessive defense) ] Phosphatidylinositol 3-kinase signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the phosphatidylinositol 3-kinase (PI3K). This process is dependent on the tumor cell proliferation and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003422 EGFR signaling (primitive) [Phospholipidosis (excessive defense) - cell proliferation ] http://purl.obolibrary.org/obo/TXPO_0001493 EGFR signaling (primitive) [Phospholipidosis (excessive defense) ] EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR This process is dependent on the cell proliferation and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003423 EGFR signaling (primitive) [Phospholipidosis (excessive defense) - tumor cell proliferation ] http://purl.obolibrary.org/obo/TXPO_0001493 EGFR signaling (primitive) [Phospholipidosis (excessive defense) ] EGFR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal transmitted by the EGFR (epidermal growth factor receptor) on the surface of a cell, starting with a ligand binding to a EGFR This process is dependent on the tumor cell proliferation and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003430 kupffer cell differentiation http://purl.obolibrary.org/obo/GO_0030225 macrophage differentiation Kupffer cell differentiation is a subtype of macrophage differentiation: The process that acquires the specialized features of a kupffer cell. http://purl.obolibrary.org/obo/TXPO_0003431 hyperfunction of phospholipid phagocytosis by Kupffer cells [Phospholipidosis (excessive defense)] http://purl.obolibrary.org/obo/TXPO_0003432 hyperfunction of phospholipid phagocytosis by Kupffer cells Hyperfunction of phospholipid phagocytosis by Kupffer cells is a subtype of hyperfunctioning: A process that performs an excessive phospholipid phagocytosis by Kupffer cells. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense). http://purl.obolibrary.org/obo/TXPO_0003432 hyperfunction of phospholipid phagocytosis by Kupffer cells http://purl.obolibrary.org/obo/TXPO_0001483 hyperfunction of phospholipid removing Hyperfunction of phospholipid phagocytosis by Kupffer cells is a subtype of hyperfunctioning: A process that performs an excessive phospholipid phagocytosis by Kupffer cells. http://purl.obolibrary.org/obo/TXPO_0003433 hyperfunction of cell differentiation http://purl.obolibrary.org/obo/TXPO_0000435 hyperfunctioning Hyperfunction of cell differentiation is a subtype of hyperfunctioning: A process that performs an excesssive cell differentiation. http://purl.obolibrary.org/obo/TXPO_0003434 hyperfunction of Kupffer cell differentiation http://purl.obolibrary.org/obo/TXPO_0003433 hyperfunction of cell differentiation Hyperfunction of Kupffer cell differentiation is a subtype of hyperfunction of cell differentiation: A process that performs an excesssive kupffer cell differentiation. http://purl.obolibrary.org/obo/TXPO_0003435 phospholipid homeostasis imbalance [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0000907 phospholipid homeostasis imbalance [Phospholipidosis] Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003436 decreasing lysosomal membrane permeability [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003438 decreasing lysosomal membrane permeability Decreasing lysosomal membrane permeability is a subtype of decreasing membrane permeability: A process that changes the permeability of the lysosomal membrane to be lower. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003438 decreasing lysosomal membrane permeability http://purl.obolibrary.org/obo/TXPO_0003439 decreasing membrane permeability Decreasing lysosomal membrane permeability is a subtype of decreasing membrane permeability: A process that changes the permeability of the lysosomal membrane to be lower. http://purl.obolibrary.org/obo/TXPO_0003439 decreasing membrane permeability http://purl.obolibrary.org/obo/TXPO_0002704 changing permeability Decreasing membrane permeability is a subtype of changing permeability: A process that changes the permeability of the membrane to be lower. http://purl.obolibrary.org/obo/TXPO_0003440 hyperfunction of phospholipid material transport http://purl.obolibrary.org/obo/TXPO_0002351 hyperfunction of transport Hyperfunction of phospholipid material transport is a subtype of hyperfunction of transport: A process that performs an excesssive phospholipid material transport. http://purl.obolibrary.org/obo/TXPO_0003441 pattern recognition receptor http://purl.obolibrary.org/obo/TXPO_0002463 signaling receptor Combining role with a pathogen-associated molecular pattern (PAMP), a structure conserved among microbial species, or damage-associated molecular pattern (DAMP), an endogenous molecule released from damaged cells), to initiate a change in cell activity. http://purl.obolibrary.org/obo/TXPO_0003442 negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0003414 negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis] Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003443 negative regulation of phospholipid hydrolysis [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0003448 negative regulation of phospholipid hydrolysis [Phospholipidosis] A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis moderately. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003444 negative regulation of phospholipid degradation [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0000905 negative regulation of phospholipid degradation [Phospholipidosis] A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid degradation. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003445 hypofunction of ceramide degradation [sphingomyelin disorder ] http://purl.obolibrary.org/obo/TXPO_0001829 hypofunction of ceramide degradation Hypofunction of ceramide degradation is a subtype of hypofunction of lipid degradation: A process that performs a decreased or insufficient ceramide degradation. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (sphingomyelin disorder). http://purl.obolibrary.org/obo/TXPO_0003446 negative regulation of phospholipase-mediated phospholipid degradation by CAD http://purl.obolibrary.org/obo/TXPO_0001256 negative regulation of phospholipid degradation Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid deradation by phospholipase. http://purl.obolibrary.org/obo/TXPO_0003447 negative regulation of phospholipid hydrolysis [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0003448 negative regulation of phospholipid hydrolysis [Phospholipidosis] A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis severely. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003448 negative regulation of phospholipid hydrolysis [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003413 negative regulation of phospholipid hydrolysis Negative regulation of phospholipid hydrolysis is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003449 CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0001399 CAD insertion into phospholipase binding site to lysosomal inner membrane [Phospholipidosis] CAD insertion into phospholipase binding site to lysosomal inner membrane is a subtype of binding: A process that CAD inserts and replaces the phospholipase binding site in the lysosomal inner membrane. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003450 negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0003414 negative regulation of phospholipase-mediated phospholipid degradation by CAD [Phospholipidosis] Negative regulation of phospholipase-mediated phospholipid degradation by CAD is a subtype of negative regulation of phospholipid degradation: A process that stops, prevents, or reduces the frequency, rate or extent of phospholipase-mediated phospholipid deradation regulated by CAD. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003451 CAD accumulation in lysosome [Phospholipidosis (severe)] http://purl.obolibrary.org/obo/TXPO_0003367 CAD accumulation in lysosome [Phospholipidosis] CAD accumulation in lysosome is a subtype of compound accumulation in lysosome: A process that keeps CAD (Cationic Amphiphilic Drugs cationic amphiphile drug) in the lysosome. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003452 phospholipidosis (severe) http://purl.obolibrary.org/obo/TXPO_0002215 phospholipidosis (toxic course) The totality of all processes through which the phospholipidosis is realized. The severity is severe. http://purl.obolibrary.org/obo/TXPO_0003453 compound accumulation in lysosome [Phospholipidosis (mild)] http://purl.obolibrary.org/obo/TXPO_0000930 compound accumulation in lysosome [Phospholipidosis] Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild). http://purl.obolibrary.org/obo/TXPO_0003454 compound accumulation in lysosome [Phospholipidosis (moderate) ] http://purl.obolibrary.org/obo/TXPO_0000930 compound accumulation in lysosome [Phospholipidosis] Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (moderate). http://purl.obolibrary.org/obo/TXPO_0003455 negative regulation of cell cycle gene expression http://purl.obolibrary.org/obo/GO_0010629 negative regulation of gene expression Negative regulation of cell cycle regulator gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of cell cycle regulator gene expression. http://purl.obolibrary.org/obo/TXPO_0003457 increasing hepatic portal pressure [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Increasing hepatic portal pressure is a subtype of increasing pressure: A process that changes the hepatic portal pressure to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003458 increasing hepatic venous pressure [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Increasing hepatic venous pressure is a subtype of increasing pressure: A process that changes the hpatic venous pressure to be higher. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003459 hyperfunction of hepatic lymph production [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Hyperfunction of hepatic lymph production is a subtype of hyperfunction of biosynthesis: A process that performs an excessive hepatic lymph production. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003460 hepatic lymph leakage [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Hepatic lymph leakage is a subtype of leaking: A process that leaks lymph out from the liver lymphatic vessel. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003461 ascites (process) [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Ascites (process) is a subtype of accumulation of fluids: A process that keeps fluid in the peritoneal cavity. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003462 inzreasing size of the spleen [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0001360 inzreasing size of the spleen Inzreasing size of the spleen is a subtype of increasing size: A process that changes the size of the of the spleen to be larger. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003463 stomach congestion [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Stomach congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the stomach. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003464 intestine congestion [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Intestine congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the intestine. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003465 intestine congestion http://purl.obolibrary.org/obo/TXPO_0000916 hyperfunction of accumulation Intestine congestion is a subtype of hyperfunctioning of accumulation: A process that performs an excessive accumulation of blood in the intestine. http://purl.obolibrary.org/obo/TXPO_0003466 bypass formation [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Bypass formation is a subtype of biological structure formation: A process that constructs an alternate passage of a bodily substancepassage carrying blood. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003467 varicosity of veins formation [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0001364 varicosity of veins formation Varicosity of veins formation is a subtype of biological structure formation: A process that have a varicosity of veins. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003468 sphingomyelinase gene mutation [Niemann Pick Disease Type A] http://purl.obolibrary.org/obo/TXPO_0001446 sphingomyelinase gene mutation [Niemann Pick Disease Type A/ B] Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A. http://purl.obolibrary.org/obo/TXPO_0003473 sphingomyelinase gene mutation [Niemann Pick Disease Type B] http://purl.obolibrary.org/obo/TXPO_0001446 sphingomyelinase gene mutation [Niemann Pick Disease Type A/ B] Sphingomyelinase gene mutation is a subtype of phopholipase gene mutation: A process that changes the sequence of a sphingomyelinase gene. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B. http://purl.obolibrary.org/obo/TXPO_0003474 dysfunction of sphingomyelin degradation [Niemann Pick Disease Type A] http://purl.obolibrary.org/obo/TXPO_0001475 dysfunction of sphingomyelin degradation [Niemann Pick Disease Type A/ B] Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A. http://purl.obolibrary.org/obo/TXPO_0003475 dysfunction of sphingomyelin degradation [Niemann Pick Disease Type B] http://purl.obolibrary.org/obo/TXPO_0001475 dysfunction of sphingomyelin degradation [Niemann Pick Disease Type A/ B] Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B. http://purl.obolibrary.org/obo/TXPO_0003476 lipid accumulation in hepatocyte (severe) [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001129 lipid strorage in hepatocyte [Lipidosis] Lipid accumulation in hepatocyte (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003478 positive regulation of autophagy [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003480 increasing hepatocellular volume [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Increasing hepatocellular volume is a changing process to change the volume of the hepatocyte to increase. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003481 hyperfunction of glucose transport to liver http://purl.obolibrary.org/obo/TXPO_0002351 hyperfunction of transport Hyperfunction of glucose transport to liver is a subtype of hyperfunction of transport: A process that performs an excesssive glucose transport to liver. http://purl.obolibrary.org/obo/TXPO_0003482 hyperfunction of glucose transport to liver [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003481 hyperfunction of glucose transport to liver Hyperfunction of glucose transport to liver is a subtype of hyperfunction of transport: A process that performs an excesssive glucose transport to liver. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003483 hypofunction of triglyceride transport from hepatocyte to extrahepatic http://purl.obolibrary.org/obo/TXPO_0001911 hypofunction of transport Hypofunction of triglyceride transport from hepatocyte to extrahepatic is a subtype of hypofunction of transport: A process that performs a decreased or insufficient triglyceride transport from hepatocyte to extrahepatic. http://purl.obolibrary.org/obo/TXPO_0003484 hypofunction of triglyceride transport from hepatocyte to extrahepatic [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003483 hypofunction of triglyceride transport from hepatocyte to extrahepatic Hypofunction of triglyceride transport from hepatocyte to extrahepatic is a subtype of hypofunction of transport: A process that performs a decreased or insufficient triglyceride transport from hepatocyte to extrahepatic. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003486 triglyceride transport from hepatocyte to extrahepatic http://purl.obolibrary.org/obo/GO_0034197 triglyceride transport Triglyceride transport from hepatocyte to extrahepatic is a subtype of triglyceride transport: A process that of the transfer of a triglyceride from the hepatocyte to the exrrahepatic tissues. http://purl.obolibrary.org/obo/TXPO_0003487 triglyceride transport from hepatocyte to extrahepatic [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003486 triglyceride transport from hepatocyte to extrahepatic Triglyceride transport from hepatocyte to extrahepatic is a subtype of triglyceride transport: A process that of the transfer of a triglyceride from the hepatocyte to the exrrahepatic tissues. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003488 lipid homeostasis imbalance http://purl.obolibrary.org/obo/TXPO_0001656 chemical homeostasis imbalance Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. http://purl.obolibrary.org/obo/TXPO_0003490 tumor cell survial [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process Tumor cell survial is a subtype of cell survival: A process that keeps the viability of a tumor cell. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003491 lipid homeostasis imbalance [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003488 lipid homeostasis imbalance Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003492 increaing in fatty acid inflow into hepatocyte http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. http://purl.obolibrary.org/obo/TXPO_0003493 increase in lipid inflow into hepatocyte http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger. http://purl.obolibrary.org/obo/TXPO_0003494 increase in lipid inflow into hepatocyte [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003493 increase in lipid inflow into hepatocyte Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003495 necrosis [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003496 insulin resistance (process) [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0002189 insulin resistance (process) Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003497 insulin deficiency [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003498 non-alcoholic fatty liver disease http://purl.obolibrary.org/obo/TXPO_0000888 lipidosis [toxic course] The totality of all processes through which non-alcoholic fatty liver disease (NAFLD) is realized. http://purl.obolibrary.org/obo/TXPO_0003499 vacuolation [Liver Pathological Findings][Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003524 fatty change [Liver Pathological Findings] Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology. This finding is observable in the course of lipidosis. http://purl.obolibrary.org/obo/TXPO_0003501 eosinophilic granular degeneration [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0001507 pathological finding Eosinophilic granular degeneration [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology. http://purl.obolibrary.org/obo/TXPO_0003502 hepatocellular hypertrophy [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0001507 pathological finding Hypertrophy [liver findings] is a type of finding observed in the liver. An increase in size (volume) of hepatocytes is observed based on pathological morphology. It is sometimes accompanied by an increase in the number of cells. http://purl.obolibrary.org/obo/TXPO_0003503 cholestasis [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0001507 pathological finding Cholestasis [liver findings] is a type of finding observed in the liver. A pathological findings caused by obstruction in intrahepatic or extrahepatic biliary system. Bile thrombus appears in the intrahepatic bile duct, and in general, bile pigment is observed in hepatocytes and Kupffer cells. http://purl.obolibrary.org/obo/TXPO_0003504 hyperplasia [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0001507 pathological finding Hyperplasia [ [Liver PathologicalFindings] is a type of finding observed in the liver. An increase in cell number is observed based on pathological morphology. http://purl.obolibrary.org/obo/TXPO_0003505 hepatic fibrosis [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0001507 pathological finding Hepatic fibrosis [Liver PathologicalFindings] is a type of finding observed in the liver. Lesions are observed as a proliferation of fibrous tissue in the liver based on pathological morphology. http://purl.obolibrary.org/obo/TXPO_0003506 hypofunction of lipoprotein biosynthesis http://purl.obolibrary.org/obo/TXPO_0001958 hypofunction of protein synthesis Hypofunction of lipoprotein biosynthesis is a subtype of hypofunction of protein synthesis: A process that performs a decreased or insufficient lipoprotein biosynthesis. http://purl.obolibrary.org/obo/TXPO_0003507 hypofunction of lipoprotein biosynthesis [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003506 hypofunction of lipoprotein biosynthesis Hypofunction of lipoprotein biosynthesis is a subtype of hypofunction of protein synthesis: A process that performs a decreased or insufficient lipoprotein biosynthesis. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001089 lipidosis dependent chemical entity Lipidosis dependent chemical compound is a subtype of toxic course dependent chemical entity. This entity (drug) can participate in the course of lipidosis. http://purl.obolibrary.org/obo/TXPO_0003510 increasing demand for response to oxidative stress [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Increasing demand for response to oxidative stress is a subtype of increasing the demand for stress response : A process that changes the functional demand for the response to the oxidative stress to be higher. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003511 malfunctioning of cellular membrane [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0002198 malfunctioning of cellular membrane Malfunctioning of cellular membrane is a subtype of malfunctioning process: A process that cannot perform a cellular membrane function appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003512 cellular membrane lipoperoxidation [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003513 cellular membrane lipoperoxidation Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003513 cellular membrane lipoperoxidation http://purl.obolibrary.org/obo/TXPO_0003514 lipoperoxidation Cellular membrane lipoperoxidation is a subtype of lipoperoxidation: A process that the degradation of lipids of cellular membrane caused by an oxidative attack from free radicals. http://purl.obolibrary.org/obo/TXPO_0003514 lipoperoxidation http://purl.obolibrary.org/obo/GO_0034440 lipid oxidation Lipoperoxidation is a subtype of lipid oxidation: The degradation of lipids caused by an oxidative attack from free radicals. http://purl.obolibrary.org/obo/TXPO_0003515 eosinophilic change [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0000662 cytoplasmic alternation [Liver Pathological Findings] Eosinophilic change [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on pathological morphology, lesions are stained with eosin. http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001089 lipidosis dependent chemical entity Lipidosis dependent molecule is a subtype of toxic course dependent chemical entity. This molecule can participate in the course of lipidosis as a gene product. Gene profile:caonical that described in textbooks or articles. http://purl.obolibrary.org/obo/TXPO_0003517 APOE (canonical)[Lipidosis] http://purl.obolibrary.org/obo/TXPO_1000006 APOE (mol) The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. [provided by RefSeq, Jun 2016] http://purl.obolibrary.org/obo/TXPO_0003518 acidophilic http://purl.obolibrary.org/obo/PATO_0002070 affinity An affinity inhering in a tissue constituent by virtue of the bearer exhibiting a molecular interaction for acidic dyes under specific ph conditions. http://purl.obolibrary.org/obo/TXPO_0003520 metabolic intermediate accumulation [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process Metabolic intermediate accumulation is a subtype of accumulation of substances in a biological object: A process that keeps intermediate(s) of metabolism in an organism, tissue, organelle, or cell. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0003521 power (attribute) http://purl.obolibrary.org/obo/TXPO_0000305 non-meta generic quality A physical attribute inhering in a bearer by virtue of the bearer's rate of doing work. http://purl.obolibrary.org/obo/TXPO_0003522 ground glass appearance [Liver Pathological Findings] [Ground glass appearance (course)] http://purl.obolibrary.org/obo/TXPO_0000060 ground glass appearance [Liver Pathological Findings] Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes. This finding is observable in the course of ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003523 eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (course) ] http://purl.obolibrary.org/obo/TXPO_0003501 eosinophilic granular degeneration [Liver Pathological Findings] Eosinophilic granular degeneration [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology. This finding is observable as a result of increasing peroxisome caused by PPAR. http://purl.obolibrary.org/obo/TXPO_0003524 fatty change [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0001507 pathological finding Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology. http://purl.obolibrary.org/obo/TXPO_0003525 vacuolation [Liver Pathological Findings][Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003524 fatty change [Liver Pathological Findings] Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology. This finding is observable in the course of phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003526 myelin figure in lysosome [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001508 myelin figure [Liver Pathological Findings] myelin figure in lysosome [Liver Pathological Findings] is a type of finding observed in the liver. Based on pathological morphology, lesions are observed as myelin-like layered structures under electron microscopy. This finding is observable in the course of phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003527 moderate accumulation of abnormal proteins in ER http://purl.obolibrary.org/obo/TXPO_0002187 accumulation of abnormal proteins in ER Moderate accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins in ER: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum) moderately. http://purl.obolibrary.org/obo/TXPO_0003528 severe accumulation of abnormal proteins in ER http://purl.obolibrary.org/obo/TXPO_0002187 accumulation of abnormal proteins in ER Severe accumulation of abnormal proteins in ER is a subtype of accumulation of abnormal proteins in ER: A process that keeps abnormal protein(s) in the ER (endoplasmic reticulum) severely. http://purl.obolibrary.org/obo/TXPO_0003532 refolding-unfolding imbalance (mild) http://purl.obolibrary.org/obo/TXPO_0002459 refolding-unfolding imbalance Refolding-unfolding imbalance (mild) is a subtype of refolding-unfolding imbalance: A process that lacks a balance between protein refolding and unfolding mildly. http://purl.obolibrary.org/obo/TXPO_0003533 refolding-unfolding imbalance (moderate) http://purl.obolibrary.org/obo/TXPO_0002459 refolding-unfolding imbalance Refolding-unfolding imbalance (moderate) is a subtype of refolding-unfolding imbalance: A process that lacks a balance between protein refolding and unfolding moderately. http://purl.obolibrary.org/obo/TXPO_0003534 regulator of tumor cell proliferation http://purl.obolibrary.org/obo/TXPO_0003159 regulator of cell proliferation A role played by the entity which regulates the process of tumor cell proliferation. http://purl.obolibrary.org/obo/TXPO_0003535 eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (mild) ] http://purl.obolibrary.org/obo/TXPO_0003523 eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (course) ] Eosinophilic granular degeneration [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology. The degree is mild. This finding is observable as a result of increasing peroxisome caused by PPAR. http://purl.obolibrary.org/obo/TXPO_0003536 eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (moderate) ] http://purl.obolibrary.org/obo/TXPO_0003523 eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (course) ] Eosinophilic granular degeneration [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology. The degree is moderate. This finding is observable as a result of increasing peroxisome caused by PPAR. http://purl.obolibrary.org/obo/TXPO_0003537 eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (severe) ] http://purl.obolibrary.org/obo/TXPO_0003523 eosinophilic granular degeneration [Liver Pathological Findings] [eosinogranular degeneration (course) ] Eosinophilic granular degeneration [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed in the form that the cytoplasm presents eosinophilic granules based on pathological morphology. The degree is severe. This finding is observable as a result of increasing peroxisome caused by PPAR. http://purl.obolibrary.org/obo/TXPO_0003538 vacuolation [Liver Pathological Findings][Lipidosis(mild)] http://purl.obolibrary.org/obo/TXPO_0003499 vacuolation [Liver Pathological Findings][Lipidosis] Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology. This finding is observable in the course of lipidosis. The degree is mild. http://purl.obolibrary.org/obo/TXPO_0003539 phosphatidylcholine efflux http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B Phosphatidylcholine efflux is a subtype of moving A to the outside of B: A process that excretes phosphatidylcholine to the outside of a cell or organelle. http://purl.obolibrary.org/obo/TXPO_0003540 vacuolation [Liver Pathological Findings][Lipidosis(moderate)] http://purl.obolibrary.org/obo/TXPO_0003499 vacuolation [Liver Pathological Findings][Lipidosis] Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology. This finding is observable in the course of lipidosis. The degree is moderate. http://purl.obolibrary.org/obo/TXPO_0003541 vacuolation [Liver Pathological Findings][Lipidosis(severe)] http://purl.obolibrary.org/obo/TXPO_0003499 vacuolation [Liver Pathological Findings][Lipidosis] Fatty change [Liver PathologicalFindings] is a type of finding observed in hepatocytes. Lesions are observed as lipid droplets consisting of neutral fat in the hepatocyte based on pathological morphology. This finding is observable in the course of lipidosis. The degree is severe. http://purl.obolibrary.org/obo/TXPO_0003542 ground glass appearance [Liver Pathological Findings] [Ground glass appearance (severe)] http://purl.obolibrary.org/obo/TXPO_0003522 ground glass appearance [Liver Pathological Findings] [Ground glass appearance (course)] Ground glass appearance [Liver PathologicalFindings] is a type of finding observed in hepatocyte cytoplasm. Based on the pathological morphology, lesions are observed as a frosted-like change in whole or most of the hepatocytes. This finding is observable in the course of ground glass appearance. The degree is severe. http://purl.obolibrary.org/obo/TXPO_0003544 changing cell survival-cell death balance http://purl.obolibrary.org/obo/TXPO_0001847 changing balance Changing cell survival-cell death balance is a subtype of changing balance: A process that changes the steady state of cell number between cell death and cell survival within an organ or an organism. http://purl.obolibrary.org/obo/TXPO_0003545 maintaining cell survival - cell death balance http://purl.obolibrary.org/obo/TXPO_0000682 maintaining balance Maintaining cell survival-cell death balance is a subtype of maintaining balance: A process that keeps a balance between cell death and cell survival within an organ or an organism. http://purl.obolibrary.org/obo/TXPO_0003546 cell survival-cell death imbalance http://purl.obolibrary.org/obo/TXPO_0000567 imbalance Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism. http://purl.obolibrary.org/obo/TXPO_0003547 cell survival-cell death imbalance [Phospholipidosis (severe)] http://purl.obolibrary.org/obo/TXPO_0003548 changing cell survival-cell death balance [Phospholipidosis] Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003548 changing cell survival-cell death balance [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003544 changing cell survival-cell death balance Changing cell survival-cell death balance is a subtype of changing balance: A process that changes the steady state of cell number between cell death and cell survival within an organ or an organism. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003549 maintaining cell survival-cell death balance [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003548 changing cell survival-cell death balance [Phospholipidosis] Maintaining cell survival-cell death balance is a subtype of maintaining balance: A process that keeps a balance between cell death and cell survival within an organ or an organism. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003551 changing cell homeostasis http://purl.obolibrary.org/obo/TXPO_0001847 changing balance Changing cell homeostasis is a subtype of changing balance: A process that changes the steady state of cell within an organ or an organism. http://purl.obolibrary.org/obo/TXPO_0003552 maintaining cell homeostasis http://purl.obolibrary.org/obo/GO_0042592 homeostatic process Any process involved in the maintenance of an internal steady state of cell within an organ or an organism. http://purl.obolibrary.org/obo/TXPO_0003553 cell homeostasis imbalance http://purl.obolibrary.org/obo/TXPO_0000568 homeostasis imbalance Cell homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a cell homeostastasis balance. http://purl.obolibrary.org/obo/TXPO_0003554 sequestering of calcium ion [ER stress] http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process The process of binding or confining calcium ions such that they are separated from other components of a biological system. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003561 G-Protein Coupled Receptor http://purl.obolibrary.org/obo/TXPO_0000057 transmembrane signaling receptor role Combining role with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. http://purl.obolibrary.org/obo/TXPO_0003562 G1/S transition of mitotic cell cycle http://purl.obolibrary.org/obo/TXPO_0003564 positive regulator of cell cycle phase transition role A role played by the entity that positively regulates the process ofof G1/S transition of mitotic cell cycle role. http://purl.obolibrary.org/obo/TXPO_0003563 increased affinity http://purl.obolibrary.org/obo/PATO_0002070 affinity An affinity which is relatively high. http://purl.obolibrary.org/obo/TXPO_0003564 positive regulator of cell cycle phase transition role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity that positively regulates the process of cell cycle phase transition. http://purl.obolibrary.org/obo/TXPO_0003565 forming a complex of CAD and phospholipid (mild) http://purl.obolibrary.org/obo/TXPO_0003364 forming a complex of CAD and phospholipid Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is mild. http://purl.obolibrary.org/obo/TXPO_0003566 forming a complex of CAD and phospholipid (moderate) http://purl.obolibrary.org/obo/TXPO_0003364 forming a complex of CAD and phospholipid Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is moderate. http://purl.obolibrary.org/obo/TXPO_0003567 forming a complex of CAD and phospholipid (severe) http://purl.obolibrary.org/obo/TXPO_0003364 forming a complex of CAD and phospholipid Forming a complex of CAD and phospholipid is a subtype of forming a complex of drugs and biological substance: A process that forms a complex consisiting phospholipids and CAD (Cationic Amphiphilic Drug) in the lysosomal membrane, which causes structural change of the membrane. The degree is severe. http://purl.obolibrary.org/obo/TXPO_0003568 cell death [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any biological process that results in permanent cessation of all vital functions of a cell. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder]. http://purl.obolibrary.org/obo/TXPO_0003569 glutathione depletion [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Glutathione depletion is a subtype of depleting: A process that lessens markedly in the amount of glutathione. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0003575 substance with cytokine role http://purl.obolibrary.org/obo/CHEBI_24431 chemical entity Substance with cytokine role is a subtype of substance with role. http://purl.obolibrary.org/obo/TXPO_0003576 Insulin resistance (process) [Type II Diabetes] http://purl.obolibrary.org/obo/TXPO_0003342 Diabetes dependent process [diabetes course] Insulin resistance (process) is a subtype of decreasing sensitivity: A process that changes the sensitivity to the circulating insulin to be lower. This entity is a specific course-dependent process. This process can constitute the course of type II diabetes. http://purl.obolibrary.org/obo/TXPO_0003577 insulin absolute deficiency http://purl.obolibrary.org/obo/TXPO_0003289 insulin deficiency [diabetes course] Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required absolutely. This entity is a specific course-dependent process. This process can constitute the course of type I diabetes. http://purl.obolibrary.org/obo/TXPO_0003578 negative regulation of phospholipid hydrolysis [Phospholipidosis (latent)] http://purl.obolibrary.org/obo/TXPO_0003448 negative regulation of phospholipid hydrolysis [Phospholipidosis] A process that stops, prevents, or reduces the frequency, rate or extent of phospholipid hydrolysis. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent). http://purl.obolibrary.org/obo/TXPO_0003579 sphingomyelin biosynthetic process[Niemann Pick Disease Type A] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A. http://purl.obolibrary.org/obo/TXPO_0003580 sphingomyelin biosynthetic process[Niemann Pick Disease Type B] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process The chemical reactions and pathways resulting in the formation of sphingomyelin, N-acyl-4-sphingenyl-1-O-phosphorylcholine. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B. http://purl.obolibrary.org/obo/TXPO_0003581 insulin relative deficiency [diabetes course] http://purl.obolibrary.org/obo/TXPO_0003289 insulin deficiency [diabetes course] Insulin deficiency is a subtype of malfunctioning process: A process that lacks performing the insulin function required. This entity is a specific course-dependent process. This process can constitute the course of type II diabetes. http://purl.obolibrary.org/obo/TXPO_0003583 hyperfunction of phospholipid degradation (severe) http://purl.obolibrary.org/obo/TXPO_0001430 hyperfunction of phospholipid degradation Hyperfunction of phospholipid degradation (severe) is a subtype of hyperfunction of phospholipid degradation: A process that performs an excessive phospholipid degradation severely. http://purl.obolibrary.org/obo/TXPO_0003584 increasing phospholipid inflow (severe) http://purl.obolibrary.org/obo/TXPO_0001251 increasing phospholipid inflow Increasing phospholipid inflow (severe) is a subtype of increase in phospholipid inflow: A process that changes the phospholipid inflow into the hepatocyte to be larger. http://purl.obolibrary.org/obo/TXPO_0003587 Niemann–Pick disease course http://purl.obolibrary.org/obo/OGMS_0000063 disease course The totality of all processes through which a given Niepamnn-pick disease instance is realized. http://purl.obolibrary.org/obo/TXPO_0003589 cell homeostasis imbalance [Phospholipidosis (severe)] http://purl.obolibrary.org/obo/TXPO_0003590 changing cell homeostasis [Phospholipidosis] Cell homeostasis imbalance is a subtype of homeostasis imbalance: A process that becomes lacking a cell homeostastasis balance. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003590 changing cell homeostasis [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003551 changing cell homeostasis Changing cell homeostasis is a subtype of changing balance: A process that changes the steady state of cell within an organ or an organism. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003591 maintaining cell homeostasis [Phospholiipidosis] http://purl.obolibrary.org/obo/TXPO_0003590 changing cell homeostasis [Phospholipidosis] Any process involved in the maintenance of an internal steady state of cell within an organ or an organism. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003592 increasing energy [Phospholipidosis(severe)] http://purl.obolibrary.org/obo/TXPO_0003593 increasing energy [Phospholipidosis] Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003593 increasing energy [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003594 energy supply [Phospholipidosis(severe)] http://purl.obolibrary.org/obo/TXPO_0004077 energy supply Energy supply is a subtype of providing process to perform a meta-function “to provide energy. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003595 energy supply [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004077 energy supply Energy supply is a subtype of providing process to perform a meta-function “to provide energy. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003596 increasing number of dead cells in liver [Phosholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Increasing number of dead cells in liver is a subtype of cell proliferation: A process that becomes larger in the number of dead cells in the liver. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0003597 cell survival-cell death imbalance [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003546 cell survival-cell death imbalance Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003598 maintaining cell survival-cell death balance [ER stress] http://purl.obolibrary.org/obo/TXPO_0003546 cell survival-cell death imbalance Cell survival-cell death imbalance is a subtype is a subtype of imbalance: A process that lacks a balance between cell death and cell survival within an organ or an organism. This entity is a specific course-dependent process. This process can constitute the course of ER stress. http://purl.obolibrary.org/obo/TXPO_0003609 oranic anion export http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B Oranic anion export is a subtype of moving A to the outside of B: A process of the directed movement of organic anions into, out of a cell, or an organelle, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/TXPO_0003615 severe sphingomyelin accumulation in lysosome of nervous system http://purl.obolibrary.org/obo/TXPO_0001691 sphingomyelin accumulation in lysosome of nervous system Severe sphingomyelin accumulation in lysosome of nervous system is a subtype of sphingomyelin accumulation in lysosome of nervous system: A process that keeps sphingomyelin in the lysosome of nervous system severely. http://purl.obolibrary.org/obo/TXPO_0003616 spleen hyperfunction [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0001361 spleen hyperfunction Spleen hyperfunction is a subtype of hyperfunctioning: A process that performs an excessive spleen function. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003617 malfunctioning of hepatic blood circulation [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Malfunctioning of hepatic blood circulation is a subtype of malfunctioning process: A process that cannot perform hepatic blood circulation function appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Hepatic vascular circulation disorder dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic vascular circulation disorder. http://purl.obolibrary.org/obo/TXPO_0003619 hepatic shunt formtion [hepatic blood circulatory disorder] http://purl.obolibrary.org/obo/TXPO_0003618 hepatic vascular circulation disorder dependent process Hepatic shunt formtion is a subtype of biological structure formation: A process that makes abnormal communications between the hepatic arteries, portal veins, and hepatic or systemic veins. This entity is a specific course-dependent process. This process can constitute the course of hepatic blood circulatory disorder. http://purl.obolibrary.org/obo/TXPO_0003620 inflammatory response [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003621 hepatic fibrosis [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003622 inflammatory cell infiltration [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the  outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003623 lipid accumulation in hepatocyte http://purl.obolibrary.org/obo/GO_0019915 lipid storage Lipid accumulation in hepatocyte is a subtype of lipid storage: A process that keeps lipids in hepatocytes. http://purl.obolibrary.org/obo/TXPO_0003624 lipid accumulation in hepatocyte (mild) [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001129 lipid strorage in hepatocyte [Lipidosis] Lipid accumulation in hepatocyte (mild) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes mildly. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003625 decreased cross-sectional area http://purl.obolibrary.org/obo/PATO_0002058 decreased area An cross-sectional area which is relatively low. http://purl.obolibrary.org/obo/TXPO_0003626 cross-sectional area http://purl.obolibrary.org/obo/TXPO_0000310 area (attribute) A 2-D extent attribute of the bearer which has been cut off to an axis. http://purl.obolibrary.org/obo/TXPO_0003627 balooning [Liver Pathological Findings] http://purl.obolibrary.org/obo/TXPO_0001507 pathological finding Balooning [Liver PathologicalFindings] is a type of finding observed in the liver. On the basis of pathological morphology, the cytoplasm becomes enlarged like balloons accompanied by the vacuolation. http://purl.obolibrary.org/obo/TXPO_0003628 balooning [Liver Pathological Findings] [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003627 balooning [Liver Pathological Findings] Balooning [Liver PathologicalFindings] is a type of finding observed in the liver. On the basis of pathological morphology, the cytoplasm becomes enlarged like balloons accompanied by the vacuolation . This finding is observable in the course of lipidosis. http://purl.obolibrary.org/obo/TXPO_0003629 hypofunction of peroxisomal fatty acid beta-oxidation http://purl.obolibrary.org/obo/TXPO_0002147 hypofunction of fatty acid oxidation Hypofunction of peroxisomal fatty acid beta-oxidation is a subtype of hypofunction of fatty acid beta-oxidation: A process that performs a decreased or insufficient fatty acid degradation. http://purl.obolibrary.org/obo/TXPO_0003632 toxic course based on fatty change http://purl.obolibrary.org/obo/TXPO_0003763 toxic course based on pathological findings This course is categorized from the viewpoint of the findings of fatty change. This entity is inferred from Description Logic. http://purl.obolibrary.org/obo/TXPO_0003634 fluid flow rate http://purl.obolibrary.org/obo/PATO_0001574 flow rate quality A physical quality inhering in a fluid (liquid or gas) by virtue of the amount of fluid which passes through a given surface per unit time. http://purl.obolibrary.org/obo/TXPO_0003635 mutation [Niemann Pick Disease] http://purl.obolibrary.org/obo/TXPO_0003642 Niemann–Pick disease dependent process [diabetes course] Mutation is a subtype of changing an operand: A process that changes the nucleotide sequence of DNA randomly and permanently. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease. http://purl.obolibrary.org/obo/TXPO_0003636 regulation of transmitting http://purl.obolibrary.org/obo/TXPO_0000113 controlling Regulation of transmitting is a subtype of controlling: A process that modulates the frequency, rate or extent of transmitting. http://purl.obolibrary.org/obo/TXPO_0003637 regulation of bile acid and bile salt transport http://purl.obolibrary.org/obo/GO_0051049 regulation of transport (biology) Regulation of bile acid and bile salt transport is a subtype of regulation of transport (biology): Any process that modulates the frequency, rate or extent of the directed movement of bile acid and bile salts . http://purl.obolibrary.org/obo/TXPO_0003638 transporter http://purl.obolibrary.org/obo/TXPO_0001393 transmitter role A role which enables the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells. http://purl.obolibrary.org/obo/TXPO_0003639 channel http://purl.obolibrary.org/obo/TXPO_0003638 transporter A role enables the energy-independent facilitated diffusion, mediated by passage of a solute through a transmembrane aqueous pore or channel. Stereospecificity is not exhibited but this transport may be specific for a particular molecular species or class of molecules. http://purl.obolibrary.org/obo/TXPO_0003640 phosphholipid binding by phospholipase http://purl.obolibrary.org/obo/GO_0005543 phospholipid binding Phosphholipid binding by phospholipase is a subtype of phospholipid binding: Interacting selectively and non-covalently with phospholipids byphospholipases. http://purl.obolibrary.org/obo/TXPO_0003641 protein dimerization http://purl.obolibrary.org/obo/GO_0051258 protein polymerization Protein dimerization is a subtype of protein polymerization: The formation of a protein dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits. http://purl.obolibrary.org/obo/TXPO_0003642 Niemann–Pick disease dependent process [diabetes course] http://purl.obolibrary.org/obo/TXPO_0000808 disease course dependent process Niemann–Pick disease dependent process is a subtype of disease course dependent process: A process that can constitute the course of Niemann–Pick disease. http://purl.obolibrary.org/obo/TXPO_0003644 transcription elongation regulation factor http://purl.obolibrary.org/obo/TXPO_0000330 transcription regulator A role played by the entity that regulates transcriptional elongation by enabling the transition from transcription initiation to elongation or by altering the elongation properties of the enzyme during the elongation phase of transcription. http://purl.obolibrary.org/obo/TXPO_0003645 transcription factor http://purl.obolibrary.org/obo/TXPO_0003715 type converter A role played by the entity to initiate or regulate transcription. http://purl.obolibrary.org/obo/TXPO_0003646 acute phase responses by cytokines http://purl.obolibrary.org/obo/GO_0006955 immune response An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma. http://purl.obolibrary.org/obo/TXPO_0003647 phospholipid metabolic regulator role http://purl.obolibrary.org/obo/TXPO_0002358 lipid metabolic regulator role A role played by the entity which regulates the formation of phospholipids. http://purl.obolibrary.org/obo/TXPO_0003648 fatty accid metabolic regulator role http://purl.obolibrary.org/obo/TXPO_0004023 metabolic regulator role A role played by the entity which regulates fatty acid metabolic process. http://purl.obolibrary.org/obo/TXPO_0003650 gene expression regulator role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which involves in regulating a gene expression process. http://purl.obolibrary.org/obo/TXPO_0003651 phospholipid metabolism balance [Phospholipidosis (adaptation2)] http://purl.obolibrary.org/obo/TXPO_0001434 phospholipid metabolism balance Phospholipid metabolism balance is a subtype of maintaining balance: A process that keeps a balance of phospholipid metabolism at small level. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense). http://purl.obolibrary.org/obo/TXPO_0003652 dysfunction of fatty acid degradation http://purl.obolibrary.org/obo/TXPO_0001741 dysfunction of lipid degradation Dysfunction of fatty acid degradation is a subtype of dysfunctioning: A process that performs an abnormal and incomplete fatty acid degradation. http://purl.obolibrary.org/obo/TXPO_0003653 tranquilizing drug http://purl.obolibrary.org/obo/CHEBI_35488 central nervous system depressant A traditional grouping of drugs said to have a soothing or calming effect on mood, thought or behaviour. http://purl.obolibrary.org/obo/TXPO_0003654 glutathione synthesis regulating agent role http://purl.obolibrary.org/obo/TXPO_0004023 metabolic regulator role A role played by the entity which regulates the glutathione synthesis. http://purl.obolibrary.org/obo/TXPO_0003655 potassium channel http://purl.obolibrary.org/obo/TXPO_0002803 cation channel A role played by the entity which enables the facilitated diffusion of a potassium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. http://purl.obolibrary.org/obo/TXPO_0003656 sodium channel http://purl.obolibrary.org/obo/TXPO_0002803 cation channel A role played by the entity which enables the facilitated diffusion of a sodium ion (by an energy-independent process) involving passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. http://purl.obolibrary.org/obo/TXPO_0003657 adaptor protein role http://purl.obolibrary.org/obo/TXPO_0000564 signalling molecule role A role played by the entity that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way. http://purl.obolibrary.org/obo/TXPO_0003658 antipsychotic agent http://purl.obolibrary.org/obo/TXPO_0003653 tranquilizing drug Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. http://purl.obolibrary.org/obo/TXPO_0003659 first generation antipsychotic http://purl.obolibrary.org/obo/TXPO_0003658 antipsychotic agent Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased. http://purl.obolibrary.org/obo/TXPO_0003660 enzyme http://purl.obolibrary.org/obo/CHEBI_51086 chemical role Protein that catalyze a specific chemical reaction. http://purl.obolibrary.org/obo/TXPO_0003662 helicase http://purl.obolibrary.org/obo/TXPO_0003660 enzyme Catalysis role of the reaction: NTP + H2O = NDP + phosphate, to drive the unwinding of a DNA or RNA helix. http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase http://purl.obolibrary.org/obo/TXPO_0003660 enzyme Catalysis role of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3. http://purl.obolibrary.org/obo/TXPO_0003664 ATPase http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase Catalysis role of the reaction: ATP + H2O = ADP + phosphate + 2 H+. May or may not be coupled to another reaction. http://purl.obolibrary.org/obo/TXPO_0003665 opioid analgesic http://purl.obolibrary.org/obo/CHEBI_35480 analgesic A narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood. http://purl.obolibrary.org/obo/TXPO_0003666 glycosylase http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase Catalysis role of the hydrolysis of any glycosyl bond. http://purl.obolibrary.org/obo/TXPO_0003667 DNA N-glycosylase http://purl.obolibrary.org/obo/TXPO_0003666 glycosylase Catalysis role of the removal of damaged bases by cleaving the N-C1' glycosidic bond between the target damaged DNA base and the deoxyribose sugar. The reaction releases a free base and leaves an apurinic/apyrimidinic (AP) site. http://purl.obolibrary.org/obo/TXPO_0003668 GTPase http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase Catalysis role of the reaction: GTP + H2O = GDP + phosphate. http://purl.obolibrary.org/obo/TXPO_0003669 small GTPase http://purl.obolibrary.org/obo/TXPO_0003668 GTPase A role of the RAS superfamily of GTP (guanosine triphosphate) hydrolysis-coupled signal transduction relay protein. It can be subclassified into RAS, RHO, RAB, and ARF families, as well as the closely related G alpha family. The members of each family can, in turn, be arranged into evolutionarily conserved branches. These groupings reflect structural, biochemical, and functional conservation. http://purl.obolibrary.org/obo/TXPO_0003670 histone deacetylase http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase Catalysis role of the reaction: histone N6-acetyl-L-lysine + H2O = histone L-lysine + acetate. This reaction represents the removal of an acetyl group from a histone, a class of proteins complexed to DNA in chromatin and chromosomes. http://purl.obolibrary.org/obo/TXPO_0003672 phosphoric diester hydrolase http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase Catalysis role of the hydrolysis of a phosphodiester to give a phosphomonoester and a free hydroxyl group. http://purl.obolibrary.org/obo/TXPO_0003673 phosphatase http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase Catalysis of the hydrolysis of phosphoric monoesters, releasing inorganic phosphate. http://purl.obolibrary.org/obo/TXPO_0003674 glucose-6-phosphatase http://purl.obolibrary.org/obo/TXPO_0003673 phosphatase Catalysis role of the reaction: D-glucopyranose 6-phosphate + H2O = D-glucose + phosphate. D-glucopyranose is also known as D-glucose 6-phosphate. http://purl.obolibrary.org/obo/TXPO_0003675 phosphoprotein phosphatase http://purl.obolibrary.org/obo/TXPO_0003673 phosphatase Catalysis role of the reaction: a phosphoprotein + H2O = a protein + phosphate. Together with protein kinases, these enzymes control the state of phosphorylation of cell proteins and thereby provide an important mechanism for regulating cellular activity. http://purl.obolibrary.org/obo/TXPO_0003676 protein serine/threonine phosphatase http://purl.obolibrary.org/obo/TXPO_0003675 phosphoprotein phosphatase Catalysis role of the reaction: protein serine phosphate + H2O = protein serine + phosphate, and protein threonine phosphate + H2O = protein threonine + phosphate. http://purl.obolibrary.org/obo/TXPO_0003677 protein serine/threonine/tyrosine phosphatase http://purl.obolibrary.org/obo/TXPO_0003675 phosphoprotein phosphatase Catalysis role of the reactions: protein serine + H2O = protein serine + phosphate; protein threonine phosphate + H2O = protein threonine + phosphate; and protein tyrosine phosphate + H2O = protein tyrosine + phosphate. http://purl.obolibrary.org/obo/TXPO_0003678 compound accumulation in lysosome [Phospholipidosis (latent)] http://purl.obolibrary.org/obo/TXPO_0000930 compound accumulation in lysosome [Phospholipidosis] Compound accumulation in lysosome is a subtype of accumulation of xenobiotics: A process that keeps compound in the lysosome. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (latent). http://purl.obolibrary.org/obo/TXPO_0003679 protein tyrosine phosphatase http://purl.obolibrary.org/obo/TXPO_0003675 phosphoprotein phosphatase Catalysis of the reaction: protein tyrosine phosphate + H2O = protein tyrosine + phosphate. http://purl.obolibrary.org/obo/TXPO_0003680 ligand-gated ion channel http://purl.obolibrary.org/obo/TXPO_0000328 ion channel A role played by the entity which enables the transmembrane transfer of an ion by a channel that opens when a specific ligand has been bound by the channel complex or one of its constituent parts. http://purl.obolibrary.org/obo/TXPO_0003681 SH2/SH3 adaptor protein role http://purl.obolibrary.org/obo/TXPO_0003657 adaptor protein role A role played by the entity interacting selectively and non-covalently and simultaneously with one or more signal transduction molecules, usually acting as a scaffold to bring these molecules into close proximity either using their own SH2/SH3 domains (e.g. Grb2) or those of their target molecules (e.g. SAM68). http://purl.obolibrary.org/obo/TXPO_0003682 DD-containing adaptor protein role http://purl.obolibrary.org/obo/TXPO_0003657 adaptor protein role A role played by the entity interacting selectively and non-covalently and simultaneously with one or more signal transduction molecules, usually acting as a scaffold to bring these molecules into close using Death Domains. http://purl.obolibrary.org/obo/TXPO_0003683 size (attribute) http://purl.obolibrary.org/obo/TXPO_0000305 non-meta generic quality An attribute of morphology inhering in a bearer by virtue of the bearer's physical magnitude. http://purl.obolibrary.org/obo/TXPO_0003684 docking protein http://purl.obolibrary.org/obo/TXPO_0003657 adaptor protein role A role played by the entity that acts as docking sites for multiple signaling molecules. http://purl.obolibrary.org/obo/TXPO_0003685 translation initiation factor http://purl.obolibrary.org/obo/TXPO_0003730 changing state role A role of involving the initiation of ribosome-mediated translation of mRNA into a polypeptide. http://purl.obolibrary.org/obo/TXPO_0003686 lipid mediator http://purl.obolibrary.org/obo/CHEBI_33280 molecular messenger Lipid Mediator role is played by a lipid having bioactivity, which is transiently produced locally, acts on a cell membrane receptor located in its place, transmits a signal, and usually is decomposed promptly. http://purl.obolibrary.org/obo/TXPO_0003687 structural constituent of ribosome http://purl.obolibrary.org/obo/TXPO_0003691 structural molecule The role of a molecule that contributes to the structural integrity of the ribosome. http://purl.obolibrary.org/obo/TXPO_0003688 adhesion molecule http://purl.obolibrary.org/obo/TXPO_0003691 structural molecule A role played by the molecule to mediate adhesion of the cell to the external substrate or to another cell. http://purl.obolibrary.org/obo/TXPO_0003689 cytoskeletal protein http://purl.obolibrary.org/obo/TXPO_0003691 structural molecule The role played by the molecule that contributes to the structural integrity of a cytoskeletal structure. http://purl.obolibrary.org/obo/TXPO_0003690 motor protein http://purl.obolibrary.org/obo/TXPO_0003689 cytoskeletal protein A role played by the entity that catalyses the generation of force resulting either in movement along a microfilament or microtubule, or in torque resulting in membrane scission, coupled to the hydrolysis of a nucleoside triphosphate. http://purl.obolibrary.org/obo/TXPO_0003691 structural molecule http://purl.obolibrary.org/obo/TXPO_0003731 keeping structure role The role of a molecule that contributes to the structural integrity of a complex or its assembly within or outside a cell. http://purl.obolibrary.org/obo/TXPO_0003692 microfilament protein http://purl.obolibrary.org/obo/TXPO_0003694 cytoskeletal fiber protein The role played by the molecule that contributes to the structural integrity of an microfilament (actin filament). Actin filaments are a major component of the contractile apparatus of skeletal muscle and the microfilaments of the cytoskeleton of eukaryotic cells http://purl.obolibrary.org/obo/TXPO_0003693 intermediate filament protein http://purl.obolibrary.org/obo/TXPO_0003694 cytoskeletal fiber protein The role played by the molecule that contributes to the structural integrity of the intermediate filaments. http://purl.obolibrary.org/obo/TXPO_0003694 cytoskeletal fiber protein http://purl.obolibrary.org/obo/TXPO_0003691 structural molecule The role played by the molecule that contributes to the structural integrity of cytoskeletal fibers. http://purl.obolibrary.org/obo/TXPO_0003695 extracellular matrix structural constituent http://purl.obolibrary.org/obo/TXPO_0003691 structural molecule The role of a molecule that contributes to the structural integrity of the extracellular matrix. http://purl.obolibrary.org/obo/TXPO_0003696 water channel http://purl.obolibrary.org/obo/TXPO_0003639 channel A role played by the entity of transport systems. This type enable facilitated diffusion of water (by an energy-independent process) by passage through a transmembrane aqueous pore or channel without evidence for a carrier-mediated mechanism. http://purl.obolibrary.org/obo/TXPO_0003697 amino acid transmembrane transporter http://purl.obolibrary.org/obo/TXPO_0003698 transmembrane transporter A role played by the entity which enables the transfer of amino acids from one side of a membrane to the other. Amino acids are organic molecules that contain an amino group and a carboxyl group. http://purl.obolibrary.org/obo/TXPO_0003698 transmembrane transporter http://purl.obolibrary.org/obo/TXPO_0003638 transporter A role played by the entity which enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other. http://purl.obolibrary.org/obo/TXPO_0003699 lipid transportor http://purl.obolibrary.org/obo/TXPO_0003638 transporter A role played by the entity which enables the directed movement of lipids into, out of or within a cell, or between cells. http://purl.obolibrary.org/obo/TXPO_0003700 phospholipid transporter http://purl.obolibrary.org/obo/TXPO_0003699 lipid transportor A role played by the entity which enables the directed movement of phospholipids into, out of or within a cell, or between cells. Phospholipids are a class of lipids containing phosphoric acid as a mono- or diester. http://purl.obolibrary.org/obo/TXPO_0003701 sugar transmembrane transporter http://purl.obolibrary.org/obo/TXPO_0003698 transmembrane transporter A role played by the entity which enables the transfer of a sugar from one side of a membrane to the other. A sugar is any member of a class of sweet, water-soluble, crystallizable carbohydrates, which are the monosaccharides and smaller oligosaccharides. http://purl.obolibrary.org/obo/TXPO_0003702 ion transmembrane transporter http://purl.obolibrary.org/obo/TXPO_0003702 ion transmembrane transporter A role played by the entity which enables the transfer of an ion from one side of a membrane to the other up the solute's concentration gradient. This is carried out by binding the solute and undergoing a series of conformational changes. Transport works equally well in either direction. http://purl.obolibrary.org/obo/TXPO_0003703 bile acid transmembrane transporter http://purl.obolibrary.org/obo/TXPO_0003698 transmembrane transporter A role played by the entity which enables the transfer of bile acid from one side of a membrane to the other. Bile acids are any of a group of steroid carboxylic acids occurring in bile, where they are present as the sodium salts of their amides with glycine or taurine. http://purl.obolibrary.org/obo/TXPO_0003704 bile acid:sodium symporter http://purl.obolibrary.org/obo/TXPO_0003703 bile acid transmembrane transporter A role played by the entity which enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: bile acid(out) + Na+(out) = bile acid(in) + Na+(in). http://purl.obolibrary.org/obo/TXPO_0003705 role related to changing size http://purl.obolibrary.org/obo/TXPO_0003708 role related to changing quality A role played by the entity which changes the size of the operand(s). http://purl.obolibrary.org/obo/TXPO_0003707 trimeric G-protein http://purl.obolibrary.org/obo/TXPO_0003706 GTP-binding protein The entity of the alpha, beta, and gamma subunits (or beta-gamma dimers) of heterotrimeric guanine nucleotide binding (G) proteins. It is an intracellular membrane-associated protein activated by various receptors (e.g., beta adrenergic). It serves as transducers of the receptor-initiated response linked to intracellular elements, such as enzymes, that generate second messengers to initiate an effect. http://purl.obolibrary.org/obo/TXPO_0003708 role related to changing quality http://purl.obolibrary.org/obo/TXPO_0003712 changer role A role played by the entity which changes the quality of the operand(s). http://purl.obolibrary.org/obo/TXPO_0003709 role related to assembling http://purl.obolibrary.org/obo/TXPO_0003727 functional role A role played by the entity to make multiple components to an assembly http://purl.obolibrary.org/obo/TXPO_0003711 molecular inhibitor http://purl.obolibrary.org/obo/TXPO_0003713 molecular (activity) regulator A role played by the entity that inhibits molecular activity. http://purl.obolibrary.org/obo/TXPO_0003713 molecular (activity) regulator http://purl.obolibrary.org/obo/TXPO_0003710 regulator role A role played by the entity which regulates molecular activities. http://purl.obolibrary.org/obo/TXPO_0003714 molecular activator http://purl.obolibrary.org/obo/TXPO_0003713 molecular (activity) regulator A role played by the entity that activates molecular activity. http://purl.obolibrary.org/obo/TXPO_0003715 type converter http://purl.obolibrary.org/obo/TXPO_0003712 changer role type converter is a role played by the entity to change the type of the operand(s) http://purl.obolibrary.org/obo/TXPO_0003716 transcription coregulator http://purl.obolibrary.org/obo/TXPO_0000330 transcription regulator A role played by the entity that interacts specifically and non-covalently with a DNA-bound DNA-binding transcription factor to either activate or repress the transcription of specific genes. Coregulators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second ATP-dependent class modifies the conformation of chromatin. A third class modulates interactions of DNA-binding transcription factor with other transcription coregulators. http://purl.obolibrary.org/obo/TXPO_0003717 transcriptional co-activator http://purl.obolibrary.org/obo/TXPO_0003716 transcription coregulator A role played by the entity that interacts specifically and non-covalently with a DNA-bound DNA-binding transcription factor to activate the transcription of specific genes. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second ATP-dependent class modifies the conformation of chromatin. Another type of coregulator activity is the bridging of a DNA-binding transcription factor to the basal transcription machinery. The Mediator complex, which bridges transcription factors and RNA polymerase, is also a transcription coactivator. http://purl.obolibrary.org/obo/TXPO_0003720 pathway regulator http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role of the entity which positively/negatively regulates a signaling pathway or metabolic pathway. http://purl.obolibrary.org/obo/TXPO_0003722 enzyme regulator http://purl.obolibrary.org/obo/TXPO_0003713 molecular (activity) regulator A role played by the entity which binds to and modulates the activity of an enzyme. http://purl.obolibrary.org/obo/TXPO_0003723 molecular carrier http://purl.obolibrary.org/obo/TXPO_0001393 transmitter role A role of the entity of binding to a specific ion or molecule and delivering it either to an acceptor molecule or to a specific location. http://purl.obolibrary.org/obo/TXPO_0003724 positive regulator of tumorigenesis role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which positively regulates the process of tumorigenesis. http://purl.obolibrary.org/obo/TXPO_0003725 regulator of tumor cell activity role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity that regulates the activity of tumor cells. http://purl.obolibrary.org/obo/TXPO_0003726 regulator of immune response http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which regulates the process of infmammatory response. http://purl.obolibrary.org/obo/TXPO_0003727 functional role http://purl.obolibrary.org/obo/BFO_0000023 role A role played by the entity of funtion as realizable entity. http://purl.obolibrary.org/obo/TXPO_0003729 hardness (attribute) http://purl.obolibrary.org/obo/TXPO_0000305 non-meta generic quality A physical attribute inhering in a bearer by virtue of the bearer's resistance to pressure, being broken, or pierced http://purl.obolibrary.org/obo/TXPO_0003730 changing state role http://purl.obolibrary.org/obo/TXPO_0003712 changer role A role played by the entity involved in changing some state. http://purl.obolibrary.org/obo/TXPO_0003731 keeping structure role http://purl.obolibrary.org/obo/TXPO_0003712 changer role A role played by the entity that contributes to keep the structural integrity. http://purl.obolibrary.org/obo/TXPO_0003732 molecular (activity) co-regulator http://purl.obolibrary.org/obo/TXPO_0003727 functional role A role played by the entity which assists the molecule activity. http://purl.obolibrary.org/obo/TXPO_0003733 keeping structure http://purl.obolibrary.org/obo/TXPO_0002566 changing structure Keeping structure is a subtype of changing structure: A process that maintains the structure of the object at a constant level . http://purl.obolibrary.org/obo/TXPO_0003736 ER stress dependent process (molecular level) http://purl.obolibrary.org/obo/TXPO_0001717 ER stress dependent process ER stress dependent process (molecular level) is a subtype of ER stress dependent process: A process that can constitute the course of endoplasmic reticulum stress and specifies the molecular level. http://purl.obolibrary.org/obo/TXPO_0003737 apoptosome assembly [Cell death] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process The aggregation, arrangement and bonding together of the apoptosome, a multisubunit protein complex involved in the signaling phase of the apoptotic process. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003739 leaking content from cell [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000526 leaking content from cell Leaking content from cell is a subtype of leaking: A process that leaks contents from the cell. This entity is a specific course-dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003740 inflammatory cell infiltration [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000540 inflammatory cell infiltration Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course dependent process. This process can constitute the course of Cholestasis. http://purl.obolibrary.org/obo/TXPO_0003741 increasing organelle volume http://purl.obolibrary.org/obo/TXPO_0000139 increasing volume Increasing organelle volume is a subtype of increasing volume: A process that changes the volume of the organelle to be higher. http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process http://purl.obolibrary.org/obo/TXPO_0001715 toxic course dependent process Hepatic fibrosis dependent process is a subtype of toxic course dependent process: A process that can constitute the course of hepatic fibrosis. http://purl.obolibrary.org/obo/TXPO_0003743 kupffer cell activation [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process Kupffer cell activation is a subtype of macrophage activation: A change in morphology and behavior of a kupffer cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003744 permeability (attribute) http://purl.obolibrary.org/obo/TXPO_0000305 non-meta generic quality It is an attribute of structure inhering in a bearer by virtue of the bearer's disposition to being permeated or pervaded by a gas or liquid (as by osmosis or diffusion). http://purl.obolibrary.org/obo/TXPO_0003745 cytokine secretion [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process The regulated release of cytokines from a cell. Cytokines are any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003746 hepatic stellate cell activation [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process A change in the morphology or behavior of a hepatic stellate cell resulting from exposure to a cytokine, chemokine, hormone, cellular ligand or soluble factor. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003747 fluid flow rate (attribute) http://purl.obolibrary.org/obo/PATO_0001574 flow rate quality A physical attribute inhering in a fluid (liquid or gas) by virtue of the amount of fluid which passes through a given surface per unit time. http://purl.obolibrary.org/obo/TXPO_0003749 hepatic fibrosis dependent chemical entity http://purl.obolibrary.org/obo/TXPO_0001731 toxic course dependent chemical entity Hepatic fibrosis dependent chemical entity is a subtype of toxic course dependent chemical entity. This entity can participate in the course of hepatic fibrosis. http://purl.obolibrary.org/obo/TXPO_0003750 hepatic fibrosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003749 hepatic fibrosis dependent chemical entity Hepatic fibrosis dependent gene is a subtype of toxic course dependent chemical entity. This gene can participate in the course of hepatic fibrosis as a gene product. Gene profile:caonical that described in textbooks or articles. http://purl.obolibrary.org/obo/TXPO_0003753 counting quality http://purl.obolibrary.org/obo/BFO_0000019 quality Counting numbers of objects and how many times an event happens are essential not to individuals in them but to collectives of objects or events. http://purl.obolibrary.org/obo/TXPO_0003754 addition of xenobiotics http://purl.obolibrary.org/obo/TXPO_0000166 addition of foreign substance Addition of xenobiotics is a subtype of addition of foreign substance: A process that xenobiotics to make an addition to a cell, organelle, or an organism. http://purl.obolibrary.org/obo/TXPO_0003755 hepatic stellate cell proliferation [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process The multiplication or reproduction of hepatic stellate cells, resulting in the expansion of a hepatic stellate cell population. Hepatic stellate cells are found in the perisinusoidal space of the liver, and are capable of multiple roles including storage of retinol, presentation of antigen to T cells (including CD1d-restricted NKT cells), and upon activation, production of extracellular matrix components. This cell type comprises approximately 8-15% of total cells in the liver. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003756 Increasing drug metabolite [lipidosis] http://purl.obolibrary.org/obo/TXPO_0002364 increasing drug metabolite Increasing drug metabolite is a subtype of increasing quantity: A process that changes the amount of drug metabolites to be higher. This entity is a specific course-dependent process. This process can constitute the course of lipidosis. http://purl.obolibrary.org/obo/TXPO_0003757 myoblast differentiation [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process The process in which a relatively unspecialized cell acquires specialized features of a myoblast. A myoblast is a mononucleate cell type that, by fusion with other myoblasts, gives rise to the myotubes that eventually develop into striated muscle fibers. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003758 decreased number (quality) http://purl.obolibrary.org/obo/TXPO_0003753 counting quality A number quality which is relatively few. http://purl.obolibrary.org/obo/TXPO_0003759 extracellular structure organization [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts, or disassembly of structures in the space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane, and also covers the host cell environment outside an intracellular parasite. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003761 negative regulation of extracellular matrix disassembly [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process Any process that decreases the rate, frequency or extent of extracellular matrix disassembly. Extracellular matrix disassembly is a process that results in the breakdown of the extracellular matrix. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003763 toxic course based on pathological findings http://purl.obolibrary.org/obo/TXPO_0000608 process sequence This course is categorized from the viewpoint of pathological findings derived by inference. http://purl.obolibrary.org/obo/TXPO_0003764 toxic course based on the eosinogranular degeneration (finding) http://purl.obolibrary.org/obo/TXPO_0003763 toxic course based on pathological findings This course is categorized from the viewpoint of the findings of eosinogranular degeneration. http://purl.obolibrary.org/obo/TXPO_0003765 toxic course based on ground glass appearance http://purl.obolibrary.org/obo/TXPO_0003763 toxic course based on pathological findings This course is categorized from the viewpoint of the findings of ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003766 CERB processing http://purl.obolibrary.org/obo/GO_0016485 protein processing CERB processing is a subtype of protein processing: CREB maturation process achieved by the cleavage of a peptide bond or bonds within CREB protein. http://purl.obolibrary.org/obo/TXPO_0003770 cytoplasm protein quality control by the ubiquitin-proteasome system http://purl.obolibrary.org/obo/GO_0043161 proteasome-mediated ubiquitin-dependent protein catabolic process The chemical reactions resulting in the breakdown of misfolded proteins in the cytoplasm, which are targeted to cytoplasmic proteasomes for degradation. http://purl.obolibrary.org/obo/TXPO_0003771 hepatic fibrosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003749 hepatic fibrosis dependent chemical entity Hepatic fibrosis dependent chemical compound is a subtype of toxic course dependent chemical entity. This entity (drug) can participate in the course of hepatic fibrosis. http://purl.obolibrary.org/obo/TXPO_0003779 necrosis [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003780 CCL3 production http://purl.obolibrary.org/obo/TXPO_0000019 generating substance CCL3 production is a subtype of generating a substance : A process that synthesizes trichloromethyl(.) as output. http://purl.obolibrary.org/obo/TXPO_0003781 decreasing blood flow [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process Decreasing blood flow is a subtype of decreasing flow: A process that changes the blood flow to be smaller. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003782 scarring [fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process Scarring is a subtype of changing material: A process of keeping area replaced into fibrous tissue by injury. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003783 nodule formation [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process The process in which the anatomical structures of the nodule are generated and organized. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003786 negative regulation of apoptotic process [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003787 CCL3 production [NASH] http://purl.obolibrary.org/obo/TXPO_0003780 CCL3 production CCL3 production is a subtype of generating a substance : A process that synthesizes trichloromethyl(.) as output. This entity is a specific course-dependent process. This process can constitute the course of NASH. http://purl.obolibrary.org/obo/TXPO_0003789 decreasing stored glycogen http://purl.obolibrary.org/obo/TXPO_0002050 decreasing glycogen level Decreasing stored glycogen is a subtype of decreasing glycogen level: A process that changes the stored amount of glycogen level to be lower. http://purl.obolibrary.org/obo/TXPO_0003790 negative regulation of gap junction assembly [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Any process that stops, prevents or reduces the frequency, rate or extent of gap junction assembly. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003791 CAR (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003862 CAR (mol) This gene encodes a member of the nuclear receptor superfamily, and is a key regulator of xenobiotic and endobiotic metabolism. The protein binds to DNA as a monomer or a heterodimer with the retinoid X receptor and regulates the transcription of target genes involved in drug metabolism and bilirubin clearance, such as cytochrome P450 family members. Unlike most nuclear receptors, this transcriptional regulator is constitutively active in the absence of ligand but is regulated by both agonists and inverse agonists. Ligand binding results in translocation of this protein to the nucleus, where it activates or represses target gene transcription. These ligands include bilirubin, a variety of foreign compounds, steroid hormones, and prescription drugs. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008] http://purl.obolibrary.org/obo/TXPO_0003793 cell division [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process The process resulting in division and partitioning of components of a cell to form more cells. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003794 negative regulation of mRNA degradation http://purl.obolibrary.org/obo/TXPO_0000126 negative regulation of mRNA catabolic process Prevention of degradation of mRNA molecules. In the absence of compensating changes in other processes, the slowing of mRNA degradation can result in an overall increase in the population of active mRNA molecules. http://purl.obolibrary.org/obo/TXPO_0003795 positive regulation of cell division [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Any process that activates or increases the frequency, rate or extent of cell division. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003796 negative regulation of adherens junction assembly [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003813 negative regulation of adherens junction assembly Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003797 changing cycle phase http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Changing cycle phase is a subtype of changing quality: A process that changes the cycle phase. http://purl.obolibrary.org/obo/TXPO_0003798 maintaining cyclicity http://purl.obolibrary.org/obo/TXPO_0003797 changing cycle phase Maintaining cyclicity is a subtype of changing cyclicity: A process that keepss the repeating values in regular cycles (periods). http://purl.obolibrary.org/obo/TXPO_0003799 Cytochrome P450 activation [NASH] http://purl.obolibrary.org/obo/TXPO_0001758 cytochrome P450 activation Cytochrome P450 activation is a subtype of molecular activation: A process that changes the activity of the cytochrome P450 to be higher. This entity is a specific course-dependent process. This process can constitute the course of NASH. http://purl.obolibrary.org/obo/TXPO_0003800 extracellular matrix production- degradation imbalance [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003801 extracellular matrix production- degradation imbalance Extracellular matrix production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between extracellular matrix production and degradation. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003801 extracellular matrix production- degradation imbalance http://purl.obolibrary.org/obo/TXPO_0000567 imbalance Extracellular matrix production- degradation imbalance is a subtype of imbalance: A process that lacks a balance between extracellular matrix production and degradation. http://purl.obolibrary.org/obo/TXPO_0003802 hepatic fibrosis [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003742 hepatic fibrosis dependent process Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury. This entity is a specific course-dependent process. This process can constitute the course of Fibrosis. http://purl.obolibrary.org/obo/TXPO_0003803 hepatic fibrosis by alcoholic liver injury http://purl.obolibrary.org/obo/TXPO_0002329 hepatic fibrosis [toxic course] The totality of all processes through which hepatic fibrosis is realized by alcoholic liver injury. http://purl.obolibrary.org/obo/TXPO_0003804 hepatic fibrosis by NASH http://purl.obolibrary.org/obo/TXPO_0002329 hepatic fibrosis [toxic course] The totality of all processes through which hepatic fibrosis is realized by NASH. http://purl.obolibrary.org/obo/TXPO_0003806 overeating [NAFLD] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Overeating is a subtype of increasing quantity: A process that changes the ingestion amount of food to be larger. This entity is a specific course-dependent process. This process can constitute the course of NAFLD. http://purl.obolibrary.org/obo/TXPO_0003807 increasing fatty acid synthesis substrate [lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Increasing fatty acid synthesis substrate is a subtype of increasing quantity: A process that changes the production amount of the substrate of the fatty acid synthesis. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0003808 converting to acetyl CoA [NAFLD] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Converting to acetyl CoA is a subtype of metabolic process. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (NAFLD). http://purl.obolibrary.org/obo/TXPO_0003809 increasing amount of carbohydrate [NAFLD] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Increasing amount of carbohydrate is a subtype of increasing quantity: A process that changes the amount of carbohydrates to be higher. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis (NAFLD). http://purl.obolibrary.org/obo/TXPO_0003810 increase in lipid inflow into hepatocyte [NAFLD] http://purl.obolibrary.org/obo/TXPO_0003494 increase in lipid inflow into hepatocyte [Lipidosis] Increase in lipid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the lipid inflow into the hepatocyte to be larger. This entity is a specific course-dependent process. This process can constitute the course of NAFLD. http://purl.obolibrary.org/obo/TXPO_0003811 increaing in fatty acid inflow into hepatocyte [NAFLD] http://purl.obolibrary.org/obo/TXPO_0000892 increaing in fatty acid inflow into hepatocyte [Lipidosis] Increaing in fatty acid inflow into hepatocyte is a subtype of increasing quantity: A process that changes the fatty acid inflow into the hepatocyte to be larger. This entity is a specific course-dependent process. This process can constitute the course of NAFLD. http://purl.obolibrary.org/obo/TXPO_0003813 negative regulation of adherens junction assembly http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of adherens junction assembly is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of adherens junction assembly. http://purl.obolibrary.org/obo/TXPO_0003814 signal role http://purl.obolibrary.org/obo/TXPO_0001393 transmitter role A role played by the entity to transmit something to be detected. http://purl.obolibrary.org/obo/TXPO_0003815 molecular assembly http://purl.obolibrary.org/obo/TXPO_0000468 assembling Molecular assembly is a subtype of assembling: The aggregation, arrangement and bonding together of molecules. http://purl.obolibrary.org/obo/TXPO_0003816 stress signal role http://purl.obolibrary.org/obo/TXPO_0003814 signal role A role played by the entity to transmit the stress to be detected. http://purl.obolibrary.org/obo/TXPO_0003822 steatosis inducer role http://purl.obolibrary.org/obo/TXPO_0003710 regulator role A role played by the entity which involves in inducing lipidosis http://purl.obolibrary.org/obo/TXPO_0003824 lysosomal cholesterol storage (severe)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001537 lysosomal cholesterol storage Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome severely. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003825 Inflammasome activation [pyroptosis] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Inflammasome activation is a subtype of activating: A process that changes the activity of the inflammasome to be higher. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003827 Inflammatory cytokine gene expression[pyroptosis] http://purl.obolibrary.org/obo/TXPO_0002266 inflammatory cytokine gene expression Inflammatory cytokine gene expression is a subtype of gene expression: The process in which a gene sequence is converted into a mature inflammatory cytokine gene product or products (proteins or RNA). This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003829 compound accumulation in liver [Cell death] http://purl.obolibrary.org/obo/TXPO_0002325 accumulation of drug in hepatocyte Compound accumulation in liver is a subtype of accumulation of xenobiotics: A process that keeps compound in the liver. This entity is a specific course-dependent process. This process can constitute the course of Cell death. http://purl.obolibrary.org/obo/TXPO_0003830 inflammatory response [pyroptosis] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Inflammatory response is a subtype of changing material: The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. This entity is a specific course-dependent process. This process can constitute the course of pyroptosis. http://purl.obolibrary.org/obo/TXPO_0003831 inflammatory cell infiltration [pyroptosis] http://purl.obolibrary.org/obo/TXPO_0001727 cell death dependent process Inflammatory cell infiltration is a subtype of moving A to the inside of B: A process that that moves the outside inflammatory cell to the inside in response to an inflammatory reaction. This entity is a specific course-dependent process. This process can constitute the course of pyroptosis. http://purl.obolibrary.org/obo/TXPO_0003844 hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003864 hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 [Ground glass appearance] Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003845 smooth endoplasmic reticulum membrane organization (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001615 smooth endoplasmic reticulum membrane organization Smooth endoplasmic reticulum membrane organization is a subtype of endoplasmic reticulum membrane organization: A process that is carried out at the cellular level which results in the assembly, arrangement of constituent parts of a smooth endoplasmic reticulum membrane. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003846 hyperfunction of drug metabolism phase I (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000938 hyperfunction of drug metabolism phase I [Ground glass appearance] Hyperfunction of drug metabolism phase I is a subtype of hyperfunction of drug metabolism: A process that performs an excesssive drug metabolism phase I. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003847 hyperfunction of decreasing the amount of phenobarbital (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001654 hyperfunction of decreasing the amount of phenobarbital [Ground glass appearance] Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003848 hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001663 hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite [Ground glass appearance] Hyperfunction of glucuronic acid conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glucuronic acid conjugation. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003849 hyperfunction of drug metabolism phase II (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000943 hyperfunction of drug metabolism phase II [Ground glass appearance] Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003850 reactive oxygen species biosynthetic process (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000948 reactive oxygen species biosynthetic process [Ground glass appearance] The chemical reaction resulting in the formation of reactive oxygen species, any molecules or ions formed by the incomplete one-electron reduction of oxygen. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003851 mitochondrial dysfunction [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002361 mitochondrial dysfunction Mitochondrial dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete mitochondrial function. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003852 necrosis [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process A type of cell death that is morphologically characterized by an increasingly translucent cytoplasm, swelling of organelles, minor ultrastructural modifications of the nucleus (specifically, dilatation of the nuclear membrane and condensation of chromatin into small, irregular, circumscribed patches) and increased cell volume (oncosis), culminating in the disruption of the plasma membrane and subsequent loss of intracellular contents. Necrotic cells do not fragment into discrete corpses as their apoptotic counterparts do. Moreover, their nuclei remain intact and can aggregate and accumulate in necrotic tissues. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003853 glycogen catabolic process (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000958 glycogen catabolic process [Ground glass appearance] The chemical reactions and pathways resulting in the breakdown of glycogen, a polydisperse, highly branched glucan composed of chains of D-glucose residues. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003854 making existence of drug http://purl.obolibrary.org/obo/TXPO_0001851 making existence of xenobiotics Making existence of drug is a subtype of making existence of xenobiotics: A process that makes a drug to be present in in a cell, organelle, or an organism. http://purl.obolibrary.org/obo/TXPO_0003855 nuclear receptor activation [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Nuclear receptor activation is a subtype of activation of transcription factor: A process that changes the activity of the molecule with a nuclear receptor role to be higher. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003856 phenobarbital metabolism imbalance [Ground glass appearance (severe) - tumorigenesis] http://purl.obolibrary.org/obo/TXPO_0003860 phenobarbital metabolism imbalance [Ground glass appearance] Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism. And the degree is severe. This process is dependent on the tumorigenesis and can constitute the course of Ground glass appearance (severe). http://purl.obolibrary.org/obo/TXPO_0003857 ground glass appearance with Cytochrome P450 activation [toxic course] http://purl.obolibrary.org/obo/TXPO_0001432 ground glass apperance [toxic corse] The totality of all processes through which ground glass appearance is realized. This toxic course has processes of CYP activation. http://purl.obolibrary.org/obo/TXPO_0003858 hyperfunction of cytochrome p450 gene expression by phenobarbital [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002051 hyperfunction of Cyp gene expression Hyperfunction of cytochrome p450 gene expression by phenobarbital is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450 by phenobarbital. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003859 hyperfunction of decreasing the amount of drugs [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001834 hyperfunction of decreasing the amount of drugs Hyperfunction of decreasing the amount of drugs is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of drugs. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003860 phenobarbital metabolism imbalance [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001665 drug metabolism imbalance [Ground glass appearance] Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003861 hyperfunction of decreasing the amount of drugs by Cytochrome P450 [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003859 hyperfunction of decreasing the amount of drugs [Ground glass appearance] Hyperfunction of decreasing the amount of drugs is a process of performing an excessive function of decreasing the amount of drugs by Cytochrome P450. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003863 xenosensor http://purl.obolibrary.org/obo/TXPO_0000882 sensor A role played by the entity which receives xenobiotics (signal) and transmits operand(s). http://purl.obolibrary.org/obo/TXPO_0003864 hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001621 hyperfunction of drug metabolism phase I by Cytochrome P450 [Ground glass appearance] Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003865 regulation of generation of precursor metabolites and energy (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003953 regulation of generation of precursor metabolites and energy by phenobarbital [Ground glass appearance] Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003866 phenobarbital induced liver tumor via ground glass appearance http://purl.obolibrary.org/obo/TXPO_0001588 ground glass appearance with Cytochrome P450 activation by phenobarbital The totality of all processes through which ground glass appearance is realized. This toxic course has a process of CYP activation by phenobarbital and manifests liver tumor. http://purl.obolibrary.org/obo/TXPO_0003867 clonal expansion of preneoplastic cell http://purl.obolibrary.org/obo/NCIT_C20613 clonal expansion Clonal expansion of preneoplastic cell is a subtype of clonal expansion: A process that becomes larger in the number of preneoplastic cells by cell division of a population of identical cells descended from a single progenitor. http://purl.obolibrary.org/obo/TXPO_0003868 hyperfunction of increasing the amount of phenobarbital [Ground glass appearance (moderate) ] http://purl.obolibrary.org/obo/TXPO_0001840 hyperfunction of increasing the amount of phenobarbital [Ground glass appearance] Hyperfunction of increasing the amount of drug is a process of performing an excessive function of increasing the amount of drugs. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003869 phenobarbital metabolism imbalance [Ground glass appearance (moderate) ] http://purl.obolibrary.org/obo/TXPO_0003860 phenobarbital metabolism imbalance [Ground glass appearance] Phenobarbital metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of the phenobarbital metabolism. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003870 phenobarbital accumulation in liver [Ground glass appearance (moderate) ] http://purl.obolibrary.org/obo/TXPO_0000934 phenobarbital accumulation in liver [Ground glass appearance] Phenobarbital accumulation in liver is a subtype of compound accumulation in liver: A process that keeps phenobarbital in the liver. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003871 hyperfunction of decreasing the amount of phenobarbital [Ground glass appearance (moderate) ] http://purl.obolibrary.org/obo/TXPO_0001654 hyperfunction of decreasing the amount of phenobarbital [Ground glass appearance] Hyperfunction of decreasing the amount of phenobarbital is a subtype of hyperfunction of decreasing: A process that performs an excesssive decreasing the amount of the phenobarbital. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003872 hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite [Ground glass appearance (moderate) ] http://purl.obolibrary.org/obo/TXPO_0001663 hyperfunction of glucuronic acid conjugation for phenobarbital intermediate metabolite [Ground glass appearance] Hyperfunction of glucuronic acid conjugation is a subtype of hyperfunction of drug metabolism phase II: A process that performs an excessive glucuronic acid conjugation. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003873 hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 [Ground glass appearance (moderate) ] http://purl.obolibrary.org/obo/TXPO_0003864 hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 [Ground glass appearance] Hyperfunction of phenobarbital metabolism phase I by Cytochrome P450 is a subtype of hyperfunction of drug metabolism phase I: A process that performs an excesssive phenobarbital metabolism phase I by Cytochrome P450. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003874 hyperfunction of cytochrome p450 gene expression  by phenobarbital [Ground glass appearance (moderate) ] http://purl.obolibrary.org/obo/TXPO_0003858 hyperfunction of cytochrome p450 gene expression by phenobarbital [Ground glass appearance] Hyperfunction of cytochrome p450 gene expression is a subtype of hyperfunction of drug metabolizing enzyme gene expression: A process that performs an excesssive gene expression of cytochrome p450. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003875 constitutive androstane receptor activation by phenobarbital (moderate) [Ground glass appearance ] http://purl.obolibrary.org/obo/TXPO_0002309 constitutive androstane receptor activation by phenobarbital [Ground glass appearance] Constitutive androstane receptor activation by phenobarbital is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003876 hyperfunction of moving phenobarbital to the inside of liver [Ground glass appearance (moderate) ] http://purl.obolibrary.org/obo/TXPO_0002719 hyperfunction of moving phenobarbital to the inside of liver [Ground glass appearance] A process that performs an excesssive moving the phenobarbital to the inside of liver. And the degree is moderate. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (moderate) . http://purl.obolibrary.org/obo/TXPO_0003877 positive regulation of autophagy [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Any process that activates, maintains or increases the rate of autophagy. Autophagy is the process in which cells digest parts of their own cytoplasm. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis http://purl.obolibrary.org/obo/TXPO_0003880 tumor metastasis inducer http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which positively regulates the tumor metastasis. http://purl.obolibrary.org/obo/TXPO_0003882 negative regulation of arachidonic acid metabolic process http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of arachidonic acid metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of the arachidonic acid metabolism. http://purl.obolibrary.org/obo/TXPO_0003883 hyperfunctioning of autophagy http://purl.obolibrary.org/obo/TXPO_0000435 hyperfunctioning Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive autophagy. http://purl.obolibrary.org/obo/TXPO_0003884 arachidonic acid metabolism http://purl.obolibrary.org/obo/GO_0001676 long-chain fatty acid metabolic process The chemical reactions and pathways involving arachidonic acid, a straight chain fatty acid with 20 carbon atoms and four double bonds per molecule. Arachidonic acid is the all-Z-(5,8,11,14)-isomer. http://purl.obolibrary.org/obo/TXPO_0003885 omega-hydroxylase P450 pathway http://purl.obolibrary.org/obo/TXPO_0003884 arachidonic acid metabolism The chemical reactions and pathways by which arachidonic acid is converted to other compounds initially by omega-hydroxylation. http://purl.obolibrary.org/obo/TXPO_0003886 negative regulation of arachidonic acid metabolic process [phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003882 negative regulation of arachidonic acid metabolic process Negative regulation of arachidonic acid metabolic process is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of the arachidonic acid metabolism. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003888 tumor progression inhibitor http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which inhibits the tumor progression. http://purl.obolibrary.org/obo/TXPO_0003889 Hyperfunctioning of apoptotic process [Phospholipidosis (excessive defense) ] http://purl.obolibrary.org/obo/TXPO_0003883 hyperfunctioning of autophagy Hyperfunctioning of apoptotic process is a subtype of hyperfunctioning: A process that performs an excesssive apoptosis. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003890 TGF beta receptor signaling (primitive) [Phospholipidosis (excessive defense) - apoptosis inhibition ] http://purl.obolibrary.org/obo/TXPO_0001853 TGF beta receptor signaling (primitive) [Phospholipidosis (excessive defense)] TGFbeta signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the cytokine TGFbeta. This process is dependent on the apoptosis inhibition and can constitute the course of Phospholipidosis (excessive defense) . http://purl.obolibrary.org/obo/TXPO_0003898 degradation of Dab2 http://purl.obolibrary.org/obo/GO_0030163 protein catabolic process Degradation of Dab2 is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of Dab2. http://purl.obolibrary.org/obo/TXPO_0003899 degradation of Dab2 [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003898 degradation of Dab2 Degradation of Dab2 is a subtype of protein catabolic process: A process of the chemical reactions resulting in the breakdown of Dab2. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0003901 smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance - Cyp] http://purl.obolibrary.org/obo/TXPO_0001230 smooth endoplasmic reticulum proliferation in hepatocyte Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s). This process is dependent on the Cyp activation and can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003902 hyperfunction of drug metabolism phase II [Ground glass appearance - Cyp] http://purl.obolibrary.org/obo/TXPO_0000943 hyperfunction of drug metabolism phase II [Ground glass appearance] Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II. This process is dependent on the CYP activation and can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003903 smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance - Cyp - PB] http://purl.obolibrary.org/obo/TXPO_0003901 smooth endoplasmic reticulum proliferation in hepatocyte [Ground glass appearance - Cyp] Smooth endoplasmic reticulum proliferation in hepatocyte is a subtype of endoplasmic reticulum proliferation in hepatocyte: A process that becomes larger in the number of smooth endoplasmic reticulum in hepatocyte(s). This process is dependent on the phenobarbital induced CYP activation and can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003904 clonal expansion of preneoplastic cell [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003867 clonal expansion of preneoplastic cell Clonal expansion of preneoplastic cell is a subtype of clonal expansion: A process that becomes larger in the number of preneoplastic cells by cell division of a population of identical cells descended from a single progenitor. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003905 negative regulation of epidermal growth factor receptor signaling pathway [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003911 EGFR pathway negative regulator role http://purl.obolibrary.org/obo/CHEBI_76932 pathway inhibitor A role of the entity which negatively regulates the EGFR signaling pathway. http://purl.obolibrary.org/obo/TXPO_0003917 Translocation of CAR from the cytosol to the nucleus http://purl.obolibrary.org/obo/GO_0051169 nuclear transport Translocation of CAR from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of CAR from the cytoplasm to the nucleus. http://purl.obolibrary.org/obo/TXPO_0003918 Translocation of CAR from the cytosol to the nucleus [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003917 Translocation of CAR from the cytosol to the nucleus Translocation of CAR from the cytosol to the nucleus is a subtype of nuclear transport: A process that of the directed movement of CAR from the cytoplasm to the nucleus. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003919 hypofunction of gluconeogenesis [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003920 hypofunction of gluconeogenesis Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003920 hypofunction of gluconeogenesis http://purl.obolibrary.org/obo/TXPO_0001910 hypofunction of biosynthesis Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis. http://purl.obolibrary.org/obo/TXPO_0003921 AMPK activation [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003925 negative regulation of ATP consuming via CAR activation (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003954 negative regulation of ATP consuming via CAR activation [Ground glass appearance] Any process that stops, prevents, or reduces the frequency, rate or extent of an ATP consuming process in the course of the ground glass degeneration via Constitutive Androstane Receptor (CAR). This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003926 negative regulation of gluconeogenesis [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003928 gluconeogenic factor http://purl.obolibrary.org/obo/TXPO_0003712 changer role A role played by the entity involved in gluconeogenesis. http://purl.obolibrary.org/obo/TXPO_0003929 gluconeogenesis inhibitor role http://purl.obolibrary.org/obo/TXPO_0003949 carbohydrate sysnthesis regulator role A role played by the entity which inhibits gluconeogenesis. http://purl.obolibrary.org/obo/TXPO_0003932 negative regulation of gluconeogenesis (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003926 negative regulation of gluconeogenesis [Ground glass appearance] Any process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis in the course of ground grlass appearence. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003934 AMPK activator http://purl.obolibrary.org/obo/TXPO_0003714 molecular activator A role played by the entity that activates AMPK activity. http://purl.obolibrary.org/obo/TXPO_0003935 FOXO1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower. http://purl.obolibrary.org/obo/TXPO_0003936 FOXO1 inactivation [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003935 FOXO1 inactivation FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003937 regulation of gluconeogenesis gene expression http://purl.obolibrary.org/obo/GO_0010468 regulation of gene expression Regulation of gluconeogenesis gene expression is a subtype of regulation of gene expression: A process that modulates the frequency, rate or extent of gluconeogenesis gene expression. http://purl.obolibrary.org/obo/TXPO_0003938 negative regulation of gluconeogenesis gene expression http://purl.obolibrary.org/obo/TXPO_0003937 regulation of gluconeogenesis gene expression Negative regulation of gluconeogenesis gene expression is a subtype of regulation of gluconeogenesis gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis gene expression. http://purl.obolibrary.org/obo/TXPO_0003939 negative regulation of gluconeogenesis gene expression [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003938 negative regulation of gluconeogenesis gene expression Negative regulation of gluconeogenesis gene expression is a subtype of regulation of gluconeogenesis gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of gluconeogenesis gene expression. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003940 negative regulation of G6Pase expression http://purl.obolibrary.org/obo/GO_0010629 negative regulation of gene expression Negative regulation of G6Pase expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of G6Pase expression. http://purl.obolibrary.org/obo/TXPO_0003942 negative regulation of glucogenesis related gene expression [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003940 negative regulation of G6Pase expression Negative regulation of glucogenesis related gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of glucogenesis related gene expression expression. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003943 hypofunction of gluconeogenesis (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003919 hypofunction of gluconeogenesis [Ground glass appearance] Hypofunction of gluconeogenesis is a subtype of hypofunction of biosynthesis: A process that performs a decreased or insufficient gluconeogenesis. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003944 negative regulation of glucogenesis related gene expression (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003942 negative regulation of glucogenesis related gene expression [Ground glass appearance] Negative regulation of glucogenesis related gene expression is a subtype of negative regulation of gene expression: A process that stops, prevents, or reduces the frequency, rate or extent of glucogenesis related gene expression expression. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003945 FOXO1 inactivation (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003936 FOXO1 inactivation [Ground glass appearance] FOXO1 inactivation is a subtype of inactivating: A process that changes the activity of the FOXO1 to be lower.This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003946 trannscriptional repressor of FOXO1 http://purl.obolibrary.org/obo/TXPO_0001531 trannscriptional repressor A role that represses the rate, timing and/or magnitude of transcription of FOXO1. http://purl.obolibrary.org/obo/TXPO_0003947 positive regulator of gluconeogenic gene transcription role http://purl.obolibrary.org/obo/TXPO_0000330 transcription regulator A role that activates, or increases the rate, timing and/or magnitude of transcription of gluconeogenic gene. http://purl.obolibrary.org/obo/TXPO_0003949 carbohydrate sysnthesis regulator role http://purl.obolibrary.org/obo/TXPO_0004023 metabolic regulator role A role played by the entity which regulates carbohydrate metabolic process. http://purl.obolibrary.org/obo/TXPO_0003950 increasing AMP/ATP ratio http://purl.obolibrary.org/obo/TXPO_0000352 increasing concentration Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher. http://purl.obolibrary.org/obo/TXPO_0003951 increasing AMP/ATP ratio [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003950 increasing AMP/ATP ratio Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003952 increasing AMP/ATP ratio (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003951 increasing AMP/ATP ratio [Ground glass appearance] Increasing AMP/ATP ratio is a subtype of increasing ratio: A process that changes the ratio of AMP to ATP to be higher. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003953 regulation of generation of precursor metabolites and energy by phenobarbital [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001619 regulation of generation of precursor metabolites and energy [Ground glass appearance] Any process that modulates the frequency, rate or extent of the chemical reactions resulting in the formation of precursor metabolites, substances from which energy is derived, and the processes involved in the liberation of energy from these substances regulated by phenobarbital. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003954 negative regulation of ATP consuming via CAR activation [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000945 negative regulation of ATP consuming [Ground glass appearance] Any process that stops, prevents, or reduces the frequency, rate or extent of an ATP consuming process in the course of the ground glass degeneration via Constitutive Androstane Receptor (CAR). This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003955 constitutive androstane receptor activation by phenobarbital_2 [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000935 constitutive androstane receptor activation [Ground glass appearance] Constitutive androstane receptor activation by phenobarbital_2 is a subtype of activating nuclear receptor: A process that changes the activity of the activating CAR ( constitutive androstane receptor) with a nuclear receptor role to be higher by phenobarbital. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003956 negative regulation of lipid biosynthetic process [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001728 ground glass degeneration dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003958 SREBP1 inactivation [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003959 SREBP1 inactivation SREBP1 inactivation is a subtype of inactivating: A process that changes the activity of the SREBP1 to be lower. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003959 SREBP1 inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation SREBP1 inactivation is a subtype of inactivating: A process that changes the activity of the SREBP1 to be lower. http://purl.obolibrary.org/obo/TXPO_0003960 decreasing cholesterol [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003963 decreasing cholesterol Decreasing cholesterol is a subtype of decreasing lipid: A process that changes the amount of cholesterol to be lower. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003961 decreasing hepatic triglyceride [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003962 decreasing hepatic triglyceride Decreasing hepatic triglyceride is a subtype of decreasing lipid: A process that changes the quantity of the hepatic triglyceride to be lower. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003962 decreasing hepatic triglyceride http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing hepatic triglyceride is a subtype of decreasing lipid: A process that changes the quantity of the hepatic triglyceride in lysosomal membranes to be lower. http://purl.obolibrary.org/obo/TXPO_0003963 decreasing cholesterol http://purl.obolibrary.org/obo/TXPO_0000644 decreasing lipid Decreasing cholesterol is a subtype of decreasing lipid: A process that changes the amount of cholesterol to be lower. http://purl.obolibrary.org/obo/TXPO_0003967 lipid synthesis positive regulator role http://purl.obolibrary.org/obo/TXPO_0002196 lipid synthesis regulator role A role played by the entity which positively regulates the formation of lipids. http://purl.obolibrary.org/obo/TXPO_0003968 cholesterol synthesis positive regulator role http://purl.obolibrary.org/obo/TXPO_0003967 lipid synthesis positive regulator role A role played by the entity which positively regulates the formation of cholesterol. http://purl.obolibrary.org/obo/TXPO_0003969 hyperfunction of mitochondrial fatty acid beta-oxidation [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002344 hyperfunction of mitochondrial fatty acid beta-oxidation Hyperfunction of mitochondrial fatty acid beta-oxidation is a subtype of hyperfunction of fatty acid beta-oxidation: A process that performs an excessive mitochondrial fatty acid beta-oxidation. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance. http://purl.obolibrary.org/obo/TXPO_0003970 ACC (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis. There are two ACC forms, alpha and beta, encoded by two different genes. ACC-alpha is highly enriched in lipogenic tissues. The enzyme is under long term control at the transcriptional and translational levels and under short term regulation by the phosphorylation/dephosphorylation of targeted serine residues and by allosteric transformation by citrate or palmitoyl-CoA. Multiple alternatively spliced transcript variants divergent in the 5' sequence and encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jul 2008] http://purl.obolibrary.org/obo/TXPO_0003973 fatty acid synthesis positive regulator role http://purl.obolibrary.org/obo/TXPO_0003967 lipid synthesis positive regulator role A role played by the entity which positively regulates the formation of fatty acid. http://purl.obolibrary.org/obo/TXPO_0003978 negative regulation of ATP consuming http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of ATP consuming is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of ATP consuming. http://purl.obolibrary.org/obo/TXPO_0003979 AMPK activation (sustained) [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003921 AMPK activation [Ground glass appearance] AMPK activation is a subtype of molecular activation: A process that changes the activity of the AMPK (AMP-activated protein kinase) to be higher. This process persists for a certain period or over a long period. This entity is a specific course-dependent process. This process can constitute the course of Ground glass appearance (sustained) . http://purl.obolibrary.org/obo/TXPO_0003984 sphingomyelin homeostasis imbalance [Phospholipidosis - genetic] http://purl.obolibrary.org/obo/TXPO_0004159 sphingomyelin homeostasis imbalance [Phospholipidosis - sphingomyelin disorder] Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. This process is dependent on the genetic and can constitute the course of Phospholipidosis (genetic). http://purl.obolibrary.org/obo/TXPO_0003985 phospholipid homeostasis imbalance [Phospholipidosis - genetic] http://purl.obolibrary.org/obo/TXPO_0000907 phospholipid homeostasis imbalance [Phospholipidosis] Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. This process is dependent on the genetic and can constitute the course of Phospholipidosis (genetic). http://purl.obolibrary.org/obo/TXPO_0003986 sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A] http://purl.obolibrary.org/obo/TXPO_0003988 sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A/ B] Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A. http://purl.obolibrary.org/obo/TXPO_0003987 sphingomyelin homeostasis imbalance [Niemann Pick Disease Type B] http://purl.obolibrary.org/obo/TXPO_0003988 sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A/ B] Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type B. http://purl.obolibrary.org/obo/TXPO_0003988 sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A/ B] http://purl.obolibrary.org/obo/TXPO_0003984 sphingomyelin homeostasis imbalance [Phospholipidosis - genetic] Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A/ B. http://purl.obolibrary.org/obo/TXPO_0003989 competitive inhibitor http://purl.obolibrary.org/obo/CHEBI_35222 inhibitor A role played by the entity that diminishes the rate of a chemical reaction competitively. http://purl.obolibrary.org/obo/TXPO_0003990 leukocyte infiltration http://purl.obolibrary.org/obo/TXPO_0000540 inflammatory cell infiltration Leukocyte infiltration is a subtype of inflammatory cell inflow: A process that that moves the outside leukocyte cell to the inside. http://purl.obolibrary.org/obo/TXPO_0003991 glutathione conjugation http://purl.obolibrary.org/obo/GO_0006749 glutathione metabolic process Glutathione conjugation is a detoxication reaction. Four types of activation reaction have been recognized: direct-acting compounds, conjugates that are activated through cysteine conjugate beta-lyase, conjugates that are activated through redox cycling and lastly conjugates that release the original reactive parent compound. The glutathione S-transferases have three connections with the formation of biactivated conjugatesto make them more soluble for excretion. http://purl.obolibrary.org/obo/TXPO_0003992 toxicological imbalance http://purl.obolibrary.org/obo/TXPO_0000270 state In the imbalance model, the basic units are as follows: 1) a functioning process (supply) for biological defense and maintaining homeostasis; 2) a functional demand process (demand) as toxic activity; 3) balance/imbalance between toxic activity and defense processes; and 4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations. This entity is a compound state that inculdes step 1 to 4. http://purl.obolibrary.org/obo/TXPO_0003995 protooncogene role http://purl.obolibrary.org/obo/CHEBI_52209 aetiopathogenetic role A role played by the oncogene that is altered forms of normal cellular genes. Many proto-oncogenes are homologous to viral oncogenes and involved in the control of cell proliferation or differentiation. Mutations, amplifications or rearrangements of proto-oncogenes lead to upregulated or deregulated cell growth and allow them to function as oncogenes. http://purl.obolibrary.org/obo/TXPO_0003997 chaperone role http://purl.obolibrary.org/obo/TXPO_0003712 changer role A role of the cytoplasmic proteins that bind to nascent or unfolded polypeptides and ensure correct folding or transport. Chaperone proteins do not covalently bind to their targets and do not form part of the finished product. Heat-shock proteins are an important sub set of chaperones. Three major families are recognised, the chaperonins (groEL and hsp60), the hsp70 family and the hsp90 family. Outside these major families are other proteins with similar functions including nucleoplasmin, secB and T-cell receptor associated protein. http://purl.obolibrary.org/obo/TXPO_0004001 recycling endososomal dysfunction [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0004002 recycling endosome dysfunction Recycling endosome dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete recycling endosomal function. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (severe). http://purl.obolibrary.org/obo/TXPO_0004002 recycling endosome dysfunction http://purl.obolibrary.org/obo/TXPO_0000438 dysfunctioning Recycling endosome dysfunction is a subtype of dysfunctioning: A process that performs an abnormal and incomplete recycling endosomal function. And the degree is severe. http://purl.obolibrary.org/obo/TXPO_0004004 hyperfunction of heme biosynthesis http://purl.obolibrary.org/obo/TXPO_0002346 hyperfunction of biosynthesis Hyperfunction of phospholipid biosynthesis is a subtype of hyperfunction of biosynthesis: A process that performs an excessive heme biosynthesis. http://purl.obolibrary.org/obo/TXPO_0004008 tumor tissue http://purl.obolibrary.org/obo/TXPO_0004047 abnormal cell tissue Tumor tissue is a subtype of abnormal cellular tissue that consists of tumor cells . http://purl.obolibrary.org/obo/TXPO_0004009 hypofunction of endocytic recycling http://purl.obolibrary.org/obo/TXPO_0001911 hypofunction of transport Hypofunction of eidocytic recycling from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient endocytic recycling. http://purl.obolibrary.org/obo/TXPO_0004010 hypofunction of endocytic recycling [Phospholipidosis (severe) ] http://purl.obolibrary.org/obo/TXPO_0004009 hypofunction of endocytic recycling Hypofunction of eidocytic recycling from ER to mitochondrial membrane is a subtype of hypofunction of transport: A process that performs a decreased or insufficient endocytic recycling. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004014 negative regulation of release of arachidonic acid from cell membrane http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Negative regulation of release of arachidonic acid from cell membrane is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of the release of arachidonic acid from cell membrane. http://purl.obolibrary.org/obo/TXPO_0004015 Dissociation of FLCN:FNIP complex [Phospholipidosis (severe)] http://purl.obolibrary.org/obo/TXPO_0004016 Dissociation of FLCN:FNIP complex Dissociation of FLCN:FNIP complex is a subtype of detaching: A process that disaggregates the FLCN:FNIP complex. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004016 Dissociation of FLCN:FNIP complex http://purl.obolibrary.org/obo/TXPO_0000462 detaching Dissociation of FLCN:FNIP complex is a subtype of detaching: A process that disaggregates the FLCN:FNIP complex. http://purl.obolibrary.org/obo/TXPO_0004023 metabolic regulator role http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which regulates the metabolism. http://purl.obolibrary.org/obo/TXPO_0004028 TOR signaling (primitive) http://purl.obolibrary.org/obo/GO_0023052 signaling [biological] (primitive) TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) . http://purl.obolibrary.org/obo/TXPO_0004032 negative regulation of release of arachidonic acid from cell membrane [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004014 negative regulation of release of arachidonic acid from cell membrane Negative regulation of release of arachidonic acid from cell membrane is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of the release of arachidonic acid from cell membrane. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004034 TOR signaling (primitive)　[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004028 TOR signaling (primitive) TOR signaling (primitive) is a subtype of signaling [biological]: A process that in which a signal is transmitted by the TOR (Target of rapamycin) . This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis . http://purl.obolibrary.org/obo/TXPO_0004035 release of tumor inhibitor from lysosome http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The directed movement of tumor inhibitor from the lysosome. http://purl.obolibrary.org/obo/TXPO_0004040 release of tumor inhibitor from lysosome [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004035 release of tumor inhibitor from lysosome The directed movement of tumor inhibitor from the lysosome. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004043 negative regulator of tumor cell proliferation http://purl.obolibrary.org/obo/TXPO_0004045 negative regulator of cell proliferation A role played by the entity which negatively regulates the process of tumor cell proliferation. http://purl.obolibrary.org/obo/TXPO_0004045 negative regulator of cell proliferation http://purl.obolibrary.org/obo/TXPO_0003159 regulator of cell proliferation A role played by the entity which negatively regulates the process of cell proliferation. http://purl.obolibrary.org/obo/TXPO_0004046 forming adduct http://purl.obolibrary.org/obo/TXPO_0000168 having extra parts Forming adduct is a subtype of having extra parts: A process that changes to have connection or association with another entity. http://purl.obolibrary.org/obo/TXPO_0004047 abnormal cell tissue http://purl.obolibrary.org/obo/TXPO_0000065 cellular tissue Abnormal cell tissue is a subtype of cellular tissue that consists of abnormal cells and tissues. http://purl.obolibrary.org/obo/TXPO_0004048 proteasome-mediated ubiquitin-dependent FNIP2 catabolic process http://purl.obolibrary.org/obo/GO_0043161 proteasome-mediated ubiquitin-dependent protein catabolic process The chemical reaction resulting in the breakdown of FNIP2, which is mediated by the proteasome. http://purl.obolibrary.org/obo/TXPO_0004049 proteasome-mediated FNIP2 degradation [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004048 proteasome-mediated ubiquitin-dependent FNIP2 catabolic process The chemical reaction resulting in the breakdown of FNIP2, which is mediated by the proteasome. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis http://purl.obolibrary.org/obo/TXPO_0004053 PPARalpha activation [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process PPARalpha activation is a subtype of activating nuclear receptor: A process that changes the activity of the activating PPAR alpha ( (Peroxisome Proliferator Activated Receptor Alpha)) with a nuclear receptor role to be higher. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004065 ketone biosynthetic process[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process The chemical reactions and pathways resulting in the formation of ketones, a class of organic compounds that contain the carbonyl group, CO, and in which the carbonyl group is bonded only to carbon atoms. The general formula for a ketone is RCOR, where R and R are alkyl or aryl groups. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004066 hypofunction of anti-oxidative stress http://purl.obolibrary.org/obo/TXPO_0000436 hypofunctioning Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function. http://purl.obolibrary.org/obo/TXPO_0004069 hypofunction of anti-oxidative stress[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004066 hypofunction of anti-oxidative stress Hypofunction of anti-oxidative stress is a subtype of hypofunctioning: A process that performs a decreased or insufficient anti-oxidative stress function. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis http://purl.obolibrary.org/obo/TXPO_0004077 energy supply http://purl.obolibrary.org/obo/TXPO_0000741 supplying (from stored substance(s)) Energy supply is a subtype of providing process to perform a meta-function “to provide energy. http://purl.obolibrary.org/obo/TXPO_0004079 positive regulation of cell death http://purl.obolibrary.org/obo/GO_0010941 regulation of cell death Any process that increases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death. http://purl.obolibrary.org/obo/TXPO_0004081 negative regulation of mitochondrial electron transport, ubiquinol to cytochrome c http://purl.obolibrary.org/obo/TXPO_0002342 negative regulation of respiratory electron transport chain Any process that stops, prevents or reduces the frequency, rate or extent of tmitochondrial electron transport, ubiquinol to cytochrome c http://purl.obolibrary.org/obo/TXPO_0004082 negative regulation of cell death http://purl.obolibrary.org/obo/GO_0010941 regulation of cell death Any process that decreases the rate or frequency of cell death. Cell death is the specific activation or halting of processes within a cell so that its vital functions markedly cease, rather than simply deteriorating gradually over time, which culminates in cell death. http://purl.obolibrary.org/obo/TXPO_0004084 negative regulation of potassium ion transport [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of potassium ions (K+) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. http://purl.obolibrary.org/obo/TXPO_0004085 positive regulation of macrophage derived foam cell differentiation [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004088 malfunctioning of insulin signaling [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Malfunctioning of insulin signaling is a subtype of malfunctioning process: A process that cannot perform insulin signaling [biological] appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of Phosphoipidosis. http://purl.obolibrary.org/obo/TXPO_0004096 protein ubiquitination http://purl.obolibrary.org/obo/TXPO_0004107 protein modification by small protein conjugation The process in which one or more ubiquitin groups are added to a protein. http://purl.obolibrary.org/obo/TXPO_0004097 genetic information carrier role http://purl.obolibrary.org/obo/TXPO_0001393 transmitter role genetic information carrier role is a subtype of role dependent on transmitting genetic information process http://purl.obolibrary.org/obo/TXPO_0004098 positive regulation of glutathione biosynthetic process [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000889 glutathione depletion dependent process Any process that activates or increases the frequency, rate or extent of glutathione biosynthetic process. This entity is a specific course-dependent process. This process can constitute the course of Glutathione depletion. http://purl.obolibrary.org/obo/TXPO_0004099 negative regulation of mitochondrial electron transport, succinate to ubiquinone http://purl.obolibrary.org/obo/TXPO_0002342 negative regulation of respiratory electron transport chain Any process that stops, prevents or reduces the frequency, rate or extent of the transfer of electrons from succinate to ubiquinone. http://purl.obolibrary.org/obo/TXPO_0004100 malfunctioning of cobalamin biosynthetic process http://purl.obolibrary.org/obo/TXPO_0003267 malfunction of biosynthesis Malfunctioning of cobalamin biosynthetic process is a subtype of malfunctioning process: A process that cannot perform cobalamin biosynthetic process appropriately or cannot realize it at all. http://purl.obolibrary.org/obo/TXPO_0004101 malfunctioning of cobalamin biosynthetic process[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004100 malfunctioning of cobalamin biosynthetic process Malfunctioning of cobalamin biosynthetic process is a subtype of malfunctioning process: A process that cannot perform cobalamin biosynthetic process appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of Phosphoipidosis. http://purl.obolibrary.org/obo/TXPO_0004107 protein modification by small protein conjugation http://purl.obolibrary.org/obo/GO_0070647 protein modification by small protein conjugation or removal A protein modification process in which one or more groups of a small protein, such as ubiquitin or a ubiquitin-like protein, are covalently attached to a target protein. http://purl.obolibrary.org/obo/TXPO_0004109 negative regulation of mitochondrial electron transport, NADH to ubiquinone [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Any process that stops, prevents or reduces the frequency, rate or extent of mitochondrial electron transport, NADH to ubiquinone. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004110 lipid droplet formation http://purl.obolibrary.org/obo/GO_0034389 lipid droplet organization A process that results in the assembly, arrangement of constituent parts of a lipid droplet. http://purl.obolibrary.org/obo/TXPO_0004111 lipid droplet formation [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004110 lipid droplet formation A process that results in the assembly, arrangement of constituent parts of a lipid droplet. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004113 macrophage migration [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process The orderly movement of a macrophage from one site to another. This entity is a specific course-dependent process. This process can constitute the course of phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004115 tumor metastasis inhibitor http://purl.obolibrary.org/obo/TXPO_0003230 process regulator role A role played by the entity which negatively regulates the tumor metastasis. http://purl.obolibrary.org/obo/TXPO_0004117 hyperfunction of drug metabolism phase II [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Hyperfunction of drug metabolism phase II is a subtype of hyperfunction of drug metabolism: A process that performs an excessive drug metabolism phase II. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004119 negative regulation of mitochondrial electron transport, succinate to ubiquinone [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004099 negative regulation of mitochondrial electron transport, succinate to ubiquinone Any process that stops, prevents or reduces the frequency, rate or extent of the transfer of electrons from succinate to ubiquinone. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004120 negative regulation of mitochondrial electron transport, ubiquinol to cytochrome c [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004081 negative regulation of mitochondrial electron transport, ubiquinol to cytochrome c Any process that stops, prevents or reduces the frequency, rate or extent of tmitochondrial electron transport, ubiquinol to cytochrome c. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004121 DNA damage [Mitochondrial disorder] http://purl.obolibrary.org/obo/NCIT_C16507 DNA damage Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004122 positive regulation of tumor cell death http://purl.obolibrary.org/obo/TXPO_0004079 positive regulation of cell death Any process that increases the rate or frequency of tumor cell death. http://purl.obolibrary.org/obo/TXPO_0004123 positive regulation of tumor cell death [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004122 positive regulation of tumor cell death Any process that increases the rate or frequency of tumor cell death. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004124 negative regulation of heat generation [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0002054 negative regulation of heat generation Negative regulation of heat generation is a subtype of negative regulation process: Any process that stops, prevents, or reduces the rate or extent of heat generation. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004125 negative regulation of oxidative phosphorylation [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Negative regulation of oxidative phosphorylation is a subtype of negative regulation process: Any process that stops, prevents or reduces the frequency, rate or extent of the oxidative phosphorylation. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004126 malfunctioning of TCA cycle [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Malfunctioning of TCA cycle is a subtype of malfunctioning of metabolism: A process that cannot perform a tricarboxylic acid cycle appropriately or cannot realize it at all. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004127 increasing acetyl CoA [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process Increasing acetyl CoA is a subtype of increasing quantity: A process that changes the amount of acetyl CoA to be larger. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder]. http://purl.obolibrary.org/obo/TXPO_0004128 increasing volume of mitochondria [lipidosis] http://purl.obolibrary.org/obo/TXPO_0001720 hepatic steatosis dependent process Increasing volume of mitochondria is a changing process to change the volume of the mitochondria to increase. This entity is a specific course-dependent process. This process can constitute the course of Lipidosis. http://purl.obolibrary.org/obo/TXPO_0004129 tumor cell death http://purl.obolibrary.org/obo/GO_0008219 cell death Any biological process that results in permanent cessation of tumor cells. http://purl.obolibrary.org/obo/TXPO_0004130 increasing uptake amount of mitochondrial proton ion http://purl.obolibrary.org/obo/TXPO_0000395 increasing quantity Increasing uptake amount of mitochondrial proton is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial proton to be higher. http://purl.obolibrary.org/obo/TXPO_0004131 increasing uptake amount of mitochondrial proton ion [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004130 increasing uptake amount of mitochondrial proton ion Increasing uptake amount of mitochondrial proton is a subtype of increasing quantity: A process that changes the uptake amount of mitochondrial proton to be higher. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004132 negative regulation of tumor cell proliferation [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002124 negative regulation of tumor cell proliferation Negative regulation of tumor cell proliferation is a subtype of negative regulation process: A process that stops, prevents, or reduces the frequency, rate or extent of tumor cell proliferation. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004133 oxidative phosphorylation uncoupling http://purl.obolibrary.org/obo/TXPO_0000369 negative regulation process Any process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis. http://purl.obolibrary.org/obo/TXPO_0004134 positive regulation of oxidative phosphorylation uncoupling http://purl.obolibrary.org/obo/TXPO_0001223 positive regulation process Any process that activates or increases the frequency, rate or extent of oxidative phosphorylation uncoupling. Oxidative phosphorylation uncoupling is a process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis. http://purl.obolibrary.org/obo/TXPO_0004135 positive regulation of oxidative phosphorylation uncoupling [Mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004134 positive regulation of oxidative phosphorylation uncoupling Any process that activates or increases the frequency, rate or extent of oxidative phosphorylation uncoupling. Oxidative phosphorylation uncoupling is a process that enables the transfer of protons from mitochondrial intermembrane space into mitochondrial matrix, dissipating the proton gradient across the mitochondrial inner membrane established by the electron transport chain during the oxidative phosphorylation (proton leak). Proton leak uncouples the processes of electron transport/proton generation and ATP synthesis. This entity is a specific course-dependent process. This process can constitute the course of Mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0004136 energy supply [Phospholipidosis(normal)] http://purl.obolibrary.org/obo/TXPO_0004077 energy supply Energy supply is a subtype of providing process to perform a meta-function “to provide energy. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition). http://purl.obolibrary.org/obo/TXPO_0004137 increasing energy [Phospholipidosis (normal)] http://purl.obolibrary.org/obo/TXPO_0003593 increasing energy [Phospholipidosis] Increasing energy is a subtype of increasing quantity: A process that changes the amount of energy to be larger. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (normal condition). http://purl.obolibrary.org/obo/TXPO_0004138 decreasing energy http://purl.obolibrary.org/obo/TXPO_0000396 decreasing quantity Decreasing energy is a subtype of decreasing quantity: A process that changes the amount of energy to be smaller. http://purl.obolibrary.org/obo/TXPO_0004139 decreasing energy [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004138 decreasing energy Decreasing energy is a subtype of decreasing quantity: A process that changes the amount of energy to be smaller. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004141 hepatic fibrosis [Niemann-Pick disease] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process Hepatic fibrosis is a subtype of fibrosis: A process that replaces liver tissues to fibrous connective tissues, usually as a consequence of inflammation or other injury. This entity is a specific course-dependent process. This process can constitute the course of Niemanne-Pick disease. http://purl.obolibrary.org/obo/TXPO_0004143 ceramide acumulation http://purl.obolibrary.org/obo/GO_0019915 lipid storage ceramide accumulation is a subtype of accumulation of substances in a biological object: A process that keeps ceramide in an organism, tissue, organelle, or cell. http://purl.obolibrary.org/obo/TXPO_0004144 extracellular matrix disassembly [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process A process that results in the breakdown of the extracellular matrix. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (excessive defense). http://purl.obolibrary.org/obo/TXPO_0004145 hypofunction of cholesterol efflux from hepatoyte http://purl.obolibrary.org/obo/TXPO_0001911 hypofunction of transport A process that performs a decreased or insufficient cholesterol efflux http://purl.obolibrary.org/obo/TXPO_0004146 hypofunction of cholesterol efflux [Niemann-pick disease] http://purl.obolibrary.org/obo/TXPO_0004145 hypofunction of cholesterol efflux from hepatoyte A process that performs a decreased or insufficient cholesterol export. This entity is a specific course-dependent process. This process can constitute the course of Niemann-Pick disease. http://purl.obolibrary.org/obo/TXPO_0004147 sphingomyelin [Niemann-Pick disease] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound Any of a class of phospholipids in which the amino group of a sphingoid base is in amide linkage with one of several fatty acids, while the terminal hydroxy group of the sphingoid base is esterified to phosphorylcholine. http://purl.obolibrary.org/obo/TXPO_0004148 myelin figureformation in lysosome [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process A process that forms myelin-like layered structures This process is dependent on the course of phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004150 Removing ceramide by Kupffer cell or macrophage http://purl.obolibrary.org/obo/TXPO_0000458 removing (from A) Removing ceramide by Kupffer cell or macrophage is a subtype of removing: A process that takes ceramide from a cell by Kupffer cells or macrophages . http://purl.obolibrary.org/obo/TXPO_0004151 hyperfunction of ceramide phagocytosis by Kupffer cell or macrophage http://purl.obolibrary.org/obo/TXPO_0001483 hyperfunction of phospholipid removing Hyperfunction of ceramide phagocytosis by Kupffer cell or macrophage is a subtype of hyperfunctioning: A process that performs an excessive ceramide phagocytosis by Kupffer cells or macrophages. http://purl.obolibrary.org/obo/TXPO_0004152 acid ceramidase inactivation http://purl.obolibrary.org/obo/TXPO_0000021 inactivation Acid ceramidase inactivation is a subtype of molecular inactivation: A process that changes the activity of the acid ceramidase to be lower. http://purl.obolibrary.org/obo/TXPO_0004153 acid ceramidase inactivation [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004152 acid ceramidase inactivation Acid ceramidase inactivation is a subtype of molecular inactivation: A process that changes the activity of the acid ceramidase to be lower. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004154 increasing number of macrophage derived foam cell [Phospholipidosis(severe)] http://purl.obolibrary.org/obo/TXPO_0000918 increasing number of macrophage derived foam cell [Phospholipidosis] Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(severe). http://purl.obolibrary.org/obo/TXPO_0004155 phospholipid homeostasis imbalance [Phospholipidosis (mild) ] http://purl.obolibrary.org/obo/TXPO_0000907 phospholipid homeostasis imbalance [Phospholipidosis] Phospholipid homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. And the degree is mild. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis (mild). http://purl.obolibrary.org/obo/TXPO_0004156 dysfunction of sphingomyelin degradation [Phospholipidosis-sphingomyelin disorder] http://purl.obolibrary.org/obo/TXPO_0004162 hypofunction of sphingomyelin degradation [Phospholipidosis-sphingomyelin disorder] Dysfunction of sphingomyelin degradation is a subtype of dysfunction of phosphosphingolipid degradation: A process that performs an abnormal and incomplete sphingomyelin degradation. This process can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_0004157 sphingomyelin disorder (phospholipidosis)　 http://purl.obolibrary.org/obo/TXPO_0002215 phospholipidosis (toxic course) The totality of all processes through which the sphingomyelin disorder is realized. http://purl.obolibrary.org/obo/TXPO_0004158 lysosomal cholesterol storage (moderate)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0000694 lysosomal cholesterol storage [Phospholipidosis] Lysosomal cholesterol storage is a subtype of cholesterol storage: A process that keeps cholesterol in the lysosome moderately. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(moderate). http://purl.obolibrary.org/obo/TXPO_0004159 sphingomyelin homeostasis imbalance [Phospholipidosis - sphingomyelin disorder] http://purl.obolibrary.org/obo/TXPO_0000907 phospholipid homeostasis imbalance [Phospholipidosis] Sphingomyelin homeostasis imbalance is a subtype of phospholipid homeostasis imbalance: A process that becomes lacking asphingomyelin homeostastasis balance. This process is dependent on the genetic and can constitute the course of Phospholipidosis (sphingomyelin disorder. http://purl.obolibrary.org/obo/TXPO_0004160 positive regulation of macrophage derived foam cell differentiation [sphingomyelin disorder] http://purl.obolibrary.org/obo/TXPO_0004085 positive regulation of macrophage derived foam cell differentiation [Phospholipidosis] Any process that increases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions. This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder. http://purl.obolibrary.org/obo/TXPO_0004161 increasing number of macrophage derived foam cell [Phospholipidosis(sphingomyelin disorder )] http://purl.obolibrary.org/obo/TXPO_0000918 increasing number of macrophage derived foam cell [Phospholipidosis] Increasing number of macrophage derived foam cell is a subtype of increasing number of objects: A process that becomes larger in the number of foam cell, a type of macrophage containing lipids in small vacuoles, in the liver. This entity is a specific course-dependent process. This process can constitute the course of sphingomyelin disorder. http://purl.obolibrary.org/obo/TXPO_0004162 hypofunction of sphingomyelin degradation [Phospholipidosis-sphingomyelin disorder] http://purl.obolibrary.org/obo/TXPO_0001676 hypofunction of sphingomyelin degradation Dysfunction of sphingomyelin degradation is a subtype of hypofunction of decomposing: A process that performs a decreased or insufficient sphingomyelin degradation. This process can constitute the course of sphingomyelin disorder. http://purl.obolibrary.org/obo/TXPO_0004163 sphingomyelin metabolism imbalance [Phospholipidosis ] http://purl.obolibrary.org/obo/TXPO_0002324 phospholipid metabolism imbalance [Phospholipidosis] A process that becomes lacking a homeostastasis balance of the sphingomyelin metabolism. This process is dependent on the sphingomyelin disorder and can constitute the course of Phospholipidosis. http://purl.obolibrary.org/obo/TXPO_1000327 ritonavir http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity An L-valine derivative that is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. http://purl.obolibrary.org/obo/TXPO_1000418 chloroquine http://purl.obolibrary.org/obo/CHEBI_25367 molecule An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis. http://purl.obolibrary.org/obo/TXPO_0002327 toxicological imbalance VL(defense) http://purl.obolibrary.org/obo/TXPO_0003992 toxicological imbalance In the imbalance model, the basic units are as follows: 1) a functioning process (supply) for biological defense and maintaining homeostasis; 2) a functional demand process (demand) as toxic activity; 3) balance/imbalance between toxic activity and defense processes; and 4) outcome from organelles, cells, or tissues to the organ exhibiting toxicity manifestations. This entity is a compound state that inculdes step 1 to 4. The defense performance level is very low (L) than the moderate (M) in normal condition. Threfore even if the functional demand level is Moderatelevel (M) in the daily life in the helathy person, which leads to the imbalance and leads to toxicity manifestation. http://purl.obolibrary.org/obo/TXPO_0002328 very low level http://purl.obolibrary.org/obo/TXPO_0004208 degree level The level of degree is very low. http://purl.obolibrary.org/obo/TXPO_0005106 NDUFA12 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process NDUFA12 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFA12 (NADH:ubiquinone oxidoreductase core subunit A12) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005109 NDUFB6 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process NDUFB6 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFB6 (NADH:ubiquinone oxidoreductase core subunit B6) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005112 NDUFS2 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process NDUFS2 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFS2 (NADH:ubiquinone oxidoreductase core subunit S2) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005115 NDUFV1 inactivation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process NDUFV1 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFV1 (NADH:ubiquinone oxidoreductase core subunit V1) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005118 NDUFV3 inactovation [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0001987 mitochondrial disorder dependent process NDUFV3 inactivation is a subtype of molecular inactivation: A process that changes the activity of the NDUFV3 (NADH:ubiquinone oxidoreductase core subunit V3) to be lower. This entity is a specific course-dependent process. This process can constitute the course of mitochondrial disorder. http://purl.obolibrary.org/obo/TXPO_0005138 bis(2-ethylhexyl) phthalate [hepatocarcinogenesis] http://purl.obolibrary.org/obo/CHEBI_17747 bis(2-ethylhexyl) phthalate A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid. http://purl.obolibrary.org/obo/TXPO_0005139 release of inflammatory DAMPs http://purl.obolibrary.org/obo/TXPO_0002588 moving A to the outside of B The process that results in the movement of inflammatory DAMPs from the mitochondria. http://purl.obolibrary.org/obo/IMR_0003045 BMP-1/TLD family http://purl.obolibrary.org/obo/CHEBI_25367 molecule The BMP-1/TLD metalloproteinases, conserved in species ranging from Drosophila to humans, act in dorsal-ventral patterning via activation of BMP2, BMP4 (vertebrates) and Dpp (arthropods). There are four mammalian BMP-1/TLD-like proteinases, including BMP-1/mTLD, which is encoded by alternatively spliced mRNA produced by the Bmp1 gene, and TLL1 and TLL2, which are genetically distinct. http://purl.obolibrary.org/obo/IMR_0100074 peptide YY http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion. http://purl.obolibrary.org/obo/IMR_0100090 pituitary hormone release inhibiting hormone http://purl.obolibrary.org/obo/IMR_0100082 hypothalamic hormone Polypeptide hormones produced in the hypothalamus which inhibit the release of pituitary hormones. Used for PHRIH in general or for which there is no specific heading. http://purl.obolibrary.org/obo/IMR_0100103 pituitary hormone, posterior http://purl.obolibrary.org/obo/IMR_0100084 pituitary hormone Hormones released from the posterior lobe of the pituitary, including vasopressin (antidiuretic hormone) and oxytocin. They are formed in the neuronal cells of the hypothalamic nuclei and stored in nerve cell endings in the posterior pituitary (neurohypophysis). http://purl.obolibrary.org/obo/IMR_0100201 vasopressin http://purl.obolibrary.org/obo/IMR_0100103 pituitary hormone, posterior Octapeptide antidiuretic hormones released by the NEUROHYPOPHYSIS of all vertebrates (chemical composition varies with species). They control water metabolism and balance by regulating LUNG; GILLS; KIDNEY; etc., and water loss, and also contract smooth muscle. They may also be NEUROTRANSMITTERS. http://purl.obolibrary.org/obo/IMR_0100211 gastrin http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters. http://purl.obolibrary.org/obo/IMR_0100213 somatostatin http://purl.obolibrary.org/obo/IMR_0100090 pituitary hormone release inhibiting hormone A polypeptide hormone produced in the HYPOTHALAMUS, and other tissues and organs. It inhibits the release of growth hormone ( SOMATOTROPIN), and also modulates important physiological functions of the kidney, pancreas, and gastrointestinal tract. Somatostatin receptors are widely expressed throughout the body. Somatostatin also acts as a neurotransmitter in the central and peripheral nervous systems. http://purl.obolibrary.org/obo/IMR_0000906 eIF4A http://purl.obolibrary.org/obo/IMR_0000912 eIF4F subunit eIF4A is a DEADbox helicase that can unwind RNA secondary structure in the cap-proximal region of the mRNA. http://purl.obolibrary.org/obo/IMR_0003083 BMP-2 subfamily http://purl.obolibrary.org/obo/IMR_0000040 BMP family BMP-related proteins can be subdivided into several groups based on their structures and functions. BMP-2, BMP-4, and the Drosophila Dpp form one subgroup. http://purl.obolibrary.org/obo/OGMS_0000073 diagnosis http://purl.obolibrary.org/obo/TXPO_0000614 data item The representation of a conclusion of a diagnostic process. http://purl.obolibrary.org/obo/NCIT_C19427 hepatocarcinogenesis http://purl.obolibrary.org/obo/NCIT_C18078 carcinogenesis The processes which result in cancers in the liver. http://purl.obolibrary.org/obo/NCIT_C20613 clonal expansion http://purl.obolibrary.org/obo/GO_0008283 cell proliferation Multiplication or reproduction by cell division of a population of identical cells descended from a single progenitor. In immunology, may refer to the clonal proliferation of cells responsive to a specific antigen as part of an immune response. (NCI) http://purl.obolibrary.org/obo/NCIT_C50678 occlusion http://purl.obolibrary.org/obo/TXPO_0002656 changing topology Obstruction or a closure of hollow organ, passageway or vessel; also the transient approximation of the edges of a natural opening; imperforation. http://purl.obolibrary.org/obo/GOCHE_22586 substance with antioxidant role http://purl.obolibrary.org/obo/GOCHE_50906 substance with role Substance with antioxidant role is a subtype of substance with role. This entity is participating in a oxidative stress response and playing an antioxidant role. http://purl.obolibrary.org/obo/GOCHE_50906 substance with role http://purl.obolibrary.org/obo/BFO_0000030 object Substance with role is a subtype of object. This entity is participating in a specific process and playing a role. http://purl.obolibrary.org/obo/TXPO_0004207 lipid metabolism imbalance (severe) [Alcoholic fatty liver] http://purl.obolibrary.org/obo/TXPO_0001044 lipid metabolism imbalance (severe) [Lipidosis] Lipid metabolism imbalance is a subtype of imbalance: A process that becomes lacking a homeostastasis balance of lipid metabolism. The degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Alcoholic fatty liver. http://purl.obolibrary.org/obo/TXPO_0004209 lipid homeostasis imbalance (severe) [Alcoholic fatty liver] http://purl.obolibrary.org/obo/TXPO_0003488 lipid homeostasis imbalance Lipid homeostasis imbalance is a subtype of chemical homeostasis imbalance: A process that becomes lacking a lipid homeostastasis balance. The degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Alcoholic fatty liver. http://purl.obolibrary.org/obo/TXPO_0004210 lipid accumulation in hepatocyte (severe) [Alcoholic fatty liver] http://purl.obolibrary.org/obo/TXPO_0003476 lipid accumulation in hepatocyte (severe) [Lipidosis] Lipid accumulation in hepatocyte (severe) is a subtype of lipid strorage in hepatocyte: A process that keeps lipids in hepatocytes. And the degree is severe. This entity is a specific course-dependent process. This process can constitute the course of Alcoholic fatty liver. http://purl.obolibrary.org/obo/TXPO_0005141 changing quality of tumor http://purl.obolibrary.org/obo/TXPO_0000415 changing quality Tumor malignancy alteration is a subtype of changing quality: A process that changes the tumor malignancy. Changing quality of tumor is a subtype of changing quality: A process that changes the quailty of tumor cells. http://purl.obolibrary.org/obo/IMR_0002804 FOXO family http://purl.obolibrary.org/obo/CHEBI_25367 molecule FOXO proteins are conserved from worm to human. To date, only one FOXO species has been identified in invertebrates (called dauer formation-16 in Caenorhabditis elegans and dFOXO in Drosophila). In mammals, four subfamily members have been identified: FOXO1 (previously known as FKHR), FOXO3 (previously known as FKHRL1), FOXO4 (previously known as AFX) and FOXO6. http://purl.obolibrary.org/obo/IMR_0002090 immunoglobulin http://purl.obolibrary.org/obo/CHEBI_25367 molecule Antibody molecule (immunoglobulin) consists of four polypeptides chains, two identical light (L) chains and two identical heavy (H) chains. In mammals, there are five classes of antibodies, IgA, IgD, IgE, IgG, and IgM. http://purl.obolibrary.org/obo/IMR_0000451 Bcl-2 family http://purl.obolibrary.org/obo/CHEBI_25367 molecule The Bcl-2 family consists of about 20 homologues of important pro- and anti-apoptotic regulators of programmed cell death. http://purl.obolibrary.org/obo/IMR_0000375 STAT1 (mol) http://purl.obolibrary.org/obo/IMR_0000374 STAT There are two STAT1 isoforms (STAT1alpha and STAT1beta) produced by alternative splicing of a single mRNA. http://purl.obolibrary.org/obo/IMR_0001469 DOCK http://purl.obolibrary.org/obo/IMR_0001954 RhoGEF Superfamily members of DOCK180 possess the DHR-2 domain and bind to and exchange GDP for GTP on either Rac or Cdc42. http://purl.obolibrary.org/obo/IMR_0002835 insulin family http://purl.obolibrary.org/obo/CHEBI_25367 molecule Insulin superfamily genes are ubiquitous in vertebrates, and have been identified in invertebrates, including insects, molluscs, and the nematode Caenorhabditis elegans. Seven members of the insulin superfamily have been identified in humans, including insulin, insulin-like growth factors (IGFs) I and II, relaxins HI and HII, early placenta insulin-like peptide (EPIL), and relaxin-like factor. http://purl.obolibrary.org/obo/IMR_0001422 ISGF3 http://purl.obolibrary.org/obo/CHEBI_25367 molecule ISGF3 is a heterotrimer of STAT1, STAT2 and p48/ISGF3gamma/IRF9. http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/TXPO_0000635 Phospholipase family phosphatidylcholine + H2O = 1-acylglycerophosphocholine + a carboxylate. http://purl.obolibrary.org/obo/IMR_0000812 CD86 http://purl.obolibrary.org/obo/IMR_0002950 CD80/CD86 B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively. http://purl.obolibrary.org/obo/IMR_0002950 CD80/CD86 http://purl.obolibrary.org/obo/CHEBI_25367 molecule B7.1 (CD80) and B7.2 (CD86) - the two structurally homologous ligands of CD28 - are expressed by professional antigen-presenting cells (APCs), such as dendritic cells (DCs), macrophages and activated B cells, belong to the immunoglobulin superfamily and might exist as dimers and monomers, respectively. http://purl.obolibrary.org/obo/NCIT_C15958 in vitro assay http://purl.obolibrary.org/obo/OBI_0000070 assay A laboratory test or analysis of the biological activity of a substance performed by studying its effect in an experimental situation outside the organism, e.g. in the test tube rather than in living systems. http://purl.obolibrary.org/obo/NCIT_C3340 polyp http://purl.obolibrary.org/obo/TXPO_0004047 abnormal cell tissue A usually exophytic mass attached to the underlying tissue by a broad base or a thin stalk. Polyps can be neoplastic or non-neoplastic. Neoplastic polyps usually represent proliferations of the epithelium, and are commonly seen in the gastrointestinal tract. Polyps of the gastrointestinal tract are often called adenomas, are associated with dysplasia, and may eventually transform into carcinomas. Non-neoplastic polyps may be inflammatory, degenerative, or the result of malformations. http://purl.obolibrary.org/obo/NCIT_C49508 high level http://purl.obolibrary.org/obo/TXPO_0004208 degree level The level of degree is high in comparison to medium. http://purl.obolibrary.org/obo/CHEBI_140921 Hedgehog signaling pathway inhibitor http://purl.obolibrary.org/obo/CHEBI_76932 pathway inhibitor Any pathway inhibitor that inhibits the Hedgehog signalling pathway. http://purl.obolibrary.org/obo/TXPO_0004208 degree level http://purl.obolibrary.org/obo/TXPO_0000288 qualitative quantity The deree level is a subtype of qualitative value. The extent or measure of the condition/action. http://purl.obolibrary.org/obo/TXPO_0005189 phospholipid biosynthetic process [Phospholipidosis(latent)] http://purl.obolibrary.org/obo/TXPO_0001716 phospholipidosis dependent process The chemical reactions and pathways resulting in the formation of phospholipids, any lipid containing phosphoric acid as a mono- or diester. This entity is a specific course-dependent process. This process can constitute the course of Phospholipidosis(latent). http://purl.obolibrary.org/obo/NCIT_C16507 DNA damage http://purl.obolibrary.org/obo/TXPO_0000222 damaging Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis. http://purl.obolibrary.org/obo/NCIT_C18078 carcinogenesis http://purl.obolibrary.org/obo/TXPO_0002703 converting cell type A pathological process in which normal cells are transformed into malignant cancer cells within a primary tumor. http://purl.obolibrary.org/obo/NCIT_C18121 tumorigenesis http://purl.obolibrary.org/obo/TXPO_0000134 biological structure formation A pathologic process that involves the transformation of normal cells to a neoplastic state and resulting in polyclonal or monoclonal neoplastic cell proliferation. http://purl.obolibrary.org/obo/IMR_0100096 pituitary hormone, anterior http://purl.obolibrary.org/obo/IMR_0100084 pituitary hormone Hormones secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). http://purl.obolibrary.org/obo/IMR_0100099 follicle stimulating hormone http://purl.obolibrary.org/obo/IMR_0100098 gonadotropin, pituitary A major gonadotropin secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. http://purl.obolibrary.org/obo/IMR_0000036 TGF-beta superfamily http://purl.obolibrary.org/obo/TXPO_0001382 growth factor family The TGF-beta superfamily of growth factors regulate many cellular functions, which includes TGF-betas, activins and inhibins, nodal, BMPs and GDFs. TGF-beta/BMP-like proteins are found in various species, including Xenopus, C.elegans and D.melanogaster. http://purl.obolibrary.org/obo/IMR_0000143 MHC class I molecule http://purl.obolibrary.org/obo/IMR_0000142 MHC family MHC class Ia (classical) molecules, termed human leukocyte antigen (HLA)-A, HLA-B and HLA-C in humans and H2-K, H2-D and H2-L in mice, are highly polymorphic glycoproteins composed of a single membrane-spanning alpha chain paired with the soluble protein beta2 microglobulin. http://purl.obolibrary.org/obo/IMR_0002951 Arrow/LRP5/LRP6 http://purl.obolibrary.org/obo/IMR_0000974 LDL receptor family Arrow/Lrp5/Lrp6 is a subfamily of the LDL receptor (LDLR) family. Arrow, and also its counterparts LRP5 and LRP6 in mammals and in frogs, appears to function as a coreceptor for Wnt together with the seven-transmembrane receptor Frizzled (frz) in forming the Wnt receptor signaling complex. http://purl.obolibrary.org/obo/IMR_0003085 GDF-5 subfamily http://purl.obolibrary.org/obo/IMR_0000040 BMP family BMP-related proteins can be subdivided into several groups based on their structures and functions. GDF-5 (CDMP- 1), GDF-6 (CDMP-2 or BMP-13), and GDF-7 (BMP-12) form one sugroup. http://purl.obolibrary.org/obo/IMR_0000040 BMP family http://purl.obolibrary.org/obo/IMR_0000036 TGF-beta superfamily BMPs belong to the TGF-beta superfamily. BMP-like molecules have been identified in various species including D.melanogaster (Dpp, Gbb/60A and Scw) and C.elegans. http://purl.obolibrary.org/obo/IMR_0100057 growth hormone-releasing hormone http://purl.obolibrary.org/obo/IMR_0100093 pituitary hormone-releasing hormone Hypothalamic peptide that regulates the synthesis and secretion of GROWTH HORMONE in the anterior pituitary gland. http://purl.obolibrary.org/obo/IMR_0100165 kinin http://purl.obolibrary.org/obo/CHEBI_25367 molecule The kinins are pharmacologically active polypeptides released in the tissues and body fluids as a result of the enzymatic action of kallikreins on kininogens. The kinin family includes bradykinin (Arg-Pro-Pro-gly-Phe-Ser-Pro-Phe-Arg), kallidin (Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) and methionyl-lysyl-bradykinin (Met-Lys-Arg-Pro-Pro-Gly-Phe-Arg). http://purl.obolibrary.org/obo/IMR_0000903 eIF2B http://purl.obolibrary.org/obo/IMR_0010016 eIF heteropentamer of alpha, beta, gamma, delta, epsilon subunits. guanine nucleotide exchange factor (GEF) activity of eIF2B is necessary to recycle eIF2:GTP to eIF2:GTP. http://purl.obolibrary.org/obo/IMR_0002121 biogenic amine http://purl.obolibrary.org/obo/IMR_0001693 amine A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology. http://purl.obolibrary.org/obo/CHEBI_137736 anxiogenic http://purl.obolibrary.org/obo/CHEBI_35471 psychotropic drug Any psychotropic drug that induces anxiety or panic. http://purl.obolibrary.org/obo/TXPO_0005143 central nervous system sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A] http://purl.obolibrary.org/obo/TXPO_0003988 sphingomyelin homeostasis imbalance [Niemann Pick Disease Type A/ B] Sphingomyelin homeostasis imbalance is a subtype of lipid homeostasis imbalance: A process that becomes lacking a phospholipid homeostastasis balance. This entity is a specific course-dependent process. This process can constitute the course of Niemann Pick Disease Type A. http://purl.obolibrary.org/obo/IMR_0001091 importin/exportin http://purl.obolibrary.org/obo/CHEBI_25367 molecule Members of importin beta family (importins/exportins, karyopherins) have been classified as importins or exportins on the basis of the direction they carry their cargo. http://purl.obolibrary.org/obo/IMR_0011141 eIF3j http://purl.obolibrary.org/obo/IMR_0000916 eIF3 subunit This subunit is not part of the Saccharomyces cerevisiae core eIF3 complex. http://purl.obolibrary.org/obo/IMR_0100050 gastric inhibitory polypeptide http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones A gastrointestinal peptide hormone of about 43-amino acids. http://purl.obolibrary.org/obo/IMR_0100056 thyrotropin-releasing hormone http://purl.obolibrary.org/obo/IMR_0100093 pituitary hormone-releasing hormone A tripeptide hormone that originates in the HYPOTHALAMUS and stimulates the secretion of THYROTROPIN from the PITUITARY GLAND. In humans, it also acts as a prolactin-releasing factor. It is also a neurotransmitter in the central nervous system. http://purl.obolibrary.org/obo/IMR_0100071 vasoactive intestinal peptide http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors ( RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE). http://purl.obolibrary.org/obo/IMR_0100100 luteinizing hormone http://purl.obolibrary.org/obo/IMR_0100098 gonadotropin, pituitary A major gonadotropin secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. http://purl.obolibrary.org/obo/IMR_0100197 lipotropin http://purl.obolibrary.org/obo/IMR_0100096 pituitary hormone, anterior Lipotropic or pituitary lipotropic hormone. A pituitary hormone mobilizing fat from adipose tissue. Beta-lipotropin is a single-chain peptide of about 90 residues that contains the sequences of endorphins and metenkephalin, and may be a precursor of beta-melanotropin and beta-endorphin. Gamma-lipotropin is shorter and is identical in sequence to the first 58 residues of beta-lipotropin. Both contain sequences common to ACTH and beta-melanotropin. http://purl.obolibrary.org/obo/IMR_0000172 integrin http://purl.obolibrary.org/obo/CHEBI_25367 molecule Integrins comprise a large family of cell surface receptors that are found in many animal species, ranging from sponge to mammals. They are composed of two subunits, alpha and beta, and each alpha beta combination has its own binding specificity and signaling properties. http://purl.obolibrary.org/obo/IMR_0100072 gastrointestinal hormones http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs. http://purl.obolibrary.org/obo/IMR_0003084 BMP-5 subfamily http://purl.obolibrary.org/obo/IMR_0000040 BMP family BMP-related proteins can be subdivided into several groups based on their structures and functions. BMP-5, BMP-6, BMP-7 (OP-1), BMP-8 (OP-2), and the Drosophila Gbb form one subgroup. http://purl.obolibrary.org/obo/IMR_0000421 NF-AT http://purl.obolibrary.org/obo/CHEBI_25367 molecule NFAT proteins are a family of transcription factors (NFATC1~C4) whose activation is controlled by calcineurin, a Ca2+-dependent phosphatase. http://purl.obolibrary.org/obo/IMR_0000052 insulin http://purl.obolibrary.org/obo/IMR_0002835 insulin family A protein hormone secreted by beta cells of the pancreas. Insulin plays a major role in the regulation of glucose metabolism, generally promoting the cellular utilization of glucose. It is also an important regulator of protein and lipid metabolism. Insulin is used as a drug to control insulin-dependent diabetes mellitus. http://purl.obolibrary.org/obo/IMR_0010252 fatty acid synthase http://purl.obolibrary.org/obo/TXPO_0001385 acyltransferase A role played by the entity which catalyses the reaction: acetyl-CoA + n malonyl-CoA + 2n NADPH + 2n H+ = long-chain fatty acid + n+1 CoA + n CO2 + 2n NADP+. http://purl.obolibrary.org/obo/IMR_0100507 Smad1/5/8 http://purl.obolibrary.org/obo/IMR_0000371 R-Smad Smads 1, 5, and 8 serve principally as substrates for the BMP and anti-Muellerian receptors. http://purl.obolibrary.org/obo/IMR_0100045 calcitonin http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. http://purl.obolibrary.org/obo/IMR_0100194 prolactin http://purl.obolibrary.org/obo/IMR_0100098 gonadotropin, pituitary A lactogenic hormone secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. http://purl.obolibrary.org/obo/IMR_0100198 MSH http://purl.obolibrary.org/obo/IMR_0100084 pituitary hormone Peptide hormones secreted by the intermediate lobe of the pituitary that stimulate melanin release and dispersal. Melanocyte-stimulating hormones are also found in the brain where they are presumed to play a signaling role. http://purl.obolibrary.org/obo/IMR_0100273 MNK http://purl.obolibrary.org/obo/IMR_0100271 MAPKAPK MNK1/2 are regulated by p38 and ERK, but not by JNK. MNK1/2 can phosphorylate eukaryotic initiation factor-4E (eIF-4E). http://purl.obolibrary.org/obo/IMR_0001206 cytochrome c http://purl.obolibrary.org/obo/CHEBI_25367 molecule Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV. http://purl.obolibrary.org/obo/IMR_0100143 somatomedin http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone Somatomedin is a group of hormones that is produced, when stimulated by somatotropin (STH), to promote cell growth and division. In this way, they mediate the effect of somatotropin (also known as growth hormone). They have similar biological effects to somatotropin. Three forms include: * somatomedin A, which is another name for insulin-like growth factor 2 * somatomedin B, which is derived from vitronectin * somatomedin C, which is another name for insulin-like growth factor 1 http://purl.obolibrary.org/obo/IMR_0100196 alpha-MSH http://purl.obolibrary.org/obo/IMR_0100198 MSH A 13-amino acid peptide derived from the ANTERIOR PITUITARY GLAND in man and from the pars intermedia in lower vertebrates. Its amino acid sequence is identical to the first 13 amino acids of ACTH. It influences the formation of deposition of MELANIN in the body. http://purl.obolibrary.org/obo/IMR_0100200 thyrotropin http://purl.obolibrary.org/obo/IMR_0100096 pituitary hormone, anterior A glycoprotein hormone secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones ( THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity. http://purl.obolibrary.org/obo/IMR_0100470 SCF ubiquitin ligase complex http://purl.obolibrary.org/obo/TXPO_0002107 molecular complex SCF ubiquitin ligase complex is a subtype of molecular complex. http://purl.obolibrary.org/obo/IMR_0100082 hypothalamic hormone http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone Hormones isolated from the hypothalamus which exercise control over other organs, primarily the pituitary gland. Well-known members include certain pituitary hormone-releasing hormones and pituitary hormone release inhibiting hormones. Vasopressin and oxytocin which are found in the posterior pituitary may also be secreted by the hypothalamus but are not grouped here ( PITUITARY HORMONES, POSTERIOR). http://purl.obolibrary.org/obo/IMR_0100097 glycoprotein hormone, alpha subunit http://purl.obolibrary.org/obo/IMR_0100200 thyrotropin The alpha chain of pituitary glycoprotein hormones ( THYROTROPIN; FOLLICLE STIMULATING HORMONE; LUTEINIZING HORMONE) and the placental CHORIONIC GONADOTROPIN. Within a species, the alpha subunits of these four hormones are identical; the distinct functional characteristics of these glycoprotein hormones are determined by the unique beta subunits. Both subunits, the non-covalently bound heterodimers, are required for full biologic activity. http://purl.obolibrary.org/obo/IMR_0100102 growth hormone (mol) http://purl.obolibrary.org/obo/IMR_0100096 pituitary hormone, anterior A polypeptide that is secreted by the adenohypophysis ( PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. http://purl.obolibrary.org/obo/NCIT_C54214 pathway http://purl.obolibrary.org/obo/TXPO_0000608 process sequence A set or series of interactions, often forming a network, which biologists have found useful to group together for organizational, historic, biophysical, or other reasons. http://purl.obolibrary.org/obo/CHEBI_142468 1,2-dichloropropane http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity A chloroalkane that is propane in which a hydrogen from each of two adjacent carbons has been replaced by chlorines. http://purl.obolibrary.org/obo/GO_0062093 lysophagy http://purl.obolibrary.org/obo/GO_0006914 autophagy The selective autophagy process in which a damaged lysosome is degraded by macroautophagy. http://purl.obolibrary.org/obo/OGG_3000029028 ATAD2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PRO2000 http://purl.obolibrary.org/obo/OGG_3000029078 NDUFAF4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens bA22L21.1 http://purl.obolibrary.org/obo/OGG_3000029089 UBE2T http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PIG50 http://purl.obolibrary.org/obo/OGG_3000029103 DNAJC15 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HSD18 http://purl.obolibrary.org/obo/OGG_3000029118 DDX25 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens GRTH http://purl.obolibrary.org/obo/OGG_3000029128 UHRF1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens huNp95 http://purl.obolibrary.org/obo/OGG_3000029896 TRA2A http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HSU53209 http://purl.obolibrary.org/obo/OGG_3000029923 HILPDA http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HIG-2 http://purl.obolibrary.org/obo/OGG_3000029948 OSGIN1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens BDGI http://purl.obolibrary.org/obo/OGG_3000049855 SCAPER http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens Zfp291 http://purl.obolibrary.org/obo/OGG_3000050810 HDGFRP3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HRP-3 http://purl.obolibrary.org/obo/OGG_3000051129 ANGPTL4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens pp1158 http://purl.obolibrary.org/obo/OGG_3000051147 ING4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens my036 http://purl.obolibrary.org/obo/OGG_3000051250 C6orf203 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PRED31 http://purl.obolibrary.org/obo/OGG_3000051277 DNAJC27 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens RabJS http://purl.obolibrary.org/obo/OGG_3000051330 TNFRSF12A http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TWEAKR http://purl.obolibrary.org/obo/OGG_3000051378 ANGPT4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens AGP4 http://purl.obolibrary.org/obo/OGG_3000051386 EIF3L http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MSTP005 http://purl.obolibrary.org/obo/OGG_3000051390 AIG1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens dJ95L4.1 http://purl.obolibrary.org/obo/OGG_3000051477 ISYNA1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens INOS http://purl.obolibrary.org/obo/OGG_3000051512 GTSE1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens B99 http://purl.obolibrary.org/obo/OGG_3000051594 NBAS http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SOPH http://purl.obolibrary.org/obo/OGG_3000051726 DNAJB11 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens UNQ537 http://purl.obolibrary.org/obo/OGG_3000053354 PANK1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PANK http://purl.obolibrary.org/obo/OGG_3000054431 DNAJC10 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PDIA19 http://purl.obolibrary.org/obo/OGG_3000054541 DDIT4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens REDD1 http://purl.obolibrary.org/obo/OGG_3000054658 UGT1A1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HUG-BR1 http://purl.obolibrary.org/obo/OGG_3000054788 DNAJB12 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens DJ10 http://purl.obolibrary.org/obo/OGG_3000054943 DNAJC28 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens C21orf78 http://purl.obolibrary.org/obo/OGG_3000055089 SLC38A4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PAAT http://purl.obolibrary.org/obo/OGG_3000055109 AGGF1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HUS84971 http://purl.obolibrary.org/obo/OGG_3000055190 NUDT11 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens DIPP3beta http://purl.obolibrary.org/obo/OGG_3000055224 ETNK2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HMFT1716 http://purl.obolibrary.org/obo/OGG_3000055304 SPTLC3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens hLCB2b http://purl.obolibrary.org/obo/OGG_3000055331 ACER3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens APHC http://purl.obolibrary.org/obo/OGG_3000055350 VNN3 http://purl.obolibrary.org/obo/OGG_2070009606 pseudo gene of Homo sapiens HSA238982 http://purl.obolibrary.org/obo/OGG_3000055571 CNOT11 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens C2orf29 http://purl.obolibrary.org/obo/OGG_3000055632 G2E3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PHF7B http://purl.obolibrary.org/obo/OGG_3000055729 ATF7IP http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens p621 http://purl.obolibrary.org/obo/OGG_3000055735 DNAJC11 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens dJ126A5.1 http://purl.obolibrary.org/obo/OGG_3000055741 EDEM2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens bA4204.1 http://purl.obolibrary.org/obo/OGG_3000055819 RNF130 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens GOLIATH http://purl.obolibrary.org/obo/OGG_3000055856 ACOT13 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PNAS-27 http://purl.obolibrary.org/obo/OGG_3000056478 EIF4ENIF1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens Clast4 http://purl.obolibrary.org/obo/OGG_3000056521 DNAJC12 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens JDP1 http://purl.obolibrary.org/obo/OGG_3000056603 CYP26B1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens RHFCA http://purl.obolibrary.org/obo/OGG_3000056648 EIF5A2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens eIF5AII http://purl.obolibrary.org/obo/OGG_3000056910 STARD7 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens GTT1 http://purl.obolibrary.org/obo/OGG_3000057153 SLC44A2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PP1292 http://purl.obolibrary.org/obo/OGG_3000057216 VANGL2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens STBM1 http://purl.obolibrary.org/obo/OGG_3000057404 CYP20A1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens CYP-M http://purl.obolibrary.org/obo/OGG_3000057546 PDP2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PPM2C2 http://purl.obolibrary.org/obo/OGG_3000057600 FNIP2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MAPO1 http://purl.obolibrary.org/obo/OGG_3000057761 TRIB3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TRB3 http://purl.obolibrary.org/obo/OGG_3000057834 CYP4F11 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens CYPIVF11 http://purl.obolibrary.org/obo/OGG_3000060312 AFAP1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens AFAP110 http://purl.obolibrary.org/obo/OGG_3000063934 ZNF667 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MIPU1 http://purl.obolibrary.org/obo/OGG_3000064081 PBLD http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MAWDBP http://purl.obolibrary.org/obo/OGG_3000064215 DNAJC1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MTJ1 http://purl.obolibrary.org/obo/OGG_3000064241 ABCG8 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens STSL http://purl.obolibrary.org/obo/OGG_3000064327 LMBR1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens ZRS http://purl.obolibrary.org/obo/OGG_3000064332 NFKBIZ http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MAIL http://purl.obolibrary.org/obo/OGG_3000064344 HIF3A http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HIF-3A http://purl.obolibrary.org/obo/OGG_3000064782 AEN http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens pp12744 http://purl.obolibrary.org/obo/OGG_3000064787 EPS8L2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens EPS8R2 http://purl.obolibrary.org/obo/OGG_3000064838 FNDC4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens FRCP1 http://purl.obolibrary.org/obo/OGG_3000065992 DDRGK1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens dJ1187M17.3 http://purl.obolibrary.org/obo/OGG_3000066002 CYP4F12 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens F22329_1 http://purl.obolibrary.org/obo/OGG_3000079071 ELOVL6 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens FAE http://purl.obolibrary.org/obo/OGG_3000079882 ZC3H14 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens UKp68 http://purl.obolibrary.org/obo/OGG_3000079962 DNAJC22 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens wus http://purl.obolibrary.org/obo/OGG_3000079982 DNAJB14 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PRO34683 http://purl.obolibrary.org/obo/OGG_3000080063 ATF7IP2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MCAF2 http://purl.obolibrary.org/obo/OGG_3000080235 PIGZ http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SMP3 http://purl.obolibrary.org/obo/OGG_3000080267 EDEM3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens C1orf22 http://purl.obolibrary.org/obo/OGG_3000080331 DNAJC5 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens DNAJC5A http://purl.obolibrary.org/obo/OGG_3000003833 KIFC1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens KNSL2 http://purl.obolibrary.org/obo/OGG_3000003956 LGALS1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens GBP http://purl.obolibrary.org/obo/OGG_3000004001 LMNB1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens LMN http://purl.obolibrary.org/obo/OGG_3000004018 LPA http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens APOA http://purl.obolibrary.org/obo/OGG_3000004047 LSS http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens OSC http://purl.obolibrary.org/obo/OGG_3000004051 CYP4F3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens CYP4F http://purl.obolibrary.org/obo/OGG_3000004189 DNAJB9 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MSTP049 http://purl.obolibrary.org/obo/OGG_3000004193 MDM2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HDMX http://purl.obolibrary.org/obo/OGG_3000004199 ME1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HUMNDME http://purl.obolibrary.org/obo/OGG_3000004258 MGST2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MGST-II http://purl.obolibrary.org/obo/OGG_3000004313 MMP2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MMP-II http://purl.obolibrary.org/obo/OGG_3000004318 MMP9 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MANDP2 http://purl.obolibrary.org/obo/OGG_3000004345 CD200 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens OX-2 http://purl.obolibrary.org/obo/OGG_3000004605 MYBL2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens B-MYB http://purl.obolibrary.org/obo/OGG_3000004609 MYC http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens c-Myc http://purl.obolibrary.org/obo/OGG_3000004613 MYCN http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens ODED http://purl.obolibrary.org/obo/OGG_3000004616 GADD45B http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens GADD45BETA http://purl.obolibrary.org/obo/OGG_3000004673 NAP1L1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens NAP1L http://purl.obolibrary.org/obo/OGG_3000004747 NEFL http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens NFL http://purl.obolibrary.org/obo/OGG_3000004763 NF1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens WSS http://purl.obolibrary.org/obo/OGG_3000004780 NFE2L2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens NRF2 http://purl.obolibrary.org/obo/OGG_3000004790 NFKB1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens NFkappaB http://purl.obolibrary.org/obo/OGG_3000004791 NFKB2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens NF-kB2 http://purl.obolibrary.org/obo/OGG_3000004830 NME1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens NM23-H1 http://purl.obolibrary.org/obo/OGG_3000004925 NUCB2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HEL-S-109 http://purl.obolibrary.org/obo/OGG_3000005021 OXTR http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens OT-R http://purl.obolibrary.org/obo/OGG_3000005034 P4HB http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PROHB http://purl.obolibrary.org/obo/OGG_3000005105 PCK1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PEPCKC http://purl.obolibrary.org/obo/OGG_3000005106 PCK2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PEPCK http://purl.obolibrary.org/obo/OGG_3000005138 PDE2A http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PED2A4 http://purl.obolibrary.org/obo/OGG_3000005241 PGR http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens NR3C3 http://purl.obolibrary.org/obo/OGG_3000005288 PIK3C2G http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PI3K-C2GAMMA http://purl.obolibrary.org/obo/OGG_3000005290 PIK3CA http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens p110-alpha http://purl.obolibrary.org/obo/OGG_3000005308 PITX2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens IRID2 http://purl.obolibrary.org/obo/OGG_3000005319 PLA2G1B http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PPLA2 http://purl.obolibrary.org/obo/OGG_3000005322 PLA2G5 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens hVPLA(2) http://purl.obolibrary.org/obo/OGG_3000005350 PLN http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PLB http://purl.obolibrary.org/obo/OGG_3000005366 PMAIP1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens APR http://purl.obolibrary.org/obo/OGG_3000005372 PMM1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens Sec53 http://purl.obolibrary.org/obo/OGG_3000005447 POR http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens P450R http://purl.obolibrary.org/obo/OGG_3000005463 POU6F1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TCFB1 http://purl.obolibrary.org/obo/OGG_3000005465 PPARA http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens hPPAR http://purl.obolibrary.org/obo/OGG_3000005562 PRKAA1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens AMPKa1 http://purl.obolibrary.org/obo/OGG_3000005570 PKIB http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PRKACN2 http://purl.obolibrary.org/obo/OGG_3000005579 PRKCB http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PRKCB2 http://purl.obolibrary.org/obo/OGG_3000005599 MAPK8 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SAPK1c http://purl.obolibrary.org/obo/OGG_3000005608 MAP2K6 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SAPKK-3 http://purl.obolibrary.org/obo/OGG_3000005610 EIF2AK2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PRKR http://purl.obolibrary.org/obo/OGG_3000005611 DNAJC3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HP58 http://purl.obolibrary.org/obo/OGG_3000005734 PTGER4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens EP4R http://purl.obolibrary.org/obo/OGG_3000005775 PTPN4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PTPMEG1 http://purl.obolibrary.org/obo/OGG_3000005777 PTPN6 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SHP-1L http://purl.obolibrary.org/obo/OGG_3000005824 PEX19 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PMPI http://purl.obolibrary.org/obo/OGG_3000005890 RAD51B http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens REC2 http://purl.obolibrary.org/obo/OGG_3000005933 RBL1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens CP107 http://purl.obolibrary.org/obo/OGG_3000006045 RNF2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens RING1B http://purl.obolibrary.org/obo/OGG_3000006046 BRD2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens FSRG1 http://purl.obolibrary.org/obo/OGG_3000006093 ROCK1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens ROCK-I http://purl.obolibrary.org/obo/OGG_3000006235 RPS29 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens S29 http://purl.obolibrary.org/obo/OGG_3000006319 SCD http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SCDOS http://purl.obolibrary.org/obo/OGG_3000006341 SCO1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SCOD1 http://purl.obolibrary.org/obo/OGG_3000006347 CCL2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SMC-CF http://purl.obolibrary.org/obo/OGG_3000006372 CXCL6 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SCYB6 http://purl.obolibrary.org/obo/OGG_3000006400 SEL1L http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SEL1L1 http://purl.obolibrary.org/obo/OGG_3000006426 SRSF1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SRp30a http://purl.obolibrary.org/obo/OGG_3000006506 SLC1A2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens GLT-1 http://purl.obolibrary.org/obo/OGG_3000006515 SLC2A3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens GLUT3 http://purl.obolibrary.org/obo/OGG_3000006519 SLC3A1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens D2H http://purl.obolibrary.org/obo/OGG_3000006554 SLC10A1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens NTCP http://purl.obolibrary.org/obo/OGG_3000006606 SMN1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TDRD16A http://purl.obolibrary.org/obo/OGG_3000006608 SMO http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens Gx http://purl.obolibrary.org/obo/OGG_3000006609 SMPD1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens ASMASE http://purl.obolibrary.org/obo/OGG_3000006720 SREBF1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SREBP-1c http://purl.obolibrary.org/obo/OGG_3000006733 SRPK2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SFRSK2 http://purl.obolibrary.org/obo/OGG_3000006742 SSBP1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens mtSSB http://purl.obolibrary.org/obo/OGG_3000006747 SSR3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TRAPG http://purl.obolibrary.org/obo/OGG_3000006772 STAT1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens STAT91 http://purl.obolibrary.org/obo/OGG_3000006774 STAT3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HIES http://purl.obolibrary.org/obo/OGG_3000006782 HSPA13 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens STCH http://purl.obolibrary.org/obo/OGG_3000006794 STK11 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens hLKB1 http://purl.obolibrary.org/obo/OGG_3000006819 SULT1C2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens humSULTC2 http://purl.obolibrary.org/obo/OGG_3000006876 TAGLN http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TAGLN1 http://purl.obolibrary.org/obo/OGG_3000006880 TAF9 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TAFIID32 http://purl.obolibrary.org/obo/OGG_3000007057 THBS1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens THBS-1 http://purl.obolibrary.org/obo/OGG_3000007076 TIMP1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HCI http://purl.obolibrary.org/obo/OGG_3000007099 TLR4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TOLL http://purl.obolibrary.org/obo/OGG_3000007112 TMPO http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PRO0868 http://purl.obolibrary.org/obo/OGG_3000007124 TNF http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens DIF http://purl.obolibrary.org/obo/OGG_3000007157 TP53 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TRP53 http://purl.obolibrary.org/obo/OGG_3000007184 HSP90B1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HEL35 http://purl.obolibrary.org/obo/OGG_3000007186 TRAF2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MGC:45012 http://purl.obolibrary.org/obo/OGG_3000007187 TRAF3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens IIAE5 http://purl.obolibrary.org/obo/OGG_3000007266 DNAJC7 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens DJC7 http://purl.obolibrary.org/obo/OGG_3000007291 TWIST1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens BPES3 http://purl.obolibrary.org/obo/OGG_3000007296 TXNRD1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TXNR http://purl.obolibrary.org/obo/OGG_3000007298 TYMS http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HST422 http://purl.obolibrary.org/obo/OGG_3000007329 UBE2I http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens C358B7.1 http://purl.obolibrary.org/obo/OGG_3000007352 UCP3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens SLC25A9 http://purl.obolibrary.org/obo/OGG_3000007357 UGCG http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens GCS http://purl.obolibrary.org/obo/OGG_3000007364 UGT2B7 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens UGT2B9 http://purl.obolibrary.org/obo/OGG_3000007376 NR1H2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens RIP15 http://purl.obolibrary.org/obo/OGG_3000007392 USF2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens bHLHb12 http://purl.obolibrary.org/obo/OGG_3000007410 VAV2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens VAV-2 http://purl.obolibrary.org/obo/OGG_3000007458 EIF4H http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens eIF-4H http://purl.obolibrary.org/obo/OGG_3000007494 XBP1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens XBP2 http://purl.obolibrary.org/obo/OGG_3000007804 LRP8 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens MCI1 http://purl.obolibrary.org/obo/OGG_3000007832 BTG2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TIS21 http://purl.obolibrary.org/obo/OGG_3000007873 MANF http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens ARP http://purl.obolibrary.org/obo/OGG_3000007965 AIMP2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens JTV-1 http://purl.obolibrary.org/obo/OGG_3000285126 DNAJC5G http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens CSP-gamma http://purl.obolibrary.org/obo/OGG_3000285440 CYP4V2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens CYP4AH1 http://purl.obolibrary.org/obo/OGG_3000317649 EIF4E3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens eIF4E-3 http://purl.obolibrary.org/obo/OGG_3000319118 EIF4BP1 http://purl.obolibrary.org/obo/OGG_2070009606 pseudo gene of Homo sapiens EIF4BP http://purl.obolibrary.org/obo/OGG_3000340485 ACER2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens ALKCDase2 http://purl.obolibrary.org/obo/OGG_3000340665 CYP26C1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens FFDD4 http://purl.obolibrary.org/obo/OGG_3000347252 IGFBPL1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens bA113O24.1 http://purl.obolibrary.org/obo/OGG_3000348158 ACSM2B http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HXMA http://purl.obolibrary.org/obo/OGG_3000348235 SKA2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens FAM33A http://purl.obolibrary.org/obo/OGG_3000353322 ANKRD37 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens Lrp2bp http://purl.obolibrary.org/obo/OGG_3000374383 NCR3LG1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens DKFZp686O24166 http://purl.obolibrary.org/obo/OGG_3000374407 DNAJB13 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens TSARG5 http://purl.obolibrary.org/obo/OGG_3000387103 CENPW http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens CUG2 http://purl.obolibrary.org/obo/OGG_3000414061 DNAJB3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens HCG3 http://purl.obolibrary.org/obo/OGG_3000415116 PIM3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens pim-3 http://purl.obolibrary.org/obo/OGG_3000440275 EIF2AK4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens PVOD2 http://purl.obolibrary.org/obo/OGG_3000548645 DNAJC25 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens bA16L21.2.1 http://purl.obolibrary.org/obo/OGG_3000641371 ACOT1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens LACH2 http://purl.obolibrary.org/obo/OGG_3000641372 ACOT6 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens c14_5530 http://purl.obolibrary.org/obo/IMR_0100535 GCK family http://purl.obolibrary.org/obo/IMR_0000253 mammalian Ste20-like kinases (MAPKKKK) http://purl.obolibrary.org/obo/IMR_0100355 Raf-1 http://purl.obolibrary.org/obo/IMR_0000231 Raf http://purl.obolibrary.org/obo/IMR_0001126 chondroitin sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0000552 proteoglycan http://purl.obolibrary.org/obo/IMR_0001127 chondroitin/dermatan sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0000552 proteoglycan http://purl.obolibrary.org/obo/IMR_0001128 keratan sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0000552 proteoglycan http://purl.obolibrary.org/obo/IMR_0001125 heparan sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0000552 proteoglycan http://purl.obolibrary.org/obo/IMR_0100731 presenilin 1 http://purl.obolibrary.org/obo/IMR_0000560 presenilin http://purl.obolibrary.org/obo/IMR_0000042 TGF-beta1 http://purl.obolibrary.org/obo/IMR_0000041 TGF-beta family http://purl.obolibrary.org/obo/IMR_0000044 TGF-beta3 http://purl.obolibrary.org/obo/IMR_0000041 TGF-beta family http://purl.obolibrary.org/obo/IMR_0100323 IFNGR-1 http://purl.obolibrary.org/obo/IMR_0000136 IFNR type II http://purl.obolibrary.org/obo/IMR_0100324 IFNGR-2 http://purl.obolibrary.org/obo/IMR_0000136 IFNR type II http://purl.obolibrary.org/obo/IMR_0100841 SOCS-5 http://purl.obolibrary.org/obo/IMR_0000460 SOCS http://purl.obolibrary.org/obo/IMR_0000732 PLC gamma1 http://purl.obolibrary.org/obo/IMR_0000285 PLC gamma http://purl.obolibrary.org/obo/IMR_0000388 IRF-2 http://purl.obolibrary.org/obo/IMR_0000386 IRF family http://purl.obolibrary.org/obo/IMR_0001660 RGS2 http://purl.obolibrary.org/obo/IMR_0000431 RGS http://purl.obolibrary.org/obo/IMR_0001672 RGS14 http://purl.obolibrary.org/obo/IMR_0000431 RGS http://purl.obolibrary.org/obo/IMR_0001673 RGS16 http://purl.obolibrary.org/obo/IMR_0000431 RGS http://purl.obolibrary.org/obo/IMR_0001674 RGS17 http://purl.obolibrary.org/obo/IMR_0000431 RGS http://purl.obolibrary.org/obo/IMR_0001676 RGS19 http://purl.obolibrary.org/obo/IMR_0000431 RGS http://purl.obolibrary.org/obo/TXPO_0002818 TRAF2 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000871 ER stress dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0100645 Sic1 http://purl.obolibrary.org/obo/IMR_0000445 CKI http://purl.obolibrary.org/obo/IMR_0011138 eIF2B-delta http://purl.obolibrary.org/obo/IMR_0000915 eIF2B subunit http://purl.obolibrary.org/obo/IMR_0011136 eIF2B-alpha http://purl.obolibrary.org/obo/IMR_0000915 eIF2B subunit http://purl.obolibrary.org/obo/IMR_0100280 I-kappaB alpha http://purl.obolibrary.org/obo/IMR_0000464 I-kappaB http://purl.obolibrary.org/obo/TXPO_0005105 NDUFA12 - inactive form (human)[mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005104 NDUFA12 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005108 NDUFB6 - inactive form (human)[mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005107 NDUFB6 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005111 NDUFS2 - inactive form (human)[mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005110 NDUFS2 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005114 NDUFV1 - inactive form (human)[mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005113 NDUFV1 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005117 NDUFV3 - inactive form (human)[mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005116 NDUFV3 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0005123 PCK1 - inactive form (predicted)(human) [mitochondrial damage] http://purl.obolibrary.org/obo/TXPO_0004176 PCK1 (predicted)(human) [mitochondrial damage] http://purl.obolibrary.org/obo/TXPO_0005075 CDT1 (human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004467 CDT1 (mol) http://purl.obolibrary.org/obo/TXPO_0005089 HHIP (human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004608 HHIP (mol) http://purl.obolibrary.org/obo/TXPO_0005095 IGFBP3 (human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004645 IGFBP3 (mol) http://purl.obolibrary.org/obo/TXPO_0005097 KIAA0101 tv2 (predicted)(human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004193 KIAA0101 (predicted)(human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0005121 ORC1 (human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004730 ORC1 (mol) http://purl.obolibrary.org/obo/TXPO_0005122 PCK1 (human) [Hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_1000524 PCK1 (mol) http://purl.obolibrary.org/obo/TXPO_0005124 PHB (human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004748 PHB (mol) http://purl.obolibrary.org/obo/TXPO_0005129 PROM1 - activation state (human)[hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004780 PROM1 (human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0005131 SFRP1 (human) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0004799 SFRP1 (mol) http://purl.obolibrary.org/obo/TXPO_0005090 HIF1A(canonical) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004613 HIF1A (mol) http://purl.obolibrary.org/obo/TXPO_0005120 NRF2(canonical) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0002527 NRF2 (mol) http://purl.obolibrary.org/obo/TXPO_0005125 PPARA(canonical) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0000159 PPARA (mol) http://purl.obolibrary.org/obo/TXPO_0005081 FZD1 (mol) http://purl.obolibrary.org/obo/TXPO_0004562 FZD http://purl.obolibrary.org/obo/TXPO_0005082 FZD2 (mol) http://purl.obolibrary.org/obo/TXPO_0004562 FZD http://purl.obolibrary.org/obo/TXPO_0005083 FZD5 (mol) http://purl.obolibrary.org/obo/TXPO_0004562 FZD http://purl.obolibrary.org/obo/TXPO_0005084 FZD6 (mol) http://purl.obolibrary.org/obo/TXPO_0004562 FZD http://purl.obolibrary.org/obo/TXPO_0005085 FZD7 (mol) http://purl.obolibrary.org/obo/TXPO_0004562 FZD http://purl.obolibrary.org/obo/TXPO_0005086 FZD9 (mol) http://purl.obolibrary.org/obo/TXPO_0004562 FZD http://purl.obolibrary.org/obo/TXPO_0005091 HNF4A (canonical) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0005063 liver cancer dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0005104 NDUFA12 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004707 NDUFA12 (mol) http://purl.obolibrary.org/obo/TXPO_0005107 NDUFB6 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004709 NDUFB6 (mol) http://purl.obolibrary.org/obo/TXPO_0005110 NDUFS2 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004711 NDUFS2 (mol) http://purl.obolibrary.org/obo/TXPO_0005113 NDUFV1 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004713 NDUFV1 (mol) http://purl.obolibrary.org/obo/TXPO_0005116 NDUFV3 (human) [mitochondrial disorder] http://purl.obolibrary.org/obo/TXPO_0004715 NDUFV3 (mol) http://purl.obolibrary.org/obo/TXPO_0005099 MSH2 (canonical) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0005100 MSH2 (mol) http://purl.obolibrary.org/obo/TXPO_0005101 MSH6 (canonical) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0005102 MSH6 (mol) http://purl.obolibrary.org/obo/TXPO_0005126 PPARA(mouse) [hepatocarcinogenesis] http://purl.obolibrary.org/obo/TXPO_0000159 PPARA (mol) http://purl.obolibrary.org/obo/TXPO_0000788 valproic acid [Lipidosis] http://purl.obolibrary.org/obo/CHEBI_39867 valproic acid http://purl.obolibrary.org/obo/TXPO_0001857 LPA [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0000834 fatty acid http://purl.obolibrary.org/obo/TXPO_0001144 carboxylic acid http://purl.obolibrary.org/obo/TXPO_0000780 ARRB2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0000785 GPRC5B (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0000849 HMGB1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0000856 GGT1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0000877 KEAP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001002 BIP (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001007 DDB2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001014 GOT1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001020 ARID5A [Ground glass appearance] http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001022 GPT (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001094 ADH family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001098 OXTR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001106 CMPK2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001111 USF (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001124 CHREBP (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001148 ACER http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001312 CD36 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001382 growth factor family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001417 DGAT(mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001424 FASN http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001443 ABCA1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001509 nuclear receptor family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001517 Ang (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001528 IRE1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001558 Cytochrome P450 http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001792 PERK (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001877 NLRP3 (mol) http://purl.obolibrary.org/obo/TXPO_0000871 ER stress dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001883 PYCARD (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0001931 GSS (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0002331 glutamate-cysteine ligase modifier subunit http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0002365 GCLC (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0002527 NRF2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0002802 IKB http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003119 FXR (mol) http://purl.obolibrary.org/obo/TXPO_0001509 nuclear receptor family http://purl.obolibrary.org/obo/TXPO_0003120 PXR (mol) http://purl.obolibrary.org/obo/TXPO_0001509 nuclear receptor family http://purl.obolibrary.org/obo/TXPO_0003121 GR (mol) http://purl.obolibrary.org/obo/TXPO_0001509 nuclear receptor family http://purl.obolibrary.org/obo/TXPO_0003158 catenin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003223 PI3K (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003241 CDK (family) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003254 PEX5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003284 NPC1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003287 NPC2 (mol) http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003817 ITGB3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003823 CREB1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003832 SULT1C2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003833 MMAA (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003834 SPON2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003835 RSAD2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003836 CYP4A11 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003837 FNIP2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003838 PKIB (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003839 KCNMA1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003840 ASPA (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003841 DAB2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003842 NCR3LG1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003843 CTSB (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003966 SREBF1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003974 ACACB (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0003981 NUAK http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0004020 MTOR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000001 AFAP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000002 ANGPTL4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000003 AP1M2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000004 AP1S1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000005 APAF1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000006 APOE (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000007 APOLD1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000008 APR molecule http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000009 ASAH1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000010 DBF4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000014 ATP-binding cassette (ABC) transporter superfamily http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000015 Abc1b1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000016 Abhd1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000017 Acaa1a (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000018 Acbd6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000029 Aen (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000030 Ahr (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000031 Aig1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000032 Aimp2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000033 Akr7a3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000034 Alas1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000035 ALDH1A1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000036 Ankrd37 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000037 Arfgap3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000038 Ataxn10 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000039 Atr (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000043 Bbs9 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000044 Bcl3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000045 Bhlha15 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000046 Bhmt (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000047 Bip- stress sensor complex (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000048 Brd2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000050 Btg2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000051 C18ORF (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000052 C1orf162 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000053 C6orf203 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000054 C9orf72 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000055 CA12 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000056 CACNB1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000057 LRRC16B (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000058 CASP8 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000059 CASP8AP2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000060 CCDC126 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000061 CCNB2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000062 CD200 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000063 CDK5R1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000064 CENPE (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000065 CFLAR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000066 CHAC1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000067 DDIT3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000068 CHORDC1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000070 CLU (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000071 CNOT6L (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000072 COL4A2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000073 COX6B1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000074 CRBPH (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000075 CRELD2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000076 CRP (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000077 CXCR3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000085 Car2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000086 CCL2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000089 Ccng1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000090 Cdc34 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000091 Cdkn1a (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000092 Cenpw (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000093 Cnot11 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000094 Ctnnb1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000095 Commd8 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000096 Cpq (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000097 Cpt1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000098 Cpt2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000110 DDIT4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000111 DDRGK1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000112 DDX25 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000114 DNAJB9 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000115 DNAJC3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000116 DPH6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000118 Ddit4l (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000119 Ddx21 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000120 Ddx6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000121 Dnajc7 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000123 EIF4BP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000124 ELAVL4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000125 ELOVL6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000126 ERO1LB (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000127 DNAJC10 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000128 ET-1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000129 Ech1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000131 Ehhadh (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000134 Eps8l2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000135 Ero1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000136 Etnk2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000137 FABP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000138 FAF1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000139 FAS (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000140 FASLG (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000141 FGF14 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000142 FGF18 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000143 FGF19 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000144 FGF2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000145 FGF21 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000146 FHAD1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000147 FHIT (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000148 FLCN (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000149 FN1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000150 FNDC4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000152 Faah (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000153 Fabp5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000154 Fat1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000156 Fnta (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000157 G2e3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000158 G6PD (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000159 GABARAPL3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000160 GADD45B (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000161 GAS1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000162 GCC2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000163 GCLC [canonical] (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000164 GDF15 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000165 GDPD1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000166 GFPT1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000167 GLIPR1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000168 GNE (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000169 GPR39 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000170 GRM8 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000171 HSP90B1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000173 GTSE1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000174 Gadd45a (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000177 Glutathione peroxidase (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000178 Gpx2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000181 H3f3b (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000182 HCK (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000183 HDGFRP3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000184 HERPUD1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000185 HIF3A (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000186 HLADPB2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000187 HMGA1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000188 HMGCS1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000189 HMGCS2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000190 HSPA13 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000191 HYOU1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000192 Hacl1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000193 Hadhb (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000194 Hist1h2bcl1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000195 Hist2h2aa3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000196 Hmox1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000197 Hnrnpab (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000198 Hsdl2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000199 Htatip2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000202 IL2RB (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000203 INHBE (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000204 INSC (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000205 INTS6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000206 ITGB1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000207 Ier3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000209 Ing4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000210 Insig1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000211 Insig2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000212 Irf1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000213 Isyna1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000214 JMJD6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000215 JMY (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000216 MAPK8 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000217 KIFC1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000218 Kdelr2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000219 Klf6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000220 L3hypdh (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000221 LEAP2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000222 LEMD1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000223 LGALS1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000224 LINC00342 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000225 LMBR1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000227 NR5A2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000228 LSS (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000229 Lamtor5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000230 Lmnb1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000231 Lpgat1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000232 MAB21L2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000233 MANF (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000234 MAP2K6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000235 MAP3K13 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000236 MED23 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000238 MMP2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000239 MMP9 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000240 M6PR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000241 MS4A2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000242 MUC3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000243 MYCN (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000244 Me1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000245 Mgll (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000246 Mybl2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000248 NAP1L1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000249 NBAS (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000250 NEFL (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000251 NFKB1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000252 NLRP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000253 NME1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000254 NUCB2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000255 NUDT4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000256 Ndufaf4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000258 NfkB (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000259 Nfkbiz (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000260 Nifib (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000261 Nolc1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000262 Nqo1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000263 Nr1h2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000264 Nrg1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000265 Nudt11 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000266 Nudt5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000267 Nudt7 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000268 Nup153 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000269 Nus1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000270 OATPs family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000271 OCT family (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000272 Osgin1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000273 PCDH9 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000274 PCK2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000275 PDGF (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000276 P4HB (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000277 PDLIM5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000278 PEX11a (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000279 PITX2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000280 PRRT2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000285 PLD4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000286 PLIN2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000287 PLK2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000288 POU6F1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000289 PPM1E (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000290 PRDM1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000292 PTGER4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000293 PTPN4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000294 Pank1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000295 Pcca (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000296 Pcsk7 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000297 Pde2A (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000298 Pdk4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000299 Pdp2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000300 Pex19 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000301 Pias3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000302 Pigz (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000303 Pik3c2g (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000304 Pir (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000305 Plbd2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000306 Pln (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000307 Pmm1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000308 Pnrc2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000309 Por (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000310 Prkcb (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000311 Prmt5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000313 Qprt (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000314 RASGRP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000315 RBL1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000316 RBbp9 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000317 RECQL5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000318 RFX3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000319 RNF130 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000320 RNF2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000321 RT1-CE5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000322 Rad51b (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000323 Rasgef1b (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000324 Rbm8a (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000325 Rem2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000328 Rnase1l2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000329 Rock1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000330 Rraga (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000331 APCS (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000332 SCO1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000333 SDF2L1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000334 SEC24D (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000335 SEC61B (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000336 SERPINA3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000337 SESN1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000338 SLC10A1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000339 SLC1A2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000340 SLC25A4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000341 SLC29A2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000342 SLC2A3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000343 SLC35F5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000344 SLC44A2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000345 SMARCD3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000346 SMO (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000347 SMPD1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000348 SMPDL3A (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000349 SORBS1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000350 SPTLC2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000351 SRPK2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000352 SRSF1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000353 STARD7 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000354 STF-083010 http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000355 STK11 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000356 STUB1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000357 SYNGR2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000358 PTPN6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000359 Skap2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000360 Slc25a20 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000361 Slc5a6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000362 Smn1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000364 Srnx1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000365 Srxn1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000366 Ssbp1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000367 Ssr3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000368 Sub1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000369 TAGLN (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000370 TGF (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000371 TGFbeta1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000372 THBS1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000374 TNF-a (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000375 TNFRSF9 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000376 TP53INP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000377 TRA2A (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000378 TRIB3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000379 TSHZ2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000380 TWIST1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000381 Taf9 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000383 Tnfrsf12a (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000384 Tnfrsf21 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000385 Tomm20 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000386 Tor1aip2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000387 Tsc22d3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000388 TUBB4A (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000389 Txnrd1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000390 Txrnd1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000391 Tyms (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000392 UBE2I (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000393 UCP3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000394 UGCG (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000395 UGT1a1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000397 Ugt2b1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000398 Ugt2b7 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000399 VNN3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000400 Vangl2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000401 Vav2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000403 Vnn1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000405 XBP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000406 ZNF385B (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000407 ZNF667 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000408 Zc3h14 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000409 Zfand2a (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000414 caspase (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000415 cebpd (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000419 cxc family (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000422 gentamicin (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000431 TIMP family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000435 calreticulin (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005079 EPB41L3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005087 GJA1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005088 GJB1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005092 HOTAIR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005093 MST1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005094 STK3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005096 KDR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005098 MET (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005100 MSH2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005102 MSH6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005103 MTAP (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005119 NOS2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005127 PPARGC1A (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005128 PROCR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005130 PTK2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005132 SNAI1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005133 TERT (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005134 TFAM (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005135 TGFA (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005136 USP7 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_0005137 YAP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000192 tropomyosin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100002 cGMP phosphodiesterase http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100702 PKA regulatory subunit http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000212 Csk http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100465 MyD88 http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000180 N-CAM http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000558 disabled http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000211 Src family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000068 PDGF receptor http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000156 FcR http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000255 PDK http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000003 Wnt http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000092 TGF-beta receptor http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0010024 Heterogeneous nuclear ribonucleoprotein http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000825 ATF http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000193 troponin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000289 Ras family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000189 alpha-actinin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100382 Grb7/10/14 family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100463 FADD http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100648 separase http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100755 Dsh family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000124 TLR http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000701 IKK family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000774 ryanodine receptor http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000868 Myb family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000027 Interferon http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000167 cadherin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000271 SHIP http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000426 p300/CBP http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000432 Axin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0010281 GLUT2 http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0010283 GLUT4 http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000331 COX http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000433 GEF http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000305 caspase (family) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000463 I-kappaB family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000075 insulin receptor family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100466 CRADD http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0001865 ADAM family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000206 ankyrin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000520 arrestin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100149 angiotensin http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000153 BCR http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000422 C/EBP http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000347 Shc http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100512 Smurf http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100718 Delta http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000254 G-protein coupled receptor kinase http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0001372 Ci/Gli http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000021 TNF superfamily http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100207 MAPKKKK http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0100192 kinesin superfamily http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0000295 Rho family http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000500 ACSM2A (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000501 ACSM2B (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000502 AGGF1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000503 ATAD2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000504 BCL2A1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000506 CDCA5 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000507 CDK1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000508 CLMN (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000509 CXCL6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000510 CXCL8 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000511 CYP1A1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000512 CYP1A2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000513 DHFR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000514 DPYD (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000515 FEN1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000516 GFRA1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000517 GPHN (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000518 HILPDA (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000519 HMMR (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000520 KIAA0101 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000521 NEAT1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000522 ORC6 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000523 PBLD (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000524 PCK1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000525 PIM3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000526 PMAIP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000527 PTPRD (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000528 RAD51AP1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000529 RHNO1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000530 RPS29 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000531 SCAPER (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000532 SEL1L (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000533 SKA2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000534 SLC38A4 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000535 SLC3A1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000536 SPTLC3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000537 SRPX2 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000538 TMEM139 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000539 TMEM150C (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000540 TMPO (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000541 TNFSF10 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000542 TRIM55 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000543 TSKU (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000544 TTC39A (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000545 UBE2T (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000546 UGT2A3 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/TXPO_1000547 UHRF1 (mol) http://purl.obolibrary.org/obo/CHEBI_25367 molecule http://purl.obolibrary.org/obo/IMR_0200292 GMP http://purl.obolibrary.org/obo/CHEBI_36976 nucleotide http://purl.obolibrary.org/obo/TXPO_0002035 ibuprofen [lipidosis] http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0000880 amiodarone [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003226 amiodarone - apotosis inducing factor [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003227 amiodarone - phospholipase competition inhibitor [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001566 amitriptyline [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001981 Ccl4 [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003509 CCL4 [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003772 CCL4 [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003771 hepatic fibrosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003128 phosphorus atom http://purl.obolibrary.org/obo/CHEBI_33250 atom http://purl.obolibrary.org/obo/TXPO_0001609 S1P -apoptosis inhibitor (inactivated state)[Phospholipidosis - positive regulation of apoptosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003349 S1P[Phospholipidosis - tumor proliferation] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003570 S1P -apoptosis inhibitor[Phospholipidosis - positive regulation of apoptosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001897 clofibrate [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0000121 fibrate [Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0003721 negative regulator of Wnt signaling pathway http://purl.obolibrary.org/obo/CHEBI_76932 pathway inhibitor http://purl.obolibrary.org/obo/TXPO_0003131 erythromycin estolate [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0002720 rosiglitazone [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001802 BMP (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0002296 di-22:6-BMP [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003115 esgtradiol‐17β‐ glucuronide [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_1000208 IGFBP1 (mol) http://purl.obolibrary.org/obo/IMR_0002688 IGFBP http://purl.obolibrary.org/obo/IMR_0001124 basement membrane collagen http://purl.obolibrary.org/obo/IMR_0000541 collagen http://purl.obolibrary.org/obo/TXPO_0003192 IL-10 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002045 glutathione depletion dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0010541 40S ribosomal protein S16 http://purl.obolibrary.org/obo/IMR_0000896 40S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010539 40S ribosomal protein S14 http://purl.obolibrary.org/obo/IMR_0000896 40S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010557 40S ribosomal protein S3a http://purl.obolibrary.org/obo/IMR_0000896 40S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010563 40S ribosomal protein S7 http://purl.obolibrary.org/obo/IMR_0000896 40S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010544 40S ribosomal protein S19 http://purl.obolibrary.org/obo/IMR_0000896 40S ribosomal protein http://purl.obolibrary.org/obo/TXPO_1000132 Eif2s1 (mol) http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/TXPO_1000133 Eif4a1 (mol) http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/TXPO_1000421 eIF2a (mol) http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/IMR_0011152 eIF1A http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/IMR_0011159 eIF4H http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/IMR_0011160 eIF5 http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/IMR_0000908 eIF1 (mol) http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/IMR_0000912 eIF4F subunit http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/IMR_0000913 eIF2 subunit http://purl.obolibrary.org/obo/IMR_0010016 eIF http://purl.obolibrary.org/obo/TXPO_0001799 AKT (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0002105 AKT (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000871 ER stress dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0001149 PKC epsilon http://purl.obolibrary.org/obo/IMR_0000246 nPKC http://purl.obolibrary.org/obo/IMR_0000676 cGMP-dependent protein kinase I http://purl.obolibrary.org/obo/IMR_0000251 PKG http://purl.obolibrary.org/obo/TXPO_0000894 CASP1 (predicted)(human)[Glutathone depletion] http://purl.obolibrary.org/obo/TXPO_0001916 glutathione depletion dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0001079 CASP1 -IL1beta activator (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001104 CASP1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001104 CASP1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003826 CASP1 (canonical)[pyroptopsis] http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0100810 CKI-alpha http://purl.obolibrary.org/obo/IMR_0100809 Casein kinase I http://purl.obolibrary.org/obo/IMR_0000611 IL-11 receptor http://purl.obolibrary.org/obo/IMR_0000096 interleukin receptor http://purl.obolibrary.org/obo/IMR_0000469 cytokeratin 6 http://purl.obolibrary.org/obo/IMR_0000050 type II cytokeratin http://purl.obolibrary.org/obo/IMR_0000162 cytokeratin 5 http://purl.obolibrary.org/obo/IMR_0000050 type II cytokeratin http://purl.obolibrary.org/obo/TXPO_0003245 Myc (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0000648 eosinogranular degeneration dependent molecule (mice) http://purl.obolibrary.org/obo/TXPO_0003983 Myc (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000985 ground glass appearance dependent molecule (rat invivo) http://purl.obolibrary.org/obo/IMR_0100315 Smad4 http://purl.obolibrary.org/obo/IMR_0000372 Co-Smad http://purl.obolibrary.org/obo/IMR_0010443 60S ribosomal protein L10a http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010444 60S ribosomal protein L13a http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010466 60S ribosomal protein L15 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010474 60S ribosomal protein L24 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010476 60S ribosomal protein L27 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010479 60S ribosomal protein L27a http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010491 60S ribosomal protein L3 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010503 60S acidic ribosomal protein P1 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010492 60S ribosomal protein L40 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010493 60S ribosomal protein L41 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010495 60S ribosomal protein L4 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010498 60S ribosomal protein L7a http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010462 60S ribosomal protein L11 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010478 60S ribosomal protein L29 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010483 60S ribosomal protein L32 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010484 60S ribosomal protein L34 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010464 60S ribosomal protein L13 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010446 60S ribosomal protein L26-like 1 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010448 60S ribosomal protein L35a http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010468 60S ribosomal protein L18 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010470 60S ribosomal protein L18a http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010471 60S ribosomal protein L21 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010473 60S ribosomal protein L23 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010480 60S ribosomal protein L23a http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010481 60S ribosomal protein L30 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0010488 60S ribosomal protein L38 http://purl.obolibrary.org/obo/IMR_0000897 60S ribosomal protein http://purl.obolibrary.org/obo/IMR_0100408 BDNF http://purl.obolibrary.org/obo/IMR_0000034 NGF family http://purl.obolibrary.org/obo/TXPO_0003752 PDGF (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000275 PDGF (mol) http://purl.obolibrary.org/obo/IMR_0100739 IHH (mol) http://purl.obolibrary.org/obo/IMR_0000004 hedgehog http://purl.obolibrary.org/obo/IMR_0100738 DHH (mol) http://purl.obolibrary.org/obo/IMR_0000004 hedgehog http://purl.obolibrary.org/obo/IMR_0100620 cyclin E2 http://purl.obolibrary.org/obo/IMR_0100618 cyclin E http://purl.obolibrary.org/obo/IMR_0100630 cyclin T2 http://purl.obolibrary.org/obo/IMR_0100628 cyclin T http://purl.obolibrary.org/obo/IMR_0100714 Notch 1 (mol) http://purl.obolibrary.org/obo/IMR_0100712 Notch http://purl.obolibrary.org/obo/IMR_0100717 Notch 4 http://purl.obolibrary.org/obo/IMR_0100712 Notch http://purl.obolibrary.org/obo/IMR_0000970 LRP6 http://purl.obolibrary.org/obo/IMR_0002954 LRP5/LRP6 http://purl.obolibrary.org/obo/IMR_0000978 LRP12 http://purl.obolibrary.org/obo/IMR_0100798 LRP family http://purl.obolibrary.org/obo/IMR_0000963 LRP4 http://purl.obolibrary.org/obo/IMR_0100798 LRP family http://purl.obolibrary.org/obo/TXPO_0002702 prostaglandin [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound http://purl.obolibrary.org/obo/IMR_0200457 Prostaglandin D2 http://purl.obolibrary.org/obo/IMR_0100019 prostaglandin http://purl.obolibrary.org/obo/IMR_0200497 Prostaglandin G2 http://purl.obolibrary.org/obo/IMR_0100019 prostaglandin http://purl.obolibrary.org/obo/IMR_0200253 Prostaglandin H2 http://purl.obolibrary.org/obo/IMR_0100019 prostaglandin http://purl.obolibrary.org/obo/TXPO_0003206 TRAF3 (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0001147 PKC gamma http://purl.obolibrary.org/obo/IMR_0100486 cPKC http://purl.obolibrary.org/obo/IMR_0000891 IRAK-2 http://purl.obolibrary.org/obo/IMR_0100488 IRAK http://purl.obolibrary.org/obo/IMR_0100548 CaM-kinase II http://purl.obolibrary.org/obo/IMR_0100543 CaMK http://purl.obolibrary.org/obo/TXPO_0001942 BSO [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001921 glutathione depletion dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001225 toxicity prediction related role http://purl.obolibrary.org/obo/BFO_0000023 role http://purl.obolibrary.org/obo/IMR_0100744 LEF-1 http://purl.obolibrary.org/obo/IMR_0000418 TCF/LEF-1 family http://purl.obolibrary.org/obo/IMR_0000695 HRAS (mol) http://purl.obolibrary.org/obo/IMR_0000290 Ras http://purl.obolibrary.org/obo/TXPO_0002955 BIM (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000871 ER stress dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001634 acetaldehyde [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003769 acetaldehyde [Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003771 hepatic fibrosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001425 gentamicin_phospholipase inhibitor [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/IMR_0200251 L-Alanine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0200274 L-Phenylalanine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0200459 L-Aspartic acid http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0200113 L-Asparagine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0200140 L-Lysine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0200428 L-Arginine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0200448 L-Glutamine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0200453 L-Serine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0100118 glycine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0100120 taurine http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/IMR_0100119 glutamic acid http://purl.obolibrary.org/obo/CHEBI_33709 amino acid http://purl.obolibrary.org/obo/TXPO_0001922 Acetaminophen [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001921 glutathione depletion dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001122 organophosphate http://purl.obolibrary.org/obo/CHEBI_72695 organic molecule http://purl.obolibrary.org/obo/TXPO_0001144 carboxylic acid http://purl.obolibrary.org/obo/CHEBI_72695 organic molecule http://purl.obolibrary.org/obo/TXPO_0001962 tunicamycin-protein glycosylation inhibitor [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003818 tunicamycin - apoptosis inducer [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003819 tunicamycin - lipidosis inducer [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003132 cyclosporineA [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0000787 tamoxifen [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0002042 nimesulide [lipidosis] http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003021 bortezomib [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001941 diethyl malate [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001921 glutathione depletion dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0000931 troglitazone [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound http://purl.obolibrary.org/obo/OGG_3000029785 CYP2S1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000051141 INSIG2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000051302 CYP39A1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000054905 CYP2W1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000054951 COMMD8 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000055192 DNAJC17 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000055289 ACOXL http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000055629 PNRC2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000056605 ERO1LB http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000064816 CYP3A43 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000079094 CHAC1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000079174 CRELD2 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000079789 CLMN http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000079799 UGT2A3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000080255 SLC35F5 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000004023 LPL http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000004257 MGST1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000004259 MGST3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000005095 PCCA http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000005101 PCDH9 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000005166 PDK4 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000005872 RAB13 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000005991 RFX3 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000284541 CYP4A22 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000339761 CYP27C1 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000387755 INSC http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000441027 TMEM150C http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000552891 DNAJC25-GNG10 http://purl.obolibrary.org/obo/OGG_2060009606 protein-coding gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000005820 PVT1 http://purl.obolibrary.org/obo/OGG_2100009606 ncRNA gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000390756 OR3A4 http://purl.obolibrary.org/obo/OGG_2100009606 ncRNA gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000406925 MIR135A1 http://purl.obolibrary.org/obo/OGG_2100009606 ncRNA gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000406926 MIR135A2 http://purl.obolibrary.org/obo/OGG_2100009606 ncRNA gene of Homo sapiens http://purl.obolibrary.org/obo/OGG_3000406942 MIR150 http://purl.obolibrary.org/obo/OGG_2100009606 ncRNA gene of Homo sapiens http://purl.obolibrary.org/obo/IMR_0002980 TEL1 http://purl.obolibrary.org/obo/IMR_0000397 ets http://purl.obolibrary.org/obo/IMR_0001093 ERM http://purl.obolibrary.org/obo/IMR_0000397 ets http://purl.obolibrary.org/obo/IMR_0001411 Gab2 http://purl.obolibrary.org/obo/IMR_0001409 Gab http://purl.obolibrary.org/obo/IMR_0001412 Gab3 http://purl.obolibrary.org/obo/IMR_0001409 Gab http://purl.obolibrary.org/obo/IMR_0001502 Rac2 http://purl.obolibrary.org/obo/IMR_0000297 Rac http://purl.obolibrary.org/obo/IMR_0100040 vitamin D http://purl.obolibrary.org/obo/IMR_0000877 fat-soluble vitamin http://purl.obolibrary.org/obo/IMR_0010630 TFIIB http://purl.obolibrary.org/obo/IMR_0000888 TFII http://purl.obolibrary.org/obo/IMR_0002799 S6K2 http://purl.obolibrary.org/obo/IMR_0001845 p70S6K http://purl.obolibrary.org/obo/IMR_0002798 S6K1 http://purl.obolibrary.org/obo/IMR_0001845 p70S6K http://purl.obolibrary.org/obo/TXPO_1000069 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity http://purl.obolibrary.org/obo/TXPO_1000172 GSK2606414 http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity http://purl.obolibrary.org/obo/TXPO_1000442 fibrate http://purl.obolibrary.org/obo/CHEBI_50860 organic molecular entity http://purl.obolibrary.org/obo/TXPO_0001524 phenobarbital [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000560 ground glass appearance dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001980 DTT [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0002623 nucleoside phosphate http://purl.obolibrary.org/obo/CHEBI_37734 phosphoric ester http://purl.obolibrary.org/obo/TXPO_0003630 trichloromethyl(.) [NASH] http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003011 lopinavir [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003024 atazanavir [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001560 imipramine _CAD [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003225 imipramine - apotosis inducing factor [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003228 imipramine - phospholipase competition inhibitor [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001849 phospholipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003025 sorafenib [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003023 nelfinavir [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003020 MG-132 [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003333 NR0B2 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002668 phospholipidosis dependent molecule (HepG2_24h_sawada) http://purl.obolibrary.org/obo/TXPO_0002726 PXR (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003120 PXR (mol) http://purl.obolibrary.org/obo/IMR_0000555 kalinin http://purl.obolibrary.org/obo/IMR_0000554 laminin family http://purl.obolibrary.org/obo/TXPO_0001145 caspase-3 http://purl.obolibrary.org/obo/IMR_0000306 effector caspase http://purl.obolibrary.org/obo/IMR_0100299 caspase-9 http://purl.obolibrary.org/obo/IMR_0000306 effector caspase http://purl.obolibrary.org/obo/IMR_0011142 eIF3i http://purl.obolibrary.org/obo/IMR_0000916 eIF3 subunit http://purl.obolibrary.org/obo/TXPO_0003027 resveratrol [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0002013 perhexiline [lipidosis] http://purl.obolibrary.org/obo/TXPO_0003508 lipidosis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0001924 phorone [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001921 glutathione depletion dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003015 thapsigargin [ER stress] http://purl.obolibrary.org/obo/TXPO_0003012 ER stress dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0002697 glibenclamide [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003118 sulindac [Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000749 cholestasis dependent chemical compound http://purl.obolibrary.org/obo/TXPO_0003272 CASPASE-2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0011349 Elongin C protein http://purl.obolibrary.org/obo/IMR_0010020 Elongin http://purl.obolibrary.org/obo/IMR_0000617 neuregulin-4 http://purl.obolibrary.org/obo/IMR_0000048 neuregulin http://purl.obolibrary.org/obo/IMR_0000057 CD40 http://purl.obolibrary.org/obo/IMR_0000056 TNFR family http://purl.obolibrary.org/obo/IMR_0001202 TRAIL-R2 http://purl.obolibrary.org/obo/IMR_0000056 TNFR family http://purl.obolibrary.org/obo/IMR_0100222 MEKK1 http://purl.obolibrary.org/obo/IMR_0000234 MEKK http://purl.obolibrary.org/obo/IMR_0100450 MEKK2 http://purl.obolibrary.org/obo/IMR_0000234 MEKK http://purl.obolibrary.org/obo/IMR_0000673 PAK7 http://purl.obolibrary.org/obo/IMR_0000238 PAK http://purl.obolibrary.org/obo/IMR_0000362 cytokeratin 10 http://purl.obolibrary.org/obo/IMR_0000035 type I cytokeratin http://purl.obolibrary.org/obo/IMR_0000366 cytokeratin 15 http://purl.obolibrary.org/obo/IMR_0000035 type I cytokeratin http://purl.obolibrary.org/obo/IMR_0000466 cytokeratin 20 http://purl.obolibrary.org/obo/IMR_0000035 type I cytokeratin http://purl.obolibrary.org/obo/IMR_0000367 cytokeratin 16 http://purl.obolibrary.org/obo/IMR_0000035 type I cytokeratin http://purl.obolibrary.org/obo/IMR_0000459 cytokeratin 19 http://purl.obolibrary.org/obo/IMR_0000035 type I cytokeratin http://purl.obolibrary.org/obo/IMR_0000467 cytokeratin 23 http://purl.obolibrary.org/obo/IMR_0000035 type I cytokeratin http://purl.obolibrary.org/obo/IMR_0000471 cytokeratin 21 http://purl.obolibrary.org/obo/IMR_0000035 type I cytokeratin http://purl.obolibrary.org/obo/IMR_0000364 cytokeratin 13 http://purl.obolibrary.org/obo/IMR_0000035 type I cytokeratin http://purl.obolibrary.org/obo/IMR_0000821 MafF http://purl.obolibrary.org/obo/IMR_0000411 Maf family http://purl.obolibrary.org/obo/IMR_0000822 MafG http://purl.obolibrary.org/obo/IMR_0000411 Maf family http://purl.obolibrary.org/obo/TXPO_0003774 IL-1 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003750 hepatic fibrosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0000843 TP53 (canonical)[Cell death] http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001801 P53 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003202 TP53 (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0100614 cyclin D http://purl.obolibrary.org/obo/IMR_0100670 G1-cyclin http://purl.obolibrary.org/obo/IMR_0100610 cyclin B http://purl.obolibrary.org/obo/IMR_0100673 M-cyclin http://purl.obolibrary.org/obo/IMR_0100392 IFNAR-2 http://purl.obolibrary.org/obo/IMR_0000135 IFNR type I http://purl.obolibrary.org/obo/TXPO_0004103 IL32 (mol) http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/TXPO_1000200 IL-1b (mol) http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/TXPO_1000201 IL2 (mol) http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/IMR_0000587 IL-8 http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/IMR_0000590 IL-12 http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/IMR_0000595 IL-13 http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/IMR_0000599 IL-17 http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/IMR_0000013 IL-11 http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/IMR_0000601 IL-18 http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/IMR_0000010 IL-6 (mol) http://purl.obolibrary.org/obo/IMR_0000007 Interleukin http://purl.obolibrary.org/obo/IMR_0000486 beta-actin http://purl.obolibrary.org/obo/IMR_0000190 actin http://purl.obolibrary.org/obo/IMR_0000218 Fak http://purl.obolibrary.org/obo/IMR_0000217 Fak/Pyk2 http://purl.obolibrary.org/obo/IMR_0000686 p38alpha http://purl.obolibrary.org/obo/IMR_0000226 p38 http://purl.obolibrary.org/obo/IMR_0000688 p38gamma http://purl.obolibrary.org/obo/IMR_0000226 p38 http://purl.obolibrary.org/obo/IMR_0000689 p38delta http://purl.obolibrary.org/obo/IMR_0000226 p38 http://purl.obolibrary.org/obo/IMR_0100248 ZAK http://purl.obolibrary.org/obo/IMR_0000239 MLK family http://purl.obolibrary.org/obo/IMR_0100254 DLK http://purl.obolibrary.org/obo/IMR_0000239 MLK family http://purl.obolibrary.org/obo/IMR_0001847 RSK2 http://purl.obolibrary.org/obo/IMR_0000248 RSK http://purl.obolibrary.org/obo/IMR_0001848 RSK3 http://purl.obolibrary.org/obo/IMR_0000248 RSK http://purl.obolibrary.org/obo/TXPO_0003203 TRADD (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_1000040 BAK1 (mol) http://purl.obolibrary.org/obo/IMR_0000452 BAK http://purl.obolibrary.org/obo/TXPO_0001572 ethanoleamines http://purl.obolibrary.org/obo/IMR_0001693 amine http://purl.obolibrary.org/obo/IMR_0000865 14-3-3 zeta http://purl.obolibrary.org/obo/IMR_0000456 14-3-3 http://purl.obolibrary.org/obo/IMR_0000862 14-3-3 eta http://purl.obolibrary.org/obo/IMR_0000456 14-3-3 http://purl.obolibrary.org/obo/IMR_0000861 14-3-3 epsilon http://purl.obolibrary.org/obo/IMR_0000456 14-3-3 http://purl.obolibrary.org/obo/IMR_0100380 G-alpha-12 http://purl.obolibrary.org/obo/IMR_0000324 G-alpha-12/13 class http://purl.obolibrary.org/obo/IMR_0100381 G-alpha-13 http://purl.obolibrary.org/obo/IMR_0000324 G-alpha-12/13 class http://purl.obolibrary.org/obo/IMR_0001102 importin 7 http://purl.obolibrary.org/obo/IMR_0100010 importin http://purl.obolibrary.org/obo/IMR_0001101 importin 5 http://purl.obolibrary.org/obo/IMR_0100010 importin http://purl.obolibrary.org/obo/IMR_0100202 importin alpha http://purl.obolibrary.org/obo/IMR_0100010 importin http://purl.obolibrary.org/obo/IMR_0001097 transportin SR http://purl.obolibrary.org/obo/IMR_0100010 importin http://purl.obolibrary.org/obo/IMR_0100203 importin beta http://purl.obolibrary.org/obo/IMR_0100010 importin http://purl.obolibrary.org/obo/IMR_0100108 thymic factor, circulating http://purl.obolibrary.org/obo/IMR_0100089 thymus hormone http://purl.obolibrary.org/obo/IMR_0100109 thymopoietin http://purl.obolibrary.org/obo/IMR_0100089 thymus hormone http://purl.obolibrary.org/obo/IMR_0100110 thymosin http://purl.obolibrary.org/obo/IMR_0100089 thymus hormone http://purl.obolibrary.org/obo/IMR_0100583 syndecan-4 http://purl.obolibrary.org/obo/IMR_0100579 syndecan http://purl.obolibrary.org/obo/IMR_0100159 adrenorphin http://purl.obolibrary.org/obo/IMR_0100157 enkephalin http://purl.obolibrary.org/obo/IMR_0100158 leucine enkephalin http://purl.obolibrary.org/obo/IMR_0100157 enkephalin http://purl.obolibrary.org/obo/IMR_0100706 Bcl-2 subfamily http://purl.obolibrary.org/obo/IMR_0100705 anti-apoptotic Bcl-2 family http://purl.obolibrary.org/obo/IMR_0000317 G-alpha-s class http://purl.obolibrary.org/obo/IMR_0000316 G-alpha http://purl.obolibrary.org/obo/IMR_0000318 G-alpha-i class http://purl.obolibrary.org/obo/IMR_0000316 G-alpha http://purl.obolibrary.org/obo/TXPO_0003820 lipofuscin granule http://purl.obolibrary.org/obo/GO_0048770 pigment granule http://purl.obolibrary.org/obo/TXPO_0003821 melanin granule http://purl.obolibrary.org/obo/GO_0048770 pigment granule http://purl.obolibrary.org/obo/IMR_0100322 Tyk2 http://purl.obolibrary.org/obo/IMR_0000213 JAK http://purl.obolibrary.org/obo/IMR_0100311 Smad2 http://purl.obolibrary.org/obo/IMR_0100504 Smad2/3 http://purl.obolibrary.org/obo/TXPO_0000845 MDM2 (canonical)[Cell death] http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001004 MDM2 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000472 ground glass appearance dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001932 Mdm2 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001927 glutathione depletion dependent molecule (rat) http://purl.obolibrary.org/obo/TXPO_0003193 IL-4 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002045 glutathione depletion dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0000606 IL-8RA http://purl.obolibrary.org/obo/IMR_0000605 IL-8 receptor http://purl.obolibrary.org/obo/IMR_0001016 cAMP-specific 3',5'-cyclic phosphodiesterase 4A http://purl.obolibrary.org/obo/IMR_0100700 cAMP phosphodiesterase http://purl.obolibrary.org/obo/IMR_0000380 STAT5b http://purl.obolibrary.org/obo/IMR_0100733 STAT5 http://purl.obolibrary.org/obo/IMR_0001141 cerebroglycan http://purl.obolibrary.org/obo/IMR_0001139 glypican (mol) http://purl.obolibrary.org/obo/IMR_0002958 Dlp/Dally http://purl.obolibrary.org/obo/IMR_0001139 glypican (mol) http://purl.obolibrary.org/obo/IMR_0001114 exportin 5 http://purl.obolibrary.org/obo/IMR_0100015 exportin http://purl.obolibrary.org/obo/IMR_0100155 alpha-endorphin http://purl.obolibrary.org/obo/IMR_0100154 endorphin http://purl.obolibrary.org/obo/IMR_0100156 gamma-endorphin http://purl.obolibrary.org/obo/IMR_0100154 endorphin http://purl.obolibrary.org/obo/IMR_0100167 endothelin-1 http://purl.obolibrary.org/obo/IMR_0100166 endothelin http://purl.obolibrary.org/obo/IMR_0001208 Bmf http://purl.obolibrary.org/obo/IMR_0100709 BH3 subfamily http://purl.obolibrary.org/obo/IMR_0100289 Bid (mol) http://purl.obolibrary.org/obo/IMR_0100709 BH3 subfamily http://purl.obolibrary.org/obo/IMR_0001552 Rab2A http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001558 Rab3B http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001560 Rab3C http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001563 Rab3D http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001565 Rab4B http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001568 Rab5B http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001572 Rab6A http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001574 Rab6C http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001578 Rab7L http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001580 Rab8B http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001582 Rab9B http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001588 Rab11A http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001592 Rab12 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001593 Rab13 (mol) http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001595 Rab14 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001598 Rab15 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001601 Rab17 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001602 Rab18 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001603 Rab19 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001604 Rab20 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001605 Rab21 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001607 Rab23 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001608 Rab24 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001611 Rab26 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001612 Rab27A http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001613 Rab27B http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001616 Rab30 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001617 Rab31 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001625 Rab34 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001626 Rab35 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001628 Rab37 http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/IMR_0001636 Rab40C http://purl.obolibrary.org/obo/IMR_0000299 Rab http://purl.obolibrary.org/obo/TXPO_0000866 BAD (human)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000840 cell death dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0001097 BAD (human)[Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001090 lipidosis dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0003197 BAD (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0100627 cyclin K http://purl.obolibrary.org/obo/IMR_0100606 cyclin http://purl.obolibrary.org/obo/IMR_0100671 G1/S-cyclin http://purl.obolibrary.org/obo/IMR_0100606 cyclin http://purl.obolibrary.org/obo/IMR_0100613 cyclin C http://purl.obolibrary.org/obo/IMR_0100606 cyclin http://purl.obolibrary.org/obo/IMR_0100672 S-cyclin http://purl.obolibrary.org/obo/IMR_0100606 cyclin http://purl.obolibrary.org/obo/IMR_0000871 NF1-C http://purl.obolibrary.org/obo/IMR_0000409 NF1 (mol) http://purl.obolibrary.org/obo/IMR_0000872 NF1-X http://purl.obolibrary.org/obo/IMR_0000409 NF1 (mol) http://purl.obolibrary.org/obo/IMR_0100386 IFN alpha http://purl.obolibrary.org/obo/IMR_0000028 IFN type I http://purl.obolibrary.org/obo/IMR_0100387 IFN omega http://purl.obolibrary.org/obo/IMR_0000028 IFN type I http://purl.obolibrary.org/obo/TXPO_0001798 EGFR (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003912 EGFR (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000472 ground glass appearance dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0002394 TCR gamma http://purl.obolibrary.org/obo/IMR_0000151 TCR family http://purl.obolibrary.org/obo/IMR_0100351 TCR beta http://purl.obolibrary.org/obo/IMR_0000151 TCR family http://purl.obolibrary.org/obo/TXPO_0005074 CDH1 (mol) http://purl.obolibrary.org/obo/IMR_0000168 E-cadherin http://purl.obolibrary.org/obo/TXPO_0001813 JNK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000216 MAPK8 (mol) http://purl.obolibrary.org/obo/TXPO_0002298 JNK (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000216 MAPK8 (mol) http://purl.obolibrary.org/obo/IMR_0000685 JNK3 http://purl.obolibrary.org/obo/IMR_0000225 JNK/SAPK http://purl.obolibrary.org/obo/IMR_0000697 K-Ras2A http://purl.obolibrary.org/obo/IMR_0000291 KRAS (mol) http://purl.obolibrary.org/obo/IMR_0100375 G-alpha-11 http://purl.obolibrary.org/obo/IMR_0000323 G-alpha-q class http://purl.obolibrary.org/obo/IMR_0100379 G-alpha-Y http://purl.obolibrary.org/obo/IMR_0000323 G-alpha-q class http://purl.obolibrary.org/obo/IMR_0100377 G-alpha-15 http://purl.obolibrary.org/obo/IMR_0000323 G-alpha-q class http://purl.obolibrary.org/obo/IMR_0100378 G-alpha-q http://purl.obolibrary.org/obo/IMR_0000323 G-alpha-q class http://purl.obolibrary.org/obo/IMR_0100376 G-alpha-14 http://purl.obolibrary.org/obo/IMR_0000323 G-alpha-q class http://purl.obolibrary.org/obo/IMR_0000404 EGR2 http://purl.obolibrary.org/obo/IMR_0000402 EGR family http://purl.obolibrary.org/obo/TXPO_0003341 EGR1 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000793 ER stress dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0001948 Jun (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001927 glutathione depletion dependent molecule (rat) http://purl.obolibrary.org/obo/TXPO_0003162 JUN (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002045 glutathione depletion dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0000817 c-JUN http://purl.obolibrary.org/obo/IMR_0000416 JUN (mol) http://purl.obolibrary.org/obo/IMR_0100348 RasGRF2 http://purl.obolibrary.org/obo/IMR_0000440 RasGRF http://purl.obolibrary.org/obo/IMR_0100206 Ran GAP http://purl.obolibrary.org/obo/IMR_0000442 GAP family http://purl.obolibrary.org/obo/IMR_0100268 Rho GAP http://purl.obolibrary.org/obo/IMR_0000442 GAP family http://purl.obolibrary.org/obo/IMR_0001117 RASA4 http://purl.obolibrary.org/obo/IMR_0000443 Ras GAP http://purl.obolibrary.org/obo/IMR_0001115 IQGAP2 http://purl.obolibrary.org/obo/IMR_0000443 Ras GAP http://purl.obolibrary.org/obo/IMR_0100331 XIAP http://purl.obolibrary.org/obo/IMR_0000454 IAP-family http://purl.obolibrary.org/obo/IMR_0100332 Survivin http://purl.obolibrary.org/obo/IMR_0000454 IAP-family http://purl.obolibrary.org/obo/TXPO_0000853 Jund (rat)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000839 cell death dependent molecule (rat) http://purl.obolibrary.org/obo/IMR_0003026 alpha PIX http://purl.obolibrary.org/obo/IMR_0001954 RhoGEF http://purl.obolibrary.org/obo/IMR_0010453 NELF-E http://purl.obolibrary.org/obo/IMR_0010013 NELF http://purl.obolibrary.org/obo/TXPO_0001151 Sgpl1 (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001134 phospholipidosis dependent molecule (rat) http://purl.obolibrary.org/obo/TXPO_0002090 SGPL1(human) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001135 phospholipidosis dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0003529 Sgpl1 (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003278 phospholipidosis dependent molecule (mouse) http://purl.obolibrary.org/obo/TXPO_0003760 LEAP2 (human)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000221 LEAP2 (mol) http://purl.obolibrary.org/obo/TXPO_0003762 HMGA1 (human)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000187 HMGA1 (mol) http://purl.obolibrary.org/obo/TXPO_1000027 Acox1 (mol) http://purl.obolibrary.org/obo/TXPO_0000033 ACOX family http://purl.obolibrary.org/obo/TXPO_0002901 ATF6 - signaling factor (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0000044 ATF6 (golgi apparatus) (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002902 ATF6 - signaling factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000044 ATF6 (golgi apparatus) (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002910 ATF6 - signaling factor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0000044 ATF6 (golgi apparatus) (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002958 ATF6 - signaling factor (canonical)[ER stress -ERAD] http://purl.obolibrary.org/obo/TXPO_0000044 ATF6 (golgi apparatus) (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002745 NRF2 - transcriptional regulator (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000047 NRF2 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001803 PLA1 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0002934 GADD34 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000871 ER stress dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001328 PPARA (canonical)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001280 eosinogranular degeneration dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001632 PPAR alpha (canonical) [lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0002501 Peroxisome Proliferator-Activated Receptor Alpha [lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003243 Ppara (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0000648 eosinogranular degeneration dependent molecule (mice) http://purl.obolibrary.org/obo/TXPO_0004061 PPAR alpha [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001951 GCLC - inactivated state (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0000193 GCLC (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0001504 SLCO2B1 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000272 OATPS family (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003127 SLCO1A2 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0000272 OATPS family (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001506 ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_1000014 ATP-binding cassette (ABC) transporter superfamily http://purl.obolibrary.org/obo/TXPO_0002643 FXR (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003119 FXR (mol) http://purl.obolibrary.org/obo/TXPO_0002647 OCT family (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_1000271 OCT family (mol) http://purl.obolibrary.org/obo/TXPO_0002724 CAR (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003862 CAR (mol) http://purl.obolibrary.org/obo/TXPO_0002725 GR (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003121 GR (mol) http://purl.obolibrary.org/obo/TXPO_0003125 LRH1 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_1000227 NR5A2 (mol) http://purl.obolibrary.org/obo/TXPO_0003148 FGF19 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_1000143 FGF19 (mol) http://purl.obolibrary.org/obo/TXPO_0002426 biological sex value http://purl.obolibrary.org/obo/TXPO_0000277 categorical http://purl.obolibrary.org/obo/TXPO_0002062 LPL (canonical)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001280 eosinogranular degeneration dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003346 FADS2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003325 ELOVL6 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000125 ELOVL6 (mol) http://purl.obolibrary.org/obo/NCIT_C16407 cell survival http://purl.obolibrary.org/obo/TXPO_0000414 keeping quantity http://purl.obolibrary.org/obo/TXPO_0000944 AMPK (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003221 AMPK (mol) http://purl.obolibrary.org/obo/TXPO_0000953 UGT1A1 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000395 UGT1a1 (mol) http://purl.obolibrary.org/obo/TXPO_0000975 GADD45B (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000160 GADD45B (mol) http://purl.obolibrary.org/obo/TXPO_0000989 AHR (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000030 Ahr (mol) http://purl.obolibrary.org/obo/TXPO_0000999 TGF (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000370 TGF (mol) http://purl.obolibrary.org/obo/TXPO_0001019 DDB2 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001007 DDB2 (mol) http://purl.obolibrary.org/obo/TXPO_0001797 G6PC (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000563 G6PC (mol) http://purl.obolibrary.org/obo/TXPO_0003923 FOXO1 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/IMR_0002805 FOXO1 (mol) http://purl.obolibrary.org/obo/TXPO_0003964 SREBP1 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003966 SREBF1 (mol) http://purl.obolibrary.org/obo/TXPO_0003971 ACC1 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003970 ACC (mol) http://purl.obolibrary.org/obo/TXPO_0003975 ACC2 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003974 ACACB (mol) http://purl.obolibrary.org/obo/TXPO_0003980 ARK5 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003982 NUAK1 (mol) http://purl.obolibrary.org/obo/TXPO_0005080 FOXO1 (canonical)[mitochondrial disorder] http://purl.obolibrary.org/obo/IMR_0002805 FOXO1 (mol) http://purl.obolibrary.org/obo/TXPO_0001282 CASPASE-2 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000502 CASPASE (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003887 fatty acid omega-hydroxylase activity http://purl.obolibrary.org/obo/TXPO_0000519 oxidoreductase http://purl.obolibrary.org/obo/TXPO_0001395 ASAH1 (human)[Phospholipidosis - tumor cell proliferation induction] http://purl.obolibrary.org/obo/TXPO_0000529 ASAH1 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003456 ASAH1 - inactivated (human)[Phospholipidosis - hypofunctioning of ceramide degradation] http://purl.obolibrary.org/obo/TXPO_0000529 ASAH1 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0000886 ER process http://purl.obolibrary.org/obo/TXPO_0000538 process on structural viewpoint http://purl.obolibrary.org/obo/TXPO_0003718 lysosomal process http://purl.obolibrary.org/obo/TXPO_0000538 process on structural viewpoint http://purl.obolibrary.org/obo/TXPO_0003719 mitochondrial procress http://purl.obolibrary.org/obo/TXPO_0000538 process on structural viewpoint http://purl.obolibrary.org/obo/TXPO_0003220 conpetitive inhibitor of phospholipase http://purl.obolibrary.org/obo/TXPO_0000559 phospholipase inhibitor role http://purl.obolibrary.org/obo/TXPO_0003910 CITCO [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000069 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime http://purl.obolibrary.org/obo/TXPO_0001301 SCD (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003327 SCD (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002668 phospholipidosis dependent molecule (HepG2_24h_sawada) http://purl.obolibrary.org/obo/TXPO_0001303 PLB http://purl.obolibrary.org/obo/TXPO_0000635 Phospholipase family http://purl.obolibrary.org/obo/IMR_0000284 PLC (mol) http://purl.obolibrary.org/obo/TXPO_0000635 Phospholipase family http://purl.obolibrary.org/obo/TXPO_0003214 Osgin1 - apotosis inducing factor (rat)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000641 Osgin1 (rat)[Cell death] http://purl.obolibrary.org/obo/TXPO_0003215 Osgin1 - cancer repressor (rat)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000641 Osgin1 (rat)[Cell death] http://purl.obolibrary.org/obo/TXPO_0003216 Osgin1 - oxidative stress response protein (rat)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000641 Osgin1 (rat)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000846 Acot5 (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0000868 Acot5 (mol) http://purl.obolibrary.org/obo/TXPO_0000870 Acot8 (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000026 Acot8 (mol) http://purl.obolibrary.org/obo/TXPO_0001045 Pex11a (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000278 PEX11a (mol) http://purl.obolibrary.org/obo/TXPO_0001055 Plin2 (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000286 PLIN2 (mol) http://purl.obolibrary.org/obo/TXPO_0001057 Acot3 (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000023 Acot3 (mol) http://purl.obolibrary.org/obo/TXPO_0001058 Acot2 (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000022 Acot2 (mol) http://purl.obolibrary.org/obo/TXPO_0002017 Acot1 (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0002018 Acot1 (mol) http://purl.obolibrary.org/obo/TXPO_0003238 Cdk1 (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0003239 Cdk1 (mol) http://purl.obolibrary.org/obo/TXPO_0003242 Cdk4(mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0003240 Cdk4 (mol) http://purl.obolibrary.org/obo/TXPO_0003247 Acaa1a (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000017 Acaa1a (mol) http://purl.obolibrary.org/obo/TXPO_0003248 Acox1 (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000027 Acox1 (mol) http://purl.obolibrary.org/obo/TXPO_0003250 Ehhadh (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000131 Ehhadh (mol) http://purl.obolibrary.org/obo/TXPO_0000924 PLA2G2E (human) positively regulator of immune response[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001135 phospholipidosis dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0001308 Lgpat1 http://purl.obolibrary.org/obo/TXPO_0000740 Lgpat http://purl.obolibrary.org/obo/TXPO_0000768 Hmox1 (rat)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000196 Hmox1 (mol) http://purl.obolibrary.org/obo/TXPO_0000771 Cebpd (rat)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000415 cebpd (mol) http://purl.obolibrary.org/obo/TXPO_0000779 Trib3 (rat)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000378 TRIB3 (mol) http://purl.obolibrary.org/obo/TXPO_0000783 Dnajb9 (rat)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000114 DNAJB9 (mol) http://purl.obolibrary.org/obo/TXPO_0002164 Hyou1 (rat)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000191 HYOU1 (mol) http://purl.obolibrary.org/obo/TXPO_1000281 PLA2G15 (mol) http://purl.obolibrary.org/obo/TXPO_0000772 group XV phospholipaseA2 http://purl.obolibrary.org/obo/TXPO_0004072 PLA2G15 (canonical) positively regulator of immune response[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0000784 Arrb2 -inactivation (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000777 Arrb2 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000777 Arrb2 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001071 ground glass appearance dependent molecule (mouse) http://purl.obolibrary.org/obo/TXPO_0000786 GPRC5B (human)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001009 ground glass appearance dependent gene (human in vitro) http://purl.obolibrary.org/obo/TXPO_0001975 tamoxifen -fatty acid oxidation inhibitor [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0000787 tamoxifen [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0002019 tamoxifen -mitochondrial respiratory chain inhibitor [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0000787 tamoxifen [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001976 valproic acid - fatty acid oxidation inhibitor [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0000788 valproic acid [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0000778 CCL2 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000086 CCL2 (mol) http://purl.obolibrary.org/obo/TXPO_0000796 FGF21 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000145 FGF21 (mol) http://purl.obolibrary.org/obo/TXPO_0000798 MANF (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000233 MANF (mol) http://purl.obolibrary.org/obo/TXPO_0000800 HYOU1 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000191 HYOU1 (mol) http://purl.obolibrary.org/obo/TXPO_0000802 HSP90B1 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000171 HSP90B1 (mol) http://purl.obolibrary.org/obo/TXPO_0000805 ERO1LB (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000126 ERO1LB (mol) http://purl.obolibrary.org/obo/TXPO_0000806 GFPT1 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000166 GFPT1 (mol) http://purl.obolibrary.org/obo/TXPO_0000810 HERPUD1 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000184 HERPUD1 (mol) http://purl.obolibrary.org/obo/TXPO_0000811 SEC61B (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000335 SEC61B (mol) http://purl.obolibrary.org/obo/TXPO_0002165 DNAJB9 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000114 DNAJB9 (mol) http://purl.obolibrary.org/obo/TXPO_0002167 DDIT3 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000067 DDIT3 (mol) http://purl.obolibrary.org/obo/TXPO_0002168 TRIB3 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000378 TRIB3 (mol) http://purl.obolibrary.org/obo/TXPO_0002169 CRELD2 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000075 CRELD2 (mol) http://purl.obolibrary.org/obo/TXPO_0001442 in vitro (human) 24hr http://purl.obolibrary.org/obo/TXPO_0000795 in vitro assay (human) http://purl.obolibrary.org/obo/TXPO_0003437 in vitro (human) 8hr http://purl.obolibrary.org/obo/TXPO_0000795 in vitro assay (human) http://purl.obolibrary.org/obo/TXPO_0003631 in vitro (human) 2hr http://purl.obolibrary.org/obo/TXPO_0000795 in vitro assay (human) http://purl.obolibrary.org/obo/TXPO_0000828 HSP90B1 - chaperone -vitro (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000802 HSP90B1 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003485 HSP90B1 - apotosis repressor -vitro (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000802 HSP90B1 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003735 HSP90B1 - tumor cell production promoting factor (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000802 HSP90B1 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000790 Creld2 (mouse)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000075 CRELD2 (mol) http://purl.obolibrary.org/obo/TXPO_0000791 Ddit3 (mouse)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000067 DDIT3 (mol) http://purl.obolibrary.org/obo/TXPO_0000792 Bhlha15 (mouse)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000045 Bhlha15 (mol) http://purl.obolibrary.org/obo/TXPO_0003274 Fgf21 (mouse)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000145 FGF21 (mol) http://purl.obolibrary.org/obo/TXPO_0003277 Ero1lb (mouse)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000126 ERO1LB (mol) http://purl.obolibrary.org/obo/TXPO_0002556 P-EIF2A -ATF4 promoting factor (canonical)[ER stress - proteinrefolding] http://purl.obolibrary.org/obo/TXPO_0000829 P-EIF2A (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002896 P-EIF2A - translation initiation inhibitor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000829 P-EIF2A (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002931 P-EIF2A - translation initiation inhibitor (canonical)[ER stress - translation] http://purl.obolibrary.org/obo/TXPO_0000829 P-EIF2A (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001152 unsaturated fatty acid http://purl.obolibrary.org/obo/TXPO_0000834 fatty acid http://purl.obolibrary.org/obo/TXPO_0004044 Aen (rat)[Cell death] http://purl.obolibrary.org/obo/TXPO_1000029 Aen (mol) http://purl.obolibrary.org/obo/TXPO_0000863 TNF (human)[Cell death] http://purl.obolibrary.org/obo/TXPO_1000374 TNF-a (mol) http://purl.obolibrary.org/obo/TXPO_0000864 BCL2 (human)[Cell death] http://purl.obolibrary.org/obo/TXPO_1000041 BCL2 (mol) http://purl.obolibrary.org/obo/TXPO_0000867 FASLG (human)[Cell death] http://purl.obolibrary.org/obo/TXPO_1000140 FASLG (mol) http://purl.obolibrary.org/obo/TXPO_0002382 TP53 - cell cycle regulation factor (canonical)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000843 TP53 (canonical)[Cell death] http://purl.obolibrary.org/obo/TXPO_0003217 TP53 - apotosis inducing factor (canonical)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000843 TP53 (canonical)[Cell death] http://purl.obolibrary.org/obo/TXPO_0000847 Hmgb1 (mouse)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002285 glutathione depletion dependent gene [mouse] http://purl.obolibrary.org/obo/TXPO_0000857 GGT1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0000873 AMPK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003221 AMPK (mol) http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001792 PERK (mol) http://purl.obolibrary.org/obo/TXPO_0000879 ATF6 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000013 ATF6 (mol) http://purl.obolibrary.org/obo/TXPO_0001275 EIF2A (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000421 eIF2a (mol) http://purl.obolibrary.org/obo/TXPO_0001907 ATF4 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000012 ATF4 (mol) http://purl.obolibrary.org/obo/TXPO_0001960 HSP90B1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000171 HSP90B1 (mol) http://purl.obolibrary.org/obo/TXPO_0001968 XBP1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000405 XBP1 (mol) http://purl.obolibrary.org/obo/TXPO_0002385 GRP78 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001002 BIP (mol) http://purl.obolibrary.org/obo/TXPO_0002410 GRP94 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000171 HSP90B1 (mol) http://purl.obolibrary.org/obo/TXPO_0002411 PKCΕ (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000280 PRRT2 (mol) http://purl.obolibrary.org/obo/TXPO_0002497 ERO1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000135 Ero1 (mol) http://purl.obolibrary.org/obo/TXPO_0002601 IRE1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001528 IRE1 (mol) http://purl.obolibrary.org/obo/TXPO_0002769 NFKB (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000258 NfkB (mol) http://purl.obolibrary.org/obo/TXPO_0002771 PDI (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000276 P4HB (mol) http://purl.obolibrary.org/obo/TXPO_0002776 ERDJ5 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000127 DNAJC10 (mol) http://purl.obolibrary.org/obo/TXPO_0002880 PERK dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001792 PERK (mol) http://purl.obolibrary.org/obo/TXPO_0002897 CALRETICULIN (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000435 calreticulin (mol) http://purl.obolibrary.org/obo/TXPO_0002914 CHOP (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000067 DDIT3 (mol) http://purl.obolibrary.org/obo/TXPO_0002921 HYOU1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000191 HYOU1 (mol) http://purl.obolibrary.org/obo/TXPO_0002942 ASK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000010 DBF4 (mol) http://purl.obolibrary.org/obo/TXPO_0002972 IRE1 dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001528 IRE1 (mol) http://purl.obolibrary.org/obo/TXPO_0003006 CCND1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000088 Cyclin D1 (mol) http://purl.obolibrary.org/obo/TXPO_0003037 IL-6 (canonical)[ER stress] http://purl.obolibrary.org/obo/IMR_0000010 IL-6 (mol) http://purl.obolibrary.org/obo/TXPO_0003039 NLRP1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000252 NLRP1 (mol) http://purl.obolibrary.org/obo/TXPO_0003048 APR gene (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000008 APR molecule http://purl.obolibrary.org/obo/TXPO_0003052 DNAJC3 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000115 DNAJC3 (mol) http://purl.obolibrary.org/obo/TXPO_0003069 CRP (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000076 CRP (mol) http://purl.obolibrary.org/obo/TXPO_0003082 CRBPH (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000074 CRBPH (mol) http://purl.obolibrary.org/obo/TXPO_0003086 SAP (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_1000331 APCS (mol) http://purl.obolibrary.org/obo/TXPO_0001172 KEAP1 [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002045 glutathione depletion dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001841 PERK - signal sensor (canonical)[Perk signalling system] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001852 PERK - signaling factor (canonical)[Perk signalling system] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002839 PERK - stress sensor (canonical)[ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002845 PERK - stress sensor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002846 PERK - stress sensor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002856 PERK - kinase (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002857 PERK - kinase (canonical)[ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002858 PERK - autophosphorylation kinase (canonical)[ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002859 PERK - autophosphorylation kinase (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002860 PERK - autophosphorylation kinase (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002861 PERK - autophosphorylation kinase (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002862 PERK - kinase (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002863 PERK - kinase (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002864 PERK - stress sensor (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002996 PERK - stress sensor (canonical)[ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002998 PERK - autophosphorylation kinase (canonical)[ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002999 PERK - kinase (canonical)[ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0000878 PERK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002468 ATF6F (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000879 ATF6 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002900 ATF6 - stress sensor (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0000879 ATF6 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003032 ATF6 - stress sensor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0000879 ATF6 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001983 amiodarone - fatty acid oxidation inhibitor http://purl.obolibrary.org/obo/TXPO_0000880 amiodarone [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0002026 amiodarone -mitochondrial respiratory chain inhibitor [lipidosis] http://purl.obolibrary.org/obo/TXPO_0000880 amiodarone [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003931 AMPK - inhibitor (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000944 AMPK (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003948 AMPK - activation state (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000944 AMPK (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003957 AMPK - lipogenic inhibitor (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000944 AMPK (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000990 Cyp2b1 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000101 Cyp2b1 (mol) http://purl.obolibrary.org/obo/TXPO_0000991 Cyp1a1 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000100 Cyp1A1 (mol) http://purl.obolibrary.org/obo/TXPO_0000992 Ugt2b1 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000397 Ugt2b1 (mol) http://purl.obolibrary.org/obo/TXPO_0000994 Alas1 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000034 Alas1 (mol) http://purl.obolibrary.org/obo/TXPO_0000995 Por (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000309 Por (mol) http://purl.obolibrary.org/obo/TXPO_0000996 Gsta3 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000179 GSTA3 (mol) http://purl.obolibrary.org/obo/TXPO_0000997 Txnrd1 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000389 Txnrd1 (mol) http://purl.obolibrary.org/obo/TXPO_0000998 Srnx1 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000364 Srnx1 (mol) http://purl.obolibrary.org/obo/TXPO_0001000 Vav2 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000401 Vav2 (mol) http://purl.obolibrary.org/obo/TXPO_0001001 Aldh1 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000035 ALDH1A1 (mol) http://purl.obolibrary.org/obo/TXPO_0001003 Lmnb1 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000230 Lmnb1 (mol) http://purl.obolibrary.org/obo/TXPO_0001008 Ankrd37 (rat)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000036 Ankrd37 (mol) http://purl.obolibrary.org/obo/TXPO_0001072 Ctnnb1 -tumor positive regulator (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000986 Ctnnb1 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001073 Ctnnb1 -apoptosis inhibitor (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000986 Ctnnb1 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001076 Ctnnb1 -cell senescence inhibitor (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000986 Ctnnb1 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0000979 CYP2B6 (human)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000078 CYP2B6 (mol) http://purl.obolibrary.org/obo/TXPO_0001032 MRP2 (human)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002496 ABCC2 (mol) http://purl.obolibrary.org/obo/TXPO_0001035 ARID5A (human)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001020 ARID5A [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003909 CYP3A4 (human)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000082 CYP3A4 (mol) http://purl.obolibrary.org/obo/TXPO_0001017 GOT1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001939 DDB2 -inactivation (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001019 DDB2 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001024 GPT (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001037 PTPN4 (human)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000293 PTPN4 (mol) http://purl.obolibrary.org/obo/TXPO_0001046 ACOT4 (human)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000024 Acot4 (mol) http://purl.obolibrary.org/obo/TXPO_0001069 ACOT8 (human)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000026 Acot8 (mol) http://purl.obolibrary.org/obo/TXPO_0001084 PLIN2 (human)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000286 PLIN2 (mol) http://purl.obolibrary.org/obo/TXPO_0003246 ACAA1A (human)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000017 Acaa1a (mol) http://purl.obolibrary.org/obo/TXPO_0003249 ACOX1 (human)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000027 Acox1 (mol) http://purl.obolibrary.org/obo/TXPO_0003253 ATM (human)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0003252 ATM (mol) http://purl.obolibrary.org/obo/TXPO_0003255 PEX5 (human)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0003254 PEX5 (mol) http://purl.obolibrary.org/obo/TXPO_0000986 Ctnnb1 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000094 Ctnnb1 (mol) http://purl.obolibrary.org/obo/TXPO_0003263 Mrp2 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0002496 ABCC2 (mol) http://purl.obolibrary.org/obo/TXPO_0003907 Cyp2b10 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000102 Cyp2b10 (mol) http://purl.obolibrary.org/obo/TXPO_0003908 Cyp3a11 (mouse)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_1000106 Cyp3a11 (mol) http://purl.obolibrary.org/obo/TXPO_0001047 Elovl6 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000125 ELOVL6 (mol) http://purl.obolibrary.org/obo/TXPO_0001048 Hsdl2 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000198 Hsdl2 (mol) http://purl.obolibrary.org/obo/TXPO_0001051 Mgll (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000245 Mgll (mol) http://purl.obolibrary.org/obo/TXPO_0001053 Cyp4a3 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000108 Cyp4a3 (mol) http://purl.obolibrary.org/obo/TXPO_0001060 Acox1 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000027 Acox1 (mol) http://purl.obolibrary.org/obo/TXPO_0001061 Ehhadh (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000131 Ehhadh (mol) http://purl.obolibrary.org/obo/TXPO_0001064 Cpt2 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000098 Cpt2 (mol) http://purl.obolibrary.org/obo/TXPO_0001066 Slc25a20 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000360 Slc25a20 (mol) http://purl.obolibrary.org/obo/TXPO_0001067 Acot12 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000021 Acot12 (mol) http://purl.obolibrary.org/obo/TXPO_0001068 Acot7 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000025 Acot7 (mol) http://purl.obolibrary.org/obo/TXPO_0001070 Hadhb (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000193 Hadhb (mol) http://purl.obolibrary.org/obo/TXPO_0001074 Acaa1a (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000017 Acaa1a (mol) http://purl.obolibrary.org/obo/TXPO_0001081 Cyp4a1 (rat)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000107 Cyp4a1 (mol) http://purl.obolibrary.org/obo/TXPO_0001226 Acaa1a (rat)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000017 Acaa1a (mol) http://purl.obolibrary.org/obo/TXPO_0001405 Dgat1 (rat)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001423 DGAT1 (mol) http://purl.obolibrary.org/obo/TXPO_0001091 ADH1B (human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001092 ADH1B (mol) http://purl.obolibrary.org/obo/TXPO_0001093 BID (human)[Lipidosis] http://purl.obolibrary.org/obo/IMR_0100289 Bid (mol) http://purl.obolibrary.org/obo/TXPO_0001103 USF2 (human)[Lipidosis] http://purl.obolibrary.org/obo/TXPO_1000396 USF2 (mol) http://purl.obolibrary.org/obo/TXPO_0001774 ALAS1 (human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000034 Alas1 (mol) http://purl.obolibrary.org/obo/TXPO_0004007 ADH1B(predicted)(human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001786 lipidosis marker gene http://purl.obolibrary.org/obo/TXPO_0001092 ADH1B (mol) http://purl.obolibrary.org/obo/TXPO_0001094 ADH family http://purl.obolibrary.org/obo/TXPO_0004011 ADH1 (mol) http://purl.obolibrary.org/obo/TXPO_0001094 ADH family http://purl.obolibrary.org/obo/TXPO_0004012 Adh1 (mouse)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001094 ADH family http://purl.obolibrary.org/obo/TXPO_0001099 OXTR (human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001786 lipidosis marker gene http://purl.obolibrary.org/obo/TXPO_0001252 Elovl6 (mouse)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000125 ELOVL6 (mol) http://purl.obolibrary.org/obo/TXPO_0004003 Alas1 (mouse) [Lipidosis] http://purl.obolibrary.org/obo/TXPO_1000034 Alas1 (mol) http://purl.obolibrary.org/obo/TXPO_0001102 CMPK2 (human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001786 lipidosis marker gene http://purl.obolibrary.org/obo/TXPO_0001108 USF1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001110 USF1 (mol) http://purl.obolibrary.org/obo/TXPO_0001111 USF (mol) http://purl.obolibrary.org/obo/TXPO_1000396 USF2 (mol) http://purl.obolibrary.org/obo/TXPO_0001111 USF (mol) http://purl.obolibrary.org/obo/TXPO_0001119 LXRA (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0001385 inositol phosphate http://purl.obolibrary.org/obo/TXPO_0001122 organophosphate http://purl.obolibrary.org/obo/TXPO_0001123 CHREBP (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001158 Gadd45a (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000174 Gadd45a (mol) http://purl.obolibrary.org/obo/TXPO_0001159 Cyp2b1 (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000101 Cyp2b1 (mol) http://purl.obolibrary.org/obo/TXPO_0001171 Etnk2 (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000136 Etnk2 (mol) http://purl.obolibrary.org/obo/TXPO_0001173 Cyp2c6v1 (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000103 Cyp2c6v1 (mol) http://purl.obolibrary.org/obo/TXPO_0001175 Faah (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000152 Faah (mol) http://purl.obolibrary.org/obo/TXPO_0001176 Lpgat1 (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000231 Lpgat1 (mol) http://purl.obolibrary.org/obo/TXPO_0001452 Bhmt (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000046 Bhmt (mol) http://purl.obolibrary.org/obo/TXPO_0001136 SLC44A2 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000344 SLC44A2 (mol) http://purl.obolibrary.org/obo/TXPO_0001138 PLB1 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000284 PLB1 (mol) http://purl.obolibrary.org/obo/TXPO_0001140 FGF18 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000142 FGF18 (mol) http://purl.obolibrary.org/obo/TXPO_0001142 PLA2G5 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000283 PLA2G5 (mol) http://purl.obolibrary.org/obo/TXPO_0001143 IL2RB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000202 IL2RB (mol) http://purl.obolibrary.org/obo/TXPO_0001549 CYP2C19 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000079 CYP2C19 (mol) http://purl.obolibrary.org/obo/TXPO_0001563 CYP2B6 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000078 CYP2B6 (mol) http://purl.obolibrary.org/obo/TXPO_0001568 CYP2D6 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000080 CYP2D6 (mol) http://purl.obolibrary.org/obo/TXPO_0001789 SPON2(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003834 SPON2 (mol) http://purl.obolibrary.org/obo/TXPO_0001859 CYP4A11(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003836 CYP4A11 (mol) http://purl.obolibrary.org/obo/TXPO_0001903 RSAD2(predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003835 RSAD2 (mol) http://purl.obolibrary.org/obo/TXPO_0002579 FNIP2 (predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003837 FNIP2 (mol) http://purl.obolibrary.org/obo/TXPO_0002668 phospholipidosis dependent molecule (HepG2_24h_sawada) http://purl.obolibrary.org/obo/TXPO_0001135 phospholipidosis dependent molecule (human in vitro) http://purl.obolibrary.org/obo/TXPO_0003280 ANG (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001517 Ang (mol) http://purl.obolibrary.org/obo/TXPO_0003558 HMOX1 (predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000196 Hmox1 (mol) http://purl.obolibrary.org/obo/TXPO_0003559 PKIB (predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003838 PKIB (mol) http://purl.obolibrary.org/obo/TXPO_0003560 KCNMA1 (predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003839 KCNMA1 (mol) http://purl.obolibrary.org/obo/TXPO_0003573 ASPA (predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003840 ASPA (mol) http://purl.obolibrary.org/obo/TXPO_0003574 DAB2 (predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003841 DAB2 (mol) http://purl.obolibrary.org/obo/TXPO_0003582 CYP4A11(predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003836 CYP4A11 (mol) http://purl.obolibrary.org/obo/TXPO_0003586 NCR3LG1 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003842 NCR3LG1 (mol) http://purl.obolibrary.org/obo/TXPO_0003788 CTSB (predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003843 CTSB (mol) http://purl.obolibrary.org/obo/TXPO_0003893 TGFB1(human)[Phospholipidosis] http://purl.obolibrary.org/obo/IMR_0000042 TGF-beta1 http://purl.obolibrary.org/obo/TXPO_0003894 FNIP2(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003837 FNIP2 (mol) http://purl.obolibrary.org/obo/TXPO_0003900 DAB2(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003841 DAB2 (mol) http://purl.obolibrary.org/obo/TXPO_0003941 CTSB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003843 CTSB (mol) http://purl.obolibrary.org/obo/TXPO_0004050 HMGCS2 (predicted)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000189 HMGCS2 (mol) http://purl.obolibrary.org/obo/TXPO_0004052 HMGCS2(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000189 HMGCS2 (mol) http://purl.obolibrary.org/obo/TXPO_0004070 Hmox1 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000196 Hmox1 (mol) http://purl.obolibrary.org/obo/TXPO_0004086 ITGB3(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003817 ITGB3 (mol) http://purl.obolibrary.org/obo/TXPO_0004087 KCNMA1(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003839 KCNMA1 (mol) http://purl.obolibrary.org/obo/TXPO_0004095 MMAA (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003833 MMAA (mol) http://purl.obolibrary.org/obo/TXPO_0004105 NCR3LG1 (predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003842 NCR3LG1 (mol) http://purl.obolibrary.org/obo/TXPO_0004106 PKIB(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003838 PKIB (mol) http://purl.obolibrary.org/obo/TXPO_0004112 SPON2(predicted)(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003834 SPON2 (mol) http://purl.obolibrary.org/obo/TXPO_0004118 SULT1C2(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003832 SULT1C2 (mol) http://purl.obolibrary.org/obo/TXPO_0004149 ASPA(human) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003840 ASPA (mol) http://purl.obolibrary.org/obo/TXPO_0002290 PLA2G5 - anntiinflammation factor (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001142 PLA2G5 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002267 IL2RB - apotosis inhibitor (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001143 IL2RB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002268 IL2RB - cell cycle progression promoting factor (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001143 IL2RB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003408 IL2RB (human)[Phospholipidosis - inflammation] http://purl.obolibrary.org/obo/TXPO_0001143 IL2RB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001222 hydoroxy acid http://purl.obolibrary.org/obo/TXPO_0001144 carboxylic acid http://purl.obolibrary.org/obo/TXPO_0003166 CASPASE 3 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002045 glutathione depletion dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003205 CASPASE-3 (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_0003195 cell death dependent dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003273 CASPASE-3 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0000868 Acot5 (mol) http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/TXPO_0003252 ATM (mol) http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/TXPO_1000021 Acot12 (mol) http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/TXPO_1000022 Acot2 (mol) http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/TXPO_1000023 Acot3 (mol) http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/TXPO_1000024 Acot4 (mol) http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/TXPO_1000025 Acot7 (mol) http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/TXPO_1000026 Acot8 (mol) http://purl.obolibrary.org/obo/TXPO_0001146 ACOT family http://purl.obolibrary.org/obo/TXPO_1000019 Acer2 (mol) http://purl.obolibrary.org/obo/TXPO_0001148 ACER http://purl.obolibrary.org/obo/TXPO_1000020 Acer3 (mol) http://purl.obolibrary.org/obo/TXPO_0001148 ACER http://purl.obolibrary.org/obo/TXPO_0003261 Sgpl1 - lipid metabolism regulator (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001151 Sgpl1 (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001166 arachidonic acid http://purl.obolibrary.org/obo/TXPO_0001152 unsaturated fatty acid http://purl.obolibrary.org/obo/TXPO_0002249 Gadd45a - cell cycle arrest factor (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001158 Gadd45a (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002251 Gadd45a - fibrosis inhibitor (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001158 Gadd45a (rat)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001238 citric acid http://purl.obolibrary.org/obo/TXPO_0001222 hydoroxy acid http://purl.obolibrary.org/obo/TXPO_0001239 lactic acid http://purl.obolibrary.org/obo/TXPO_0001222 hydoroxy acid http://purl.obolibrary.org/obo/TXPO_0000829 P-EIF2A (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001275 EIF2A (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002932 EIF2A - translation initiation factor (canonical)[ER stress - translation] http://purl.obolibrary.org/obo/TXPO_0001275 EIF2A (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003588 EIF2A - cell cycle arresr inducer (canonical)[ER stress - translation] http://purl.obolibrary.org/obo/TXPO_0001275 EIF2A (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001050 CPT1 (canonical)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_1000097 Cpt1 (mol) http://purl.obolibrary.org/obo/TXPO_1000284 PLB1 (mol) http://purl.obolibrary.org/obo/TXPO_0001303 PLB http://purl.obolibrary.org/obo/TXPO_0001319 CD36 [lipidosis] http://purl.obolibrary.org/obo/TXPO_0001312 CD36 (mol) http://purl.obolibrary.org/obo/TXPO_0001498 CD36 -translocator role [lipidosis] http://purl.obolibrary.org/obo/TXPO_0001319 CD36 [lipidosis] http://purl.obolibrary.org/obo/TXPO_0003409 PPARA - glucose metabolism regulator (canonical)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001328 PPARA (canonical)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0004006 PPARA lipid metabolism regulator (canonical)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0001328 PPARA (canonical)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/IMR_0000045 GDNF http://purl.obolibrary.org/obo/TXPO_0001382 growth factor family http://purl.obolibrary.org/obo/IMR_0000031 VEGF (mol) http://purl.obolibrary.org/obo/TXPO_0001382 growth factor family http://purl.obolibrary.org/obo/IMR_0000047 EGF family http://purl.obolibrary.org/obo/TXPO_0001382 growth factor family http://purl.obolibrary.org/obo/IMR_0000049 FGF http://purl.obolibrary.org/obo/TXPO_0001382 growth factor family http://purl.obolibrary.org/obo/TXPO_0001967 carnitine palmitoyltransferase http://purl.obolibrary.org/obo/TXPO_0001385 acyltransferase http://purl.obolibrary.org/obo/TXPO_0001423 DGAT1 (mol) http://purl.obolibrary.org/obo/TXPO_0001417 DGAT(mol) http://purl.obolibrary.org/obo/TXPO_1000113 DGAT2 (mol) http://purl.obolibrary.org/obo/TXPO_0001417 DGAT(mol) http://purl.obolibrary.org/obo/TXPO_0001394 FATTY Acid Synthase (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001428 ABCA1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003469 SMPD1 (canonical)[Niemann Pick Disease Type A -B] http://purl.obolibrary.org/obo/TXPO_0001464 SMPD1 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002615 ABCG5 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001506 ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002616 ABCG8 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_1000000 ABCG8 (mol) http://purl.obolibrary.org/obo/TXPO_0002631 ABCB4 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001506 ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002634 MRP2 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001506 ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002635 ABCG2 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001506 ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002636 MDR1 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001506 ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002640 MRP3 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0001506 ATP-BINDING cassette (ABC) transporter superfamily (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002642 MRP4 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003019 ABCC4 (mol) http://purl.obolibrary.org/obo/TXPO_0001120 LXRa (mol) http://purl.obolibrary.org/obo/TXPO_0001509 nuclear receptor family http://purl.obolibrary.org/obo/TXPO_0003862 CAR (mol) http://purl.obolibrary.org/obo/TXPO_0001509 nuclear receptor family http://purl.obolibrary.org/obo/IMR_0000088 Estrogen receptor http://purl.obolibrary.org/obo/TXPO_0001509 nuclear receptor family http://purl.obolibrary.org/obo/IMR_0000090 RAR http://purl.obolibrary.org/obo/TXPO_0001509 nuclear receptor family http://purl.obolibrary.org/obo/TXPO_0002244 Ang (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003278 phospholipidosis dependent molecule (mouse) http://purl.obolibrary.org/obo/TXPO_0000976 phenobarbital - apotosis inhibitor [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001524 phenobarbital [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001767 phenobarbital - tumor promoting factor [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001524 phenobarbital [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003906 phenobarbital -EGFR signalling inhibitor [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001524 phenobarbital [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003922 phenobarbital - gluconeogenic inhibitor [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001524 phenobarbital [Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001514 continuousness (attribute) http://purl.obolibrary.org/obo/TXPO_0001536 time attribute http://purl.obolibrary.org/obo/TXPO_0003633 Cyp1A2 (mol) http://purl.obolibrary.org/obo/TXPO_0001552 Cyp1 http://purl.obolibrary.org/obo/TXPO_1000100 Cyp1A1 (mol) http://purl.obolibrary.org/obo/TXPO_0001552 Cyp1 http://purl.obolibrary.org/obo/TXPO_0001791 CYP2C8 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000078 CYP2B6 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000079 CYP2C19 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000080 CYP2D6 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000081 CYP2E1 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000101 Cyp2b1 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000102 Cyp2b10 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000103 Cyp2c6v1 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000104 Cyp2d3 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000105 Cyp2d4 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_0005076 CYP2A13 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_0005077 CYP2A6 (mol) http://purl.obolibrary.org/obo/TXPO_0001553 Cyp2 http://purl.obolibrary.org/obo/TXPO_1000082 CYP3A4 (mol) http://purl.obolibrary.org/obo/TXPO_0001554 Cyp3 http://purl.obolibrary.org/obo/TXPO_1000083 CYP3A5 (mol) http://purl.obolibrary.org/obo/TXPO_0001554 Cyp3 http://purl.obolibrary.org/obo/TXPO_1000106 Cyp3a11 (mol) http://purl.obolibrary.org/obo/TXPO_0001554 Cyp3 http://purl.obolibrary.org/obo/TXPO_0005078 CYP3A7 (mol) http://purl.obolibrary.org/obo/TXPO_0001554 Cyp3 http://purl.obolibrary.org/obo/TXPO_1000084 CYP4X1 (mol) http://purl.obolibrary.org/obo/TXPO_0001555 Cyp4 http://purl.obolibrary.org/obo/TXPO_1000107 Cyp4a1 (mol) http://purl.obolibrary.org/obo/TXPO_0001555 Cyp4 http://purl.obolibrary.org/obo/TXPO_1000108 Cyp4a3 (mol) http://purl.obolibrary.org/obo/TXPO_0001555 Cyp4 http://purl.obolibrary.org/obo/TXPO_1000109 Cyp4f4 (mol) http://purl.obolibrary.org/obo/TXPO_0001555 Cyp4 http://purl.obolibrary.org/obo/TXPO_0001573 ethanoleamine http://purl.obolibrary.org/obo/TXPO_0001572 ethanoleamines http://purl.obolibrary.org/obo/TXPO_0003022 PPARA - inactivated (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001632 PPAR alpha (canonical) [lipidosis] http://purl.obolibrary.org/obo/TXPO_0001711 AMPK - inactivation state (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001652 AMPK (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001808 CYP2C8 (human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001791 CYP2C8 (mol) http://purl.obolibrary.org/obo/TXPO_0001888 CYP3A4 (human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000082 CYP3A4 (mol) http://purl.obolibrary.org/obo/TXPO_0003915 ALAS1(predicted)(human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000034 Alas1 (mol) http://purl.obolibrary.org/obo/TXPO_0004114 SPON2(human) - tumor metastasis inhibitor[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001789 SPON2(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004116 SPON2(human) - immune responsor[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001789 SPON2(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003927 GLUCOSE-6- phosphatase - gluconeogenic (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0001797 G6PC (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003424 EGFR (canonical)[Phospholipidosis - cell proliferation factor] http://purl.obolibrary.org/obo/TXPO_0001798 EGFR (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003425 EGFR (canonical)[Phospholipidosis - tumor cell proliferation factor] http://purl.obolibrary.org/obo/TXPO_0001798 EGFR (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002280 AKT - apotosis inhibitor (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001799 AKT (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003229 AKT - cell proliferation promoting factor (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001799 AKT (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003417 AKT - tumor cell proliferation promoting factor (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001799 AKT (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003419 PI3K - cell proliferation promoting factor (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001800 PI3K (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003420 PI3K - tumor cell proliferation promoting factor (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001800 PI3K (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003571 PLA2positively regulator of immune response (canonical) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0002927 JNK - kinase (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0001813 JNK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002928 JNK - kinase (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0001813 JNK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002929 JNK - signalling factor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0001813 JNK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002930 JNK - signalling factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0001813 JNK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002625 PERK - signal sensor (canonical)[ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0001841 PERK - signal sensor (canonical)[Perk signalling system] http://purl.obolibrary.org/obo/TXPO_0002730 PERK - signal sensor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0001841 PERK - signal sensor (canonical)[Perk signalling system] http://purl.obolibrary.org/obo/TXPO_0002848 PERK - signal sensor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0001841 PERK - signal sensor (canonical)[Perk signalling system] http://purl.obolibrary.org/obo/TXPO_0002993 PERK - signal sensor (canonical)[ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0001841 PERK - signal sensor (canonical)[Perk signalling system] http://purl.obolibrary.org/obo/TXPO_0002994 PERK - signal sensor (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0001841 PERK - signal sensor (canonical)[Perk signalling system] http://purl.obolibrary.org/obo/TXPO_0002119 PERK - signaling factor (canonical)[Perk-eIF2a signalling system] http://purl.obolibrary.org/obo/TXPO_0001852 PERK - signaling factor (canonical)[Perk signalling system] http://purl.obolibrary.org/obo/TXPO_0002553 CYP4A11 - tumor progression marker (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001859 CYP4A11(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003881 CYP4A11 - arachidonic acid metabolic factor (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001859 CYP4A11(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0001876 NLRP3 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001886 PYCARD (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0001891 CYP3A4 -inactitication state (human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001888 CYP3A4 (human)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0002558 ATF4 - transcriptional regulator (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0001907 ATF4 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002559 ATF4 - transcriptional regulator (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0001907 ATF4 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002560 ATF4 - transcriptional regulator (canonical)[ER stress - insulin resistance] http://purl.obolibrary.org/obo/TXPO_0001907 ATF4 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002965 ATF4 - transcriptional regulator (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0001907 ATF4 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002969 ATF4 - transcriptional regulator (canonical)[ER stress - glucose metabolism disorder] http://purl.obolibrary.org/obo/TXPO_0001907 ATF4 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002970 ATF4 - transcriptional regulator (canonical)[ER stress - dyslipidemia] http://purl.obolibrary.org/obo/TXPO_0001907 ATF4 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003055 ATF4 - transcriptional regulator (canonical)[ER stress - translation] http://purl.obolibrary.org/obo/TXPO_0001907 ATF4 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001917 G6PD (predicted)(human)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000158 G6PD (mol) http://purl.obolibrary.org/obo/TXPO_0001918 BLHA15 (predicted)(human)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000045 Bhlha15 (mol) http://purl.obolibrary.org/obo/TXPO_0001919 HISTH1H2BG (predicted)(human)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000194 Hist1h2bcl1 (mol) http://purl.obolibrary.org/obo/TXPO_0001329 Hmox1 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000196 Hmox1 (mol) http://purl.obolibrary.org/obo/TXPO_0001928 Srxn1 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000365 Srxn1 (mol) http://purl.obolibrary.org/obo/TXPO_0001930 Txnrd1 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000389 Txnrd1 (mol) http://purl.obolibrary.org/obo/TXPO_0001934 Akr7a3 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000033 Akr7a3 (mol) http://purl.obolibrary.org/obo/TXPO_0001935 Osgin1 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000272 Osgin1 (mol) http://purl.obolibrary.org/obo/TXPO_0001936 Me1 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000244 Me1 (mol) http://purl.obolibrary.org/obo/TXPO_0001938 Aldh1a1 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000035 ALDH1A1 (mol) http://purl.obolibrary.org/obo/TXPO_0001940 Gsta3 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000179 GSTA3 (mol) http://purl.obolibrary.org/obo/TXPO_0001943 Gclc (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000163 GCLC [canonical] (mol) http://purl.obolibrary.org/obo/TXPO_0001945 Gadd45a (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000174 Gadd45a (mol) http://purl.obolibrary.org/obo/TXPO_0001949 Cyp2b1 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000101 Cyp2b1 (mol) http://purl.obolibrary.org/obo/TXPO_0001950 Pdk4 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000298 Pdk4 (mol) http://purl.obolibrary.org/obo/TXPO_0001952 Gpx2 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000178 Gpx2 (mol) http://purl.obolibrary.org/obo/TXPO_0001953 Trib3 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000378 TRIB3 (mol) http://purl.obolibrary.org/obo/TXPO_0001954 Gstm3 (rat)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000180 GSTM3 (mol) http://purl.obolibrary.org/obo/TXPO_0003034 HSP90B1 - chaperone (canonical)[ER stress -Refolding [persist]] http://purl.obolibrary.org/obo/TXPO_0001960 HSP90B1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0001974 CPT1 -inactivation state(canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0001961 CPT1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0002605 XBP1 - transcriptional regulator (canonical)[ER stress -ERAD] http://purl.obolibrary.org/obo/TXPO_0001968 XBP1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002923 XBP1 - transcriptional regulator (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0001968 XBP1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003050 XBP1 - transcriptional regulator (canonical)[ER stress - Refolding -ATF6 pathway] http://purl.obolibrary.org/obo/TXPO_0001968 XBP1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003066 XBP1 - transcriptional regulator (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0001968 XBP1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002011 perhexiline - fatty acid oxidation inhibitor [lipidosis] http://purl.obolibrary.org/obo/TXPO_0002013 perhexiline [lipidosis] http://purl.obolibrary.org/obo/TXPO_0002030 pergexiline -mitochondrial respiratory chain inhibitor [lipidosis] http://purl.obolibrary.org/obo/TXPO_0002013 perhexiline [lipidosis] http://purl.obolibrary.org/obo/TXPO_0002003 Acot1 (rat)[Uncoupling] http://purl.obolibrary.org/obo/TXPO_0002018 Acot1 (mol) http://purl.obolibrary.org/obo/TXPO_0002015 Ucp3 (rat)[Uncoupling] http://purl.obolibrary.org/obo/TXPO_1000393 UCP3 (mol) http://purl.obolibrary.org/obo/TXPO_0002016 Acot12 (rat)[Uncoupling] http://purl.obolibrary.org/obo/TXPO_1000021 Acot12 (mol) http://purl.obolibrary.org/obo/TXPO_0002022 Angptl4 (rat)[Uncoupling] http://purl.obolibrary.org/obo/TXPO_1000002 ANGPTL4 (mol) http://purl.obolibrary.org/obo/TXPO_0002036 ibuprofen - oxidative phosphorylation inhibitor [lipidosis] http://purl.obolibrary.org/obo/TXPO_0002035 ibuprofen [lipidosis] http://purl.obolibrary.org/obo/TXPO_0002043 nimesulide [lipidosis - oxidative phosphorylation inhibitor] http://purl.obolibrary.org/obo/TXPO_0002042 nimesulide [lipidosis] http://purl.obolibrary.org/obo/TXPO_0000850 NRF2 -inflammasone activator (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002392 NRF2 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002300 GCLM (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002331 glutamate-cysteine ligase modifier subunit http://purl.obolibrary.org/obo/TXPO_0002392 NRF2 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002527 NRF2 (mol) http://purl.obolibrary.org/obo/TXPO_0002493 MRP2 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002496 ABCC2 (mol) http://purl.obolibrary.org/obo/TXPO_0002512 ABCC1(canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002500 ABCC1 (mol) http://purl.obolibrary.org/obo/TXPO_0002787 ABCC4 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003019 ABCC4 (mol) http://purl.obolibrary.org/obo/TXPO_0002792 ABCC5 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003018 ABCC5 (mol) http://purl.obolibrary.org/obo/TXPO_0003165 GLUTATHIONE peroxidase (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000177 Glutathione peroxidase (mol) http://purl.obolibrary.org/obo/TXPO_0003167 NFKB (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000258 NfkB (mol) http://purl.obolibrary.org/obo/TXPO_0003170 CYP2E1 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000081 CYP2E1 (mol) http://purl.obolibrary.org/obo/TXPO_0003171 CYP3A4 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000082 CYP3A4 (mol) http://purl.obolibrary.org/obo/TXPO_0003172 IL-6 - inflammatory cytokine (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/IMR_0000010 IL-6 (mol) http://purl.obolibrary.org/obo/TXPO_0003190 BAX (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/IMR_0000453 BAX (mol) http://purl.obolibrary.org/obo/TXPO_0003191 IL-1B (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000200 IL-1b (mol) http://purl.obolibrary.org/obo/TXPO_0003194 TNF-A (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000374 TNF-a (mol) http://purl.obolibrary.org/obo/TXPO_0003805 CYP1A2(canonical) [Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003633 Cyp1A2 (mol) http://purl.obolibrary.org/obo/TXPO_0001947 GSTA1 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002032 GSTA2 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002067 GSTA4 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002093 GSTM1 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002104 GSTM2 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002120 GSTM4 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002121 GSTM5 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002127 GSTO1 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002151 GSTO2 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002179 GSTK1 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002180 GSTP1 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002181 GSTT1 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002185 GSTT2 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002186 GSTT2B (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002205 MGST1 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002206 MGST2 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0002208 MGST3 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_1000179 GSTA3 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_1000180 GSTM3 (mol) http://purl.obolibrary.org/obo/TXPO_0002089 glutathione transferase family http://purl.obolibrary.org/obo/TXPO_0003380 SGPL1 - apoptosis inducer (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002090 SGPL1(human) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003531 SGPL1 - tumor cell proliferation regulating factor (human) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002090 SGPL1(human) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002162 PERK - signaling factor (canonical)[ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0002119 PERK - signaling factor (canonical)[Perk-eIF2a signalling system] http://purl.obolibrary.org/obo/TXPO_0002728 PERK - signaling factor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0002119 PERK - signaling factor (canonical)[Perk-eIF2a signalling system] http://purl.obolibrary.org/obo/TXPO_0002729 PERK - signaling factor (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0002119 PERK - signaling factor (canonical)[Perk-eIF2a signalling system] http://purl.obolibrary.org/obo/TXPO_0002850 PERK - signaling factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002119 PERK - signaling factor (canonical)[Perk-eIF2a signalling system] http://purl.obolibrary.org/obo/TXPO_0003003 PERK - signaling factor (canonical)[ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0002119 PERK - signaling factor (canonical)[Perk-eIF2a signalling system] http://purl.obolibrary.org/obo/TXPO_0000801 DNAJB9 - chaperone -vitro (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002165 DNAJB9 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003471 DNAJB9 - apotosis repressor -vitro (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002165 DNAJB9 (human)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003671 phospholipase http://purl.obolibrary.org/obo/TXPO_0002283 lipase http://purl.obolibrary.org/obo/TXPO_0002291 Gstm3 (mouse)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000180 GSTM3 (mol) http://purl.obolibrary.org/obo/TXPO_0002453 Gclc (mouse)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000163 GCLC [canonical] (mol) http://purl.obolibrary.org/obo/TXPO_0003389 Cyp3a11 (mouse)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000106 Cyp3a11 (mol) http://purl.obolibrary.org/obo/TXPO_0003519 Bhlha15(mouse)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_1000045 Bhlha15 (mol) http://purl.obolibrary.org/obo/TXPO_0003426 IL2 (canonical)[Phospholipidosis - inflammatory cytokine] http://purl.obolibrary.org/obo/TXPO_0002288 IL2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003427 IL2 (canonical)[Phospholipidosis - apotosis inhibitor] http://purl.obolibrary.org/obo/TXPO_0002288 IL2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003428 IL2 (canonical)[Phospholipidosis - tumor cell proliferation promoting factor] http://purl.obolibrary.org/obo/TXPO_0002288 IL2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003429 IL2 (canonical)[Phospholipidosis - cell cycle progression promoting factor] http://purl.obolibrary.org/obo/TXPO_0002288 IL2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0002540 GRP78 - chaperone (canonical)[ER stress - refolding [early stage] http://purl.obolibrary.org/obo/TXPO_0002385 GRP78 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002619 GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [short-term]] http://purl.obolibrary.org/obo/TXPO_0002385 GRP78 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002621 GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [persist] -IRE1 pathway] http://purl.obolibrary.org/obo/TXPO_0002385 GRP78 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002622 GRP78 - stress sensor inhibitor (canonical)[ER stress - proteinrefolding [persist] -ATF6 pathway] http://purl.obolibrary.org/obo/TXPO_0002385 GRP78 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002677 GRP78 - chaperone (canonical)[ER stress - proteinrefolding (sustained)] http://purl.obolibrary.org/obo/TXPO_0002385 GRP78 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003489 GRP78 - apotosis repressor (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002385 GRP78 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003550 GRP78 - tumor cell enhanced survlival factor (canonical)[ER stress - tumor survival] http://purl.obolibrary.org/obo/TXPO_0002385 GRP78 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000855 NRF2 -antioxidant (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0002392 NRF2 (canonical)[Glutathione depletion] http://purl.obolibrary.org/obo/TXPO_0003049 GRP94 - chaperone (canonical)[proteinrefolding [persist]] http://purl.obolibrary.org/obo/TXPO_0002410 GRP94 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003734 GRP94 - tumor cell enhanced survlival factor (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002410 GRP94 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002899 ATF6 - transcriptional factor (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0002468 ATF6F (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002913 ATF6 - transcriptional factor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0002468 ATF6F (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003046 ATF6 - transcriptional factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002468 ATF6F (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003477 NRF2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003213 phospholipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0002602 IRE1 - signal sensor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0002601 IRE1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002603 IRE1 - signaling factor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0002601 IRE1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002978 IRE1 - autophosphorylation kinase (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0002601 IRE1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002979 IRE1 - autophosphorylation kinase (canonical)[ER stress -ERAD] http://purl.obolibrary.org/obo/TXPO_0002601 IRE1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003088 IRE1 - autophosphorylation kinase (canonical)[ER stress -RIDD] http://purl.obolibrary.org/obo/TXPO_0002601 IRE1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0000824 IRE - stress sensor (canonical)[ER stress -Refolding] http://purl.obolibrary.org/obo/TXPO_0002602 IRE1 - signal sensor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0000875 IRE - stress sensor (canonical)[ER stress -ERAD] http://purl.obolibrary.org/obo/TXPO_0002602 IRE1 - signal sensor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0000906 IRE - stress sensor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0002602 IRE1 - signal sensor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0002886 IRE - stress sensor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002602 IRE1 - signal sensor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0002890 IRE1 - signal sensor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002602 IRE1 - signal sensor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0002891 IRE1 - signaling factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002603 IRE1 - signaling factor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0002892 IRE1 - signaling factor (canonical)[ER stress -ERAD] http://purl.obolibrary.org/obo/TXPO_0002603 IRE1 - signaling factor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0002941 IRE1 - signaling factor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0002603 IRE1 - signaling factor (canonical)[IRE1 signalling system] http://purl.obolibrary.org/obo/TXPO_0002386 OCT1 (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0002647 OCT family (canonical)[Cholestasis] http://purl.obolibrary.org/obo/TXPO_0003320 FNDC4 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000150 FNDC4 (mol) http://purl.obolibrary.org/obo/TXPO_0003322 SMPDL3A (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000348 SMPDL3A (mol) http://purl.obolibrary.org/obo/TXPO_0003323 GDPD1 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000165 GDPD1 (mol) http://purl.obolibrary.org/obo/TXPO_0003330 LSS (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000228 LSS (mol) http://purl.obolibrary.org/obo/TXPO_0003334 TAGLN (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000369 TAGLN (mol) http://purl.obolibrary.org/obo/TXPO_0003335 SLC2A3 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000342 SLC2A3 (mol) http://purl.obolibrary.org/obo/TXPO_0002496 ABCC2 (mol) http://purl.obolibrary.org/obo/TXPO_0002694 ABC transporter http://purl.obolibrary.org/obo/TXPO_0002500 ABCC1 (mol) http://purl.obolibrary.org/obo/TXPO_0002694 ABC transporter http://purl.obolibrary.org/obo/TXPO_0003018 ABCC5 (mol) http://purl.obolibrary.org/obo/TXPO_0002694 ABC transporter http://purl.obolibrary.org/obo/TXPO_0003019 ABCC4 (mol) http://purl.obolibrary.org/obo/TXPO_0002694 ABC transporter http://purl.obolibrary.org/obo/TXPO_1000000 ABCG8 (mol) http://purl.obolibrary.org/obo/TXPO_0002694 ABC transporter http://purl.obolibrary.org/obo/TXPO_0002700 EDEM -ERAD promoting factor (canonical)[ER stress -ERAD] http://purl.obolibrary.org/obo/TXPO_0002699 EDEM (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002768 NFKB - transcriptional regulator (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002769 NFKB (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002801 I-kappaB -NfkB inhibitor [ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002802 IKB http://purl.obolibrary.org/obo/TXPO_0002819 TRAF2 -IRE1 adaptor protein (canonical)[ER stress - inflammation -IRE1-NfkB] http://purl.obolibrary.org/obo/TXPO_0002818 TRAF2 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002822 TRAF2 -IRE1 adaptor protein (canonical)[ER stress - inflammation -IRE1-JNK] http://purl.obolibrary.org/obo/TXPO_0002818 TRAF2 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002938 TRAF2 -IRE1 adaptor protein (canonical)[ER stress - apotosis -IRE1-JNK] http://purl.obolibrary.org/obo/TXPO_0002818 TRAF2 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002881 PERK dimer (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0002880 PERK dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002882 PERK dimer (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002880 PERK dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002883 PERK dimer (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0002880 PERK dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002884 PERK dimer (canonical)[ER stress - translation attenuation] http://purl.obolibrary.org/obo/TXPO_0002880 PERK dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003005 PERK dimer (canonical)[ER stress - cell cycle arrest] http://purl.obolibrary.org/obo/TXPO_0002880 PERK dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002893 IRE1 - signaling factor (canonical)[ER stress - inflammation -Xbp1] http://purl.obolibrary.org/obo/TXPO_0002891 IRE1 - signaling factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002894 IRE1 - signaling factor (canonical)[ER stress - inflammation -TRAF2] http://purl.obolibrary.org/obo/TXPO_0002891 IRE1 - signaling factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002898 CALRETICULIN - chaperone (canonical)[ER stress -Refolding [persist]] http://purl.obolibrary.org/obo/TXPO_0002897 CALRETICULIN (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002915 CHOP - apotosis inducing factor (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0002914 CHOP (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002920 HYOU1 - chaperone (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0002921 HYOU1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002935 GADD34 - phosphatase (canonical)[ER stress - translation] http://purl.obolibrary.org/obo/TXPO_0002934 GADD34 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002943 ASK - signaling factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0002942 ASK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002944 ASK - signaling factor (canonical)[ER stress - inflammation -TRAF2] http://purl.obolibrary.org/obo/TXPO_0002942 ASK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002945 ASK - signaling factor (canonical)[ER stress - apotosis -TRAF2] http://purl.obolibrary.org/obo/TXPO_0002942 ASK (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002954 BIM (canonical)[ER stress - apotosis] http://purl.obolibrary.org/obo/TXPO_0002955 BIM (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002973 IRE1 dimer (canonical)[ER stress - Refolding] http://purl.obolibrary.org/obo/TXPO_0002972 IRE1 dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0002974 IRE1 dimer (canonical)[ER stress -ERAD] http://purl.obolibrary.org/obo/TXPO_0002972 IRE1 dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003090 IRE1 dimer (canonical)[ER stress -RIDD] http://purl.obolibrary.org/obo/TXPO_0002972 IRE1 dimer (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003010 ritonavir [ER stress] http://purl.obolibrary.org/obo/TXPO_1000327 ritonavir http://purl.obolibrary.org/obo/TXPO_0003028 STF-083010 [ER stress] http://purl.obolibrary.org/obo/TXPO_1000354 STF-083010 http://purl.obolibrary.org/obo/TXPO_0003029 GSK2606414 [ER stress] http://purl.obolibrary.org/obo/TXPO_1000172 GSK2606414 http://purl.obolibrary.org/obo/TXPO_0003038 IL-6 - inflammatory cytokine (canonical)[ER stress - inflammation -ATF4 pathway] http://purl.obolibrary.org/obo/TXPO_0003037 IL-6 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003067 IL-6 - inflammatory cytokine (canonical)[ER stress - inflammation -XBP1 pathway] http://purl.obolibrary.org/obo/TXPO_0003037 IL-6 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003040 NLRP1 - inflammatory substance (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003039 NLRP1 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003047 ATF6 -APR transcriptional factor (canonical)[ER stress - inflammation -APR] http://purl.obolibrary.org/obo/TXPO_0003046 ATF6 - transcriptional factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003053 DNAJC3 -cochaperone (canonical)[ER stress -Refolding [persist]] http://purl.obolibrary.org/obo/TXPO_0003052 DNAJC3 (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003070 CRP - inflammatory substance (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003069 CRP (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003083 CREBPH - signaling factor (canonical)[ER stress - inflammation] http://purl.obolibrary.org/obo/TXPO_0003082 CRBPH (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003085 CREBPH -APR transcriptional factor (canonical)[ER stress - inflammation -APR] http://purl.obolibrary.org/obo/TXPO_0003082 CRBPH (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003087 SAP - inflammatory factor (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003086 SAP (canonical)[ER stress] http://purl.obolibrary.org/obo/TXPO_0003265 FXR (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0000177 beta-catenin http://purl.obolibrary.org/obo/TXPO_0003158 catenin http://purl.obolibrary.org/obo/TXPO_0003196 APAF1 (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_1000005 APAF1 (mol) http://purl.obolibrary.org/obo/TXPO_0003198 BAK1 (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_1000040 BAK1 (mol) http://purl.obolibrary.org/obo/TXPO_0003199 BID (canonical)[apotosis] http://purl.obolibrary.org/obo/IMR_0100289 Bid (mol) http://purl.obolibrary.org/obo/TXPO_0003200 FAS (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_1000139 FAS (mol) http://purl.obolibrary.org/obo/TXPO_0003201 TNF (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_1000374 TNF-a (mol) http://purl.obolibrary.org/obo/TXPO_0003204 CASP8 (canonical)[apotosis] http://purl.obolibrary.org/obo/TXPO_1000058 CASP8 (mol) http://purl.obolibrary.org/obo/TXPO_0003236 BAX (canonical)[cell death] http://purl.obolibrary.org/obo/IMR_0000453 BAX (mol) http://purl.obolibrary.org/obo/TXPO_0003828 IL-1B (canonical)[pyroptosis] http://purl.obolibrary.org/obo/TXPO_1000200 IL-1b (mol) http://purl.obolibrary.org/obo/TXPO_0000775 PLA2G15 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000281 PLA2G15 (mol) http://purl.obolibrary.org/obo/TXPO_0001464 SMPD1 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000347 SMPD1 (mol) http://purl.obolibrary.org/obo/TXPO_0001800 PI3K (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003223 PI3K (mol) http://purl.obolibrary.org/obo/TXPO_0001804 PLA2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/TXPO_0001806 M6PR (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000240 M6PR (mol) http://purl.obolibrary.org/obo/TXPO_0002288 IL2 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000201 IL2 (mol) http://purl.obolibrary.org/obo/TXPO_0002408 PLA2G5 (human)(canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000283 PLA2G5 (mol) http://purl.obolibrary.org/obo/TXPO_0003347 FABP5 (canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000153 Fabp5 (mol) http://purl.obolibrary.org/obo/TXPO_0003556 PLA2G2A(mol) http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/TXPO_0003892 TGFB1(canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/IMR_0000042 TGF-beta1 http://purl.obolibrary.org/obo/TXPO_0004019 FLCN(canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_1000148 FLCN (mol) http://purl.obolibrary.org/obo/TXPO_0004026 MTOR (canonical) [phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004020 MTOR (mol) http://purl.obolibrary.org/obo/TXPO_0004090 insulin(canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/IMR_0000052 insulin http://purl.obolibrary.org/obo/TXPO_0001652 AMPK (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/IMR_0002778 AMPK gamma subunit http://purl.obolibrary.org/obo/TXPO_0003221 AMPK (mol) http://purl.obolibrary.org/obo/IMR_0000267 PI3-kinase p110 subunit http://purl.obolibrary.org/obo/TXPO_0003223 PI3K (mol) http://purl.obolibrary.org/obo/TXPO_0002398 CDK5R1(mol) http://purl.obolibrary.org/obo/TXPO_0003241 CDK (family) http://purl.obolibrary.org/obo/TXPO_0003239 Cdk1 (mol) http://purl.obolibrary.org/obo/TXPO_0003241 CDK (family) http://purl.obolibrary.org/obo/TXPO_0003240 Cdk4 (mol) http://purl.obolibrary.org/obo/TXPO_0003241 CDK (family) http://purl.obolibrary.org/obo/IMR_0100597 Cdc2 (mol) http://purl.obolibrary.org/obo/TXPO_0003241 CDK (family) http://purl.obolibrary.org/obo/IMR_0100598 CDK2 (mol) http://purl.obolibrary.org/obo/TXPO_0003241 CDK (family) http://purl.obolibrary.org/obo/IMR_0100599 CDK3(mol) http://purl.obolibrary.org/obo/TXPO_0003241 CDK (family) http://purl.obolibrary.org/obo/TXPO_0003244 Ppara - cell cycle regulator (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0003243 Ppara (mouse)[Eosinophilic granular degeneration] http://purl.obolibrary.org/obo/TXPO_0003266 FXR -inactivated state (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003265 FXR (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003895 Tgfb1(mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/IMR_0000042 TGF-beta1 http://purl.obolibrary.org/obo/TXPO_0003897 Tgfb1(mouse)[Phospholipidosis - apotosis inhibitor] http://purl.obolibrary.org/obo/IMR_0000042 TGF-beta1 http://purl.obolibrary.org/obo/TXPO_0003916 DAB2(mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003841 DAB2 (mol) http://purl.obolibrary.org/obo/TXPO_0003996 Ctsb (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003843 CTSB (mol) http://purl.obolibrary.org/obo/TXPO_0004018 Fnip2(mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003837 FNIP2 (mol) http://purl.obolibrary.org/obo/TXPO_0004092 Kcnma1(mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003839 KCNMA1 (mol) http://purl.obolibrary.org/obo/TXPO_0004108 Rsad2(mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003835 RSAD2 (mol) http://purl.obolibrary.org/obo/TXPO_0003283 NPC1 (canonical)[Niemann Pick Type C] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003285 NPC2 (canonical)[Niemann-Pick Type C] http://purl.obolibrary.org/obo/TXPO_0003516 lipidosis dependent molecule (canonical) http://purl.obolibrary.org/obo/TXPO_0003470 SMPD1 (canonical)[Niemann Pick Disease Type A] http://purl.obolibrary.org/obo/TXPO_0003469 SMPD1 (canonical)[Niemann Pick Disease Type A -B] http://purl.obolibrary.org/obo/TXPO_0003472 SMPD1 (canonical)[Niemann Pick Disease Type B] http://purl.obolibrary.org/obo/TXPO_0003469 SMPD1 (canonical)[Niemann Pick Disease Type A -B] http://purl.obolibrary.org/obo/TXPO_0003748 CCL4 [NASH] http://purl.obolibrary.org/obo/TXPO_0003509 CCL4 [Lipidosis] http://purl.obolibrary.org/obo/TXPO_0001109 insulin(canonical)[lipidosis] http://purl.obolibrary.org/obo/IMR_0000052 insulin http://purl.obolibrary.org/obo/TXPO_0001401 ACC1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_0003970 ACC (mol) http://purl.obolibrary.org/obo/TXPO_0001875 IL-1B (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000200 IL-1b (mol) http://purl.obolibrary.org/obo/TXPO_0001884 FGF21 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000145 FGF21 (mol) http://purl.obolibrary.org/obo/TXPO_0001901 TNF alpha (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000374 TNF-a (mol) http://purl.obolibrary.org/obo/TXPO_0001961 CPT1 (canonical)[lipidosis] http://purl.obolibrary.org/obo/TXPO_1000097 Cpt1 (mol) http://purl.obolibrary.org/obo/TXPO_0003738 AP1M2 (canonical)[Lipidosis] http://purl.obolibrary.org/obo/TXPO_1000003 AP1M2 (mol) http://purl.obolibrary.org/obo/TXPO_0003792 CYP2E1 (canonical)[Lipidosis] http://purl.obolibrary.org/obo/TXPO_1000081 CYP2E1 (mol) http://purl.obolibrary.org/obo/TXPO_0003812 SREBP1C (canonical)[Lipidosis] http://purl.obolibrary.org/obo/TXPO_0003966 SREBF1 (mol) http://purl.obolibrary.org/obo/TXPO_0001586 Sgpl1 - apoptosis inducer (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003529 Sgpl1 (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003262 Sgpl1 - tumor cell proliferationregulating factor (mouse) [Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003529 Sgpl1 (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003530 Sgpl1 - lipid metabolism regulator (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003529 Sgpl1 (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003557 PLA2G2A(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003556 PLA2G2A(mol) http://purl.obolibrary.org/obo/TXPO_0003661 phenothiazine antipsychotic drug http://purl.obolibrary.org/obo/TXPO_0003659 first generation antipsychotic http://purl.obolibrary.org/obo/IMR_0001043 thiolester hydrolases http://purl.obolibrary.org/obo/TXPO_0003663 hydrolase http://purl.obolibrary.org/obo/TXPO_0003706 GTP-binding protein http://purl.obolibrary.org/obo/TXPO_0003709 role related to assembling http://purl.obolibrary.org/obo/TXPO_0003572 positive regulator of immune response http://purl.obolibrary.org/obo/TXPO_0003726 regulator of immune response http://purl.obolibrary.org/obo/TXPO_0003710 regulator role http://purl.obolibrary.org/obo/TXPO_0003727 functional role http://purl.obolibrary.org/obo/TXPO_0003712 changer role http://purl.obolibrary.org/obo/TXPO_0003727 functional role http://purl.obolibrary.org/obo/TXPO_0003728 role related to receiving http://purl.obolibrary.org/obo/TXPO_0003727 functional role http://purl.obolibrary.org/obo/TXPO_0003062 TIMP1 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000373 TIMP1 (mol) http://purl.obolibrary.org/obo/TXPO_0003643 NFKB (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000258 NfkB (mol) http://purl.obolibrary.org/obo/TXPO_0003649 STAT1 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/IMR_0000375 STAT1 (mol) http://purl.obolibrary.org/obo/TXPO_0003751 TGFB1 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/IMR_0000042 TGF-beta1 http://purl.obolibrary.org/obo/TXPO_0003767 ET-1 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000128 ET-1 (mol) http://purl.obolibrary.org/obo/TXPO_0003768 CCL2 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000086 CCL2 (mol) http://purl.obolibrary.org/obo/TXPO_0003773 MMP9 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000239 MMP9 (mol) http://purl.obolibrary.org/obo/TXPO_0003775 IL-6 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/IMR_0000010 IL-6 (mol) http://purl.obolibrary.org/obo/TXPO_0003776 TNFΑ (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000374 TNF-a (mol) http://purl.obolibrary.org/obo/TXPO_0003777 MMP2 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000238 MMP2 (mol) http://purl.obolibrary.org/obo/TXPO_0003778 CXCR3 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_1000077 CXCR3 (mol) http://purl.obolibrary.org/obo/TXPO_0003785 TIMP2 (canonical)[Fibrosis] http://purl.obolibrary.org/obo/TXPO_0003784 TIMP2 (mol) http://purl.obolibrary.org/obo/TXPO_0001543 CAR -cell senescence inhibitor (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003791 CAR (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003930 CAR -FOXO1 transcriptional repression factor (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003791 CAR (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003977 CAR - gluconeogenic inhibitor (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003791 CAR (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0004102 CAR - apotosis inhibitor (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003791 CAR (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003891 TGFbeta (canonical)[Phospholipidosis - apotosis inhibitor] http://purl.obolibrary.org/obo/TXPO_0003892 TGFB1(canonical)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003896 TGFB1(canonical)[Phospholipidosis - apotosis inhibitor] http://purl.obolibrary.org/obo/TXPO_0003893 TGFB1(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003914 DAB2(human)[Phospholipidosis - apotosis inhibitor] http://purl.obolibrary.org/obo/TXPO_0003900 DAB2(human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003913 EGFR - inactivation (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003912 EGFR (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003933 Dab2(mouse)[Phospholipidosis - apotosis inhibitor] http://purl.obolibrary.org/obo/TXPO_0003916 DAB2(mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003924 FOXO1 - inactive form (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/IMR_0002805 FOXO1 (mol) http://purl.obolibrary.org/obo/TXPO_0003878 CTSB- autophagy inducing factor (human)[Phospholipidosis - autophagy indution] http://purl.obolibrary.org/obo/TXPO_0003941 CTSB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003879 CTSB- tumor cell metastasis factor (human)[Phospholipidosis - tumor metasitasis] http://purl.obolibrary.org/obo/TXPO_0003941 CTSB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003993 CTSB- apoptosis inhibitor (human)[Phospholipidosis - tumor metasitasis] http://purl.obolibrary.org/obo/TXPO_0003941 CTSB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004142 CTSB (human)Niemann-Pick disease - fibrosis] http://purl.obolibrary.org/obo/TXPO_0003941 CTSB (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003965 SREBP1 - inactive form (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003964 SREBP1 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003972 ACC1 - inactive form (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003971 ACC1 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003976 ACC2 - inactive form (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003975 ACC2 (canonical)[Ground glass appearance] http://purl.obolibrary.org/obo/TXPO_0003982 NUAK1 (mol) http://purl.obolibrary.org/obo/TXPO_0003981 NUAK http://purl.obolibrary.org/obo/TXPO_0003998 Ctsb- apoptosis inhibitor (mouse)[Phospholipidosis - apoptosis inhibitor] http://purl.obolibrary.org/obo/TXPO_0003996 Ctsb (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0003999 Ctsb- tumor cell metastasis factor (human)[Phospholipidosis - tumor metasitasis] http://purl.obolibrary.org/obo/TXPO_0003996 Ctsb (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004000 Ctsb- apoptosis inhibitor (mouse)[Phospholipidosis - tumor metasitasis] http://purl.obolibrary.org/obo/TXPO_0003996 Ctsb (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004140 Ctsb (mouse)[Niemann-Pick disease - fibrosis] http://purl.obolibrary.org/obo/TXPO_0003996 Ctsb (mouse)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004104 IL32 (human)[Phospholipidosis] http://purl.obolibrary.org/obo/TXPO_0004103 IL32 (mol) http://purl.obolibrary.org/obo/IMR_0000831 ATF-6 alpha http://purl.obolibrary.org/obo/TXPO_1000013 ATF6 (mol) http://purl.obolibrary.org/obo/TXPO_0003281 CXCL10 (mol) http://purl.obolibrary.org/obo/TXPO_1000419 cxc family (mol) http://purl.obolibrary.org/obo/TXPO_0003784 TIMP2 (mol) http://purl.obolibrary.org/obo/TXPO_1000431 TIMP family http://purl.obolibrary.org/obo/TXPO_1000373 TIMP1 (mol) http://purl.obolibrary.org/obo/TXPO_1000431 TIMP family http://purl.obolibrary.org/obo/IMR_0100300 caspase-8 http://purl.obolibrary.org/obo/IMR_0000308 signaling (initiator) caspase http://purl.obolibrary.org/obo/IMR_0001024 Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase gamma-subunit http://purl.obolibrary.org/obo/IMR_0100002 cGMP phosphodiesterase http://purl.obolibrary.org/obo/IMR_0001028 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase delta-subunit http://purl.obolibrary.org/obo/IMR_0100002 cGMP phosphodiesterase http://purl.obolibrary.org/obo/IMR_0100091 MSH release-inhibiting hormone http://purl.obolibrary.org/obo/IMR_0100090 pituitary hormone release inhibiting hormone http://purl.obolibrary.org/obo/IMR_0001088 importin alpha6 http://purl.obolibrary.org/obo/IMR_0100202 importin alpha http://purl.obolibrary.org/obo/IMR_0001085 importin alpha2 http://purl.obolibrary.org/obo/IMR_0100202 importin alpha http://purl.obolibrary.org/obo/IMR_0001086 importin alpha3 http://purl.obolibrary.org/obo/IMR_0100202 importin alpha http://purl.obolibrary.org/obo/IMR_0001084 importin alpha1 http://purl.obolibrary.org/obo/IMR_0100202 importin alpha http://purl.obolibrary.org/obo/IMR_0001087 importin alpha4 http://purl.obolibrary.org/obo/IMR_0100202 importin alpha http://purl.obolibrary.org/obo/IMR_0011153 eIF4A-I http://purl.obolibrary.org/obo/IMR_0000906 eIF4A http://purl.obolibrary.org/obo/IMR_0011154 eIF4A-II http://purl.obolibrary.org/obo/IMR_0000906 eIF4A http://purl.obolibrary.org/obo/IMR_0000165 cytokeratin 6A http://purl.obolibrary.org/obo/IMR_0000469 cytokeratin 6 http://purl.obolibrary.org/obo/IMR_0000208 cytokeratin 6B http://purl.obolibrary.org/obo/IMR_0000469 cytokeratin 6 http://purl.obolibrary.org/obo/IMR_0000244 cytokeratin 6C http://purl.obolibrary.org/obo/IMR_0000469 cytokeratin 6 http://purl.obolibrary.org/obo/IMR_0000808 disabled-1 http://purl.obolibrary.org/obo/IMR_0000558 disabled http://purl.obolibrary.org/obo/IMR_0100352 Fyn http://purl.obolibrary.org/obo/IMR_0000211 Src family http://purl.obolibrary.org/obo/IMR_0000069 alpha PDGF receptor http://purl.obolibrary.org/obo/IMR_0000068 PDGF receptor http://purl.obolibrary.org/obo/IMR_0000070 beta PDGF receptor http://purl.obolibrary.org/obo/IMR_0000068 PDGF receptor http://purl.obolibrary.org/obo/IMR_0000158 FcgammaRI http://purl.obolibrary.org/obo/IMR_0000156 FcR http://purl.obolibrary.org/obo/IMR_0000321 G-alpha-t http://purl.obolibrary.org/obo/IMR_0000318 G-alpha-i class http://purl.obolibrary.org/obo/IMR_0002805 FOXO1 (mol) http://purl.obolibrary.org/obo/IMR_0002804 FOXO family http://purl.obolibrary.org/obo/IMR_0002808 FOXO6 http://purl.obolibrary.org/obo/IMR_0002804 FOXO family http://purl.obolibrary.org/obo/IMR_0100783 Wnt-16 http://purl.obolibrary.org/obo/IMR_0000003 Wnt http://purl.obolibrary.org/obo/IMR_0002093 IgE http://purl.obolibrary.org/obo/IMR_0002090 immunoglobulin http://purl.obolibrary.org/obo/IMR_0002094 IgG http://purl.obolibrary.org/obo/IMR_0002090 immunoglobulin http://purl.obolibrary.org/obo/IMR_0100707 pro-apoptotic Bcl-2 family http://purl.obolibrary.org/obo/IMR_0000451 Bcl-2 family http://purl.obolibrary.org/obo/IMR_0000093 TGF-beta receptor type I http://purl.obolibrary.org/obo/IMR_0000092 TGF-beta receptor http://purl.obolibrary.org/obo/IMR_0100033 steroid hormone http://purl.obolibrary.org/obo/IMR_0000966 chemical hormone http://purl.obolibrary.org/obo/IMR_0001132 versican http://purl.obolibrary.org/obo/IMR_0001126 chondroitin sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0001133 aggrecan http://purl.obolibrary.org/obo/IMR_0001126 chondroitin sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0001130 neurocan http://purl.obolibrary.org/obo/IMR_0001126 chondroitin sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0001137 decorin http://purl.obolibrary.org/obo/IMR_0001127 chondroitin/dermatan sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0000625 Integrin alpha-3 http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000623 Integrin alpha-1 http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000624 Integrin alpha-2 http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000630 Integrin alpha-8 http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000632 Integrin alpha-10 http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000635 Integrin alpha-D http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000637 Integrin alpha-L http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000640 Integrin alpha-X http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000629 Integrin alpha-7 http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000634 Integrin alpha-IIb http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000638 Integrin alpha-M http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000636 Integrin alpha-E http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000631 Integrin alpha-9 http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000639 Integrin alpha-V http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0001470 DOCK2 http://purl.obolibrary.org/obo/IMR_0001469 DOCK http://purl.obolibrary.org/obo/IMR_0001471 DOCK3 http://purl.obolibrary.org/obo/IMR_0001469 DOCK http://purl.obolibrary.org/obo/IMR_0001473 DOCK5 http://purl.obolibrary.org/obo/IMR_0001469 DOCK http://purl.obolibrary.org/obo/IMR_0100145 insulin-like growth factor II http://purl.obolibrary.org/obo/IMR_0100143 somatomedin http://purl.obolibrary.org/obo/IMR_0010511 Heterogeneous nuclear ribonucleoprotein F http://purl.obolibrary.org/obo/IMR_0010024 Heterogeneous nuclear ribonucleoprotein http://purl.obolibrary.org/obo/TXPO_0000772 group XV phospholipaseA2 http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/TXPO_0003555 PLA2G1B(mol) http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/TXPO_1000282 PLA2G16 (mol) http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/TXPO_1000283 PLA2G5 (mol) http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/IMR_0001037 group X secretory phospholipase A2 http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/IMR_0001034 group IID secretory phospholipase A2 http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/IMR_0001040 group IVA phospholipase A2 http://purl.obolibrary.org/obo/IMR_0000283 PLA2 (mol) http://purl.obolibrary.org/obo/IMR_0000286 PLCbeta http://purl.obolibrary.org/obo/IMR_0000284 PLC (mol) http://purl.obolibrary.org/obo/IMR_0000715 PLCbeta2 http://purl.obolibrary.org/obo/IMR_0000286 PLCbeta http://purl.obolibrary.org/obo/IMR_0000714 PLCbeta1 http://purl.obolibrary.org/obo/IMR_0000286 PLCbeta http://purl.obolibrary.org/obo/TXPO_1000011 ATF3 (mol) http://purl.obolibrary.org/obo/IMR_0000825 ATF http://purl.obolibrary.org/obo/TXPO_1000012 ATF4 (mol) http://purl.obolibrary.org/obo/IMR_0000825 ATF http://purl.obolibrary.org/obo/TXPO_1000013 ATF6 (mol) http://purl.obolibrary.org/obo/IMR_0000825 ATF http://purl.obolibrary.org/obo/IMR_0000827 ATF-2 (mol) http://purl.obolibrary.org/obo/IMR_0000825 ATF http://purl.obolibrary.org/obo/IMR_0000833 ATF-7 (mol) http://purl.obolibrary.org/obo/IMR_0000825 ATF http://purl.obolibrary.org/obo/IMR_0011155 eIF4E http://purl.obolibrary.org/obo/IMR_0000912 eIF4F subunit http://purl.obolibrary.org/obo/IMR_0000294 Rap http://purl.obolibrary.org/obo/IMR_0000289 Ras family http://purl.obolibrary.org/obo/IMR_0000292 R-Ras http://purl.obolibrary.org/obo/IMR_0000289 Ras family http://purl.obolibrary.org/obo/IMR_0000483 alpha-actinin 2 http://purl.obolibrary.org/obo/IMR_0000189 alpha-actinin http://purl.obolibrary.org/obo/IMR_0000484 alpha-actinin 3 http://purl.obolibrary.org/obo/IMR_0000189 alpha-actinin http://purl.obolibrary.org/obo/IMR_0000479 alpha-actinin 1 http://purl.obolibrary.org/obo/IMR_0000189 alpha-actinin http://purl.obolibrary.org/obo/IMR_0000736 Grb10 http://purl.obolibrary.org/obo/IMR_0100382 Grb7/10/14 family http://purl.obolibrary.org/obo/IMR_0000357 Grb7 http://purl.obolibrary.org/obo/IMR_0100382 Grb7/10/14 family http://purl.obolibrary.org/obo/IMR_0100349 RasGRP http://purl.obolibrary.org/obo/IMR_0100440 RasGEF http://purl.obolibrary.org/obo/IMR_0001976 RapGEF http://purl.obolibrary.org/obo/IMR_0100440 RasGEF http://purl.obolibrary.org/obo/IMR_0100537 GCKR http://purl.obolibrary.org/obo/IMR_0100535 GCK family http://purl.obolibrary.org/obo/IMR_0100115 noradrenalin http://purl.obolibrary.org/obo/IMR_0001694 catecholamine http://purl.obolibrary.org/obo/IMR_0100114 adrenalin http://purl.obolibrary.org/obo/IMR_0001694 catecholamine http://purl.obolibrary.org/obo/IMR_0001449 TLR1 http://purl.obolibrary.org/obo/IMR_0000124 TLR http://purl.obolibrary.org/obo/IMR_0001450 TLR2 http://purl.obolibrary.org/obo/IMR_0000124 TLR http://purl.obolibrary.org/obo/IMR_0001451 TLR5 http://purl.obolibrary.org/obo/IMR_0000124 TLR http://purl.obolibrary.org/obo/IMR_0000029 IFN type II http://purl.obolibrary.org/obo/IMR_0000027 Interferon http://purl.obolibrary.org/obo/IMR_0000046 Nodal family http://purl.obolibrary.org/obo/IMR_0000036 TGF-beta superfamily http://purl.obolibrary.org/obo/IMR_0000037 inhibin http://purl.obolibrary.org/obo/IMR_0000036 TGF-beta superfamily http://purl.obolibrary.org/obo/IMR_0000171 VE-cadherin http://purl.obolibrary.org/obo/IMR_0000167 cadherin http://purl.obolibrary.org/obo/IMR_0000647 Integrin beta-7 http://purl.obolibrary.org/obo/IMR_0000174 Integrin beta http://purl.obolibrary.org/obo/IMR_0000641 Integrin beta-1 http://purl.obolibrary.org/obo/IMR_0000174 Integrin beta http://purl.obolibrary.org/obo/IMR_0000642 Integrin beta-2 http://purl.obolibrary.org/obo/IMR_0000174 Integrin beta http://purl.obolibrary.org/obo/IMR_0000644 Integrin beta-4 http://purl.obolibrary.org/obo/IMR_0000174 Integrin beta http://purl.obolibrary.org/obo/IMR_0000646 Integrin beta-6 http://purl.obolibrary.org/obo/IMR_0000174 Integrin beta http://purl.obolibrary.org/obo/IMR_0100593 PI3-kinase p110 subunit beta http://purl.obolibrary.org/obo/IMR_0000267 PI3-kinase p110 subunit http://purl.obolibrary.org/obo/IMR_0100594 PI3-kinase p110 subunit delta http://purl.obolibrary.org/obo/IMR_0000267 PI3-kinase p110 subunit http://purl.obolibrary.org/obo/IMR_0003065 GDF-6 http://purl.obolibrary.org/obo/IMR_0003085 GDF-5 subfamily http://purl.obolibrary.org/obo/IMR_0000734 COX-1 http://purl.obolibrary.org/obo/IMR_0000331 COX http://purl.obolibrary.org/obo/IMR_0000735 COX-2 (mol) http://purl.obolibrary.org/obo/IMR_0000331 COX http://purl.obolibrary.org/obo/IMR_0001138 keratocan http://purl.obolibrary.org/obo/IMR_0001128 keratan sulfate proteoglycan http://purl.obolibrary.org/obo/IMR_0100138 kallidin http://purl.obolibrary.org/obo/IMR_0100165 kinin http://purl.obolibrary.org/obo/IMR_0100137 bradykinin http://purl.obolibrary.org/obo/IMR_0100165 kinin http://purl.obolibrary.org/obo/IMR_0001694 catecholamine http://purl.obolibrary.org/obo/IMR_0002121 biogenic amine http://purl.obolibrary.org/obo/IMR_0100123 serotonin http://purl.obolibrary.org/obo/IMR_0002121 biogenic amine http://purl.obolibrary.org/obo/IMR_0100125 histamine http://purl.obolibrary.org/obo/IMR_0002121 biogenic amine http://purl.obolibrary.org/obo/IMR_0000438 cytohesin http://purl.obolibrary.org/obo/IMR_0000433 GEF http://purl.obolibrary.org/obo/IMR_0100440 RasGEF http://purl.obolibrary.org/obo/IMR_0000433 GEF http://purl.obolibrary.org/obo/IMR_0001110 RanBP6 http://purl.obolibrary.org/obo/IMR_0001091 importin/exportin http://purl.obolibrary.org/obo/IMR_0001507 Rap2 http://purl.obolibrary.org/obo/IMR_0000294 Rap http://purl.obolibrary.org/obo/IMR_0000308 signaling (initiator) caspase http://purl.obolibrary.org/obo/IMR_0000305 caspase (family) http://purl.obolibrary.org/obo/IMR_0100305 caspase-5 http://purl.obolibrary.org/obo/IMR_0000305 caspase (family) http://purl.obolibrary.org/obo/TXPO_1000088 Cyclin D1 (mol) http://purl.obolibrary.org/obo/IMR_0100614 cyclin D http://purl.obolibrary.org/obo/IMR_0100615 cyclin D1 http://purl.obolibrary.org/obo/IMR_0100614 cyclin D http://purl.obolibrary.org/obo/IMR_0100616 cyclin D2 http://purl.obolibrary.org/obo/IMR_0100614 cyclin D http://purl.obolibrary.org/obo/IMR_0100617 cyclin D3 http://purl.obolibrary.org/obo/IMR_0100614 cyclin D http://purl.obolibrary.org/obo/IMR_0100607 cyclin A http://purl.obolibrary.org/obo/IMR_0100672 S-cyclin http://purl.obolibrary.org/obo/IMR_0002345 beta lipotropin http://purl.obolibrary.org/obo/IMR_0100197 lipotropin http://purl.obolibrary.org/obo/IMR_0000173 Integrin alpha http://purl.obolibrary.org/obo/IMR_0000172 integrin http://purl.obolibrary.org/obo/IMR_0000174 Integrin beta http://purl.obolibrary.org/obo/IMR_0000172 integrin http://purl.obolibrary.org/obo/TXPO_1000028 Adam8 (mol) http://purl.obolibrary.org/obo/IMR_0001865 ADAM family http://purl.obolibrary.org/obo/IMR_0001871 ADAM10 http://purl.obolibrary.org/obo/IMR_0001865 ADAM family http://purl.obolibrary.org/obo/IMR_0002956 beta-arrestin 1 http://purl.obolibrary.org/obo/IMR_0000520 arrestin http://purl.obolibrary.org/obo/IMR_0002957 beta-arrestin 2 http://purl.obolibrary.org/obo/IMR_0000520 arrestin http://purl.obolibrary.org/obo/IMR_0100132 angiotensin III http://purl.obolibrary.org/obo/IMR_0100149 angiotensin http://purl.obolibrary.org/obo/IMR_0100150 angiotensin II http://purl.obolibrary.org/obo/IMR_0100149 angiotensin http://purl.obolibrary.org/obo/IMR_0001433 BMP-8b http://purl.obolibrary.org/obo/IMR_0003084 BMP-5 subfamily http://purl.obolibrary.org/obo/IMR_0001430 BMP-6 http://purl.obolibrary.org/obo/IMR_0003084 BMP-5 subfamily http://purl.obolibrary.org/obo/IMR_0000837 C/EBP gamma http://purl.obolibrary.org/obo/IMR_0000422 C/EBP http://purl.obolibrary.org/obo/TXPO_1000041 BCL2 (mol) http://purl.obolibrary.org/obo/IMR_0100706 Bcl-2 subfamily http://purl.obolibrary.org/obo/IMR_0100292 Bfl-1 http://purl.obolibrary.org/obo/IMR_0100706 Bcl-2 subfamily http://purl.obolibrary.org/obo/IMR_0100293 Bcl-xL http://purl.obolibrary.org/obo/IMR_0100706 Bcl-2 subfamily http://purl.obolibrary.org/obo/IMR_0000453 BAX (mol) http://purl.obolibrary.org/obo/IMR_0100708 Bax subfamily http://purl.obolibrary.org/obo/IMR_0100275 betacellulin http://purl.obolibrary.org/obo/IMR_0000047 EGF family http://purl.obolibrary.org/obo/IMR_0100276 epiregulin http://purl.obolibrary.org/obo/IMR_0000047 EGF family http://purl.obolibrary.org/obo/IMR_0100274 amphiregulin http://purl.obolibrary.org/obo/IMR_0000047 EGF family http://purl.obolibrary.org/obo/IMR_0100278 TGF-alpha http://purl.obolibrary.org/obo/IMR_0000047 EGF family http://purl.obolibrary.org/obo/IMR_0100277 HB-EGF http://purl.obolibrary.org/obo/IMR_0000047 EGF family http://purl.obolibrary.org/obo/IMR_0100513 Smurf1 http://purl.obolibrary.org/obo/IMR_0100512 Smurf http://purl.obolibrary.org/obo/IMR_0100514 Smurf2 http://purl.obolibrary.org/obo/IMR_0100512 Smurf http://purl.obolibrary.org/obo/IMR_0001690 MNK1 http://purl.obolibrary.org/obo/IMR_0100273 MNK http://purl.obolibrary.org/obo/IMR_0100708 Bax subfamily http://purl.obolibrary.org/obo/IMR_0100707 pro-apoptotic Bcl-2 family http://purl.obolibrary.org/obo/IMR_0002955 GRK2 http://purl.obolibrary.org/obo/IMR_0000254 G-protein coupled receptor kinase http://purl.obolibrary.org/obo/IMR_0001366 Gli2 http://purl.obolibrary.org/obo/IMR_0001372 Ci/Gli http://purl.obolibrary.org/obo/IMR_0000026 LT alpha http://purl.obolibrary.org/obo/IMR_0000021 TNF superfamily http://purl.obolibrary.org/obo/IMR_0000252 Ste20 homolog family http://purl.obolibrary.org/obo/IMR_0100207 MAPKKKK http://purl.obolibrary.org/obo/IMR_0100255 DLK family http://purl.obolibrary.org/obo/IMR_0100254 DLK http://purl.obolibrary.org/obo/IMR_0100256 LZK http://purl.obolibrary.org/obo/IMR_0100254 DLK http://purl.obolibrary.org/obo/IMR_0000581 IFN alpha-14 http://purl.obolibrary.org/obo/IMR_0100386 IFN alpha http://purl.obolibrary.org/obo/IMR_0000578 IFN alpha-8 http://purl.obolibrary.org/obo/IMR_0100386 IFN alpha http://purl.obolibrary.org/obo/IMR_0000579 IFN alpha-9 http://purl.obolibrary.org/obo/IMR_0100386 IFN alpha http://purl.obolibrary.org/obo/IMR_0000580 IFN alpha-10 http://purl.obolibrary.org/obo/IMR_0100386 IFN alpha http://purl.obolibrary.org/obo/IMR_0000583 IFN alpha-17 http://purl.obolibrary.org/obo/IMR_0100386 IFN alpha http://purl.obolibrary.org/obo/IMR_0000574 IFN alpha-4 http://purl.obolibrary.org/obo/IMR_0100386 IFN alpha http://purl.obolibrary.org/obo/IMR_0000582 IFN alpha-16 http://purl.obolibrary.org/obo/IMR_0100386 IFN alpha http://purl.obolibrary.org/obo/IMR_0100698 IP2 http://purl.obolibrary.org/obo/IMR_0001385 inositol phosphate http://purl.obolibrary.org/obo/IMR_0100193 kinesin-like protein http://purl.obolibrary.org/obo/IMR_0100192 kinesin superfamily http://purl.obolibrary.org/obo/IMR_0100561 FGF-11 http://purl.obolibrary.org/obo/IMR_0000049 FGF http://purl.obolibrary.org/obo/BFO_0000001 entity http://purl.obolibrary.org/obo/RO_0000081 role of http://purl.obolibrary.org/obo/RO_0000052 inheres in is role of a relation between a role and an independent continuant (the bearer), in which the role specifically depends on the bearer for its existence http://purl.obolibrary.org/obo/RO_0002234 has output http://purl.obolibrary.org/obo/RO_0000057 has participant P has output c iff c is a participant in p, c is present at the end of p http://purl.obolibrary.org/obo/RO_0000079 function of http://purl.obolibrary.org/obo/RO_0000052 inheres in A relation between a function and an independent continuant (the bearer), in which the function specifically depends on the bearer for its existence http://purl.obolibrary.org/obo/RO_0000080 quality of http://purl.obolibrary.org/obo/RO_0000052 inheres in a relation between a quality and an independent continuant (the bearer), in which the quality specifically depends on the bearer for its existence http://purl.obolibrary.org/obo/RO_0000085 has function http://purl.obolibrary.org/obo/RO_0000053 bearer of a relation between an independent continuant (the bearer) and a function, in which the function specifically depends on the bearer for its existence http://purl.obolibrary.org/obo/RO_0000086 has quality http://purl.obolibrary.org/obo/RO_0000053 bearer of a relation between an independent continuant (the bearer) and a quality, in which the quality specifically depends on the bearer for its existence http://purl.obolibrary.org/obo/RO_0000087 has role http://purl.obolibrary.org/obo/RO_0000053 bearer of a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence http://purl.obolibrary.org/obo/RO_0002212 negatively regulates http://purl.obolibrary.org/obo/RO_0002211 regulates Process(P1) negatively regulates process(P2) iff: P1 terminates P2, or P1 descreases the the frequency of initiation of P2 or the magnitude or rate of output of P2. http://purl.obolibrary.org/obo/RO_0002213 positively regulates http://purl.obolibrary.org/obo/RO_0002211 regulates Process(P1) postively regulates process(P2) iff: P1 initiates P2, or P1 increases the the frequency of initiation of P2 or the magnitude or rate of output of P2. http://purl.obolibrary.org/obo/RO_0002180 has component http://purl.obolibrary.org/obo/BFO_0000051 has part W 'has component' p if w 'has part' p and w is such that it can be directly disassembled into into n parts p, p2, p3, ..., pn, where these parts are of similar type. http://purl.obolibrary.org/obo/RO_0002233 has input http://purl.obolibrary.org/obo/RO_0000057 has participant P has output c iff c is a participant in p, c is present at the beginning of p. http://purl.obolibrary.org/obo/RO_0002352 input of http://purl.obolibrary.org/obo/RO_0000056 participates in 'input of' is a relation between a participant and a process, where the participant is present at the start of the process. http://purl.obolibrary.org/obo/RO_0002353 output of http://purl.obolibrary.org/obo/RO_0000056 participates in 'output of' is a relation between a participant and a process, where the participant is present at the end of the process. http://purl.obolibrary.org/obo/RO_0002473 composed_primarily_of http://purl.obolibrary.org/obo/BFO_0000051 has part x composed_primarily_of_y if:more than half of the mass of x is made from parts of y http://purl.obolibrary.org/obo/TXPO_0000005 metafuntioning type of http://purl.obolibrary.org/obo/RO_0000080 quality of 'Metafunctioning type of' is a relation between the type of metafunctioning and functioning process. Metafunctioning is a functional process to other process, for example, preventing, controlling and so on. http://purl.obolibrary.org/obo/TXPO_0000012 has molecular reaction http://purl.obolibrary.org/obo/TXPO_0002523 has occurrent part 'has molecular reaction' is a relation that holds between a whole occurrent (process) and its molecular process. http://purl.obolibrary.org/obo/TXPO_0000039 component of http://purl.obolibrary.org/obo/BFO_0000050 part of 'component of' is a relation between molecular components and a molecular complex. http://purl.obolibrary.org/obo/TXPO_0000069 has result http://purl.obolibrary.org/obo/RO_0002427 causally downstream of or within inverse of 'has cause': p 'has cause' q if p exerts some causal influence on q directly, where p is a cause and q is its effect. http://purl.obolibrary.org/obo/TXPO_0000076 has cause http://purl.obolibrary.org/obo/RO_0002418 causally upstream of or within p 'has cause' q if p exerts some causal influence on q directly, where p is a cause and q is its effect. http://purl.obolibrary.org/obo/TXPO_0000683 has family member http://purl.obolibrary.org/obo/RO_0002351 has member 'has family member' is a relation between (molecule ) family and a molecule. http://purl.obolibrary.org/obo/TXPO_0000716 dysfunctioning of http://purl.obolibrary.org/obo/TXPO_0001518 malfunctioning of 'dysfunctioning of' is a relation between an impaired or abnormal functioning and a normal functioning process. http://purl.obolibrary.org/obo/TXPO_0000750 molecular reaction of http://purl.obolibrary.org/obo/RO_0002012 occurent part of 'molecular reaction of' is a relation that holds between a molecular process and its whole process. http://purl.obolibrary.org/obo/TXPO_0001502 hyperfunction of http://purl.obolibrary.org/obo/TXPO_0001518 malfunctioning of 'dysfunctioning of' is a relation between an increasing function process and a normal one. http://purl.obolibrary.org/obo/TXPO_0001862 has attribute http://purl.obolibrary.org/obo/RO_0000086 has quality 'has attribute' is a relation between an entity and its attribute, in which the attribute specifically depends on the bearer for its existence. http://purl.obolibrary.org/obo/TXPO_0001868 has agent http://purl.obolibrary.org/obo/RO_0000057 has participant 'has agent' is a relation between a participant and a process, in which the participant is active in the relevant process. http://purl.obolibrary.org/obo/TXPO_0001870 metafunctioning type http://purl.obolibrary.org/obo/RO_0000086 has quality Metafunctioning type is a relation between functional process and the type of metafunction. Metafunctioning is a functional process to other process, for example, preventing, controlling and so on. http://purl.obolibrary.org/obo/TXPO_0001871 property of http://purl.obolibrary.org/obo/RO_0000080 quality of 'property of' is a relation between a property and the entity, , in which the property specifically depends on the bearer for its existence. http://purl.obolibrary.org/obo/TXPO_0001872 attribute of http://purl.obolibrary.org/obo/RO_0000080 quality of 'is attribute of' is a relation that associates an attribute with an entity. http://purl.obolibrary.org/obo/TXPO_0001896 agent of http://purl.obolibrary.org/obo/RO_0000056 participates in 'agent of' is a relation between a participant and a process, in which the participant is active in the relevant process. http://purl.obolibrary.org/obo/TXPO_0002260 family of http://purl.obolibrary.org/obo/RO_0002350 member of 'famly of' is a relationship between a molecule and its family. http://purl.obolibrary.org/obo/TXPO_0002523 has occurrent part http://purl.obolibrary.org/obo/BFO_0000051 has part "has ocurrent part" is a relation that holds between a whole occurrent (process) and its part. http://purl.obolibrary.org/obo/TXPO_0002524 has pathway http://purl.obolibrary.org/obo/TXPO_0002523 has occurrent part "has pathway" is a relation that holds between a whole occurrent (process) for signaling and its pathway. http://purl.obolibrary.org/obo/TXPO_0002525 pathway of http://purl.obolibrary.org/obo/RO_0002012 occurent part of 'pathway of' is a relation that holds between a pathway and its whole (signaling) process. http://purl.obolibrary.org/obo/RO_0002335 negatively regulated by http://purl.obolibrary.org/obo/RO_0002334 regulated by inverse of negatively regulates: Process(P1) negatively regulates process(P2) iff: P1 terminates P2, or P1 descreases the the frequency of initiation of P2 or the magnitude or rate of output of P2. http://purl.obolibrary.org/obo/RO_0002336 positively regulated by http://purl.obolibrary.org/obo/RO_0002334 regulated by inverse of positively regulates: Process(P1) postively regulates process(P2) iff: P1 initiates P2, or P1 increases the the frequency of initiation of P2 or the magnitude or rate of output of P2. http://purl.obolibrary.org/obo/RO_0002418 causally upstream of or within http://purl.obolibrary.org/obo/RO_0002501 causal relation between processes p 'causally upstream or within' q iff (1) the end of p is before the end of q and (2) the execution of p exerts some causal influence over the outputs of q; i.e. if p was abolished or the outputs of p were to be modified, this would necessarily affect q. http://purl.obolibrary.org/obo/RO_0002427 causally downstream of or within http://purl.obolibrary.org/obo/RO_0002501 causal relation between processes inverse of causally upstream of or within: p 'causally upstream or within' q iff (1) the end of p is before the end of q and (2) the execution of p exerts some causal influence over the outputs of q; i.e. if p was abolished or the outputs of p were to be modified, this would necessarily affect q. http://purl.obolibrary.org/obo/RO_0002598 capable of positively regulating http://purl.obolibrary.org/obo/RO_0002596 capable of regulating Holds between c and p if and only if c is capable of some activity a, and a positively regulates p. http://purl.obolibrary.org/obo/RO_0002599 capable of negatively regulating http://purl.obolibrary.org/obo/RO_0002596 capable of regulating Holds between c and p if and only if c is capable of some activity a, and a negatively regulates p. http://purl.obolibrary.org/obo/RO_0002012 occurent part of http://purl.obolibrary.org/obo/BFO_0000050 part of http://purl.obolibrary.org/obo/RO_0002350 member of member part of is member of is a mereological relation between a item and a collection. http://purl.obolibrary.org/obo/BFO_0000066 occurs in unfolds in b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t http://purl.obolibrary.org/obo/RO_0002178 supplies relation between an artery and the structure is supplies with blood http://purl.obolibrary.org/obo/BFO_0000067 contains process a relation between a continuant and a process, in which the process takes place entirely within the independent continuant http://purl.obolibrary.org/obo/RO_0000052 inheres in a relation between a specifically dependent continuant (the dependent) and an independent continuant (the bearer), in which the dependent specifically depends on the bearer for its existence http://purl.obolibrary.org/obo/RO_0000053 bearer of a relation between an independent continuant (the bearer) and a specifically dependent continuant (the dependent), in which the dependent specifically depends on the bearer for its existence http://purl.obolibrary.org/obo/RO_0000056 participates in a relation between a continuant and a process, in which the continuant is somehow involved in the process http://purl.obolibrary.org/obo/RO_0000057 has participant a relation between a process and a continuant, in which the continuant is somehow involved in the process http://purl.obolibrary.org/obo/RO_0002351 has member has member is a mereological relation between a collection and an item. http://purl.obolibrary.org/obo/OGG_0000000016 is gene of organism a relation between a gene and the organism where this gene belongs to the organism in nature. It does not include a foreign gene that is transferred to an organism by a genetic engineering method. http://purl.obolibrary.org/obo/BFO_0000051 has part a core relation that holds between a whole and its part http://purl.obolibrary.org/obo/BFO_0000050 part of a core relation that holds between a part and its whole http://purl.obolibrary.org/obo/RO_0002211 regulates process(P1) regulates process(P2) iff: P1 results in the initiation or termination of P2 OR affects the frequency of its initiation or termination OR affects the magnitude or rate of output of P2. http://purl.obolibrary.org/obo/TXPO_0000004 has core process a relation between a toxic course (the bearer) and a process. Core process is a crucial process to the manifestation of toxicity and depends on the bearer for its existence. http://purl.obolibrary.org/obo/TXPO_0000026 finding of 'finding of' is a relation between a finding and an entity, where the finding is a representational artifact that a result of a laboratory test or an observation. http://purl.obolibrary.org/obo/TXPO_0000178 relation between a role and a process 'Relation between a role and a process' is a relationship that holds between a role of material entity and a process in which causality is involved, with either the material entity or some part of the material entity plays a role and some influence over the process. http://purl.obolibrary.org/obo/TXPO_0000530 manifested phenotype of 'manifested phenotype of' is a relation between a phenotype and an entity, where there is a bearer of the realizable entity that participates in the process, and the phenotype comes to be realized in the course of the process. http://purl.obolibrary.org/obo/TXPO_0000531 manifests phenotype 'mainfests phenotype' is a relation between an entity and quality, where there is a bearer of the realizable entity that participates in the process, and the phenotype comes to be realized in the course of the process. http://purl.obolibrary.org/obo/TXPO_0000615 inherit Inherit means to receive a property (or an attribute and its value) from another entity (other than the ancestor) . http://purl.obolibrary.org/obo/TXPO_0000756 relateds assay 'relates assay' is a relation between an entity and the assay in which the entity was related (e.g., can be expressed, observed, and so on). http://purl.obolibrary.org/obo/TXPO_0000774 has context 'has context' is a relation between an entity and its context dependent on. Role is intrinsically context-dependent. http://purl.obolibrary.org/obo/TXPO_0000819 has related human gene 'has related human gene' is a relation between a molecule and the related gene. http://purl.obolibrary.org/obo/TXPO_0000826 has attribute value 'has attribute value' is a relation between an attribute and its value. http://purl.obolibrary.org/obo/TXPO_0001518 malfunctioning of 'malfunctioning of' is a relation between an abnormal functioning and a normal functioning process. http://purl.obolibrary.org/obo/TXPO_0001733 has state 'has state' is a relation between an entity and the state. http://purl.obolibrary.org/obo/TXPO_0001873 has finding 'has finding' is a relation between an entity and its finding, where the finding is a representational artifact that a result of a laboratory test or an observation. http://purl.obolibrary.org/obo/TXPO_0001887 context of 'context of' is a relation between a context and an entity. Role is intrinsically context-dependent. http://purl.obolibrary.org/obo/TXPO_0001893 related assay of 'related assay of' is a relationship between an assay and the entity, in which the entity can be related (e.g., can be expressed, observed, and so on) in the assay like in vivo, in vitro or clinical test. http://purl.obolibrary.org/obo/TXPO_0003360 is entity in organism 'Is substance in organism' is a relation between substance and organism where the substance is existed in. http://purl.obolibrary.org/obo/TXPO_0003585 realizes disease A relation between a process/process sequence and a disease. http://purl.obolibrary.org/obo/uberon/core#channel_for channel for 'channel for' is a relation between a channel that is a passage and an entity such a solvent (e.g., ion) to pass. http://purl.obolibrary.org/obo/RO_0002334 regulated by inverse of regulates: process(P1) regulates process(P2) iff: P1 results in the initiation or termination of P2 OR affects the frequency of its initiation or termination OR affects the magnitude or rate of output of P2. http://purl.obolibrary.org/obo/RO_0002501 causal relation between processes p is causally related to q if and only if p or any part of p and q or any part of q are linked by a chain of events where each event pair is one of direct activation or direct inhibition. p may be upstream, downstream, part of or a container of q. http://purl.obolibrary.org/obo/RO_0002596 capable of regulating Holds between c and p if and only if c is capable of some activity a, and a regulates p. http://purl.obolibrary.org/obo/RO_0002338 has target start location This relationship holds between p and l when p is a transport or localization process in which the outcome is to move some cargo c from some initial location l to some destination. http://purl.obolibrary.org/obo/TXPO_0000043 located_in http://purl.obolibrary.org/obo/TXPO_0001562 has related rat gene http://purl.obolibrary.org/obo/TXPO_0003399 has dysfunctioning http://purl.obolibrary.org/obo/TXPO_0003479 attribute value of http://purl.obolibrary.org/obo/TXPO_0003500 observed in http://purl.obolibrary.org/obo/RO_0002339 has target end location